nct_id,official_title,acronym,phase,countries,locations,condition,num_arms,arms_description,inclusion_criteria,exclusion_criteria
NCT06667076,"A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer",COPERNICUS,PHASE2,Puerto Rico,"Auxilio Mutuo Cancer Center, San Juan, Puerto Rico, [RECRUITING]","Carcinoma, Non-Small-Cell Lung",2,"[1] Cohort 1: Amivantamab and Lazertinib (EXPERIMENTAL): Participants will receive Amivantamab in combination with Lazertinib orally in 28-day cycles until disease progression, withdrawal of consent, death, or the investigator decides to discontinue trea... || [2] Cohort 2: Amivantamab and Chemotherapy (EXPERIMENTAL): Participants will receive Amivantamab in combination with chemotherapy (carboplatin and pemetrexed) intravenous (IV) infusion in 21-day cycles until disease progression, withdrawal of consent, deat...","* Have histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC) that is not amenable to curative intent therapy * Epidermal growth factor resistance-mutation (EGFRm) must be an Ex19del or Ex21 L858R substitution, as detected by food and drug administration (FDA)-approved or other validated test in a clinical laboratory improvement amendments (CLIA)-certified laboratory (sites in the US), or an accredited local laboratory (sites outside of the US) in accordance with site standard of care. In the European union (EU), the local test must be Conformité Européenne (CE)-marked or an in-house laboratory-developed test from health institutions in the EU in accordance with Article 5(5) of the in vitro diagnostic regulations (IVDR ) 2071/746, as amended * Have at least 1 measurable lesion, according to RECIST version (v)1.1, that has not been previously irradiated * Any toxicities from prior systemic anticancer therapy must have resolved to national cancer institute common terminology criteria for adverse events (NCI-CTCAE) version 5.0 grade 1 or baseline level (except for alopecia \[any grade\], grade \<=2 peripheral neuropathy, or grade \<=2 hypothyroidism stable on hormone replacement) * Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1","* Medical history of active interstitial lung disease (ILD), including drug-induced ILD or radiation pneumonitis. Participants with medical history of radiation pneumonitis, including radiation pneumonitis which required steroid treatment, should consult with the medical monitor and eligibility be assessed on a case-by-case basis * Had major surgery excluding placement of vascular access or tumor biopsy or had significant traumatic injury within 4 weeks before the first dose of anticancer treatments or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study * Participant has uncontrolled tumor-related pain (symptomatic lesions amenable to palliative radiotherapy should be treated prior to first dosing) * Received an investigational treatment that has not been cleared (based on at least 5 half lives of any pharmaceutical treatment) before the planned first dose of study treatment or is currently enrolled in an investigational study * Has a prior or concurrent second malignancy (other than the disease under study) which natural history or treatment could likely interfere with any study endpoints of safety or the efficacy of the study treatment(s)"
NCT06984328,"Efficacy and Safety Study of Acasunlimab as Monotherapy and in Combination With Pembrolizumab in Subjects With Relapsed/Refractory, Unresectable Locally Advanced or Metastatic Cutaneous Melanoma That Progressed On or After Treatment With a Checkpoint Inhibitor (ABBIL1TY MELANOMA-07)",,PHASE2,Puerto Rico,"Pan American Center for Oncology Trials, LLC, San Juan, Puerto Rico, [RECRUITING]","Cutaneous Melanoma | Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID) | Metastatic Cutaneous Melanoma (Stage IV)",2,"[1] Acasunlimab in Combination with Pembrolizumab (EXPERIMENTAL): Participants with relapsed/refractory, unresectable locally advanced or metastatic cutaneous melanoma that progressed on/after prior CPI(s) will receive acasunlimab once every 6 weeks (Q6W) in comb... || [2] Acasunlimab (EXPERIMENTAL): Participants with relapsed/refractory, unresectable locally advanced or metastatic cutaneous melanoma that progressed on/after prior CPI(s) will receive acasunlimab Q6W.","* Participants ≥ 18 years of age with histologically or cytologically confirmed diagnosis of relapsed/refractory, locally advanced unresectable (Stage IIIB, IIIC, or IIID) or metastatic (Stage IV) cutaneous melanoma, per American Joint Committee on Cancer (8th edition) staging. * Participant must have radiographic progression based on RECIST v1.1 on or following ≥ 1 prior systemic therapy, according to local and international guidelines, including a programmed cell death protein 1 blocking antibody (anti-PD-1) treatment or combination treatment containing an anti-PD-1. * Participant must have received a minimum of 2 cycles of an approved anti-PD-1 as monotherapy or a combination therapy containing an anti-PD-1. * Neoadjuvant and/or adjuvant systemic therapy count as the first line of prior systemic therapy if there is documented disease progression ≤ 6 months after completion of therapy. * Participants with a BRAF V600 mutation should have received prior BRAF-directed therapy (with or without a MEK inhibitor) prior to enrollment in the trial, unless deemed not clinically indicated by the Investigator due to concurrent medical condition or prior toxicity. * Participant has an Eastern Cooperative Oncology Group performance status of 0 or 1 within 7 days prior to Cycle 1 Day 1. Key",* Participants with non-cutaneous or acral melanoma. * Participants with newly identified or known unstable or symptomatic central nervous system metastases or history of carcinomatous meningitis. Note: Other protocol-defined Inclusion and Exclusion criteria may apply.
NCT06295367,Effectiveness of Out-of-Pocket Cost COMmunication and Financial Navigation (CostCOM) in Cancer Patients,,NA,Puerto Rico,"Cancer Center-Metro Medical Center Bayamon, Bayamón, Puerto Rico, [RECRUITING] | Puerto Rico Hematology Oncology Group, Bayamón, Puerto Rico, [RECRUITING] | Doctors Cancer Center, Manatí, Puerto Rico, [RECRUITING] | San Juan Community Oncology Group, San Juan, Puerto Rico, [RECRUITING] | Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico, [RECRUITING] | PROncology, San Juan, Puerto Rico, [RECRUITING] | San Juan City Hospital, San Juan, Puerto Rico, [RECRUITING]",Malignant Solid Neoplasm,3,"[1] ARM A (Enhanced usual care) (ACTIVE_COMPARATOR): Patients receive PAF brochure describing financial navigation services. || [2] ARM B (CostCOM) (EXPERIMENTAL): Patients receive usual financial care per practice standard of care and CostCOM financial counseling sessions over 1 hour within 30 days after enrollment and at 3, 6 and 12 months. || [3] Non-patient participants: (interview) (EXPERIMENTAL): Non-patient participants complete surveys and participant in 1 on 1 in depth semi-structured interview over 20-30 minutes at 15-39 months after first patient enrollment.","* NON-PATIENTS PARTICIPANTS: Participant must speak English * NON-PATIENTS PARTICIPANTS: Participant must be employed at National Cancer Institute Community Oncology Research Program (NCORP) site for at least six months * NON-PATIENTS PARTICIPANTS: Participant must be able to provide informed consent to participate in this study * NON-PATIENTS PARTICIPANTS: Participant must be one of the following: * A study coordinator with a role involving use of CostCOM intervention price transparency and financial navigation platform * A practice oncology provider (i.e., physician or mid-level), or * A practice financial counselor, social workers, financial navigators, or pharmacist who have provided care or been in contact (in the last 3 months) to a patient who was assigned to the CostCOM arm, and who completed the at least 6 month study follow-up * PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must be ≥ 18 years of age * PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must be fluent in written and spoken English OR patient must be fluent in written and spoken Spanish * PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must be within 120 days of a new diagnosis of any solid cancer of any stage at the time of Step 0 * PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must have had their first medical oncology visit at the time of Step 0 * PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must have initiated oral or intravenous (IV) cancer systemic therapy or have received a prescription order with stated intent to initiate within 30 days following Step 0 consent * PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patients must not have indolent cancer undergoing observation alone (i.e., active surveillance) * PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patients must not be receiving","* PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must not have an Eastern Cooperative Oncology Group (ECOG) performance status ≥ 3, OR * Patient must not be deemed medically unable to participate in the study by the study investigators or an oncology clinician (i.e., referral to hospice) * PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must not be enrolled in treatment clinical trials where cancer systemic therapy is provided at no cost to the patient * PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must not be enrolled in EAQ221CD or S1912CD given financial navigation is offered as part of these two trials. * NOTE: If S1912CD is activated in a participating practice, S1912CD should be offered first to patients with metastatic cancer meeting eligibility criteria for S1912CD. Only if a patient is not eligible or not interested in participating in S1912CD, the EAQ222CD can be offered. For early stage cancer, EAQ222CD can be offered first given S1912CD does not enroll patients with early stage cancer * PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must not be enrolled in other clinical trials where OOPC communication or financial navigation (i.e., professional guidance to identify financial assistance programs to alleviate cost of care) is being offered as part of the trial * NOTE: If a trial is offering financial counseling alone without financial navigation patients are allowed to co-enroll * NOTE: Gift cards for survey completion, or parking passes are not considered financial navigation * PATIENT ELIGIBILITY CRITERIA FOR STEP 1 (OPEN RANDOMIZATION): Patient must meet all the eligibility criteria for step 0 * PATIENT ELIGIBILITY CRITERIA FOR STEP 1 (OPEN RANDOMIZATION): Patient must have signed a written informed consent form * PATIENT ELIGIBILITY CRITERIA FOR STEP 1 (OPEN RANDOMIZATION): Patient must have a completed baseline survey in EC"
NCT06086990,Effects in Quality of Life of a Telemonitoring Platform Amongst Patients With Cancer: A Randomized Trial,EQUALITE,NA,Chile,"UC Christus Cancer Centre, Santiago, Chile, [RECRUITING]",Cancer | Telemonitoring | Telemedicine | Symptoms and Signs | Quality of Life,2,"[1] Telemonitoring Platform (EXPERIMENTAL): Patients assigned to the active intervention group will have access to a smartphone application named ""Contigo."" This application is designed to identify signs and symptoms of oncology drug toxicit... || [2] Traditional Follow-Up (NO_INTERVENTION): Individuals designated to the traditional follow-up group will undergo standard care, including in-person check-ups as determined by their attending physician.","* Adult patients (\>18 years old). * Recent histologically confirmed diagnosis (within the last 3 months) of bronchogenic, breast, gallbladder, gastric, colorectal, or prostate cancer in any of its forms. * Awaiting initiation of curative intent treatment for the disease using any modality (radiation therapy, chemotherapy, immunotherapy, etc.) at the UC-Christus Cancer Center. * Possession of a smartphone, regardless of its native operating system (iOS® or Android®). * Willingness to sign an informed consent form to participate in the study.",* Any form of sensory impairment preventing app usage. * Cognitive impairment. * Psychiatric pathology hindering app usage. * Unwillingness to participate in the study. * Concurrent participation in another clinical trial addressing healthcare technologies.
NCT05429632,"Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Mocravimod as Adjunctive and Maintenance Treatment in Adult AML Patients Undergoing Allogeneic HCT",MO-TRANS,PHASE3,"Argentina, Brazil","Hospital El Cruce - Dr. Nestor Kirchner, Buenos Aires, Argentina, [ACTIVE_NOT_RECRUITING] | Centro de Educacion Medica E Investigacines Clinicas Norberto Quirno CEMIC, Buenos Aires, Argentina, [ACTIVE_NOT_RECRUITING] | Sanatorio Allende (SA) - Nueva Cordoba, Córdoba, Argentina, [ACTIVE_NOT_RECRUITING] | Hospital Italiano La Plata, La Plata, Argentina, [ACTIVE_NOT_RECRUITING] | CEPON - Centro de Pesquisas Oncologicas, Florianópolis, Brazil, [ACTIVE_NOT_RECRUITING] | Hospital Erasto Gaertner, Curicica, Brazil, [ACTIVE_NOT_RECRUITING] | Hospital Alemao Oswaldo Cruz (HAOC), São Paulo, Brazil, [ACTIVE_NOT_RECRUITING] | Universidade de Sao Paulo (USP) - Hospital das Clinicas da Faculdade de Medicina (HCFMUSP), São Paulo, Brazil, [RECRUITING] | Hospital Israelita Albert Einstein, São Paulo, Brazil, [ACTIVE_NOT_RECRUITING] | Unicamp, São Paulo, Brazil, [RECRUITING]",Adult Acute Myeloid Leukemia,3,[1] 3mg mocravimod arm (EXPERIMENTAL): 3 mg of mocravimod orally once per day for 12 months || [2] 1mg mocravimod arm (EXPERIMENTAL): 1 mg of mocravimod orally once per day for 12 months || [3] Placebo arm (PLACEBO_COMPARATOR): placebo orally once per day for 12 months,"* Diagnosis of AML (excluding acute promyelocytic leukemia) according to the WHO 2022 classification of AML and related precursor neoplasm, including AML with myelodysplasia-related gene mutations * European Leukemia Net (ELN) high-risk or intermediate-risk AML in CR1, or AML of any risk in CR2, \[CRi\] is also allowable * Planned allogeneic HCT from fully matched related or unrelated donor with no more than 1 antigen mismatch or planned use of haploidentical donor using PBSC graft * Any conditioning regimen with a Transplant Conditioning Score (TCI) ≥ 1.5 * Planned use of TAC-based GvHD prophylaxis * age ≥ 18 years and ≤ 75 years * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1","* Use of CsA, anti-thymocyte globulin (ATG), alemtuzumab, abatacept for GvHD prophylaxis * Diagnosis of macular edema during screening * Cardiac/pulmonary/hepatic/renal dysfunction * Hepatic dysfunction as defined by aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \> 2.5 x upper limit of normal (ULN); or total bilirubin \> 1.5 mg/dL * Renal dysfunction with estimated creatinine clearance \< 45 mL/min by the Cockcroft-Gault formula * Diabetes mellitus * History or presence of uveitis at screening * History or diagnosis of macular edema"
NCT05584670,"A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy or in Combination With Other Anticancer Therapies in Adults With Advanced Solid Tumors",,"PHASE1, PHASE2",Chile,"Investigational Site Number : 1520002, Rancagua, Chile, [RECRUITING] | Investigational Site Number : 1520007, Providencia, Chile, [RECRUITING] | Investigational Site Number : 1520004, Recoleta, Chile, [RECRUITING] | Investigational Site Number : 1520008, Santiago, Chile, [RECRUITING]",Solid Tumor,11,[1] SAR445877 Escalation Phase (Part 1) (EXPERIMENTAL): SAR445877 monotherapy will be administered intravenously in participants with solid tumors over a 14-day cycle. || [2] SAR445877 Expansion/Optimization Phase: Cohort A1 (Part 2A) (EXPERIMENTAL): SAR445877 monotherapy will be administered intravenously (IV) in participants with non-small cell lung cancer (NSCLC). || [3] SAR445877 Expansion/Optimization Phase: Cohort A2 (Part 2A) (EXPERIMENTAL): SAR445877 monotherapy will be administered intravenously in participants with non-small cell lung cancer (NSCLC). || [4] SAR445877 Expansion/Optimization Phase: Cohort B (Part 2A) (EXPERIMENTAL): SAR445877 monotherapy will be administered IV in participants with hepatocellular carcinoma (HCC). || [5] SAR445877 Expansion/Optimization Phase: Cohort C1 (Part 2A) (EXPERIMENTAL): SAR445877 monotherapy will be administered IV in participants with gastric cancer/gastro esophageal junction adenocarcinoma (GC/GEJ). || [6] SAR445877 Expansion/Optimization Phase: Cohort C2 (Part 2A) (EXPERIMENTAL): SAR445877 monotherapy will be administered IV in participants with gastric cancer/gastro esophageal junction adenocarcinoma (GC/GEJ). || [7] SAR445877 Expansion/Optimization Phase: Cohort D (Part 2A) (EXPERIMENTAL): SAR445877 monotherapy will be administered IV in participants with immune infiltrated tumor type. || [8] SAR445877 Expansion/Optimization Phase: Cohort E1 (Part 2A) (EXPERIMENTAL): SAR445877 monotherapy will be administered IV in participants with colorectal cancer (CRC). || [9] SAR445877 Expansion/Optimization Phase: Cohort E2 (Part 2A) (EXPERIMENTAL): SAR445877 monotherapy will be administered IV in participants with colorectal cancer (CRC). || [10] SAR445877 Expansion/Optimization Phase: Cohort E3 (Part 2B) (EXPERIMENTAL): SAR445877 will be administered IV in combination with cetuximab in participants with colorectal cancer (CRC).,"1. Dose escalation Part 1 and Japan Cohort F * Participants with advanced unresectable or metastatic solid tumors for which, in the judgement of the investigator, no standard alternative therapy is available or is not in the best interest of the participant 2. Dose expansion/optimization Part 2 Cancer diagnosis: * Participants in Cohorts A1 and A2: Histologically or cytologically confirmed diagnosis of metastatic non-small cell lung cancer (NSCLC) * Participants in Cohort B: Histologically or cytologically confirmed diagnosis of advanced unresectable or metastatic hepatocellular carcinoma (HCC), or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic participants (participants without cirrhosis must have had histological confirmation of diagnosis) * Participants in Cohorts C1 and C2: Histologically or cytologically confirmed diagnosis of advanced unresectable or metastatic gastric cancer (GC) or Siewert Type 2 \& 3 gastro esophageal junction (GEJ) adenocarcinoma * For participants in Cohorts C1 and C2: Disease with any CPS scoring. No need for CPS determination at local laboratory) * For participants in Cohorts C1 and C2: Participants must have MSI (metastatic microsatellite instability) or MMR (mismatch repair) status known or determined locally and must have non-MSI-H or proficient MMR (pMMR) disease to be eligible. * For participants in Cohorts C1 and C2: Participants with unknown HER2/neu status must have their HER2/neu status determined locally. Participants with HER2/neu negative are eligible. Participants with HER2/neu positive tumors must have documentation of disease progression on treatment containing an approved HER2 targeted therapy to be eligible. Measurable Disease: * At least 1 measurable lesion per RECIST 1.1 criteria Participants in Cohorts E1, E2 and E3 * Histologically or cytologically confirmed diagnosis of advanced unresectable or metastatic colorectal cancer * Participants must have MSI status known o","* Eastern Cooperative Oncology Group (ECOG) performance status of ≥2. * Predicted life expectancy ≤3 months. * For participants with HCC- Cohort B (Part 2): Child Pugh Class B or C liver score. Participants with Child Pugh Class B-7 score are allowed for Part 1. * Diagnosed of any other malignancies, either progressing or requiring active treatments, within 2 years prior to enrollment. * Known active brain metastases or leptomeningeal metastases. * History of treatment-related immune-mediated (or immune-related) AEs from immune-modulatory agents (including but not limited to anti-PD1/PD-L1 agents and anti-cytotoxic T lymphocyte associated protein 4 monoclonal antibodies) that caused permanent discontinuation of the agent, or that were Grade 4 in severity or have not resolved to Grade ≤1. * Has any condition requiring ongoing/continuous corticosteroid therapy (\>10 mg prednisone/day or an anti-inflammatory equivalent) within 1 week prior to the first dose of the study medicine. * Any clinically significant cardiac (including valvular) or vascular (thromboembolic disorders) disease, within 6 months prior to the first IMP administration. * Ongoing or recent (within 2 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune-related adverse events. * Has a known history or any evidence of interstitial lung disease or active, non-infectious pneumonitis within 3 years prior to the first dose of the study drug. * Organ transplant requiring immunosuppressive treatment. * Uncontrolled or active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection, or has a diagnosis of immunodeficiency. NOTE: Other Inclusion/Exclusion criteria may apply. The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial."
NCT05853367,"A Phase 1/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors.",,PHASE1,Chile,"Centro de Estudios Clínicos SAGA ( Site 0701), Santiago, Chile, [RECRUITING] | Fundacion Arturo Lopez Perez ( Site 0700), Santiago, Chile, [RECRUITING] | Centro de Investigacion Clinicadela Universidad Catolica ( Site 0703), Santiago, Chile, [RECRUITING] | Bradfordhill ( Site 0702), Santiago, Chile, [RECRUITING]",Metastatic Solid Tumors | Advanced Solid Tumors,3,"[1] MK-0472 (EXPERIMENTAL): Participants receive MK-0472 via oral capsule according to one of the protocol-specified dosing regimens until disease progression or withdrawal/discontinuation. || [2] MK-0472 + Pembrolizumab (EXPERIMENTAL): Participants receive MK-0472 via oral capsule according to one of the protocol-specified dosing regimens until disease progression or withdrawal/discontinuation, plus pembrolizumab 200 mg via intra... || [3] MK-0472 + MK-1084 (EXPERIMENTAL): Participants receive MK-0472 via oral capsule according to one of the protocol-specified dosing regimens, plus MK-1084 via oral capsule QD until disease progression or withdrawal/discontinuation.","The main inclusion criteria include but are not limited to the following: * Has histologically or cytologically confirmed solid tumor by pathology report that is advanced/metastatic * Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to study enrollment * Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening * Participants with human immunodeficiency virus (HIV) infection must have well controlled HIV on stable (\>4 weeks) antiretroviral therapy (ART) * Arm 1: Oncogenic receptor tyrosine kinase (RTK) pathway alterations confirmed by a historical report or local testing (tissue or blood) and have received, or been intolerant to, all available treatment known to confer clinical benefit * Arm 2: Tumor types known to be sensitive to anti-programmed cell death 1 protein (PD-1)/ligand 1 (L1) therapies are eligible. Tumor types permitted include: melanoma, non-small cell lung cancer (NSCLC) without epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK)/ROS1 mutations, renal cell carcinoma, urothelial carcinoma, Merkel cell carcinoma, MSI-high CRC, endometrial cancer, cervical cancer, small cell lung cancer, triple negative breast cancer, esophageal cancer, gastric cancer, biliary tract cancer, hepatocellular carcinoma, head and neck squamous cancer, cutaneous squamous cancer, anal squamous cancer, and mesothelioma * Arm 3: Has histologically OR blood-based confirmation of Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutation","The main exclusion criteria include but are not limited to the following: * Has not recovered to common terminology criteria for adverse events (CTCAE) Grade 1 or better from any adverse events that were due to cancer therapeutics administered more than 4 weeks earlier. Participants receiving ongoing replacement hormone therapy for endocrine immune-related AEs will not be excluded from participation in this study * Has history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years * History of hyperparathyroidism or hypercalcemia * Has one or more of the following ophthalmological findings/conditions: a) Intraocular pressure \>21 mm Hg and/or any diagnosis of glaucoma b) Diagnosis of central serous retinopathy, retinal vein occlusion, or retinal artery occlusion and c) Diagnosis of retinal degenerative disease * Has clinically significant cardiovascular disease * Bullous exfoliative skin disorders of any grade * Known hypersensitivity to MK-0472, MK-1084, or pembrolizumab, or any of their excipients * Received therapy with a proton-pump inhibitor or an H2 histamine blocker receptor antagonist within 7 days before the first scheduled day of study dosing * Has discontinued prior therapy with an anti-programmed cell death-1 (PD-1), anti-programmed death-ligand 1 (PD-L1), or anti-programmed death-ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor due to an adverse event * Received prior systemic anticancer therapy including investigational agents within 4 weeks before first dose * Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention * Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration * Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within"
NCT05558007,Phase 2 Clinical Trial to Evaluate Safety and Efficacy of BZ371A in a Gel Applied in Patients That Performed Radical Prostatectomy,,PHASE2,Brazil,"Hospital Urológica, Belo Horizonte, Brazil, [RECRUITING]",Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction | Prostate Cancer | Radical Prostatectomy,3,[1] Daily oral Tadalafil 5mg + Topical Placebo (ACTIVE_COMPARATOR): Patient that underwent Radical Prostatectomy will receive daily oral Tadalafil 5mg and topical placebo || [2] Daily oral placebo + topical BZ371A (EXPERIMENTAL): Patient that underwent Radical Prostatectomy will receive daily oral placebo and topical BZ371A || [3] Daily oral Tadalafil 5mg + topical BZ371A (ACTIVE_COMPARATOR): Patient that underwent Radical Prostatectomy will receive daily oral Tadalafil 5mg and topical BZ371A,"1. Men between the ages of 40 and 65 years; 2. Exclusive heterosexual men, regardless of race or social class. 3. RP due to prostate cancer without metastasis; 4. RP performed less than 60 days before the screening visit; 5. Erectile function prior to normal RP, defined as IIEF questionnaire with more than 22 points in domain A; 6. Stable sexual partner (more than 2 months prior to RP), and intention to maintain the relationship during the study. 7. Continuous use of 5mg Tadalafil from the 30th up to the 60th day after RP.","1. Prostate cancer in TNM stage classified as T3 or T4. 2. Perineal and/or open RP; 3. Necessity of other therapy for prostate cancer than RP, including radiation therapy or hormone therapy; 4. Uncontrolled diabetes at screening visit (HbA1C \> 10%); 5. Prior spinal cord injury with lower limb paralysis; 6. Current male hormone use, or hypogonadism, defined by total testosterone below 8 nmol/L (2300 pg/mL) or total testosterone between 8 and 11 nmol/L (2300 and 3170 pg/mL) and free testosterone \< 220 pmol/L (\< 64 ng/dL); 7. Patients with current depression, characterized by use or need for use of antidepressants. 8. Presence of genital lesions (such as severe penile fibrosis or Peyronie's disease) or active sexually transmitted disease (STD) (such as herpes, gonorrhea, candidiasis, HPV, and others) that impair analysis of local adverse effects on the genitalia; 9. Use of topical medications in the genital region that may interfere in the IP evaluation, as well as in its absorption or drug interaction; 10. Possession of penile prosthesis; 11. History of symptomatic hypotension, or diseases that increase the risk of symptomatic hypotension, such as patient with heart diseases (including history of angina and/or heart failure) and nephropathies; 12. Current use of nitrates, such as propatilnitrate (Sustrate®), isosorbide (Monocordil®, Cincordil®, Isordil®), nitroglycerin (Nitradisc®, Nitroderm TTS®, Nitronal®, Tridil®) and isosorbitol dinitrate (Isocord®);ketoconazole; ritonavir; and rifampicin. 13. Findings on ECG and/or laboratory tests that, in the Investigator's criteria, are considered significant and offer risk to the research volunteer's participation or may hinder the study analyses; 14. BP outside the limits considered safe: SBP below 90 mmHg or above 170 mmHg; or DBP below 50 mmHg or above 100 mmHg, except situations such as ""white coat syndrome""; 15. Diseases that can cause priapism, such as sickle cell anemia, multiple myeloma, or leukemia; 16. Histroy of"
NCT06619236,"A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer",RAINFOL-02,PHASE3,Puerto Rico,"UPR Comprehensive Cancer Center Hospital, Monacillo, Puerto Rico, [RECRUITING]",Platinum-resistant Ovarian Cancer,2,[1] Rina-S (EXPERIMENTAL): No description || [2] Investigator's Choice (ACTIVE_COMPARATOR): No description,"* Participants must have histologically or cytologically confirmed high grade serous or endometrioid epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. * Participants may be enrolled regardless of FRα expression level. * Participants must have received 1 to 4 prior lines of therapy. Participants must have progressed radiographically on or after their most recent line of therapy. * Participants must have received prior treatment with the following therapies: * Platinum chemotherapy * Prior bevacizumab (or biosimilar) treatment is required, if labeled and available as standard of care per institutional guidelines, unless the participant has a documented contraindication or unless the participant is not eligible for treatment with bevacizumab (or biosimilar) due to precautions/intolerance * Participants with known or suspected deleterious germline or somatic breast cancer gene (BRCA) mutations and who achieved a complete or partial response to platinum-based chemotherapy must have been treated with a poly ADP-ribose polymerase (PARP) inhibitor as maintenance treatment unless the participant is not eligible for treatment with PARP inhibitor * Mirvetuximab soravtansine, if: * Mirvetuximab soravtansine is available in the enrollment region, and * The participant is eligible based on positive FRα expression per Food and Drug Administration (FDA)-approved (or local equivalent) test, and * The participant does not have a documented medical exception, including chronic corneal disorders, history of corneal transplantation, or active ocular conditions requiring ongoing treatment/monitoring, such as uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and /or monocular vision. * Participants must have platinum-resistant disease: * Participants who have only had 1 line of platinum-based therapy must have received at","* Prior therapy with an antibody-drug conjugate containing a topoisomerase 1 inhibitor. * Have primary platinum-refractory disease, defined as ovarian cancer that did not respond (CR or PR) to or progressed ≤ 91 days after the last dose of a first-line platinum-containing regimen. * History of another malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death (e.g., 5-year OS ≥90%), including, but not limited to, adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, ductal carcinoma in situ, or Stage I uterine cancer. * Known active central nervous system metastases or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment, they have no new or enlarging brain metastases, and are off corticosteroids and anticonvulsants prescribed for symptoms associated with brain metastases for at least 7 days prior to the first dose of study drug. Participants with suspected brain metastases at screening should undergo a computed tomography (CT)/magnetic resonance imaging (MRI) of the brain prior to study entry. * Hospitalization or clinical symptoms due to gastrointestinal obstruction within the past 91 days or radiographic evidence of gastrointestinal obstruction at the time of screening. Enrollment of participants who currently require parenteral nutrition must be discussed with the study medical monitor to determine eligibility. * Ascites requiring frequent paracentesis (more often than approximately every 4 weeks) for symptomatic management. Enrollment of participants with an indwelling peritoneal catheter must be discussed with the medical monitor to determine eligibility. NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply."
NCT06119581,"SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression",SUNRAY-01,PHASE3,"Brazil, Mexico","Fundação Pio XII - Hospital de Câncer de Barretos, Barretos, Brazil, [RECRUITING] | Oncocentro de Minas Gerais, Belo Horizonte, Brazil, [NOT_YET_RECRUITING] | Hospital Tacchini, Bento Gonçalves, Brazil, [RECRUITING] | Hospital São Domingos, Bequimão, Brazil, [RECRUITING] | Sirio-Libanes Brasilia - Centro de Oncologia - Asa Sul, Brasília, Brazil, [RECRUITING] | Hospital Universitário Evangélico Mackenzie, Curitiba, Brazil, [RECRUITING] | Centro de Pesquisa Clínica do Instituto do Câncer do Ceará, Fortaleza, Brazil, [RECRUITING] | ONCOSITE - Centro de Pesquisa Clinica em Oncologia, Ijuí, Brazil, [RECRUITING] | Hospital Brasilia, Lago Sul, Brazil, [RECRUITING] | Hospital de Cancer de Londrina, Londrina, Brazil, [RECRUITING]","Carcinoma, Non-Small-Cell Lung | Neoplasm Metastasis",7,"[1] Dose Optimization: LY3537982 Dose Level 1 plus Pembrolizumab (EXPERIMENTAL): LY3537982 Dose level 1 administered orally in combination with pembrolizumab administered intravenously (IV) in 21-day cycles. Participants may continue to receive treatment until discontinuation c... || [2] Dose Optimization: LY3537982 Dose Level 2 plus Pembrolizumab (EXPERIMENTAL): LY3537982 Dose level 2 administered orally in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. || [3] Safety Lead In: LY3537982 plus Pembrolizumab, Pemetrexed and Platinum (EXPERIMENTAL): LY3537982 administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment... || [4] Part A: LY3537982 plus Pembrolizumab (EXPERIMENTAL): LY3537982 administered orally in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. || [5] Part A: Placebo plus Pembrolizumab (PLACEBO_COMPARATOR): Placebo administered orally in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. || [6] Part B: LY3537982 plus Pembrolizumab, Pemetrexed, and Platinum (EXPERIMENTAL): LY3537982 administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment... || [7] Part B: Placebo plus Pembrolizumab, Pemetrexed, and Platinum (PLACEBO_COMPARATOR): Placebo administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment u...","* Histologically or cytologically confirmed NSCLC with Stage IIIB-IIIC or Stage IV disease, not suitable for curative intent radical surgery or radiation therapy. * Part B and Safety Lead-In Part B: the histology of the tumor must be predominantly non-squamous (in line with pemetrexed label). * Must have disease with evidence of KRAS G12C mutation. * Must have known programmed death-ligand 1 (PD-L1) expression * Part A: Greater than or equal to (≥)50 percent (%). * Part B: 0% to 100%. * Must have measurable disease per RECIST v1.1. * Must have an ECOG performance status of 0 or 1. * Estimated life expectancy ≥12 weeks. * Ability to swallow capsules. * Must have adequate laboratory parameters. * Contraceptive use should be consistent with local regulations for those participating in clinical studies. * Women of childbearing potential must * Have a negative pregnancy test. * Not be breastfeeding during treatment","* Have a documented additional validated targetable oncogenic driver mutation or alteration in genes such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF (V600E), human epidermal growth factor receptor 2 (HER2), MET (exon 14), ROS1, rearranged during transfection (RET), or neurotrophic tyrosine receptor kinase (NTRK)1/2/3. * Have had any of the following prior to randomization: \-- Prior systemic therapy (chemotherapy, immunotherapy, targeted therapy, or biological therapy) for advanced or metastatic NSCLC. \--- 1 cycle of standard-of-care treatment prior to study enrollment will be allowed for cases where immediate treatment is clinically indicated: * Have known active central nervous system metastases and/or carcinomatous meningitis. Exclusion Criteria for Participants receiving Pemetrexed and Platinum (Part B and Safety Lead-In Part B) * Have predominantly squamous cell histology for NSCLC * Only for participants with mild to moderate renal insufficiency: Unable to avoid aspirin, ibuprofen, or other nonsteroidal anti-inflammatory drugs (NSAIDs) two days before (5 days for long acting NSAIDs), day of, and two days after administration of pemetrexed * Is unable or unwilling to take folic acid or vitamin B12 supplementation."
NCT06581432,"Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2-mutated or Overexpressed/Amplified Solid Tumours",,PHASE2,Puerto Rico,"Pan American Center for Oncology Trials, LLC, Rio Piedras, Puerto Rico, [RECRUITING]",Solid Tumours,1,[1] Zongertinib treatment (EXPERIMENTAL): No description,"* Signed and dated written informed consent in accordance with International Council for Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial. * Patients ≥18 years old or over the legal age of consent in countries where that is greater than 18 years at the time of signature of the Informed consent form (ICF). * Documented (previously established by local testing) Human epidermal growth factor receptor 2 (HER2) status of: * HER2 overexpression/amplification * Known activating HER2 mutations * Availability and willingness to provide a sample of archival formalin-fixed paraffin embedded (FFPE) tumour tissue material * Patient with histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumour who has had at least one prior line of therapy for metastatic disease. In the opinion of the Investigator, patients must be unlikely to tolerate or derive clinically meaningful benefit from further standard of care therapy known to prolong survival. Further inclusion criteria apply.","* Diagnosis of HER2 mutant Non-small cell lung cancer (NSCLC) (except where there is co-existing presence of HER2 overexpression / amplification) * Previous or concomitant malignancies other than the 1 treated in this trial within the previous 3 years except: * effectively treated non-melanoma skin cancers * effectively treated carcinoma in situ of the cervix * effectively treated ductal carcinoma in situ of the breast * localised prostate cancer on watchful waiting or active surveillance * other effectively treated malignancy that is considered cured by local treatment. * Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial * Not completely recovered from major surgery (major according to the investigator's assessment) performed prior to screening or planned within 6 months after screening, e.g. hip replacement Further exclusion criteria apply."
NCT06627647,"A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)",,PHASE3,"Argentina, Brazil, Peru, Puerto Rico","Research Site, Buenos Aires, Argentina, [RECRUITING] | Research Site, CABA, Argentina, [RECRUITING] | Research Site, La Plata, Argentina, [WITHDRAWN] | Research Site, Pilar, Argentina, [RECRUITING] | Research Site, Rosario, Argentina, [RECRUITING] | Research Site, Ijuí, Brazil, [RECRUITING] | Research Site, Londrina, Brazil, [RECRUITING] | Research Site, Passo Fundo, Brazil, [RECRUITING] | Research Site, Porto Alegre, Brazil, [RECRUITING] | Research Site, Salvador, Brazil, [RECRUITING]",Non-squamous Non-small Cell Lung Cancer,2,[1] Arm A (EXPERIMENTAL): Rilvegostomig in combination with platinum-based doublet chemotherapy followed by rilvegostomig monotherapy plus pemetrexed in maintenance. || [2] Arm B (ACTIVE_COMPARATOR): Pembrolizumab in combination with platinum-based doublet chemotherapy followed by pembrolizumab monotherapy plus pemetrexed in maintenance.,"* Histologically or cytologically documented non-squamous NSCLC. * Stage IV mNSCLC (based on the American Joint Committee on Cancer Edition 8) not amenable to curative treatment. * Absence of sensitizing EGFR mutations (including, but not limited to, exon 19 deletion and exon 21 L858R, exon 21 L861Q, exon 18 G719X, and exon 20 S768I mutations) and ALK and ROS1 rearrangements. * Absence of documented tumor genomic mutation results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved targeted 1L therapies. * Provision of acceptable tumor sample, to confirm tumor PD-L1 expression TC ≥ 1%. * At least one lesion not previously irradiated that qualifies as a RECIST 1.1 TL at baseline and can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have short axis ≥ 15 mm) with CT or MRI and is suitable for accurate repeated measurements. * Adequate organ and bone marrow function","* Presence of small cell and neuroendocrine histology components. * Brain metastases unless asymptomatic, stable, and not requiring steroids or anticonvulsants for at least 7 days prior to randomization. A minimum of 2 weeks must have elapsed between the end of local therapy (brain radiotherapy or surgery) and randomization. Participants must have recovered from the acute toxic effect of radiotherapy (eg, dizziness and signs of increased intracranial pressure) or surgery prior to randomization. * Any prior systemic therapy received for advanced or mNSCLC. Prior systemic therapy in the neoadjuvant or adjuvant setting and/or definitive radio- or chemoradiotherapy for early-stage disease are allowed, provided that recurrence or progression has occurred \> 12 months after the end of treatment. * Any prior exposure to an anti-TIGIT therapy or any other anticancer therapy targeting immune-regulatory receptors or mechanisms. * Any prior treatment with an anti-PD-1 or anti-PD-L1 agent. * History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥ 2 years before the first dose of study intervention and of low potential risk for recurrence. * Active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment. * Active primary immunodeficiency/active infectious disease(s). * Active tuberculosis infection."
NCT05668988,"A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation",,PHASE3,"Argentina, Brazil","Centro de Educación Médica e Investigaciones Clínicas, CEMIC, Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Centro Diabaid, Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Centro Medico Austral, Buenos Aires, Argentina, [COMPLETED] | Consultorios Medicos Dr. Doreski - Fundacion Respirar, Buenos Aires, Argentina, [COMPLETED] | Fundacion Cenit Para El Estudio De Neurociencias, Buenos Aires, Argentina, [COMPLETED] | Hospital Italiano de Buenos Aires (HIBA), Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Instituto Alexander Fleming, Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Instituto Argentino de Diagnositco y Tratamiento S.A, Buenos Aires, Argentina, [COMPLETED] | Fundación Estudios Clínicos, Rosario, Argentina, [COMPLETED] | Fundación Ars Médica, San Salvador, Argentina, [COMPLETED]",Non-small Cell Lung Cancer,2,[1] sunvozertinib (EXPERIMENTAL): No description || [2] Platinum-based Chemotherapy (ACTIVE_COMPARATOR): No description,"1. Aged at least 18 years old (or per local regulatory/IRB requirement). 2. Histologically or cytologically confirmed diagnosis of non-squamous NSCLC, locally advanced (Stage IIIB and IIIC according to the 8th edition of the AJCC TNM staging criteria) or metastatic (Stage IV), not suitable for curative therapy. 3. Adequate tumor tissue available, for central laboratory confirmation of EGFR exon 20 insertion mutation 4. At least 1 measurable lesion per RECIST Version 1.1 5. Life expectancy ≥ 12 weeks 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 7. Adequate organ and hematologic function","1. Prior treatment with any systemic anti-cancer therapy for locally advanced or metastatic NSCLC. 2. Spinal cord compression or leptomeningeal metastasis. 3. Concurrent EGFR mutations: exon 19 deletion, L858R, T790M, G719X, S768I, or L861Q. 4. History of stroke or intracranial hemorrhage within 6 months before randomization. 5. As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses (i.e., hemophilia and Von Willebrand disease)."
NCT05852990,Effect of Glutamine Plus Lactobacillus Reuteri Added to an Astringent Diet in Preventing Diarrhea Caused by Tyrosine Kinase Inhibitors (TKIs) in Patients With Advanced Non-small Cell Lung Cancer,,PHASE3,Mexico,"Instituto Nacional de Cancerologia de Mexico, Mexico City, Mexico, [RECRUITING]",Non-Small Cell Lung Cancer With EGFR Mutation,2,"[1] Intervention diet (EXPERIMENTAL): Astringent diet supplemented with one sachet containing 10 grams of glutamine plus 100 million Colony Forming Units (CFU) of Lactobacillus reueri every 12 hours, from baseline treatment up to 6 wee... || [2] Standard diet (NO_INTERVENTION): Astringent diet from baseline treatment up to 6 weeks or death.",* Both sexes * ≥ 18 years old * Pathologically confirmed diagnosis of NSCLC * Stage IIIB - IV by the American Joint Committee of Cancer Version 8. * Candidates to receive EGFR-TKI treatment (1st \& 2nd generation TKI) * ECOG score ≤ 2 * Life expectancy \> eight weeks * Signed written informed consent,"* Patients who cannot attend the first protocol appointment. * Treatment with other anti-cancer therapy * Participating in other clinical trials in the former four weeks * Any other serious condition or uncontrolled active infection, altered mental status or psychiatric disorder that, in the investigator´s opinion, would limit the ability of an individual to meet the requirements of the study or which affects the interpretability of the results. * Active hepatitis virus infection (any serotype) or chronic infection with a potential risk of reactivation evaluated through a serological panel. * Active HIV infection. * Breastfeeding."
NCT05254743,"A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)",BRUIN-CLL-314,PHASE3,"Argentina, Brazil, Chile","Alexander Fleming, Ciudad Autónoma de Buenos Aire, Argentina, [ACTIVE_NOT_RECRUITING] | Hospital Privado De Comunidad, Mar del Plata, Argentina, [ACTIVE_NOT_RECRUITING] | Clínica de Nefrología, Urología y Enfermedades Cardiovasculares, Santa Fe, Argentina, [ACTIVE_NOT_RECRUITING] | Fundação Pio XII - Hospital de Câncer de Barretos, Barretos, Brazil, [ACTIVE_NOT_RECRUITING] | Upeclin - Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu - UNESP, Botucatu, Brazil, [ACTIVE_NOT_RECRUITING] | Hemocentro Unicamp, Campinas, Brazil, [ACTIVE_NOT_RECRUITING] | Hospital Uopeccan - Centro de Pesquisa Clinica, Cascavel, Brazil, [ACTIVE_NOT_RECRUITING] | Centro Integrado de Oncologia de Curitiba, Curitiba, Brazil, [ACTIVE_NOT_RECRUITING] | Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer, Curitiba, Brazil, [ACTIVE_NOT_RECRUITING] | Instituto do Câncer - Hospital São Vicente de Paulo, Passo Fundo, Brazil, [ACTIVE_NOT_RECRUITING]","Chronic Lymphocytic Leukemia | Leukemia, Lymphocytic | Leukemia, B-cell | Small Lymphocytic Lymphoma",3,[1] Pirtobrutinib Part 1 (EXPERIMENTAL): Participants will receive pirtobrutinib orally. || [2] Ibrutinib (ACTIVE_COMPARATOR): Participants will receive ibrutinib orally. || [3] Pirtobrutinib Part 2 (EXPERIMENTAL): Participants will receive pirtobrutinib orally.,"* Confirmed diagnosis of CLL/SLL requiring therapy per iwCLL 2018 criteria * Part 1 - Known 17p deletion status (wildtype or deleted). Part 2 - Must have deletion of 17p as determined by FISH testing * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2 * Adequate organ function * Platelets greater than or equal to ≥ 50 x 10⁹/liter (L) or ≥30 x 10⁹/L in participants with documented bone marrow involvement considered to impair hematopoiesis, * Hemoglobin ≥8 grams/deciliter (g/dL) or ≥6 g/dL in participants with documented bone marrow involvement considered to impair hematopoiesis * Absolute neutrophil count ≥0.75 x 10⁹/L or ≥0.50 × 10⁹/L in participants with documented bone marrow involvement considered to impair hematopoiesis * Kidney function: Estimated creatinine clearance ≥30 milliliters per minute (mL/min)","* Known or suspected Richter's transformation to diffuse large B-cell lymphoma (DLBCL), prolymphocytic leukemia, or Hodgkin's lymphoma at any time preceding enrollment * Known or suspected central nervous system (CNS) involvement * A significant history of renal, neurologic, psychiatric, endocrine, metabolic or immunologic disease * Active uncontrolled auto-immune cytopenia (e.g., autoimmune hemolytic anemia \[AIHA\], idiopathic thrombocytopenic purpura \[ITP\]) * Significant cardiovascular disease including ejection fraction \< 40% and any grade ongoing atrial fibrillation or atrial flutter * Hepatitis B or hepatitis C testing indicating active/ongoing infection, based on Screening laboratory tests * Active cytomegalovirus (CMV) infection * Active uncontrolled systemic bacterial, viral, or fungal infection * Known human immunodeficiency virus (HIV) infection, regardless of cluster of differentiation 4 (CD4) count * Clinically significant active malabsorption syndrome or other condition likely to affect GI absorption of the oral-administered study treatments * Ongoing inflammatory bowel disease * Previous treatment for CLL/SLL - Part 1: Treatment-naïve and previously treated, except prior exposure to BTK inhibitor (covalent or noncovalent). Part 2: participants must be treatment naïve * Concurrent use of investigational agent or anticancer therapy except hormonal therapy * Participants requiring therapeutic anticoagulation with warfarin or another Vitamin K antagonist * Use of \> 20 mg prednisone daily or equivalent dose of steroid at the time of first dose of study drug * Vaccination with a live vaccine within 28 days prior to randomization * Participants receiving chronic therapy with a strong cytochrome P450 (CYP)3A inhibitor (except posaconazole and voriconazole) which cannot be stopped within 3-5 half lives of the CYP3A inhibitor therapy prior to start of study drug treatment * Participants with known hypersensitivity, including anaphylaxis, to any component or"
NCT05552976,"A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2",SUCCESSOR-2,PHASE3,"Argentina, Brazil, Colombia, Puerto Rico","Local Institution - 0008, Ciudad Autónoma de Buenos Aires, Argentina, [ACTIVE_NOT_RECRUITING] | Local Institution - 0079, ABB, Argentina, [ACTIVE_NOT_RECRUITING] | Local Institution - 0182, Rosario, Argentina, [ACTIVE_NOT_RECRUITING] | Local Institution - 0319, San Miguel de Tucumán, Argentina, [ACTIVE_NOT_RECRUITING] | Local Institution - 0150, Buenos Aires, Argentina, [COMPLETED] | Local Institution - 0151, Córdoba, Argentina, [ACTIVE_NOT_RECRUITING] | Local Institution - 0121, Salvador, Brazil, [ACTIVE_NOT_RECRUITING] | Local Institution - 0076, Porto Alegre, Brazil, [COMPLETED] | Local Institution - 0085, São Paulo, Brazil, [ACTIVE_NOT_RECRUITING] | Local Institution - 0075, Rio de Janeiro, Brazil, [ACTIVE_NOT_RECRUITING]",Relapsed or Refractory Multiple Myeloma,2,[1] MeziKd (Mezigdomide + Carfilzomib + Dexamethasone) (EXPERIMENTAL): No description || [2] Kd (Carfilzomib + Dexamethasone) (ACTIVE_COMPARATOR): No description,"\- Participant has documented diagnosis of multiple myeloma and measurable disease, defined as any of the following:. i) Myeloma-protein (M-protein) ≥ 0.5 grams/deciliter (g/dL) by serum protein electrophoresis (sPEP), or. ii) M-protein ≥ 200 milligrams (mg)/24-hour urine collection by urine protein electrophoresis (uPEP) or,. iii) For participants without measurable disease in sPEP or uPEP: serum free light chain levels \> 100 mg/liter (L) (10 mg/dL) involved light chain and an abnormal κ/λ free light chain ratio. * Participant has received at least one prior line of anti-myeloma therapy. Note: One line can contain several phases (e.g., induction, \[with or without\] hematopoietic stem cell transplant, (with or without) consolidation, and/or \[with or without\] maintenance therapy). * Participant must have received prior treatment with lenalidomide and at least 2 cycles of an anti-CD38 monoclonal antibody (mAb) (participants who were intolerant of an anti-CD38 mAb and received \< 2 cycles are still eligible). * Participant achieved minimal response or better to at least 1 prior anti-myeloma therapy. * Participant must have documented disease progression during or after their last antimyeloma regimen.",* Participant who has had prior treatment with mezigdomide or carfilzomib. * Participant has previously received allogeneic stem cell transplant at any time or received autologous stem cell transplant within 12 weeks of initiating study treatment. * Other protocol-defined Inclusion/Exclusion criteria apply.
NCT06551142,"A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of GSK5764227 as Monotherapy and in Combination in Participants With Advanced Solid Tumors",,PHASE1,Argentina,"GSK Investigational Site, Rosario, Argentina, [RECRUITING] | GSK Investigational Site, Viedma, Argentina, [RECRUITING]",Neoplasms,3,[1] Phase 1a: Dose escalation-GSK5764227 Monotherapy (EXPERIMENTAL): No description || [2] Phase 1a- Dose escalation- Combination therapy (EXPERIMENTAL): No description || [3] Phase 1b- Dose optimisation/ expansion- GSK5764227 Monotherapy (EXPERIMENTAL): No description,"* Male or female participants at least 18 years of age (≥18 years) * Participants with histologically confirmed advanced/metastatic solid tumors, irrespective of mutational status, as defined per study phase and cohort, as follows: o Phase 1a: * Participants with advanced/metastatic solid tumors. * For monotherapy dose escalation: participants must have progressed on or become intolerant to all available SOC therapies. * For combination dose escalation: participants must have received 3 or fewer prior lines of systemic anticancer therapy in the advanced/metastatic setting * Has at least 1 target lesion per RECIST 1.1, as determined by the investigator. * Has an ECOG performance status of 0 or 1, with no deterioration in the 2 weeks before first dose. * Has a life expectancy \>12 weeks. * Has adequate organ function. Screening specimens must be collected at least 3-5 days prior to pre-dose specimens, and pre-dose specimens must be collected within 24 hours prior to first dose. * Where available, participants should provide a formalin fixed and paraffin embedded (FFPE) tumor sample from the most recent biopsy of primary cancer or from a metastatic site for central testing. Tumor tissue (archival tumor tissue or a fresh biopsy) for all except ES-SCLC participants. Exemptions can be granted by the medical monitor for participants with bladder cancer and mCRPC. Tumor tissue is necessary for retrospective detection of B7 homolog 3 protein (B7-H3) expression by Immunohistochemistry (IHC) and other biomarker analysis. * At least one of the following treatment combinations/monotherapy (a, b, c, or d) are not contraindicated. 1. Atezolizumab, durvalumab, or pembrolizumab in combination with cisplatin or carboplatin (for combination 1 only). 2. Atezolizumab, durvalumab, or pembrolizumab as monotherapy (for combination 2 only) 3. Bevacizumab as monotherapy (for combination 3 only) 4. Cetuximab as monotherapy (for combination 4 only) * Has received no more than 4 cycles of cispl","* Has ongoing adverse reaction(s) from prior therapy that has(have) not recovered to ≤Grade 1 or to the baseline status preceding prior therapy. * Prior treatment with orlotamab, enoblituzumab, I-Dxd, or other B7-H3 targeted agents. * Evidence of brain metastasis (unless meeting the following criteria at the same time: asymptomatic; medically stable for at least 4 weeks prior to initial dosing; no steroid treatment required for at least 2 weeks prior to initial dosing; and no midline shift due to herniation); or untreated progression due to brain metastasis during or after the last treatment prior to screening; or evidence of meningeal/brainstem metastasis; or evidence of spinal cord compression (detected by radiographic examination, symptomatic or not). * Any of the following cardiac examination abnormality: * Has QT interval, corrected for heart rate (QTc) \>450 msec or QTc \>480 msec for participants with bundle branch block. * Evidence of current clinically significant arrhythmias or ECG abnormalities (e.g., complete left bundle branch block, third-degree atrioventricular \[AV\] block, second-degree AV block, PR interval \>250 msec). * Risk factors of prolonged QTc or arrhythmia events, such as heart failure, refractory hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death of any direct relative under 40 years old or any concomitant medications that prolong the QT interval. * Left ventricular ejection fraction (LVEF) \<50%. * Has severe, uncontrolled or active CV disorders, serious or poorly controlled hypertension, clinically significant bleeding symptoms or serious arteriovenous thromboembolic events Any evidence of current interstitial lung disease (ILD) or pneumonitis or a prior history of ILD or non-infectious pneumonitis requiring high-dose glucocorticoids. * Has donated blood or blood products in excess of 500 mL (approximately 1 pint) within one month prior to first dose of study treatment. * Has a hist"
NCT05899608,"A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer (HARMONi-3)",,PHASE3,Mexico,"Clinical Study Site, Guadalajara, Mexico, [RECRUITING] | Clinical Study Site, Monterrey, Mexico, [RECRUITING] | Clinical Study Site, Monterrey, Mexico, [RECRUITING] | Clinical Study Site, Monterrey, Mexico, [RECRUITING]",Non-Small Cell Lung Cancer,2,[1] Arm A - Ivonescimab and chemotherapy (EXPERIMENTAL): Subject will receive ivonescimab and chemotherapy || [2] Arm B - Pembrolizumab and chemotherapy (ACTIVE_COMPARATOR): Subject will receive pembrolizumab and chemotherapy,"* Age ≥ 18 years old at the time of enrollment * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 * Expected life expectancy ≥ 3 months * Metastatic (Stage IV) NSCLC * Histologically or cytologically confirmed squamous or non-squamous NSCLC * Recorded measurement of the Tumor Proportion Score (TPS) for PD-L1 expression, irrespective of the PD-L1 expression, prior to randomization * At least one measurable noncerebral lesion according to RECIST 1.1 * No prior systemic treatment for metastatic NSCLC","* Histologic or cytopathologic evidence of the presence of small cell lung carcinoma * Known actionable genomic alterations (EGFR, ALK, ROS1, and BRAF V600E) or genes for which first-line approved therapies are available. * For non-squamous histology patients, actionable driver mutation testing results are required before randomization. * Has received any prior therapy for NSCLC in the metastatic setting * Tumor invasion, encasement of organs (e.g. heart, trachea, esophagus, central bronchi), or major blood vessels (e.g aorta, central veins), if poses a significant increased risk of bleeding."
NCT04291105,Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Select Solid Tumors,,PHASE2,Brazil,"Hospital Sao Rafael, Salvador, Brazil, [RECRUITING] | INCA, Rio de Janeiro, Brazil, [RECRUITING] | Hospital Moinhos de Vento, Porto Alegre, Brazil, [RECRUITING] | Hospital de Amor de Barretos, Barretos, Brazil, [ACTIVE_NOT_RECRUITING]",Melanoma | Head and Neck Squamous Cell Carcinoma | Colo-rectal Cancer,3,"[1] Melanoma intratumoral (EXPERIMENTAL): Melanoma, IT VV1 + IV cemiplimab Patients will receive both treatments on Day 1 and every 3 weeks thereafter until lack of clinical benefit or limiting toxicity. VV1 or cemiplimab can continue afte... || [2] Head and Neck SCC intratumoral (EXPERIMENTAL): HNSCC, IT VV1 + IV cemiplimab, Patients will receive both treatments on Day 1 and every 3 weeks thereafter until lack of clinical benefit or limiting toxicity. VV1 or cemiplimab can continue after ... || [3] Colo-rectal Carcinoma intratumoral (Arm closed) (EXPERIMENTAL): (CLOSED) IT VV1 + IV cemiplimab, Patients will receive both treatments on Day 1 and every 3 weeks thereafter until lack of clinical benefit or limiting toxicity. VV1 or cemiplimab can continue afte...","1. Age ≥18 years on day of signing informed consent. 2. Specific by tumor cohorts: a. For the HSNCC cohort, histologically confirmed diagnosis of advanced and/or metastatic HSNCC suitable for first line immunotherapy. i. HPV+ and HPV- patients are allowed. ii. Primary tumor locations of oropharynx, oral cavity, hypopharynx, or larynx. Participants may not have a primary tumor site of nasopharynx (any histology) or salivary gland tumors. iii. PD-L1 status ≥ 1% per local CPS score. Samples should be provided to central lab for post-hoc centralized testing. iv. At least 12 months between last dose of prior adjuvant therapy and date of relapse diagnosis (if given). For the purposes of this protocol, ""prior adjuvant therapy"" only applies to full dose systemic chemotherapy (such as pre-operative systemic induction chemotherapy), but does not include radiation + surgery, or radiation + low or partial dose platinum radiosensitization. There is no time limit (washout) between the end of any prior radiation/ chemoradiation and the start of study drug v. No prior anti-PD-(L)1 treatment for HNSCC. b. For the melanoma cohorts, histologically confirmed diagnosis of advanced and/or metastatic cutaneous melanoma for which no existing options are considered to provide clinical benefit. i. Best response of uPR, SD or PD to an anti-PD-(L)1-containing regimen. ii. Prior anti-PD-(L)1 therapy must have lasted ≥ 12 weeks. iii. Radiological progression was demonstrated during or after therapy with a PD-(L)1 immune CPI (only one prior line of PD-(L)1 therapy is permitted. iv. If patient received anti-PD-1 as prior adjuvant therapy, patient should have relapsed during therapy or within the subsequent 6 months after last dose. Note: Progression on ipilimumab is not required. v. Patients with BRAF V600-positive tumor(s) should have received prior treatment with a BRAF inhibitor (alone or in combination with a MEK inhibitor) in addition to treatment with an anti-PD-1 or to have declined targete","Patients meeting any of the following exclusion criteria at screening/Day -1 of first dosing will not be enrolled in the study: 1. Availability of and patient acceptance of an alternative curative therapeutic option. 2. Patients with tumor lesion(s) \> 5cm in diameter. 3. Recent or ongoing serious infection, including any active Grade 3 or higher per the NCI CTCAE, v5.0 viral, bacterial, or fungal infection within 2 weeks of registration. 4. Patients who have a diagnosis of ocular, mucosal or acral melanoma. 5. Known seropositivity for and with active infection with HIV. 6. Seropositive for and with evidence of active viral infection with HBV. 7. Seropositive for and with active viral infection with HCV. 8. Known history of active or latent TB. 9. Any concomitant serious health condition, which, in the opinion of the investigator, would place the patient at undue risk from the study, including uncontrolled hypertension and/or diabetes, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease requiring hospitalization within 3 months) or neurological disorder (e.g., seizure disorder active within 3 months). 10. Prior therapy within the following timeframe before the planned start of study treatment as follows: 1. Small molecule inhibitors, and/or other investigational agent: ≤ 2 weeks or 5 half-lives, whichever is shorter. 2. Chemotherapy, other monoclonal antibodies, antibody-drug conjugates, or other similar experimental therapies: ≤ 3 weeks or 5 half-lives, whichever is shorter. 3. Radioimmunoconjugates or other similar experimental therapies ≤ 6 weeks or 5 half-lives, whichever is shorter. 11. NYHA classification III or IV, known symptomatic coronary artery disease, or symptoms of coronary artery disease on systems review, or known cardiac arrhythmias (atrial fibrillation or SVT). 12. Any known or suspected active organ-threatening autoimmune disease, such as inflammatory bowel disease, autoimmune hepatitis, lupus, or pneumonitis, wit"
NCT03825861,Neoadjuvant FOLFIRINOX in the Treatment of Locally Advanced Gastric Cancer,FOLFIRINOX,PHASE2,Brazil,"Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil, [RECRUITING]",Gastric Cancer,1,"[1] FOLFIRINOX (EXPERIMENTAL): Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, Irinotecan 180mg/m2, 5-FU 400mg/m2 bolus followed by 2400mg/m2 continuous infusion.","* Histological diagnosis of gastric adenocarcinoma that is amenable to surgical resection at diagnosis, with locally advanced disease criteria for clinical evaluation (T3 tumors, T4 tumors and / or regional lymph node involvement). * Absence of metastatic disease at a distance (computerized tomography, diagnostic laparoscopy and peritoneal lavage). * Age 18-75 years. * Clinical functionality by the ECOG scale between 0 and 1. * Preserved renal function (creatinine clearance greater than 50 mL / min). * Signature of Informed Consent Form","* Active neoplasm of another primary site other than non-melanoma skin carcinoma. * Lesions of the esophagogastric transition * Unresectable lesions by computed tomography and / or diagnostic laparoscopy. * Obstructive tumors (acute intestinal occlusion or subocclusion). * Tumors with signs of significant or persistent bleeding. * Carcinoma in situ. * Different histological type of adenocarcinoma. * Gastric stump tumors. * Previous chemotherapeutic or radiotherapy treatment. * Current pregnancy or breastfeeding. * Total bilirubin above 1.5mg / dL. * Hepatic transaminases greater than 1.5 times the upper limit of normality. * Decompensated and / or symptomatic cardiomyopathy: congestive heart failure with functional class greater than 2 by the New York Heart Association; active coronary disease; uncontrolled cardiac arrhythmia; history of acute myocardial infarction in the last 6 months. * Psychological, familial, social or even geographical condition that potentially hinders adherence to the study protocol and the pre-established follow-up. * Current or previous psychiatric or neurological diagnosis that is decompensated, compromises the cognition, functionality or adherence to the proposed treatment. * Other comorbidities that are decompensated at the time of treatment. * Pregnant or breastfeeding women."
NCT03418961,"Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients With Metastatic HER-2+ Breast Cancer, Phase III",,PHASE3,Puerto Rico,"Advance Oncology Center, Aguadilla, Puerto Rico, [ACTIVE_NOT_RECRUITING] | Doctor's Cancer Center-Arecibo, Arecibo, Puerto Rico, [ACTIVE_NOT_RECRUITING] | Cancer Center-Metro Medical Center Bayamon, Bayamón, Puerto Rico, [ACTIVE_NOT_RECRUITING] | Hematologia Oncologia San Pablo, Bayamón, Puerto Rico, [ACTIVE_NOT_RECRUITING] | HIMA San Pablo Oncologic Hospital, Caguas, Puerto Rico, [ACTIVE_NOT_RECRUITING] | Doctors Cancer Center, Manatí, Puerto Rico, [ACTIVE_NOT_RECRUITING] | Instituto Oncologia Moderna Ponce, Ponce, Puerto Rico, [ACTIVE_NOT_RECRUITING] | San Juan Community Oncology Group, San Juan, Puerto Rico, [ACTIVE_NOT_RECRUITING] | Primary Care Physician Group, San Juan, Puerto Rico, [ACTIVE_NOT_RECRUITING] | San Juan City Hospital, San Juan, Puerto Rico, [ACTIVE_NOT_RECRUITING]",Cardiotoxicity | HER2/Neu Positive | Metastatic Malignant Neoplasm in the Brain | Recurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7,3,"[1] Arm I (carvedilol) (EXPERIMENTAL): Patients not taking beta blocker, ARB, or ACE inhibitor at registration receive carvedilol PO BID. Courses repeat every 12 weeks for 108 weeks in the absence of disease progression or unacceptable ... || [2] Arm II (no intervention) (ACTIVE_COMPARATOR): Patients not taking beta blocker, ARB, or ACE inhibitor at registration receive no study intervention for up to 108 weeks. || [3] Arm III (observation) (ACTIVE_COMPARATOR): Patients undergo observation for up to 108 weeks.","* STEP 1 REGISTRATION * Patients must have metastatic breast cancer and be initiating within 7 days of step 1 registration or continuing trastuzumab?based HER-2 targeted therapy without concurrent anthracyclines in first or second line setting; patients may have brain metastasis; there is no limit for number of doses of HER-2 targeted therapy prior to registration; examples of eligible HER-2 targeted therapy: * Trastuzumab * Trastuzumab + chemotherapy or hormonal therapy * Trastuzumab + other HER-2 targeted agent with or without chemotherapy (such as pertuzumab) * Ado-trastuzumab (Kadcyla) * NOTE: Patients on lapatinib without trastuzumab are not eligible; planned treatment with concurrent HER-2 targeted therapy and anthracyclines is not permitted * Patients must be at increased risk for cardiotoxicity defined by at least one of the following: * Previous anthracycline exposure, OR * 1 or more of the following risk factors for heart disease: * Left ventricular ejection fraction (LVEF) 50-54% by local echocardiography (ECHO) read * Age \>= 65 * Body mass index (BMI) \>= 30 kg/m\^2 * Current or prior anti-hypertensive therapy * Diagnosis of coronary artery disease (CAD) * Diabetes mellitus * Atrial fibrillation/flutter * Patients must not have taken within 21 days prior to step 1 registration, be currently taking at the time of step 1 registration, or planning to take once registered to step 1 a beta blocker, ARB, or ACE inhibitor in order to be randomized (Arms 1 and 2) * Patients currently taking a beta blocker, ARB, or ACE inhibitor at the time of step 1 registration are eligible to register for the non-randomized observational cohort (Arm 3) * Patients must not be currently taking or planning to take during study treatment the following medications: * B2 agonists * Bosutinib * Ceritinib * Floctafenine * Methacholine * Pazopanib * Rivastigmine * Vincristine * Silodosin * Patients must have a Zubrod Performance status of 0-2 * Patients must have a complete physical e",
NCT03815903,"A Phase 3, Randomized, Open-label Clinical Trial of Induction Chemotherapy Followed by Chemoradiotherapy Versus Chemoradiotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma",INDUCTION,PHASE3,Brazil,"Barretos Cancer Hospital, Barretos, Brazil, [RECRUITING]",Locally Advanced Malignant Neoplasm,2,[1] A - induction chemotherapy (ACTIVE_COMPARATOR): No description || [2] B - chemoradiotherapy (EXPERIMENTAL): No description,"* Confirmed histological diagnosis of squamous cell carcinoma or undifferentiated carcinoma of the oropharynx, hypopharynx or larynx; * Locally advanced stage (stage IVa / b - AJCC 8th edition), classified as resectable \*\* or unresectable and candidate for treatment based on radiotherapy and chemotherapy; * Locally advanced stage (stage III - AJCC 8th edition), classified as resectable or unresectable, positive p16 and candidate for treatment based on radiotherapy and chemotherapy; * It will be allowed to include a patient with cervical lymphadenectomy if the primary lesion is measurable; * Presence of measurable disease according to RECIST 1.1 criteria; * ECOG performance status of 0-1; * ≥ 18 years; * Adequate marrow reserve indicated by: * Absolute neutrophil count (ANC) ≥ 1500 / mm³ or Platelets\> 100,000 / mm³ * Hemoglobin ≥ 9 g / dL - red blood cell transfusion will be allowed in the screening period if necessary * Adequate renal and hepatic function: * Serum bilirubin ≤ 1.5 times the upper limit of normal the TGO and TGP ≤ 3 upper limit of normal. If hepatic metastasis ≤ 5 upper limit of normal * Serum creatinine ≤ 1.5 mg / dL and creatinine clearance ≥ 60 mL / min calculated by Cockcroft-Gault.","* Patient submitted to curative resection of the primary site and / or metastatic site. NOTE: Patients submitted to cervical lymphadenectomy without surgery to the primary tumor are eligible; * Radiation therapy or previous chemotherapy for head / neck tumor; * Patients with occult primary tumor; * T4 from any site, resectable, with invasion of cartilage or jaw; * History of BMT or stem cell therapy; * Synchronous tumor or previous history of neoplasia, except for in situ carcinoma of the cervix, basal cell carcinoma or epidermoid carcinoma. Patients with previous history of cancer already treated and without evidence of disease for more than 3 years may participate in the study; * Prophylactic use of G-CSF or GM-CSF two weeks prior to the study; * Clinically significant heart disease: unstable angina or myocardial infarction 6 months prior to study entry Symptomatic ventricular arrhythmia the ICC classified as NYHA ≥ II • Uncontrolled hypercalcemia; * Uncontrolled infection; * Any other comorbidity that the investigator's judgment is inappropriate for the study; * Peripheral neuropathy\> grade 2; * Hearing loss\> grade 2; * Known positive serology for hepatitis B, hepatitis C or HIV * Use of antiretrovirals;"
NCT06498661,NCI Cervical Cancer 'Last Mile' Initiative 'Self-Collection for HPV Testing to Improve Cervical Cancer Prevention' (SHIP) Trial LMI-001-A-S01,SHIP-A-S01,NA,Puerto Rico,"University of Puerto Rico, San Juan, Puerto Rico, [RECRUITING]",Cervical Carcinoma | Human Papillomavirus Infection,1,[1] Prevention (self-collected and clinician-collected samples) (EXPERIMENTAL): Patients undergo self-collection of two vaginal samples and then undergo clinician-collection of a cervical test sample. Patients then undergo standard of care colposcopy with biopsy/endocervical c...,"* Willingness and ability to provide a documented informed consent * Is 25 years or older * Has an intact cervix * Has had a referral for colposcopy and/or cervical excisional procedure in which routine cervical cancer screening has included HPV testing (HPV primary screening, co-testing, or atypical squamous cells of undetermined significance \[ASC-US\] cytology triage) or abnormal cytology performed within the past 12 months preceding the referral visit * Willing and able to undergo colposcopy, and if clinically indicated for SOC purposes, a biopsy, endocervical curettage, and/or a cervical excisional procedure, as applicable","* Is pregnant when presenting for the referral visit or gave birth within the past 3 months * Has a known history of excisional or ablative therapy to the cervix (e.g., loop electrosurgical excision procedure \[LEEP\], cone biopsy, cervical laser surgery, cryotherapy, thermal ablation) in the last 12 months prior to the referral visit * Has had a complete or partial hysterectomy, either supracervical or involving removal of the cervix, via self-report or confirmation via medical records * Known medical conditions that, in the opinion of the investigator, preclude study participation * Previous participation in the SHIP trial. Participation is defined as completing the self-collection * Is experiencing unusual bleeding or pelvic pain"
NCT06492616,"Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study",ELEGANT,PHASE3,"Argentina, Brazil","Fundacion Respirar, Buenos Aires, Argentina, [RECRUITING] | Organizacion Medica de Investigacion (OMI), Buenos Aires, Argentina, [RECRUITING] | Centro de Investigación CIPREC, C.a.b.a., Argentina, [RECRUITING] | Centro Oncológico Korben, CABA, Argentina, [RECRUITING] | Centro Medico Privado CEMAIC, Córdoba, Argentina, [RECRUITING] | Inst Med Fund Estudios Clinicos, Rosario, Argentina, [RECRUITING] | Instituto de Oncologia de Rosario, Rosario, Argentina, [RECRUITING] | Clinica Adventista Belgrano, Buenos Aires, Argentina, [RECRUITING] | Instituto Argentino de Diagnostico y Tratamiento, Buenos Aires, Argentina, [RECRUITING] | Centro Oncologico de Excelencia, San Juan, Argentina, [RECRUITING]",Breast Cancer,2,"[1] Elacestrant (EXPERIMENTAL): Participants will receive 345 milligrams (mg) elacestrant once daily (QD) for 5 years || [2] Standard of Care (SoC) Endocrine Therapy (EXPERIMENTAL): Participants will receive the SoC endocrine therapy that was used prior to randomization:

* AI (anastrozole 1 mg QD, letrozole 2.5 mg QD, or exemestane 25 mg QD); or
* Tamoxifen 20 mg QD","* Histopathologically or cytologically confirmed ER-positive (≥ 10% by immunohistochemistry \[IHC\]), HER2-negative \[IHC = 0 or 1, or (IHC = 2 and in situ hybridization \[ISH\]-negative)\] on tumor biopsy or final surgical pathology specimen early stage resected invasive breast cancer without evidence of recurrence or distant metastases, per local laboratory, according to the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines * Participants considered at high risk of recurrence at initial staging * Participants who have received at least 24 months but not more than 60 months of endocrine therapy (AIs or tamoxifen) with or without a CDK 4 and CKD 6 inhibitor (CDK4/6i) * Participants who received prior CDK4/6i or a poly adenosine diphosphate-ribose polymerase (PARP) inhibitor must have already completed or discontinued these treatments. Key","* Participants with inflammatory breast cancer * History of any prior (ipsilateral and/or contralateral) invasive breast cancer * Participant with history of malignancy within 3 years of the date of randomization, except for adequately treated basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix * Participants who have had more than a 6-month continuous interruption of prior SoC adjuvant endocrine therapy or who discontinued adjuvant endocrine therapy more than 6 months prior to randomization Note: Other protocol defined Inclusion/Exclusion criteria may apply."
NCT05595447,Rescue With Brentuximab Plus PD-1 Blockade Followed by Autotransplantation and Consolidation With Brentuximab Plus PD-1 Blockade in Patients With Relapsed/Refractory Hodgkin Lymphoma: Exploratory Single-arm Analysis,,"PHASE2, PHASE3",Mexico,"Hospital Regional Alta Especialidad Bajio, León, Mexico, [RECRUITING]","Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Relapsed Hodgkin's Disease, Adult",1,[1] Brentuximab plus PD-1 blocked plus ASCT plus maintenance Brentuximab plus PD-1 (EXPERIMENTAL): Brentuximab plus PD-1 blocked x 8 cycles plus ASCT plus maintenance Brentuximab plus PD-1 x 8 cycles,"1. Relapsed/refractory Hodgkin lymphoma to ABVD with definition of high risk. 2. Age ≥ 18 years and ≤ 90 years. 3. Adequate liver function, defined as: * Total serum bilirubin ≤ 1.5 x upper limit of normal (ULN) * Serum aspartate aminotransferase (AST) ≤ 3.0 x ULN * Serum alanine aminotransferase (ALT) ≤ 3.0 x ULN 4. Adequate renal functions, defined as: • Serum creatinine ≤ 1.5x ULN or glomerular filtration rate \&gt; 50ml/min. 5. ECOG performance status ≤ 3 6. Women of reproductive potential should have a serum pregnancy test or negative urine. 7. Prior signature of the informed consent.",1. Voluntary withdrawal from the study. 2. Develop grade 3 or 4 toxicity according to the INH scale. 3. Loss of follow-up
NCT06717347,"A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)",,PHASE3,"Argentina, Brazil, Chile, Colombia, Guatemala, Mexico, Peru, Puerto Rico","Clinica Adventista Belgrano ( Site 0309), Caba., Argentina, [RECRUITING] | Instituto de Investigaciones Clinicas Mar del Plata ( Site 0306), Mar del Plata, Argentina, [RECRUITING] | Hospital Universitario Austral ( Site 0307), Pilar, Argentina, [RECRUITING] | Hospital Aleman ( Site 0301), Buenos Aites, Argentina, [RECRUITING] | Fundacion Estudios Clinicos ( Site 0311), Rosario, Argentina, [RECRUITING] | C.I.C.E. 9 de Julio ( Site 0305), San Miguel de Tucumán, Argentina, [RECRUITING] | Hospital Italiano de Buenos Aires ( Site 0304), CABA, Argentina, [RECRUITING] | Clinica EL Castaño ( Site 0312), San Juan, Argentina, [RECRUITING] | CEONC ( Site 0412), Cascavel, Brazil, [RECRUITING] | Hospital Erasto Gaertner ( Site 0401), Curitiba, Brazil, [RECRUITING]",Diffuse Large B-Cell Lymphoma,2,"[1] Zilovertamab vedotin + Rituximab + Cyclophosphamide, Doxorubicin, Prednisone (R-CHP) (EXPERIMENTAL): Participants receive a dose of zilovertamab vedotin (1.75 mg/kg) plus 750 mg/m\^2 cyclophosphamide, 50 mg/m\^2 doxorubicin, and 375 mg/m\^2 rituximab or rituximab biosimilar administered by intrave... || [2] Rituximab + Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) (ACTIVE_COMPARATOR): Participants receive 750 mg/m\^2 cyclophosphamide, 50 mg/m\^2 doxorubicin, and 375 mg/m\^2 rituximab or rituximab biosimilar, 1.4 mg/m\^2 vincristine administered by intravenous (IV) infusion on Da...","* Has histologically confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL), by prior biopsy, based on local testing according to the WHO classification of neoplasms of the hematopoietic and lymphoid tissues * Has positron emission tomography (PET) positive disease at screening, defined as 4 to 5 on the Lugano 5-point scale * Has received no prior treatment for their DLBCL * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 assessed within 7 days before randomization * Has an ejection fraction ≥45% as determined by either echocardiogram (ECHO) or multigated acquisition (MUGA) * Human immunodeficiency virus (HIV) infected participants must have well controlled HIV on antiretroviral therapy (ART) * Who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy and have undetectable HBV viral load prior to randomization * Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening","* Has a history of transformation of indolent disease to DLBCL * Has received a diagnosis of primary mediastinal B-cell lymphoma (PMBCL) or Grey zone lymphoma * Has Ann Arbor Stage I DLBCL * Has clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (\<6 months prior to enrollment), myocardial infarction (\<6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), or serious cardiac arrhythmia requiring medication * Has clinically significant pericardial or pleural effusion * Has ongoing Grade \>1 peripheral neuropathy * Has a demyelinating form of Charcot-Marie-Tooth disease * HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Has ongoing corticosteroid therapy * Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed * Known additional malignancy that is progressing or has required active treatment within the past 2 years * Known active central nervous system (CNS) lymphoma * Has active autoimmune disease that has required systemic treatment in the past 2 years * Has active infection requiring systemic therapy * Has concurrent active HBV (defined as HBsAg positive and detectable HBV DNA) and HCV (defined as anti-HCV antibody positive and detectable HCV ribonucleic acid (RNA)) infection * Has history of allogeneic tissue/solid organ transplant"
NCT06016738,"A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)",OPERA-01,PHASE3,"Argentina, Brazil, Mexico, Puerto Rico","Clinical Trial Site, Bahía Blanca, Argentina, [RECRUITING] | Clinical Trial Site, Mar del Plata, Argentina, [RECRUITING] | Clinical Trial Site, Mar del Plata, Argentina, [RECRUITING] | Clinical Trial Site, Córdoba, Argentina, [RECRUITING] | Clinical Trial Site, Córdoba, Argentina, [RECRUITING] | Clinical Trial Site, San Salvador de Jujuy, Argentina, [RECRUITING] | Clinical Trial Site, La Rioja, Argentina, [RECRUITING] | Clinical Trial Site, Viedma, Argentina, [RECRUITING] | Clinical Trial Site, Rosario, Argentina, [RECRUITING] | Clinical Trial Site, Rosario, Argentina, [RECRUITING]",Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | ER Positive Breast Cancer | HER2 Negative Breast Carcinoma,2,"[1] Palazestrant (OP-1250) (EXPERIMENTAL): Participants will receive Palazestrant || [2] Standard of Care Endocrine Therapy (ACTIVE_COMPARATOR): Participants will receive Investigator's choice of one of the Standard of Care drugs (fulvestrant, anastrozole, letrozole, or exemestane)","* Adult female or male participants. * ER+, HER2- locally advanced or metastatic breast cancer that is not amenable to curative therapy. * Evaluable disease (measurable disease or bone-only disease). * Previously received a CDK4/6 inhibitor in combination with an endocrine therapy in the advanced setting. One additional line of ET as a monotherapy is allowed. Duration of the most recent prior ET must be at least 6 months. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Adequate hematologic, hepatic, and renal functions. * Female participants can be pre-, peri- or postmenopausal. * Male and pre- or peri-menopausal female participants must be willing to take a GnRH (or LHRH) agonist. Key","* Symptomatic visceral disease, imminent organ failure, or any other reason that makes the participant ineligible for endocrine monotherapy. * Previously received chemotherapy in the advanced/metastatic setting. * Previously received treatment with elacestrant or an investigational estrogen receptor-directed therapy. * History of allergic reactions to study treatment. * Any contraindications to the selected standard-of-care endocrine therapy in the local prescribing information. * Symptomatic central nervous system metastases, carcinomatous meningitis, leptomeningeal disease, or a spinal cord compression that require immediate treatment. * Clinically significant comorbidities such as significant cardiac or cerebrovascular disease, gastrointestinal disorders that could affect absorption of study treatment."
NCT04557449,"A PHASE 1/2A STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS",CDK4i,PHASE1,"Argentina, Mexico","Hospital Británico de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina, [RECRUITING] | Fundación Cenit Para La Investigación En Neurociencias, CABA, Argentina, [RECRUITING] | Fundación Respirar, Buenos Aires, Argentina, [RECRUITING] | Clínica Universitaria Reina Fabiola, Córdoba, Argentina, [RECRUITING] | Fundación CORI para la Investigación y Prevención del Cáncer, La Rioja, Argentina, [RECRUITING] | Hospital MAC Periferico Sur, Mexico City, Mexico, [RECRUITING] | INCAN, Mexico City, Mexico, [RECRUITING] | COI Centro Oncologico Internacional S.A.P.I. de C.V., Mexico City, Mexico, [RECRUITING] | Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"", Monterrey, Mexico, [RECRUITING] | Hospital Reforma, Oaxaca City, Mexico, [RECRUITING]",Liposarcoma | Prostate Cancer | Breast Neoplasms | Adenocarcinoma of Lung,17,[1] 1A Monotherapy Escalation Arm 1 (EXPERIMENTAL): PF-07220060 Monotherapy Escalation || [2] 1A Monotherapy Escalation Arm 2 (EXPERIMENTAL): PF-07220060 Monotherapy Escalation || [3] 1A Monotherapy Escalation Arm 3 (EXPERIMENTAL): PF-07220060 Monotherapy Escalation || [4] 1A Monotherapy Escalation Arm 4 (EXPERIMENTAL): PF-07220060 Monotherapy Escalation || [5] 1B Combination Dose Finding Arm 1 (EXPERIMENTAL): PF-07220060 with Letrozole combination Escalation || [6] 1B Combination Dose Finding Arm 2 (EXPERIMENTAL): PF-07220060 with Letrozole Combination Escalation || [7] 1C Combination Dose Finding Arm 1 (EXPERIMENTAL): PF-07220060 with Fulvestrant Combination Escalation || [8] 1C Combination Dose Finding Arm 2 (EXPERIMENTAL): PF-07220060 with Fulvestrant Combination Escalation || [9] 2B Combination Dose Expansion (EXPERIMENTAL): PF-07220060 with Letrozole Combination Expansion || [10] 2C Combination Dose Expansion (EXPERIMENTAL): PF-07220060 with fulvestrant Combination Expansion,"* Part 1: Breast Cancer (BC) * Refractory Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) BC * Part 1A/Part 1D/Part1E also include: Refractory HR-positive/HER2-positive BC * Part 1: Tumors other than BC (Part 1A/Part 1D/Part 1E): NSCLC, prostate, CRC, liposarcoma, or tumors with previously confirmed CDK4 or CCND1 amplification according to local standard tests * Part 1F: prostate cancer * Part 2A, 2B, 2C and 2E: * HR-positive/HER2-negative BC * Patients who are either postmenopausal women or pre/peri-menopausal (Part 2C only) * Part 1D: metastatic castration resistant prostate cancer * Lesion: * Part 1: evaluable lesion (including skin or bone lesion only) * Part 2A, 2B, 2C and 2E: measurable lesion per RECIST v1.1 * Part 2D: Participants with evaluable disease as per PCWG3; participants with bone metastases only are allowed. Participants with biochemical recurrence only are excluded. * Prior systemic Treatment * Part 1: HR-positive/HER2-negative BC * At least 1 line of SOC, including CD4/6 inhibitor therapy for advanced or metastatic disease, or if CDK4/6 inhibitors are not considered appropriate in the opinion of the investigator * At least 1 line of anti-endocrine in countries without CDK4/6 inhibitor approval or reimbursement, for advanced or metastatic disease * HR-positive/HER2-positive BC (Parts 1A/1D/1E): at least 1 prior treatment of approved HER2 targeting therapy * Tumors other than BC (Parts 1A/1D/1E/1F): tumor that is resistant to at least 2 lines of SOC for advanced or recurrent disease or for which no standard therapy is available * Part 2A and 2E: participants must have received at least 1 line of standard of care (including prior CDK4/6i) for advanced/metastatic disease; Prior chemo is allowed; Prior fulvestrant, mTOR and/or PI3K inhibitors are allowed * Part 2B: participants who have not received any prior systemic anti-cancer therapies for advanced/metastatic BC * Part 2C: * Progressed during treatment or","* Part 1D: participants who have had a gastrectomy or have dietary or other restrictions that preclude a 10 hour overnight fast or consumption of the high fat, high calorie meal * Part 2B: prior neoadjuvant or adjuvant treatment with a non-steroidal aromatase inhibitor with disease recurrence while on or within 12 months of completing treatment. Prior treatment with any CDK4/6 inhibitor * Part 2C: prior treatment with any CDK inhibitor, fulvestrant, everolimus, or any agent whose mechanism of action is to inhibit the PI3K-mTOR pathway * Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases carcinomatous meningitis, or leptomeningeal disease * Other active malignancy within 3 years prior to randomization, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ * Major surgery or radiation within 4 weeks prior to study intervention * Last anti-cancer treatment within 2 weeks prior to study intervention * Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry * Pregnant or breastfeeding female participant * Active inflammatory gastrointestinal (GI) disease, known diverticular disease or previous gastric resection or lap band surgery including impairment of gastrointestinal function or GI disease"
NCT04603807,"Randomized, Open Label, Multicenter, Phase III Study of Entrectinib Versus Crizotinib in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring ROS1 Gene Rearrangements With and Without Central Nervous System Metastases",,PHASE3,"Brazil, Mexico","Oncocentro Serviços Médicos e Hospitalares Ltda, Fortaleza, Brazil, [RECRUITING] | Hospital Sao Rafael - HSR, Salvador, Brazil, [RECRUITING] | Hospitais Integrados da Gavea S/A, Brasília, Brazil, [ACTIVE_NOT_RECRUITING] | Oncocentro Belo Horizonte, Belo Horizonte, Brazil, [WITHDRAWN] | Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda, Ijuí, Brazil, [WITHDRAWN] | Centro de Pesquisa e Ensino em Oncologia de Santa Catarina - CEPEN, Florianópolis, Brazil, [RECRUITING] | Hospital de Cancer de Barretos, Barretos, Brazil, [ACTIVE_NOT_RECRUITING] | Instituto do Cancer do Estado de Sao Paulo - ICESP, São Paulo, Brazil, [ACTIVE_NOT_RECRUITING] | Oncoclinicas Rio de Janeiro S.A., Rio de Janeiro, Brazil, [COMPLETED] | Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Mexico, [RECRUITING]","Carcinoma, Non-Small-Cell Lung",2,"[1] Entrectinib (EXPERIMENTAL): Participants will be enrolled to receive 600 mg entrectinib orally once daily until progressive disease, unacceptable toxicity, death, or withdrawal from the study, whichever occurs first. || [2] Crizotinib (ACTIVE_COMPARATOR): Participants will be enrolled to receive 250 mg crizotinib orally twice daily until progressive disease, unacceptable toxicity, death, or withdrawal from the study, whichever occurs first.","* Histologically or cytologically-confirmed diagnosis of advanced or recurrent (Stage IIIB/C not amenable for radical treatment) or metastatic (Stage IV) NSCLC that harbors a documented ROS1 gene rearrangement. * No prior treatment with a ROS1 tyrosine kinase inhibitor, chemotherapy or other systemic therapy for advanced or recurrent (Stage IIIB/C not amenable for radical treatment) or metastatic (Stage IV) NSCLC * Prior radiotherapy is allowed if more than 14 days have elapsed between the end of treatment and randomization * Measurable systemic disease according to RECIST v1.1 * Participants with measurable and non-measurable CNS lesions per RECIST v1.1, including leptomeningeal carcinomatosis * Life expectancy of at least 12 weeks * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 * Adequate hematologic, renal, liver functions * Participants must have recovered from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatment * Ability to swallow entrectinib and crizotinib intact without chewing, crushing, or opening the capsules * For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods with a failure rate of \<1% per year during the treatment period and for up to 5 weeks after the last dose of entrectinib or for at least 90 days after the last dose of crizotinib * For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm.","* Prior treatment with a ROS1 tyrosine kinase inhibitor, chemotherapy or other systemic therapy for advanced or recurrent (Stage IIIB/C not amenable for radical treatment) or metastatic (Stage IV) NSCLC * NCI-CTCAE v5.0 Grade 3 or higher toxicities due to any prior therapy (excluding alopecia, fatigue, nausea and lack of appetite), which have not shown improvement and are strictly considered to interfere with current study drug * History of recent (within the past 3 months) symptomatic congestive heart failure or ejection fraction ≤ 50% observed during screening for the study * History of prolonged corrected QTc interval * Peripheral sensory neuropathy ≥ Grade 2 * Known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase inhibitor-induced pneumonitis * Previous malignancy within the past 3 years * Incomplete recovery from any surgery prior to the start of study treatment * Active GI disease (e.g., Crohn's disease, ulcerative colitis or short gut syndrome) or other malabsorption syndrome that would reasonably impact drug absorption * History of prior therapy-induced pneumonitis * Any condition (in the past 3 months) e.g., myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, cerebrovascular accident or transient ischemic attack, stroke, symptomatic bradycardia, or uncontrolled arrhythmias requiring medication * Known active infections (bacterial, fungal or viral, including human immunodeficiency virus positive) * History of hypersensitivity to any of the additives in the entrectinib and/or crizotinib drug formulations * Pregnant or lactating women * Known human immunodeficiency virus (HIV) positivity or acquired immunodeficiency syndrome (AIDS)-related illness * Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or the absorption of oral medications."
NCT05633667,A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung),VELOCITY-Lung,PHASE2,Brazil,"Centro Gaúcho Integrado de Oncologia Hematologia, Ensino e Pesquisa Ltda./Hospital Mãe de Deus,Substudy-03, Porto Alegre, Brazil, [RECRUITING] | Hospital Mae de Deus, Porto Alegre, Brazil, [RECRUITING] | Hospital Sao Lucas da PUC Rio Grande do Sul,Substudy-03, Porto Alegre, Brazil, [RECRUITING] | Fundação Antonio Prudente/A.C. Camargo Cancer Center,Substudy-03, São Paulo, Brazil, [RECRUITING] | Real e Benemérita Associação Portuguesa de Beneficência/Hospital Beneficência Portuguesa de São Paulo (Hospital BP),Substudy-03, São Paulo, Brazil, [RECRUITING]",Lung Cancer | Advanced or Metastatic Non-Small-Cell Lung Cancer | Resectable Non-Small-Cell Lung Cancer,10,"[1] Substudy 01: Zimberelimab (ZIM) + Sacituzumab govitecan-hziy (SG) + Domvanalimab (DOM) (EXPERIMENTAL): Participants will receive ZIM, SG and DOM until disease progression (PD), unacceptable toxicity, or protocol specified discontinuation criteria are met. || [2] Substudy 01: ZIM + DOM + Etrumadenant (ETRUMA) (EXPERIMENTAL): Participants will receive ZIM, DOM and ETRUMA until PD, unacceptable toxicity, or protocol specified discontinuation criteria are met. || [3] Substudy 01: ZIM + ETRUMA (EXPERIMENTAL): Participants will receive ZIM and ETRUMA until PD, unacceptable toxicity, or protocol specified discontinuation criteria are met. || [4] Substudy 01: Zimberelimab (ZIM) + Sacituzumab govitecan-hziy (SG) (EXPERIMENTAL): Participants will receive ZIM and SG until disease progression (PD), unacceptable toxicity, or protocol specified discontinuation criteria are met. || [5] Substudy 01: ZIM + Platinum Based Chemotherapy (ACTIVE_COMPARATOR): Expansion Stage Only: Participants will receive ZIM plus any one of the chemotherapy (choice of chemotherapy is dependent on histology).

Platinum Based Chemotherapy will be cisplatin or carboplati... || [6] Substudy 02: SG + ZIM + ETRUMA (EXPERIMENTAL): Participants will receive SG, ZIM and ETRUMA until PD, unacceptable toxicity, or protocol specified discontinuation criteria are met. || [7] Substudy 02: Either Docetaxel or SG (Monotherapy Only) (ACTIVE_COMPARATOR): Participants will receive either Docetaxel or SG until PD, unacceptable toxicity, or protocol specified discontinuation criteria are met. || [8] Substudy 03 - ZIM + DOM + Platinum-based Chemotherapy (EXPERIMENTAL): Participants will receive ZIM plus DOM and any one of the chemotherapy (choice of chemotherapy is dependent on histology).

Platinum Based Chemotherapy will be carboplatin and pemetrexed (non-squam... || [9] Substudy 03 - ZIM + Platinum-based Chemotherapy (EXPERIMENTAL): Participants will receive ZIM plus any one of the chemotherapy (choice of chemotherap","All Substudies: * Histologically or cytologically documented non-small-cell lung cancer (NSCLC). * No known actionable genomic alterations for which targeted therapies are available. * Eastern cooperative oncology group (ECOG) performance status score of 0 or 1. * Measurable disease per response evaluation criteria in solid tumors. * Adequate hematologic and end-organ function. * Individuals of childbearing potential who engage in heterosexual intercourse must agree to use specified method(s) of contraception. Substudy 01: All Experimental arms * Stage IV NSCLC. * For individuals with nonsquamous histology: Epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) alteration negative. * PD-L1 status by central confirmation. * No prior systemic treatment for metastatic NSCLC. Substudy 02: All Experimental arms * Stage IV NSCLC. * In individuals with nonsquamous histology and actionable EGFR, ALK, or other known genomic alterations must have received treatment with at least 1 targeted therapy to the appropriate genomic alteration. Substudy 03: All Experimental arms * Previously untreated individuals with resectable (Stage II, IIIA, IIIB (T\[3-4\]N2) NSCLC (per American Joint Committee on Cancer (AJCC) Edition 8). * Planned surgery must comprise of lobectomy, sleeve lobectomy, or bi-lobectomy. * PD-L1 status by central confirmation. * For individuals with nonsquamous histology: Epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) alteration negative. Key",All Substudies: * Mixed small-cell lung cancer and NSCLC histology. * Active second malignancy. * Active autoimmune disease. * History of or current non-infectious pneumonitis/interstitial lung disease. * Active serious infection within 4 weeks prior to study treatment. Substudy 01 and 02 * Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. * Received previous anticancer therapy within 4 weeks prior to enrollment. Substudy 03: All Experimental arms * NSCLC previously treated with systemic therapy or radiotherapy. * Received prior treatment with any anti-PD-(L)-1 or other immune checkpoint inhibitors (CPIs). Note: Other protocol defined inclusion/exclusion criteria may apply
NCT05519085,"A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1",SUCCESSOR-1,PHASE3,"Argentina, Brazil, Chile, Puerto Rico","Sanatorio Chivilcoy, Chivilcoy, Argentina, [RECRUITING] | Centro Medico Barrio Parque, Buenos Aires, Argentina, [RECRUITING] | Hospital Privado Universitario de Córdoba, Córdoba, Argentina, [RECRUITING] | Clinica Viedma S. A, Viedma, Argentina, [RECRUITING] | Hospital Privado de Rosario, Rosario, Argentina, [RECRUITING] | Hospital Británico de Buenos Aires, Buenos Aires, Argentina, [RECRUITING] | Clínica de Nefrología, Urología y Enfermedades Cardiovasculares, Santa Fe, Argentina, [RECRUITING] | Instituto D'Or de Pesquisa e Ensino (IDOR) - Filial Salvador, Salvador, Brazil, [RECRUITING] | Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa, Porto Alegre, Brazil, [RECRUITING] | Instituto Joinvilense de Hematologia e Oncologia, Joinville, Brazil, [RECRUITING]",Relapsed or Refractory Multiple Myeloma,2,"[1] MeziVd (mezigdomide, bortezomib and dexamethasone) (EXPERIMENTAL): No description || [2] PVd (pomalidomide, bortezomib and dexamethasone) (EXPERIMENTAL): No description","\- Participant has documented diagnosis of MM and measurable disease, defined as any of the following:. i) M-protein ≥ 0.5 grams per deciliter (g/dL) by serum protein electrophoresis (sPEP) or. ii) M-protein ≥ 200 milligrams (mg) per 24-hour urine collection by urine protein electrophoresis (uPEP). iii) For participants without measurable disease in sPEP or uPEP: serum free light chain (sFLC) levels \> 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda FLC ratio. * Participants received 1 to 3 prior lines of antimyeloma therapy. * Participants achieved minimal response \[MR\] or better to at least 1 prior antimyeloma therapy.","\- Participant has had progression during treatment or within 60 days of the last dose of a proteasome inhibitor, except as noted below:. i) Subjects who progressed while being treated with, or within 60 days of last dose of bortezomib maintenance given once every 2 weeks (or less frequently) are not excluded. ii) Participants who progressed while being treated with ixazomib monotherapy maintenance ≥ 6 months prior to the time of starting study treatment are not excluded. * For participants with prior treatment of a bortezomib containing regimen, the best response achieved was not a minimal response (MR) or better, or participant discontinued bortezomib due to toxicity. * Participant has had prior treatment with mezigdomide or pomalidomide. * Other protocol-defined Inclusion/Exclusion criteria apply."
NCT06614192,"AndroMETa-CRC-064: An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to LONSURF (Trifluridine and Tipiracil) Plus Bevacizumab in Subjects With Refractory Metastatic Colorectal Cancer Expressing c-Met Protein Level Above a Defined Cutoff",,PHASE3,Puerto Rico,"Pan American Center for Oncology Trials /ID# 267888, Rio Piedras, Puerto Rico, [RECRUITING]",Metastatic Colorectal Cancer,4,"[1] Stage 1: Telisotuzumab Adizutecan Dose A (EXPERIMENTAL): Participants will receive telisotuzumab adizutecan dose A, as part of the approximately 4 year study duration. || [2] Stage 1: Telisotuzumab Adizutecan Dose B (EXPERIMENTAL): Participants will receive telisotuzumab adizutecan dose B, as part of the approximately 4 year study duration. || [3] Stage 2: Telisotuzumab Adizutecan Optimal Dose (EXPERIMENTAL): Participants will receive the optimal dose of telisotuzumab adizutecan, as part of the approximately 4 year study duration. || [4] Stage 2: Standard of Care (SOC) (EXPERIMENTAL): Participants will receive the SOC, as part of the approximately 4 year study duration.","* Life expectancy \>= 12 weeks per investigator assessment. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 during the screening period prior to the first dose of the study drug. * Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.","* Prior systemic regimen containing c-MET targeting antibody/bispecific or Antibody Drug Conjugate (c-Met targeting Antibody Drug Conjugate \[ADC\]). * History of allergic reactions or hypersensitivity to bevacizumab or any of its excipients, or to compounds similar to trifluridine/tipiracil. * Active infection as noted in the protocol."
NCT04155034,MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK),,PHASE3,"Chile, Colombia, Mexico","Instituto Nacional del Cancer, Independence, Chile, [RECRUITING] | Instituto Nacional De Cancerologia, Bogotá, Colombia, [RECRUITING] | Instituto Nacional De Cancerologia de Mexico, Mexico City, Mexico, [RECRUITING]",Extensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Lung Small Cell Carcinoma,2,"[1] Arm I (PCI, MRI) (ACTIVE_COMPARATOR): Patients undergo conventional or hippocampal avoidance PCI over 20 minutes 5 days per week for 2 weeks. Patients also undergo MRI scan at 3, 6, 9, 12, 18, and 24 months. || [2] Arm II (MRI) (EXPERIMENTAL): Patients undergo MRI scan at 3, 6, 9, 12, 18, and 24 months.","* Patient must have a histologically confirmed diagnosis of small-cell lung cancer (SCLC) * Patient must have an MRI of the brain performed within 28 days prior to registration documenting no evidence of brain metastases or leptomeningeal disease. Patient also must not have a history of brain metastases or leptomeningeal disease * Immunotherapy concurrent with and/or adjuvant to first-line therapy is allowed at the discretion of the treating physician. Patients with limited-stage (LS)-SCLC must have completed platinum-based chemotherapy and either definitive thoracic radiotherapy (including stereotactic body radiation therapy \[SBRT\] for early-stage T1-2 N0 M0 disease who do not undergo surgery) or definitive surgical resection; thoracic radiation in addition to definitive surgical resection is allowed at the discretion of the treating physician, but is not required. Patients with extensive-stage (ES)-SCLC must have completed platinum-based chemotherapy either with or without thoracic radiotherapy at the discretion of the treating physician * All adverse events from prior treatment must have resolved to =\< grade 2 (Common Terminology Criteria for Adverse Events \[CTCAE\] version 5.0) prior to randomization * Patient must have had a response to first-line therapy and no evidence of progression in opinion of the treating investigator. Systemic imaging (computed tomography \[CT\] or positron emission tomography \[PET\]/CT including the chest and abdomen) must be performed within 28 days prior to randomization * No more than 8 weeks may have elapsed between day 1 of the last cycle of chemotherapy and randomization * Patient must not have received prior radiotherapy to the brain or whole brain radiotherapy. Patients who have undergone prior stereotactic radiosurgery for benign tumors or conditions (e.g., acoustic neuroma, grade I meningioma, trigeminal neuralgia) may be considered on a case-by-case basis * Patient must have Zubrod performance status of 0-2 * Patient mu",
NCT06911502,"A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) Vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma",,PHASE3,"Brazil, Chile","Local Institution - 0159, Vitória, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0088, Niterói, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0087, Porto Alegre, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0079, São Paulo, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0089, Rio de Janeiro, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0066, São Paulo, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0092, São Paulo, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0154, Santiago, Chile, [NOT_YET_RECRUITING] | Local Institution - 0155, Santiago, Chile, [NOT_YET_RECRUITING] | Local Institution - 0153, Santiago, Chile, [NOT_YET_RECRUITING]",Follicular Lymphoma,2,"[1] Golcadomide + Rituximab (EXPERIMENTAL): No description || [2] Rituximab + Lenalidomide/Chemotherapy (ACTIVE_COMPARATOR): Rituximab + Lenalidomide or R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone/prednisolone) or Rituximab + Bendamustine","* Participant has histologically confirmed FL (Grade 1, 2, or 3a) as assessed by local pathology. Adequate fresh tumor biopsy tissue or archived tumor biopsy from the latest relapse if available with corresponding pathology report for retrospective central pathology confirmation of relapse, is required. Evaluation from fine needle aspirate is not permitted. * Relapsed or refractory disease: 1. Relapsed FL is defined as relapse after an initial response of CR or PR to the most recent prior therapy. 2. Refractory FL is defined as best response of SD or PD to the most recent prior therapy. * Eastern Cooperative Oncology Group (ECOG) 0-2 (ECOG 3 authorized if it is due to lymphoma and not comorbidities). * Participant must have positron emission tomography (PET)-positive disease with at least one PET-positive lesion and measurable disease on cross section imaging by CT, as defined by Lugano classification. * Participants with an indication for anti-lymphoma treatment as per investigator assessment based on modified Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria. * Participant has received at least 1 or more prior lines of systemic therapy with one line consisting of a combination including an anti-CD20 monoclonal antibody (eg, rituximab, obinutuzumab) and an alkylating agent (eg, cyclophosphamide, bendamustine). Prior treatment with radiation therapy does not count as a line of therapy for eligibility. * Lab parameters: 1. Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3 (1.0 x 109 /L), 2. PLT count ≥ 75,000 cells/mm3 (75 x 109 /L) 3. Hb ≥ 7.5 g/dL * estimated glomerular filtration rate (eGFR) ≥ 30 ml/min/1.73m². * Serum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT) ≤ 2.5 x upper limit of normal (ULN). In case of documented liver involvement by lymphoma, ALT/SGPT and AST/SGOT must be ≤ 5.0× ULN. * Serum total bilirubin ≤ 1.5 × ULN (corresponding to mild dysfunction as per National Cancer Institute Organ Dysfunction Working Group \[NCI","* Evidence or history of composite Diffuse large B-cell lymphoma (DLBCL) and FL or of transformed Non-Hodgkin Lymphoma (NHL) or any other indolent lymphoma. * Follicular large cell as per 5th World Health Organization (WHO) sub-classification (grade 3b FL per WHO 4th classification) or duodenal-type FL. * Participant has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the participant from compliantly participating in the study based on Investigator's judgment. * Participant has any condition that confounds the ability to interpret data from the study based on Investigator's or Sponsor's judgment. * Presence or history of central nervous system (CNS) involvement by lymphoma. * History of stroke or intracranial hemorrhage within 6 months prior to enrollment. * Deep venous thrombosis/Pulmonary embolism within 1 month prior to enrollment. * Participants with a history of progressive multifocal leukoencephalopathy. * Participant has any other subtype of lymphoma. * Participant has persistent diarrhea or malabsorption ≥ Grade 2 (NCI CTCAE v5.0), despite medical management. * History of another primary malignancy that has not been in remission for ≥ 3 years except for non-invasive malignancies. * Participants who are refractory to both chemotherapies as well as lenalidomide, defined as: 1. SD/progressive disease as best response to CHOP and Bendamustine based immunochemotherapy or a response to CHOP and Bendamustine based immunochemotherapy that lasted less than 6 months AND 2. SD/progressive disease as best response to lenalidomide based regimen or a response to lenalidomide based regimen that lasted less than 6 months. * Other protocol-defined Inclusion/Exclusion criteria apply."
NCT05811195,"Comparison of Two Prophylactic Photobiomodulation Protocols in Chemoinduced Oral Mucositis in Pediatric and Adolescent Oncology Patients: a Randomized, Controlled, Blinded Clinical Trial",,NA,Brazil,"Federal University of Rio Grande do Sul, Porto Alegre, Brazil, [RECRUITING]",Oral Mucositis | Chemotherapeutic Toxicity | Childhood Cancer,2,"[1] Intraoral photobiomodulation (PBMI) (ACTIVE_COMPARATOR): Intraoral application: A low-power laser (Diode Semiconductor, Duo, MMOptics Ltda, São Carlos, SP, Brazil) with a wavelength of 660 nm (red). Four anatomical areas will be irradiated perpendicularl... || [2] Extraoral photobiomodulation (PBME) (ACTIVE_COMPARATOR): A gallium-aluminum arsenide diode laser (Gemini® manufactured by Azena Medical, LLC, distributed by Ultradent Products, Inc.) with double wavelength 810 + 980 nm. The equipment will be programmed w...","* Diagnosis of malignant neoplasia (hematological or solid tumors); * Responsible and participants agree to the study participation after reading and signing the Informed Consent Form (ICF) and Informed Term of Consent (TALE) for participation in Clinical Research; * They performed the chemotherapy infusions hospitalized in the pediatric oncology department of the 3rd east of HCPA; * Received the following chemotherapy protocols: MTX-HD, combination chemotherapy of MTX-HD, doxorubicin and cyclophosphamide; and MTX-HD and cyclophosphamide.",* Participants will be excluded who: * Patients over the age of 18 years * Patients who will undergo HSCT
NCT06452277,"A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations",SOHO-02,PHASE3,"Argentina, Brazil, Mexico","Fundación Cenit para la Investigación en Neurociencias, CABA, Argentina, [WITHDRAWN] | Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, [WITHDRAWN] | Centro de Educacion Medica e Investigaciones Clinicas ""Norberto Quirno"" (CEMIC), Buenos Aires, Argentina, [WITHDRAWN] | Centro Médico Privado CEMAIC, Córdoba, Argentina, [WITHDRAWN] | Instituto Argentino de Diagnostico y Tratamiento (IADT), TBC, Argentina, [WITHDRAWN] | Centro de Investigaciones Clínicas, Clínica Viedma, Viedma, Argentina, [WITHDRAWN] | Rede DoR Recife - PE, Recife, Brazil, [RECRUITING] | Liga Norte Riograndense Contra o Cancer | Centro de Pesquisa Clínica, Natal, Brazil, [RECRUITING] | Irmandade Santa Casa de Misericordia de Porto Alegre | Oncology, Porto Alegre, Brazil, [RECRUITING] | Centro de Pesquisa da Clínica de Oncologia Reichow, Blumenau, Brazil, [RECRUITING]",Advanced Non-small Cell Lung Cancer | HER2 Mutation,2,"[1] BAY2927088 (EXPERIMENTAL): Participants will receive BAY2927088 20 mg BID until disease progression per RECIST v1.1, unacceptable toxicity, or until any other withdrawal criteria. || [2] Standard of care (SoC) (ACTIVE_COMPARATOR): Participants will receive SoC (pembrolizumab in combination with platinum-based chemotherapy, in 21-day cycles per the approved labels) until disease progression per RECIST v1.1, unacceptable toxic...","* Participant must be ≥18 years of age or over the legal age of consent in countries where that is greater than 18 years at the time of signing the informed consent. * Documented histologically or cytologically confirmed locally advanced non-squamous NSCLC, not suitable for definitive therapy or metastatic non-squamous NSCLC at screening (small cell or mixed histologies are excluded) (Stage III-IV NSCLC). * Documented activating HER2 mutation in the tyrosine kinase domain (TKD) assessed by tissue molecular test in a CLIA-certified (US sites) or an equally accredited (outside of the US) local laboratory. However, participants may be included at the discretion of the investigator if the laboratory performing the assay is not CLIA or similar certified but the laboratory is locally accredited. * No prior systemic therapy for locally advanced or metastatic disease. No prior treatment with a HER2 ex20ins-targeted therapy (e.g. poziotinib, trastuzumab deruxtecan). Participants who received adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the start of screening. * Eligible to receive treatment with the selected platinum-based doublet-chemotherapy (i.e. cisplatin/pemetrexed or carboplatin/pemetrexed) and pembrolizumab in accordance with the SmPC/Product Information.","* Known history of prior malignancy except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for five years since initiation of that therapy. Exception: the following cancer types are acceptable within five years if curatively treated or under surveillance: * a. in situ cancers of cervix, breast, or skin, * b. superficial bladder cancer (Ta, Tis and T1), * c. limited-stage prostate cancer, * d. basal or squamous cancers of the skin. * Tumors with targetable alterations with approved available therapy, with the exception of HER2 mutation in the TKD. * Inability to discontinue treatment with chronic systemic corticosteroids. Participants who require intermittent use of bronchodilators, inhaled steroids, or local steroid injections would not be excluded from the study. Replacement therapy (e.g., physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is acceptable, provided that the dose is stable for \>4 weeks prior to planned start of study intervention. * Pre-existing peripheral neuropathy that is Grade ≥2 by CTCAE (v5.0). * History of severe hypersensitivity reaction to treatment with a monoclonal antibody. * Prior radiotherapy outside of the brain within 21 days before of planned start of study intervention. Participants must have recovered from all radiation-related toxicities and not require corticosteroids."
NCT06560697,Randomized Phase II Study to Measure the Safety and Efficacy of Concomitant CT/RT Followed by Ablative Stereotactic Radiotherapy (SABR) vs Brachytherapy in Patients With Cervical Carcinoma in Clinical Stage IB3-IIIC1 at INCAN,SABRVICAL,NA,Mexico,"Instituto Nacional de Cancerologia, Mexico City, Mexico, [RECRUITING]",Uterine Cervical Neoplasm,2,[1] Cervical Boost with SABR (EXPERIMENTAL): patients with CC clinical stages IB3-IIIC1 who will be treated with CT/RT with a minimum dose of 45Gy and boost in the case of macroscopic nodes (1.8Gy per fraction from Monday to Friday) with cisp... || [2] Cervical Boost with Intracavitary Brachytherapy (ACTIVE_COMPARATOR): Patients with CC clinical stages IB3-IIIC1 will be treated with CT/RT with a minimum dose of 45Gy and boost in the case of macroscopic nodes (1.8Gy per fraction from Monday to Friday) with cisplati...,"1. People with cervical cancer \>18 years of age. 2. Signed informed consent form approved by the regulatory committees of both institutes and, obtained before each procedure related to the protocol, and that is not considered part of the normal care of the patient. 3. Able to comply with scheduled visits, treatment schedules, laboratory and imaging studies, and completing quality of life questionnaires. 4. Histological confirmation of CaCu and staged as IB3-IIIC1. 5. Squamous cell, adenosquamous, or adenocarcinoma histology. 6. No prior treatment for cervical cancer. 7. With disease measurable by CT, MRI, or PET/CT according to REC 1.1 criteria. This measurement must be carried out 28 days before randomization. 8. Functional status of 0-2 according to WHO criteria. 9. Charlson Comorbidity Index of 1-4 10. Candidates to receive cisplatin. 11. Normal hematological, kidney, and hepatic function according to: Hematological: Hemoglobin equal to or \>10g/L. (With the possibility of transfusion prior to treatment to reach this hemoglobin level). Leukocytes \>4000/mm3. Platelets\>100,000mm3. Neutrophils \>1500 / μL Hepatic: Total bilirubin \<1.5 X times the normal value. Transaminases \<1.5 X times the normal value. Renal: Creatinine \<1.3mg/dl or creatinine clearance \> 40 mL/minute (using the Cockcroft/Gault formula). Women: DepCr = (140 - Age in years) x Weight in kg x 0.85 \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ 72 x Serum Creatinine in mg/dL Men: DepCr = (140 - Age in years) x Weight in kg x 1.00 \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ 72 x Serum Creatinine in mg/dL 12. Chest tomography without metastatic disease or infectious diseases. 13. Negative pregnancy test in women of childbearing age. 14. Not a candidate for another clinical trial within the institution.","1. Patients with small-cell carcinoma or other rare histologies (glassy cell carcinoma, melanoma, sarcomas, lymphomas) 2. Patients with non-measurable disease. 3. Patients in whom pregnancy is confirmed during the recruitment procedure. 4. Clinical stages IIIC2-IVB. 5. Serious infections or diseases that can be reactivated with the use of chemotherapy or that could limit its use (hepatitis or HIV). 6. Pre-existing neuropathy of any etiology. 7. Concomitant treatment with another experimental drug. 8. Mental illnesses: With the intention of maximizing adherence to the study, those patients who are at risk of imminent physical aggression (evident during the interview), have intellectual disabilities or autism, and who come for consultation due to coercion will not be included in the study. their accompanying Severe major depressive disorder, with or without psychotic symptoms; patients in whom a psychiatric diagnosis coexists in addition to the abuse of some recreational substance, eating disorders, schizophrenia, or Bipolar-type Schizoaffective Disorder. 9. Grade 3 obesity with body mass index \>40kg/m2 according to the World Health Organization: Patients treated with pelvic radiotherapy and a body mass index \>40kg/m2 are associated with a decrease in quality of life due to sexual, intestinal, genitourinary alterations, as well as greater toxicity due to oncological treatments offered such as intracavitary brachyter in which the positioning of the equipment in the vaginal area is significantly difficult in sedated patients. Patients with grade III obesity will not be included. 10. Any patient who is absent from follow-up for 5 subsequent appointments will be excluded from the study. 11. History of total or partial hysterectomy. 12. Patients with a history of neoadjuvant chemotherapy or use of another antineoplastic drug differ from cisplatin (40 mg/m2). 13. History of use of Bevacizumab to manage a pathology other than CC or intention to use this drug as part of the"
NCT04965129,"Effect of Supplementation of Poly-unsaturated n-3 Fatty Acids and High-protein Diet on Epigenetic Modulation of Muscle Mass, Dose-limiting Toxicity and Intestinal Microbiota in Patients With Lung Cancer Submitted to Treatment With Immunotherapy, Chemotherapy and Tyrosine Kinase Inhibitors.",,NA,Brazil,"Federal University of Rio de Janeiro, Rio de Janeiro, Brazil, [RECRUITING]",Lung Cancer,2,"[1] Placebo Comparator: Placebo (PLACEBO_COMPARATOR): Placebo Comparator: Placebo All subjects will be given placebo identically matched with regard to shape, color and taste. They will be given four tablet/day for four mounths. || [2] Experimental: Fish oil (EXPERIMENTAL): All subjects will be given fish oil with a dose of 2.100 mg of EPA and 924 mg of DHA, in four tablet twice daily for four mounths.","* Diagnosis of non-small cell lung cancer, both sexes, ECOG performance status (0-2) eligible for treatment with immunotherapy, chemotherapy and tyrosine Kinase Inhibitors.","* supplementation of PUFA n-3 in the last 6 months; weight loss\> 10% in 6 months, chronic liver disease, previous chronic kidney disease, anorexia, decompensated diabetes mellitus and dementia."
NCT06952660,A PROSPECTIVE LOW-INTERVENTIONAL PHASE 4 SINGLE ARM STUDY OF OCULAR ASSESSMENTS IN PATIENTS TREATED WITH TIVDAK® IN RECURRENT OR METASTATIC CERVICAL CANCER,,PHASE4,Puerto Rico,"Puerto Rico Cancer Specialists Clinical Trials, San Juan, Puerto Rico, [NOT_YET_RECRUITING]",Cervical Cancer,1,[1] Tisotumab vedotin (EXPERIMENTAL): Participants will receive tisotumab vedotin by IV infusion.,1. Must have recurrent or metastatic cervical cancer with disease progression on or after chemotherapy 2. Treating physician has determined that treatment with Tivdak is appropriate for the participant according to US Prescribing Information 3. Must sign an informed consent form indicating that the participant understands the purpose and procedures required for the study and are willing to participate 4. Must be willing to undergo repeated ocular assessments as required by the study and regular clinic visits according to local standard practice of the study site 5. Must agree to use effective contraception according to the US Prescribing Information,"1. Active ocular disease at baseline per investigator assessment 2. Previous treatment with Tivdak 3. Previous administration of an investigational drug within 30 days 4. Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may, in the investigator'"
NCT04537936,Adaptation and Pilot Feasibility of a Psychotherapy Intervention for Latinos With Advanced Cancer,,NA,Puerto Rico,"Ponce Health Sciences University, Ponce, Puerto Rico, [RECRUITING]","Solid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, Adult",2,[1] Meaning Centered Psychotherapy for Latinos (MCP-L) (EXPERIMENTAL): No description || [2] Control (ACTIVE_COMPARATOR): No description,"Phase I: Quantitative * Diagnosed with stages III or IV solid tumor cancer \*(as per self report for ICCAN patients) * Age 18 or older * As per self report, Latino/a or Hispanic ethnicity * As per self report, fluent in oral Spanish (monolingual) or fluent in oral Spanish and English (bilingual) Phase 2: Qualitative * Enrolled in the quantitative phase of study (as seen above) * Completes the quantitative phase questionnaire * Scores above or below the threshold for the Distress Thermometer (DT≥4 or ≤3) * In the judgment of the investigator, willing and able to be interviewed in Spanish only * Agrees to be audio- recorded Phase 3: Provider Feedback * Professionals working in the mental health field; * Have a caseload of five or more Latino cancer patients per month * Able to communicate and read in Spanish * Agrees to be audio or video-recorded Phase 4: Patient Feedback * Diagnosed with stages III or IV solid tumor cancer \*(as per self report for ICCAN patients) * Age 18 or older * As per self report, Latino/a or Hispanic ethnicity * In the judgment of the investigator, willing and able to be interviewed in Spanish only * Agrees to be audio-recorded Phase 5: Pilot RCT * Diagnosed with stages III or IV solid tumor cancer * Age 18 or older * Latino/a or Hispanic ethnicity * Fluent in oral Spanish (monolingual or bilingual) * Scores above the threshold for the Distress Thermometer (DT≥4) * Agrees to be audio-recorded","Phase 1: Quantitative * In the judgment of the treating physician and/or the consenting professional, presence of significant cognitive impairment (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection * In the judgment of the consenting professional, significant or major disabling medical or psychiatric condition sufficient to preclude meaningful informed consent, interview, or completion of assessment measures (patients whose psychiatric disorder is well controlled by treatment will be eligible) Phase 2: Qualitative * In the judgment of the treating physician and/or the consenting professional, presence of significant cognitive impairment (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection * In the judgment of the consenting professional, significant or major disabling medical or psychiatric condition sufficient to preclude meaningful informed consent, interview, or completion of assessment measures (patients whose psychiatric disorder is well controlled by treatment will be eligible) Phase 4: Patient Feedback * Diagnosed with a major disabling medical or psychiatric condition * Unable to understand the consent procedure * Too ill to participate, all as reported by the patient and/or determined by the investigator's judgment. Phase 5: Pilot RCT * Diagnosed with a major disabling medical * Diagnosed with a major disabling psychiatric condition * Unable to understand the consent procedure * Too ill to participate, all as reported by the patient and/or determined by the investigator's judgment"
NCT07167329,"The BELIEVE-VHL Trial: A Real-world Longitudinal Study on Belzutifan's Effectiveness, Pharmacogenetics, and Pharmacoeconomics in Von Hippel-Lindau (VHL) Syndrome Using the HIF2α Inhibitor Belzutifan",BELIEVE-VHL,PHASE2,Brazil,"AC Camargo Cancer Center, São Paulo, Brazil, [RECRUITING]",Von Hippel Lindau | Von Hippel Lindau Disease | Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma | Hemangioblastoma (HB) of the Central Nervous System (CNS) | PNET,1,[1] Oral Belzutifan (WELIREG™) (EXPERIMENTAL): Patients with von Hippel-Lindau Syndrome presenting with lesions or neoplasms requiring treatment with oral Belzutifan (WELIREG™),"* Age ≥ 14 years. * Clinical or genetic confirmation of von Hippel-Lindau (VHL) syndrome. * Presence of measurable or progressive VHL-associated tumors, as defined by RECIST 1.1 or disease-specific imaging criteria. * ECOG performance status of 0-2. * Adequate bone marrow, hepatic, and renal function as defined by laboratory reference values. * Ability to swallow oral medication. * Provision of written informed consent prior to enrollment.","* Age \< 14 years. * Absence of a confirmed diagnosis of von Hippel-Lindau (VHL) syndrome. * Presence of an active malignancy outside the VHL tumor spectrum within the past 3 years, except for adequately treated basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, or other malignancies considered cured for \>2 years. * Known hypersensitivity or allergic reaction to belzutifan or any excipient in the formulation. * History of severe or uncontrolled cardiovascular disease, including but not limited to unstable angina, myocardial infarction within the past 6 months, congestive heart failure requiring treatment, or uncontrolled hypertension. * Active infectious diseases, including HIV, hepatitis B, or hepatitis C. * Immunosuppressed status, whether due to underlying disease or ongoing therapy. * History of significant bleeding disorders, including bleeding diathesis, thrombocytopenia, or coagulopathy. * Radiotherapy administered within 4 weeks prior to study enrollment. * Major surgical procedure, including for VHL-related tumors, within 4 weeks prior to study enrollment, or immediate need for surgical intervention for tumor management. * Malabsorption secondary to prior gastrointestinal surgery or active gastrointestinal disease. * Current use of concomitant medications known to interact with belzutifan and significantly alter its bioavailability. * Anticipated low adherence to or planned interruption of belzutifan therapy."
NCT06467357,"DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer",DESTINY-BTC01,PHASE3,Brazil,"Research Site, Natal, Brazil, [NOT_YET_RECRUITING] | Research Site, Porto Alegre, Brazil, [RECRUITING] | Research Site, Porto Alegre, Brazil, [NOT_YET_RECRUITING] | Research Site, Santa Maria, Brazil, [NOT_YET_RECRUITING] | Research Site, São Paulo, Brazil, [RECRUITING] | Research Site, São Paulo, Brazil, [NOT_YET_RECRUITING] | Research Site, Vitória, Brazil, [NOT_YET_RECRUITING]",Biliary Tract Cancer,3,[1] Trastuzumab deruxtecan + rilvegostomig (EXPERIMENTAL): Trastuzumab deruxtecan (T-DXd; DS-8201a) in combination with rilvegostomig arm || [2] Trastuzumab deruxtecan (EXPERIMENTAL): Trastuzumab deruxtecan (T-DXd; DS-8201a) arm || [3] Standard of Care (ACTIVE_COMPARATOR): Gemcitabine and cisplatin in combination with durvalumab arm,"* Participants must be ≥ 18 years of age at the time of screening. Other age restrictions may apply as per local regulations; * Male and female; * Unresectable, previously untreated, locally advanced or metastatic BTC. Prior treatment in the perioperative and/or adjuvant setting is permissible provided there is \> 6 months (180 days) between the end of adjuvant treatment and the diagnosis of locally advanced or metastatic disease. * histologically confirmed HER2-expressing (IHC 3+ or IHC 2+) BTC; * Provision of FFPE tumor sample that is no older than 3 years; * At least one target lesion assessed by the Investigator based on RECIST v1.1 (randomized portion only); * WHO/ECOG performance status of 0 or 1; * Adequate organ and bone marrow function within 14 days before randomization; * Evidence of post-menopausal status or negative serum pregnancy test for females of childbearing potential; Key","* Prior exposure to other HER2 targeting therapies, ADCs, immune checkpoint inhibitors and therapeutic anticancer vaccines; * histologically confirmed ampullary carcinoma; * history of substance abuse or any other medical conditions such as clinically significant cardiac or psychological conditions; * spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms; * medical history of myocardial infarction within 6 months before randomization/enrollment, symptomatic congestive heart failure (New York Heart Association Class II to IV), unstable angina pectoris, clinically important cardiac arrhythmias, or a recent (\< 6 months) cardiovascular event including stroke; * Serious chronic gastrointestinal conditions associated with diarrhea (eg, active inflammatory bowel disease); active non-infectious skin disease (including any grade rash, urticaria, dermatitis, ulceration, or psoriasis) requiring systemic treatment; * active autoimmune, connective tissue or inflammatory disorders that has required systemic treatment in the past 2 years, or where there is documented, or a suspicion of pulmonary involvement at the time of screening; * Corrected QT interval (QTcF) prolongation to \> 470 msec (females) or \> 450 msec (males) based on average of the screening triplicate 12-lead ECG; * History of (non-infectious) ILD/pneumonitis, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening; * Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder; * Prior pneumonectomy (complete); * Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals; * Active primary immunodeficiency, known uncontrolled active HIV infection or HCV; * Pregnant or breastfeeding female patients, or patients who are planning to "
NCT04858334,"APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation",,PHASE2,Puerto Rico,"Pan American Center for Oncology Trials LLC, San Juan, Puerto Rico, [RECRUITING]",Pancreatic Acinar Cell Carcinoma | Pancreatic Adenosquamous Carcinoma | Pancreatic Squamous Cell Carcinoma | Resectable Pancreatic Acinar Cell Carcinoma | Resectable Pancreatic Adenocarcinoma,2,[1] Arm I (olaparib) (EXPERIMENTAL): Patients receive olaparib PO BID on days 1-28 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT s... || [2] Arm II (placebo) (PLACEBO_COMPARATOR): Patients receive placebo PO BID on days 1-28 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT sc...,"* STEP 0 (PRE-REGISTRATION) INCLUSION CRITERIA * Patient must be \>= 18 years of age on day of consent * Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Patient must have a diagnosis of pancreatic cancer and have successfully undergone a curative intent surgical resection and must have no evidence of recurrent disease as determined by the investigator * NOTE: This includes patients with adenocarcinoma, acinar carcinoma, squamous cell carcinoma adenosquamous and variants thereof. Patients with neuroendocrine tumors are excluded from enrolling * Patient must (1) be planning to receive, (2) be receiving or (3) have received at least three combined months (i.e., 12 weeks) of perioperative (neoadjuvant, adjuvant or a combination of both) systemic, multi-agent chemotherapy. Patients may have had up to 6 months of perioperative systemic therapy as deemed appropriate by their primary treating medical team (patients can have received radiation or chemoradiation in addition to this 6 month course) * Patient must be no more than 12 weeks from their most recent treatment (this may be chemotherapy, radiotherapy or surgery) * Patient must have a known pathogenic or likely pathogenic germline or somatic mutation in BRCA1, BRCA2, or PALB2, as determined by a Clinical Laboratory Improvement Amendments (CLIA) certified or equivalently-accredited laboratory. Mutations must be considered pathogenic or likely pathogenic by a reference database such as ClinVar or OncoKb.org * STEP 1 (RANDOMIZATION) INCLUSION CRITERIA * Patient must have met the eligibility criteria outlined above * Patient must have undergone at least 3 combined months (i.e., 12 weeks) of perioperative (neoadjuvant, adjuvant or a combination of both) systemic, multi-agent chemotherapy. Patients may have had up to 6 months of perioperative systemic therapy as deemed appropriate by their primary treating medical team (patients can have received radiation or chemoradiation in addit",
NCT06174987,A Master Rollover Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s),,PHASE3,Brazil,"Instituto Aericas, Rio de Janeiro, Brazil, [NOT_YET_RECRUITING] | A.C. Camargo Cancer Center, São Paulo, Brazil, [NOT_YET_RECRUITING] | IBCC Nucleo de Pequisa e Ensino, São Paulo, Brazil, [NOT_YET_RECRUITING]",Advanced Cancer | Metastatic Cancer,1,[1] T-DXd (EXPERIMENTAL): Participants who choose to continue treatment with T-DXd may be enrolled. Participants who were on the comparator arm in the parent study will be provided the option to access the drug through stan...,"* Signed informed consent form, prior to the start of any study-specific qualification procedures and willing to comply with all study requirements. * Currently enrolled in a DS or DS/AZ-sponsored parent study that has met EOS definition. * No evidence of progressive disease and determined to have investigator-assessed clinical benefit from continued treatment with a DS or DS/AZ alliance study drug(s).",* Participants with any unresolved/ongoing AE(s) that meets the study drug discontinuation criteria * Participant who has been off T-DXd therapy for \>18 weeks (126 days) between the last dose from the parent study and the initiation of study drug administration on this study
NCT07025213,"Metabolic Effect of a Physical Activity and Dietary Intervention, and Its Association With Musculoskeletal Changes, in Endometrial Cancer Patients Eligible for Staging Surgery, Compared to Patients Not Receiving the Physical Activity Intervention. A Pilot Study.",,NA,Mexico,"Instituto Nacional de Cancerología, México, Mexico, [RECRUITING]",Endometrial Cancer,2,[1] Diet. (ACTIVE_COMPARATOR): This group will only receive recommendations to follow an anti-inflammatory diet. || [2] Diet and exercise. (EXPERIMENTAL): The intervention group will receive both dietary and exercise interventions.,"1. -Ability to understand the nature of the study and provide written informed consent. 2. -Women aged over 18 and under 65 years. 3. -Availability to attend exercise sessions. 4. -Willingness and ability to comply with scheduled visits, the proposed nutritional algorithm, treatment plan, and laboratory tests. 5. -Histologically confirmed diagnosis of endometrioid-type endometrial cancer by biopsy. 6. -Normal electrocardiogram (ECG) result. 7. -No prior oncological treatment. 8. -Body mass index (BMI) greater than 20 kg/m². 9. -Availability of a computed tomography (CT) scan. 10. -Candidates for staging surgery.","1. -Patients with advanced clinical stage or stage IVB disease (according to FIGO 2018 criteria). 2. -Patients with a prior or concurrent malignancy, except non-melanoma skin cancer. 3. -Patients with uncontrolled systemic arterial hypertension. 4. -Patients with renal dysfunction (eGFR ≤ 60 mL/min/1.73 m²). 5. -Patients with uncontrolled psychiatric disorders, including claustrophobia. 6. -Patients with concurrent infections. 7. -Patients with autoimmune disease. 8. -Patients with neuromuscular disease. 9. -Contraindications to physical exercise. 10. -Vulnerable situations (e.g., homelessness preventing adherence to diet, or incarceration)."
NCT04294927,TUBectomy With Delayed Oophorectomy as Alternative for Risk-reducing Salpingo-oophorectomy in High Risk Women to Assess the Safety of Prevention: TUBA-WISP II Study.,TUBA-WISP-II,NA,"Brazil, Mexico, Uruguay","AC Camargo Cancer Centre, São Paulo, Brazil, [RECRUITING] | Instituto Nacional de Cancerología, Mexico City, Mexico, [RECRUITING] | Hospital Británico, Montevideo, Uruguay, [RECRUITING]",BRCA1 Gene Mutation | BRCA2 Gene Mutation | RAD51C Gene Mutation | RAD51D Gene Mutation | BRIP1 Gene Mutation,2,[1] Risk-reducing salpingectomy with delayed oophorectomy (EXPERIMENTAL): Risk-reducing salpingectomy after the completion of childbearing with delayed oophorectomy. || [2] Risk-reducing salpingo-oophorectomy (ACTIVE_COMPARATOR): Risk-reducing salpingo-oophorectomy.,"* Women with a class 5 (definitely pathogenic) BRCA1, BRCA2, RAD51C, RAD51D or BRIP1 germline mutation in one of the participating centers. * Age at inclusion; * BRCA1: 25-40 years * BRCA2: 25-45 years * RAD51C, RAD51D, BRIP1: 25-50 years * Childbearing completed * Presence of at least one fallopian tube * Participants may have a personal history of non-ovarian malignancy * Informed consent must be obtained and documented according to national and local regulatory requirements and the local rules followed in the institution.","* Postmenopausal status (natural menopause or due to treatment) * Wish for second stage RRO within two years after RRS * Legally incapable * Prior bilateral salpingectomy * A personal history of ovarian, fallopian tube or peritoneal cancer * Current diagnosis or treatment for malignant disease"
NCT05566795,"LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy",,PHASE3,Brazil,"Grupo de Apoio ao Adolescente e à Criança com Câncer (GRAACC), São Paulo, Brazil, [RECRUITING]",Low-grade Glioma | Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma | Pediatric Low-grade Glioma,2,[1] Tovorafenib (EXPERIMENTAL): No description || [2] Investigator's choice of Standard of care therapy (ACTIVE_COMPARATOR): No description,* Less than 25 years of age with LGG with known activating RAF alteration. * Histopathologic diagnosis of glioma or glioneuronal tumor. * At least one measurable lesion as defined by RANO criteria. * Meet indication for first-line systemic therapy.,"* Participant has any of the following tumor-histological findings: 1. Schwannoma 2. Subependymal giant cell astrocytoma (Tuberous Sclerosis) 3. Diffuse intrinsic pontine glioma, even if histologically diagnosed as World Health Organization (WHO) Grade I-II * Participant's tumor has additional pathogenic molecular alterations, including but not limited to a) isocitrate dehydrogenase (IDH) 1/2 mutation, b) Histone H3 mutation, and c) neurofibromatosis Type 1 (NF-1) loss of function alteration. * Known or suspected diagnosis of NF-1/ neurofibromatosis Type 2 (NF-2). * Prior or ongoing nonsurgical anticancer therapy for this indication (eg, chemotherapy, oral/IV targeted therapy) including radiation."
NCT06435286,"Effectiveness and Performance of a Mobile, Automated, Optical Biopsy Technology for Esophageal Cancer Screening: A Clinical Study in Brazil and the United States",,PHASE2,Brazil,"Hospital de Cancer de Barretos - Fundacao Pio XII, Barretos, Brazil, [RECRUITING] | Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil, [RECRUITING]",Suspected or Known Squamous Cell Neoplasia | Prior History of Squamous Cell Dysplasia and /or Neoplasia,1,"[1] Artificial Intelligence Mobile High Resolution Microendoscope (AI-mHRME) imaging (EXPERIMENTAL): All subjects will receive White Light Imaging (WLI) and Lugol's Chromoendoscopy (LCE), the current standard of care (SOC) procedure. Following LCE, all subjects will receive the artificial intellig...","* Outpatients undergoing routine (standard of care) Lugol's chromoendoscopic screening for squamous cell neoplasia will be eligible for enrollment, including patients with a known history of head/neck squamous cell cancer; heavy smoking and alcohol, other dietary or geographic risk factors or prior dysplasia * Patients \>18 years old. * Patients of any sex or gender. * Patients who are willing and able to give informed consent.","* Allergy or prior reaction to the fluorescent contrast agent proflavine hemisulfate. * Patients who are unable to give informed consent. * Known advanced squamous cell carcinoma of the distal esophagus or dysplastic/suspected malignant esophageal lesion greater than or equal to 2 cm in size not amenable to endoscopic therapy. * Patient unable to undergo routine endoscopy with biopsy: * Women who are pregnant or breast feeding, * Prothrombin time greater than 50% of control; PTT greater than 50 sec, or INR greater than 2.0, * Inability to tolerate sedated upper endoscopy due to cardio-pulmonary instability or other significant medical issues."
NCT07023627,"A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression",,PHASE2,Puerto Rico,"Panoncology Trials, San Juan, Puerto Rico, [RECRUITING]",Ovarian Cancer,3,[1] Cohort 1 (EXPERIMENTAL): INCB123667 will be administered at the protocol defined dose based on their tumor cyclin E1 expression levels as defined in the protocol. || [2] Cohort 2 (EXPERIMENTAL): INCB123667 will be administered at the protocol defined dose based on their tumor cyclin E1 expression levels as defined in the protocol. || [3] Cohort 3 (EXPERIMENTAL): INCB123667 will be administered at the protocol defined dose based on their tumor cyclin E1 expression levels as defined in the protocol.,"* Histological diagnosis of a high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. * Have platinum-resistant disease: * Participants who have only had 1 line of platinum-based therapy must have received at least 4 cycles of a platinum-containing regimen. * Participants who have received 2 to 4 lines of platinum-based therapy must have progressed on or within 6 months after the last dose of platinum. * Archival FFPE tumor tissue block or slides from a specimen no older than 5 years must be available. If not available, participant must be willing to undergo a pretreatment tumor biopsy. * Received at least 1 and no more than 4 prior lines of systemic therapy following the initial diagnosis, after which single-agent therapy is considered an appropriate next therapeutic option. * Must have received bevacizumab unless there was a contraindication for its use. * If the tumor tests positive for FRα, participants must have received mirvetuximab soravtansine unless there is an exception for its use on medical grounds.","* Have endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of these histologies, or low-grade/borderline ovarian cancer. * Have primary platinum-refractory disease: either did not respond (CR or PR) to first-line platinum-containing therapy or progressed on or within 3 months after the last dose of the first line platinum-containing therapy. * The tumor tests positive for FRα but the participant has not received mirvetuximab soravtansine for any reason other than medical contraindication. * Clinically significant or uncontrolled cardiac disease within 6 months before the first dose of study drug. * Known active CNS metastases and/or carcinomatous meningitis. * Known additional malignancy that is progressing or requires active treatment. Other protocol-defined Inclusion/Exclusion Criteria may apply."
NCT06576986,"Effect of Synbiotic Supplementation on the Prevention of Mucositis in Cancer Patients Undergoing Chemotherapy: Randomized, Double-masked, Parallel, Single-center Clinical Trial",,NA,Brazil,"Escola de Enfermagem - UFMG, Belo Horizonte, Brazil, [RECRUITING]",Colo-rectal Cancer,4,"[1] Capecitabine alone control (PLACEBO_COMPARATOR): n the Control Group, patients received Maltodextrin as supplementation || [2] Capecitabine alone synbiotic (EXPERIMENTAL): In the Intervention Group, patients received the symbiotic Simbioflora as supplementation. || [3] Capecitabine associated with control Oxaliplatin (PLACEBO_COMPARATOR): n the Control Group, patients received Maltodextrin as supplementation || [4] Capecitabine associated with synbiotic Oxaliplatin (EXPERIMENTAL): In the Intervention Group, patients received the symbiotic Simbioflora as supplementation.",* Colorectal tumor in the first oncological treatment * Age over 18 years old * Both sexes * Eligible for protocol with capecitabine alone or associated with oxaliplatin * Patients WITHOUT colostomy or WITH colostomy in the transverse/descending/sigmoid region * Patient undergoing Radiotherapy treatment associated with Chemotherapy * Patients residing in Belo Horizonte and the metropolitan region * Patients who Accept and sign the Informed Consent Form (TCLE),* Diagnosis of gastrointestinal carcinoid and stromal tumor (GIST) * Patients with Ileostomy * Patients with colostomy in the ascending region of the colon * Inflammatory bowel diseases: Crohn's and Colitis * Use of antibiotics and antifungals in the last 15 days * Use of prebiotic/probiotic and/or synbiotic in the last 15 days * Use of antidiarrheal medication in the last 15 days * Presence of fever and mucus discharge * Pregnant or breastfeeding women * Patients who refuse to participate in the study.
NCT07044336,Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4 Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (Bluestar-Endometrial01),,PHASE3,"Argentina, Brazil","Research Site, Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Research Site, Capital Federal, Argentina, [NOT_YET_RECRUITING] | Research Site, La Rioja, Argentina, [NOT_YET_RECRUITING] | Research Site, Pergamino, Argentina, [NOT_YET_RECRUITING] | Research Site, Rio de Janeiro, Brazil, [NOT_YET_RECRUITING] | Research Site, Sorocaba, Brazil, [NOT_YET_RECRUITING]",Endometrial Cancer | Malignant Solid Tumour,2,"[1] Puxitatug Samrotecan (EXPERIMENTAL): P-Sam IV (intravenous) Q3W . || [2] Chemotherapy (ACTIVE_COMPARATOR): Physician's choice of chemotherapy

Doxorubicin IV Q3W or Paclitaxel IV on Days 1, 8, and 15 in 28 day cycles.","* Histologically confirmed diagnosis of endometrial carcinoma or carcinosarcoma. * Recurrent/metastatic EC ie, with radiological or objective evidence of recurrence or progression. * Has received prior platinum-based chemotherapy and anti-programmed cell death 1 protein (PD-1)/anti- programmed cell death ligand 1 (PD-L1) therapy, either separately or in combination. * A WHO/ECOG performance status of 0 or 1 at Screening. * Has radiographically measurable disease by RECIST 1.1","* Had uterine sarcomas or uterine neuroendocrine carcinoma. * Has had a recurrence of endometrial carcinoma or carcinosarcoma more than \> 12 months after completing platinum-based therapy administered in the curative-intent setting without any additional platinum-based therapy received in the recurrent setting. * Had previously received treatment with any therapy (approved or investigational) that contained a TOP1i including ADCs . * Had previously received treatment with AZD8205 or another B7-H4 targeting agent. * History of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. * Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses. * Active or previously documented autoimmune or inflammatory disorders"
NCT05911295,"An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy in Subjects With Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (IHC 1+ and Greater)",,PHASE3,"Argentina, Brazil, Chile, Peru","Clinica Viedma, Viedma, Argentina, [RECRUITING] | Fundación Dr. Ruben Kowalyszyn, Viedma, Argentina, [RECRUITING] | Comisión Provincial de Evaluación de Proyectos de Investigación en Salud Humana (CEEPISH), Viedma, Argentina, [RECRUITING] | Centro de Oncologia e Investigacion de Buenos Aires (COIBA), Berazategui, Argentina, [RECRUITING] | Instituto Médico Especializado Alexander Fleming, Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Centro Medico Austral, Buenos Aire, Argentina, [RECRUITING] | Centro Oncologico Korben, Buenos Aire, Argentina, [RECRUITING] | Fundacion Cenit, CABA, Argentina, [RECRUITING] | Investigaciones Clinicas Moleculares (ICM), CABA, Argentina, [RECRUITING] | CEMAIC - Centro Medico Privado, Córdoba, Argentina, [RECRUITING]",Urothelial Carcinoma,2,[1] Disitamab vedotin arm (EXPERIMENTAL): disitamab vedotin + pembrolizumab || [2] Standard of care arm (ACTIVE_COMPARATOR): gemcitabine + cisplatin OR carboplatin,"* Histopathological confirmation of locally advanced unresectable or metastatic urothelial carcinoma (LA/mUC), including UC originating from the renal pelvis, ureters, bladder, or urethra. * Measurable disease by investigator assessment per RECIST v1.1. * Participant must not have received prior systemic therapy for LA/mUC. Exception will be made for neoadjuvant or adjuvant therapy, if disease recurrence/progression occurred more than 12 months after the last dose of therapy. * Eligible to receive cisplatin- or carboplatin-containing chemotherapy. * Able to provide archived formalin-fixed paraffin-embedded tumor tissue blocks from a muscle-invasive or metastatic UC lesion or biopsy of metastatic UC prior to treatment initiation. If archival tissue is not available a newly obtained baseline biopsy of an accessible tumor lesion is required within 28 days of cycle 1 day 1. * HER2 expression of 1+ or greater on immunohistochemistry (IHC). * Eastern Cooperative Oncology Group (ECOG) performance score of 0, 1, or 2 within 7 days prior to randomization.","* Known hypersensitivity to disitamab vedotin, cisplatin, carboplatin, gemcitabine, or pembrolizumab or any of their components. * History of severe/life threatening immune-related adverse event (irAE) with PD-(L)1 inhibitors are excluded. * Central nervous system (CNS) and/or leptomeningeal metastasis. Participants with treated CNS metastases are permitted if all of the following are met. * CNS metastases have been clinically stable for at least 4 weeks and baseline scans show no evidence of new or worsening CNS metastasis. * Participant is on a stable dose of ≤ 10 mg/day of prednisone or equivalent for at least 2 weeks. * History of or active autoimmune disease that has required systemic treatment in the past 2 years. * Prior treatment with an agent directed to another stimulatory or co-inhibitory T cell receptor (including but not limited to CD137 agonists, CAR-T cell therapy, CTLA-4 inhibitors, or OX-40 agonists). * Prior solid organ or bone marrow transplantation. * Pleural effusion or ascites with symptoms or requiring symptomatic treatment. * Estimated life expectancy \<12 week * Prior treatment with an MMAE agent or anti-HER2 therapy"
NCT06868277,"A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients With PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04)",ARTEMIDELung04,PHASE3,"Argentina, Brazil, Colombia","Research Site, Córdoba, Argentina, [NOT_YET_RECRUITING] | Research Site, Rosario, Argentina, [NOT_YET_RECRUITING] | Research Site, Blumenau, Brazil, [NOT_YET_RECRUITING] | Research Site, Fortaleza, Brazil, [NOT_YET_RECRUITING] | Research Site, Ijuí, Brazil, [NOT_YET_RECRUITING] | Research Site, Itajaí, Brazil, [NOT_YET_RECRUITING] | Research Site, Londrina, Brazil, [NOT_YET_RECRUITING] | Research Site, Passo Fundo, Brazil, [NOT_YET_RECRUITING] | Research Site, Porto Alegre, Brazil, [NOT_YET_RECRUITING] | Research Site, Porto Alegre, Brazil, [NOT_YET_RECRUITING]","Carcinoma, Non-Small Cell Lung",2,[1] Arm A (EXPERIMENTAL): Drug: rilvegostomig || [2] Arm B (ACTIVE_COMPARATOR): Drug: Pembrolizumab,"* Histologically or cytologically documented NSCLC (non small lung cancer), including all histological subtypes. * Stage IV mNSCLC (metastatic non-small cell lung cancer) (based on the American Joint Committee on Cancer Edition 8) not amenable to curative treatment. * Absence of sensitizing EGFR (epidermal growth factor) mutations and ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) rearrangements. Negative assay result is required for all non-squamous histology subtypes. * Absence of documented tumor genomic mutation results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved targeted 1L (first line) therapies. * WHO (World Health Organization)/ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1, with no deterioration over the previous 2 weeks prior to baseline at screening and prior to randomization. * Minimum life expectancy of 12 weeks. * Provision of acceptable tumor sample for the central testing prior to randomization. * At least one lesion not previously irradiated that qualifies as a RECIST 1.1 (Response Evaluation Criteria in Solid Tumors, Version 1.1) TL (target lesion) at baseline and can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have short axis ≥ 15 mm) with CT (computed tomography) or MRI (magnetic resonance imaging) and is suitable for accurate repeated measurements. * Adequate organ and bone marrow function","* As judged by the investigator, any severe or uncontrolled systemic diseases, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol. * History of organ transplant. * Active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment. * History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥ 2 years before the first dose of study intervention and of low potential risk for recurrence. * Presence of small cell and neuroendocrine histology components. * Brain metastases unless asymptomatic, stable, and not requiring steroids or anticonvulsants for at least 4 weeks prior to start of study intervention. * Active primary immunodeficiency/active infectious disease(s) * Active tuberculosis infection * Any prior systemic therapy received for advanced or mNSCLC (metastatic non-small cell lung cancer). * Any prior exposure to an anti-TIGIT (T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain) therapy or any other anticancer therapy targeting immune-regulatory receptors or mechanisms. * Any prior treatment with an anti-PD-1 (programmed cell death protein 1) or anti-PD-L1 (anti-programmed death-ligand 1) agent."
NCT05379595,"A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer",OrigAMI-1,"PHASE1, PHASE2",Puerto Rico,"Ad Vance Medical Research, Ponce, Puerto Rico, [RECRUITING] | Pan American Center for Oncology Trials LLC, Rio Piedras, Puerto Rico, [RECRUITING]",Advanced or Metastatic Colorectal Cancer,4,"[1] Cohorts A, B, and C: Amivantamab Monotherapy (EXPERIMENTAL): Participants with left-sided colorectal cancer (CRC) in Cohort A (no prior anti-epidermal growth factor receptor \[EGFR\] therapy) and in Cohort B (post anti-EGFR therapy), and right-sided CRC in C... || [2] Cohorts Ph1b-D and D: Amivantamab+5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) (ACTIVE_COMPARATOR): Participants who are anti-EGFR treatment naïve, have not received oxaliplatin-based chemotherapy in the metastatic setting, will be administered IV infusion of amivantamab 1050 or 700 mg (dose leve... || [3] Cohorts Ph1b-E and E: Amivantamab+5-Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) (ACTIVE_COMPARATOR): Participants who are anti-EGFR treatment naïve, have not received irinotecan-based chemotherapy in the metastatic setting, will be administered IV infusion of Amivantamab along with FOLFIRI SOC che... || [4] Cohort F: Amivantamab + mFOLFOX6 (ACTIVE_COMPARATOR): Participant who are treatment-naïve for right-sided unresectable or metastatic CRC. Participants will receive Amivantamab along with mFOLFOX6 SoC chemotherapy.","* Participant must have been previously diagnosed with histologically or cytologically confirmed unresectable or metastatic adenocarcinoma of the colon or rectum * Participant must have tumor previously characterized as having wild-type Kirsten rat sarcoma viral oncogene (KRAS), neuroblastoma RAS viral oncogene homolog (NRAS), v-raf murine sarcoma viral oncogene homolog B (BRAF), and without evidence of Erb-b2 receptor tyrosine kinase 2/human epidermal growth factor receptor 2 (ERBB2/HER2) amplification. Additional cohort-specific requirements: * Phase (Ph) 2 (Cohorts A, B, and C) Amivantamab monotherapy: Participant must have received at least 2 but not more than 3 prior lines of systemic therapy in the metastatic setting. Participant must have been diagnosed with left-sided colorectal cancer (CRC) (Cohort A and B) and right-sided (Cohort C)and have received or been intolerant to standard of care (SoC) fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and an anti-vascular endothelial growth factor (VEGF) treatment. Participant must be anti-EGFR treatment naive in Cohort A, an anti-epidermal growth factor receptor (EGFR) treatment Cohort B, with or without an anti-EGFR treatment in Cohort C * Ph 1b Dose Confirmation Cohorts (Ph1b-D and Ph1b-E), Ph2 (Cohorts D and E) Amivantamab+mFOLFOX6/FOLFIRI: Participant must been diagnosed with CRC and have received no more than 1 prior line of systemic therapy in the metastatic setting. Cohort Ph1b-D/Cohort D: Participant must be anti-EGFR treatment naïve, have not received oxaliplatin-based chemotherapy in the metastatic setting, and be eligible for treatment with mFOLFOX6 according to local regulatory approvals and SoC guidelines. Cohort Ph1b-E/Cohort E: Participant must be anti-EGFR treatment naïve, have not received irinotecan-based chemotherapy in the metastatic setting, and be eligible for treatment with FOLFIRI according to local regulatory approvals and SoC guidelines * Ph2 Cohorts F Amivantamab subcuta","* Cohorts A, B, C, Ph1b-D, D, Ph1b-E, and E: Participant with identified mutation in Kirsten rat sarcoma viral oncogene (KRAS), neuroblastoma RAS viral oncogene homolog (NRAS), v-raf murine sarcoma viral oncogene homolog B (BRAF), or epidermal growth factor receptor (EGFR) ectodomain, or ERBB2/HER2 amplification by central circulating tumor deoxyribonucleic acid (ctDNA) testing at screening; Cohort F: Participant with identified mutation in KRAS, NRAS, BRAF V600, or PTEN, identified fusions in ALK, ROS-1, RET, and NTRK 1, ERBB2/HER2 amplification, or identified to have MSI-H status by central ctDNA testing at screening * Participant with symptomatic or untreated brain metastasis * History or known presence of leptomeningeal disease * Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (for example, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments"
NCT04540692,NEOSAMBA Clinical Trial - Stage I,NEOSAMBA,PHASE3,Brazil,"Hospital Evangélico de Cachoeiro de Itapemirim - Centro de Pesquisas Clínicas em Oncologia (CPCO), Cachoeiro de Itapemirim, Brazil, [RECRUITING] | Santa Casa de Misericórdia da Bahia - Hospital Santa Izabel, Salvador, Brazil, [RECRUITING] | Centro de Pesquisa do Hospital Araújo Jorge, Goiânia, Brazil, [RECRUITING] | ICTR - Instituto do Câncer e Transplante de Curitiba, Curitiba, Brazil, [RECRUITING] | HUEM/CEON - Hospital Universitário Evangélico Mackenzie, Curitiba, Brazil, [RECRUITING] | Hospital Erasto Gaertner, Curitiba, Brazil, [RECRUITING] | IMIP - Instituto de Medicina Integral Professor Fernando Figueira, Recife, Brazil, [RECRUITING] | Hospital Universitário Oswaldo Cruz (UNIPECLIN), Recife, Brazil, [RECRUITING] | HINJA - Hospital Jardim Amália, Volta Redonda, Brazil, [RECRUITING] | HCPA - Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil, [RECRUITING]",Breast Cancer,2,"[1] Start with Cyclophosphamide + Doxorrubicin (ACTIVE_COMPARATOR): Patients will receive the following treatment schedule: Doxorubicin 60mg/m²; Cyclophosphamide 600mg/m² intravenously every 21 days for 3 cycles, followed by docetaxel 75-100mg/m2 intravenously ever... || [2] Start with Docetaxel or Paclitaxel (EXPERIMENTAL): Patients will receive the following treatment schedule: Docetaxel 75-100mg/m² intravenously every 21 days for 4 cycles or weekly paclitaxel 80mg/m² for 12 weeks, followed by Doxorubicin 60mg/m²; Cy...","* Female participants, with at least 18 years old on the day of signing the free and informed consent; * Invasive breast carcinoma stage III (RH positive) or IIB/III (RH negative), according to TNM 8th edition; Histologically confirmed diagnosis of invasive breast carcinoma (with any histology), HER-2 negative; * The participant (or legally acceptable representative, if applicable) provides written informed consent for the study; * The participant must agree to use a contraceptive as detailed in Appendix B of this protocol during the treatment period and for at least 120 days after the last dose of the study treatment; * Have a functional capacity according to the Eastern Cooperative Oncology Group (ECOG) from 0 to 2. The evaluation of the ECOG must be carried out within 7 days before the inclusion date. * Have adequate organic function. The samples must be collected within 60 days before the start of the study treatment; * Have adequate cardiac function as assessed by echocardiogram or MUGA performed up to 60 days before the start of treatment under study.",\- Individuals who do not meet the inclusion criteria above-mentioned.
NCT06841354,"A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10 (TroFuse-011)",,PHASE3,"Argentina, Brazil, Chile, Colombia","Instituto de Investigaciones Clinicas Mar del Plata ( Site 2401), Mar del Plata, Argentina, [RECRUITING] | Instituto Alexander Fleming ( Site 2402), Mar del Plata, Argentina, [RECRUITING] | Clinica Viedma ( Site 2403), Viedma, Argentina, [RECRUITING] | Fundacion Estudios Clinicos ( Site 2405), Rosario, Argentina, [RECRUITING] | Hospital Italiano de Cordoba ( Site 2406), Córdoba, Argentina, [RECRUITING] | Fundacion Centro Oncologico de Integración Regional ( Site 2400), Mendoza, Argentina, [RECRUITING] | Hospital de Câncer de Recife ( Site 2300), Recife, Brazil, [RECRUITING] | Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 2301), São Jose Do Rio Preto, Brazil, [RECRUITING] | IC La Serena Research ( Site 2007), La Serena, Chile, [RECRUITING] | FALP ( Site 2000), Santiago, Chile, [RECRUITING]",Triple Negative Breast Neoplasms,3,"[1] Arm A: Sacituzumab Tirumotecan (EXPERIMENTAL): Participants receive sacituzumab tirumotecan intravenously (IV) at a dose of 4 mg/kg every 2 weeks (Q2W) until disease progression, toxicity or discontinuation. || [2] Arm B: Sacituzumab Tirumotecan + Pembrolizumab (EXPERIMENTAL): Participants receive sacituzumab tirumotecan IV 4 mg/kg Q2W until disease progression, toxicity or discontinuation PLUS pembrolizumab IV 400 mg every 6 weeks (Q6W) for up to 18 administrations (up ... || [3] Arm C: Treatment of Physician's Choice (TPC) (ACTIVE_COMPARATOR): Participants receive physician's choice of chemotherapy agent(s): paclitaxel IV 80 mg/m\^2 once every week (Q1W) OR paclitaxel IV 90 mg/m\^2 on Days 1, 8, and 15, every 4 weeks (Q4W) OR nab-paclita...","The main inclusion criteria include but are not limited to the following: * Has locally recurrent unresectable or metastatic TNBC that cannot be treated with curative intent * Has not received systemic treatment for locally recurrent unresectable or metastatic breast cancer * Participants previously treated for early-stage breast cancer must have completed all prior therapy for early-stage breast cancer with curative intent at least 6 months before the first disease recurrence * Is a candidate for treatment with pembrolizumab and one of the TPC options: paclitaxel or nab-paclitaxel or gemcitabine + carboplatin * Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline with the exception of alopecia or vitiligo. Participants with endocrine-related AEs who are adequately treated with hormone replacement are eligible * Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load * Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable","The main exclusion criteria include but are not limited to the following: * Has breast cancer amenable to treatment with curative intent * Has TNBC with evaluable tumor programmed death ligand 1 (PD-L1) expression at combined positive score (CPS) ≥10 * Has received prior systemic therapy for treatment of locally recurrent unresectable or metastatic breast cancer * Has Grade ≥2 peripheral neuropathy * Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing * Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease * Has uncontrolled, significant cardiovascular disease or cerebrovascular disease * Has skin only metastatic disease * Has advanced/metastatic, symptomatic visceral spread at risk of rapidly evolving into life-threatening complications * Human immunodeficiency virus (HIV)-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Has known additional malignancy that is progressing or has required active treatment within the past 5 years * Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable * Active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed * History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease * Concurrent active Hepatitis B (defined as HBsAg positive and/or detectable HBV deoxyribonucleic acid (DNA)) and Hepatitis C virus (HCV) (defined as anti-HCV antibody (Ab) positive and detectable HCV ribonucleic acid (RNA)) infection * History of stem cell/solid organ transplant * Has not adequately r"
NCT07039877,Efficacy of Low-dose Venetoclax With Itraconazole + TACL in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia,,PHASE2,Mexico,"Hospital Universitario Dr. Jose E. Gonzalez, Monterrey, Mexico, [RECRUITING]",Acute Lymphobkastic Leukemia | Acute Lymphoblastic Leukaemia Recurrent | Philadelphia Chromosome Negative ALL,1,"[1] TACL plus low dose Venetoclax and Itraconazole (EXPERIMENTAL): Salvage chemotherapy will be assigned as follows:

* Venetoclax 100 mg orally every day for 7 days
* Itraconazole 100 mg orally every 12 hours for 7 days
* Vincristine 1.4 mg/m2 intravenously on da...","* B-cell or T-cell acute lymphoblastic leukemia. * Philadelphia chromosome negative * Relapsed disease after any line of treatment, defined as detection of disease activity at any time after remission * Refractory disease after first-line treatment, defined as: more than 5% blasts after completion of induction/consolidation by flow cytometry * Not having included venetoclax in any prior regimen. * No prior organ damage, defined as the absence of any serious, life-threatening disease prior to the start of treatment. * Performance status defined by the ECOG scale between 0 and 2.","* Isolated CNS relapse. * Performance status defined by ECOG scale between 3 and 4. * CTCAE-classified sensory or motor neuropathy of grade 3 or higher. * History of hypersensitivity or intolerance to the drugs included in the regimen. * Prior organ damage, defined as the presence of any serious, life-threatening illness prior to the start of treatment."
NCT06501261,Preliminary Efficacy and Acceptability of CALM Psychotherapy in Chile,CALM-Ch,NA,Chile,"Fundacion Arturo Lopez Perez, Providencia, Chile, [RECRUITING]",Metastatic Cancer,1,[1] CALM arm (EXPERIMENTAL): patients receiving CALM sessions,* be ≥18 years of age; * be fluent in Spanish; * be able to give informed consent; and * have received a diagnosis of advanced or metastatic solid tumor cancer with a reduced life expectancy but greater than six months.,* significant verbal communication difficulties; * cognitive impairment indicated by the clinical team or in the patient's file. * Patients currently in psychotherapy. * Active suicidal ideation
NCT06074588,"A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations",,PHASE3,"Brazil, Chile, Mexico","Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 0447), Natal, Brazil, [ACTIVE_NOT_RECRUITING] | Hospital Nossa Senhora da Conceição-Centro Integrado de Pesquisa em Oncologia ( Site 0440), Porto Alegre, Brazil, [ACTIVE_NOT_RECRUITING] | Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0444), Barretos, Brazil, [ACTIVE_NOT_RECRUITING] | Hospital Paulistano-Americas Oncologia ( Site 0441), São Paulo, Brazil, [ACTIVE_NOT_RECRUITING] | A. C. Camargo Cancer Center-CAPEC ( Site 0442), São Paulo, Brazil, [ACTIVE_NOT_RECRUITING] | Núcleo de Pesquisa Clínica da Rede São Camilo ( Site 0446), São Paulo, Brazil, [ACTIVE_NOT_RECRUITING] | Clinica Universidad Catolica del Maule-Oncology ( Site 0501), Talca, Chile, [ACTIVE_NOT_RECRUITING] | Centro de Estudios Clínicos SAGA ( Site 0517), Santiago, Chile, [ACTIVE_NOT_RECRUITING] | Orlandi Oncologia-Oncology ( Site 0504), Santiago, Chile, [ACTIVE_NOT_RECRUITING] | FALP-UIDO ( Site 0509), Santiago, Chile, [ACTIVE_NOT_RECRUITING]",Non-small Cell Lung Cancer (NSCLC),2,"[1] Sacituzumab tirumotecan (EXPERIMENTAL): Participants will receive 4 mg/kg of sacituzumab tirumotecan via intravenous (IV) infusion on Days 1, 15 and 29 of each 6-week cycle. Additionally, participants receive diphenhydramine (or equivale... || [2] Chemotherapy (ACTIVE_COMPARATOR): Participants will receive 75 mg/m\^2 of docetaxel or 500 mg/m\^2 of pemetrexed by IV infusion on Days 1 and 22 of every 6-week cycle.","* Histologically- or cytologically-documented advanced (Stage III not eligible for resection or curative radiation) or metastatic non-squamous NSCLC with specific mutations. * Documentation of locally assessed radiological disease progression while on or after last treatment based on Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1. * Participants with genome mutations must have received 1 or 2 prior lines of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), including a third generation TKI for participants with a T790M mutation; and 1 platinum-based therapy after progression on or after EGFR TKI. * Measurable disease per RECIST 1.1 as assessed by the local site investigator. * Archival tumor tissue sample or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated has been provided * Participants who have AEs due to previous anticancer therapies must have recovered to Grade ≤1 or baseline. * Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to randomization. * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy. * Have an ECOG performance status of 0 or 1 within 3 days before randomization.","* Has predominantly squamous cell histology NSCLC. * Has mixed tumor(s) with small cell elements. * Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease. * Has Grade ≥2 peripheral neuropathy. * Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or corneal disease that prevents/delays corneal healing. * Has uncontrolled, significant cardiovascular disease or cerebrovascular disease. * Has an EGFR T790M mutation and has not received a third generation EGFR TKI (eg, osimertinib). * Received prior systemic anticancer therapy including investigational agents within 4 weeks or 5 half-lives (whichever is shorter) before randomization. * Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. * Completed palliative radiotherapy within 7 days of the first dose. Participants must have recovered from all radiation-related toxicities and not require corticosteroids. * Received radiation therapy to the lung that is \>30 Gy within 6 months of the first dose of study intervention. * Received prior treatment with a trophoblast cell-surface antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC). * Received prior treatment with a topoisomerase I-containing ADC. * Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration. * Known additional malignancy that is progressing or has required active treatment within the past 3 years. * Active infection requiring systemic therapy. * History of noninfectious pneumonitis/ILD that required steroids or has current pneumonitis/ILD. * Has known active central nervous system metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are clinically stable, radiologically stable for at least 4 weeks and do not require glucocorticoids for"
NCT06698042,"A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Versus Intravenous Pembrolizumab, in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS 50% or Greater",,PHASE3,"Guatemala, Peru","MEDI-K ( Site 1101), Guatemala City, Guatemala, [RECRUITING] | CELAN,S.A ( Site 1104), Guatemala City, Guatemala, [RECRUITING] | Private Practice- Dr. Rixci Augusto Lenin Ramírez ( Site 1102), Guatemala City, Guatemala, [RECRUITING] | Centro Medico Integral De Cancerología (CEMIC) ( Site 1103), Quetzaltenango, Guatemala, [RECRUITING] | Clínica San Antonio ( Site 1006), Trujillo, Peru, [RECRUITING] | Clínica Internacional - Sede San Borja ( Site 1002), Lima, Peru, [RECRUITING] | IPOR Instituto Peruano de Oncología & Radioterapia ( Site 1004), Lima, Peru, [RECRUITING] | Oncosalud ( Site 1000), Lima, Peru, [RECRUITING]",Lung Cancer | Non-Small Cell Lung Cancer,2,"[1] Pembrolizumab (+) Berahyaluronidase alfa (EXPERIMENTAL): Pembrolizumab (+) Berahyaluronidase alfa SC will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course. || [2] Pembrolizumab (ACTIVE_COMPARATOR): ""Pembrolizumab by IV Infusion will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course,",* Histologically or cytologically confirmed diagnosis of squamous or nonsquamous non-small cell lung cancer (NSCLC). * Measurable disease as assessed by the local site investigator/radiology.,"* Diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements. * Received prior systemic anticancer therapy for their metastatic NSCLC. * Known additional malignancy that is progressing or has required active treatment within the past 3 years. * Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. * Active autoimmune disease that has required systemic treatment in the past 2 years. * History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease. * Active infection requiring systemic therapy."
NCT06120283,"A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors",,PHASE1,Brazil,"Fundacao Pio Xii Hospital de Amor de Barretos, Barretos, Brazil, [RECRUITING] | Hospital Sirio Libanes Brasilia, Brasília, Brazil, [RECRUITING] | Centro de Pesquisas Oncologicas Cepon, Florianópolis, Brazil, [RECRUITING] | Liga Norte Riograndene Contra O Cancer, Natal, Brazil, [RECRUITING] | Fundacao Universidade de Caxias Do Sul Instituto de Pesquisas Em Saude, Petrópolis, Brazil, [RECRUITING] | Hospital Sao Lucas Da Pucrs Uniao Brasileira de Educacao E Assistencia, Porto Algre, Brazil, [RECRUITING] | Instituto Nacional de Cancer, Rio de Janeiro, Brazil, [RECRUITING] | Instituto Dor de Pesquisa E Ensino Hospital Sao Rafael, Salvador, Brazil, [RECRUITING] | Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira, São Paulo, Brazil, [RECRUITING] | Clinica de Pesquisa E Centro de Estudos Em Oncologia Ginecologica E Mamaria, São Paulo, Brazil, [RECRUITING]",Advanced Solid Tumor | Advanced Breast Cancer | Metastatic Breast Cancer | Hormone-receptor-positive Breast Cancer | Hormone Receptor Positive Breast Carcinoma,2,"[1] Dose Escalation and Safety Expansion (EXPERIMENTAL): Phase 1a: Sequential cohorts of increasing dose levels of BGB-43395 will be evaluated as monotherapy and in combination with either fulvestrant, letrozole, or elacestrant to assess for safety and t... || [2] Dose Expansion (EXPERIMENTAL): Phase 1b: The recommended dose for expansion (RFDE) for BGB-43395 (in combination with fulvestrant or letrozole) from Phase 1a will be evaluated in HR+ breast cancer and selected tumor-specific coh...","* Phase 1a (Dose Escalation) and 1b (Dose Expansion): Participants with histologically or cytologically confirmed advanced, metastatic, or unresectable solid tumors associated with dependency on CDK4, including HR+ breast cancer, ovarian cancer, endometrial cancer, non-small cell lung cancer, and others. * Phase 1a: Received prior therapy for their condition (if available) and should be refractory to, or intolerant of standard-of-care therapies. In regions where approved and available, participants with HR+ breast cancer must have received at least 2 prior lines of treatment including endocrine therapy and a CDK4/6 inhibitor. For combination with elacestrant, participants must have received at least 1 prior line of treatment for advanced/metastatic disease including prior endocrine therapy and CDK4/6 inhibitor in either the adjuvant or advanced/metastatic setting. * Phase 1b: Selected tumor cohorts will include HR+/HER2- breast cancer and additional tumor types. * Phase 1b: Participants with HR+/HER2- breast cancer enrolled in regions where CDK4/6 inhibitors are approved and available must have received at least one line of therapy for advanced disease including endocrine therapy and a CDK4/6 inhibitor. Participants can have received up to 2 lines of prior cytotoxic chemotherapy for advanced disease. * Stable Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1. * Female participants with metastatic HR+/HER2- breast cancer must be postmenopausal or receiving ovarian function suppression treatment. * Adequate organ function without symptomatic visceral disease.","* Prior therapy selectively targeting CDK4 (prior CDK4/6 inhibitor therapy is permitted and required in local regions where it is approved and available). * Known leptomeningeal disease or uncontrolled, untreated brain metastases. * Any malignancy ≤ 3 years before the first dose of study treatment(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast). * Uncontrolled diabetes. * Infection requiring systemic antibacterial, antifungal, or antiviral therapy ≤ 28 days before the first dose of study drug(s), or symptomatic COVID-19 infection. * Participants with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers with HBV DNA ≥ 500 IU/mL (or ≥ 2500 copies/mL) at screening. * Participants with active hepatitis C infection. * Prior allogeneic stem cell transplantation, or organ transplantation. Note: Other protocol defined Inclusion/Exclusion criteria may apply."
NCT05984277,"A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).",eVOLVE-Lung02,PHASE3,"Argentina, Brazil, Mexico","Research Site, Buenos Aires, Argentina, [WITHDRAWN] | Research Site, CABA, Argentina, [RECRUITING] | Research Site, CABA, Argentina, [COMPLETED] | Research Site, CABA, Argentina, [SUSPENDED] | Research Site, Córdoba, Argentina, [RECRUITING] | Research Site, Córdoba, Argentina, [RECRUITING] | Research Site, La Plata, Argentina, [RECRUITING] | Research Site, La Plata, Argentina, [RECRUITING] | Research Site, Rosario, Argentina, [RECRUITING] | Research Site, Barretos, Brazil, [RECRUITING]",Metastatic Non-small Cell Lung Cancer,2,[1] Arm 1 (EXPERIMENTAL): Volrustomig plus histology-specific chemotherapy (carboplatin plus either pemetrexed or paclitaxel) via iv infusion || [2] Arm 2 (ACTIVE_COMPARATOR): Pembrolizumab plus histology-specific chemotherapy (carboplatin plus either pemetrexed or paclitaxel) via iv infusion,"* Histologically or cytologically documented squamous or non-squamous NSCLC. * Stage IV NSCLC (according to Version 8 of the IASLC Staging Manual in Thoracic Oncology 2016), not amenable to curative surgery or radiation. * Absence of sensitizing EGFR mutations and ALK and ROS1 rearrangements. * Absence of documented tumor genomic alteration results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved targeted first-line therapies. Key","* Mixed small-cell lung cancer and NSCLC histology or sarcomatoid variant. Rare subtypes are excluded. * Spinal cord compression. * Symptomatic brain metastases. Brain metastases may be treated or untreated, but participants must be asymptomatic and off steroids for at least 14 days prior to start of study intervention. A minimum of 2 weeks must have elapsed between the end of brain radiotherapy and study enrollment. * History of another primary malignancy except for: 1. Malignancy treated with curative intent with no known active disease ≥ 2 years before the first dose of study intervention and of low potential risk for recurrence. 2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease. 3. Adequately treated carcinoma in situ without evidence of disease. * As judged by the investigator, any condition that would interfere with evaluation of the study intervention or interpretation of participant safety or study results."
NCT06806852,A Phase Ib Open Label Randomised Clinical Trial to Evaluate Safety and Efficacy of BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Compared With Pembrolizumab Monotherapy for the First-line Treatment of Patients With Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC),,PHASE1,"Brazil, Mexico","Hospital de Amor, Barretos, Brazil, [RECRUITING] | Liga Norte Riograndense contra o cancer, Natal, Brazil, [RECRUITING] | Fundação Faculdade Regional de Medicina de São José do Rio Preto, São José do Rio Preto, Brazil, [RECRUITING] | Unidad Clinica Farmacologica Bioemagno, Mexico City, Mexico, [NOT_YET_RECRUITING] | Instituto Nacional de Cancerologia, México, Mexico, [NOT_YET_RECRUITING] | Centro Oncológico Internacional, Tlajomulco de Zuñiga, Mexico, [NOT_YET_RECRUITING]",Head and Neck Squamous Cell Carcinoma,3,[1] Pembrolizumab (EXPERIMENTAL): No description || [2] Pembrolizumab + BI 770371 (EXPERIMENTAL): No description || [3] Pembrolizumab + BI 770371 + Cetuximab (EXPERIMENTAL): No description,"* Patients with histologically confirmed metastatic or recurrent HNSCC of the primary tumour location of oral cavity, oropharynx, hypopharynx, and larynx not amenable to locoregional treatment with curative intent. * Willingness to provide pretreatment (baseline) biopsy/tissue to the sponsor (fresh or archival one). A newly obtained biopsy is preferred but an archival sample is acceptable, with tumor tissue (formalin fixed paraffin embedded \[FFPE\] block preferred, or at least 10 freshly sectioned unstained FFPE slides) from a core or excisional biopsy. Any deviation from this rule requires approval by the sponsor. Details on the requirements for archival tumour tissue and on biopsy sample collection are provided in the Laboratory Manual. * Patients who have not received prior systemic treatment for metastatic or recurrent HNSCC. Systemic therapy (including cetuximab) which was completed more than 6 months prior to progression of disease if given as part of multimodal treatment for locally advanced disease is allowed. * Patients who do not have contraindications to pembrolizumab monotherapy according to pembrolizumab local label, guidelines, treatment standards, regulations or the document (label of another country if pembrolizumab local label is not available) provided in the investigator site file (ISF) by the sponsor. * Patients who do not have contraindications to treatment with cetuximab according to cetuximab local label, guidelines, treatment standards, regulations, or the document (label of another country if cetuximab local label is not available) provided in the ISF by the sponsor. * Presence of at least one measurable non-central nervous system (CNS) lesion (according to RECIST v1.1.). * Further inclusion criteria apply.","* Nasopharyngeal carcinoma (NPC) of any histology, primary tumour location at nasal cavity, paranasal sinuses of any histology, any cancer of unknown primary. * Any tumour location necessitating an urgent therapeutic intervention (e.g., palliative care, surgery, or radiation therapy), such as spinal cord compression, other compressive mass, uncontrolled painful lesion, bone fracture. * Patients with progressive HNSCC within 6 months of completion of systemic therapy for locoregionally advanced disease with curative intent. * Receiving treatment for brain metastases or leptomeningeal disease (LMD) which may interfere with safety and/or endpoint assessment. Patients with previously diagnosed brain metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to trial entry, have discontinued corticosteroid treatment for these metastases and are clinically stable, off anticonvulsants for at least 4 weeks and are neurologically stable before enrollment. * Patients for whom single agent pembrolizumab is not the preferred treatment (e.g. patients for whom chemotherapy or anti-PD-1 in combination with chemotherapy is considered the preferred therapy by the investigator or treating physician). * Prior treatment with any anti signal regulatory protein alpha (SIRPα) or anti-integrin-associated protein (CD47) agent, regardless of treatment intent. * Prior cancer treatment with any anti PD-1 or anti PD-L1 agent or with an agent directed to another stimulatory or co-inhibitory Tcell receptor (e.g. CTLA-4, OX 40, CD137), regardless of treatment intent. * Prior allogeneic stem cell or solid organ transplantation. * Further exclusion criteria apply."
NCT05458297,"A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (waveLINE-006)",,PHASE2,"Brazil, Chile, Peru","Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 1807), Natal, Brazil, [RECRUITING] | Instituto Nacional de Câncer - INCA-Divisão de Pesquisa Clínica e Desenvolvimento Tecnológico HC1 ( Site 1809), Rio de Janeiro, Brazil, [RECRUITING] | ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 1808), São Paulo, Brazil, [RECRUITING] | Hospital Paulistano-Americas Oncologia ( Site 1805), São Paulo, Brazil, [RECRUITING] | IC La Serena Research ( Site 1909), La Serena, Chile, [RECRUITING] | Centro de Estudios Clínicos SAGA-CECSAGA ( Site 1907), Santiago, Chile, [RECRUITING] | Clínica Inmunocel ( Site 1910), Santiago, Chile, [RECRUITING] | Clínica Alemana de Santiago ( Site 1903), Santiago, Chile, [RECRUITING] | Centro Medico Monte Carmelo ( Site 1702), Arequipa, Peru, [RECRUITING] | INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS ( Site 1700), Lima, Peru, [RECRUITING]",Chronic Lymphocytic Leukemia | Mantle Cell Lymphoma | Follicular Lymphoma | Richter Transformation Lymphoma,5,"[1] Cohort A, Relapsed or Refractory MCL with 2 Prior Lines of Therapy (EXPERIMENTAL): Participants will receive zilovertamab vedotin intravenous (IV) infusion at Dose 1 every 3 weeks (Q3W) until disease progression or discontinuation. || [2] Cohort B, Relapsed or Refractory RT with 1 Prior Line of Therapy (EXPERIMENTAL): Participants will receive zilovertamab vedotin IV infusion at Dose 1 every 3 weeks (Q3W) until disease progression or discontinuation. || [3] Cohort C, Relapsed or Refractory MCL with 1 Prior Line of Therapy (EXPERIMENTAL): Participants will receive zilovertamab vedotin IV infusion at Dose 2 every 3 weeks (Q3W) combined with nemtabrutinib oral dose daily until disease progression or discontinuation. || [4] Cohort D, Relapsed or Refractory FL and CLL with 2 Prior Lines of Therapy (EXPERIMENTAL): Participants will receive either zilovertamab vedotin IV infusion Dose 1 every 3 weeks (Q3W) until disease progression or discontinuation. || [5] Cohort E, Relapsed or Refractory FL with 2 Prior Lines of Therapy (EXPERIMENTAL): Participants will receive either zilovertamab vedotin IV infuison Dose 1 every 3 weeks (Q3W) until disease progression or discontinuation.","* For aggressive B-cell malignancies mantle cell lymphoma (MCL): Has histologically confirmed biopsy according to the 2016 World Health Organization (WHO) classification of neoplasms of the hematopoietic and lymphoid tissues and has relapsed or refractory disease after at least 2 prior systemic therapies including a Bruton's tyrosine kinase inhibition/inhibitor(s) (BTKi), and is post chimeric antigen receptor T (CAR-T) cell therapy or is ineligible for CAR-T cell therapy. * For aggressive B-cell malignancies MCL Cohort C: Has histologically confirmed biopsy according to the 2016 World Health Organization (WHO) classification of neoplasms of the hematopoietic and lymphoid tissues and has relapsed or refractory disease after at least 1 prior systemic therapy and has no prior exposure to a non-covalent BTKi. * For aggressive B-cell malignancies Richter transformation lymphoma (RTL): Has histologically confirmed biopsy according to the 2016 World Health Organization (WHO) classification of neoplasms of the hematopoietic and lymphoid tissues and has relapsed or refractory disease. * For indolent B-cell malignancies follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL): Has histologically confirmed biopsy and has relapsed or refractory disease after at least 2 prior systemic therapies and no other available therapy. * Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization/allocation. * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 assessed within 7 days before cycle 1 day 1.","* Has received solid organ transplant at any time. * Has clinically significant (ie, active) cardiovascular disease: cerebral vascular accident/stroke (\<6 months prior to enrollment), myocardial infarction (\<6 months prior to enrollment), unstable angina (\<6 months prior to enrollment), congestive heart failure (New York Heart Association Classification Class ≥II), or serious cardiac arrhythmia requiring medication. * Has pericardial effusion or clinically significant pleural effusion. * Has ongoing Grade \>1 peripheral neuropathy. * Has a demyelinating form of Charcot-Marie-Tooth disease. * Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years. * Participants with FL who have transformed to a more aggressive type of lymphoma. * Has received prior systemic anticancer therapy within 5 half-lives or 4 weeks (if prior therapy was a monoclonal antibodies) or 2 weeks (if prior therapy was small molecules like kinase inhibitors) prior to the first dose of study intervention. * Has received prior radiotherapy within 28 days of start of study intervention. Participants must have recovered from all radiation-related toxicities. * Has ongoing corticosteroid therapy exceeding 30 mg daily of prednisone equivalent. * Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. * Has known active central nervous system (CNS) lymphoma involvement or active CNS involvement by lymphoma. * Has an active infection requiring systemic therapy. * Has a known history of human immunodeficiency virus (HIV) infection not well controlled on antiretroviral therapy (ART) * Active HBV or hepatitis C virus (HCV) infection. * For Cohort C only: has any clinically significant gastrointestinal abnormalities that might alter absorption."
NCT05734820,Real-time Computer-aided Polyp/Adenoma Detection During Screening Colonoscopy: a Single-center Crossover Trial,,NA,Ecuador,"Instituto Ecuatoriano de Enfermedades Digestivas (IECED), Guayaquil, Ecuador, [RECRUITING]",Colorectal Polyp | Colorectal Cancer | Colorectal Adenoma,2,[1] HD-colonoscopy + AI-HD colonoscopy (EXPERIMENTAL): This group is comprised by patients \>45 years of age submitted for diagnostic colonoscopy. In the same session a HD-colonoscopy will be performed followed by an HD-colonoscopy with artificial inte... || [2] AI-HD colonoscopy + HD-colonoscopy (EXPERIMENTAL): This group is comprised by patients \>45 years of age submitted for diagnostic colonoscopy. In the same session a HD-colonoscopy assisted by artificial intelligence will be performed followed by an...,"* Adults ≥45 years old * Patients referred for screening colonoscopy * Adequate bowel preparation, Boston Bowel Preparation Scale (BBPS) ≥8 * Patients who authorized for endoscopic approach.",* Pregnancy * Any clinical condition which makes endoscopy inviable. * Patients with history of Colorectal Carcinoma. * Patients with history of Inflammatory Bowel Disease (IBD) * Inability to provide informed consent
NCT05170204,"A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer",HORIZON 1,PHASE3,"Brazil, Chile, Colombia, Costa Rica, Mexico","Crio - Centro Regional Integrado de Oncologia, Fortaleza, Brazil, [WITHDRAWN] | Hospital Sao Rafael - HSR, Salvador, Brazil, [WITHDRAWN] | Instituto do Cancer Brasil, Três Lagoas, Brazil, [WITHDRAWN] | Oncocentro Belo Horizonte, Belo Horizonte, Brazil, [ACTIVE_NOT_RECRUITING] | COT - Centro Oncologico do Triangulo, Uberlândia, Brazil, [WITHDRAWN] | Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil, [ACTIVE_NOT_RECRUITING] | Hospital Nossa Senhora da Conceicao, Porto Alegre, Brazil, [RECRUITING] | Clínica de Oncologia Reichow, Blumenau, Brazil, [ACTIVE_NOT_RECRUITING] | Hospital de Cancer de Barretos, Barretos, Brazil, [RECRUITING] | Instituto do Cancer do Estado de Sao Paulo - ICESP, São Paulo, Brazil, [RECRUITING]",Non-Small Cell Lung Cancer,4,"[1] Cohort A1: ALK-Positive (alectinib arm) (EXPERIMENTAL): Participants will receive alectinib 600 mg orally twice daily until completion of treatment period (3 years), or until disease progression, unacceptable toxicity, patient or physician decision to d... || [2] Cohort A1: ALK-positive (durvalumab arm) (ACTIVE_COMPARATOR): Participants will receive 1500 mg of intravenous (IV) durvalumab every 4 weeks until completion of treatment period (1 year) or until disease progression, unacceptable toxicity, patient or physicia... || [3] Cohort A2: ROS 1-positive (entrectinib arm) (EXPERIMENTAL): Participants will receive entrectinib 600 mg orally once daily until completion of treatment period (3 years), or until disease progression, unacceptable toxicity, patient or physician decision to ... || [4] Cohort A2: ROS 1-positive (durvalumab arm) (ACTIVE_COMPARATOR): Participants will receive 1500 mg of IV durvalumab every 4 weeks until completion of treatment period (1 year) or until disease progression, unacceptable toxicity, patient or physician decision to ...","* NSCLC known to have a known or likely oncogenic-driver mutation in the EGFR gene, as identified by site local testing or Sponsor central testing * Liver disease, characterized by any of the following: impaired excretory function (e.g., hyperbilirubinemia), synthetic function, or other conditions of decompensated liver disease, such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices or active viral or active autoimmune, alcoholic, or other types of acute hepatitis * Positive hepatitis B surface antigen (HBsAg) test at screening * Participants known to be positive for hepatitis C virus (HCV) antibody (Ab) are excluded with the following exception: participants who are HCV Ab positive but HCV RNA negative due to prior treatment or natural resolution are eligible * HIV infection: participants are excluded if not well-controlled as defined by the protocol * Known active tuberculosis * History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on the screening chest CT scan * Grade \>/= 2 pneumonitis from prior cCRT or sCRT * Any Grade \> 2 unresolved toxicity from prior cCRT or sCRT * Any gastrointestinal (GI) disorder that may affect absorption of oral medications, such as malabsorption syndrome or status post-major bowel resection * Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications * Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren sy",
NCT04994717,"Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study)",,PHASE3,"Brazil, Chile, Mexico","Igesd Instituto de Gestao Estrategica da Saude do Distrito Federal, Brasília, Brazil, [RECRUITING] | Hospital das Clinicas da Universidade Federal de Goias, Goiânia, Brazil, [RECRUITING] | Hospital das Clinicas de Porto Alegre, Porto Alegre, Brazil, [RECRUITING] | Fundacao Amaral Carvalho, Jaú, Brazil, [RECRUITING] | Hosp Clin Fac Med Ribeirao Preto Usp, Ribeirão Preto, Brazil, [RECRUITING] | Hospital de Base de Sao Jose do Rio Preto, São Jose Do Rio Preto, Brazil, [RECRUITING] | Hemorio, Rio de Janeiro, Brazil, [RECRUITING] | Instituto Cancer Sao Paulo Icesp, São Paulo, Brazil, [RECRUITING] | Fundacion Arturo Lopez Perez, Santiago, Chile, [RECRUITING] | Inmunocel, Santiago, Chile, [RECRUITING]",Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL),3,[1] Safety Run-in: Blinatumomab alternating with low-intensity chemotherapy (EXPERIMENTAL): The safety run-in will be performed prior to initiating the phase 3 randomized part of the study. This safety run-in is to evaluate the safety and tolerability of blinatumomab alternating with low-... || [2] Phase 3: Blinatumomab alternating with low-intensity chemotherapy (EXPERIMENTAL): Participants will receive blinatumomab alternating with low-intensity chemotherapy. || [3] Phase 3: Standard of care (SOC) chemotherapy (ACTIVE_COMPARATOR): Participants will receive 1 of 2 SOC chemotherapy regimens (GMALL or HyperCVAD) per investigator's choice.,"\- Age ≥ 55 years at the time of informed consent. OR Age 40 to \< 55 years of age if at least 1 of the following comorbidities at the time of informed consent: * history of grades 3 and 4 pancreatitis * diabetes mellitus with end-organ damage * severe liver disease such as cirrhosis stage 2 with portal hypertension or history of esophageal variceal bleeding and aspartate transaminase (AST)/alanine aminotransferase (ALT) \> 10 x upper limit of normal (ULN) (liver cirrhosis must be confirmed by biopsy) * body mass index (BMI) ≥ 40 combined with relevant comorbidities such as metabolic syndrome * Any further combination of documented severe comorbidities that the investigator judges to be incompatible with administering an intensive pediatric based, adult adapted standard chemotherapy regimen but still compatible with the suggested protocol for older participants in both the experimental and the SOC arm. The participant history will be reviewed by the medical monitor during screening to determine enrollment acceptability based on a standard list with types of comorbidities allowed. * Participants with newly diagnosed Philadelphia (Ph)-negative B-cell precursor acute lymphoblastic leukemia (ALL) * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2, higher ECOG score allowed if due to underlying leukemia * All participants must have adequate organ function as defined below: * renal: estimated glomerular filtration rate based on MDRD calculation ≥ 50 mL/min/1.73 m\^2 * liver function: total bilirubin ≤ 2x upper limit of normal (ULN; unless Gilbert's Disease or if liver involvement with leukemia); exception for participants 40 to \< 55 years of age if they have a comorbidity listed above: severe liver disease such as cirrhosis stage 2 with portal hypertension or history of esophageal variceal bleeding and AST/ALT \> 10 x ULN (liver cirrhosis must be confirmed by biopsy) * cardiac: left ventricular ejection fraction (LVEF) ≥ 50% and no clinically significant,","* Active central nervous system (CNS) leukemia (i.e., CNS 3 leukemia, confirmed by lumbar puncture) not resolved with IT chemotherapy during screening. * History of other malignancy within the past 3 years, with the following exceptions: * Malignancy treated with curative intent and with no known active disease present for ≥ 3 years before enrollment and felt to be at low risk for recurrence by the treating physician * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease * Adequately treated cervical carcinoma in situ without evidence of disease * Adequately treated breast ductal carcinoma in situ without evidence of disease * Prostatic intraepithelial neoplasia without evidence of prostate cancer * Adequately treated urothelial papillary noninvasive carcinoma or carcinoma in situ * Clinically relevant CNS pathology or event such as epilepsy, childhood or adult seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychiatric conditions that preclude the use of high dose of corticosteroids * Current autoimmune disease or history of autoimmune disease with potential CNS involvement * Known infection with human immunodeficiency virus (HIV) * Known infection with chronic or active infection with hepatitis B (eg, hepatitis b surface \[HBs\] antigen reactive or quantifiable hepatitis b virus \[HBV\] viral load) or hepatitis C virus (HCV) (eg, HCV RNA \[qualitative\] is detected). Active hepatitis B and C based on the following results: * positive for hepatitis B surface antigen (HepBsAg) (indicative of chronic hepatitis B or recent acute hepatitis B) * negative HepBsAg and positive for hepatitis B core antibody: negative HBV DNA by PCR result is necessary to enroll. * positive Hepatitis C virus antibody (HepCAb): negative hepatitis C virus RNA by PCR result is necessary to enroll. * Participant with symptoms and/or clinical signs and/or radiographic and"
NCT04482309,"A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)",DPT02,PHASE2,Brazil,"Research Site, Barretos, Brazil, [WITHDRAWN] | Research Site, Curitiba, Brazil, [WITHDRAWN] | Research Site, Natal, Brazil, [WITHDRAWN] | Research Site, Porto Alegre, Brazil, [RECRUITING] | Research Site, Porto Alegre, Brazil, [WITHDRAWN] | Research Site, Porto Alegre, Brazil, [WITHDRAWN] | Research Site, Ribeirão Preto, Brazil, [WITHDRAWN] | Research Site, São Paulo, Brazil, [RECRUITING] | Research Site, Vitória, Brazil, [RECRUITING]","Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer | Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer",12,"[1] Part 1 Cohort 1 (EXPERIMENTAL): Biliary tract cancer || [2] Part 1 Cohort 2 (EXPERIMENTAL): Bladder cancer || [3] Part 1 Cohort 3 (EXPERIMENTAL): Cervical cancer || [4] Part 1 Cohort 4 (EXPERIMENTAL): Endometrial cancer || [5] Part 1 Cohort 5 (EXPERIMENTAL): Ovarian cancer || [6] Part 1 Cohort 6 (EXPERIMENTAL): Pancreatic cancer || [7] Part 1 Cohort 7 (EXPERIMENTAL): Rare tumors || [8] Part 2 Cohort A (EXPERIMENTAL): Any tumor type that is HER2 IHC 3+ (excluding breast, gastric cancer, and colorectal cancer) || [9] Part 2 Cohort B (EXPERIMENTAL): Any tumor type that is HER2 IHC 2+/ISH+ (excluding breast, gastric cancer, and colorectal cancer) || [10] Part 2 Cohort C (EXPERIMENTAL): HER2 IHC 2+ or 1+ endometrial cancer","* Locally advanced, unresectable, or metastatic disease based on most recent imaging. * Part 1:The respective cohorts for patient inclusion are: * Cohort 1: Biliary tract cancer * Cohort 2: Bladder cancer * Cohort 3: Cervical cancer * Cohort 4: Endometrial cancer * Cohort 5: Epithelial ovarian cancer * Cohort 6: Pancreatic cancer * Cohort 7: Rare tumors: This cohort will consist of patients with tumors that express HER2, excluding the tumors mentioned above, and breast, non-small cell lung cancer, gastric cancer, and colorectal cancer. * Part 2:The respective cohorts for patient inclusion are: * Cohort A: Metastatic or advanced solid tumors that are HER2 IHC 3+ (excluding breast, gastric cancer, and colorectal cancer). Patients with non-small cell lung cancer can be included. * Cohort B: Metastatic or advanced solid tumors that are HER2 IHC 2+/ISH+ any tumor type (excluding breast, gastric cancer, and colorectal cancer). Patients with non-small cell lung cancer can be included. * Cohort C: Metastatic or advanced solid endometrial cancer that is HER2 IHC 2+ or 1+. * Cohort D: Metastatic or advanced ovarian cancer that is HER2 IHC 2+ or 1+. * Cohort E: Metastatic or advanced solid cervical cancer that is HER2 IHC 2+ or 1+. * Progressed following prior treatment or who have no satisfactory alternative treatment option. * Prior HER2 targeting therapy is permitted. * HER2 expression scored using current ASCO/CAP guidelines for scoring HER2 for gastric cancer. * Part 1: IHC 3+ or IHC 2+ by local or central assessment * Part 2: IHC and ISH results by central assessment as pre-defined for each cohort * Has measurable target disease assessed by the Investigator based on RECIST version 1.1. * Has protocol- defined adequate organ function including cardiac, renal and hepatic function.","* History of non-infectious pneumonitis/ILD that required steroids, current ILD, or where suspected ILD that cannot be ruled out by imaging at screening * Lung-specific intercurrent clinically significant severe illnesses * Uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or antifungals * Pleural effusion, ascites or pericardial effusion that requires drainage, peritoneal shunt, or Cell-free and Concentrated Ascites Reinfusion Therapy (CART * Known Somatic DNA mutation of HER2 (ERBB2) without tumoral HER2 protein expression. * Primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the colon or rectum, adenocarcinoma of the gastric body or gastro-esophageal junction, or non-small cell lung cancer for Part 1. For Part 2, patients with primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the colon or rectum, adenocarcinoma of the gastric body or gastro-esophageal junction will be excluded. * Medical conditions that may interfere with the subject's participation in the study."
NCT05827016,"A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplantation (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance)",,PHASE3,"Argentina, Brazil, Chile, Colombia, Mexico","Hospital Italiano de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina, [RECRUITING] | ""Centro de Educación Médica e Investigaciones Clínicas """"Norberto Quirno"""""", Ciudad Autonoma Buenos Aires, Argentina, [RECRUITING] | Local Institution - 0259, Mar del Plata, Argentina, [WITHDRAWN] | Hospital Universitario Austral, Pilar, Argentina, [RECRUITING] | Sanatorio Allende, Córdoba, Argentina, [RECRUITING] | Local Institution - 0245, Curitiba, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0214, Niterói, Brazil, [NOT_YET_RECRUITING] | Instituto Nacional de Câncer, Rio de Janeiro, Brazil, [RECRUITING] | Local Institution - 0081, Ribeirão Preto, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0277, São Paulo, Brazil, [NOT_YET_RECRUITING]",Multiple Myeloma,4,[1] Arm A1: Iberdomide Dose 1 (EXPERIMENTAL): No description || [2] Arm A2: Iberdomide Dose 2 (EXPERIMENTAL): No description || [3] Arm A3: Iberdomide Dose 3 (EXPERIMENTAL): No description || [4] Arm B: Lenalidomide (ACTIVE_COMPARATOR): No description,"* Confirmed diagnosis of symptomatic multiple myeloma (MM). * Eastern Cooperative Oncology Group performance status (ECOG) score of 0, 1, or 2. * Received 3 to 6 cycles of an induction therapy that includes a proteasome inhibitor (PI) and immunomodulatory (IMiD) \[eg, bortezomib thalidomide and dexamethasone (VTd), lenalidomide, bortezomib and dexamethasone (RVd)\] with or without a CD38 monoclonal antibody, daratumumab + bortezomib/thalidomide/dexamethasone \[D-VTd\] and daratumumab + bortezomib/ lenalidomide/dexamethasone \[D-VRd\]), or VCd / daratumumab + bortezomib/cyclophosphamide/dexamethasone \[D-VCd\], and followed by a single or tandem autologous stem cell transplantation (ASCT). Post-stem cell transplant consolidation is permitted. * Participants within 12 months (single transplant) or 15 months (tandem transplant) from initiation of induction therapy who achieved at least a partial response (PR) after autologous stem cell transplantation (ASCT) with or without consolidation, according to International Myeloma Working Group (IMWG 2016) criteria.","* Progressive disease or clinical relapse (as defined by IMWG response criteria) following ASCT with or without consolidation or is not responsive to primary therapy. * Smoldering myeloma, solitary plasmacytoma or nonsecretory myeloma. * Known central nervous system/meningeal involvement of MM. * Prior history of malignancies, other than MM, unless the participant has been free of the disease for ≥ 5 years. * Other protocol-defined Inclusion/Exclusion criteria apply."
NCT06084936,"A Phase III, Open-Label, Multicenter Randomized Study Evaluating Glofitamab as a Single Agent Versus Investigator's Choice in Patients With Relapsed/Refractory Mantle Cell Lymphoma",GLOBRYTE,PHASE3,"Brazil, Puerto Rico","Hospital Sao Rafael - HSR, Salvador, Brazil, [RECRUITING] | ICTR Curitiba, Curitiba, Brazil, [RECRUITING] | Hospital Mae de Deus, Porto Alegre, Brazil, [RECRUITING] | Hospital Paulistano, São Paulo, Brazil, [RECRUITING] | Hospital Alemao Oswaldo Cruz, São Paulo, Brazil, [RECRUITING] | Hospital A. C. Camargo, São Paulo, Brazil, [RECRUITING] | Instituto D'Or Pesquisa e Ensino, São Paulo, Brazil, [RECRUITING] | Americas Medical City, Rio de Janeiro, Brazil, [RECRUITING] | Beneficencia Portuguesa de Sao Paulo, São Paulo, Brazil, [RECRUITING] | Auxilio Mutuo Cancer Center, San Juan, Puerto Rico, [RECRUITING]",Lymphoma,2,"[1] Glofitamab monotherapy (EXPERIMENTAL): Participants will receive two intravenous (IV) obinutuzumab pretreatments prior to receiving IV glofitamab for 12 cycles (cycle length = 21 days). || [2] BR or R-Len (ACTIVE_COMPARATOR): Participants will receive bendamustine + rituximab for up to 6 cycles (cycle length = 28 days), or rituximab + lenalidomide (cycle length = 28 days) until disease progression.","* Life expectancy at least 12 weeks * Histologically-confirmed MCL, with documentation of either overexpression of cyclin D1 or the presence of t(11:14) * Relapsed (disease progression after the last treatment regimen) or refractory (failure to achieve a partial or complete response from the last treatment regimen) disease * At least 1 line of prior systemic therapy including a BTK inhibitor and additional systemic therapy option * Confirmed availability of tumor tissue, unless deemed unsafe per investigator assessment * At least one bi-dimensionally measurable (defined as at least 1.5 cm) nodal lesion, or one bi-dimensionally measurable (at least 1 cm) extranodal lesion, as measured on CT scan * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 * Negative HIV test at screening * Adequate hematological function","* Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 3 months after the final dose of tocilizumab, 2 months after the final dose of glofitamab, whichever is longer * Leukemic, non-nodal MCL * History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies (or recombinant antibody-related fusion proteins) or known sensitivity or allergy to murine products * Contraindication to obinutuzumab or rituximab, and either bendamustine or lenalidomide * Prior treatment with glofitamab or other bispecific antibodies targeting both CD20 and CD3 * Prior treatment with CAR-T cell therapy * Treatment with systemic therapy or BTK inhibitors, or any investigational agent for the purposes of treating cancer within 2 weeks or 5 half-lives (whichever is shorter) prior to first study treatment * Primary or secondary CNS lymphoma at the time of recruitment or history of CNS lymphoma * Current or history of CNS disease, such as stroke, epilepisy, CNS vasculitis, or neurodegenerative disease * History of other malignancy that could affect compliance with the protocol or interpretation of results * Significant or extensive cardiovascular disease * Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection at study enrollment or any major episode of infection within 4 weeks prior to the first study treatment * Suspected or latent tuberculosis * Positive test for hepatitis B virus (HBV) or hepatitis C virus (HCV) * Known or suspected chronic active Epstein-Barr viral infection (EBV) * Known or suspected history of hemophagocytic lymphohistiocytosis (HLH) * Known history of progressive multifocal leukoencephalopathy (PML) * Adverse events from prior anti-cancer therapy that have not resolved to Grade 1 or better * Administration of a live, attenuated vaccine within 4 weeks before first study treatment administration or anticipation that such a live, attenuated vaccine will be required during the st"
NCT05954702,Supercharged TRAM Evaluation in Cervical Esophagogastroplasty After Esophagectomy,Supercharged,NA,Brazil,"Instituto do Cancer do Estado de São Paulo (ICESP), São Paulo, Brazil, [RECRUITING]",Esophagus Cancer | Carcinoma Esophagus,2,"[1] Conventional Esophagectomy group (ACTIVE_COMPARATOR): Patients with malignant esophagus neoplasms randomized to Conventional Esophagectomy will undergo to an esophagectomy, immediately followed by an esophagus reconstruction trough esophagogastroplasty. || [2] Supercharged TRAM esophagectomy group (EXPERIMENTAL): Patients with malignant esophagus neoplasms randomized to Supercharged TRAM esophagectomy will undergo to esophagectomy, immediately followed by supercharged esophagogastroplasty.",* Diagnosis of esophageal malignancy cancer; * Ability to understand and collaborate during treatment;,* Previous gastrectomy; * Previous abdominal surgery with risk of altering stomach vascularization; * Previous head and neck surgery with risk of alteration of cervical vessels.
NCT06279013,Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment,SYMON,NA,Puerto Rico,"Puerto Rico Hematology Oncology Group, Bayamón, Puerto Rico, [RECRUITING] | Doctors Cancer Center, Manatí, Puerto Rico, [RECRUITING] | Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico, [RECRUITING] | PROncology, San Juan, Puerto Rico, [RECRUITING]",Hematopoietic and Lymphatic System Neoplasm | Malignant Solid Neoplasm,2,"[1] Arm I (IVR monitoring) (ACTIVE_COMPARATOR): Patients receive IVR symptom monitoring calls once a week for 12 weeks, and a summary symptom report is sent to their provider. Call duration is approximately 15 minutes. || [2] Arm II (ATSM, TIPC) (EXPERIMENTAL): Patients receive the Symptom Management and Survivorship handbook and receive IVR symptom monitoring calls for 12 weeks, with summary symptom reports sent to their provider. Call duration is approx...","* PRACTICES: All institutions participating in the practice are National Cancer Institute Community Oncology Research Program (NCORP) affiliates or sub-affiliates. * PRACTICES: Administer oral therapy to at least 40 patients per year that meet protocol eligibility criteria. * PRACTICES: Completion and submission of the NRG-CC012CD Letter of Intent (LOI) (posted on the Cancer Trials Support Unit \[CTSU\] website). * PRACTICES: Having a social worker licensed in behavioral counseling or other person eligible for behavioral licensing in the practice's state or territory (if licensure is required by state or territory) who can be trained to deliver TIPC or willingness of practice to work with TIPC intervener contracted by the study team. Note: If the practice's social worker or other behavioral health professional is trained to deliver TIPC, they will be compensated for their time training and delivering the TIPC intervention. * PRACTICE PERSONNEL: Age ≥ 18 years. * PRACTICE PERSONNEL: Planned to be involved in usual care for at least one enrolled patient during patient's participation in the study. * PRACTICE PERSONNEL: For a social worker or other behavioral health professional who will deliver TIPC intervention, licensure, or eligibility for licensure in behavioral counseling if required by the state or territory. * PRACTICE PERSONNEL: The practice personnel must provide study-specific informed consent prior to study entry. * RETAIN PRACTICE PARTICIPATION: In order to maintain participation in the study, practices must enroll at least 8 patients in the first 6 months (based upon the practice's monthly tracking reports) the practice is open to patient accrual to ensure that the practice can meet the accrual goals. If a practice does not meet this criterion they will be replaced. * RETAIN PRACTICE PARTICIPATION: Complete monthly forms on actions taken on IVR symptom reports. If fewer than 2 forms are completed in the first 6 months of practice's participation, practice","* PRACTICES: Active telephone symptom management program at the practice that is beyond symptom and oral agent adherence monitoring. * PATIENTS: Only receiving treatment with sex hormone inhibitors. * PATIENTS: Enrollment in the intervention arm of another symptom management trial at intake into the trial. Participation in lifestyle trials with primary outcomes other than symptoms is acceptable. * PATIENTS: Currently receiving regular behavioral counseling for psychological symptoms. Regular behavioral counseling is defined as at least two counseling sessions with a behavioral health care provider scheduled within the past two months. Patients who completed behavioral counseling within 2 months prior to registration are eligible. Behavioral counseling for issues other than psychological symptoms (e.g., as part of weight loss or smoking cessation program) is not an exclusion criterion. * PATIENTS: Pregnancy at intake into the trial."
NCT06666556,"Bowel Preparation in Colonoscopy: Lactulose Vs Polyethyleneglycol, Randomized Double-blind Comparative Clinical Trial, Multicenter Study.",,PHASE4,Mexico,"Antigüo Hospital Civil de Guadalajara ""Fray Antonio Alcalde"", Guadalajara, Mexico, [RECRUITING] | Nuevo Hospital Civil de Guadalajara ""Juan I. Menchaca"", Guadalajara, Mexico, [RECRUITING] | IMSS Hospital General Regional 220 ""José Vicente Villada"", México, Mexico, [RECRUITING]",Colorectal Cancer Screening,2,[1] Bowel preparation with lactulose before de colonoscopy (ACTIVE_COMPARATOR): Patients will be randomized and assigned the bowel preparation the day that provide them the day of the colonoscopy || [2] Bowel preparation with plyethylenglycol before the colonoscopy (ACTIVE_COMPARATOR): Patients will be randomized and assigned the bowel preparation the day that provide them the day of the colonoscopy,* Patients with indication for colonoscopy in our coloproctology service * Both women and men * Patients within an age range of 18-79 years * Patients who agree having a colonoscopy and who sign the informed consent to participate in the protocol,"* Patients under 18 or over 80 years old * All patients that won´t like to participate in the protocol or won´t sign the informed consent * Pregnant women * Patients with a medical record of colonic resection, ostomy status, severe cardiopulmonary and renal diseases, major psychiatric disorders, therapeutic colonoscopy or any contraindications for colonoscopy * Non compliance with the colonic preparation regimen * Active bleeding during the procedure * Patients with a known diagnosis of colorectal cancer"
NCT04262466,Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers,,"PHASE1, PHASE2",Brazil,"Hospital Nossa Senhora da Conceicao, Porto Alegre, Brazil, [RECRUITING] | D'Or Institute for Research and Education, Rio de Janeiro, Brazil, [ACTIVE_NOT_RECRUITING] | National Cancer Institute, Rio de Janeiro, Brazil, [RECRUITING] | Hospital Israelita Albert Einstein, São Paulo, Brazil, [ACTIVE_NOT_RECRUITING]",Select Advanced Solid Tumors,5,"[1] Brenetafusp Monotherapy (EXPERIMENTAL): Participants receive brenetafusp. || [2] Brenetafusp and Anti-PD(L)1 Agent (EXPERIMENTAL): Participants receive brenetafusp and pembrolizumab. || [3] Brenetafusp and Chemotherapy (EXPERIMENTAL): Participants receive brenetafusp and chemotherapy. Choice of chemotherapy is dependent on cohort. || [4] Brenetafusp and Targeted Therapy (EXPERIMENTAL): Participants receive brenetafusp and a selected targeted therapy. Receipt of kinase inhibitor is dependent on histology. || [5] Brenetafusp and Multimodal Therapy (EXPERIMENTAL): Participants receive brenetafusp, biologics (eg, pembrolizumab, bevacizumab) IV infusions and chemotherapy IV infusions based on histology.","1. ECOG PS 0 or 1 2. HLA-A\*02:01 positive 3. PRAME positive tumor 4. Relapsed from, refractory to, or intolerant of standard therapies; or, in combination with standard therapies 5. If applicable, must agree to use highly effective contraception","1. Symptomatic or untreated central nervous system metastasis 2. Recent bowel obstruction 3. Ongoing ascites or effusion requiring recent drainages 4. Significant immune-mediated adverse event with prior immunotherapy (Participants in checkpoint inhibitor combination treatment) 5. Inadequate washout from prior anticancer therapy 6. Significant ongoing toxicity from prior anticancer treatment 7. Out-of-range laboratory values 8. Clinically significant lung, heart, or autoimmune disease 9. Ongoing requirement for immunosuppressive treatment 10. Prior solid organ or bone marrow transplant 11. Active hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) infection 12. Significant secondary malignancy 13. Hypersensitivity to study drug or excipients 14. Antibiotics, vaccines or surgery within 2-4 weeks prior to the first dose of study intervention 15. Pregnant or lactating participants 16. Any other contraindication for applicable combination partner based on local prescribing information"
NCT04293562,"A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations",,PHASE3,Puerto Rico,"University Pediatric Hospital, San Juan, Puerto Rico, [RECRUITING]",Acute Myeloid Leukemia,14,[1] Arm A High Risk Group (EXPERIMENTAL): Arm A High Risk Group: See Detailed Description. || [2] Arm A Low Risk Group 1 (EXPERIMENTAL): Arm A Low Risk Group 1: See Detailed Description. (CLOSED TO ACCRUAL 11/19/2024) || [3] Arm A Low Risk Group 2 (EXPERIMENTAL): Arm A Low Risk Group 2: See Detailed Description. || [4] Arm AC High Risk Group (EXPERIMENTAL): Arm AC High Risk Group: See Detailed Description. || [5] Arm AC Low Risk Group 2 (EXPERIMENTAL): Arm AC Low Risk Group 2: See Detailed Description. || [6] Arm AD High Risk Group (EXPERIMENTAL): Arm AD High Risk Group: See Detailed Description. || [7] Arm AD Low Risk Group 2 (EXPERIMENTAL): Arm AD Low Risk Group 2: See Detailed Description. || [8] Arm B High Risk Group (EXPERIMENTAL): Arm B High Risk Group: See Detailed Description. (CLOSED TO ACCRUAL 11/19/2024) || [9] Arm B Low Risk Group 1 (EXPERIMENTAL): Arm B Low Risk Group 1: See Detailed Description. (CLOSED TO ACCRUAL 11/19/2024) || [10] Arm B Low Risk Group 2 (EXPERIMENTAL): Arm B Low Risk Group 2: See Detailed Description. (CLOSED TO ACCRUAL 11/19/2024),"* All patients must be enrolled on APEC14B1 and consented to Eligibility Screening (Part A) prior to enrollment and treatment on AAML1831 * Patients must be less than 22 years of age at the time of study enrollment * Patient must be newly diagnosed with de novo AML according to the 2016 World Health Organization (WHO) classification with or without extramedullary disease * Patient must have 1 of the following: * \>= 20% bone marrow blasts (obtained within 14 days prior to enrollment) * In cases where extensive fibrosis may result in a dry tap, blast count can be obtained from touch imprints or estimated from an adequate bone marrow core biopsy * \< 20% bone marrow blasts with one or more of the genetic abnormalities associated with childhood/young adult AML as provided in the protocol (sample obtained within 14 days prior to enrollment) * A complete blood count (CBC) documenting the presence of at least 1,000/uL (i.e., a white blood cell \[WBC\] count \>= 10,000/uL with \>= 10% blasts or a WBC count of \>= 5,000/uL with \>= 20% blasts) circulating leukemic cells (blasts) if a bone marrow aspirate or biopsy cannot be performed (performed within 7 days prior to enrollment) * ARM C: Patient must be \>= 2 years of age at the time of Late Callback * ARM C: Patient must have FLT3/ITD allelic ratio \> 0.1 as reported by Molecular Oncology * ARM C: Patient does not have any congenital long QT syndrome or congenital heart block * ARM C: Females of reproductive potential must agree to use effective contraception during treatment and for at least 6 months after the last dose of gilteritinib * ARM C: Lactating women must agree not to breastfeed during treatment with gilteritinib and for 2 months after the last dose of gilteritinib * ARM C: Males of reproductive potential must agree to use effective contraception during treatment and for at least 4 months after the last dose of gilteritinib * ARM D: Patient must be \>= 2 years of age at the time of Late Callback * ARM D: Patient","* Fanconi anemia * Shwachman Diamond syndrome * Patients with constitutional trisomy 21 or with constitutional mosaicism of trisomy 21 * Telomere disorders * Germline predispositions known, or suspected by the treating physician to increase risk of toxicity with AML therapy * Any concurrent malignancy * Juvenile myelomonocytic leukemia (JMML) * Philadelphia chromosome positive AML * Mixed phenotype acute leukemia * Acute promyelocytic leukemia * Acute myeloid leukemia arising from myelodysplasia * Therapy-related myeloid neoplasms * Patients with persistent cardiac dysfunction prior to enrollment, defined as ejection fraction (EF) \< 50% (preferred method Biplane Simpson's EF) or if EF unavailable, shortening fraction (SF) \< 24%. \*Note: if clinically safe and feasible, repeat echocardiogram is strongly advised in order to confirm cardiac dysfunction following clinical stabilization, particularly if occurring in the setting of sepsis or other transient physiologic stressor. If the repeat echocardiogram demonstrates an EF \>= 50%, the patient is eligible to enroll and may receive an anthracycline-containing Induction regimen * Administration of prior anti-cancer therapy except as outlined below: * Hydroxyurea * All-trans retinoic acid (ATRA) * Corticosteroids (any route) * Intrathecal therapy given at diagnosis * In particular, strong inducers of CYP3A4 and/or P-glycoprotein (P-gp) should be avoided from the time of enrollment until it is determined whether the patient will receive gilteritinib. Patients receiving gilteritinib will be required to avoid strong CYP3A4 inducers and/or strong P-gp inducers for the duration of the study treatment * Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential * Lactating females who plan to breastfeed their infants * Sexually active patients of reproductive potential who have not ag"
NCT06149286,"A Phase 3, Open Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination With Lenalidomide Versus Rituximab in Combination With Lenalidomide Therapy in Relapsed/Refractory Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)",OLYMPIA-5,PHASE3,Brazil,"Uopeccan Hospital do Cancer de Cascavel, Cascavel, Brazil, [RECRUITING] | Hospital Erasto Gaertner, Curitiba, Brazil, [RECRUITING] | Centro Gaucho Integrado, Porto Alegre, Brazil, [RECRUITING]",Relapsed/Refractory Follicular Lymphoma | Marginal Zone Lymphoma (MZL),2,"[1] Odronextamab+Lenalidomide (EXPERIMENTAL): In part 1 (safety run-in), participants with R/R indolent lymphoma (FL and MZL), will receive odronextamab in combination with lenalidomide.

In part 2, 1:1 randomized participants with indolent ly... || [2] Rituximab+Lenalidomide (EXPERIMENTAL): In part 2 only, 1:1 randomized participants with R/R lymphoma (FL and ML), will receive rituximab in combination with lenalidomide (R2) followed by lenalidomide monotherapy.","1. Local histologic confirmation of FL grade 1-3a or MZL (nodal, splenic, or extra nodal MZL) as assessed by the investigator, as described in the protocol. 2. Must have refractory disease or relapsed after at least 1 prior line (with a duration of at least 2 cycles) of systemic chemo-immunotherapy or immunotherapy. Prior systemic therapy should have included at least one anti-Cluster of Differentiation 20 (CD20) monoclonal antibody and participant should meet indication for treatment, as described in the protocol. 3. Have measurable disease on cross sectional imaging documented by diagnostic Computed Tomography \[CT\], or magnetic resonance imaging \[MRI\] imaging, as described in the protocol. 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. 5. Adequate hematologic and organ function, as described in the protocol. 6. All study participants must: 1. Have an understanding that lenalidomide could have a potential teratogenic risk. 2. Agree to abstain from donating blood while taking study drug therapy and for 28 days after discontinuation of lenalidomide. 3. Agree not to share study medication with another person. 4. Agree to be counseled about pregnancy precautions and risk of fetal exposure associated with lenalidomide. Key","1. Primary Central Nervous System (CNS) lymphoma or known involvement (either current or prior history of CNS involvement) by non-primary CNS NHL, as described in the protocol. 2. Participants with histological evidence of transformation to a high-grade or diffuse large B-cell lymphoma, or any histology other than FL grade 1-3a or MZL. 3. History of or current relevant CNS pathology, as described in the protocol. 4. A malignancy other than NHL unless the participant is adequately and definitively treated and is cancer free for at least 3 years, with the exception of localized prostate cancer treated with hormone therapy or local radiotherapy (ie, pellets), cervical carcinoma in situ, breast cancer in situ, or nonmelanoma skin cancer that was definitively treated. 5. Any other significant active disease or medical condition that could interfere with the conduct of the study or put the participant at significant risk, as described in the protocol. 6. Allergy/hypersensitivity to study drugs or excipients. as described in the protocol. 7. Active infection as defined in the protocol. Note: Other protocol-defined Inclusion/Exclusion criteria apply"
NCT06170788,"A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)",TroFuse-007,PHASE3,"Argentina, Brazil, Chile, Colombia, Mexico, Peru","Instituto Alexander Fleming ( Site 0306), Ciudad Autónoma de Buenos Aires, Argentina, [RECRUITING] | Hospital Británico de Buenos Aires-Oncology ( Site 0304), Buenos Aires, Argentina, [RECRUITING] | Centro Privado de RMI Río Cuarto S.A. II ( Site 0310), Río Cuarto, Argentina, [RECRUITING] | Instituto de Oncología de Rosario ( Site 0301), Rosario, Argentina, [RECRUITING] | Hospital Aleman-Oncology ( Site 0300), Buenos Aires, Argentina, [RECRUITING] | Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 0409), Porto Alegre, Brazil, [RECRUITING] | Clinica Viver ( Site 0400), Santa Maria, Brazil, [RECRUITING] | Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0402), Barretos, Brazil, [RECRUITING] | Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0406), São José do Rio Preto, Brazil, [RECRUITING] | Instituto Nacional de Câncer - INCA ( Site 0405), Rio de Janeiro, Brazil, [RECRUITING]",Non-small Cell Lung Cancer (NSCLC),2,"[1] Pembrolizumab + Sacituzumab tirumotecan (EXPERIMENTAL): Participants receive sacituzumab tirumotecan via intravenous (IV) infusion on Days 1, 15 and 29 of each 6-week cycle + 400 mg Pembrolizumab every 6 weeks (q6w) via IV infusion on Day 1 of each 6-we... || [2] Pembrolizumab (ACTIVE_COMPARATOR): Participants receive 400 mg Pembrolizumab via IV infusion q6w on Day 1 of each 6-week cycle for 18 cycles","* Histologically or cytologically confirmed diagnosis of squamous or nonsquamous NSCLC * Confirmation that epidermal growth factor receptor- (EGFR-), anaplastic lymphoma kinase- (ALK-), or proto-oncogene tyrosine-protein kinase ROS (ROS1-) directed therapy is not indicated as primary therapy * Provided tumor tissue that demonstrates programmed cell death ligand 1 (PD-L1) expression in ≥50% of tumor cells as assessed by an immunohistochemistry (IHC) central laboratory * An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 7 days before randomization. * A life expectancy of at least 3 months. * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)","* Diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements. * Has Grade ≥2 peripheral neuropathy. * History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing. * Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea). * Has uncontrolled, significant cardiovascular disease or cerebrovascular disease within the 6 months preceding study intervention. * Received prior systemic anticancer therapy for their metastatic NSCLC. * Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor Note: Prior treatment with an anti-PD-1, anti-PD- L1, or anti-PD-L2 agent in the neoadjuvant or adjuvant setting for nonmetastatic resectable NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC. * Received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization. * Received radiation therapy to the lung that is \>30 Gy within 6 months of start of study intervention. * Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids. * Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed. * Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy * Known additional malignancy that is progressing or has required active treatment within the past 3 years. * Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. * Known intolerance to sacituzumab tirumotecan or pembrolizumab and/or any of their excipients; for pembroli"
NCT06136702,EarLy dEtection of cerVical cAncer in Hard-to-reach Populations of Women Through Portable and Point-of-care HPV TEsting Acceptability Study,ELEVATE AS,NA,"Brazil, Ecuador","Barretos Cancer Hospital - Fundação Pio XII, Barretos, Brazil, [NOT_YET_RECRUITING] | Universidad de Cuenca, Cuenca, Ecuador, [COMPLETED]",Cervical Cancer | HPV Infection | Acceptability of Health Care,2,"[1] Educational session and follow-up assessment (ACTIVE_COMPARATOR): A community-based researcher will educate women about sexual health and cervical cancer by using the materials that will be developed by the ELEVATE team. Women will be informed about cervical canc... || [2] Educational session, self-sampling and follow-up assessment (EXPERIMENTAL): A community-based researcher will educate women about sexual health and cervical cancer by using the materials that will be developed by the ELEVATE team. In addition, women will receive informatio...","* are between the ages of 25 to 65 years of age, in line with the European Guidelines for initiating and stopping cervical cancer screening * (ever been) sexually active; * not diagnosed or in treatment for cervical cancer; * not having had a hysterectomy * not being pregnant * Speaking the local language",* younger than 25 years old or older than 65 years old * diagnosed or in treatment for cervical cancer * having had a hysterectomy * being pregnant
NCT06116136,"Open Label, Non-randomized, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of S095029 (Anti-NKG2A Antibody) as a Part of Combination Therapy in Participants With Locally Advanced and Unresectable or Metastatic MSI-H/dMMR Gastro-esophageal Junction /Gastric Cancer",,"PHASE1, PHASE2","Brazil, Puerto Rico","Cepon - Centro de Pesquisas Oncologicas, Florianópolis, Brazil, [COMPLETED] | Supera Oncologia, Santa Catarina, Brazil, [ACTIVE_NOT_RECRUITING] | Icesp - Instituto Do Câncer Do Estado de São Paulo, São Paulo, Brazil, [COMPLETED] | Instituto Brasileiro de Controle Do Câncer, São Paulo, Brazil, [ACTIVE_NOT_RECRUITING] | Hospital Albert Einstein, São Paulo, Brazil, [COMPLETED] | Pan American Center For Oncology Trials, Llc, Rio Piedras, Puerto Rico, [RECRUITING]",MSI-H/dMMR Gastroesophageal-junction Cancer | MSI-H/dMMR Gastric Cancer,1,"[1] S095029 and pembrolizumab (EXPERIMENTAL): Participants diagnosed with gastric cancer (GC) or gastroesophageal junction cancer (GEJ), not previously treated with checkpoint inhibitors (CPIs) may first be enrolled into a Phase 1b safety lead...","* Have a confirmed diagnosis of locally advanced and unresectable or metastatic gastric or gastro-esophageal junction adenocarcinoma * Participants' tumor must have an MSI-H/dMMR status according to institutional guidelines and/or according to the College of American Pathologists, determined at any time prior to enrolment.","* Has received more than one previous line of treatment in the locally advanced and unresectable or metastatic setting. * Has received prior therapy with any checkpoint inhibitor (anti-PD-1, anti-programmed cell death ligand 1 (PDL1), anti-CTLA4). * Participants who have received prior systemic anti-cancer therapy including investigational agents within 4 weeks (shorter interval, at least 5 half-lives, for kinase inhibitors or other short half-life drugs) prior to first study treatment. * Prior radiotherapy if completed less than 2 weeks before first study treatment * Major surgery less than 4 weeks prior to the first study treatment or participants who have not recovered from the side effects of the surgery."
NCT05952557,"CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease",CAMBRIA-2,PHASE3,"Argentina, Brazil, Chile, Colombia, Mexico, Peru, Puerto Rico","Research Site, Buenos Aires, Argentina, [RECRUITING] | Research Site, Buenos Aires, Argentina, [RECRUITING] | Research Site, Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Research Site, Buenos Aires, Argentina, [RECRUITING] | Research Site, CABA, Argentina, [RECRUITING] | Research Site, Capital Federal, Argentina, [RECRUITING] | Research Site, Córdoba, Argentina, [RECRUITING] | Research Site, Córdoba, Argentina, [RECRUITING] | Research Site, La Plata, Argentina, [RECRUITING] | Research Site, Rosario, Argentina, [RECRUITING]","Breast Cancer, Early Breast Cancer",2,"[1] Arm A: standard endocrine therapy of investigator´s choice ± abemaciclib (ACTIVE_COMPARATOR): standard endocrine therapy of investigator's choice (aromatase inhibitors \[AI; exemestane, letrozole, anastrozole\] or tamoxifen) ± abemaciclib || [2] Arm B: camizestrant ± abemaciclib (EXPERIMENTAL): camizestrant ± abemaciclib","* Women and Men; ≥18 years at the time of screening (or per national guidelines) * Histologically confirmed ER+/HER2- early-stage resected invasive breast cancer with absence of any evidence of metastatic disease as defined in the protocol. * Completed adequate (definitive) locoregional therapy (surgery with or without radiotherapy) for the primary breast tumour(s), with or without (neo)adjuvant chemotherapy. * Patients must be randomised within 12 months of definitive breast surgery. * Patients may have received up to 12 weeks of endocrine therapy prior to randomisation. * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 * Adequate organ and bone marrow function","* Inoperable locally advanced or metastatic breast cancer * Pathological complete response following treatment with neoadjuvant therapy * History of any other cancer (except non-melanoma skin cancer or carcinoma in situ of the cervix or considered a very low risk of recurrence per investigator judgement) unless in complete remission with no therapy for a minimum of 5 years from the date of randomisation * Any evidence of severe or uncontrolled systemic diseases which, in the investigator's opinion precludes participation in the study or compliance "" * Known LVEF \<50% with heart failure NYHA Grade ≥2. * Mean resting QTcF interval \> 480 ms at screening * Concurrent exogenous reproductive hormone therapy or non topical hormonal therapy for non-cancer-related conditions * Any concurrent anti-cancer treatment not specified in the protocol with the exception of bisphosphonates (e.g. zoledronic acid) or RANKL inhibitors ( eg, denosumab) * Previous treatment with camizestrant, investigational SERDs/investigational ER targeting agents, or fulvestrant * Currently pregnant (confirmed with positive serum pregnancy test) or breastfeeding. * Patients with known hypersensitivity to active or inactive excipients of camizestrant or drugs with a similar chemical structure or class to camizestrant. In pre-/peri-menopausal female and male patients, known hypersensitivity or intolerance to LHRH agonists that would preclude the patient from receiving any LHRH agonist."
NCT06152575,"A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY",,PHASE3,"Argentina, Brazil","Instituto Alexander Fleming, Ciudad Autónoma de Buenos Aires, Argentina, [RECRUITING] | Hospital Universitario Austral, Pilar, Argentina, [RECRUITING] | Hospital Italiano de Buenos Aires, Ciudad de Buenos Aires, Argentina, [RECRUITING] | Hospital Italiano de La Plata, La Plata, Argentina, [RECRUITING] | Instituto D'Or de Pesquisa e Ensino (IDOR) - Filial Salvador, Salvador, Brazil, [NOT_YET_RECRUITING] | Instituto Oncomed de Educação e Pesquisa, Niterói, Brazil, [NOT_YET_RECRUITING] | Hospital Moinhos de Vento, Porto Alegre, Brazil, [NOT_YET_RECRUITING] | Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa, Porto Alegre, Brazil, [RECRUITING] | Centro de Pesquisa Clínica - Área Administrativa, Porto Alegre, Brazil, [RECRUITING] | Hospital Mae de Deus, Porto Alegre, Brazil, [RECRUITING]",Multiple Myeloma,2,"[1] Elranatamab (EXPERIMENTAL): Participants will receive elranatamab monotherapy || [2] Investigator's Choice (ACTIVE_COMPARATOR): Participants will receive either Elotuzumab, Pomalidomide and Dexamethasone (EPd), or Pomalidomide, Bortezomib and Dexamethasone (PVd), or Carfilzomib and Dexamethasone (Kd)",* Prior diagnosis of multiple myeloma as defined by International Myeloma Working Group (IMWG) criteria and previously received 1 to 4 prior lines of therapy including prior anti-cluster of differentiation 38 (CD38) antibody and prior lenalidomide. * Documented evidence of progressive disease or failure to achieve a response to last line of therapy per IMWG criteria. * Measurable disease defined as at least 1 of the following: (a) Serum M-protein ≥0.5 g/dL; (b) Urinary M-protein excretion ≥200 mg/24 hours; (c) Serum involved immunoglobulin FLC ≥10 mg/dL AND abnormal serum immunoglobulin kappa to lambda FLC ratio (\<0.26 or \>1.65). * Have clinical laboratory values within the specified range. * ECOG (Eastern Cooperative Oncology Group) performance status ≤2. * Not pregnant or breastfeeding and willing to use contraception.,"* Smoldering multiple myeloma. * Plasma cell leukemia. * Amyloidosis. * Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin abnormalities (POEMS) syndrome. * Known central nervous system (CNS) involvement or clinical signs of myelomatous meningeal involvement. * Stem cell transplant within 12 weeks prior to enrolment, or active graft versus host disease. * Any active, uncontrolled bacterial, fungal, or viral infection. * Any other active malignancy within 3 years prior to enrolment (exceptions include, adequately treated basal cell or squamous cell skin cancer, carcinoma in situ) * Previous treatment with a B cell maturation antigen (BCMA)-directed therapy or CD3-redirecting therapy. * Unable to receive investigator's choice therapy. * Live attenuated vaccine within 4 weeks of the first dose of study intervention. * Administration with an investigational product (e.g. drug or vaccine) within 30 days preceding the first dose of study intervention used in this study."
NCT05665920,Clinical Trial to Assess the Efficacy and Safety of Ultra_HYPofractionated RadiotHerapy in Women With BrEast CaNcer Receiving Regional Nodal Radiation vs Nodal Moderate Hypofractionated Radiotherapy,HYPHEN,NA,Brazil,"IBCC Oncologia, São Paulo, Brazil, [RECRUITING]",Malignant Breast Neoplasm,2,"[1] Standard Whole breast Radiotherapy (ACTIVE_COMPARATOR): Standard Radiation: Whole Breast Irradiation, at 40 Gy, in 15 fractions and drainage || [2] Ultra-hypofractionated whole breast radiotherapy (EXPERIMENTAL): Ultra-hypofractionated radiation: Ultra-hypofractionated whole breast radiotherapy, 26 Gray (26Gy) in 5 fractions for one week","* Information to the patient and signed informed consent; * Women aged ≥18 years; * Breast conserving surgery; * Invasive adenocarcinoma (except classic invasive lobular carcinoma); * TNM (Tumor, Nodes, Metastasis) pathologic stage pT1-3 and pN1-3a M0, with indication of lymphatic drainage according to institutional protocol; * Eastern Cooperative Oncology Group (ECOG) 0 -1; * Minimum microscopic margin of non-cancerous tissue of 2 mm (excluding deep margin if in the deep fascia); * No previous breast or mediastinal radiotherapy; * No hematogenous metastases; * Ability to carry out long-term follow-up;","* Previous local irradiation; * Concomitant chemotherapy. Concomitance with trastuzumab or hormone blockade will be allowed; * Histology of metaplastic carcinoma; * History of another neoplasm: non-melanoma skin cancer, carcinoma in situ of the uterine cervix. Another neoplasm treated with curative intent and without evidence of disease in the last 5 years will be allowed. * Diagnosis of autoimmune and connective tissue diseases; * Diagnosis of genetic alterations in cell repair genes (Ex: Fanconi anemia, ataxia teleangiectasia); * Indication of internal breast irradiation."
NCT06469944,"A Phase 1/2 Open-Label, Umbrella Platform Design Study of MK-2870 With Pembrolizumab (MK-3475) and Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma): Substudy 06C",,"PHASE1, PHASE2","Brazil, Chile","Liga Norte Riograndense Contra o Câncer ( Site 6303), Natal, Brazil, [RECRUITING] | Hospital Nossa Senhora da Conceição ( Site 6301), Porto Alegre, Brazil, [RECRUITING] | IBCC - Instituto Brasileiro de Controle do Câncer ( Site 6304), São Paulo, Brazil, [RECRUITING] | Clínica Puerto Montt ( Site 6409), Port Montt, Chile, [RECRUITING] | Centro de Investigación del Maule ( Site 6408), Talca, Chile, [RECRUITING] | FALP-UIDO ( Site 6400), Santiago, Chile, [RECRUITING] | Centro de Oncología de Precisión-Oncology ( Site 6404), Santiago, Chile, [RECRUITING] | Clínica UC San Carlos de Apoquindo ( Site 6405), Santiago, Chile, [RECRUITING] | Bradfordhill-Clinical Area ( Site 6401), Santiago, Chile, [RECRUITING] | Bradford Hill Norte ( Site 6407), Antofagasta, Chile, [RECRUITING]",Gastroesophageal Junction | Gastroesophageal Adenocarcinoma | Esophageal Neoplasms | Esophageal Cancer,2,"[1] Pembrolizumab plus Chemotherapy (ACTIVE_COMPARATOR): Participants will receive pembrolizumab 400 mg via intravenous (IV) injection on day 1 of every 6 week cycle for up to 18 cycles (up to \~2 years) AND investigator's choice of CAPOX chemotherapy (c... || [2] Pembrolizumab plus Sacituzumab Tirumotecan plus Chemotherapy (EXPERIMENTAL): Participants will receive sacituzumab tirumotecan via IV infusion on Days 1, 15, and 29 of each 6 week cycle until discontinuation, pembrolizumab 400 mg via IV injection on day 1 of every 6 week cy...","The main inclusion criteria include but are not limited to the following: * Has histologically and/or cytologically confirmed diagnosis of previously untreated locally advanced unresectable or metastatic 1L gastroesophageal adenocarcinoma * Has gastroesophageal adenocarcinoma that is known to be human epidermal growth factor receptor 2 (HER2)/neu-positive are excluded. HER2 status is not required if HER2/neu testing is not mandatory per local standard of care (SOC) * Is not expected to require tumor resection during the treatment course * Has not had prior systemic therapy administered in the recurrent or metastatic setting * Has provided an archival tumor tissue sample or most recently obtained core, or incisional, or excisional biopsy for a tumor lesion * Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to \<Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement therapy are eligible * Has adequate organ function * Has measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as determined by the local site investigator/radiology assessment and verified by blind independent review committee (BICR) * Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed within 3 days before allocation/randomization. * Has a life expectancy of at least 6 months * Who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to randomization. * Who has history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening. * Human immunodeficiency virus (HIV)-infected participants must have well-controlled HIV on antiretroviral therapy (ART)","The main exclusion criteria include but are not limited to the following: * Has squamous cell or undifferentiated gastroesophageal cancer. * Has had previous therapy for locally advanced unresectable or metastatic gastric/GEJ/esophageal adenocarcinoma * Has experienced weight loss \>20% over 3 months before the first dose of study intervention * Has a history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing * Has Grade \>2 peripheral neuropathy * Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease * Has uncontrolled, significant cardiovascular disease or cerebrovascular disease within 6 months preceding study intervention * Has accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks prior to enrollment * HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Has received prior treatment with a trophoblast antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC) * Has received prior treatment with a topoisomerase I inhibitor-based ADC and/or a topoisomerase I inhibitor-based chemotherapy * Has received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study intervention * Has received prior therapy with an anti-Programmed Cell Death Protein 1 (PD-1), anti-Programmed Cell Death-Ligand 1 (PD-L1), anti-Programmed Cell Death-Ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (TCR) * Has received prior radiotherapy within 2 weeks of start of study intervention, or has radiation related toxicities, requiring corticosteroids * Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention * Has received a strong inducer/inhibitor of CYP3A4 that canno"
NCT06790693,"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer",INAVO123,PHASE3,"Argentina, Brazil, Mexico, Puerto Rico","Centro Oncologico Korben, Caba, Argentina, [RECRUITING] | Centro Médico Fleischer, Capital Federal, Argentina, [RECRUITING] | Hospital Privado Centro Medico de Cordoba, Córdoba, Argentina, [RECRUITING] | Instituto de Oncologia de Rosario, Rosario, Argentina, [RECRUITING] | Centro Oncológico de Excelencia, San Juan, Argentina, [RECRUITING] | Crio - Centro Regional Integrado de Oncologia, Fortaleza, Brazil, [RECRUITING] | Hospital Santa Rita de Cassia Vitoria, Vitória, Brazil, [RECRUITING] | Obras Sociais Irma Dulce - Osid, Salvador, Brazil, [RECRUITING] | Hospital Araujo Jorge, Goiânia, Brazil, [RECRUITING] | Centro de Oncologia de Alfenas, Alfenas, Brazil, [RECRUITING]",Breast Cancer,2,"[1] Inavolisib + Letrozole + CDK4/6i (EXPERIMENTAL): Participants will receive inavolisib, letrozole and CDK4/6i. || [2] Placebo + Letrozole + CDK4/6i (PLACEBO_COMPARATOR): Participants will receive placebo, letrozole and CDK4/6i.","* Women or men with histologically or cytologically confirmed carcinoma of the breast * Documented ER-positive and/or progesterone receptor-positive tumor according to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines * Documented HER2-negative tumor according to ASCO/CAP guidelines * De-novo HR+ , HER2- ABC, or, alternatively, relapsed HR+ , HER2- ABC after at least 2 years of standard neoadjuvant/adjuvant endocrine therapy without disease progression during that treatment and disease-free interval of at least 1 year since the completion of that treatment * Participants who have bilateral breast cancers which are both HR-positive and HER2-negative * Confirmation of biomarker eligibility * Consent to provide fresh or archival tumor tissue specimen * Measurable disease per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Adequate hematologic and organ function within 14 days prior to initiation of study treatment","* Pregnant or breastfeeding, or intention of becoming pregnant during the study or within the time frame in which contraception is required * Metaplastic breast cancer * Any prior systemic therapy for locally advanced unresectable or metastatic breast cancer * Type 2 diabetes requiring ongoing systemic treatment at the time of study entry; or any history of Type 1 diabetes * Any history of leptomeningeal disease or carcinomatous meningitis * Known and untreated, or active CNS metastases. Participants with a history of treated CNS metastases are eligible * Active inflammatory or infectious conditions in either eye or history of idiopathic or autoimmune-associated uveitis in either eye * Symptomatic active lung disease * History of or active inflammatory bowel disease * Any active bowel inflammation * Prior hematopoietic stem cell or bone marrow transplantation * Treatment with strong cytochrome P450 (CYP) 3A4 inhibitors or strong CYP3A4 inducers within 4 weeks or 5 drug-elimination half-lives, prior to initiation of study treatment"
NCT05764044,Adjuvant Chemotherapy in Cell-free Human Papillomavirus Deoxyribonucleic Acid (cfHPV-DNA) Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer (CC),AddChemo,PHASE3,Brazil,"Centro Integrado de Pesquisa da Amazônia, CINPAM, Manaus, Brazil, [RECRUITING] | Hospital Evangélico de Cachoeiro de Itapemirim, Cachoeiro de Itapemirim, Brazil, [NOT_YET_RECRUITING] | Hospital Samur, Vitória da Conquista, Brazil, [NOT_YET_RECRUITING] | Hospital de Base do Distrito Federal, Brasília, Brazil, [NOT_YET_RECRUITING] | Hospital do Câncer de Muriaé, Muriaé, Brazil, [RECRUITING] | Centro de Oncologia de Cascavel, CEONC, Cascavel, Brazil, [NOT_YET_RECRUITING] | União Oeste Paranaense de Estudos e Combate ao Câncer, UOPECCAN, Cascavel, Brazil, [NOT_YET_RECRUITING] | Centro Integrado de Oncologia de Curitiba, CIONC, Curitiba, Brazil, [NOT_YET_RECRUITING] | Instituto Nacional do Câncer, INCA, Rio de Janeiro, Brazil, [RECRUITING] | Liga Norte Riograndense Contra o Câncer, Natal, Brazil, [NOT_YET_RECRUITING]",Cervical Cancer | Cervix Cancer | Cervix Neoplasm,2,"[1] Control Arm (Standard of Care) (OTHER): Patients will be followed with plasma cfDNA-HPV, computed tomography (CT) scan of the thorax and magnetic resonance (MRI) of abdomen and pelvis and clinical and gynecological examination at every f... || [2] Experimental Arm (EXPERIMENTAL): Receive two cycles of cisplatin-based adjuvant chemotherapy 50mg/m2 D1 and gemcitabine 1000mg/m2 D1 and D8 at every 21 days. After that, patients will be followed with plasma cfDNA-HPV, computed to...","* International Federation of Gynecology and Obstetrics (FIGO) 2018 stage IB3 to IVA will be included prospectively. * Previous standard treatment based on concomitant chemoradiotherapy regimen. * Karnofsky performance status score ≥70, with estimated life expectancy ≥12 weeks, * Immunocompetent, * Positive research for types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 69, 73, 82 cfHPV-DNA in plasma at the end of chemoradiotherapy, * Proper hematological, liver and kidney functions. Inclusion criteria will include absolute neutrophils count ≥1.5 x 109/L, platelets ≥100 x 10/L, serum bilirubin ≤ 2.0 x upper limit of normal (ULN), calculated creatinine clearance ≥50 mL/min and alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase ≤ 2.5 x ULN. * Patients of child-bearing potential were obligated to use an approved contraceptive method during and for 3 months after the study; * Agree with research procedures, by signing the Informed Consent Form (ICF).","* Previous cervical cancer or other malignancies, * Pregnant women, * Inability to perform concurrent cisplatin based-chemoradiotherapy. * Tumors containing different HPV genotypes * Absence of anatomopathological examination to prove the diagnosis and/or staging examinations."
NCT06356311,"A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician's Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)",TroFuse-015,PHASE3,"Brazil, Chile, Colombia, Mexico, Peru","Centro de Pesquisa Clínica do Instituto do Câncer do Ceará ( Site 0405), Fortaleza, Brazil, [RECRUITING] | Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 0406), Natal, Brazil, [RECRUITING] | Hospital de Caridade de Ijuí ( Site 0412), Ijuí, Brazil, [RECRUITING] | Hospital Nossa Senhora da Conceição-Centro Integrado de Pesquisa em Oncologia ( Site 0400), Porto Alegre, Brazil, [RECRUITING] | Centro de Hematologia e Oncologia ( Site 0404), Joinville, Brazil, [RECRUITING] | Fundação Pio XII - Hospital de Câncer de Barretos-Unidade de Pesquisa Clínica ( Site 0401), Barretos, Brazil, [RECRUITING] | Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0411), São José do Rio Preto, Brazil, [RECRUITING] | A. C. Camargo Cancer Center ( Site 0409), São Paulo, Brazil, [RECRUITING] | IBCC - Núcleo de Pesquisa e Ensino ( Site 0402), São Paulo, Brazil, [RECRUITING] | Centro de Estudios Clínicos SAGA-CECSAGA ( Site 0503), Santiago, Chile, [RECRUITING]",Gastroesophageal Cancer,2,"[1] Sacituzumab tirumotecan (EXPERIMENTAL): Participants will receive sacituzumab tirumotecan at a dose of 4mg/kg by intravenous (IV) infusion on days 1, 15, and 29 of every 42-day cycle. || [2] Treatment of Physician's Choice (TPC) (ACTIVE_COMPARATOR): TPC include either trifluridine-tipiracil (35 mg/m\^2 orally (PO) twice a day (BID) on days 1 to 5 and 8 to 12 of every 28-day cycle), irinotecan (150 mg/m\^2 IV on days 1 and 15 of every 28-day cy...","* Has a histologically-or cytologically-confirmed diagnosis of advanced, unresectable or metastatic gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma * Has measurable disease per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) as assessed by the local site investigator/radiology. Lesions situated in a previously-irradiated area are considered measurable if progression has been shown in such lesions. * Has received, and progressed on, at least 2 prior chemotherapy and/or immunotherapy regimens for advanced, unresectable or metastatic gastroesophageal adenocarcinoma. * Participants are eligible regardless of human epidermal growth factor receptor-2 (HER2) status. Participants who are HER2+ must have previously received trastuzumab where available/appropriate * Has adequate organ function * Has provided tumor tissue sample for determination of trophoblast cell-surface antigen 2 (TROP2) status by the central laboratory before randomization for stratification * Participants who have AEs due to previous anticancer therapies must have recovered to Grade ≤1 or baseline (except for alopecia and vitiligo). Participants with endocrine related AEs who are adequately treated with hormone replacement therapy are eligible * Has measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 as assessed by the local site investigator/radiology * Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 3 days before randomization * Has ability to swallow oral medication for those who may receive trifluridine-tipiracil * Human immunodeficiency virus (HIV) infected participants must have well-controlled HIV on antiretroviral therapy (ART) * Hepatitis B surface antigen (HBsAg) positive participants are eligible if they have received hepatitis B virus (HBV) antiviral therapy and have undetectable HBV viral load * Participants with a history of hepatitis C virus (HCV) infection are eligib","* Has a history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing * Has Grade ≥2 peripheral neuropathy * Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, or chronic diarrhea) * Has uncontrolled, significant cardiovascular disease or cerebrovascular disease, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of corrected QT interval (QTcF) to \>480 ms, and/or other serious cardiovascular and cerebrovascular diseases within 6 months before the first dose of study intervention * Has accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks before the first dose of study intervention * Has received prior treatment with a trophoblast antigen 2(TROP2) targeted antibody-drug conjugate (ADC), a topoisomerase 1 inhibitor based, and/or a topoisomerase 1 inhibitor-based chemotherapy. * Has received prior systemic anticancer therapy within 2 weeks before the first dose of study intervention * Has received prior radiotherapy within 2 weeks before the first dose of study intervention, has radiation-related toxicities, requiring corticosteroids, and/or has had radiation pneumonitis * Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention * Is currently receiving a strong and/or moderate inducer/inhibitor of cytochrome P450 3A4 (CYP3A4) that cannot be discontinued for the duration of treatment with study intervention. The required washout period before starting study intervention is 2 weeks * Has received an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention * Has a known addition"
NCT05261399,"A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).",SAFFRON,PHASE3,"Argentina, Brazil, Chile","Research Site, Berazategui, Argentina, [RECRUITING] | Research Site, Buenos Aires, Argentina, [RECRUITING] | Research Site, CABA, Argentina, [RECRUITING] | Research Site, Córdoba, Argentina, [WITHDRAWN] | Research Site, Florida, Argentina, [RECRUITING] | Research Site, La Rioja, Argentina, [RECRUITING] | Research Site, Rosario, Argentina, [RECRUITING] | Research Site, Rosario, Argentina, [RECRUITING] | Research Site, San Miguel de Tucumán, Argentina, [RECRUITING] | Research Site, Viedma, Argentina, [RECRUITING]",Carcinoma | Non-Small-Cell Lung,2,"[1] Chemotherapy (ACTIVE_COMPARATOR): Pemetrexed (500 mg/m2) with either cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21-day cycles (Q3W) for 4 cycles, followed by pemetrexed maintenance (500 mg/m2) Q3W || [2] Savolitinib + Osimertinib (EXPERIMENTAL): 300 mg savolitinib BID plus 80 mg osimertinib QD","* Provision of signed and dated written ICF prior to any mandatory and non-mandatory study-specific procedures, sampling and analyses. * Participant must be ≥18 years (≥ 19 years of age in South Korea) at the time of signing the informed consent. All genders are permitted. * Histologically or cytologically confirmed locally advanced or metastatic NSCLC which is not amenable to curative therapy. * Must have at least one documented sensitising EGFR mutation: exon19 deletion, L858R mutation, and/or T790M. * Documented radiologic progression on first- or second-line treatment with osimertinib as the most recent anti-cancer therapy. * Mandatory provision of FFPE tumour tissue. * MET overexpression and/or amplification in tumour specimen collected following progression on prior osimertinib treatment. * Measurable disease as defined by RECIST 1.1. * Adequate haematological, liver, renal and cardiac functions, and coagulation parameters. * ECOG performance status of 0 or 1.","* Predominant squamous NSCLC, and small cell lung cancer. * Prior or current treatment with a third-generation EGFR-TKI other than Osimertinib. * Prior or current treatment with savolitinib or another MET inhibitors. * Spinal cord compression or brain metastases, unless asymptomatic and are stable. * History or active leptomeningeal carcinomatosis. * Unresolved toxicities from any prior therapy greater than CTCAE Grade 1 and prior platinum-therapy related Grade 2 neuropathies with the exception of alopecia and haemoglobin ≥ 9.0 g/dL. * Active/unstable cardiac diseases currently or within the last 6 months, clinically significant ECG abnormalities, and/or factors/medications that may affect QTc intervals. * History of liver cirrhosis of any origin and clinical stage; or history of other serious liver disease or chronic disease with relevant liver involvement. * Known serious active infection including, but not limited to, tuberculosis, or HIV, HBV or HCV or gastrointestinal disease. * Receipt of live attenuated vaccine (including against COVID-19) within 30 days prior to the first dose of study intervention. * Past medical history of ILD, drug-induced ILD, radiation pneumonitis, which required steroid treatment, or any evidence of clinically active ILD. * Participants currently receiving medications or herbal supplements known to be strong inducers of cytochrome P450 (CYP)3A4 or strong inhibitors of CYP1A2."
NCT06068985,Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade,CHERRY-PICK,PHASE2,Brazil,"NOB - Núcleo de Oncologia da Bahia (Oncoclínicas), Salvador, Brazil, [RECRUITING] | Oncocentro de Minas Gerais (Oncoclínicas), Belo Horizonte, Brazil, [RECRUITING] | CPO - Centro de Pesquisa em Oncologia do Hospital São Lucas da PUCRS, Porto Alegre, Brazil, [RECRUITING] | Faculdade de Ciências Médicas da Unicamp, Campinas, Brazil, [RECRUITING] | INCA - Instituto Nacional de Câncer, Rio de Janeiro, Brazil, [RECRUITING] | Centro Paulista de Oncologia (Oncoclínicas), São Paulo, Brazil, [RECRUITING] | Hospital de Amor de Barretos, São Paulo, Brazil, [RECRUITING]",Breast Cancer | HER2-positive Breast Cancer,1,"[1] PHESGO™-Based Neoadjuvant Therapy for HER2-Positive Early Breast Cancer (EXPERIMENTAL): This is a single-arm phase II neoadjuvant study using PHESGO™. Participants will receive three cycles of neoadjuvant PHESGO™, with a specific dosage regimen. After three cycles, participants will b...","* Signed ICF; Women between 18-80 years of age at time of signing ICF. * ECOG ≤ 1 * HER2+ breast cancer with clinical stage at presentation: T1cN1, T2, N0-1 * HER2 3+ by IHC, with strongly positive staining for HER2 protein in ≥ 80% of cells, and absence of HER2 negative areas in the tumor * ER IHC ≤10% * PR IHC negative (\<1%) or 0% of tumor cell nuclei * Tumors must have at least 10mm measured by breast echography and be assessable for SUVMax (maximum standardized uptake value (SUVmax) ≥ 2.5) using 18FDG-PET-CT scan on baseline imaging. * Availability of formalin-fixed, paraffin-embedded (FFPE) tumor tissue block for central confirmation of HER2 and hormone receptor status and additional biomarker research. * Baseline LVEF ≥ 55% measured by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA). * For women of childbearing potential (WOCBP) who are sexually active: agreement to remain abstinent (refrain from heterosexual intercourse) or use one highly effective non-hormonal contraceptive method with a failure rate of \< 1% per year, or two effective non-hormonal contraceptive methods during the treatment period and for 7 months after the last dose of HER2-targeted therapy, and agreement to refrain from donating eggs during this same period. * A negative serum pregnancy test must be available prior to randomization for WOCBP (premenopausal women and women \< 12 months after the onset of menopause), unless they have undergone surgical sterilization (removal of ovaries and/or uterus)","* Patients with metastatic disease. * Any previous systemic chemotherapy or anti-HER2 targeted therapy directed to breast cancer. * Patients with clinical N2 or N3 disease, T4, or inflammatory breast cancer. * Concurrent serious diseases that may interfere with planned treatment. * Patients with a history of concurrent or previously treated non-breast malignancies except for appropriately treated 1) non-melanoma skin cancer and/or 2) in situ carcinomas, including cervix, colon, and skin. A patient with previous invasive non-breast cancer is eligible provided he/she has been disease free for more than 5 years. * Patients who have received any previous systemic therapy (including chemotherapy, immunotherapy, HER2-targeted agents, endocrine therapy (selective estrogen receptor modulators, aromatase inhibitors, and antitumor vaccines) for treatment or prevention of breast cancer. * Patients who have a history of ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) if they have received any systemic therapy for its treatment, or radiation therapy to the ipsilateral breast. Patients are allowed to enter the study if treated with surgery alone. * Patients with high-risk for breast cancer who have received chemopreventive drugs in the past are not allowed to enter the study. * Patients with bilateral breast cancer. * Patients who have undergone an excisional biopsy of primary tumor and/or axillary lymph nodes. * Axillary lymph node dissection (ALND) or Sentinel lymph node biopsy (SLNB) prior to initiation of neoadjuvant therapy. Patients with clinically negative axilla (by physical examination and radiographic imaging) may undergo a core or needle biopsy procedure prior to neoadjuvant systemic therapy. * Treatment with any investigational drug within 28 days prior to randomization. * Serious cardiac illness or medical conditions. * Inadequate bone marrow function. * Impaired liver function. * Inadequate renal function. * Current severe, uncontrolled systemic "
NCT06317649,A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults With Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial,,PHASE2,Puerto Rico,"Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico, [RECRUITING] | San Juan City Hospital, San Juan, Puerto Rico, [SUSPENDED]",Acute Myeloid Leukemia,3,"[1] Regimen 1 (azacitidine, venetoclax) (EXPERIMENTAL): INDUCTION: Patients receive azacitidine IV or SC on days 1-7 of each cycle and venetoclax PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until patient achieves... || [2] Regimen 2 (azacitidine, venetoclax, gilteritinib) (EXPERIMENTAL): INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax and gilteritinib PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until patient achie... || [3] Regimen 3 (azacitidine, venetoclax, gilteritinib) (EXPERIMENTAL): INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days 1-28, and gilteritinib PO on days 8-21 of each cycle. Treatment repeats every 28 days for up to 2 cycles or un...","* Patient must be ≥ 60 years of age or adults ˂ 60 who in the opinion of the treating physician are better served by azanucleoside-based therapy rather than intensive, cytarabine-based induction based on clinical status (i.e., performance status, age \> 75 years), organ dysfunction, or disease biology * Patient must have a morphologically confirmed diagnosis of AML according to the World Health Organization (WHO) 2016 classification excluding acute promyelocytic leukemia (APL) with PML-RARA, AML with RUNX1-RUNX1T1, or AML with CBFB-MYH11 * Patient must have no prior therapy for AML with the exception of hydroxyurea and all-trans retinoic acid (ATRA), or leukapheresis. Patients with cytarabine-based emergency therapy prior to the start of therapy on this trial are eligible * Patient must have no prior therapy with hypomethylating agents or FLT3 inhibitors * Patient must have the FLT3-ITD or D835 mutation based on MyeloMATCH Master Screening and Reassessment Protocol (MSRP) * Patient must be assigned to this protocol by the myeloMATCH MSRP * Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. * All patients of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy. * A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) * Patient of childbearing potential and/or sexually active patients must not expect to conceive or father ch",
NCT06079671,"A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)",eVOLVECervical,PHASE3,"Brazil, Mexico, Peru, Puerto Rico","Research Site, Barretos, Brazil, [RECRUITING] | Research Site, Belo Horizonte, Brazil, [RECRUITING] | Research Site, Curitiba, Brazil, [RECRUITING] | Research Site, Fortaleza, Brazil, [RECRUITING] | Research Site, Fortaleza, Brazil, [NOT_YET_RECRUITING] | Research Site, Natal, Brazil, [RECRUITING] | Research Site, Porto Alegre, Brazil, [RECRUITING] | Research Site, Porto Alegre, Brazil, [RECRUITING] | Research Site, Porto Velho, Brazil, [RECRUITING] | Research Site, Recife, Brazil, [NOT_YET_RECRUITING]",Locally Advanced Cervical Cancer,2,[1] Volrustomig (EXPERIMENTAL): Volrustomig || [2] Placebo (PLACEBO_COMPARATOR): Placebo,"For inclusion in the study, patients should fulfill the following criteria: 1. Female. 2. Aged at least 15 years at the time of screening. 3. Body weight \> 35 kg. 4. Histologically documented FIGO 2018 Stage IIIA to IVA cervical adenocarcinoma, cervical squamous carcinoma, or cervical adenosquamous carcinoma, with no evidence of metastatic disease. 5. Initial staging procedures performed no more than 42 days prior to the first dose of CCRT. 6. Provision of FFPE tumor sample to assess the PD-L1 expression. 7. Must not have progressed following CCRT, participants with persistent disease after definitive CCRT must not be amenable to other available therapies with curative intent. 8. WHO/ECOG performance status of 0 or 1. 9. Adequate organ and bone marrow function. 10. Capable of providing signed informed consent.","Patients should not enter the study if any of the following exclusion criteria are fulfilled: 1. Diagnosis of small cell (neuroendocrine) or mucinous adenocarcinoma of cervical cancer. 2. Evidence of metastatic disease. 3. Intent to administer a fertility-sparing treatment regimen. 4. History of organ transplant or allogenic stem cell transplant. 5. Active or prior documented autoimmune or inflammatory disorders. 6. Uncontrolled intercurrent illness. 7. History of another primary malignancy except for a) Malignancy treated with curative intent with no known active disease ≥2 years before the first dose of study intervention; b) Adequately treated nonmelanoma skin cancer or lentigo maligna, or carcinoma in situ without evidence of disease. 8. Unresolved toxicities from previous CCRT except for irreversible toxicity that is not reasonably expected to be exacerbated. 9. Prior history or presence of vesicovaginal, colovaginal, or rectovaginal fistula. 10. History of anaphylaxis to any biologic therapy or vaccine. 11. Current or prior use of immunosuppressive medication within 14 days before the first dose of the study intervention is excluded. The following are exceptions to this criterion: a) Intranasal, inhaled, topical steroids, or local steroid injections (eg, intraarticular injection); b) Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication or chemotherapy premedication) or a single dose for palliative purpose (eg, pain control). 12. Patients who have undergone a previous hysterectomy, including a supracervical hysterectomy, or will have a hysterectomy as part of their initial cervical cancer therapy. 13. Any prior (besides prior CCRT) or concurrent treatment for cervical cancer. 14. Major surgical procedures within 4 weeks prior to the first dose of the study intervention or still recovering from prior surgery. 15. Exposure to immune mediated therapy prior to the study for any indication. 16. Receipt of live attenuated vaccine within"
NCT06236438,"A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)",LIVIGNO-4,"PHASE2, PHASE3","Chile, Puerto Rico","Oncored /Id# 261801, Vitacura, Chile, [RECRUITING] | Centro de Investigacion y Desarrollo Oncologico /ID# 261800, Temuco, Chile, [RECRUITING] | Sociedad Cem-Cancer Spa /Id# 262316, Viña del Mar, Chile, [RECRUITING] | Fundacion Arturo Lopez Perez /ID# 261700, Providencia, Chile, [RECRUITING] | Hospital Clinico Universidad De Los Andes /ID# 262665, Santiago, Chile, [RECRUITING] | Pan American Center for Oncology Trials /ID# 269666, Rio Piedras, Puerto Rico, [RECRUITING]",Non-Small Cell Lung Cancer,6,"[1] Stage 1 (Cohort 1): Livmoniplimab Dose A (EXPERIMENTAL): Participants will receive livmoniplimab (dose A)+ budigalimab, + chemotherapy for 4 cycles followed by livmoniplimab + budigalimab + pemetrexed. || [2] Stage 1 (Cohort 2): Livmoniplimab Dose B (EXPERIMENTAL): Participants will receive livmoniplimab (dose B) + budigalimab, + chemotherapy for 4 cycles followed by livmoniplimab + budigalimab + pemetrexed. || [3] Stage 1 (Cohort 3): Budigalimab (EXPERIMENTAL): Participants will receive budigalimab + chemotherapy for 4 cycles followed by budigalimab + pemetrexed. || [4] Stage 1 (Cohort 4): Pembrolizumab (EXPERIMENTAL): Participants will receive pembrolizumab + chemotherapy for 4 cycles followed by pembrolizumab + pemetrexed. || [5] Stage 2 (Arm 1): Livmoniplimab (Dose Optimized) (EXPERIMENTAL): Participants will receive livmoniplimab (dose optimized) + budigalimab + chemotherapy for 4 cycles followed by livmoniplimab + budigalimab + pemetrexed. || [6] Stage 2 (Arm 2): Placebo (EXPERIMENTAL): Participants will receive placebo + pembrolizumab + chemotherapy for 4 cycles followed by pembrolizumab + pemetrexed.","* Diagnosis of histologically or cytologically confirmed metastatic nonsquamous non-small cell lung cancer (NSCLC) with no known epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) mutation, or other genomic aberration for which a locally approved targeted therapy is available. * Must have at least 1 measurable lesion per response evaluation criteria in solid tumors (RECIST) v1.1 as determined by the local site Investigator/radiology assessment. * Life expectancy of at least 3 months and adequate organ function.",\- Received prior systemic therapy for the treatment of metastatic NSCLC.
NCT06883409,Efficiency of Laparoscopic Interval Cytoreductive Surgery After Neoadjuvant Chemotherapy in Patients With Stage III and IV Epithelial Ovarian Cancer,,NA,Mexico,"Instituto Nacional de Cancerologia, México, Mexico, [RECRUITING]",Ovarian Neoplasms,1,"[1] Patients with advance ovarian cancer already treated with NACT and eligible for MIS (EXPERIMENTAL): Were enrolled patients who met the inclusion criteria by receiving 3 to 4 cycles of NACT, with ca 125 up to 200 U/ml, and partial or complete response by image (PET-CT), and subsequently underwent ...","* Diagnosis of epithelial ovarian cancer (all subtypes of epithelial ovarian cancer) in stage III-IV * Partial and complete response to treatment with QTNA after 3-4 cycles, evaluated by PET-CT imaging study, patients that the functional unit decides to incorporate into the project. * Ca 125 which will have to be less than 200 * ECOG 0 to 2 without medical contraindication to perform surgery (≤ ASA 2 or ≤ Goldman 2).","* Partial response with persistence of ascites or pleural effusion. * With unresectability criteria (multiple intrahepatic liver metastases, retroperitoneal lymph node conglomerates \>2cm above the renal lymph nodes, metastatic disease above the diaphragm, multiple intestinal involvement and mesentery retraction)."
NCT04546399,"A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged &gt;/= 1 to &lt; 31 Years Old With First Relapse",,PHASE2,Puerto Rico,"University Pediatric Hospital, San Juan, Puerto Rico, [RECRUITING]",Down Syndrome | Recurrent B Acute Lymphoblastic Leukemia,9,"[1] Arm G (dexamethasone, blinatumomab, nivolumab,MTX) DS patients (EXPERIMENTAL): Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV over 30 minutes on days 11 of cycle 1 and day 3 of cycle ... || [2] Group 1, Arm A (dexamethasone, blinatumomab, MTX) (EXPERIMENTAL): ARM A: Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1-2, MTX IT, cytarabine IT, or ITT IT on days 1, 15, and 36... || [3] Group 1, Arm B (dexamethasone, blinatumomab, MTX) (EXPERIMENTAL): Patients receive dexamethasone, blinatumomab, and MTX, cytarabine, or ITT as in Arm A. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. ... || [4] Group 2, Arm C (dexamethasone, blinatumomab, MTX) (EXPERIMENTAL): Patients receive dexamethasone PO or IV on day 1 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1 and 2, and methotrexate IT on days 1 and 15 of cycles 1 and 2 (day 1 ma... || [5] Group 2, Arm D (dexamethasone, nivolumab, blinatumomab, MTX) (EXPERIMENTAL): Patients receive dexamethasone, blinatumomab, and MTX as in Arm C. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats ev... || [6] Group 3, Arm E (dexamethasone, blinatumomab, MTX) (EXPERIMENTAL): See Outline section || [7] Group 3, Arm F (dexamethasone, blinatumomab, nivolumab) (EXPERIMENTAL): See Outline section || [8] Group 4 Arm I (Dexamethasone, blinatumomab, nivolumab) (EXPERIMENTAL): Patients receive dexamethasone PO or IV on day 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV, over 30 minutes on day 11 of cycle 1 and day 3 of cycle 2... || [9] Group 4, Arm H (dexamethasone blinatumomab) (EXPERIMENTAL): Patients receive dexamethasone PO or IV on day 1 and 8 of cycle 1 only,","* Patients must be \>= 1 and \< 31 years at time of enrollment * Patients must have first relapse of CD19+ B-ALL (relapse blasts must express CD19) in one of the following categories: * Isolated bone marrow relapse * Isolated central nervous system (CNS) (excluding known optic nerve/retinal and CNS chloromas) and/or testicular relapse * Combined bone marrow with extramedullary relapse in the CNS (excluding known optic nerve/retinal and CNS chloromas) and/or testes * Patients with Down syndrome (DS) are eligible in the following categories: * Isolated bone marrow relapse * Combined bone marrow with CNS (excluding known optic nerve/retinal and CNS chloromas) and/or testicular relapse * Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients \> 16 years of age and Lansky for patients =\< 16 years of age * Of note, for patients with developmental delay (e.g., Down syndrome) regardless of age, Lansky scale may be substituted for Karnofsky scale. However, the requirement for ECOG 0-2 remains, regardless of known history of developmental delay * Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study * Patients with prior blinatumomab or CD19+ chimeric antigen receptor therapy in the upfront setting will be eligible, provided relapsed lymphoblasts retain CD19 expression * Patients must not have had a prior hematopoietic stem cell transplant * A single intrathecal chemotherapy at the time of relapse will be allowed. If \< 7 days have elapsed between this intrathecal therapy (IT) and the start of protocol therapy, then the day 1 intrathecal chemotherapy (i.e. methotrexate, cytarabine, or triple intrathecal) may be omitted * In the 28 days prior to enrollment, up to five days of post-relapse, pre-enrollment therapy (steroids and/or hydroxyurea only) is permissible * Patients with Down syndrome","* Patients with B-lymphoblastic lymphoma (B-LLy) * Patients with Burkitt leukemia/lymphoma or mature B-cell leukemia * Patients with Philadelphia chromosome positive (Ph+) B-ALL * Patients with mixed phenotype acute leukemia (MPAL) * Patients with known Charcot-Marie-Tooth disease * Patients with known MYC translocation associated with mature (Burkitt) B-cell ALL, regardless of blast immunophenotype * Patients with active, uncontrolled infection defined as: * Positive bacterial blood culture within 48 hours of study enrollment * Receiving IV or PO antibiotics for an infection with continued signs or symptoms. Note: Patients may be receiving IV or oral antibiotics to complete a course of therapy for a prior documented infection if cultures have been negative for at least 48 hours and signs or symptoms of active infection have resolved. For patients with clostridium (C.) difficile diarrhea, at least 72 hours of antibacterial therapy must have elapsed and stools must have normalized to baseline. * Fever above 38.2 degrees Celsius (C) within 48 hours of study enrollment with clinical signs of infection. Fever without clinical signs of infection that is attributed to tumor burden is allowed if blood cultures are negative for \> 48 hours * A positive fungal culture within 30 days of study enrollment or active therapy for presumed invasive fungal infection * Active viral or protozoal infection requiring IV treatment * Patients known to have one of the following concomitant genetic syndromes: Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome are not eligible. * Patients with uncontrolled HIV, hepatitis B, or hepatitis C infection. Of note, patients with known human immunodeficiency virus (HIV) infection on effective anti-retroviral therapy with undetectable viral load for at least the last 6 months prior to enrollment are eligible. Similarly, hepatitis B and hepatitis C positive patie"
NCT06430866,"A Randomized, Double-blind Study to Compare the Pharmacokinetics Between ABP 234 and Keytruda® (Pembrolizumab) in Participants With Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy",Eucalyptus,PHASE3,"Argentina, Chile, Mexico","Fundacion ARS Medica, San Salvador de Jujuy, Argentina, [RECRUITING] | Ionc Instituto Oncologico De Cordoba, Córdoba, Argentina, [RECRUITING] | Cdiem, Providencia, Chile, [RECRUITING] | Centro de Investigaciones Clinicas Vina del Mar Ltda., ViÃ±a Del Mar, Chile, [RECRUITING] | Centro de Investigacin de Enfermedades Respiratorias e Inmunologicas Limitada CIERI, Viña del Mar, Chile, [RECRUITING] | Instituto Oncologico Fundacion Arturo Lopez Perez (FALP), Providencia, Chile, [TERMINATED] | Centro de Oncologa de Precisin, Region Metropolitana, Chile, [RECRUITING] | Clinica Santa Maria, Santiago, Chile, [RECRUITING] | K2 Oncology, Santiago, Chile, [RECRUITING] | Icegclinic Research and Care, Santiago, Chile, [RECRUITING]",Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC),2,[1] ABP 234 (EXPERIMENTAL): Participants will receive ABP 234 every 3 weeks (Q3W) for up to 12 months. || [2] Pembrolizumab (ACTIVE_COMPARATOR): Participants will receive pembrolizumab Q3W for up to 12 months.,"* Males and females ≥ 18 years of age. * Pathological diagnosis of non-squamous NSCLC. * Stage IB (T2 ≥ 4 cm), II, or IIIA NSCLC after complete surgical resection and received platinum-based chemotherapy. * For programmed death-ligand 1 (PD-L1) testing, tumor tissue from the resected site of disease must be sent, received, and analyzed for biomarkers. * Treated with platinum-based chemotherapy: 1. Chemotherapy must have begun within 12 weeks after the resection surgery. 2. The last chemotherapy dose must have been completed at least 3 weeks and no more than 12 weeks before the participant is randomized. * Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1. * Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and ROS-1 negative. * Have adequate organ function as indicated by laboratory values. * Absence of severe comorbidities that in the opinion of the investigator might hamper participation in the study and/or treatment administration. * Participants must sign approved informed consent form (ICF).","* Evidence of disease. * Prior treatment with anti-programmed cell death protein 1 and anti-PD-L1/2 modulating agents in adjuvant setting. * History or presence of immune-mediated disorders. * Participants with type 1 diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, or skin disorders not requiring systemic treatment are permitted to enroll. * Participant has positive screen for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb) or hepatitis C (HCV). * Medical conditions requiring systemic immunosuppression. * History of any other malignancy other than NSCLC within 5 years prior to screening, except for appropriately treated carcinoma in situ of the cervix, nonmelanoma skin carcinoma, papillary thyroid cancer treated with surgery, etc. * Known clinically significant history of liver disease consistent with Child-Pugh Class B or C, including active viral or other hepatitis virus, current alcohol abuse or cirrhosis. * Surgery or chemotherapy-related toxicity not resolved to grade 1 with the exception of grade ≤ 2 alopecia, fatigue, neuropathy, and lack of appetite/nausea. * Woman of childbearing potential who is pregnant or is breast feeding. * Woman of childbearing potential who is not consenting to use highly effective methods of birth control. * Man with a partner of childbearing potential who does not consent to use highly effective methods of birth control. * Participant has known hypersensitivity to monoclonal antibodies or to any of the excipients of the investigational product (IP). * Active cardiac disease or history of cardiac dysfunction, that in the judgment of the investigator would place the participant at additional risk when participating in the study. * Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current neumonitis/interstitial lung disease. * Live vaccine therapy within 4 weeks pr"
NCT04622956,GVHD Prophylaxis With Methotrexate and Cyclosporine in Haploidentical Stem Cell Transplantation Using Posttransplant Cyclophosphamide in Hematologic Malignancies: Phase I/II Trial,,"PHASE1, PHASE2",Brazil,"Instituto Nacional de Câncer José Alencar Gomes Da Silva - Inca, Rio de Janeiro, Brazil, [RECRUITING] | Centro de Hematologia e Hemoterapia - HEMOCENTRO, Campinas, Brazil, [RECRUITING] | Hospital Amaral Carvalho / Fundação Dr. Amaral Carvalho, Jaú, Brazil, [RECRUITING] | Hospital das Clinicas da Universidade de Sao Paulo, São Paulo, Brazil, [RECRUITING]",Graft Vs Host Disease | Hematopoietic Neoplasm,2,"[1] Experimental (EXPERIMENTAL): GVHD prophylaxis will consist of high-dose PTCy (50 mg/kg i.v. on days +3 and +4) with mesna, cyclosporine (initiated on day +5) and methotrexate i.v (see doses on the right). Cyclosporine will be ... || [2] Control Group (NO_INTERVENTION): GVHD prophylaxis will consist of high-dose PTCy (50 mg/kg i.v. on days +3 and +4) with mesna, cyclosporine (initiated on day +5) and mycophenolate mofetil (15 mg/kg/dose p.o. t.i.d. initiated on da...","* Diagnosis of acute myeloid leukemia and chronic myeloid leukemia in complete morphologic remission, myelodysplastic syndrome with less than 10% in bone marrow or peripheral blood, Ph-negative acute lymphoblastic leukemia in complete morphologic remission, chemosensitive Hodgkin lymphoma or non-Hodgkin lymphoma in at least partial remission * Donor type: haploidentical related donor * Graft source: bone marrow or peripheral blood * Recipients of non-myeloblative or myeloablative intensity conditioning * Left Ventricle Ejection fraction \> 40% * Estimated creatinine clearance \> 40 mL/min * Adjusted DLCO ≥ 40% and FEV1 ≥ 40% * Total bilirubin \< 2x ULN e ALT/AST \< 2.5x ULN","* Prior allogeneic transplant * Ex-vivo graft manipulation (T-cell-depleted or CD34-selected grafts) * Use of alemtuzumab or anti-thymocyte globulin * KPS \< 70% * Patients with uncontrolled bacterial, viral or fungal infections (currently taking medication and with progression or no clinical improvement) at time of enrollment * Pregnant or lactating women * Patients seropositive for human immunodeficiency virus (HIV) or active hepatitis B or C infection by PCR * Presence of fluid collection (ascites, pleural or pericardial effusion) that may interfere with methotrexate clearance or make methotrexate use contraindicated * Patients with a serious medical or psychiatric illness likely to interfere with participation in this study"
NCT06943872,"A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",,PHASE3,"Argentina, Brazil","Hospital Aleman, CABA, Argentina, [NOT_YET_RECRUITING] | FUNDALEU, Caba, Argentina, [NOT_YET_RECRUITING] | Instituto Alexander Fleming (Iaf), Ciudad Autonoma Buenos Aires, Argentina, [NOT_YET_RECRUITING] | CETUS, Belo Horizonte, Brazil, [RECRUITING] | Universidade de Campinas Centro de Hematologia E Hemoterapia, Campinas, Brazil, [NOT_YET_RECRUITING] | Hospital Erasto Gaertner, Curitiba, Brazil, [RECRUITING] | Complexo Hospitalar de Niteroi, Niterói, Brazil, [NOT_YET_RECRUITING] | Irmandade Da Santa Casa de Misericordia Hospital Porto Alegre, Porto Alegre, Brazil, [RECRUITING] | Hospital Sao Lucas, Rio de Janeiro, Brazil, [NOT_YET_RECRUITING] | Instituto Dor de Pesquisa E Ensino Rio de Janeiro, Rio de Janeiro, Brazil, [RECRUITING]",Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma,4,[1] Arm A: Sonrotoclax plus Obinutuzumab (EXPERIMENTAL): Sonrotoclax and obinutuzumab will be administered in combination. || [2] Arm B: Sonrotoclax plus Rituximab (EXPERIMENTAL): Sonrotoclax and rituximab will be administered in combination. || [3] Arm C: Sonrotoclax plus Obinutuzumab (MRD) (EXPERIMENTAL): Sonrotoclax and obinutuzumab will be administered in combination with treatment guided by evaluation of minimal residual disease (MRD). || [4] Arm D: Venetoclax plus Rituximab (ACTIVE_COMPARATOR): Venetoclax and rituximab will be administered in combination.,"* Confirmed diagnosis of CLL/SLL that meets the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria * Received one or more prior therapies for CLL/SLL. For each line of therapy, participants must have received at least 2 cycles of the therapy * Participants with prior BCL2i exposure are eligible if remission duration was ≥3 years with ≥2 years from last BCL2i intake * Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1, or 2 * Adequate organ function","* Known active prolymphocytic leukemia or currently suspected Richter's transformation * Prior autologous stem cell transplantation or chimeric antigen receptor T-cell therapy within 3 months before first dose of study drug * Prior allogeneic stem cell transplant with active graft-versus-host disease (GVHD), requiring immunosuppressive drugs for treatment of GVHD, or have taken calcineurin inhibitors within 4 weeks prior to consent * Known central nervous system involvement by CLL/SLL * Severe or debilitating pulmonary disease * Clinically significant cardiovascular disease NOTE: Other protocol defined Inclusion/Exclusion criteria may apply."
NCT05952024,"A Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With Diffuse Large B-Cell Lymphoma (ACRUE)",ACRUE,PHASE2,"Brazil, Puerto Rico","Research Site, Barretos, Brazil, [ACTIVE_NOT_RECRUITING] | Research Site, Belo Horizonte, Brazil, [ACTIVE_NOT_RECRUITING] | Research Site, Brasília, Brazil, [ACTIVE_NOT_RECRUITING] | Research Site, Brasília, Brazil, [RECRUITING] | Research Site, Brasília, Brazil, [ACTIVE_NOT_RECRUITING] | Research Site, Campinas, Brazil, [ACTIVE_NOT_RECRUITING] | Research Site, Curitiba, Brazil, [ACTIVE_NOT_RECRUITING] | Research Site, Florianópolis, Brazil, [NOT_YET_RECRUITING] | Research Site, Florianópolis, Brazil, [RECRUITING] | Research Site, Goiânia, Brazil, [ACTIVE_NOT_RECRUITING]",Diffuse Large B-Cell Lymphoma,1,[1] Acalabrutinib and Rituximab (EXPERIMENTAL): Patients will receive Dose A of acalabrutinib orally in X dosing schedule beginning on Cycle 1 Day 1 for a maximum of 28 cycles or until 2014 Lugano Classification for Non-Hodgkin's Lymphoma (NHL)-...,"* ≥ 80 years of age at the time of screening, or * ≥ 65 to 79 years of age at the time of screening and considered ineligible for chemoimmunotherapy * Histologically documented DLBCL * No prior treatment for DLBCL * Stage II, III, or IV disease by the Ann Arbor Classification . * Eastern Cooperative Oncology Group performance status of 0, 1, or 2 with no deterioration over the previous 2 weeks prior to baseline or day of the first dosing except when due to underlying lymphoma. * At least 1 lesion that can be accurately measured at baseline as ≥ 10 mm in the longest diameter with computed tomography or magnetic resonance imaging and is suitable for accurate repeated measurements. * Adequate organ and marrow function independent of growth factor or transfusion support within 1 week of Screening.","* Any evidence of diseases (such as severe or uncontrolled systemic diseases, including uncontrolled hypertension, renal transplant, and active bleeding diseases), that would make the study undesirable for the patient or that would impact compliance with the protocol. * History of prior or current malignancy, that would affect compliance with the protocol or interpretation of the results. * Serologic status reflecting active hepatitis B or C infection. * Serological positivity or known infection with HIV. * Active central nervous system involvement by lymphoma, leptomeningeal disease, or spinal cord compression. * Any comorbidity or organ system impairment rated with a single Cumulative Illness Rating Scale-Geriatric score (CIRS-G) of 4 or a total CIRS-G score of \> 17. * History of or ongoing confirmed Progressive Multifocal Leukoencephalopathy. * Known active significant infection. * History of stroke or intracranial haemorrhage within 6 months before the first dose of study drug. * History of bleeding diathesis (eg, haemophilia, von Willebrand disease). * Major surgical procedure within 30 days of first dose of study intervention or anticipated major surgery during the study timeframe. * Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists. * Received a live virus vaccination within 28 days of the first dose of study drug."
NCT06685718,"Phase 1a/1b, Open-Label Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of a CDAC Degrading EGFR, BG-60366, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer",,PHASE1,Brazil,"Fundacao Pio Xii Hospital de Amor de Barretos, Barretos, Brazil, [NOT_YET_RECRUITING] | Liga Norte Riograndene Contra O Cancer, Natal, Brazil, [NOT_YET_RECRUITING] | Hospital Sao Lucas Da Pucrs, Porto Alegre, Brazil, [NOT_YET_RECRUITING] | Hospital Sao Rafael (Rede Dor), Salvador, Brazil, [NOT_YET_RECRUITING] | Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto, São José do Rio Preto, Brazil, [NOT_YET_RECRUITING] | Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira, São Paulo, Brazil, [NOT_YET_RECRUITING] | Hospital Israelita Albert Einstein, São Paulo, Brazil, [NOT_YET_RECRUITING] | Hospital Santa Rita de Cassia Afecc, Vitória, Brazil, [NOT_YET_RECRUITING]",Non-Small Cell Lung Cancer | Lung Cancer | NSCLC | NSCLC (Non-small Cell Lung Carcinoma) | EGFR Activating Mutation,2,[1] Phase 1a: Dose Escalation and Safety Expansion (EXPERIMENTAL): Sequential cohorts of increasing dose levels of BG-60366 will be evaluated as monotherapy. || [2] Phase 1b: Dose Expansion (EXPERIMENTAL): Recommended Dose(s) for Expansion (RDFE\[s\]) of BG-60366 as monotherapy determined from Phase 1a will be evaluated.,"* Histologically or cytologically confirmed diagnosis of NSCLC, carrying an EGFR activating mutation prior to receiving standard EGFR-tyrosine kinase inhibitor (EGFR-TKI) * Phase 1a general inclusion criteria: * Disease progression on prior third-generation EGFR-TKI for advanced or metastatic disease, and either progressed or ineligible for currently available standard-of-care treatment (eg, platinum-based chemotherapy) after EGFR-TKI treatment * Phase 1a safety expansion * Documentation of EGFR resistance mutations (ie, C797s) * At least ≥ 1 evaluable lesion (for Phase 1a Dose Escalation) or at least ≥ 1 measurable lesion (for Phase 1a Safety Expansion or Phase 1b Dose Expansion) per RECIST v1.1 * EGFR resistance mutations may be detected locally either from tumor tissue or circulating tumor DNA (ctDNA) in blood, and samples used for detection of resistance mutations must be collected after progression on the most recent systemic antitumor treatment * Adequate organ function * Stable Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1","* Any previous histologic or cytologic evidence of small cell or combined small cell/non-small cell disease in the archival tumor tissue or tumor biopsy before enrollment * Symptomatic spinal cord compression * Brain metastases which are symptomatic and/or requiring emergency treatment (eg, starting steroid, or stereotactic radiation/whole-brain radiation within 2 weeks before first dose of study drug) * Prior treatment with fourth-generation EGFR-TKI, other CDAC/proteolysis-targeting chimeras (PROTAC) compounds targeting EGFR mutations, or other drugs with the mechanism of action specifically targeting EGFR resistance mutations (eg, C797X) (except for the first- to third-generation EGFR-TKIs) * Any history of interstitial lung disease (ILD) or ≥ Grade 2 noninfectious pneumonitis ≤ 2 years before the first dose of study drug, or has current ILD/noninfectious pneumonitis, or where suspected active ILD/noninfectious pneumonitis cannot be ruled out by imaging during screening * Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage Note: Other protocol defined Inclusion/Exclusion criteria may apply."
NCT06153238,"A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics of GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU Authorized Keytruda® in Participants With Stage II and III Melanoma Requiring Adjuvant Treatment With Pembrolizumab",,PHASE1,"Brazil, Mexico","Sandoz Investigational Site, Barretos, Brazil, [RECRUITING] | Sandoz Investigational Site, Belo Horizonte, Brazil, [RECRUITING] | Sandoz Investigational Site, Canoas, Brazil, [RECRUITING] | Sandoz Investigational Site, Caxias do Sul, Brazil, [RECRUITING] | Sandoz Investigational Site, Curitiba, Brazil, [RECRUITING] | Sandoz Investigational Site, Florianópolis, Brazil, [RECRUITING] | Sandoz Investigational Site, Fortaleza, Brazil, [RECRUITING] | Sandoz Investigational Site, Itajaí, Brazil, [RECRUITING] | Sandoz Investigational Site, Porto Alegre, Brazil, [RECRUITING] | Sandoz Investigational Site, Porto Velho, Brazil, [RECRUITING]",Melanoma,3,[1] GME751 (EXPERIMENTAL): Subjects will receive GME751 via intravenous (IV) infusion. || [2] Keytruda - EU (ACTIVE_COMPARATOR): Subjects will receive Keytruda-EU via intravenous (IV) infusion. || [3] Keytruda - US (ACTIVE_COMPARATOR): Subjects will receive Keytruda-US via intravenous (IV) infusion.,* At least 18 years of age * Advanced Melanoma * Completely removed melanoma by surgery performed within 13 weeks of randomization * Adequate organ function * Subject has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1,* Known history or evidence of ocular or uveal melanoma * Known history of hypersensitivity (grade ≥3) to pembrolizumab or its excipients * Known History of auto-immune disease * Received live vaccine ≤30 days before the first study treatment * Prior treatment with anti-PD-1 agents or agent against another stimulatory or co-inhibitory T cell receptor * Active autoimmune disease that has necessitated chronic systemic treatment within 2 years before the first study treatment Other protocol-defined inclusion/exclusion criteria apply
NCT06428396,"A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastic Breast Cancer After Progression on Previous Endocrine Therapy (LITESPARK-029)",,PHASE2,"Argentina, Chile, Colombia","Centro de Investigaciones Metabólicas (CINME)-Oncology ( Site 0504), CABA, Argentina, [RECRUITING] | Hospital Británico de Buenos Aires-Oncology ( Site 0500), Ciudad Autónoma de Buenos Aires, Argentina, [RECRUITING] | Instituto de Investigaciones Clínicas Mar del Plata ( Site 0502), Mar del Plata, Argentina, [RECRUITING] | Instituto Alexander Fleming-Alexander Fleming ( Site 0505), Buenos Aires, Argentina, [RECRUITING] | Sanatorio Allende - Cerro-Oncology ( Site 0506), Córdoba, Argentina, [RECRUITING] | Instituto de Oncología de Rosario ( Site 0501), Rosario, Argentina, [RECRUITING] | Centro de Investigación del Maule ( Site 4106), Talca, Chile, [RECRUITING] | FALP ( Site 4102), Santiago, Chile, [RECRUITING] | Pontificia Universidad Catolica de Chile ( Site 4108), Santiago, Chile, [RECRUITING] | Bradfordhill ( Site 4100), Santiago, Chile, [RECRUITING]",Metastatic Breast Cancer,2,"[1] Belzutifan + Fulvestrant (EXPERIMENTAL): Participants will receive belzutifan 120 mg orally once daily (QD) PLUS fulvestrant 500 mg via intramuscular (IM) injection on Days 1 and 15 of Cycle 1, and Day 1 of each 28-day cycle thereafter un... || [2] Everolimus + ET (fulvestrant or exemestane) (ACTIVE_COMPARATOR): Participants will receive everolimus 10 mg orally QD PLUS investigator's choice of fulvestrant 500 mg via IM injection on Days 1 and 15 of Cycle 1, and Day 1 of each 28-day cycle thereafter OR exem...",* Has a diagnosis of estrogen receptor positive (ER+)/human epidermal growth factor receptor negative (HER2-) invasive breast carcinoma that is either locally advanced disease not amenable to resection or metastatic disease not treatable with curative intent * Has documented radiographic confirmation of disease progression during or after the last administered endocrine therapy (ET) * Provides additional tissue from the same sample used to determine ER and HER2 status locally * Has received ET in the noncurative setting and has 1) Radiographic disease progression on 12 months or more of ET in combination with CDK4/6 inhibitor in the noncurative setting or 2) Received at least 2 lines of ET in the noncurative setting including CDK4/6 inhibitor where the CDK 4/6 inhibitor was discontinued due to intolerance * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed within 7 days of randomization * Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement or participants who have ≤Grade 2 neuropathy are eligible * Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks prior to the first dose of study intervention and have undetectable HBV viral load prior to randomization,"* Has Breast cancer amenable to treatment with curative intent * Is unable to receive any of the endocrine therapies (ETs) (ie, fulvestrant or exemestane) * Has known difficulty in tolerating oral medications, unable to swallow orally administered medication, or conditions which would impair absorption of oral medications such as uncontrolled nausea or vomiting (ie, CTCAE =Grade 3 despite antiemetic therapy), ongoing gastrointestinal obstruction, motility disorder, malabsorption syndrome, or prior gastric bypass * Has advanced/metastatic, symptomatic visceral spread at risk of rapidly evolving into life-threatening complications * Has active, bleeding diathesis, or on oral anti-vitamin K medication * Has history of noninfectious pneumonitis/interstitial lung disease including radiation pneumonitis that required steroids or has current pneumonitis/interstitial lung disease * Has a known germline BRCA mutation (deleterious or suspected deleterious) and has received previous treatment with poly-ADP ribose polymerase (PARP) inhibition either in the adjuvant or metastatic setting * Has received prior fulvestrant in the adjuvant, unresectable locally advanced, or metastatic setting * Has received any line of cytotoxic chemotherapy or PARP inhibitor in the unresectable or noncurative advanced/metastatic setting * Has received prior radiotherapy for non-central nervous system (CNS) disease or required corticosteroids for radiation-related toxicities including radiation pneumonitis, within 14 days of the first dose of study intervention * Is currently receiving either a strong inhibitor or inducer of CYP3A4 that cannot be discontinued for the duration of the study * Has received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization * Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention * Has concurrent active Hepatitis B and Hepatitis C virus infection * Has clinically signi"
NCT05139017,"A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003)",,"PHASE2, PHASE3","Argentina, Brazil, Chile, Colombia, Costa Rica, Guatemala, Mexico, Peru","Hospital Italiano de Buenos Aires ( Site 2203), Ciudad Autonoma de Buenos Aires, Argentina, [RECRUITING] | Instituto de Investigaciones Clínicas Mar del Plata ( Site 2205), Mar del Plata, Argentina, [RECRUITING] | Hospital Aleman ( Site 2200), Buenos Aites, Argentina, [RECRUITING] | Instituto Alexander Fleming ( Site 2201), CABA, Argentina, [RECRUITING] | Hospital Privado Universitario de Córdoba ( Site 2202), Córdoba, Argentina, [RECRUITING] | Hospital Erasto Gaertner ( Site 2302), Curitiba, Brazil, [RECRUITING] | Liga Norte Riograndense Contra o Câncer ( Site 2305), Natal, Brazil, [RECRUITING] | Hospital Paulistano ( Site 2300), São Paulo, Brazil, [RECRUITING] | Pesquisa Clínica do Serviço de Hematologia do Hospital das Clínicas da FMUSP ( Site 2306), São Paulo, Brazil, [RECRUITING] | IC La Serena Research ( Site 2405), La Serena, Chile, [RECRUITING]",DLBCL | Diffuse Large B-Cell Lymphoma,6,"[1] ZV + R-GemOx (Part 1) (EXPERIMENTAL): Participants in this arm will receive doses of ZV (from 1.5 mg/Kg up to 2.5 mg/Kg) plus Rituximab 375 mg/m\^2, Gemcitabine 1000 mg/m\^2 and Oxaliplatin 100 mg/m\^2 (R-GemOx) given intravenously on ... || [2] ZV + R-GemOx (Part 2) (EXPERIMENTAL): Using the recommended Phase 2 dose (RP2D) dose of ZV plus R-GemOx from Part 1, participants will receive ZV plus R-GemOx given intravenously on Day 1 of repeated 21-day cycles. Treatment will conti... || [3] R-GemOx (active control for Part 2) (ACTIVE_COMPARATOR): Participants will receive R-GemOx given intravenously on Day 1 of repeated 21-day cycles. Treatment will continue for up to 6 cycles or until progressive disease or discontinuation. || [4] ZV + BR (Part 2) (EXPERIMENTAL): Using RP2D from Part 1, participants will receive ZV plus Rituximab 375 mg/m\^2, given intravenously on Day 1 and Bendamustine 90 mg/m\^2 given intravenously on Day 1 and 2, of repeated 21-day cycl... || [5] Bendamustine Rituximab (BR) (ACTIVE_COMPARATOR): Participants will receive Rituximab 375 mg/m\^2, given intravenously on Day 1 Bendamustine 90 mg/m\^2 given intravenously on Day 1 and 2 of repeated 21-day cycles. Treatment will continue for up to... || [6] ZV + BR (Part 1) (EXPERIMENTAL): Participants in this arm will receive doses of ZV (from 1.5 mg/Kg up to 2.5 mg/Kg) plus Rituximab 375 mg/m\^2, Bendamustine 90 mg/m\^2 (BR) given intravenously on Day 1 and 2 of repeated 21-day cyc...","* Has a histologically confirmed diagnosis of Diffuse Large B-Cell Lymphoma (DLBCL). * Has radiographically measurable DLBCL per the Lugano Response Criteria, as assessed locally by the investigator. * Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2 within 7 days prior to study treatment initiation. * Has adequate organ function. * Is able to provide new or archival tumor tissue sample not previously irradiated. Zilovertamab vedotin plus R-GemOx, or R-GemOx study arms: * Has relapsed or refractory DLBCL and is ineligible for or have failed autologous stem-cell transplant (ASCT) and have failed at least 1 line of prior therapy. * Has post-chimeric antigen receptor T (post-CAR-T) cell therapy failure or is ineligible for CAR-T cell therapy. Not applicable with protocol amendment 4: Zilovertamab vedotin plus Bendamustine Rituximab (BR), and Bendamustine Rituximab study arms: * Has relapsed or refractory DLBCL and is ineligible for or have failed ASCT and have failed at least 2 lines of prior therapy. * Has post-CAR-T therapy failure or is ineligible for CAR-T cell therapy.","* Not applicable with protocol amendment 4: Has history of transformation of indolent disease to DLBCL * Has received solid organ transplant at any time. * Has received a diagnosis of primary mediastinal B-cell lymphoma (PMBCL). * Has clinically significant (ie, active) cardiovascular disease or serious cardiac arrhythmia requiring medication. * Has ongoing graft-versus-host disease (GVHD) of any grade, or is receiving treatment for their GVHD. * Has clinically significant pericardial or pleural effusion. * Has ongoing Grade \>1 peripheral neuropathy. * Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years. * Has a demyelinating form of Charcot-Marie-Tooth disease. * Has contraindication to any of the study intervention components including but not limited to prior anaphylactic reaction. * Has received prior systemic anticancer therapy, including investigational agents within 4 weeks prior to the first dose of study intervention. * Has received prior radiotherapy within 4 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. * Has ongoing corticosteroid therapy. * Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. * Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention. * Has known active central nervous system (CNS) lymphoma involvement or active CNS involvement by lymphoma. Participants with prior CNS involvement are eligible if their CNS disease is in radiographic, cytological (for cerebrospinal fluid disease), and clinical remission. * Has an active infection requiring systemic therapy. * Has a known history of human immunodeficiency virus (HIV) infection. * Has a known ac"
NCT06672146,"A Randomized Phase II Trial of ASTX727 and Venetoclax Compared With ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults With IDH2 Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy",,PHASE2,Puerto Rico,"Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico, [RECRUITING] | San Juan City Hospital, San Juan, Puerto Rico, [RECRUITING]",Acute Myeloid Leukemia,2,"[1] Arm 1 (ASTX727 + venetoclax) (ACTIVE_COMPARATOR): Patients receive ASTX727 PO QD on days 1-5 and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients unde... || [2] Arm 2 (ASTX727 + venetoclax + enasidenib) (EXPERIMENTAL): Patients receive ASTX727 PO QD on days 1-5, venetoclax PO QD on days 1-28, and enasidenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unac...","* Participants must have been registered to the MYELOMATCH Master Screening and Reassessment Protocol prior to consenting to this study. Participants must have disease with a detectable IDH2 mutation based on central testing through the MYELOMATCH and be assigned to this clinical trial via MATCHBox prior to registration to this study * Note: Pre-enrollment/diagnosis labs must have already been performed under MYELOMATCH * Participants must have newly diagnosed, untreated acute myeloid leukemia (AML) defined by having ≥ 20% blasts in the bone marrow and/or peripheral blood, excluding acute promyelocytic leukemia (APL) with PML-RARA * Participants must not be receiving or planning to receive any other investigational agents while on protocol therapy * Participants must not have received prior therapy for AML or myelodysplastic syndrome (MDS) and/or myeloproliferative neoplasm (MPN) with the exception of hydroxyurea, all-trans retinoic acid (ATRA), colony-stimulating factors, erythropoiesis-stimulating agents, immunosuppressive therapy, intrathecal chemotherapy, a single dose of cytarabine for cytoreduction, and/or leukapheresis * Participants must not be currently receiving any cytarabine-containing therapy other than up to 1 g/m\^2 of cytarabine, which is allowed for urgent cytoreduction. The use of prior hydroxyurea, all-trans retinoic acid (ATRA), BCR-ABL directed tyrosine kinase inhibitor, erythropoiesis-stimulating agent, thrombopoietin receptor agonist and lenalidomide are allowed. Participants may receive hydroxyurea prior to treatment assignment on this substudy for cytoreduction but must agree to discontinue hydroxyurea prior to beginning treatment on this substudy * White blood cell (WBC) must be \< 25 x 10\^9/L. Hydroxyurea, leukapheresis, and cytarabine \< 1 g/m\^2 are permitted to control the WBC prior to enrollment and initiation of protocol-defined therapy but must be stopped prior to initiation of protocol therapy * Participants must be ≥ 60 years old;",
NCT06627530,"A Randomized Trial of Neoadjuvant Leuprorelin, Darolutamide or Both Prior to Radical Prostatectomy for Intermediate or High-risk Prostate Cancer",COAction,PHASE4,Brazil,"Santa Casa de Misericórdia de Feira de Santana, Feira de Santana, Brazil, [RECRUITING] | Hospital Ophir Loyola, Belém, Brazil, [RECRUITING] | Hospital São Marcos, Teresina, Brazil, [ACTIVE_NOT_RECRUITING] | Hospital de Clínicas Ijuí, Ijuí, Brazil, [RECRUITING] | Hospital Universitário Pedro Ernesto, Rio de Janeiro, Brazil, [RECRUITING] | BP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil, [RECRUITING]",Prostate Cancer,3,[1] Darolutamide + ADT leuprorelin (EXPERIMENTAL): No description || [2] Darolutamide (ACTIVE_COMPARATOR): No description || [3] Leuprorelin (ACTIVE_COMPARATOR): No description,"* Men ≥18 years of age; * Histologically confirmed unfavorable intermediate or high/very high risk non metastatic (by conventional imaging) prostate adenocarcinoma intended for surgery without neuroendocrine differentiation or small cell features; * Unfavorable intermediate-risk: * ISUP grade 3, and/or \> 50% positive biopsy cores and/or at least two intermediate-risk factors. Intermediate-risk factors: * Clinical tumor stage T2b or T2c (MRI based); * ISUP grade 2 or 3; * Prostate-specific antigen (PSA) level of 10-20 ng/mL. * High-risk or very high-risk: * ≥cT3a (MRI based) or ISUP 4-5 or PSA\>20 ng/mL; * cN1. * ECOG 0-1; * Baseline testosterone \> 230 ng/dL; * No prior prostate cancer treatment; * Sexually active male subjects must agree to use condoms as an effective barrier method and refrain from sperm donation, and/or their female partners of reproductive potential to use a method of effective birth control, during the treatment with darolutamide and for 1 week after the end of treatment with darolutamide to prevent pregnancy; * Written informed consent.","* Unresectable prostate cancer; * Histology of small cell carcinoma prostate cancer or adenocarcinoma with neuroendocrine features; * Any prior prostate cancer treatment; * Any active infection requiring IV antibiotics; * Known additional malignancy that has a life-expectancy \< 2 years; * Had any of the following within 6 months before randomization: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, heart failure with New York Heart Association Class Functional III or IV; * Uncontrolled severe hypertension as indicated by a resting systolic BP ≥ 180 mmHg or diastolic BP ≥ 110 mmHg despite medical management; * A gastrointestinal (GI) disorder or procedure which is expected to interfere significantly with absorption of darolutamide; * Inability to swallow oral medications; * Receipt of medications (e.g. finasteride, dutasteride) or agents that are likely to alter serum PSA levels within \<= 42 days or 5 half-lives prior to registration, whichever is shorter."
NCT06679101,"A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)",DREAMM-10,PHASE3,Argentina,"GSK Investigational Site, Capital Federal, Argentina, [RECRUITING] | GSK Investigational Site, Ciudad Autonoma de Buenos Aire, Argentina, [RECRUITING] | GSK Investigational Site, Córdoba, Argentina, [RECRUITING] | GSK Investigational Site, Rosario, Argentina, [RECRUITING] | GSK Investigational Site, Viedma, Argentina, [RECRUITING]",Multiple Myeloma | Newly Diagnosed Multiple Myeloma,2,"[1] Arm A: Belantamab Mafodotin + Lenalidomide + Dexamethasone (EXPERIMENTAL): Belantamab mafodotin, lenalidomide, and dexamethasone will be administered.

Treatment will continue in both arms until progressive disease (PD), death, unacceptable toxicity, withdrawal of consent... || [2] Arm B: Daratumumab + Lenalidomide + Dexamethasone (ACTIVE_COMPARATOR): Daratumumab, lenalidomide, and dexamethasone will be administered.

Treatment will continue in both arms until PD, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever oc...","1. Is at least 18 or the legal age of consent in the jurisdiction in which the study is taking place, at the time of signing the informed consent. 2. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form and in the protocol. 3. NDMM with a requirement for treatment as documented per IMWG criteria. 4. Must have at least 1 aspect of measurable disease, as assessed by the central laboratory, defined as 1 of the following: 1. Urine M-protein excretion ≥200 mg/24 hours (≥0.2 g/24 hours) And/or 2. Serum M-protein concentration ≥0.5 g/dL (≥5.0 g/L) And/or 3. Serum free light-chain (FLC) assay: involved FLC level ≥10 mg/dL (≥100 mg/L) and an abnormal serum FLC ratio (\<0.26 or \>1.65). 5. Newly diagnosed and not considered candidate for high-dose chemotherapy with autologous stem cell transplant (ASCT) due to any of the following: 1. ≥70 years of age, OR 2. Age 18 to 69 years with presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT, (or for whom national guidelines do not permit transplant due to a cut-off age below 70 years), OR 3. Who refuse high-dose chemotherapy with ASCT as an initial treatment. 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. 7. Adequate organ system function as defined by the laboratory assessments. 8. Male participants: * Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. * Male participants are eligible to participate if they agree to the following during the Treatment Period and for at least 6 months after the last dose of study intervention to allow for clearance of any altered sperm: * Refrain from donating fresh unwashed semen PLUS either: * Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent ba","1. Diagnosis of systemic amyloid light chain amyloidosis, Waldenstrom's disease, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma proliferative disorder, skin changes) or Primary Plasma Cell Leukemia (defined as circulating plasma cells \>5%). 2. Prior systemic therapy for multiple myeloma, or smoldering multiple myeloma. 3. Signs of meningeal or central nervous system involvement with multiple myeloma. 4. Major surgery within 2 weeks prior to the first dose of study drugs or has not recovered fully from surgery. Kyphoplasty is not considered major surgery. 5. Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities) that could interfere with participant's safety, obtaining informed consent, or compliance with study procedures. 6. Current active liver or biliary disease (except for Gilbert's syndrome or asymptomatic gallstones, or otherwise stable chronic liver disease as per the investigator's assessment). 7. Participants with previous or concurrent malignancies other than multiple myeloma are excluded. Exceptions are any other malignancy that has been considered medically stable for at least 2 years, after discussion with the GSK Medical Monitor. The participant must not be receiving active therapy, other than hormonal therapy for this disease. 8. Evidence of cardiovascular risk including any of the following: 1. Evidence of current clinically significant untreated arrhythmias, including clinically significant electrocardiogram abnormalities including second-degree (Mobitz Type II) or third-degree atrioventricular block. 2. Recent history (within 3 months of screening) of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty or stenting, or bypass grafting. 3. Class III or IV heart failure as defined by the New York Heart Association functional classification system. 9. Known human immunodeficiency virus (HIV) infection, unless the parti"
NCT04566328,Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation,,PHASE3,Puerto Rico,"Cancer Center-Metro Medical Center Bayamon, Bayamón, Puerto Rico, [RECRUITING] | Puerto Rico Hematology Oncology Group, Bayamón, Puerto Rico, [RECRUITING] | Doctors Cancer Center, Manatí, Puerto Rico, [RECRUITING] | San Juan Community Oncology Group, San Juan, Puerto Rico, [RECRUITING] | Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico, [RECRUITING] | PROncology, San Juan, Puerto Rico, [RECRUITING] | San Juan City Hospital, San Juan, Puerto Rico, [RECRUITING]",Plasma Cell Myeloma | RISS Stage I Plasma Cell Myeloma | RISS Stage II Plasma Cell Myeloma,3,"[1] Arm A (daratumumab, lenalidomide, dexamethasone) (ACTIVE_COMPARATOR): INDUCTION: All patients receive standard induction therapy comprising the following: daratumumab subcutaneously (SC) on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 o... || [2] Arm B (bortezomib, daratumumab, lenalidomide, dexamethasone) (EXPERIMENTAL): CONSOLIDATION: Patients receive bortezomib SC on days 1, 8, and 15, daratumumab SC on day 1, lenalidomide PO daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats eve... || [3] Arm C (daratumumab, lenalidomide, dexamethasone) (ACTIVE_COMPARATOR): CONSOLIDATION: Patients receive daratumumab SC on day 1, lenalidomide PO daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absen...","* STEP 0 - Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2 (PS 3 allowed if secondary to pain) * STEP 0 - Patient must have newly diagnosed multiple myeloma (MM) by International Myeloma Working Group (IMWG) criteria * STEP 0 - Patient must agree to register to the mandatory REVLIMID Risk Evaluation and Mitigation Strategy (RevREMS) program and be willing and able to comply with the requirements of RevREMS * STEP 0 - Patient must be able to undergo diagnostic bone marrow aspirate following preregistration. * NOTE: Bone marrow aspirate specimen must be submitted to Adaptive Biotechnologies for clonoSEQ Assay * NOTE: Adaptive Biotechnologies will release results to the diagnostic Portal from the Clonality (ID) test within fourteen (14) days of receipt and reconciliation of fresh bone marrow specimen to the submitting institution * STEP 1 - Patient must meet all eligibility criteria in STEP 0 with exception of allergy requirement * STEP 1 - Institution must have received the Clonality (ID) test results from Adaptive Biotechnologies and dominant sequences were identified * STEP 1 - Patient must have standard risk MM as defined by the Revised International Staging System (RISS) stage I or II * NOTE: R-ISS stage is based on serum beta2 microglobulin, albumin and lactate dehydrogenase (LDH) levels along with presence of chromosomal abnormalities (CA) detected by interphase fluorescent in situ hybridization (iFISH). Presence of del(17p), t(4;14), and/or t(14;16) is considered high risk and absence of these, including any other findings, are standard risk * R-ISS stage * Stage I: ISS stage I \[beta2 macroglobulin \< 3.5 mg/L, albumin \> 3.5 g/dL\] AND standard-risk CA AND normal LDH * Stage II: Not R-ISS stage I or III * Stage III: ISS stage III \[beta2 macroglobulin \> 5.5 mg/L\] AND high-risk CA OR high LDH (\> upper limit of normal) \[patients with stage III are ineligible\] * STEP 1 - Patient must have measurable or evaluable","* STEP 0 - Patient must not have any known allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies or human proteins, or their excipients (refer to respective package inserts or Investigator's Brochure), or known sensitivity to mammalian-derived products * STEP 1 - Women must not be pregnant or breast-feeding due to the potential harm and teratogenic effects to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All females of childbearing potential must have a blood test or urine study with a sensitivity of at least 25 mIU/mL within 10-14 days prior to Step 1 registration to rule out pregnancy and again within 24 hours prior to the first dose of lenalidomide. Females of childbearing potential must also agree to ongoing pregnancy testing while on protocol treatment. A female of childbearing potential is defined as any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: * Has achieved menarche at some point, * Has not undergone a hysterectomy or bilateral oophorectomy; or * Has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) * STEP 1 - Women of childbearing potential must not expect to conceive children by using accepted and effective method(s) of contraception (for this protocol defined as the use of TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME for 1) at least 28 days before starting protocol treatment; 2) while participating in the study; 3) during dose interruptions; and 4) for at least 3 months days after the last dose of protocol treatment) OR by practicing true abstinence from sexual intercourse for the duration of their participation in the study (periodic a"
NCT06671912,"LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients With Molecular Low-Risk Early-Stage Breast Cancer",LoTam,PHASE3,Puerto Rico,"Doctors Cancer Center, Manatí, Puerto Rico, [RECRUITING] | Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico, [RECRUITING] | PROncology, San Juan, Puerto Rico, [RECRUITING] | San Juan City Hospital, San Juan, Puerto Rico, [RECRUITING]",Anatomic Stage 0 Breast Cancer AJCC v8 | Anatomic Stage 1 Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Estrogen Receptor-Positive Breast Carcinoma | HER2-Negative Breast Carcinoma,2,"[1] Arm I (anastrozole, letrozole, exemestane, tamoxifen) (ACTIVE_COMPARATOR): Patients receive standard of care endocrine therapy per physician choice with either anastrozole PO, letrozole PO, exemestane PO or standard dose tamoxifen PO QD for up to 5 years in the absence of... || [2] Arm II (low dose tamoxifen) (EXPERIMENTAL): Patients receive low-dose tamoxifen PO QOD for up to 5 years in the absence of disease progression or unacceptable toxicity. Patients may also undergo mammogram or MRI, DEXA, and blood sample colle...","* Unilateral invasive adenocarcinoma of the breast that is histologically confirmed * Invasive breast cancer is estrogen receptor positive in ≥ 10% of cells * HER2 negative by current American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines * The patient must have a multigene assay with a low-risk score, including any of the following (if more than one genomic assay was obtained, both are required to be low-risk): * Oncotype DX recurrence score ≤ 25 * Mamma Print low risk * Prosigna risk of recurrence ≤ 40 * Tumor size must be ≤ 3 cm by pathologic evaluation * Adequate surgical removal of all clinically evident disease in the breast with either breast conserving surgery or mastectomy. Negative margins on final pathology are required. Additional excisions may be performed to obtain clear margins before registration * No clinical (cN1, cN2, cN3) or pathologic (pN1mi, pN1, pN2, or pN3) evidence of lymph node involvement on either needle biopsy or surgical lymph node assessment. Patients with pN0(i+) or pN0 (mol+) are eligible * Surgical axillary staging (sentinel lymph node biopsy ± axillary lymph node dissection) is completed according to physician discretion * For patients with negative preoperative axillary ultrasonography, clinicians may selectively choose to forego surgical axillary staging. Ipsilateral axillary ultrasound showing no lymph node involvement with no evidence of lymphadenopathy or suspicious thickening is required in this scenario * No pathological tumor size \> 3 cm or pT4 * No definitive clinical or radiologic evidence of metastatic disease * No palpable or radiographically suspicious axillary, supraclavicular, infraclavicular, or internal mammary lymph nodes, unless there is histologic confirmation that these lymph nodes are negative for tumor * No suspicious microcalcifications, densities, or palpable abnormalities in the ipsilateral or contralateral breast, unless biopsied and found to be benign * An interva",* HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
NCT05078528,Low-cost Mobile Colposcopy and Confocal Imaging for Global Prevention of Cervical Cancer,,NA,Brazil,"Irmandade Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil, [RECRUITING] | Barretos Cancer Hospital, Barretos, Brazil, [RECRUITING]",Cervical Intraepithelial Neoplasia,1,"[1] Experimental group - MMC (EXPERIMENTAL): Imaging of study participants will be performed during the colposcopy examination. The mobile colposcope and the confocal imaging probe, together referred to as the Multimodal Mobile Colposcope (MM...",* Women \>25 years of age; * Women undergoing colposcopy due to abnormal cervical screening or follow-up for a history of dysplasia; * Women of childbearing potential must have a negative urine or blood pregnancy test; * Ability to understand and willingness to provide informed consent by signing specific Informed Consent Document.,* Women under 25 years of age; * Women who have undergone hysterectomy with removal of the cervix; * Women with known allergy to proflavine or acriflavine; * Women who are pregnant or nursing at the time of enrollment; * Incapacitated women or in vulnerable situations or who are not willing to give consent;
NCT06077981,Comparison of 0.4% Hyaluronic Acid Solution Versus Hydroxyethylamide Solution in Submucosal Endoscopic Resections of Superficial Malignant Esophageal Neoplasms: a Randomized Clinical Trial.,,NA,Brazil,"Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil, [RECRUITING]",Esophageal Neoplasms | Endoscopic Mucosal Resection | Hyaluronic Acid,2,"[1] Hydroxyethylamide Group (ACTIVE_COMPARATOR): 15 will be from the hydroxyethylamide Group, where the submucosal endoscopic dissection will be performed with submucosal injection of hydroxyethylamide. || [2] Hyaluronic acid group (TS-905 Blue Eye) (ACTIVE_COMPARATOR): 15 will be from the Hyaluronic acid group (TS-905 Blue Eye), where the submucosal endoscopic dissection with submucosal injection of hyaluronic acid (TS-905 Blue Eye) will be performed.",* Patients over 18 years of age * Superficial esophageal adenocarcinoma or squamous cell carcinoma with indication of ESD after discussion in a multidisciplinary oncological board * Signed informed consent form,"* Residual or recurrent esophageal lesions * Ulcerated esophageal lesions * Patients with severe cardiovascular, kidney or liver disease * History of hypersensitivity to hyaluronic acid * Pregnant or lactating women"
NCT06191744,"A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)",EPCORE™FL-2,PHASE3,Puerto Rico,"Pan American Center for Oncology Trials, LLC /ID# 260265, Rio Piedras, Puerto Rico, [RECRUITING] | Auxilio Mutuo Cancer Center /ID# 260262, San Juan, Puerto Rico, [RECRUITING]",Follicular Lymphoma (FL),5,"[1] Arm A1: Epcoritamab + Lenalidomide and Rituximab (R2) (EXPERIMENTAL): Participants will receive epcoritamab in combination with R2 (ER2), followed by epcoritamab during the 120 week treatment duration. || [2] Arm A2: Epcoritamab + Lenalidomide and Rituximab (R2) (EXPERIMENTAL): Participants will receive epcoritamab in combination with R2 (ER2), during the 24 week treatment duration. || [3] Arm B: Chemoimmunotherapy (CIT) Option A (EXPERIMENTAL): Participants will receive CIT Option A (obinutuzumab (G) and cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) \[G-CHOP\]/ rituximab (R)-CHOP during the 120 week treatment duration. || [4] Arm B: Chemoimmunotherapy (CIT) Option B (EXPERIMENTAL): Participants will receive CIT Option B (G and bendamustine (Benda) \[G-Benda\]/R-Benda during the 120 week treatment duration. || [5] Arm C: Lenalidomide and Rituximab (R2) (EXPERIMENTAL): Participants will receive lenalidomide and rituximab (R2) during the 120 week treatment duration.","* Diagnosis of follicular lymphoma (FL). * Have CD20+, histologically confirmed classic FL (previously Grade 1 to 3a FL) at most recent representative tumor biopsy based on the local pathology report, according to the 5th edition of World Health Organization (WHO) Classification of Haematolymphoid Tumours. * Are willing and able to comply with procedures required in the protocol. * Must have stage, III, IV or II with bulky disease \>= 7cm). * Must be in need of systemic treatment per investigator, as evidenced by meeting at least one of the Groupe d'Etude des Lymphomes Folliculaire (GELF) criteria. * Has one or more target lesions: * A positron emission tomography (PET)/computerized tomography (CT) scan demonstrating PET-positive lesion(s), and * \>=1 measurable nodal lesion (long axis \>1.5cm) or \>=1 measurable extra-nodal lesion (long axis \>1.0 cm) on CT scan or MRI * Eastern Cooperative Oncology Group (ECOG) performance status 0-2. * Able to receive at least one of the standard of care chemoimmunotherapy (CIT) treatment regimens: \[Arm B\] at the discretion of the Investigator, and rituximab and lenalidomide (R2) \[Arm C\]. * Have laboratory values meeting the criteria in the protocol.",* Had major surgery within 4 weeks prior to randomization. * Have active cytomegalovirus (CMV) disease.
NCT06309290,Prehabilitation Based on Resistance-exercise Training in Women With Breast Cancer Undergoing Neoadjuvant Therapy: From Molecular Mechanism to Clinical Benefits,NEO STRONG,NA,Chile,"Fundación Arturo López Pérez, Santiago, Chile, [RECRUITING] | Department of Rehabilitation Sciences, Faculty of Medicine, Universidad de La Frontera. Temuco, Chile, Temuco, Chile, [RECRUITING]",Prehabilitation | Breast Cancer | Postmenopause | Resistance Training,2,"[1] Prehabilitation intervention program (EXPERIMENTAL): All volunteers be subjected to 16 - 20 weeks of full body resistance exercise training (2 times per week. However, usual care program. || [2] Usual Care Program (ACTIVE_COMPARATOR): All volunteers be subjected usual care (diagnosis confirmation, chemotherapy treatment planning and an initial education session).","* Postmenopausal women with breast cancer in stages I, II and III with luminal breast tumor, HER2+ or TNBC * Indication for neoadjuvant chemotherapy * Candidates for curative breast surgery * Body mass index: 18.5 \<BMI \<30 kg/m2 * Sedentary (does not perform scheduled or planned physical activity ≥ 2 times a week) * Willingness to participate in the study and follow the proposed prehabilitation scheme.","* Present comorbidities that interact with the metabolism and mobility of the muscles of the body and that do not allow the (safe) performance of strength exercises (e.g., debilitating arthritis, all neurological disorders, paralysis, among others). * Severe or uncontrolled cardiovascular disease, cardiac ejection fraction less than 50% * Previous antineoplastic treatment * Use of nutritional supplements (leucine, glutamine, casein, whey protein, fatty acids and creatine)."
NCT06534983,"A Randomized Phase II, Double-Blind, Multicenter Study Evaluating the Efficacy and Safety of Autogene Cevumeran Plus Nivolumab Versus Nivolumab as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma",IMCODE004,PHASE2,"Argentina, Mexico","Instituto Alexander Fleming, Buenos Aires, Argentina, [SUSPENDED] | Hospital Britanico, Buenos Aires, Argentina, [SUSPENDED] | Hospital Italiano, Ciudad Autonoma Buenos Aires, Argentina, [SUSPENDED] | Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Mexico, [SUSPENDED]",Muscle Invasive Urothelial Carcinoma,2,"[1] Autogene Cevumeran + Nivolumab (EXPERIMENTAL): Participants will receive autogene cevumeran along with nivolumab intravenously (IV) at a recommended dose at specified timepoints. || [2] Saline+Nivolumab (ACTIVE_COMPARATOR): Participants will receive saline solution along with 480 milligrams (mg) of nivolumab, IV, once every 4 weeks (Q4W) for 1 year.","* Participants must have the capacity to participate/enroll in the study and to provide informed consent * Histologically confirmed muscle-invasive UC (also termed TCC) of the bladder or upper urinary tract * TNM classification (UICC/AJCC 7th edition) at pathological examination of surgical resection specimen of (y)pT3-4 or (y)pN+ and M0 * Surgical resection of MIUC of the bladder or upper tract * Participants who have not received prior neoadjuvant cisplatin chemotherapy (NAC) must be ineligible to receive adjuvant cisplatin therapy due to participant refusal, cisplatin ineligibility or investigator decision * Tumor tissue must be provided for biomarker analysis * Absence of residual disease and absence of metastasis, as confirmed by a negative baseline Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan of the pelvis, abdomen, and chest no more than 28 days prior to randomization. * Full recovery from cystectomy or nephroureterectomy within 120 days following surgery * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Negative HIV test at screening * Negative hepatitis B surface antigen (HbsAg) test at screening * Positive hepatitis B surface antibody (HBsAb), or a negative HBsAb at screening accompanied by either of the following: negative total hepatitis B core antibody (HBcAb) or positive total HBcAb test followed by quantitative hepatitis B virus (HBV) DNA \< 500 international units/milliliter (IU/mL) * Negative hepatitis C virus (HCV) antibody test at screening, or a positive HCV antibody test followed by a negative HCV RNA test at screening","* Partial cystectomy in the setting of bladder cancer primary tumor or partial nephroureterectomy in the setting of renal pelvis primary tumor * Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to initiation of study treatment * Any prior neoadjuvant immunotherapy * Adjuvant chemotherapy or radiation therapy for UC following surgical resection * Malignancies other than UC within 5 years prior to randomization * Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment"
NCT04973605,"A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)",,"PHASE1, PHASE2",Brazil,"Hospital Sirio Libanes Brasilia, Brasília, Brazil, [RECRUITING] | Instituto Dor de Pesquisa E Ensino Distrito Federal, Brasília, Brazil, [RECRUITING] | Centro Gaucho Integrado de Oncologia Hospital Mae de Deus, Porto Alegre, Brazil, [RECRUITING] | Hospital Sao Rafael (Rede Dor), Salvador, Brazil, [RECRUITING] | Hospital Sirio Libanes, São Paulo, Brazil, [RECRUITING] | Hospital Nove de Julho Dasa, São Paulo, Brazil, [COMPLETED] | Accamargo Cancer Center, São Paulo, Brazil, [COMPLETED] | Instituto Dor de Pesquisa E Ensino Sao Paulo, São Paulo, Brazil, [RECRUITING] | Clinica Sao Germano, São Paulo, Brazil, [COMPLETED] | Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein, São Paulo, Brazil, [RECRUITING]",Relapsed/Refractory Multiple Myeloma,2,"[1] Part 1 Dose Escalation (EXPERIMENTAL): Dose-escalation and de-escalation to determine maximum tolerated dose (MTD) of sonrotoclax plus dexamethasone, sonrotoclax plus dexamethasone plus carfilzomib, sonrotoclax plus dexamethasone plus d... || [2] Part 2 Cohort Expansion (EXPERIMENTAL): There will be up to 7 expansion cohorts to further evaluate the safety and efficacy of sonrotoclax monotherapy, sonrotoclax plus dexamethasone in combination with dexamethasone plus carfilzomib, an...","1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 2. A confirmed diagnosis of multiple myeloma (must have an M-component in serum and/or urine) 3. Measurable disease defined as: i. M-spike ≥ 500mg/dL, or ii. Urine protein M-spike of ≥ 200 mg/day, or iii. Serum free light chains ≥ 10 mg/dL, and an abnormal κ:λ ratio 4. Participant has documented relapsed or progressive MM on or after any regimen or who are refractory to the most recent line of therapy. i. Relapsed MM is defined as previously treated MM that progresses and requires initiation of salvage therapy but does not meet the criteria for refractory MM. ii. Refractory MM is defined as disease that is nonresponsive (failure to achieve minimal response or development of progressive disease) while on primary or salvage therapy or progresses within 60 days of last therapy. 1. In Part 1 and Part 2 Cohorts 1 and 2 participants should have relapsed or progressive disease and have had ≥ 3 prior lines of therapy including a proteasome inhibitor, an IMiD, and an anti-CD38 monoclonal antibody, and no more available approved therapies. 2. Participants in Part 2 Cohorts 3, 4, and 5 should have relapsed or progressive disease and have had ≥ 1 prior line of therapy. Prior treatment with carfilzomib is allowed but the patient must not be considered carfilzomib refractory by the investigator. 3. Participants in Part 2 Cohorts 6 and 7 should have relapsed or progressive disease and have had 1 to 3 prior lines of therapy and previously treated with a proteasome inhibitor and an IMiD 5. Positivity for t(11;14) translocation must be confirmed by validated fluorescence in situ hybridization (FISH) testing assay in a pre-defined laboratory a. fresh bone marrow aspirate sample must be collected at screening and sent to central laboratory for t(11;14) FISH testing. 6. Adequate organ function defined as: 1. Hemoglobin ≥ 8.0 g/dL within 7 days before first dose of study treatment, (transfusions, in accordance with","1. Participant has any of the following conditions: 1. Non secretory MM (Serum free light chains \< 10 mg/dL) 2. Solitary plasmacytoma 3. Active plasma cell leukemia (ie, either 20% of peripheral white blood cells or \> 2.0 x 109/L circulating plasma cells by standard differential) 4. Waldenström macroglobulinemia (WM) 5. Amyloidosis. 6. Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (POEMS) syndrome 7. Chronic respiratory disease that requires continuous oxygen 2. Significant cardiovascular disease, including but not limited to: 1. Myocardial infarction ≤ 6 months before screening 2. Ejection fraction ≤ 50% 3. Unstable angina≤ 3 months before screening 4. New York Heart Association Class III or IV congestive heart failure 5. History of clinically significant arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, or torsades de pointes) 6. Heart rate-corrected QT interval \> 480 milliseconds based on Fridericia's formula 7. History of Mobitz II second-degree or third-degree heart block without a permanent pacemaker in place 8. Uncontrolled hypertension at screening, defined as systolic blood pressure \> 170 mmHg and diastolic blood pressure \> 105 mmHg by ≥ 2 consecutive measurements. Prior therapy with sonrotoclax or other agents inhibiting BCL2 activity (eg, venetoclax) 3. Known infection with human immunodeficiency virus (HIV) 4. Serologic status reflecting active viral hepatitis B (HBV) or viral hepatitis C (HCV) infection as follows: 1. Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). Participants with presence of HBcAb, but absence of HBsAg, are eligible if HBV DNA is undetectable (limitation of sensitivity \< 20 IU/mL) ,), and if they are willing to undergo monthly monitoring for HBV reactivation. 2. Presence of HCV antibody. Participants with presence of HCV antibody are eligible if HCV RNA is undetectable (limitation of sensitivity \< 15 IU/mL). Note: Other protocol "
NCT06921785,"A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma",ARTEMIDE-HCC01,PHASE3,Brazil,"Research Site, Porto Alegre, Brazil, [RECRUITING] | Research Site, Santa Maria, Brazil, [NOT_YET_RECRUITING] | Research Site, São Paulo, Brazil, [NOT_YET_RECRUITING] | Research Site, São Paulo, Brazil, [RECRUITING] | Research Site, Vitória, Brazil, [NOT_YET_RECRUITING]",Hepatocellular Carcinoma,3,"[1] Arm A (EXPERIMENTAL): Tremelimumab , rilvegostomig and bevacizumab || [2] Arm B (EXPERIMENTAL): Rilvegostomig, and bevacizumab || [3] Arm C (ACTIVE_COMPARATOR): Atezolizumab, and bevacizumab","* Locally advanced or metastatic and/or unresectable HCC * WHO/ECOG performance status of 0 or 1 * BCLC stage B (that is not eligible for locoregional therapy) or stage C. Child-Pugh Score class A * At least one measurable target lesion * co-infected with HBV and HCV are not eligible * Adequate organ and bone marrow function measured during the screening period * Must not have received prior systemic therapy for intermediate, advanced, or metastatic HCC. * Disease that is not amenable to curative surgical and/or locoregional therapies. For participants who received locoregional therapy for HCC, locoregional therapy must have been completed ≥ 28 days prior to the baseline scan for the current study.","Medical condition * Any evidence of uncontrolled intercurrent diseases * Active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment * History of another primary malignancy * Persistent toxicities caused by previous anti-cancer therapy excluding alopecia, not yet improved to Grade ≤ 1 or baseline. * Clinically meaningful ascites, pleural effusion, or pericardial effusion requiring non-pharmacologic intervention to maintain symptomatic control within 6 months prior to the first scheduled dose. * History of active primary immunodeficiency or active infection * History of hepatic encephalopathy * Current or recent (within 10 days of first dose of study treatment) use of aspirin (≥ 325 mg/day) or treatment with dipyridamole, ticlopidine, clopidogrel, and cilostazol * Current or recent (within 10 days prior to study treatment start) use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purposes is ineligible Bleeding or other risks HCC related * Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC. * Central nervous system metastases or spinal cord compression (including asymptomatic and adequately treated disease) * Prior treatment with anti-CTLA-4 and/or anti-TIGIT. * Radiotherapy within 28 days and abdominal/ pelvic radiotherapy within 60 days prior to initiation of study treatment, except palliative radiotherapy to bone lesions within 7 days prior to initiation of study treatment"
NCT06252649,"Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)",CodeBreaK 301,PHASE3,"Argentina, Brazil, Chile, Colombia, Mexico","Hospital Universitario Fundacion Favaloro, CABA, Argentina, [RECRUITING] | Instituto Argentino de Diagnóstico y Tratamiento, CABA, Argentina, [RECRUITING] | Investigaciones Clinicas Moleculares - Centro de Endocrinologia y Diabetes Dr Raul Gutman SRL, CABA, Argentina, [RECRUITING] | Cemic, Ciudad Autonoma de Buenos Aires, Argentina, [RECRUITING] | Sanatorio Británico de Rosario, La Plata, Argentina, [RECRUITING] | Instituto de Investigaciones clinicas de Mar del Plata, Mar del Plata, Argentina, [RECRUITING] | Hospital Italiano de Córdoba, Córdoba, Argentina, [RECRUITING] | Sanatorio Allende, Córdoba, Argentina, [RECRUITING] | Clinica Universitaria Privada Reina Fabiola, Córdoba, Argentina, [RECRUITING] | Clinica Viedma, Viedma, Argentina, [RECRUITING]",Metastatic Colorectal Cancer,2,[1] Arm A: Sotorasib + Panitumumab + FOLFIRI (EXPERIMENTAL): Sotorasib will be taken daily (QD) as an oral tablet. Panitumumab and FOLFIRI will be received every 2 weeks (Q2W) via intravenous (IV) infusion. || [2] Arm B: FOLFIRI with or Without Bevacizumab-awwb (ACTIVE_COMPARATOR): Participants will receive FOLFIRI Q2W with or without bevacizumab-awwb.,* Pathologically documented metastatic colorectal adenocarcinoma with KRAS p.G12C mutation by a locally validated assay. * Central laboratory detection of KRAS p.G12C mutation. * Measurable metastatic disease per RECIST v1.1 criteria. * Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1. * Adequate organ function.,"* Active, untreated brain metastases. * Leptomeningeal disease * Previous treatment with a KRAS p.G12C inhibitor * History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline CT scan"
NCT05713006,A Phase I/II Open-label Clinical Trial to Evaluate the Pharmacokinetics of Alectinib With Sequential Dose Escalation in Patients Diagnosed With ALK-rearranged Advanced Non-small Cell Lung Cancer.,,"PHASE1, PHASE2",Mexico,"Thoracic Oncology Unit and Personalized Medicine Laboratory, Instituto Nacional de Cancerología, Mexico City, Mexico, [RECRUITING]",Non-small Cell Lung Cancer Stage IIIB | ALK Gene Mutation,1,[1] Alectinib escalation dose (EXPERIMENTAL): Alecensa 150 mg Roche,"* Both sexes * ≥ 18 years old * Pathologically confirmed diagnosis of NSCLC * Stage IIIB - IV by the American Joint Committee of Cancer Version 8. * Recurrent disease (at least 180 days from curative intent treatment) * ALK rearrangements tested by FDA-approved tests (IHQ or FISH) * Karnofsky PS scale ≥ 70% * Having received first-line treatment with anti-ALK inhibitors and one previous line of platinum-based chemotherapy. * Measurable disease as referred by RECIST version 1.1 * Symptomatic brain metastases could receive prior treatment with radiotherapy or surgery for at least two weeks before treatment initiation. * Asymptomatic brain metastases could not receive local therapy before study inclusion. * Negative highly sensitive pregnancy test (serum or urine) within 72 days before first dose intervention. * Sexually active patients should use a contraceptive method with a failure rate of less than 1% per year. * Signed written informed consent * Adequate organ function (hematological, liver, and renal function) * Life expectancy of at least 12 weeks","* Carcinomatous meningitis confirmed by a positive CRL cytology or highly suspicious brain MRI. * Previous malignancies except for any carcinoma in-situ * Treatment with other anti-cancer therapy * Participating in other clinical trials in the former four weeks * Any other serious condition or uncontrolled active infection, altered mental status, or psychiatric condition that, in the investigator´s opinion, would limit the ability of an individual to meet the requirements of the study or which affects the interpretability of the results. * Active hepatitis virus infection (any serotype) or chronic infection with a potential risk of reactivation evaluated through a serological panel. * Active HIV infection. * Breastfeeding."
NCT06508658,"A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Rituximab Plus Gemcitabine and Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",EPCORE DLBCL-4,PHASE3,"Argentina, Mexico","Fundaleu /Id# 242789, Ciudad Autonoma de Buenos Aire, Argentina, [RECRUITING] | Centro De Investigación Clinica Chapultepec /ID# 243959, Mexico City, Mexico, [RECRUITING] | Centro de Quimioterapia E Investigacion Sas de Cv /Id# 263293, Jalisco, Mexico, [RECRUITING]",Diffuse Large B-Cell Lymphoma,3,[1] Arm A: Epcoritamab Plus Lenalidomide (E-Len) (EXPERIMENTAL): Participants will receive E-Len for up to 12 cycles (each cycle is 28 days). || [2] Arm B: Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) (EXPERIMENTAL): Participants will receive R-GemOx for up to 4 cycles (each cycle is 28 days) || [3] Arm C: Epcoritamab (EXPERIMENTAL): Participants will receive epcoritamab for up to 12 cycles (each cycle is 28 days).,"* Eastern Cooperative Oncology Group Performance status score of 0 to 2. * Histologically confirmed CD20+ Diffuse Large B-Cell Lymphoma (DLBCL) and documented in the most recent and representative pathology report, inclusive of the following according to the World Health Organization (WHO) 2022 as per the protocol. * Must have relapsed or refractory (R/R) disease and have been previously treated with at least 1 line of systemic antineoplastic therapy including anti-CD20 mAb-containing combination chemotherapy since DLBCL diagnosis. * Participant must meet at least 1 of the following criteria: * Failed prior autologous stem cell transplant (ASCT), defined as relapsed after ASCT or been refractory to high-dose therapy (HDT)-ASCT. * Not be considered a candidate for ASCT due to age, performance status, comorbidities and/or insufficient response to prior treatment, or have refused ASCT. * Be ineligible for or unable to receive chimeric antigen receptor T-cell (CAR-T) meeting at least 1 of the following criteria: * Unable to receive CAR-T therapy due to fitness and/or comorbidity. * Lymphocyte apheresis failure. * Unwilling to receive CAR-T therapy. * Unable to receive CAR-T therapy due to financial, geographic, insurance, access, and/or manufacturing constraints. * Relapsed/progressed after having achieved at least a Partial Response (PR) or Complete Response (CR) while on prior CAR-T therapy. * Must have measurable disease. * Life expectancy \> 3 months on standard of care treatment at the time of enrolling in the study","* Current evidence of primary central nervous system (CNS) lymphoma or known CNS involvement by lymphoma including leptomeningeal disease, at screening. * History of prior treatment with a bispecific antibody targeting CD3 and CD20 or prior treatment with rituximab plus gemcitabine and oxaliplatin (R-GemOx) or gemcitabine and oxaliplatin (GemOx). * Documented refractoriness to lenalidomide."
NCT05853575,A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation,,PHASE2,"Brazil, Mexico, Peru","Ensino e Terapia de Inovação Clinica AMO-ÉTICA / Ética Pesquisa e Ensino, Salvador, Brazil, [RECRUITING] | Uniao Brasileira de Educacao E Assistencia, Porto Alegre, Brazil, [RECRUITING] | Clinica de Neoplasias Litoral, Itajaí, Brazil, [RECRUITING] | Oncocentro Belo Horizonte, Belo Horizonte, Brazil, [RECRUITING] | A.C. Camargo Cancer Center, São Paulo, Brazil, [RECRUITING] | A.C. Camargo Cancer Center, São Paulo, Brazil, [RECRUITING] | Local Institution - 128, Tuxtla Gutiérrez, Mexico, [NOT_YET_RECRUITING] | Local Institution - 129, Colonia Nápoles, Mexico, [NOT_YET_RECRUITING] | Local Institution - 127, Colonia Roma, Mexico, [NOT_YET_RECRUITING] | Local Institution - 125, Toluca, Mexico, [NOT_YET_RECRUITING]",Advanced Cancer | Metastatic Cancer | Malignant Neoplasm of Lung,2,[1] Adagrasib 600mg BID (EXPERIMENTAL): Adagrasib 600mg BID without regard to food || [2] Adagrasib 400mg BID (EXPERIMENTAL): Adagrasib 400mg BID with food,"* Are at least 18 years old (or old enough to legally make their own treatment decisions, according to local laws). * Have advanced NSCLC or metastatic NSCLC (NSCLC that started in the lungs and then spread to other parts of the body) with the KRAS G12C mutation. * Have had previous treatment with 1) chemotherapy that included a drug called cisplatin or a drug called carboplatin and 2) a type of drug called an immune checkpoint inhibitor. * Have recovered from their prior treatment and blood tests are within a safe range. Key","* Have had previous treatment with a drug that targets KRAS G12C. * Have cancer that can potentially be removed with surgery. * Patients with brain lesions are not eligible if 1) any untreated brain lesions are \> 2.0 cm in size 2) any brainstem lesions are present 3) ongoing steroid dosing \>10 mg daily prednisone (or equivalent) and 4) poorly controlled (\> 1/week) generalized or complex partial seizures or neurologic progression/instability due to brain lesions. * Have certain medical conditions or need to take certain medications that, in the opinion of a trial doctor, could make it unsafe for them to participate or difficult to complete the trial assessments, or are pregnant."
NCT06890598,"A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02",SUNRAY-02,PHASE3,"Brazil, Chile","Fundação Pio XII - Hospital de Câncer de Barretos, Barretos, Brazil, [NOT_YET_RECRUITING] | CTO - Centro de Tratamento Oncológico, Belém, Brazil, [NOT_YET_RECRUITING] | Oncocentro de Minas Gerais, Belo Horizonte, Brazil, [RECRUITING] | Hospital Tacchini, Bento Gonçalves, Brazil, [RECRUITING] | Centro de Pesquisa Sao Lucas, Campinas, Brazil, [RECRUITING] | Centro de Pesquisa Clínica do Instituto do Câncer do Ceará, Fortaleza, Brazil, [NOT_YET_RECRUITING] | Hospital de Cancer de Londrina, Londrina, Brazil, [NOT_YET_RECRUITING] | Liga Norte Riograndense Contra o Câncer, Natal, Brazil, [RECRUITING] | Hospital São Lucas da PUCRS, Porto Alegre, Brazil, [RECRUITING] | Centro de Tratamento de Tumores Botafogo para Oncoclinicas Rio de Janeiro SA, Rio de Janeiro, Brazil, [RECRUITING]","Carcinoma, Non-Small-Cell Lung",4,[1] Part A: Olomorasib + Pembrolizumab (EXPERIMENTAL): Participants will receive olomorasib administered orally in combination with pembrolizumab intravenously (IV) for up to 1 year followed by olomorasib alone for up to 3 years of total treatment. || [2] Part A: Placebo + Pembrolizumab (PLACEBO_COMPARATOR): Participants will receive placebo administered orally in combination with pembrolizumab administered IV for up to 1 year followed by placebo alone for up to 3 years of total treatment. || [3] Part B: Olomorasib + Durvalumab (EXPERIMENTAL): Participants will receive olomorasib administered orally in combination with durvalumab administered IV for up to 1 year followed by olomorasib alone for up to 3 years of total treatment. || [4] Part B: Placebo + Durvalumab (PLACEBO_COMPARATOR): Participants will receive placebo administered orally in combination with durvalumab administered IV for up to 1 year followed by placebo alone for up to 3 years of total treatment.,"* Histological or cytological confirmation of NSCLC. * Part A 1. Clinical Stage II-IIIB (N2) treated with presurgical chemoimmunotherapy, with residual tumor present at time of surgery. Patients with a pathologic complete response are not eligible. 2. Pathologic Stage II-IIIB (N2) NSCLC treated with initial upfront resection. * Part B - Clinical Stage III, unresectable NSCLC, without progression on concurrent platinum-based chemoradiotherapy. * Must have disease with evidence of KRAS G12C mutation. * Must have known programmed death-ligand 1 (PD-L1) expression * Must have an ECOG performance status of 0 or 1. * Able to swallow oral medication. * Must have adequate laboratory parameters. * Contraceptive use should be consistent with local regulations for those participating in clinical studies. * Women of childbearing potential must * Have a negative pregnancy test. * Not be breastfeeding during treatment","* Have known changes in the EGFR or ALK genes. * Have another type of cancer that is progressing or required active treatment within the past 3 years before screening. * Have an active autoimmune disease that required systemic treatment in the past 2 years. Endocrine replacement therapy is allowed. * Had any immune-related side effect or allergic reaction (Grade 3 or higher) from a previous immunotherapy medicine, or any immune-related side effect greater than Grade 1 that has not resolved. This does not apply for people with hormone-related diseases who are now on stable hormone replacement therapy."
NCT05660395,A Phase 1b Open-Label Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10),,PHASE1,Brazil,"Hospital Sírio-Libanês - Brasília, Brasília, Brazil, [RECRUITING] | Hospital Mãe de Deus - Centro Integrado de Oncologia, Porto Alegre, Brazil, [RECRUITING] | Hospital Sírio-Libanês - São Paulo, São Paulo, Brazil, [RECRUITING] | A Beneficência Portuguesa de São Paulo - Unidade Mirant, São Paulo, Brazil, [RECRUITING] | Hospital 9 de Julho, São Paulo, Brazil, [RECRUITING] | Albert Einstein Israelite Hospital, São Paulo, Brazil, [RECRUITING]",Diffuse Large B-Cell Lymphoma | High-grade B-cell Lymphoma,3,"[1] Arm A: Normal Hepatic Function (EXPERIMENTAL): Participants will receive loncastuximab tesirine 0.15 mg/kg once every 3 weeks (Q3W) for two cycles, then 0.075 mg/kg Q3W for subsequent cycles (1 cycle = 21 days).

Participants who have a toxicit... || [2] Arm B: Moderate Hepatic Impairment (EXPERIMENTAL): Participants will receive loncastuximab tesirine in a standard 3+3 dose-escalation design. Initial dose will be 0.09 mg/kg Q3W for two cycles, then 0.045 mg/kg Q3W for subsequent cycles (1 cycle = ... || [3] Arm C: Severe Hepatic Impairment (EXPERIMENTAL): Participants will receive loncastuximab tesirine in a standard 3+3 dose-escalation design. Initial dose will be 0.09 mg/kg Q3W for two cycles, then 0.045 mg/kg Q3W for subsequent cycles (1 cycle = ...","* Male or female participants aged 18 years or older * Pathologic diagnosis of relapsed (disease that has recurred following a response) or refractory (disease that failed to respond to prior therapy) DLBCL not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma (2016 World Health Organization classification) who have received at least one systemic treatment regimen * Measurable disease as defined by the 2014 Lugano Classification * Normal hepatic function or hepatic impairment as defined by the National Cancer Institute Organ Dysfunction Working Group hepatic impairment classification: * Arm A Normal hepatic function: bilirubin and aspartate aminotransferase (AST) ≤ upper limit of normal (ULN) * Arm B Moderate hepatic impairment: bilirubin \> 1.5 × to 3 × ULN (any AST) * Arm C Severe hepatic impairment: bilirubin \> 3 × ULN (any AST) * ECOG performance status 0 to 2 for participants with normal hepatic function. ECOG 0 to 3 for participants with moderate or severe hepatic impairment * Adequate organ function * Women of childbearing potential (WOCBP)\* must agree to use a highly effective method of contraception from the time of giving informed consent until at least 10 months after the last dose of study drug. Men with female partners who are of childbearing potential must agree to use a condom when sexually active or practice total abstinence from the time of the first dose until at least 7 months after the last dose of study drug.","* Previous therapy with loncastuximab tesirine * Allogenic or autologous stem cell transplant within 60 days prior to start of study drug (C1D1) * Human immunodeficiency virus (HIV) seropositive * Serologic evidence of chronic hepatitis B virus (HBV) infection and unable or unwilling to receive standard prophylactic antiviral therapy or with detectable HBV viral load * Serologic evidence of hepatitis C virus (HCV) infection without completion of curative treatment or with detectable HCV viral load * History of Stevens-Johnson syndrome or toxic epidermal necrolysis * Lymphoma with active central nervous system involvement at the time of screening, including leptomeningeal disease * Breastfeeding or pregnant * Significant medical comorbidities * Major surgery, radiotherapy, chemotherapy, or other anti-neoplastic therapy, within 14 days prior to start of study drug (C1D1), except shorter if approved by the Sponsor"
NCT06260111,Laser Photobiomodulation to Prevent Oral Mucositis and Functional Impairment Among Adult Hematologic Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation,POMFITT,NA,Chile,"Clinica Dávila, Santiago, Chile, [RECRUITING]",Hematologic Cancer,2,"[1] Photobiomodulation group (EXPERIMENTAL): Photobiomodulation and usual care (education, cryotherapy, and mouth hygiene). || [2] Control group (OTHER): Usual care (education, cryotherapy, and mouth hygiene).",* Adults over 18 years of age with hematological neoplasms who require medical indication of an HSCT according to the Transplant Committee at Clinica Dávila * With sufficient understanding of Spanish.,"* Observed cognitive deficit * Patients who do not meet the criteria of clinical stability, progression of the disease, and that do not fulfill requirement of the National Hematopoietic Stem Cell Transplantation Program. * Participants with an oral infection from any type of Candida prior to HSCT."
NCT05447988,Post-Marketing Clinical Follow-Up Study to Confirm the Safety and Effectiveness/Performance of Motiva Flora® Tissue Expander in Staged Breast Reconstruction Surgery,,NA,"Chile, Costa Rica, Panama","Centro de Cirugía Plástica y Reconstructiva. Dra. Viviana Spröhnle Hospital Regional de Rancagua, Rancagua, Chile, [RECRUITING] | Centro Europeo de Cirugia, San José, Costa Rica, [RECRUITING] | The Panama Clinic Complejo Hospitalario Pacific Center, Panama City, Panama, [RECRUITING]",Breast Tissue Accessory | Breast Cancer,1,[1] Two-stage reconstruction (OTHER): 136 participants will undergo two-stage reconstruction,"* The participant gives written informed consent. * The participant is genetically female, aged 18 years or older. * The participant needs tissue expansion as part of breast reconstruction treatment following mastectomy, which may include immediate reconstruction. * The participant is in a suitable clinical condition to allow breast implant placement after tissue expander placement, at the discretion of the investigator. * The participant has the physical and cognitive capacity to understand and follow the surgeon's recommendations. * Complete radiotherapy at least 1 year before surgery. * Partial or total decrease in tumour volume after radiotherapy. * The participant is able and willing to comply with all study requirements including attending follow-up appointments. * Participant with reasonable surgical risk. * Participant with a history of non-metastatic breast cancer. * Participant willing to undergo an MRI, CT scan and any other studies if required at surgeon discretion. For substudy - MRI / CT - the following additional criteria apply: \- Patient is willing to undergo one MRI and one CT anytime during the follow up","* The participant is pregnant or planning a pregnancy during the first year after surgery or is currently breastfeeding. * Participants with implanted devices that may be affected by magnetic fields (pacemakers, drug infusion devices). * Participants with abnormal haematological and biochemical values after chemotherapy. * Participants with tumour residues in or near the area where tissue expansion is to be performed. * Participants who do not have adequate tissue at the intended site for expansion, at the surgeon's discretion, due to previous radiotherapy, ulceration, vascular involvement, history of impaired wound healing or scar deformity. * Participants with current or previous infection in the area where the expansion will take place. * Presence of autoimmune diseases such as lupus or scleroderma, or immunocompromised participants due to immunosuppressive or steroid therapy. * Inadequate chest wall tissue due to damage caused by radiotherapy, tight skin grafts or radical resection of the pectoralis major muscle. * Participant who is included in another pharmacological or device research study. * Participants with a previous history of failure of attempted tissue expansion or breast implant placement at the site of intended expansion. * Participant with a history of silicone sensitivity. * Employees of Establishment Labs or any of its divisions or sites; Researchers or anyone who collaborates on the study or is directly related to a person working for Establishment Labs, sites or commissioned Researchers."
NCT06203210,"A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)",IDeate-Lung02,PHASE3,Brazil,"Departmento de Pesquisa Clinica- Hospital de Amor de Barretos, Barretos, Brazil, [RECRUITING] | Cepon - Centro de Pesquisas Oncolăgicas de Santa Catarina, Florianópolis, Brazil, [RECRUITING] | Clínica de Neoplasias Litoral, Itajaí, Brazil, [RECRUITING] | Hospital São Lucas Da Pucrs, Porto Alegre, Brazil, [RECRUITING] | Cepho Centro de Estudos E Pesquisas de Hematologia E Oncologia, Santo André, Brazil, [RECRUITING] | Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto, São José do Rio Preto, Brazil, [RECRUITING] | ICESP Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira, São Paulo, Brazil, [RECRUITING] | Hospital Sirio-Libanes, São Paulo, Brazil, [NOT_YET_RECRUITING] | Hospital Benefică Ncia Portuguesa de Să O Paulo, São Paulo, Brazil, [RECRUITING] | Hospital Alemão Oswaldo Cruz, São Paulo, Brazil, [RECRUITING]",Small Cell Lung Cancer,2,"[1] Ifinatamab deruxtecan (I-DXd) (EXPERIMENTAL): Participants randomized to receive 12 mg/kg I-DXd monotherapy on Day 1 of each 21-day cycle until unacceptable toxicity, progressive disease (PD), or withdrawal of consent as specified in the proto... || [2] Treatment of Physician's Choice (TPC) (ACTIVE_COMPARATOR): Participants randomized to receive topotecan, lurbinectedin, or amrubicin, as per investigator's choice and per locally approved label (indicated dose and frequency), until a treatment discontinuat...",Participants must meet all the following criteria to be eligible for randomization into the study: 1. Sign and date the informed consent form prior to the start of any study-specific qualification procedures. 2. Adults ≥18 years or the minimum legal adult age (whichever is greater) at the time the informed consent form is signed. 3. Has histologically or cytologically documented extensive-stage small cell lung cancer (ES-SCLC). 4. The participant must provide adequate baseline tumor samples with sufficient quantity and quality of tumor tissue content. 5. Has received prior therapy with only one prior platinum-based line as systemic therapy for SCLC with at least 2 cycles of therapy and a chemotherapy free-interval of ≥30 days. 6. Has at least 1 measurable lesion according to RECIST v1.1 as assessed by the investigator. 7. Has documentation of radiological disease progression on or after the most recent systemic therapy. 8. Has ECOG PS of ≤1 within 7 days prior to Cycle 1 Day 1 (C1D1). 9. Has no evidence of brain or leptomeningeal disease (spinal cord or central nervous system \[CNS\] metastases) based on history and physical examination. Subjects must require no treatment with steroids or anticonvulsants and have a stable neurologic status for at least 2 weeks prior to the first dose of study drug.,"Participants who meet any of the following criteria will be disqualified from entering the study: 1. Has received prior treatment with orlotamab, enoblituzumab, or other B7 homologue 3 (B7-H3) targeted agents, including I-DXd. 2. Prior discontinuation of an antibody drug conjugate (ADC) that consists of an exatecan derivative (eg, trastuzumab deruxtecan) due to treatment-related toxicities. 3. Has received any of the comparators used in this study or any topoisomerase I inhibitor. 4. Has inadequate washout period before randomization as specified in the protocol. 5. Has any of the following conditions within the past 6 months: cerebrovascular accident, transient ischemic attack, or another arterial thromboembolic event. 6. Has uncontrolled or significant cardiovascular disease. 7. Has clinically significant corneal disease. 8. Has history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required corticosteroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at Screening. 9. Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses, including, but not limited to, any underlying pulmonary disorder and potential pulmonary involvement caused by any autoimmune, connective tissue, or inflammatory disorders, prior pneumonectomy, or requirement for supplemental oxygen."
NCT06256588,"A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Dostarlimab as Sequential Therapy After Chemoradiation in Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma",JADE,PHASE3,"Argentina, Brazil, Mexico","GSK Investigational Site, Buenos Aires, Argentina, [RECRUITING] | GSK Investigational Site, Buenos Aires, Argentina, [RECRUITING] | GSK Investigational Site, Buenos Aires, Argentina, [RECRUITING] | GSK Investigational Site, Ciudad Autonoma de Buenos Aire, Argentina, [RECRUITING] | GSK Investigational Site, Córdoba, Argentina, [RECRUITING] | GSK Investigational Site, Rosario, Argentina, [RECRUITING] | GSK Investigational Site, San Juan, Argentina, [RECRUITING] | GSK Investigational Site, San Miguel de Tucumán, Argentina, [RECRUITING] | GSK Investigational Site, Viedma, Argentina, [RECRUITING] | GSK Investigational Site, Barretos, Brazil, [RECRUITING]","Neoplasms, Head and Neck",2,[1] Arm A: Dostarlimab (EXPERIMENTAL): No description || [2] Arm B: Placebo (PLACEBO_COMPARATOR): No description,"Participants are eligible to be included in the study only if all of the following criteria apply: * Has newly diagnosed unresected LA histologically confirmed HNSCC of the oral cavity, oropharynx, hypopharynx or larynx and completed cisplatin plus radiotherapy (termed ""CRT"" in this protocol) with curative intent and has no evidence of distant metastatic disease. * Has provided acceptable core or excisional tissue demonstrating: * PD-L1 positive tumor status * If the primary tumor site is oropharyngeal carcinoma, the participant must have p16 IHC testing. * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Has adequate organ function.","Participants are excluded from the study if any of the following criteria apply: * Has received prior radiation therapy, systemic therapy, targeted therapy, or radical surgery for management of head and neck cancer not considered part of CRT. * Has cancer outside of the oropharynx, larynx, hypopharynx or oral cavity, such as nasopharyngeal, sinus, other para-nasal, or other unknown primary head and neck cancer. * Has experienced any of the following with prior immunotherapy: any irAE of Grade ≥3, immune-related severe neurologic events of any grade (e.g., myasthenic syndrome/myasthenia gravis, encephalitis, Guillain-Barré Syndrome, or transverse myelitis), exfoliative dermatitis of any grade \[Stevens-Johnson Syndrome, toxic epidermal necrolysis, or DRESS (Drug Rash with Eosinophilia and Systemic Symptoms) syndrome\], or myocarditis of any grade. Non-clinically significant laboratory abnormalities are not exclusionary. * Has undergone any major surgical procedure or experienced significant traumatic injury within 28 days prior to enrolment. * Has any history of interstitial lung disease or pneumonitis (past or current). * Has cirrhosis or current unstable liver biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice. * Has a history or current evidence of any medical condition, therapy, or laboratory abnormality that might confound the study results, interfere with their participation for the full duration of the study intervention, or indicate it is not in the best interest of the participant to participate, in the opinion of the investigator. * Is receiving any other anticancer or experimental therapy. No other experimental therapies (including but not limited to chemotherapy, radiation, hormonal treatment, antibody therapy, immunotherapy, gene therapy, vaccine therapy, or other experimental drugs) of any kind are permitted while the participan"
NCT03997370,Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin,,PHASE1,Puerto Rico,"Cancer Center-Metro Medical Center Bayamon, Bayamón, Puerto Rico, [RECRUITING] | Puerto Rico Hematology Oncology Group, Bayamón, Puerto Rico, [RECRUITING] | HIMA San Pablo Oncologic Hospital, Caguas, Puerto Rico, [SUSPENDED] | Doctors Cancer Center, Manatí, Puerto Rico, [RECRUITING] | Instituto Oncologia Moderna Ponce, Ponce, Puerto Rico, [SUSPENDED] | San Juan Community Oncology Group, San Juan, Puerto Rico, [RECRUITING] | Primary Care Physician Group, San Juan, Puerto Rico, [SUSPENDED] | Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico, [RECRUITING] | PROncology, San Juan, Puerto Rico, [RECRUITING] | San Juan City Hospital, San Juan, Puerto Rico, [RECRUITING]",Malignant Solid Neoplasm,1,"[1] Treatment (iohexol, standard care carboplatin, blood samples) (EXPERIMENTAL): Patients receive iohexol IV over 30-60 seconds. Patients then receive standard of care carboplatin IV. Patients also undergo collection of 7-8 blood samples for analysis.","* Patients must have the psychological ability and general health that permits completion of the study requirements and required follow up * For men who are sexually active, the need for use of medically acceptable contraception will be dictated by the primary treatment plan/protocol * Study accrual was closed to women on 08/18/2021 and accrual is now only open to males in order to meet accrual goals and study objectives. (11-AUG-2021) * Male sex * Any patients who will receive treatment with intravenous carboplatin (any AUC, any cycle) on a National Cancer Institute (NCI)-sponsored National Clinical Trial Network (NCTN)-, Experimental Therapeutics Clinical Trials Network (ETCTN)-, trial, local trial, or through standard of care * Age \>= 18 * The patient or a legally authorized representative must provide study-specific informed consent prior to study entry","* Treated at an institute where creatinine is not measured with an IDMS calibrated assay * History of allergic reactions to computed tomography (CT) contrast, iodine or shellfish, or history of anaphylactic reaction to any food item * Recent (last 6 months) episode of acute kidney injury, have sickle cell disease, or have current indwelling nephrostomy tubes * Edema beyond trace edema, because this will impact iohexol equilibration and distribution * Ascites (including pleural effusion) beyond trace ascites, because this will impact iohexol equilibration and distribution * Whole- or part-limb amputees, because this will impact iohexol equilibration and distribution * Inability to maintain a constant dose and schedule of anti-inflammatory agents, diuretics, angiotensin II receptor blockers (ARB) and angiotensin converting enzyme inhibitors (ACEi) for one week prior to study visit, as this impacts renal function. If the patient is on a nonsteroidal anti-inflammatory drug (NSAID), diuretic, ARB or ACEi, they are eligible as long as these agents are taken on a set schedule for 7 or more days prior to study (and not on an ""as needed"" basis as that can cause fluctuations in renal function) * Inadequate venous access to obtain pharmacokinetic (PK) specimens * Multinodular goiter, Graves' disease or autoimmune thyroiditis, per iohexol package insert (hypothyroidism is allowed)"
NCT06637501,"A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia",,PHASE2,Brazil,"Centro de Pesquisas Oncologicas Cepon, Florianópolis, Brazil, [RECRUITING] | Hospital de Clinicas de Porto Alegre, Porto AlegreRS, Brazil, [RECRUITING] | Instituto Dor de Pesquisa E Ensino Sao Paulo, São Paulo, Brazil, [RECRUITING] | Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein, São Paulo, Brazil, [RECRUITING]",Chronic Lymphocytic Leukemia,2,"[1] Arm A: Combination Therapy: Sonrotoclax + Zanubrutinib (EXPERIMENTAL): Participants will receive sonrotoclax in combination with zanubrutinib daily for a fixed duration of 15 cycles. || [2] Arm B: Monotherapy: Zanubrutinib (ACTIVE_COMPARATOR): Participants will receive zanubrutinib monotherapy daily until disease progression or unacceptable toxicity, whichever occurs first.","1. Previously untreated adult patient ≥ 18 years with a confirmed diagnosis of CLL. 2. CLL requiring treatment as per pre-defined criteria. 3. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1, or 2. 4. Measurable disease by CT/MRI. 5. Adequate marrow function. 6. Adequate liver function as indicated by aspartate aminotransferase (AST) alanine aminotransferase (ALT) and serum total bilirubin. 7. Adequate renal function. 8. Life expectancy \> 6 months. 9. Signed informed consent and able to comply with the study protocol in the investigator's judgment. 10. Women of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study and for ≥ 90 days after the last dose of study drug.","1. Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation 2. Known central nervous system involvement 3. Received previous systemic treatment for CLL 4. Clinically significant cardiovascular disease 5. Severe or debilitating pulmonary disease 6. History of prior malignancy 7. Active fungal, bacterial, and/or viral infection requiring systemic therapy 8. Positive HIV serology (HIVAb) status or serologic status reflecting active hepatitis B or C infection 9. Uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia requiring treatment 10. History of severe bleeding disorder such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring blood transfusion or other medical intervention 11. History of stroke or intracranial hemorrhage ≤ 6 months before the first dose of study treatment 12. Unable to swallow capsules or tablets or diseases significantly affecting GI function 13. Hypersensitivity to zanubrutinib, sonrotoclax, or any of its excipients 14. Use of investigational agents within the last 4 weeks before screening 15. Pregnant and lactating females Note: Other protocol defined Inclusion/Exclusion criteria may apply"
NCT06124157,An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors With Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia,,PHASE3,Puerto Rico,"University Pediatric Hospital, San Juan, Puerto Rico, [RECRUITING]",B Acute Lymphoblastic Leukemia,3,[1] Stratum I (Ph+ ALL) (EXPERIMENTAL): See detailed description || [2] Stratum II (PDGFRB ABL-Class fusions) (EXPERIMENTAL): See detailed description. || [3] Stratum III (non-PDGFRB ABL-Class fusions) (EXPERIMENTAL): See detailed description.,"* Patients must be \> 365 days and \< 18 years (for AIEOP-BFM), \> 365 days and \< 22 years (for Children's Oncology Group \[COG\]) and \> 365 days and \< 46 years (for ALLTogether sites) at the time of enrollment * Newly-diagnosed Ph+ or ABL-class Ph-like B-ALL. Leukemic blasts must express CD19. ABL-class fusions are defined as rearrangements involving the following genes predicted to be sensitive to imatinib and/or dasatinib: ABL1, ABL2, CSF1R, and PDGFRB * Evidence of BCR::ABL1 should be documented by a clinically-validated assay prior to study entry on day 15 from the first dose of vinCRIStine during Induction therapy. ABL-class Ph-like B-ALL gene rearrangements should be documented by a clinically-validated assay and enrolled on study by day 1 of Blinatumomab Block 1. Accepted methods of detection include fluorescence in situ hybridization (FISH) using break-apart of colocalization signal probes, singleplex or multiplex reverse-transcription polymerase chain reaction (RT-PCR), whole-transcriptome or panel-based ribonucleic acid (RNA) sequencing (e.g., Hematologic Cancer Fusion Analysis, TruSight RNA Pan-Cancer Panel or equivalent). Confirmation of 5' fusion partner genes is not required for study enrollment * Patients with Ph+ B-ALL must have previously started Induction therapy, which includes vinCRIStine, a corticosteroid, pegaspargase or calaspargase pegol, with or without anthracycline, and/or other standard cytotoxic chemotherapy * Patients with Ph+ B-ALL have not received more than 14 days of systemic Induction therapy beginning with the first Induction dose of vinCRIStine * Patients with ABL-class Ph-like B-ALL must have previously completed 4 or 5 weeks of multiagent Induction chemotherapy (Induction 1A) * Patients may have started either imatinib or dasatinib prior to study entry but should have received no more than 14 days of TKI for Ph+ B-ALL or no more than 35 days of TKI for ABL-class Ph-like B-ALL * Patients must have a performance status corres","* Known history of chronic myeloid leukemia (CML) * ABL-class Ph-like B-ALL who are CNS2 or CNS3 at end of Induction phase * ALL developing after a previous cancer treated with cytotoxic chemotherapy * Active, uncontrolled infection or active systemic illness that requires ongoing vasopressor support or mechanical ventilation * Down syndrome (trisomy 21) * Pregnancy and breast feeding * Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A negative pregnancy test is required for female patients of childbearing potential within 7 days prior to enrollment * Lactating females who plan to breastfeed their infants * Sexually active male and female patients of reproductive potential who have not agreed to use an effective contraception method for the duration of treatment according to protocol * NOTE: Patients who could become pregnant or could father a child must use effective contraception during protocol treatment and for 30 days after the last dose of dasatinib or 14 days after the last dose of imatinib dose or per institutional standard of care for multiagent chemotherapy, whichever is longer * Prior treatment with TKIs before study entry with the exception of imatinib or dasatinib * Patients with congenital long QT syndrome, history of ventricular arrhythmias, or heart block * Patients with known Charcot-Marie-Tooth disease * Patients with significant central nervous system pathology that would preclude treatment with blinatumomab, including history of severe neurologic disorder or autoimmune disease with central nervous system (CNS) involvement * Note: Patients with a history of seizures that are well controlled on stable doses of anti-epileptic drugs are eligible. Patients with a history of cerebrovascular ischemia/hemorrhage with residual deficits are not eligible. Patients with a history of cerebrovascular ischemia/hemorrhage remain eligible provided all neurologic deficits have resolved"
NCT06091254,"A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator's Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-1)",OLYMPIA-1,PHASE3,"Brazil, Chile","Ensino e Terapia de Inovacao Clinica Amo (Etica), Salvador, Brazil, [RECRUITING] | Instituto Mario Pena de Ensino Pesquisa e Inovacao, Belo Horizonte, Brazil, [RECRUITING] | Liga Norte Riograndense Contra o Cancer, Natal, Brazil, [RECRUITING] | Instituto do Cancer em Hospital Sao Vicente de Paulo, Passo Fundo, Brazil, [RECRUITING] | Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil, [RECRUITING] | Centro de Hematologia e Oncologia, Joinville, Brazil, [RECRUITING] | Animi Unidade de Tratamento Oncologico Ltda, Lages, Brazil, [RECRUITING] | Fundacao Pio XII Hospital de Amor, Barretos, Brazil, [RECRUITING] | Amaral Carvalho Hospital, Jaú, Brazil, [RECRUITING] | Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo, Ribeirão Preto, Brazil, [RECRUITING]",Follicular Lymphoma (FL),2,"[1] Odronextamab (EXPERIMENTAL): Part 1 is a safety run-in. All participants will receive odronextamab.

In part 2 participants will be randomly assigned in a 1:1 ratio to receive odronextamab followed by odronextamab maintenance. || [2] Rituximab + Investigator's Choice Chemotherapy (ACTIVE_COMPARATOR): Part 2 only, participants will be randomized 1:1 to receive rituximab in combination with chemotherapy followed by rituximab maintenance.","1. Diagnosis of Cluster of Differentiation 20\^+ (CD20\^+) FL Grade 1-3a, stage II bulky or stage III / IV 2. Need for treatment as described in the protocol 3. Have measurable disease on cross-sectional imaging documented by diagnostic imaging Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 5. Adequate bone marrow function and hepatic function Key","1. Central Nervous System (CNS) lymphoma or leptomeningeal lymphoma 2. Histological evidence of transformation to a high-grade or diffuse large B-cell lymphoma 3. Waldenström Macroglobulinemia (WM, lymphoplasmacytic lymphoma), Grade 3b follicular lymphoma, chronic lymphocytic leukemia, or small lymphocytic lymphoma 4. Treatment with any systemic anti-lymphoma therapy 5. Infections and allergy/hypersensitivity to study drug or excipient NOTE: Other protocol defined inclusion/exclusion criteria apply"
NCT05714839,"A Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Clinical Activity of Belantamab as Monotherapy and in Combination With Other Treatments in Participants With Multiple Myeloma",DREAMM-20,PHASE1,"Argentina, Brazil","GSK Investigational Site, Ciudadela, Argentina, [COMPLETED] | GSK Investigational Site, Viedma, Argentina, [RECRUITING] | GSK Investigational Site, Joinville, Brazil, [RECRUITING] | GSK Investigational Site, Salvador, Brazil, [RECRUITING] | GSK Investigational Site, São Paulo, Brazil, [RECRUITING]",Multiple Myeloma,3,[1] Part 1: Dose escalation of belantamab monotherapy (EXPERIMENTAL): Belantamab will be administered in participants with RRMM until progressive disease (PD) || [2] Part 2: Belantamab and belantamab mafodotin (delivered as separate drugs) dose range finding (EXPERIMENTAL): Participants with RRMM will receive belantamab in combination with a fixed dose of belantamab mafodotin (delivered as separate drugs) || [3] Part 1b: Optional belantamab mafodotin (EXPERIMENTAL): Participants enrolled in Part 1 and Part 2 will be dosed until PD after which they will have the option to receive treatment with single agent belantamab mafodotin.,"* Participants at the time of signing the Informed Consent Form (ICF) are at least 18 years old or are of the legal age of consent in the jurisdiction in which the study is taking place. * Participants who have histologically or cytologically confirmed diagnosis of Multiple Myeloma (MM), as defined by the international myeloma working group (IMWG). 1\. Participants who have received at least 3 prior lines of anti-myeloma treatments, and have already received an immunomodulating agent, a proteasome inhibitor, and an anti-CD38 mAb (unless contraindicated or unavailable) and have confirmed progression on or following the last line of treatment. * Participants with a history of Autologous stem cell transplant (ASCT) are eligible for study participation provided the following eligibility criteria are met: 1. transplant was greater than (\>)100 days prior to screening. 2. no active infection(s) * Eastern cooperative oncology group-performance status (ECOG-PS) of 0 to 2. * Measurable disease defined as at least ONE of the following: 1. Serum M-protein concentration greater than (\>=) 0.5 gram (g)/ deciliter (dL) (\>=5 gram/liter \[g/L\]) 2. Urine M-protein excretion \>=200 mg/24 hours (\>=0.2 g/24 hours) 3. Serum free light chain (FLC) assay: involved FLC level \>=10 mg/dL (\>=100 milligrams per liter \[mg/L\]) and an abnormal serum FLC ratio (less than \[\<\]0.26 or \>1.65) * Have adequate organ system function as defined by the laboratory assessments. * All prior treatment-related toxicities (defined by National Cancer Institute-Common Toxicity Criteria for Adverse Events \[NCI-CTCAE\], v5.0, 2017) must be Grade \<=1 at the time of screening except for alopecia (any grade), neuropathy (Grade \<=2), or endocrinopathy managed with replacement therapy (any grade). * Participants or Legally authorized representative (LAR) capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.","* Diagnosis of primary Amyloid Light chain (AL) Amyloidosis, active Polyneuropathy, organomegaly, endocrinopathy, myeloma protein, and skin changes (POEMS) syndrome, primary plasma cell leukemia. * Any serious and/or unstable pre-existing medical, psychiatric disorder, or other conditions (including lab abnormalities) that could interfere with participant's safety, obtaining informed consent, or compliance with study procedures. * Participant is exhibiting signs of meningeal or central nervous system involvement with MM. * Current corneal epithelial disease except nonconfluent Superficial punctate keratitis (SPK). * Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice. * Presence of malignancies other than disease under study are excluded, except for any other malignancy from which the participant has been disease-free for more than 2 years and, in the opinion of the Principal investigator (PI) and GlaxoSmithKline (GSK) Medical Director, will not affect the evaluation of the effects of this clinical trial treatment on the currently targeted malignancy (MM). * Evidence of cardiovascular risk * Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to belantamab / belantamab mafodotin or any of the components of the study treatment. History of severe hypersensitivity to other Monoclonal antibodies (mAbs). * Active infection requiring antibiotic, antiviral, or antifungal treatment. * Known Human immunodeficiency virus (HIV) infection, unless the participant can meet specific criteria. * Recent history (within the past 6 months) of acute diverticulitis, inflammatory bowel disease, intra-abdominal abscess, or gastrointestinal obstruction. * Participants with Hepatitis B virus (HBV) or Hepatitis C virus (HCV) will be excluded unless specific criteria can be met * Pr"
NCT05855200,"A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer",,PHASE3,"Argentina, Brazil, Mexico, Panama","GSK Investigational Site, Buenos Aires, Argentina, [RECRUITING] | GSK Investigational Site, Buenos Aires, Argentina, [RECRUITING] | GSK Investigational Site, Buenos Aires, Argentina, [RECRUITING] | GSK Investigational Site, Capital Federal, Argentina, [RECRUITING] | GSK Investigational Site, Ciudad Autonoma de Buenos Aire, Argentina, [RECRUITING] | GSK Investigational Site, Córdoba, Argentina, [RECRUITING] | GSK Investigational Site, Mar del Plata, Argentina, [RECRUITING] | GSK Investigational Site, Rosario, Argentina, [RECRUITING] | GSK Investigational Site, San Miguel de Tucumán, Argentina, [RECRUITING] | GSK Investigational Site, Santa Fe, Argentina, [RECRUITING]","Colonic Neoplasms | Neoplasms, Colon",2,[1] Dostarlimab (EXPERIMENTAL): Participants will receive Dostarlimab pre and post surgery || [2] Standard of Care (SOC) (ACTIVE_COMPARATOR): Participants will receive SOC (FOLFOX/CAPEOX) or undergo expectant observation post surgery.,* Has untreated pathologically confirmed colon adenocarcinoma * Has resectable colon adenocarcinoma defined as clinically T4N0 or Stage III * Has radiologically evaluable disease * Has a tumor demonstrating the presence of either dMMR status or MSI-H,"* Has distant metastatic disease. * Has received prior medical therapy (chemotherapy, immunotherapy, biologic, or targeted therapy), radiation therapy or surgery for management of the current diagnosis of colon cancer * Has a tumor that, in the investigator's judgment is causing symptomatic bowel obstruction or otherwise requires urgent/emergent surgery at the time of screening. Participants with a history of colonic obstruction are eligible after obstruction is relieved by a diverting stoma (defunctioning ileostomy or colostomy). Patients with a history of colonic obstruction in the context of current colon cancer diagnosis and treated with colonic stents are not eligible. * Has undergone any major surgical procedure, open biopsy, or experienced significant traumatic injury within 28 days prior to randomization * Has any history of interstitial lung disease or pneumonitis and/or history of radiation induced enteritis. * Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice * Has a history of allogenic stem cell transplantation or organ transplantation * Is receiving any other anticancer or experimental therapy. No other experimental therapies (including but not limited to chemotherapy, radiation, hormonal treatment, antibody therapy, immunotherapy, gene therapy, vaccine therapy, or other experimental drugs) of any kind are permitted while the participant is receiving study intervention * Is pregnant, breastfeeding, or expecting to conceive children within the projected duration of the study * Has a history of severe allergic and/or anaphylactic reactions to chimeric, human or humanized antibodies, fusion proteins, or known allergies to dostarlimab, or its excipients, or any components of FOLFOX or CAPEOX"
NCT06532006,"A Randomized, Double-blinded, Multicenter, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination With Trastuzumab and Chemotherapy (XELOX) Versus Trastuzumab and Chemotherapy (XELOX) With or Without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer",,PHASE3,Chile,"Centro de Oncologia de Precision, Santiago, Chile, [RECRUITING] | Instituto del Cancer RedSalud Vitacura, Santiago, Chile, [RECRUITING]",Gastroesophageal-junction Cancer | Monoclonal Antibody | Gastric Cancer | HER2-positive Gastric Cancer,2,"[1] Experimental group (EXPERIMENTAL): Experimental group: HLX22 (15 mg/kg) + trastuzumab + chemotherapy (XELOX) ± placebo (for pembrolizumab), Q3W

Subjects in the experimental group may use one of the treatments below:

HLX22 (15 mg/k... || [2] Control group (ACTIVE_COMPARATOR): Control group: Placebo (for HLX22) + trastuzumab + chemotherapy (XELOX) ± pembrolizumab, Q3W

Subjects in the control group may use one of the treatments below:

Placebo (for HLX22) + trastuzumab +...","1. Male/female who are at least 18 years of age on the day of signing the informed consent. 2. With histologically or cytologically confirmed diagnosis of previously untreated, locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma. 3. Had measurable disease as assessed by IRRC according to the RECIST v1.1, the target lesion must not be a bone metastatic lesion only. 4. HER2-positive tumor defined as either IHC 3+ or IHC 2+ in combination with ISH+ or FISH, as assessed by a central laboratory on a primary or metastatic tumor. 5. ECOG PS within 7 days before randomization: 0-1. 6. Expected survival ≥ 6 months. 7. Had adequate organ function",1. Patients with other malignant tumors within 2 years before the randomization. 2. Evidence of disease progression within 6 months (before randomization) after completion of prior neoadjuvant or adjuvant chemotherapy (or both) or radiotherapy for gastric adenocarcinoma or gastroesophageal junction adenocarcinoma. 3. Previous treatment with any HER2-target therapy. 4. Active gastrointestinal bleeding 5. Presence of central nervous system (CNS) metastases. 6. Left ventricular ejection fraction (LVEF) \< 55%. 7. Subjects who had known history of severe allergy to any monoclonal antibody or any component of study treatment.
NCT06353386,MK-5684-01A Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC),,"PHASE1, PHASE2","Chile, Colombia","Clinica Universidad Catolica del Maule-Oncology ( Site 0304), Talca, Chile, [RECRUITING] | FALP ( Site 0301), Santiago, Chile, [RECRUITING] | Pontificia Universidad Catolica de Chile ( Site 0303), Santiago, Chile, [RECRUITING] | Bradfordhill ( Site 0300), Santiago, Chile, [RECRUITING] | CIDO SpA-Oncology ( Site 0302), Temuco, Chile, [RECRUITING] | FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0406), Bogotá, Colombia, [RECRUITING] | Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia ( Site 0402), Bogotá, Colombia, [RECRUITING] | Sociedad De Oncología y Hematología Del Cesar SAS-Oncology ( Site 0400), Valledupar, Colombia, [RECRUITING] | IMAT S.A.S ( Site 0404), Montería, Colombia, [RECRUITING] | Fundación Valle del Lili-Oncology CIC ( Site 0403), Santiago de Cali, Colombia, [RECRUITING]","Prostatic Neoplasms, Castration-Resistant",4,"[1] Arm A1: Opevesostat (EXPERIMENTAL): Participants receive 5 mg of opevesostat twice daily (BID) via oral tablet plus dexamethasone 1.5 mg by oral tablets once daily (QD) and 0.1 mg fludrocortisone acetate by oral tablet QD until progr... || [2] Arm A2: Olaparib + Opevesostat (EXPERIMENTAL): Participants receive 5 mg of opevesostat BID via oral tablet plus dexamethasone 1.5 mg by oral tablets QD and 0.1 mg fludrocortisone acetate by oral tablet QD, PLUS 300 mg of olaparib BID via oral ... || [3] Arm A3: Docetaxel + Opevesostat (EXPERIMENTAL): Participants receive 5 mg of opevesostat BID via oral tablet plus dexamethasone 1.5 mg by oral tablets QD and 0.1 mg fludrocortisone acetate by oral tablet QD, PLUS 75 mg/m\^2 of docetaxel once eve... || [4] Arm A4: Cabazitaxel + Opevesostat (EXPERIMENTAL): Participants receive 5 mg of opevesostat BID via oral tablet plus dexamethasone 1.5 mg by oral tablets QD and 0.1 mg fludrocortisone acetate by oral tablet QD, PLUS 20 mg/m\^2 of cabazitaxel Q3W vi...","The main inclusion criteria include but are not limited to the following: * Histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate without small cell histology. * Prostate cancer progression and received androgen deprivation therapy (ADT) or post bilateral orchiectomy within 6 months before screening. * Evidence of disease progression from either, \>4 weeks from last flutamide treatment, or \>6 weeks from last bicalutamide or nilutamide treatment, if receiving first generation anti-androgen therapy as last treatment therapy. * Current evidence of metastatic disease. * Prior treatment with 1 to 2 novel hormonal agent(s) (NHA) for non-metastatic, or metastatic, hormone-sensitive prostate cancer or castration-resistant prostate cancer and have disease progression during or after treatment. * Treatment with bone resorptive therapy (including, but not limited to, bisphosphonate or denosumab) must have been on stable doses for \>4 weeks before randomization. * Participants who experienced adverse events (AEs) due to previous anticancer therapies must have recovered to \<Grade 1 or baseline. * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy. * Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load. * Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable.","The main exclusion criteria include but are not limited to the following: * History of pituitary dysfunction. * Poorly controlled diabetes mellitus. * Active or unstable cardio/cerebro-vascular disease, including thromboembolic events and history of stroke or transient ischemic attack within 6 months before the first dose of study intervention, history of myocardial infarction within 6 months before the first dose of study intervention, New York Heart Association Class III or IV cardiac disease or congestive heart failure, coronary heart disease that is symptomatic, or unstable angina * History or family history of long corrected QT interval (QTc) syndrome. * Myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or features suggestive of MDS/AML. * History or current condition of adrenal insufficiency. * History of (noninfectious) pneumonitis requiring steroids, or current pneumonitis. * HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease. * Undergone major surgery, including local prostate intervention (except prostate biopsy) within 28 days before randomization, and has not recovered from the toxicities and/or complications. * Is on an unstable dose of thyroid hormone therapy within 6 months prior to first dose of study intervention. * Received a whole blood transfusion in the last 120 days before randomization (packed red blood cells and platelet transfusions are acceptable if not given within 28 days before randomization). * Received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization. * Received prior radiotherapy within 2 weeks of start of study intervention or radiation-related toxicities, requiring corticosteroids. * Received a live or live-attenuated vaccine within 30 days before the first does of study intervention. Administration of killed vaccines is allowed. * Diagnosis of immunodeficiency, or is receiving chronic systemic steroid therapy, or any ot"
NCT06351527,"A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Patients With Mature B-cell Malignancies",,PHASE1,Puerto Rico,"Pan American Center for Oncology Trials, San Juan, Puerto Rico, [RECRUITING]",Mature B-cell Malignancies,4,[1] Dose-Escalation Cohort - CLL/SLL and MCL (EXPERIMENTAL): Participants will receive ICP-248 daily from an initial dose of 5/10 mg to the target dose. Cycles will comprise 28 days. || [2] Dose-Expansion Cohort A - CLL/SLL (EXPERIMENTAL): Participants will receive ICP-248 daily from an initial dose of 5/10 mg to the target dose and obinutuzumab for 6 cycles. Cycles will comprise 28 days. || [3] Dose-Expansion Cohort B - MCL (EXPERIMENTAL): Participants will receive ICP-248 daily from an initial dose of 5/10 mg to the target dose. Cycles will comprise 28 days. || [4] Dose-Expansion Cohort C - MCL (EXPERIMENTAL): Participants will receive ICP-248 daily from an initial dose of 5/10 mg to the target dose and Rituximab for 18 cycles. Cycles will comprise 28 days.,,"1. Known central nervous system involvement by lymphoma/leukemia. 2. Known or suspected history of Richter's transformation. 3. Prior autologous stem cell transplant (unless ≥ 3 months since transplant); or prior chimeric cell therapy (unless ≥ 3 months since cell infusion). 4. A history of allogeneic stem cell transplantation. 5. An interval of less than 5 half-lives from the last dose of a strong CYP3A or CYP2C8 inhibitor or inducer (chemical agent, herbal medicine and dietary supplement) to the first dose of the investigational product, or a plan to use concurrently medications, dietary supplements or food (e.g., grapefruit or grapefruit juice) with strong CYP3A or CYP2C8 inhibitory or inductive effect during study participation 6. Presence of active infection that currently requires intravenous systemic anti-infective therapy. 7. History of immunodeficiency, including a positive human immunodeficiency virus (HIV) antibody test. 8. History of significant cardiovascular disease 9. Patients with previous or concomitant central nervous system disorders 10. Grade 2 or above toxicity due to prior anti-cancer therapy at screening 11. Known alcohol or drug dependence 12. Unable to swallow tablets or presence of disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, bariatric surgery procedures, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction."
NCT06561386,"A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%",RELATIVITY1093,PHASE3,"Argentina, Brazil, Chile, Colombia, Mexico","Hospital Británico de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina, [RECRUITING] | Instituto Alexander Fleming, Ciudad Autónoma de Buenos Aires, Argentina, [RECRUITING] | Hospital Italiano de Buenos Aires, ABB, Argentina, [RECRUITING] | Instituto Médico Río Cuarto, Río Cuarto, Argentina, [RECRUITING] | Sanatorio Parque, Rosario, Argentina, [RECRUITING] | Hospital Privado Universitario de Córdoba, Córdoba, Argentina, [RECRUITING] | Instituto Oncológico de Córdoba, Córdoba, Argentina, [RECRUITING] | Hospital Privado de Comunidad, Mar del Plata, Argentina, [RECRUITING] | Pronutrir, Fortaleza, Brazil, [RECRUITING] | Cetus Oncologia - Unidade Belo Horizonte, Belo Horizonte, Brazil, [RECRUITING]",Non-small Cell Lung Cancer,2,[1] Arm A (EXPERIMENTAL): No description || [2] Arm B (ACTIVE_COMPARATOR): No description,* Participants must have histologically confirmed Stage IV or recurrent Non-small Cell Lung Cancer (NSCLC) of non-squamous (NSQ) histology with no prior systemic anti-cancer therapy given as primary therapy for advanced or metastatic disease. * Participants must have measurable PD-L1 ≥ 1% Tumor Cell (TC) score by the investigational PD-L1 immunohistochemistry (IHC) assay VENTANA PD-L1 (SP263) CDx Assay conducted by central laboratory during the screening period prior to randomization. * Participants must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1 criteria. * Participants must have an Easter Cooperative Oncology Group (ECOG) performance status of ≤ 1 at screening. * Participants must have a life expectancy of at least 3 months at the time of randomization.,"* Participants must not be pregnant and/or breastfeeding. * Participants with epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS-1 mutations that are sensitive to available targeted inhibitor therapy. Participants with unknown EGFR, ALK, or ROS-1 status are excluded. * Participants with known BRAFV600E mutations, that are sensitive to available targeted inhibitor therapy; participants with known activating rearranged during transfection (RET) mutations or neurotrophic tyrosine receptor kinase (NTRK) fusion gene alterations are excluded. Participants with unknown or indeterminate BRAF mutation, activating RET mutations or NTRK fusion gene alterations are eligible. * Participants must not have untreated central nervous system (CNS) metastases. * Participants must not have leptomeningeal metastases (carcinomatous meningitis). * Participants must not have concurrent malignancy requiring treatment. * Participants must not have an active autoimmune disease. * Participants must not have history of interstitial lung disease or pneumonitis that required oral or intravenous (IV) glucocorticoids to assist with management. * Participants must not have a history of myocarditis. * Participants must not have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or other antibody or drug targeting T-cell co-stimulation or checkpoint pathways. * Other protocol-defined Inclusion/Exclusion criteria apply."
NCT05925257,Design and Evaluation of the Effectiveness of a Digital Health Intervention to Improve Health Care and Outcomes for Cancer Patients,,PHASE2,Mexico,"Hospital de Oncología del Centro Médico Nacional Siglo XXI, Mexico City, Mexico, [RECRUITING] | UMAE Hospital de Gineco-Obstetricia No.3 ""Dr. Víctor Manuel Espinoza de los Reyes Sánchez"" CMN La Raza., Mexico City, Mexico, [RECRUITING] | UMAE Hospital de Especialidades CMN ""Gral. de Div. Manuel Ávila Camacho"", Puebla City, Mexico, [RECRUITING]",Breast Cancer,2,"[1] Intervention group (EXPERIMENTAL): The intervention group will be given access to the ePRO application and proactive clinical care, including study nurses responding to ePROs and weekly health information videos for six months. || [2] Control group (NO_INTERVENTION): Participants of the control group will be provided with a list of electronic links to videos on breast cancer-relevant topics on the websites of recognised cancer associations and health institutions.","* Women * Age between 20 and 75 years * Breast cancer stages I, II, or III * Neoadjuvant or adjuvant treatment with chemotherapy that started within two to six weeks before enrollment * Access to the internet on mobile phone, computer or tablet * Written informed consent",* Illiterate * Stage IV breast cancer * Cognitive dysfunction * Blindness or low vision not corrected with glasses * Severe depression (≥12 points on the Hospital Anxiety and Depression Scale)
NCT06084481,A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications,,PHASE1,Puerto Rico,"Pan American Center for Oncology Trials /ID# 262903, Rio Piedras, Puerto Rico, [RECRUITING]",Hepatocellular Carcinoma | Pancreatic Ductal Adenocarcinoma | Biliary Tract Cancers | Esophageal Squamous Cell Carcinoma | Triple Negative Breast Cancer,9,"[1] Cohort 1: Hepatocellular Carcinoma (HCC) (EXPERIMENTAL): Participants with HCC will receive ABBV-400 for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years. || [2] Cohort 2: Pancreatic Ductal Adenocarcinoma (PDAC) (EXPERIMENTAL): Participants with PDAC will receive ABBV-400 for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years. || [3] Cohort 3: Biliary Tract Cancers (BTC) (EXPERIMENTAL): Participants with BTC will receive ABBV-400 for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years. || [4] Cohort 4: Esophageal Squamous Cell Carcinoma, (ESCC) (EXPERIMENTAL): Participants with ESCC will receive ABBV-400 for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years. || [5] Cohort 5: Triple Negative Breast Cancer (TNBC) (EXPERIMENTAL): Participants with TNBC will receive ABBV-400 for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years. || [6] Cohort 6: Hormone Receptor+/HER2-breast Cancer (HR+/HER2-BC) (EXPERIMENTAL): Participants with HR+/HER2-BC will receive ABBV-400 for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years. || [7] Cohort 7: Head and Neck Squamous-cell-carcinoma (HNSCC) (EXPERIMENTAL): Participants with HNSCC will receive ABBV-400 for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years. || [8] Cohort 8: PROC/Primary Peritoneal/Fallopian Tube Cancer (EXPERIMENTAL): Participants with Platinum Resistant High Grade Epithelial Ovarian Cancer (PROC)/primary peritoneal/fallopian tube cancer will receive ABBV-400 for up to 3 years during and up to the treatment peri... || [9] Cohort 9: Drug-Drug Interaction (EXPERIMENTAL): Participants with adv","* Laboratory values meeting the criteria laid out in the protocol. * Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. * Documented diagnosis of locally advanced or metastatic hepatocellular carcinoma (HCC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancers (BTC), squamous cell carcinoma of the esophagus, (ESCC), triple negative breast cancer (TNBC), hormone receptor+/HER2-breast cancer (HR+/HER2-BC), head and neck squamous-cell-carcinoma (HNSCC), or Platinum Resistant High Grade Epithelial Ovarian Cancer (PROC)/primary peritoneal/fallopian tube cancer (by World Health Organization \[WHO\] criteria). Participant meets the criteria for disease activity laid out in the protocol.","* Have received anticancer therapy including chemotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy within 28 days or 5 half-lives of the drug (whichever is shorter) prior to the first dose of ABBV-400. Palliative radiation therapy for bone, skin, or subcutaneous metastases with 10 fractions or less is permitted and not subject to a washout period. * Unresolved clinically significant AEs \> Grade 1 from prior anticancer therapy. * History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD or pneumonitis, including but not limited to those listed in the protocol. * History of clinically significant, intercurrent lung-specific illnesses, including those laid out in the protocol. * Untreated brain or meningeal metastases (i.e., participants with history of metastases are eligible provided they do not require ongoing steroid treatment for cerebral edema and have shown clinical and radiographic stability for at least 14 days after definitive therapy). Participants may continue on antiepileptic therapy if required. * History of other active malignancy, with the exception of those laid out in the protocol. * Any autoimmune, connective tissue or inflammatory disorders with documented or suspicious pulmonary involvement at screening (i.e., rheumatoid arthritis, Sjogren's, sarcoidosis etc.), and prior pneumonectomy."
NCT05067283,"A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors",KANDLELIT-001,PHASE1,"Chile, Panama","Centro de Estudios Clínicos SAGA-CECSAGA ( Site 0041), Santiago, Chile, [RECRUITING] | FALP-UIDO ( Site 0040), Santiago, Chile, [RECRUITING] | Bradfordhill ( Site 0042), Santiago, Chile, [RECRUITING] | James Lind Centro de Investigacion del Cancer ( Site 0043), Temuco, Chile, [COMPLETED] | Centro Oncologico de Panama ( Site 0160), Panama City, Panama, [RECRUITING] | Centro Hemato Oncológico Paitilla ( Site 0163), Panama City, Panama, [COMPLETED]",Advanced Solid Tumors,6,"[1] Arm 1 (EXPERIMENTAL): Participants will receive daily oral escalating doses of up to 800 mg of MK-1084 until progressive disease or discontinuation. Dosing regimen may be adjusted based on safety. || [2] Arm 2 (EXPERIMENTAL): Participants will receive MK-1084 daily oral escalating dose of up to 800 mg plus pembrolizumab given as a 200 mg intravenous infusion once every 21-day cycle up to a total of 35 cycles (up to \~24... || [3] Arm 3 (EXPERIMENTAL): Participants will receive alternate formulation of MK-1084 until progressive disease or discontinuation. Dosing regimen may be adjusted based on safety. || [4] Arm 4 (EXPERIMENTAL): Participants will receive MK-1084 daily oral dose plus an intravenous infusion of pembrolizumab (200 mg) once every 21-day cycle for up to 35 cycles (up to \~24 months). Participants will also rece... || [5] Arm 5 (EXPERIMENTAL): Participants will receive MK-1084 daily oral dose plus an intravenous infusion of cetuximab (per label) every 2 weeks of each 28-day cycle. || [6] Arm 6 (EXPERIMENTAL): Participants will receive MK-1084 daily oral dose. Additionally, participants receive an intravenous infusion of cetuximab (per label) every 2 weeks of each 28-day cycle, oxaliplatin (per label) fo...","For all participants: * Has measurable disease by RECIST 1.1 criteria * Has adequate organ function * Male participants agree to protocol-specified contraception requirements including refraining from donating sperm and using protocol-specified contraceptives unless confirmed to be azoospermic * Female participants must not be pregnant or breastfeeding, and must agree to protocol-specified contraceptive requirements and must have a negative highly sensitive pregnancy test within 24 hours (for a urine test) or 72 hours (for a serum test) before the first dose of study intervention For Arm 1 - Has locally advanced unresectable or metastatic solid-tumor malignancy with histologically OR blood-based confirmation of KRAS G12C mutation who has received at least 1 line of therapy for systemic disease For Arm 2 \- Has an untreated metastatic non-small cell lung cancer (NSCLC) with histologically OR blood-based confirmation of KRAS G12C mutation and histologic confirmation of programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥1% For Arm 3 * Has locally advanced unresectable or metastatic solid-tumor malignancy with histologically or blood-based confirmation of KRAS G12C mutation who has received at least 1 line of therapy for systemic disease Expansion Group A: 2L+NSCLC * Has histologically or cytologically confirmed diagnosis of unresectable or metastatic NSCLC with histological or blood-based confirmation of KRAS G12C mutation and submits archival tumor sample * Previous treatment failure of at least 1 line of systemic therapy Expansion Group B * Has locally advanced unresectable or metastatic solid-tumor malignancy, excluding NSCLC or CRC, with histologically or blood- based confirmation of KRAS G12C mutation who has received at least 1 line of therapy for systemic disease Arm 4 only - Has an untreated advanced or metastatic nonsquamous NSCLC with histologically or blood-based confirmation of KRAS G12C mutation Arm 5 only * Histologically or cytologicall","* Has received chemotherapy, definitive radiation, or biological cancer therapy within 4 weeks (2 weeks for palliative radiation) before first dose of study intervention * Has a history of second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 5 years * Has clinically active central nervous system (CNS) metastases and/or carcinomatous meningitis * Has an active infection requiring systemic therapy * Known history of HIV infection or. has a known history of Hepatitis B virus or known active Hepatitis C virus infection * Has a history of interstitial lung disease, noninfectious pneumonitis requiring active steroid therapy, or ongoing pneumonitis * Has an active autoimmune disease requiring systemic therapy * Has not fully recovered from any effects of major surgical procedure without significant detectable infection * Has one or more of the following ophthalmological findings/conditions: intraocular pressure \>21 mm Hg and/or any diagnosis of glaucoma; diagnosis of central serous retinopathy, retinal vein occlusion, or retinal artery occlusion and/or a diagnosis of retinal degenerative disease * Has received live or live-attenuated vaccine within 4 weeks of study start Arm 4 Only * Is unable to interrupt aspirin or other nonsteroidal anti-inflammatories (NSAIDs), other than an aspirin dose ≤1.3 grams per day, for at least 2 days (5 days for long-acting agents \[for example, piroxicam\]) before, during, and for at least 2 days after administration of pemetrexed. * Is unable/unwilling to take folic acid, vitamin B12, and dexamethasone"
NCT06886074,Efficacy of Short-course Blinatumomab in Patients With Detectable Measurable Residual Disease With Philadelphia Chromosome-negative B-cell Acute Lymphoblastyc Leukemia,,PHASE2,Mexico,"Hospital Universitario Dr. Jose E. Gonzalez, Monterrey, Mexico, [RECRUITING]",Acute Lymphoblastic Leukemia | Measurable Residual Disease (MRD),1,[1] Blinatumomab arm (EXPERIMENTAL): Patients will receive 7 days of blinatumomab with a fixed dose of 175 mcg through out 7 days,* Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia * MRD detectable in complete response (above the limit of quantification according to FCM) * Performance status 0-2 on the ECOG scale * No prior organ damage * Having a potential related or unrelated donor,* Performance status on the ECOG scale \>2 * HCT-CI \>3 points * Patients who do not wish to participate in clinical study. * Active central nervous system infiltration (CNS3) * Active extramedullary disease * Having previously received blinatumomab * Absence of related or unrelated donors
NCT06109779,"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)",,PHASE3,Brazil,"Research Site, Natal, Brazil, [ACTIVE_NOT_RECRUITING] | Research Site, Porto Alegre, Brazil, [RECRUITING] | Research Site, Porto Alegre, Brazil, [RECRUITING] | Research Site, Santa Maria, Brazil, [COMPLETED] | Research Site, Santo André, Brazil, [RECRUITING] | Research Site, São Paulo, Brazil, [RECRUITING] | Research Site, São Paulo, Brazil, [RECRUITING] | Research Site, Vitória, Brazil, [RECRUITING]",Biliary Tract Cancer,2,[1] Arm A (EXPERIMENTAL): Rilvegostomig IV infusion + Investigator choice of chemotherapy (Capecitabine or Gemcitabine/Cisplatin or S-1) || [2] Arm B (PLACEBO_COMPARATOR): Placebo IV infusion + Investigator choice of chemotherapy (Capecitabine or Gemcitabine/Cisplatin or S-1),* Histologically confirmed adenocarcinoma of the biliary tract (intrahepatic or extrahepatic cholangiocarcinoma (CCA) or muscle invasive gallbladder cancer (GBC)) after macroscopically complete resection (R0 or R1) * Provision of a tumor sample collected at surgical resection. * Randomization within 12 weeks after resection with adequate healing and removal of drains. * Confirmed to be disease-free by imaging within 28 days prior to randomization. * Eastern Cooperative Oncology Group performance status of 0 or 1,"* Participants with locally-advanced, unresectable, or metastatic disease at initial diagnosis. * Ampullary cancer, neuroendocrine, mixed neuroendocrine and non-neuroendocrine neoplasms and nonepithelial tumors. * Any anti-cancer therapy for BTC prior to surgery * Active or prior documented autoimmune or inflammatory disorders or any severe or uncontrolled systemic disease * Current or prior use of immunosuppressive medication within 14 days before the first dose * Thromboembolic event within 3 months * Active HBV or HCV infection unless treated."
NCT04995523,"Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC",ARTEMIDE-01,"PHASE1, PHASE2",Brazil,"Research Site, Florianópolis, Brazil, [RECRUITING] | Research Site, Natal, Brazil, [RECRUITING] | Research Site, Porto Alegre, Brazil, [RECRUITING] | Research Site, Rio de Janeiro, Brazil, [RECRUITING] | Research Site, São Paulo, Brazil, [RECRUITING]",Non-Small-Cell Lung Carcinoma,5,[1] Dose Escalation Part A: Checkpoint inhibitor (CPI) experienced Non-small Cell Lung Cancer (NSCLC) (EXPERIMENTAL): Rilvegostomig Intravenous (IV) monotherapy || [2] Dose Expansion Part B: CPI experienced NSCLC (EXPERIMENTAL): Rilvegostomig IV monotherapy || [3] Dose Expansion Part C: CPI Naive NSCLC (EXPERIMENTAL): Rilvegostomig IV monotherapy || [4] Dose Expansion Part D: CPI Naive NSCLC (EXPERIMENTAL): Rilvegostomig IV monotherapy || [5] Dose Expansion Part E: treatment Naive Squamous NSCLC (EXPERIMENTAL): Rilvegostomig IV monotherapy,"* Written informed consent * Aged 18 or above * Part A and Part B: Unresectable stage III or stage IV squamous or non-squamous NSCLC not amenable to curative surgery or radiation. Part C and Part D: Stage IV squamous or non-squamous NSCLC not amenable to curative surgery or radiation. Part E: Stage IV squamous NSCLC not amenable to curative surgery or radiation. * Documented PD-L1 expression by PD-L1 IHC per local report. * Part A and Part B: Confirmed progression during treatment with a CPI-including regimen. * Part C and Part D: No prior I/O treatment for metastatic NSCLC. * Part E: No prior treatment for metastatic NSCLC. * ECOG performance status of 0 or 1 at enrolment. * Life expectancy of ≥ 12 weeks at enrolment. * Have at least 1 measurable lesion per RECIST v1.1. * Adequate bone marrow, liver and kidney function","* Sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) fusion * Documented test result for any other known genomic alteration for which a targeted therapy is approved in first line per local standard of care (e.g. ROS1, NTRK fusions, BRAF, V600E mutation) * Previous treatment with an anti-TIGIT therapy * Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment. * Part A and Part B: Primary or secondary resistance after treatment with 2 or more regiments including a CPI. * Part C and Part D: Any prior systemic treatment with an immune oncology agent (prior administration of immune-oncology agent for curative intent to treat other invasive malignancy is permitted). Treatment with one previous systemic chemotherapy will be allowed. * Part E: Any prior systemic treatment for metastatic NSCLC, including but not limited to chemotherapy, anti-PD-1, anti-PD-L1, anti-CTLA-4. * Symptomatic central nervous system (CNS) metastasis. * Thromboembolic event within 3 months prior to enrolment. * Other invasive malignancy within 2 years prior to screening."
NCT03750539,Phase II Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With Standard Fractionated Compared to Hypofractionated Followed by Surgery for Patients With Locally Advanced Cervical Cancer.,,NA,Mexico,"David Cantu de Leon, Mexico City, Mexico, [ACTIVE_NOT_RECRUITING] | Instituto Nacional de Cancerologia, Mexico City, Mexico, [RECRUITING]",Cervix Cancer,2,"[1] Standard Treatment (ACTIVE_COMPARATOR): External Beam pelvic radiation therapy daily dose of 1.8-2 Gray (Gy) per session for 25 sessions to accomplish 45 Gy Chemotherapy ( cisplatin 40mg/m2), intravenous administration of chemotherapy on... || [2] hypofractionated treatment (EXPERIMENTAL): External Beam pelvic radiation therapy daily dose of 1.8-2gy per session for 15 sessions to accomplish 37.5 Gy Chemotherapy ( cisplatin 40mg/m2), intravenous administration of chemotherapy once a w...","* Patients must have International Federation of Gynecology and Obstetrics (FIGO) stage IB2-IIB squamous, adenosquamous or adenocarcinoma of cervical with no disease outside of the pelvis by via ultrasound. * No distant metastasis via chest X-ray. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Age 18 * complete blood count (CBC)/differential obtained 14 days before study entry with adequate bone marrow function defined as follows: * Absolute neutrophil count (ANC) ≥ 1,500 cells/mim3 * Platelets 100,000 cells/mim3 * Hemoglobin 8.0 g/dl * White blood count 4000 cell/m3 * An adequate renal function defined as follows: * Serum creatinine 1.5 mg/dl within 14 days before study entry * Patients with known HIV positive must have a cluster of differentiation 4 (CD4) T lymphocytes count be 350 cells/mm3 within 14 days prior to study entry (note, however, that HIV testing is not required for entry into this protocol). Excluding HIV positive patients with invasive cervical cancer and low CD4 cell counts is necessary because the treatments involved in this protocol may be significantly immunosuppressive. * Chest x-ray and ultrasound must be performed within 12 (8 or 12) weeks before the study enrollment (I took out the ct scan of abdomen and pelvis) * Patient must provide study-specific informed consent before study entry.","* Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years (For example, carcinoma in situ of the breast or oral cavity. * Patients cannot have any neuroendocrine histology in pathology. * Prior systemic chemotherapy for the current cervical cancer, note that prior chemotherapy for a different cancer is allowable. * Prior radiation therapy to the pelvis that would result in overlap of radiation therapy fields. * Severe active co-morbidity, defined as follows: * Unstable angina or congestive heart failure requiring hospitalization within the last six months. * Transmural myocardial infarction within the previous six months. * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of the study entry. * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of study entry. * Coagulation defects; note, however, that coagulation parameter are not required for entry into this protocol. * Prior allergic reaction to cisplatin or other platinum drugs. * Patients with para-aortic nodes or distant metastasis."
NCT05554328,A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients With Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial,,PHASE2,Puerto Rico,"Puerto Rico Hematology Oncology Group, Bayamón, Puerto Rico, [RECRUITING] | Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico, [RECRUITING]",Recurrent Endometrial Carcinoma | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma,2,"[1] Arm I (selumetinib, olaparib) (EXPERIMENTAL): Patients receive selumetinib PO BID and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a tumor biops... || [2] Arm II (selumetinib) (ACTIVE_COMPARATOR): Patients receive selumetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience progression may elect to cross ...","* Patient must have enrolled onto EAY191 and must have been given a treatment assignment to ComboMATCH to EAY191-N4 based on the presence of an actionable mutation as defined in EAY191 * Patients must be enrolled on the ComboMATCH Master Registration Trial EAY191 * Patients must have RAS pathway mutations as determined by the ComboMATCH screening assessment * Cohort 1: Patients with histologically confirmed RAS pathway mutant ovarian, primary peritoneal, or fallopian tube (""ovarian"") cancer (activating mutations in KRAS, NRAS, HRAS, BRAF, MEK1, MEK2, or inactivating mutations in NF1) * Cohort 2: Patients with histologically confirmed RAS pathway mutant endometrial cancer (activating mutations in KRAS, NRAS, HRAS, BRAF, MEK1, MEK2, or inactivating mutations in NF1). * Patients must have disease that can be safely biopsied and agree to a pre-treatment biopsy, if disease cannot be safely biopsied, or have archival tissue available from within 12 months prior to registration on the ComboMATCH Registration Trial (EAY191) * Patients must have progressed after first-line treatment for recurrent or persistent disease * Patients with ovarian cancer should not be eligible for further platinum-based therapy * Patients with endometrial cancer must have received or been offered an immune oncology agent (alone or in combination with lenvatinib) unless there are existing contraindications for immune oncology agents or lenvatinib * Patients may have received unlimited prior therapy * Patients must have measurable and biopsiable disease. Measurable disease is defined by RECIST 1.1 as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be \> 10 mm when measured by CT, magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or \> 20 mm when measured by chest x-ray. Lymph nodes must be \> 15 mm in short axis when measured by CT or MRI * Patients must have at least one ""target lesion"" separat","* Patients who have received any MEK inhibitors * Patients who have progressed while receiving a PARP inhibitor * Patients who have received chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to registration * Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \> grade 1) with the exception of alopecia * Patients with uncontrolled intercurrent illness * Patients with \>= grade 2 neuropathy within 14 days of registration * Patients with severe (Child-Pugh C) liver dysfunction * Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib and selumetinib or any excipients thereof * Concomitant use of known strong (e.g., phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate CYP3A inducers (e.g., bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents * Supplementation with vitamin E greater than 100% of the daily recommended dose. Any multivitamin containing vitamin E must be stopped prior to study enrollment even if less than 100% of the daily recommended dosing for vitamin E * Vitamin E must not be taken in the 7 days prior to initiation of treatment with selumetinib * Concomitant use of known strong CYP3A inhibitors (e.g., itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or known moderate CYP3A inhibitors (e.g. ciprofloxacin, erythromycin, diltiazem, Fluconazole, verapamil). The required washout period prior to starting olaparib is at least 14 days or 5 half-lives (whichever is longer) before the first dose of study medication * Concomitant use of strong CYP2C19 inhibitors (e.g., ticlopidine) or moderate"
NCT04037007,Efficacy and Safety of Precut Fistulotomy vs Conventional Cannulation Technique as a Primary Approach to Biliary Access According to the Endoscopist Experience Degree in ERCP,,NA,Mexico,"Centro Medico Nacional Siglo XXI Hospital de Especialidades, Mexico City, Mexico, [RECRUITING]",Cholangiocarcinoma | Choledocholithiasis; Cholangitis | Pancreatic Cancer | Pancreatitis,4,"[1] Fistulotomy - High experienced (ACTIVE_COMPARATOR): Fistulotomy precut with a needle knife, ERBE Endocut I, Effect 2; as the primary cannulation technique in high experienced endoscopists. || [2] Fistulotomy - Low experienced (ACTIVE_COMPARATOR): Fistulotomy precut with a needle knife, ERBE Endocut I, Effect 2; as the primary cannulation technique in low experienced endoscopists. || [3] Conventional (guidewire) cannulation- High experience (ACTIVE_COMPARATOR): Conventional cannulation with an sphincterotome and 0.035 inch hydrophilic tip guidewire as the primary cannulation technique in high experienced endoscopists. || [4] Conventional (guidewire) cannulation - Low experienced. (ACTIVE_COMPARATOR): Conventional cannulation with an sphincterotome and 0.035 inch hydrophilic tip guidewire as the primary cannulation technique in low experienced endoscopists.","* All patients undergoing ERCP with suspected or confirmed of choledocholithiasis, malignant and benign biliary stenosis.","* patients with previous ERCP, altered gastro-duodenal anatomy by previous surgery, suspicion or diagnosis of ampullary neoplasm, duodenal cancer, periampullary diverticula types 1 and 2, pregnant women, coagulopathy with INR greater than 1.5. Elimination Criteria: \- Incomplete procedure due to anesthesia adverse events."
NCT04774718,"A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available",,"PHASE1, PHASE2",Brazil,"Hospital de Cancer de Barretos, Barretos, Brazil, [RECRUITING] | Graacc-Grupo de Apoio ao adolescente e a crianca com cancer, São Paulo, Brazil, [RECRUITING]",ALK Fusion-positive Solid or CNS Tumors,1,"[1] ALK-Fusion Positive (EXPERIMENTAL): Part 1 is a dose-confirmation phase to confirm the recommended phase 2 dose (RP2D). In Parts 2 and 3, participants will receive alectinib at the RP2D on Days 1-28 of each 28-day cycle","* Histologically confirmed diagnosis of CNS or solid tumors with documented evidence of ALK gene fusions as assessed centrally through the use of the investigational F1CDx assay or based on pre-existing NGS test results * Disease status: prior treatment proven to be ineffective (i.e. relapsed or refractory), or for whom there is no satisfactory standard treatment available. Disease should be measurable and evaluable as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1, or Response Assessment in Neuro-oncology criteria (RANO) +/- bone marrow criteria for primary CNS tumors or International Neuroblastoma Response Criteria (INRC) * Available tumor tissue for submission to the Sponsor from active disease, obtained subsequent to last anti-cancer therapy regimen administered and obtained prior to study enrollment (preferred option), or archival tumor tissue from original diagnosis, or willingness to undergo a core or excisional biopsy sample collection prior to enrollment * For participants \< 16 years old, Lansky Performance Status \>/= 50% * For participants \>/= 16 years old, Karnofsky Performance Status \>/= 50% * Adequate bone marrow function as defined by the protocol within at least 28 days prior to initiation of study drug * Participant and/or caregiver willingness and ability to complete clinical outcome assessments throughout the study using either electronic, paper, or interviewer methods * For females of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating eggs, as defined by the protocol * For males who are not surgically sterile: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating sperm, as defined by the protocol","* Medical history of: prior use of ALK inhibitors; diagnosis of Anaplastic Large Cell Lymphoma (ALCL); any gastrointestinal disorder that may affect absorption of oral medications, such as mal-absorption syndrome or status post-major bowel resection; history of organ transplant; stem cell infusions as defined by the protocol * Substance abuse within 12 months prior to screening * Familial or personal history of congenital bone disorders, bone metabolism alterations, or osteopenia * Treatment with investigational therapy 28 days prior to initiation of study drug * Liver or kidney disease as defined by the protocol * National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 grade \>/=3 toxicities attributed to any prior therapy such as radiotherapy (excluding alopecia), which have not shown improvement and are strictly considered to interfere with alectinib * Co-administration of anti-cancer therapies other than those administered in this study * Active hepatitis B or C virus (HBV, HBC), or known HIV-positivity or AIDS-related illness * Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or the absorption of oral medications or that would, in the opinion of the Principal Investigator, pose an unacceptable risk to the participant in this study * Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol requirements and/or follow-up procedures; such conditions should be discussed with the participant before trial entry * Planned procedure or surgery during the study except as permitted treatment as defined by the protocol * Infection considered by the investigator to be clinically uncontrolled or of unacceptable risk to the participant upon induction of neutropenia, including participants who are, or should be, on antimicrobial agents for the treatment as active "
NCT06120491,"A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)",EvoPAR-PR01,PHASE3,"Brazil, Chile, Peru, Puerto Rico","Research Site, Curitiba, Brazil, [ACTIVE_NOT_RECRUITING] | Research Site, Pelotas, Brazil, [ACTIVE_NOT_RECRUITING] | Research Site, Porto Alegre, Brazil, [ACTIVE_NOT_RECRUITING] | Research Site, Porto Alegre, Brazil, [WITHDRAWN] | Research Site, Rio de Janeiro, Brazil, [ACTIVE_NOT_RECRUITING] | Research Site, Salvador, Brazil, [ACTIVE_NOT_RECRUITING] | Research Site, São Luís, Brazil, [WITHDRAWN] | Research Site, São Paulo, Brazil, [ACTIVE_NOT_RECRUITING] | Research Site, São Paulo, Brazil, [ACTIVE_NOT_RECRUITING] | Research Site, São Paulo, Brazil, [ACTIVE_NOT_RECRUITING]",Metastatic Castration-Sensitive Prostate Cancer,2,"[1] Arm 1: Saruparib (AZD5305) + Physician's Choice NHA (EXPERIMENTAL): Saruparib (AZD5305) + physician's choice NHA (Abiraterone, Darolutamide, or Enzalutamide) || [2] Arm 2: Placebo + Physician's Choice NHA (PLACEBO_COMPARATOR): Placebo + physician's choice NHA (Abiraterone, Darolutamide, or Enzalutamide)","* Male ≥ 18 years of age. * Histologically documented prostate adenocarcinoma which is de novo or recurrent and castration-sensitive. Participants with pathologic features of small cell, neuroendocrine, sarcomatoid, spindle cell, or signet cell histology are not eligible. * Metastatic disease as documented by the investigator prior to randomisation, with clear evidence of ≥ 1 bone lesion and/or ≥ 1 soft tissue lesion that is suitable for repeated assessment with CT and/or MRI. * Participant is receiving ADT with a GnRH analogue or has undergone bilateral orchiectomy starting ≥ 14 days and \< 4 months prior to randomisation. * ECOG performance status of 0 or 1 with no deterioration over the 2 weeks prior to randomisation. * Provision of FFPE tumour tissue sample and blood sample (for ctDNA). * Confirmed HRRm status by central tumour tissue and/or ctDNA test is required to determine cohort eligibility. * Adequate organ and bone marrow function as described in study protocol. * Participants must not father children or donate sperm from signing ICF, during the study intervention and for 6 months after the last dose of study intervention. * Participants must use a condom from signing ICF, during study intervention, and for 6 months after the last dose of study drug, with all sexual partners.","* Participants with a history of MDS/AML or with features suggestive of MDS/AML (as determined by prior diagnostic investigation). In case there is no clinical MDS/AML suspicion, no specific screening for MDS/AML (by BM/bone biopsy) is required. * Participants with any known predisposition to bleeding. * Any history of persisting (\> 2 weeks) severe cytopenia. * Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD5305 and/or the assigned NHA. * History of another primary malignancy, with exceptions. * Persistent toxicities (CTCAE Grade ≥ 2) caused by previous anticancer therapy. * Spinal cord compression or brain metastases unless asymptomatic, stable, and not requiring steroids for at least 4 weeks prior to start of study intervention. * Cardiac criteria, including history of arrhythmia and cardiovascular disease. * Any prior anticancer pharmacotherapy or surgery for metastatic prostate cancer, with exceptions. * Prior treatment within 14 days with blood product support or growth factor support. * Participants who are unevaluable for both bone and soft tissue progression."
NCT04575935,Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy,,PHASE3,Mexico,"Instituto Nacional de Cancerología (Mexico), Tlalpan, Mexico, [RECRUITING]",Advanced Ovarian Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Tumor | Fallopian Tube Serous Neoplasm | Fallopian Tube Transitional Cell Carcinoma,2,"[1] Arm A (MIS, standard of care chemotherapy) (EXPERIMENTAL): Patients undergo MIS within 6 weeks after last cycle of standard of care neoadjuvant chemotherapy. If during MIS the surgeon thinks complete gross resection can only be accomplished by performing a... || [2] Arm B (laparotomy, standard of care chemotherapy) (ACTIVE_COMPARATOR): Patients undergo laparotomy within 6 weeks after last cycle of standard of care neoadjuvant chemotherapy. Within 6 weeks after surgery, patients receive standard of care chemotherapy.","* Age ≥ 18 years old * Stage IIIC or IV, high-grade (serous, endometrioid, clear-cell, transitional carcinomas), invasive epithelial ovarian carcinoma, primary peritoneal carcinoma, or fallopian-tube carcinoma or pathology consistent with high-grade mullerian carcinoma. * Patient is considered by treating physician to be a surgical candidate after completion of 3 to 4 cycles of platinum-based chemotherapy, or an investigational neoadjuvant regimen given according to protocol, with complete radiologic resolution of any disease outside the abdominal cavity. Pleural effusions are acceptable per the local PI's discretion. * Normalization of CA-125 according to individual participating center reference range (Note: Among patients with a normal CA-125 at initiation of therapy, the CA-125 cannot exceed 35 U/mL at the completion of NACT prior to interval debulking surgery.) or has a CA-125 value ≤500 and is scheduled to undergo a diagnostic laparoscopy prior to debulking surgery. a. For patients undergoing diagnostic laparoscopy, surgeon considers that optimal debulking is feasible either by MIS or laparotomy. * Timeframe of \< 6 weeks (42 days) from the last cycle of NACT to interval debulking surgery. Overall timeframe may be extended per MD Anderson PI discretion. * ECOG performance status 0-2 * Signed informed consent and ability to comply with follow-up * Negative pregnancy test by blood or urine (within 14 days prior to surgery) * Disease free of other active malignancies in the previous five years, except basal and squamous cell carcinomas of the skin","* Evidence of tumor not amenable to minimally invasive resection on pre-operative imaging (CT, PET-CT, or MRI) including but not limited to the following findings that may preclude minimally invasive resection per surgeon's assessment. • Failure of improvement of ascites during NACT (trace ascites is allowed) • Small bowel or gastric tumor involvement • Colon or rectal tumor involvement • Diaphragmatic tumor involvement • Splenic or hepatic surface or parenchymal tumor involvement • Mesenteric tumor involvement • Tumor infiltration of the lesser peritoneal sac * History of psychological, familial, sociological or geographical condition potentially preventing compliance with the study protocol and follow-up schedule * Inability to tolerate prolonged Trendelenburg position or pneumoperitoneum as deemed by participating institution's clinicians * Any other contraindication to MIS as assessed by the clinician"
NCT04939883,A Prospective Multi-Center Randomized Study to Evaluate the Effects of Carvedilol on Cardiotoxicity in Cancer Patients Submitted to Anthracycline Therapy,CardioTox,PHASE4,Brazil,"Hospital Sirio Libanes, São Paulo, Brazil, [RECRUITING]",Cancer,2,"[1] Intervention Group (EXPERIMENTAL): Patients allocated to the intervention group will receive carvedilol 6.25 mg twice daily, then increased to 12.5 mg twice daily, until maximum dose of 25 mg twice daily according to the patients' t... || [2] Control Group (PLACEBO_COMPARATOR): Patients allocated to this group will receive placebo in a presumably staggered and progressive manner similar to the group intervention. The placebo will ideally be maintained for up to 30 days af...",* ≥18 years of age at the time of screening * Cancer patients that will receive chemotherapy with anthracyclines.,"* Inability to adequate asses left ventricular function * Previous symptoms (dyspnea on exertion, orthopnea, paroxysmal nocturnal dyspnea, and pulmonary and systemic congestion) suggestive of or a previous diagnosis of heart failure. * Previous history of any cardiomyopathy (eg.: valve disease, Chagas' disease, infiltrative cardiomyopathy) * LVEF \< 50% * Previous history of myocardial revascularization * Permanent tachyarrhythmia (flutter, atrial fibrillation, atrial tachycardia) * Congenital heart disease with left ventricular function impared * Contra-indication to the use of beta-blockers. * Pregnant or Breast-feeding females or women of childbearing age who intend to became pregnant. * On kidney replacement therapy * ECOG \>= 4 or Karnofsky \<=30 * Advanced hepatic failure (C score Child-Pugh and MELD \> 15); * Previous use of anthracycline * Have any serious concomitant systemic disease, condition, or disorder that, in the opinion of the investigator, should preclude participation in this study * Are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study"
NCT06117774,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy",DeLLphi-306,PHASE3,"Argentina, Brazil, Colombia, Mexico","Fundacion Respirar, Ciudad Autonoma de Buenos Aires, Argentina, [RECRUITING] | Hospital Italiano de La Plata, La Plata, Argentina, [RECRUITING] | Hospital Universitario Austral, Pilar, Argentina, [RECRUITING] | Instituto Oncologico de Cordoba Ionc Fundacion Richardet Longo, Córdoba, Argentina, [RECRUITING] | Hospital Aleman Buenos Aires, CABA, Argentina, [RECRUITING] | Clinica Viedma, Viedma, Argentina, [RECRUITING] | Sanatorio 9 de Julio Cice 9 de Julio, San Miguel de Tucumán, Argentina, [RECRUITING] | Instituto Argentino de Diagnóstico y Tratamiento, Buenos Aires, Argentina, [RECRUITING] | Hospital Santa Rita, Vitória, Brazil, [RECRUITING] | Oncoclinicas Onco Vida Distrito Federal, Brasília, Brazil, [RECRUITING]",Limited Stage Small Cell Lung Cancer | Small Cell Lung Cancer,2,"[1] Tarlatamab (EXPERIMENTAL): Participants will receive tarlatamab on Cycle 1 Day 1, 8 and 15, and once every 2 weeks (Q2W) thereafter (cycle is 28 days). || [2] Placebo (PLACEBO_COMPARATOR): Participants will receive placebo on Cycle 1 Day 1, 8 and 15, and Q2W thereafter (cycle is 28 days).","* Participant has provided informed consent prior to initiation of any study specific activities/procedures. * Age ≥ 18 years (or ≥ legal age within the country if it is older than 18 years). * Histologically or cytologically confirmed small-cell lung cancer (SCLC). * Diagnosed and treated for LS-SCLC with concurrent chemotherapy and radiotherapy. * Has completed chemoradiotherapy without progression per Response Evaluation Criteria in Solid Tumors v1.1 (RECIST 1.1.) (ie, achieved complete response \[CR\], partial response \[PR\], or stable disease \[SD\]). * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1. * Minimum life expectancy of 12 weeks. * Adequate organ function. * Toxicities attributed to concurrent chemoradiotherapy resolved to grade ≤ 1, unless otherwise specified. Excluding alopecia or fatigue.","Disease Related * Extensive-stage SCLC (ES-SCLC). * Any previous diagnosis of transformed non-small-cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) activating mutation positive NSCLC that has transformed to SCLC, or mixed SCLC NSCLC histology. * Evidence of interstitial lung disease or active, non-infectious pneumonitis. Other Medical Conditions * History of other malignancy within the past 2 years, with certain exceptions. * History of solid organ transplantation. * Myocardial infarction and/or symptomatic congestive heart failure (New York Heart Association \> class II) within 6 months prior to first dose of study treatment. * History of arterial thrombosis (eg, stroke or transient ischemic attack) within 6 months prior to first dose of study treatment. * Exclusion of human immunodeficiency virus (HIV) and/or hepatitis infection based on criteria per protocol. * Participant with symptoms and/or clinical signs and/or radiographic signs that indicate an acute and/or uncontrolled active systemic infection within 7 days prior to the first dose of study treatment. Prior/Concomitant Therapy * Received sequential chemotherapy and thoracic radiotherapy (no overlap of thoracic radiotherapy with chemotherapy) during chemoradiation. * Prior therapy with any selective inhibitor of the delta-like ligand 3 (DLL3) pathway. * Prior history of severe or life-threatening events from any immune-mediated therapy. * Receiving another anti-cancer therapy. Adjuvant hormonal therapy for resected breast cancer is permitted. * Receiving systemic corticosteroid therapy or any other form of immunosuppressive therapy within 7 days prior to enrollment. * Major surgical procedures within 28 days prior to first dose of study treatment. * Treatment with live virus, including live-attenuated vaccination, within 14 days prior to the first dose of study treatment. Inactive vaccines and live viral non-replicating vaccines within 3 days prior to first dose of study treatment. Prior/C"
NCT04457596,"The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib",,PHASE3,Puerto Rico,"Cancer Center-Metro Medical Center Bayamon, Bayamón, Puerto Rico, [RECRUITING] | Puerto Rico Hematology Oncology Group, Bayamón, Puerto Rico, [RECRUITING] | Doctors Cancer Center, Manatí, Puerto Rico, [RECRUITING] | San Juan Community Oncology Group, San Juan, Puerto Rico, [RECRUITING] | Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico, [RECRUITING] | PROncology, San Juan, Puerto Rico, [SUSPENDED] | San Juan City Hospital, San Juan, Puerto Rico, [RECRUITING]",Anatomic Stage IA Breast Cancer AJCC V8 | Anatomic Stage II Breast Cancer AJCC V8 | Anatomic Stage IIA Breast Cancer AJCC V8 | Anatomic Stage IIB Breast Cancer AJCC V8 | Anatomic Stage III Breast Cancer AJCC V8,2,"[1] Arm I (trastuzumab emtansine, placebo) (ACTIVE_COMPARATOR): Patients receive T-DM1 IV over 30-90 minutes on day 1 and placebo PO BID on days 1-21. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxi... || [2] Arm II (trastuzumab emtansine, tucatinib) (EXPERIMENTAL): Patients receive T-DM1 IV over 30-90 minutes on day 1 and tucatinib PO BID on days 1-21. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable to...","* HER2-positive status will be based on pretreatment biopsy material and defined as an immunohistochemistry (IHC) score of 3+ and/or positive by in situ hybridization (ISH) according to current American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines. Central testing is not required \* Known hormone receptor (HR) status as defined by ASCO/CAP guidelines (based on pretreatment biopsy material). Hormone receptor positive status can be determined by either known positive estrogen receptor (ER) or known positive progesterone receptor (PR) status; hormone receptor negative status must be determined by both known negative ER and known negative PR * Patients with clinical stage T1-4, N0-3 disease at presentation and residual invasive disease postoperatively as defined above are eligible. (Note: Patients with T1a/bN0 tumors are not eligible at initial breast cancer diagnosis are not eligible) * Patients with residual HR-negative, HER2 positive (+) disease in the breast and/or lymph nodes per the surgical pathology report are eligible; however, patients with HR+ HER2+ cancers must have node-positive residual disease per the surgical pathology report in order to qualify for the study. The presence of residual invasive disease in the breast is not mandatory for these patients * Patients with weakly ER-positive (1-10%) breast cancer (based on the pretreatment core biopsy) are eligible even if they have node-negative disease per the surgical pathology report * The residual disease tissue (breast and/or lymph nodes) is not required to be HER2-positive, as eligibility for NCI-2020-03770 (A011801) is based on a positive HER2 status at the time of the initial breast cancer diagnosis \* Note: The presence of micrometastases in lymph nodes after preoperative therapy counts as residual disease, whereas the presence of isolated tumor cells does not * Patients with synchronous bilateral invasive disease are eligible provided both lesions were confirm","* No adjuvant treatment with any anti-cancer investigational drug within 28 days prior to registration * Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative serum pregnancy test done =\< 7 days prior to registration is required * Patients with known active and/or untreated hepatitis B or hepatitis C or chronic liver disease are ineligible. Patients with a diagnosis of hepatitis B or C that has been treated and cleared and normal liver function are eligible to participate in the study if the other eligibility parameters are met * Stage IV (metastatic) breast cancer * History of any prior (ipsi- or contralateral) invasive breast cancer within 3 years of registration * Patients with ER+ HER2+ residual invasive disease that is lymph node-negative per the surgical pathology report * Evidence of recurrent disease following preoperative therapy and surgery * Patients for whom radiotherapy would be recommended for breast cancer treatment but for whom it is contraindicated because of medical reasons (e.g., connective tissue disorder or prior ipsilateral breast radiation) * History of exposure to the following cumulative doses of anthracyclines: doxorubicin \> 240 mg/m\^2; epirubicin or liposomal doxorubicin-hydrochloride (Myocet) \> 480 mg/m\^2. For other anthracyclines, exposure equivalent to doxorubicin \> 240 mg/m\^2 * Cardiopulmonary dysfunction as defined by any of the following: * History of National Cancer Institute (NCI) CTCAE version (v) 5.0 grade \>= 3 symptomatic congestive heart failure (CHF) or New York Heart Association (NYHA) criteria class \>= II * Angina pectoris requiring anti-anginal medication, serious cardiac arrhythmia not controlled by adequate medication, severe conduction abnormality, or clinically significant valvular disease * High-risk uncontrolled arrhythmias: i.e., atrial tachycardia with a heart rate \> 100"
NCT06549595,"A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 Plus Rituximab Versus Chemotherapy Plus Rituximab in Previously Untreated Participants With Follicular Lymphoma (SOUNDTRACK-F1)",,PHASE3,Brazil,"Research Site, Porto Alegre, Brazil, [NOT_YET_RECRUITING] | Research Site, São Paulo, Brazil, [NOT_YET_RECRUITING] | Research Site, São Paulo, Brazil, [NOT_YET_RECRUITING]",Untreated Follicular Lymphoma,3,"[1] Rituximab, AZD0486 - A (EXPERIMENTAL): AZD0486 regimen A plus rituximab || [2] Rituximab, AZD0486 - B (EXPERIMENTAL): AZD0486 regimen B plus rituximab || [3] Chemoimmunotherapy (ACTIVE_COMPARATOR): Investigator's choice between 3 standard immunochemotherapy regimen (R-CHOP or R-CVP followed by rituximab maintenance, or B-R followed by rituximab maintenance)","1. Participant must be at least 18 years of age, inclusive, at the time of signing the ICF. 2. Histologically confirmed diagnosis of classic FL per WHO 2022 classification 3. ECOG performance status of 0 to 2 4. No prior systemic lymphoma-directed therapy 5. Need for systemic treatment meeting at least 1 GELF criteria 6. FDG-avid and measurable disease 7. Stage II to IV and FLIPI 2-5 \[Phase III only\] 8. Adequate liver, hematological, renal and cardiac function. The above is a summary, other inclusion criteria details may apply","1. Follicular large B-cell lymphoma (WHO 2022 classification), formerly Follicular lymphoma Grade 3B (WHO 2016 classification) or suspicion for histologic transformation to high-grade/aggressive lymphoma 2. Contra-indication to BR, RCVP, and R-CHOP 3. Participants with or history of CNS lymphoma 4. Presence of \>5000 circulating lymphoma cells 5. Active or uncontrolled infection requiring systemic therapy and which places participant at unacceptable risk if he/she were to participate in the study The above is a summary, other exclusion criteria details may apply"
NCT06863272,"MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)",,"PHASE1, PHASE2","Argentina, Brazil, Chile","Instituto Alexander Fleming ( Site 0202), Ciudad Autónoma de Buenos Aires, Argentina, [RECRUITING] | Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0200), La Rioja, Argentina, [RECRUITING] | Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0263), São José do Rio Preto, Brazil, [RECRUITING] | IPITEC ( Site 0275), São Paulo, Brazil, [RECRUITING] | IBCC - Instituto Brasileiro de Controle do Câncer ( Site 0269), São Paulo, Brazil, [RECRUITING] | Clinica Universidad Catolica del Maule ( Site 0236), Talca, Chile, [RECRUITING] | ONCOCENTRO APYS ( Site 0234), Viña del Mar, Chile, [RECRUITING]",Castration-Resistant Prostatic Cancer | Metastasis,4,"[1] Docetaxel (ACTIVE_COMPARATOR): Participants will receive docetaxel at a determined dose every 3 weeks (Q3W) for a maximum of 10 cycles. Each cycle is 21 days. || [2] Ifinatamab Deruxtecan (I-DXd) (EXPERIMENTAL): Participants will receive I-DXd at a determined dose Q3W until unacceptable toxicity, progressive disease (PD), death or withdrawal of consent. || [3] I-DXd + MK-5684 (EXPERIMENTAL): Following a dose escalation regimen with I-DXd, participants will receive I-DXd at a determined dose until unacceptable toxicity, PD, death or withdrawal of consent PLUS MK-5684 at a determined dos... || [4] I-DXd +ARPI (Abiraterone or Enzalutamide) (EXPERIMENTAL): Following a dose escalation regimen with I-DXd, participants will receive I-DXd at a determined dose until unacceptable toxicity, PD, death or withdrawal of consent PLUS ARPI (Androgen Receptor Pat...","The main inclusion criteria include but are not limited to the following: * Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology * Has prostate cancer progression while on androgen deprivation therapy (ADT) (or post bilateral orchiectomy) within 6 months before Screening * Has current evidence of metastatic disease * Has received prior treatment with 1 or 2 androgen receptor pathway inhibitors (ARPIs) and progressed during or after treatment * Participants receiving bone resorptive therapy (including, but not limited to bisphosphonate or denosumab) must have been on stable doses for ≥4 weeks before allocation/randomization * An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 10 days before allocation/randomization * Has prior treatment with poly-ADP-ribose polymerase inhibitors (PARPi) if indicated by local approved regimen or were deemed ineligible to receive PARPi by the investigator","The main exclusion criteria include but are not limited to the following: * History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, or has current ILD/pneumonitis or suspected ILD/pneumonitis * Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses * Uncontrolled or significant cardiovascular disease * History of pituitary dysfunction * Poorly controlled diabetes mellitus * History or current condition of adrenal insufficiency (eg, Addison's disease) * Has received prior treatment with taxane-based chemotherapy agent for metastatic castration-resistant prostate cancer (mCRPC). * Chronic steroid treatment (dose of \>10 mg daily prednisone equivalent), except for low-dose inhaled steroids (for asthma/chronic obstructive pulmonary disease), topical steroids (for mild skin conditions), or intra-articular steroid injections * Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids * Known additional malignancy that is progressing or has required active treatment within the past 3 years * Known active central nervous system (CNS) metastases and/or carcinomatous meningitis * Active autoimmune disease that has required systemic treatment in the past 2 years * History of allogeneic tissue/solid organ transplant"
NCT06080841,Evaluation of Curcumin Supplementation on p53 Levels and Apoptosis in Tumor Cells From Patients With Locally Advanced Cervical Cancer,,NA,Mexico,"Instituto Nacional de Cancerología, Mexico City, Mexico, [RECRUITING]",Locally Advanced Cervical Cancer,6,[1] Group 1 (EXPERIMENTAL): 1g of curcumin. || [2] Group 2 (EXPERIMENTAL): 1 g curcumin + 5 mg piperine. || [3] Group 3 (EXPERIMENTAL): 3 g of curcumin. || [4] Group 4 (EXPERIMENTAL): 3 g curcumin + 15 mg piperine. || [5] Group 5 (EXPERIMENTAL): 6 g of curcumin. || [6] Group 6 (EXPERIMENTAL): 6 g curcumin + 15 mg piperine.,"1. Understanding the nature of the study and giving a written consent report. 2. Women \> 18 years old. 3. ECOG performance status: 0-2. 4. Be willing and able to comply with scheduled visits, treatment plans, and laboratory tests. 5. Patients with a histological cervical cancer diagnosis: squamous cell, adenosquamous, adenocarcinoma, and glassy cell carcinoma. 6. Classified with clinical stage IB3-IVA (FIGO 2018). 7. Candidates to receive concomitant QT-RT followed by BT. 8. With disease measurable by any imaging method (CT/MRI/PET-CT) according to RECIST v 1.1 criteria. 9. Patients without prior treatment based on QT-RT. 10. Hemoglobin ≥ 10 g/dL. 11. Leukocytes ≥ 4000/mm3. 12. Platelets ≥ 100,000/mm3. 13. Adequate liver function.","1. Patients undergoing nutritional treatment or ingesting any dietary supplement, including those containing turmeric or turmeric derivatives, ginger, or rhizome of the turmeric family. 2. Patients with uncontrolled intercurrent diseases, including active infections that contraindicate CT. 3. Patients receiving concomitant treatment with an experimental drug. 4. Patients with vesicovaginal or vesicorectal fistula are diagnosed. 5. Patients with previous or concomitant malignancy except non-melanoma skin carcinoma."
NCT06445972,"A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of MK-2870 Plus Paclitaxel as the Second-Line Treatment of Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D",,"PHASE1, PHASE2","Brazil, Chile","Liga Norte Riograndense Contra o Câncer ( Site 8303), Natal, Brazil, [RECRUITING] | Hospital Nossa Senhora da Conceição ( Site 8301), Porto Alegre, Brazil, [RECRUITING] | IBCC - Instituto Brasileiro de Controle do Câncer ( Site 8304), São Paulo, Brazil, [RECRUITING] | Clínica Puerto Montt ( Site 8409), Port Montt, Chile, [RECRUITING] | Centro de Investigación del Maule ( Site 8408), Talca, Chile, [RECRUITING] | FALP-UIDO ( Site 8400), Santiago, Chile, [RECRUITING] | Centro de Oncología de Precisión-Oncology ( Site 8404), Santiago, Chile, [RECRUITING] | Clínica UC San Carlos de Apoquindo ( Site 8405), Santiago, Chile, [RECRUITING] | Bradfordhill-Clinical Area ( Site 8401), Santiago, Chile, [RECRUITING] | Bradford Hill Norte ( Site 8407), Antofagasta, Chile, [RECRUITING]",Gastroesophageal Junction | Gastroesophageal Adenocarcinoma | Esophageal Neoplasms | Esophageal Cancer,2,"[1] Ramucirumab + Paclitaxel (ACTIVE_COMPARATOR): Participants will receive ramucirumab at 8mg/kg via intravenous (IV) infusion on days 1 and 15 of each 4-week cycle for up to \~60 weeks plus paclitaxel at 80 mg/M\^2 via IV infusion on Days 1, 8, ... || [2] Sacituzumab Tirumotecan + Paclitaxel (EXPERIMENTAL): Following a 28-day run-in with sacituzumab tirumotecan at 3 mg/kg and 4 mg/kg IV infusion on Days 1 and 15 of a 6-week cycle plus paclitaxel at 80 mg/M\^2 IV infusion on days 1, 8 and 15 of a 4-wee...","The main inclusion criteria include but are not limited to the following: * Has histologically and/or cytologically confirmed diagnosis of previously treated, 2L (received first line (1L) treatment) gastric adenocarcinoma, GEJ adenocarcinoma, or esophageal adenocarcinoma * Has metastatic disease or locally advanced, unresectable disease * Has experienced documented objective radiographic or clinical disease progression during or after 1L therapy containing any platinum/fluoropyrimidine doublet with or without immunotherapy * Participants with gastroesophageal adenocarcinoma that is known to be human epidermal growth factor receptor 2 (HER2)/neu positive are excluded. Participants with unknown HER2 status are eligible. * Has provided an archival tumor tissue sample or most recently obtained core, incisional, or excisional biopsy of a tumor lesion * AEs due to previous anticancer therapies must be ≤Grade 1 or baseline (except alopecia and vitiligo). Endocrine-related AEs adequately treated with hormone replacement are acceptable. * Has Eastern Cooperative Oncology Group performance status of 0 or 1 * Has a life expectancy of at least 3 months * Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to randomization. * Participants with history of Hepatitis C Virus (HCV) infection are eligible if HCV viral load is undetectable at screening. * Human Immunodeficiency Virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy.","The main exclusion criteria include but are not limited to the following: * Has squamous cell or undifferentiated gastroesophageal cancer * Has experienced weight loss \>20% over 3 months before the first dose of study intervention * Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing * Has Grade ≥2 peripheral neuropathy * Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease * Has a serious or nonhealing wound or peptic ulcer or bone fracture within 28 days prior to randomization * Has a bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection (hemicolectomy or extensive small intestine resection with chronic diarrhea) * Has uncontrolled, significant cardiovascular disease or cerebrovascular disease * Has experienced any arterial thrombotic event, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack, within 6 months prior to randomization * Has uncontrolled arterial hypertension ≥150/≥90 mm mercury (Hg) * Has accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks prior to enrollment * Has undergone major surgery within 28 days prior to randomization, or central venous access device placement within 7 days prior to randomization or planned major surgery following initiation of study treatment * Is receiving therapeutic anticoagulation with warfarin, low-molecular weight heparin or similar agents * Is receiving chronic therapy with nonsteroidal anti-inflammatory agents (NSAIDs) or other antiplatelet agents * Has a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered ""significant"") during the 3 months prior to ran"
NCT07062965,"An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator's Choice of Therapy in Adult Participants With Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy",,PHASE3,Puerto Rico,"Ad-Vance Medical Research, Ponce, Puerto Rico, [NOT_YET_RECRUITING]",Breast Cancer,2,[1] Arm A: PF-07248144 plus fulvestrant (EXPERIMENTAL): PF-07248144 tablet taken by mouth plus fulvestrant taken as a shot into the muscle. || [2] Arm B: everolimus plus ET (ACTIVE_COMPARATOR): Everolimus tablet taken by mouth plus investigator's choice of endocrine therapy of exemestane tablet taken by mouth or fulvestrant taken as a shot into the muscle.,"* Confirmed diagnosis of HR-positive HER2-negative breast cancer with evidence of locally advanced or metastatic disease, which is not amenable to surgical resection or radiation therapy with curative intent. * Prior CDK4/6 inhibitor therapy in combination with endocrine therapy in advance metastatic setting or in adjuvant setting with documented progression during or within 12 months after the last dose of CDK4/6i. * Participants are eligible if they previously received CDK4/6i or ET as a monotherapy, or in combination for rechallenge therapy in the advance or metastatic setting; have received prior therapy targeting estrogen receptor 1 (ESR1) or breast cancer gene (BRCA)1/2. * Measurable disease evaluable per Response Evaluation Criterion in Solid Tumors (RECIST) v.1.1 or non-measurable bone-only disease * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1.","* Documented detectable PIK3CA/AKT1/PTEN alterations in tissue * Received greater than two prior lines of systemic therapy in the advance or metastatic setting * Had received any prior chemotherapy, including antibody drug conjugates (ADCs), in advance or metastatic setting. Participants who have previously received chemotherapy in the (neo)adjuvant setting are not excluded from the study. * Any medical or psychiatric condition that may increase the risk of study participation or make the participant inappropriate for the study. * Renal impairment, hepatic dysfunction, or hematologic abnormalities."
NCT06435429,"A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment",,PHASE3,Brazil,"Hospital Nossa Senhora Da Conceição, Porto Alegre, Brazil, [RECRUITING] | IEPE Unimed Sorocaba, Sorocaba, Brazil, [RECRUITING] | DASA Hospital Brasilia, Brasília, Brazil, [RECRUITING] | Centro Regional Integrado de Oncologia, Ceará, Brazil, [RECRUITING] | Catarina Pesquisa Clinica, Itajaí, Brazil, [RECRUITING] | Irmandade Da Santa Casa de Misericordia de Porto Alegre, Portalegre, Brazil, [RECRUITING] | Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul PUCRS, Porto Alegre, Brazil, [RECRUITING] | Real Hospital Portugues de Beneficiencia Em Pernambuco, Recife, Brazil, [RECRUITING] | Nucleo de Oncologia Da Bahia, Salvador, Brazil, [RECRUITING] | Ceon Pesquisas Ltda, São Caetano do Sul, Brazil, [RECRUITING]",Metastatic HER2-positive Breast Cancer,2,"[1] Zanidatamab plus physician's choice of chemotherapy (EXPERIMENTAL): Participants with HER2-positive metastatic breast cancer (mBC) who have progressed on, or are intolerant to, previous T-DXd treatment will be randomized to receive intravenous infusion of zanidatam... || [2] Trastuzumab plus physician's choice of chemotherapy (ACTIVE_COMPARATOR): Participants with HER2-positive metastatic breast cancer (mBC) who have progressed on, or are intolerant to, previous T-DXd treatment will be randomized to receive intravenous infusion of trastuzum...","Participants are eligible to be included in the study only if all of the following criteria apply: 1. Is 18 years of age or of the legal adult age per local standard at the time of signing the informed consent. 2. Has histologically confirmed HER2-positive breast cancer according to ASCO-CAP Guidelines as evaluated by a central laboratory 3. Participants with unresectable or metastatic HER2 positive breast cancer who have progressed on, or are intolerant to, previous T-DXd treatment. 4. Has measurable disease per RECIST version 1.1. 5. Is eligible to receive one of the chemotherapy options listed in the physician's choice of chemotherapy (eribulin, gemcitabine, vinorelbine, or capecitabine). 6. Participants with history of treated or clinically inactive CNS metastases are eligible as specified in the protocol. 7. Has a life expectancy of at least 6 months, in the opinion of the investigator. 8. Has adequate hematologic parameters as defined in the protocol. 9. Has adequate hepatic function as specified in the protocol. 10. Has creatinine clearance ≥ 30 mL/minute as calculated per local institutional guidelines. 11. Has LVEF ≥ 50% as determined by either echocardiogram or MUGA obtained within 4 weeks before the first dose of study intervention. 12. Has ECOG performance status of 0 or 1. 13. Participant agrees to the following based on sex assigned at birth. 1. Male participants: Male participants are eligible to participate if they agree to the following during the study intervention period and for at least 5 months after the last dose of study intervention or the contraception period for the combination chemotherapy of choice per local guidance/standard practice, whichever is longer: * Refrain from donating fresh unwashed semen. * Use contraception as follows as specified in the protocol 2. Female participants: * A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: * Is a women of nonch",
NCT05438329,"A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1305 in Subjects With Advanced/Metastatic Solid Tumors",,"PHASE1, PHASE2",Puerto Rico,"BRCR GLOBAL Puerto Rico LLC., Mayagüez, Puerto Rico, [RECRUITING]",Advanced Solid Tumor,30,[1] DB-1305/BNT325 Dose Level 1 (EXPERIMENTAL): Enrolled subjects will receive DB-1305/BNT325 at Dose Level 1 || [2] DB-1305/BNT325 Dose Level 2 (EXPERIMENTAL): Enrolled subjects will receive DB-1305/BNT325 at Dose Level 2 || [3] DB-1305/BNT325 Dose Level 3 (EXPERIMENTAL): Enrolled subjects will receive DB-1305/BNT325 at Dose Level 3 || [4] DB-1305/BNT325 Dose Level 4 (EXPERIMENTAL): Enrolled subjects will receive DB-1305/BNT325 at Dose Level 4 || [5] DB-1305/BNT325 Dose Level 5 (EXPERIMENTAL): Enrolled subjects will receive DB-1305/BNT325 at Dose Level 5 || [6] DB-1305/BNT325 Dose Level 6 (EXPERIMENTAL): Enrolled subjects will receive DB-1305/BNT325 at Dose Level 6 || [7] DB-1305/BNT325 Dose Level 7 (EXPERIMENTAL): Enrolled subjects will receive DB-1305/BNT325 at Dose Level 7 || [8] DB-1305/BNT325 in combination with pembrolizumab (EXPERIMENTAL): Enrolled subjects will receive DB-1305/BNT325 in combination with pembrolizumab || [9] DB-1305/BNT325 Dose Expansion 1 (EXPERIMENTAL): subjects with Non-Small Cell Lung Cancer (NSCLC) with actionable genetic alterations (AGAs) who will receive DB-1305/BNT325 on either dose level 1 or dose level 2 || [10] DB-1305/BNT325 Dose Expansion 2 (EXPERIMENTAL): Enrolled subjects with NSCLC without AGAs who will receive DB-1305/BNT325 on either dose level 1 or dose level 2,* Male or female adults (defined as ≥ 18 years of age or acceptable age according to local regulations at the time of voluntarily signing of informed consent). * Histologically or cytologically confirmed unresectable advanced/ metastatic solid tumors who have relapsed or progressed on or after standard systemic treatments or for which no standard treatment is available. * At least one measurable lesion as assessed by the investigator according to RECIST version 1.1 criteria. * Has a life expectancy of ≥ 3 months. * Has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1. * Has Left Ventricular Ejection Fraction (LVEF) ≥ 50% by either echocardiography (ECHO) or multiple-gated acquisition (MUGA) within 28 days before enrollment. * Has adequate organ functions within 7 days prior to Day 1 of Cycle 1. * Has adequate treatment washout period prior to Day 1 of Cycle 1. * Is willing to provide pre-existing resected tumor samples or undergo fresh tumor biopsy for the measurement of Trop-2 level and other biomarkers if not contraindicated. * Is capable of comprehending study procedures and risks outlined in the informed consent and able to provide written consent and agree to comply with the requirements of the study and the schedule of assessments.,"* Has a medical history of symptomatic congestive heart failure (CHF) (New York Heart Association \[NYHA\] classes II-IV) or serious cardiac arrhythmia requiring treatment. * Has a medical history of myocardial infarction or unstable angina within 6 months before enrollment. * Has an average of Fredericia's formula-QT corrected interval (QTcF) prolongation to \> 470 millisecond (ms) in males and females based on a 12-lead electrocardiogram (ECG) in triplicate. * Has a medical history of non-infectious Interstitial Lung Diseases (ILD)/pneumonitis or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. * Has a lung-specific intercurrent clinically significant illness. * Has an uncontrolled infection requiring IV injection of antibiotics, antivirals, or antifungals. * Subjects have human immunodeficiency virus (HIV) infection with acquired immune deficiency syndrome (AIDS) defining illness are not eligible for enrollment; However, subjects have had HIV infection with a cluster of differentiation 4 (CD4)+ T cell count \> 350 cells/µL and no history of an AIDS-defining illness are eligible for entry. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply."
NCT05491395,Randomized Phase III Clinical Trial of Hypofractionated Radiotherapy in Breast Cancer Patients With Immediate Prosthetic Reconstruction: PROMART Trial,PROMART,NA,Brazil,"Radiation Oncology Department, Barretos, Brazil, [RECRUITING]",Breast Cancer,2,[1] Post Mastectomy Hypofractionated Radiotherapy Arm (EXPERIMENTAL): Post Mastectomy Hypofractionated Radiotherapy Arm || [2] Post Mastectomy Conventional Radiotherapy (NO_INTERVENTION): Post Mastectomy Conventional Radiotherapy,* Women with confirmed histological diagnosis of invasive ductal carcinoma and lobular breast carcinoma; * Radical mastectomy with immediate reconstruction with a prosthesis; * Patients indicated for adjuvant RT; * Any lymph node status; * With or without adjuvant chemotherapy; * ECOG performance status from 0-2; * \> 18 years old; * Informed Consent Form applied before any study-specific procedure.,* Another histological diagnosis than invasive ductal carcinoma or lobular carcinoma; * Previous history of neoplasm and/or radiotherapy and/ or quimiotherapy before this study; * Distant metastatic disease; * Palliative treatment; * Patients with scleroderma / systemic lupus erythematosus.
NCT05203172,ENCORAFENIB/BINIMETINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM ENCORAFENIB/BINIMETINIB CLINICAL STUDIES,,PHASE4,Brazil,"Liga Norte Riograndense Contra o Câncer, Natal, Brazil, [RECRUITING] | ONCOSITE - Centro de Pesquisa Clinica em Oncologia, Ijuí, Brazil, [RECRUITING] | Fundação Pio XII - Hospital de Câncer de Barretos, Barretos, Brazil, [RECRUITING] | BP - A Beneficencia Portuguesa de São Paulo, São Paulo, Brazil, [RECRUITING] | Real e Benemerita Associacao Portuguesa de Beneficencia, São Paulo, Brazil, [RECRUITING]",Solid Tumors,5,[1] Binimetinib only treatment (EXPERIMENTAL): For those participants receiving binimetinib treatment in parent studies || [2] Encorafenib only Treatment (EXPERIMENTAL): For those participants receiving encorafenib only treatment in parent studies || [3] Encorafenib & Binimetinib Treatment (EXPERIMENTAL): For those participants receiving encorafenib \& binimetinib treatment in parent studies. || [4] Treatment of Encorafenib & Binimetinib & Ribociclib (EXPERIMENTAL): For those participants receiving treatment of encorafenib \& binimetinib \& ribociclib in parent studies || [5] Treatment of Encorafenib & Binimetinib & Cetuximab (EXPERIMENTAL): For those participants receiving treatment of encorafenib \& binimetinib \& cetuximab in parent studies,"* Any participant who is receiving study intervention and deriving clinical benefit (as determined by the principal investigator) in an encorafenib/binimetinib Parent Study, with no ongoing NCI CTCAE version 4.03 Grade ≥3 or intolerable Grade 2 AEs considered to be related to study treatment. * Participants must agree to follow the reproductive criteria as outlined in the applicable Encorafenib/Binimetinib Continuation Sub-Study Protocol.","* Any medical reason that, in the opinion of the investigator or sponsor, precludes the participant from inclusion in the study."
NCT06305754,"A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors",,PHASE3,"Argentina, Colombia, Mexico","Clinica Adventista Belgrano-Oncology ( Site 0315), Caba., Argentina, [RECRUITING] | Instituto Alexander Fleming ( Site 0307), Ciudad Autónoma de Buenos Aires, Argentina, [RECRUITING] | Hospital Británico de Buenos Aires-Oncology ( Site 0304), Buenos Aires, Argentina, [RECRUITING] | Centro Privado de RMI Río Cuarto S.A. II ( Site 0310), Río Cuarto, Argentina, [RECRUITING] | Instituto de Oncología de Rosario ( Site 0301), Rosario, Argentina, [RECRUITING] | Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0303), La Rioja, Argentina, [RECRUITING] | FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0600), Bogotá, Colombia, [RECRUITING] | Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 0606), Bogotá, Colombia, [RECRUITING] | Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 0601), Valledupar, Colombia, [RECRUITING] | IMAT S.A.S ( Site 0602), Montería, Colombia, [RECRUITING]",Non-small Cell Lung Cancer (NSCLC),2,"[1] Sacituzumab tirumotecan (EXPERIMENTAL): Participants receive 4 mg/kg sacituzumab tirumotecan via intravenous (IV) infusion every 2 weeks (Days 1, 15, and 29 of every 6-week cycle) until discontinuation criteria is met. || [2] Pemetrexed Plus Carboplatin (ACTIVE_COMPARATOR): Participants receive, via IV infusion, 500 mg/m2 pemetrexed every 3 weeks (Days 1 and 22 of every 6-week cycle) plus area under the curve (AUC) 5 mg/mL\*min carboplatin every 3 weeks (Days 1 and 22...",* Histologically or cytologically confirmed diagnosis of advanced-stage nonsquamous non-small cell lung cancer (NSCLC). * Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to Grade ≤1 or baseline. * Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load. * Participants with history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable. * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy. * Life expectancy of at least 3 months.,"* Predominantly squamous cell histology NSCLC. * History of second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years. * Grade ≥2 peripheral neuropathy. * History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing. * Active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease. * Uncontrolled, or significant cardiovascular disease or cerebrovascular disease. * Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids. * Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed. * Received radiation therapy to the lung that is \>30 Gray within 6 months of the first dose of study intervention. * Known active central nervous system metastases and/or carcinomatous meningitis. * Active infection requiring systemic therapy. * History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease. * HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease. * Concurrent active HBV and HCV infection. * History of allogeneic tissue/solid organ transplant. * Participants who have not adequately recovered from major surgery or have ongoing surgical complications."
NCT05552222,"A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy",MajesTEC-7,PHASE3,Brazil,"Fundacao Pio XII, Barretos, Brazil, [RECRUITING] | Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, Brazil, [RECRUITING] | Liga Paranaense de Combate ao Cancer, Curitiba, Brazil, [RECRUITING] | Instituto Do Cancer Do Ceara, Fortaleza, Brazil, [RECRUITING] | Liga Norte Riograndense Contra O Cancer, Natal, Brazil, [RECRUITING] | Complexo Hospitalar de Niteroi, Niterói, Brazil, [RECRUITING] | Hospital De Clinicas De Porto Alegre, Porto Alegre, Brazil, [RECRUITING] | Hospital Das Clinicas Da Faculdade De Medicina De RPUSP HCRP, Ribeirão Preto, Brazil, [RECRUITING] | Hospital Sao Rafael, Salvador, Brazil, [RECRUITING] | Hospital Nove de Julho, São Paulo, Brazil, [RECRUITING]",Multiple Myeloma,3,"[1] Teclistamab, Daratumumab SC, and Lenalidomide (Tec-DR) (EXPERIMENTAL): Participants will receive teclistamab as subcutaneous (SC) injection in combination with daratumumab and lenalidomide. || [2] Talquetamab, Daratumumab SC, and Lenalidomide (Tal-DR) (EXPERIMENTAL): Participants will receive talquetamab as SC injection in combination with daratumumab and lenalidomide. || [3] Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) (ACTIVE_COMPARATOR): Participants will receive daratumumab as SC injection with lenalidomide and dexamethasone.","* Have a diagnosis of multiple myeloma according to the International Myeloma Working Group (IMWG) diagnostic criteria * Be newly diagnosed and not considered a candidate for high-dose chemotherapy with autologous stem cell transplant (ASCT) due to: ineligible due to advanced age OR; ineligible due to the presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT OR; deferral of high-dose chemotherapy with ASCT as initial treatment * Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2 * A participant must agree not to be pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of study treatment * A participant must agree not to plan to father a child while enrolled in this study or within 100 days after the last dose of study treatment","* Received any prior therapy for multiple myeloma or smoldering myeloma other than a short course of corticosteroids (not to exceed total of 160 milligrams \[mg\] dexamethasone or equivalent). In addition, received a cumulative dose of systemic corticosteroids equivalent to greater than or equals to (\>=) 20 mg of dexamethasone within 14 days before randomization * Had plasmapheresis within 28 days of randomization * Had a stroke, transient ischemic attack, or seizure within 6 months prior to randomization * Known allergies, hypersensitivity, or intolerance to teclistamab or talquetamab excipients * Known contraindications to the use of daratumumab or lenalidomide per local prescribing information * Myeloma Frailty Index of \>=2 with the exception of participants who have a score of 2 based on age alone"
NCT05501886,"Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy",VIKTORIA-1,PHASE3,"Argentina, Brazil, Mexico","Alexander Fleming Institute, Buenos Aires, Argentina, [RECRUITING] | Buenos Aires British Hospital, Buenos Aires, Argentina, [RECRUITING] | CENIT Foundation, Buenos Aires, Argentina, [RECRUITING] | Center for Medical Education and Clinical Research (CEMIC), Buenos Aires, Argentina, [RECRUITING] | Fleischer Medical Center, Buenos Aires, Argentina, [RECRUITING] | Medical Center Austral, Buenos Aires, Argentina, [RECRUITING] | Pergamino Clinic, Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Cordoba Oncology Institute (IONC), Córdoba, Argentina, [RECRUITING] | Center of Nuclear and Molecular Medicine of Entre Rios (CEMENER), Paraná, Argentina, [RECRUITING] | CEDIT Diagnostic and treatment center, Salta, Argentina, [RECRUITING]",Breast Cancer,6,[1] Arm A - Patients Lacking PIK3CA Mutations (WT) (EXPERIMENTAL): Gedatolisib + Palbociclib + Fulvestrant || [2] Arm B - Patients Lacking PIK3CA Mutations (WT) (EXPERIMENTAL): Gedatolisib + Fulvestrant || [3] Arm C - Patients Lacking PIK3CA Mutations (WT) (ACTIVE_COMPARATOR): Fulvestrant || [4] Arm D - Patients with PIK3CA Mutation (MT) (EXPERIMENTAL): Gedatolisib + Palbociclib + Fulvestrant || [5] Arm E - Patients with PIK3CA Mutation (MT) (ACTIVE_COMPARATOR): Alpelisib + Fulvestrant || [6] Arm F - Patients with PIK3CA Mutation (MT) (EXPERIMENTAL): Gedatolisib + Fulvestrant,"1. Histologically or cytologically confirmed diagnosis of metastatic or locally advanced breast cancer Adult females, pre- and/or post-menopausal, and adult males. Pre-menopausal (and peri-menopausal) women can be enrolled if amenable to treatment with an LHRH agonist. Patients are to have commenced concomitant treatment with LHRH agonist prior to or on Cycle 1, Day 1 and must be willing to continue on it for the duration of the study. 2. Negative pregnancy test for women of childbearing potential. Female subjects of childbearing potential must use an effective and/or acceptable contraceptive method from screening until 1 year after the last dose of study treatment 3. Confirmed diagnosis of estrogen receptor positive and/or progesterone receptor positive, as per American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP) guidelines (2020), based on most recent tumor biopsy utilizing an assay consistent with local standards 4. Documented HER2 immunohistochemistry (IHC) negative as per ASCO-CAP 2018 guidance 5. Adequate archival or fresh tumor tissue for the analysis of PIK3CA mutational status 6. Subject must have documentation of radiological disease progression on or after the last prior treatment and also have radiologically evaluable disease (measurable and/or non-measurable) according to RECIST v1.1, per local assessment. Subjects with bone only disease must have lytic or mixed lytic/blastic lesions that can be accurately assessed; bone only blastic lesions with no soft tissue component is not allowed. 7. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 8. Life expectancy of at least 3 months 9. Progressed during or after CDK4/6 inhibitor combination treatment with non-steroidal aromatase inhibitor (AI) 10. Adequate bone marrow, hepatic, renal and coagulation function","1. History of malignancies other than adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for ≥3 years 2. Prior treatment with a phosphoinositide 3-kinase (PI3K) inhibitor, a protein kinase B (Akt) inhibitor, or a mechanistic target of rapamycin (mTOR) inhibitor 3. Prior treatment with chemotherapy and antibody drug conjugates for advanced disease is not permitted (prior adjuvant or neoadjuvant chemotherapy is permitted) 4. More than 2 lines of prior endocrine therapy treatment 5. Bone only disease that is only blastic with no soft tissue component 6. Subjects with type 1 diabetes or uncontrolled type 2 diabetes 7. Known and untreated, or active, brain or leptomeningeal metastases a. Subjects with previously treated central nervous system (CNS) metastases may be enrolled in the study if they meet the following criteria: do not require supportive therapy with steroids; do not have seizures and do not exhibit uncontrolled neurological symptoms; stable disease confirmed by radiographic assessment within at least 4 weeks prior to enrollment 8. Patients with advanced, symptomatic, visceral spread that are at risk of life-threatening complication in the short-term 9. History of clinically significant cardiovascular abnormalities such as: Congestive heart failure (New York Heart Association (NYHA) classification ≥ II within 6 months of study entry 1. Myocardial infarction within 12 months of study entry 2. History of any uncontrolled (or untreated) clinically significant cardiac arrhythmias, (e.g., ventricular tachycardia), complete left bundle branch block, high grade AV block (e.g., bifascicular block, Mobitz type II and third degree AV block), supraventricular, nodal arrhythmias, or conduction abnormality in the previous 12 months 3. Uncontrolled hypertension defined by systolic blood pressure (SBP) ≥160 mmHg and/or diastolic blood pressure (DBP) ≥100 mmHg, wit"
NCT06745323,"A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With Small Cell Lung Cancer (SCLC) (DeLLphi-309)",DeLLphi-309,PHASE2,"Argentina, Brazil","Fundacion Respirar, Ciudad Autonoma de Buenos Aires, Argentina, [RECRUITING] | Instituto de Investigaciones clinicas de Mar del Plata, Mar del Plata, Argentina, [RECRUITING] | Liga Norte-Riograndense Contra O Cancer, Natal, Brazil, [RECRUITING] | Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil, [RECRUITING] | Hospital Sao Lucas da Pontificia Universidade Catolica do Rio Grande do Sul, Porto Alegre, Brazil, [RECRUITING] | Cipo - Centro Integrado de Pesquisa em Oncologia, Porto Alegre, Brazil, [RECRUITING] | Hospital de Amor, Barretos, Brazil, [RECRUITING] | Hospital de Base de Sao Jose do Rio Preto, São José do Rio Preto, Brazil, [RECRUITING]",Small Cell Lung Cancer (SCLC),3,[1] Treatment Arm A: Dose 1 Tarlatamab (EXPERIMENTAL): Participants will receive dose 1 of Tarlatamab by intravenous (IV) infusion during the treatment period. || [2] Treatment Arm B: Dose 2 Tarlatamab (EXPERIMENTAL): Participants will receive dose 2 of Tarlatamab by IV infusion during the treatment period. || [3] Treatment Arm C: Dose 3 Tarlatamab (EXPERIMENTAL): Participants will receive dose 3 of Tarlatamab by IV infusion during the treatment period.,"* Participant has provided informed consent prior to initiation of any study specific activities/procedures. * Age ≥ 18 years (or legal adult age within country, whichever is older) at the time of signing the informed consent. * Histologically or cytologically confirmed SCLC with demonstrated progression or relapse. * Participants who progressed or recurred following 1 platinum-based regimen. * Measurable disease as defined per RECIST 1.1 within the 21-day screening period. * Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1. * Minimum life expectancy of 12 weeks. * Adequate organ function as described per protocol.","* Disease Related * Previous diagnosis of transformed non-small cell lung cancer (NSCLC) including epidermal growth factor receptor activating mutation positive NSCLC that has transformed to SCLC. * Symptomatic central nervous system (CNS) metastases with exceptions defined in the protocol. * Other Medical Conditions * History of other malignancy within the past 2 years, with exceptions defined in the protocol. * Evidence of interstitial lung disease or active, non-infectious pneumonitis * Diagnosis or evidence of leptomeningeal disease. * Active autoimmune disease that has required systemic treatment (except replacement therapy) within the past 2 years or any other diseases requiring immunosuppressive therapy while on study. * History of solid organ transplantation. * Myocardial infarction and/or symptomatic congestive heart failure (New York Heart Association \> class II) within 6 months prior to first dose of study treatment. * History of arterial thrombosis (eg, stroke or transient ischemic attack) within 6 months prior to first dose of study treatment * Presence or history of viral infection based on criteria per protocol. * Symptoms and/or radiographic signs that indicate an acute and/or uncontrolled active systemic infection requiring antibiotics within 7 days prior to the first dose study treatment. * Known or active infection requiring parenteral antibiotic treatment. * History of severe or life-threatening events from any immune-mediated therapy. * Major surgical procedures within 21 days of prior to first dose of study treatment. * Prior/Concomitant Therapy * Prior anticancer therapy within 30 days of enrollment (14 days for conventional chemotherapy). * Prior enrollment on a tarlatamab clinical trial OR prior therapy with any selective inhibitor of the DLL3 pathway. * Current anti-cancer therapy such as chemotherapy, immunotherapy, or targeted therapy with exceptions. * Receiving systemic corticosteroid therapy or any other immunosuppressive therapy with"
NCT06149637,Comparison of Two Routes of Surgical Approach to Lateral Cervical Node Dissection in Differentiated Thyroid Cancer Patients With Lateral Metastatic Disease: Randomized Clinical Trial,,NA,Colombia,"Hospital Alma Mater de Antioquia, Medellín, Colombia, [RECRUITING]",Thyroid Cancer,2,[1] Traditional neck dissection approach (ACTIVE_COMPARATOR): Traditional neck dissection approach || [2] Anterior neck dissection approach (EXPERIMENTAL): Anterior neck dissection,"1. Patients ≥ 18 years. 2. Patients with macroscopic lymph node involvement identified by physical examination, imaging or intraoperatively in lateral neck. 3. Patients with microscopic nodal involvement confirmed by FNAB (definition by the pathologist of suspected or confirmed metastatic papillary carcinoma according to the Bethesda criteria) 4. Candidates for lateral lymph node dissection due to suspected or confirmed disease metastatic lymph nodes as defined by the treating surgeon. 5. Patients requiring or not requiring thyroidectomy and/or central dissection concomitant with the dissection",1. Patients with a history of previous neck dissection 2. Histological confirmation of medullary or anaplastic carcinoma 3. Previous spinal nerve injury
NCT06526793,"A Modular Phase 2, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of AZD0486 in Participants With Relapsed or Refractory (R/R) B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B)",SOUNDTRACK-B,PHASE2,Brazil,"Research Site, Porto Alegre, Brazil, [NOT_YET_RECRUITING] | Research Site, São Paulo, Brazil, [RECRUITING] | Research Site, São Paulo, Brazil, [RECRUITING]",B-cell Non-Hodgkin Lymphoma | Follicular Lymphoma (FL) | Diffuse Large B-Cell Lymphoma (DLBCL),2,"[1] Module 1: AZD0486 Monotherapy in Participants with Relapsed or Refractory Follicular Lymphoma (EXPERIMENTAL): In Module 1, the efficacy and safety of AZD0486 at the RP2D will be evaluated in R/R FL. AZD0486 will be administered as intravenous infusion. || [2] Module 2: AZD0486 Monotherapy in Participants with Relapsed or Refractory DLBCL (EXPERIMENTAL): In Module 2, the efficacy and safety of AZD0486 at the RP2D will be evaluated in R/R DLBCL. AZD0486 will be administered as intravenous infusion.","* Aged 18 to 80 years old * Histologically confirmed relapsed refractory FL (Module 1) and DLBCL (Module 2) after at least 2 prior lines of therapy * ECOG performance status 0 to 2 * Locally confirmed CD-19 expression in lymphoma cells after progression from last CD 19 directed therapy * FDG-avid disease with at least one bi-dimensionally measurable nodal lesion (defined as \> 1.5 cm in its longest dimension), or extranodal lesion (defined as \> 1.0 cm in its longest dimension) * Adequate hematological function: ANC ≥ 1000/mm3, platelets * 75,000/mm3, hemoglobin ≥ 9 g/dL. Transfusion and/or growth factor are allowed but counts must be stable for at least 72 hours afterwards prior to screening * Adequate liver function: total bilirubin \<1.5x ULN, AST/ALT ≤ 3xULN Note: Patients with documented history of Gilbert's Syndrome and in whom total bilirubin elevations are accompanied by elevated indirect bilirubin are eligible) * Adequate renal function: creatinine clearance (CrCl) of ≥ 45 mL/min The above is a summary, other inclusion criteria details may apply. 2. Key","* Diagnosis of CLL, Burkitt lymphoma, or Richter's transformation * Active CNS involvement by B-NHL * Leukemic presentation of B-NHL * History or presence of clinically relevant CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis * Prior therapy with T-cell engager (TCE) within 8 weeks, CAR T- cell therapy or autologous Hematopoietic Stem Cell Transplantation (HSCT) within 12 weeks, or prior allogeneic HSCT within 24 weeks of first dose of AZD0486 * Requires chronic immunosuppressive therapy * Unresolved non hematological AEs ≥ Grade 2 from prior therapies; history of ≥ Grade 3 CRS or neurotoxicity from prior CAR-T or TCE therapy * History of major cardiac abnormalities. * If female, participant must not be pregnant or breastfeeding. The above is a summary, other exclusion criteria details may apply."
NCT06238882,A Phase III Study Comparing Concurrent Nitroglycerin With Radiation Therapy vs Radiation Therapy Alone in Patients With Non-small Cell Lung Cancer With EGFR Mutations and Brain Metastases.,,NA,Mexico,"Instituto Nacional de Cancerologia, Mexico City, Mexico, [RECRUITING]",Non-small Cell Lung Cancer | Brain Metastases | EGFR Gene Mutation,2,"[1] Intervention (EXPERIMENTAL): Patients will be given patches of nitroglycerin during treatment with radiation therapy (30 Gy in 10 fractions, i.e. 10 days of treatment). || [2] Control (NO_INTERVENTION): Patients will be given a conventional treatment with radiation therapy (30 Gy in 10 fractions, i.e. 10 days of treatment).","* Patients diagnosed with advanced non-small cell lung cancer (which includes de novo stage IIIB-IV, according to the 8th edition AJCC, or recurrent disease), documented by histology and/or cytology. * Presence of brain metastases, candidates for treatment with holocranial radiation therapy. * Documented EGFR sensitivity mutation. * Disease measurable by criteria: The Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM). * 18 years and up. * Functional status, by ECOG scale 0-2 * Life expectancy at least 12 weeks. * Not receive vasodilator treatment as calcium channel blockers. * Electrocardiogram * Neutrophil count 1.5 x 103/mm3, platelet count \>100 x (103/mm3). * Serum bilirubin should be 1.5 of the upper normal limit (ULN, upper normal limit). * AST and/or ALT 2 ULN (or 5 x ULN in patients with liver metastases). * Serum creatinine 1.5 (ULN), or creatinine clearance 60ml/min. * Ability to comply with study and follow-up procedures. * Informed written (signed) consent to participate in the study. * Have tumor tissue (paraffin blocks from diagnostic biopsy) obtained before systemic treatment","* Any unstable systemic disease (including active infection, grade 4 hypertension, unstable angina, congestive heart failure, ischemic heart disease, liver, kidney disease). * Patients with a history of allergy to glyceryl tinistate * Any other malignant pathology within the previous 5 years (except for cervical carcinoma in situ or basal-cell skin cancer, treated appropriately). * Pregnant and/or breastfeeding women. * Meningeal carcinomatosis corroborated by cytopathological study. Disposal Criteria: * Failure to follow protocol rules. * Loss of patient follow-up. * Patients who express their desire not to continue the study. * Patients with unacceptable toxicity"
NCT06772623,"An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations",,"PHASE1, PHASE2",Puerto Rico,"Pan American Center for Oncology Trials /ID# 268827, Rio Piedras, Puerto Rico, [RECRUITING]",Non Small Cell Lung Carcinoma,4,"[1] Part 1: Telisotuzumab Adizutecan + Budigalimab (EXPERIMENTAL): Participants will receive several doses of telisotuzumab adizutecan in combination with budigalimab, as part of the 33 month study duration. || [2] Part 2 Arm 1: Telisotuzumab Adizutecan + Pembrolizumab (EXPERIMENTAL): Participants will receive telisotuzumab adizutecan dose A in combination with pembrolizumab, as part of the 33 month study duration. || [3] Part 2 Arm 2: Telisotuzumab Adizutecan + Pembrolizumab (EXPERIMENTAL): Participants will receive telisotuzumab adizutecan dose B in combination with pembrolizumab, as part of the 33 month study duration. || [4] Part 2: Standard of Care (EXPERIMENTAL): Participants will receive pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed, as part of the 33 month study duration.","* Must have histologically documented non-squamous (NSq) non small cell lung carcinoma (NSCLC) that is locally advanced or metastatic will be enrolled into the study. * Must have measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1. * For Part 1, participants must have had no more than 1 systemic therapy for advanced disease including platinum-based chemotherapy or an immune checkpoint inhibitor (as monotherapy or in combination with chemotherapy), or appropriate targeted therapy for an actionable gene alteration, if applicable, for epidermal growth factor receptor (EGFR) wild-type (WT) NSq NSCLC. * For Part 2, participants must have no prior systemic therapy for advanced disease, no known actionable genomic alteration. * Must have documented programmed death ligand 1 (PD-L1) status. * Must have adequate organ function.","* Known uncontrolled metastases to the central nervous system. * History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD or pneumonitis on screening chest computed tomography (CT) scan."
NCT05544240,Phase 1 Trial of SYNC-T - Immunotherapy Regimen Given After Controlled Cellular Lysis for Patients With Advanced/Metastatic Solid Tumors,,PHASE1,Mexico,"Hospital Diomed, Mexico City, Mexico, [RECRUITING]",Metastatic Cancer | Metastatic Breast Cancer | Metastatic Lung Cancer | Solid Tumor | Cancer,1,[1] Treatment Arm (EXPERIMENTAL): Treatment Arm,"1. Male or female, aged \>18 years old at the time of signed informed consent 2. Provide written informed consent and must be willing to adhere with treatment and follow-up. 3. Subjects with advanced and/or metastatic histologically or cytologically confirmed solid tumor who have not responded or progressed after standard therapies or for whom no further standard therapy exists or standard therapy is not available. 4. Meet all eligibility criteria 5. Has undergone a cardiac work-up and received cardiac clearance two months before first treatment 6. Has halted use of any anticoagulants or other blood thinners (including but not limited to heparin or warfarin) within five (5) days of each treatment. 7. Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for AEs (NCI CTCAE) v5 grade ≤ 1. 8. Measurable disease by RECIST. 9. Able to undergo general anesthesia or conscious sedation. 10. Eastern Cooperative Oncology Group (ECOG) performance status of \< 3. 11. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days prior to the study.Participants receiving bone resorptive therapy (including, but not limited to, bisphosphonate or denosumab) must be on stable doses for at least 42 days prior to the cryolysis 12. In the opinion of the Investigator, there is no other meaningful life-prolonging therapy option available. 13. Adequate bone marrow, renal, and hepatic function, defined as follows: a. Bone marrow function without transfusion 30 days before first dosing: i. Absolute neutrophil count ≥ 1.5 x 109/L; Lymphocyte count of ≥ 1.0 x 109/L; Platelet count ≥ 100 x 109/L; ii. Hemoglobin ≥ 9.0 g/dL b. Renal function: i. Estimated glomerular filtration rate ≥30 mL/min/1.73 m2 or creatinine clearance calculated by Cockcroft-Gault equation ≥30 mL/ c. Hepatic function: i. Alanine aminotransferase ≤ 3x upper limit of normal (ULN) ii. Aspartate amino","1. Has a known additional malignancy that is progressing or has required active treatment in the last 3 years, excluding basal and squamous cell carcinoma 2. Has undergone major surgery within 28 days prior to enrollment and has not recovered adequately from the toxicities and/or complications 3. Has an active infection (including tuberculosis) requiring systemic therapy 4. Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis 5. Has received a live vaccine within 30 days prior to enrollment 6. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first treatment 7. Has tumor volume or disease burden too great to provide for safe and/or effective treatment as determined by the Principal Investigator after consultation with Syncromune's Chief Medical Officer 8. Subjects who have metastases limited to subcutaneous regions (only skin) 9. Significant cardiac or other medical illness such as severe congestive heart failure, unstable angina, or serious cardiac arrhythmia (e.g., New York Heart Association Class 4), or history of previous heart failure. 10. Malignant pleural effusions or ascites that require immediate intervention 11. Prior history of autoimmune disease except hypothyroidism 12. Any primary or acquired immunodeficiency 13. Active COVID infection or tests positive for COVID day before or day of planned treatment 14. Known or suspected hepatitis B if active infection (subjects with chronic hepatitis B infection must have an undetectable Hepatitis B virus (HBV) viral load on suppressive therapy, if indicated; positive surface antibody alone is not an exclusion) 15. Known or suspected hepatitis C infection which has not been treated and cured unless currently on treatment with an undetectable viral load 16. Prior history of autoimmune disease except hypothyroidism, uncontrolled or unmanaged diabetes, cardiac arrhytmia (unsta"
NCT05485974,"A Phase 1, Open Label, Dose Escalation of HBI-2438 in Patients With Advanced Malignant Solid Tumors Harboring KRAS G12C Mutation",,PHASE1,Puerto Rico,"Pan American Center for Oncology Trials (PanOncology Trials), Rio Piedras, Puerto Rico, [RECRUITING]",Lung Cancer | Non Small Cell Lung Cancer | Colorectal Cancer | Cancer of Pancreas | Colon Cancer,1,"[1] Dose Escalation and Expansion (EXPERIMENTAL): HBI-2438 will be given orally in ascending doses (escalation cohort), until the maximum tolerated dose or recommended Phase 2 dose is reached. Up to 6-8 patients will then be enrolled in the expans...","Key Inclusion Criteria: Male or female at least 18 years of age at the time of signing the ICF prior to initiation of any study specific activities/procedures Advanced malignant solid tumors with KRAS G12C mutation- as determined by genetic testing Must have failed or refused standard of care therapy, are not eligible for standard of care therapy, or cannot benefit from standard of care therapy, in the opinion of the Investigator At least 1 measurable target lesion that meets the definition of RECIST v1.1 ECOG Performance Status of 0 or 1 Demonstrate adequate organ function Expected survival time \> 3 months in the opinion of the investigator Must be able to swallow oral medications and must not have gastrointestinal abnormalities that significantly affect drug absorption","Key Exclusion Criteria: History of another concurrent malignancy within 3 years prior to study entry, unless the malignancy was treated with curative intent and the likelihood of relapse is \<5% in 2 years Note: Subjects with a history of squamous or basal cell carcinoma of the skin or carcinoma in the situ of the cervix may be enrolled Untreated or symptomatic central nervous system (CNS) metastases Note: Subjects with asymptomatic treated CNS metastases are eligible provided they have been clinically stable and not requiring steroids for at least 4 weeks Clinically significant cardiovascular disease, including stroke or myocardial infarction within 6 months prior to first dose of HBI-2438; or the presence of unstable angina or congestive heart failure of New York Heart Association Grade 2 or higher Any unresolved Grade 2 or greater toxicity from previous anti-cancer therapy, except alopecia, within 4 weeks of first study treatment administration Active autoimmune diseases or history of autoimmune diseases that may relapse Pregnant or nursing Prior treatment with any KRAS G12C inhibitors Any condition that required systemic treatment with either corticosteroids (\>10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤14 days before the first study treatment administration Treatment with other investigational drugs/devices within 4 weeks prior to first study treatment administration"
NCT05609968,"An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)",,PHASE3,"Brazil, Chile, Mexico, Peru","CRIO - CENTRO REGIONAL INTEGRADO DE ONCOLOGIA ( Site 0320), Fortaleza, Brazil, [RECRUITING] | Hospital Tacchini ( Site 0322), Bento Gonçalves, Brazil, [RECRUITING] | Hospital da Cidade de Passo Fundo ( Site 0321), Passo Fundo, Brazil, [RECRUITING] | Instituto de Oncologia Saint Gallen ( Site 0317), Santa Cruz do Sul, Brazil, [RECRUITING] | Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0318), Barretos, Brazil, [RECRUITING] | A. C. Camargo Cancer Center ( Site 0324), São Paulo, Brazil, [RECRUITING] | Oncovida ( Site 0334), Santiago, Chile, [RECRUITING] | Pontificia Universidad Catolica de Chile ( Site 0332), Santiago, Chile, [RECRUITING] | COI Tijuana - Centro Oncológico Internacional ( Site 0350), Tijuana, Mexico, [RECRUITING] | Hospital Universitario ""Dr. Jose Eleuterio Gonzalez""-Servicio de Oncología ( Site 0352), Monterrey, Mexico, [RECRUITING]","Carcinoma, Non-Small-Cell Lung",2,"[1] Pembrolizumab + Sacituzumab Govitecan (EXPERIMENTAL): Participants receive sacituzumab govitecan 10mg/kg intravenous (IV) infusion once weekly on Day 1 and Day 8 of a continuous 21-day cycle until progressive disease (PD) requiring discontinuation, un... || [2] Pembrolizumab (EXPERIMENTAL): Participants receive pembrolizumab 200mg IV infusion on Day 1 Q3W for up to 35 cycles (each cycle length = 21 days).","The main inclusion criteria include but are not limited to the following: * Has a histologically or cytologically confirmed diagnosis of metastatic non-small cell lung cancer (NSCLC) * Has confirmation that epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase 1 (ALK-1), or ROS proto-oncogene 1 (ROS-1)-directed therapy is not indicated as primary therapy * Has provided tumor tissue that demonstrates PD-L1 tumor proportion score (TPS) ≥50% of tumor cells as assessed by immunohistochemistry (IHC) at a central laboratory * Has a life expectancy of at least 3 months","The main exclusion criteria include but are not limited to the following: * Has history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years * Has received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC * Has previously received treatment with Topoisomerase 1 inhibitors or Trop-2 targeted therapy * Has received prior therapy with an anti-programmed cell death 1 protein (anti-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), or anti anti- programmed cell death ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor * Has received prior radiotherapy within 2 weeks of start of study intervention or has radiation-related toxicities requiring corticosteroids * Has received radiation therapy to the lung that is \>30 Gray (Gy) within 6 months of the first dose of study intervention * Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention * Has received an investigational agent or has used an investigational device within 4 weeks before study intervention administration * Has cardiac disease * Myocardial infarction or unstable angina pectoris within 6 months of enrollment * History of serious ventricular arrhythmia, high-grade atrioventricular block, or other cardiac arrhythmias requiring antiarrhythmic medications; history of QT interval prolongation * New York Heart Association (NYHA) Class III or greater congestive heart failure or left ventricular ejection fraction of \<40% * Has active chronic inflammatory bowel disease * Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication * Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis * Has severe hypersensitivity (≥Grade 3) "
NCT05006716,"A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies",CaDAnCe-101,"PHASE1, PHASE2",Brazil,"Hospital Sirio Libanes Brasilia, Brasília, Brazil, [RECRUITING] | Instituto de Pesquisa Em Saude Da Universidade de Caxias Do Sul, Caxias do Sul, Brazil, [RECRUITING] | Hospital Erasto Gaertner, Curitiba, Brazil, [RECRUITING] | Centro Gaucho Integrado de Oncologia Hospital Mae de Deus, Porto Alegre, Brazil, [RECRUITING] | Hospital Ernesto Dornelles, Porto Alegre, Brazil, [RECRUITING] | Real E Benemerita Associacao Portuguesa de Sao Paulo, São Paulo, Brazil, [RECRUITING] | Hospital Alemao Oswaldo Cruz, São Paulo, Brazil, [RECRUITING] | Hospital Nove de Julho Dasa, São Paulo, Brazil, [RECRUITING] | Instituto Dor de Pesquisa E Ensino Sao Paulo, São Paulo, Brazil, [RECRUITING] | Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein, São Paulo, Brazil, [RECRUITING]",B-cell Malignancy | Marginal Zone Lymphoma | Follicular Lymphoma | Non-Hodgkin Lymphoma | Waldenström Macroglobulinemia,7,"[1] Part 1a (Monotherapy Dose Escalation) (EXPERIMENTAL): Dose escalation in specific subtypes of non-Hodgkin lymphoma (NHL), including relapsed or refractory (R/R) marginal zone lymphoma (MZL), relapsed or refractory (R/R) follicular lymphoma (FL) Grades... || [2] Part 1b (Monotherapy Safety Expansion) (EXPERIMENTAL): Participants with R/R MZL, MCL, CLL/SLL, and WM will be enrolled at selected doses to help determine the recommended dose(s) for expansion (RDFE(s)) for BGB-16673. || [3] Part 1c (Additional Monotherapy Safety Expansion) (EXPERIMENTAL): Additional safety data will be collected from participants with R/R MZL, WM, RT, DLBCL, or FL to confirm the RDFE(s) of BGB-16673 for those with non-CLL/SLL/MCL histologies. || [4] Part 1d (Additional Monotherapy Safety Expansion in R/R CLL/SLL) (EXPERIMENTAL): Participants with R/R CLL/SLL will be enrolled at selected RDFE(s) to generate additional safety and efficacy data for BGB-16673. || [5] Part 1e (Japan-only Cohort) (EXPERIMENTAL): Japanese participants with R/R MZL, FL, MCL, CLL/SLL, and WM will be enrolled at selected RDFE(s) to assess the safety and tolerability of BGB-16673. || [6] Part 1f (Additional Monotherapy Safety Expansion in BTKi Naive B-Cell Malignancies) (EXPERIMENTAL): Participants with CLL/SLL, MCL, WM, MZL, or Richter's transformation to DLBCL who have not received a prior BTKi (either covalent or noncovalent) will be enrolled at selected dose levels. || [7] Phase 2 (Monotherapy Expansion) (EXPERIMENTAL): Cohorts of participants with R/R CLL/SLL, R/R MCL, R/R WM, R/R MZL, R/R FL, R/R RT, and R/R DLBCL will be enrolled to recieve the RDFE(s) identified in Phase 1 to further evaluate the safety and ef...","1. Confirmed diagnosis (per World Health Organization (WHO) guidelines, unless otherwise noted) of one of the following: Marginal Zone Lymphoma (MZL) , Follicular Lymphoma (FL), R/R Mantle Cell Lymphoma (MCL), R/R chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), Diffuse large B-cell lymphoma (DLBCL), or \>2 treatments per the Richter's transformation to DLBCL. 2. Participants who have previously received a covalently-binding Bruton´s tyrosine kinase (BTK) inhibitor (BTKi) in any line of therapy must have received treatment with the BTK inhibitor for ≥ 8 weeks (unless reason for discontinuation is intolerance). 3. For dose-finding and dose-expansion, participants who had previously received a covalently-binding BTK inhibitor as monotherapy or in combination with other anticancer agents are eligible for the study if they meet any of the following criteria: discontinued the previous BTK inhibitor due to disease progression, experienced disease progression after completing treatment with a BTK inhibitor or discontinued the BTK inhibitor due to toxicity or intolerance. 4. Measurable disease by radiographic assessment or serum IgM level (WM only) 5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2 6. Participants enrolling in the dose finding phase of the study may be previously treated with a BTKi or may be naïve to BTKi therapy depending on the diagnosis and country of enrollment; participants with MCL enrolling in the expansion cohorts (Phase 2) must have been treated with a BTKi in a prior line of therapy; CLL/SLL participants, in addition to being treated with a BTKi in a prior line of therapy, must also have received a Bcl-2 inhibitor in a prior line of therapy as well (Phase 2).","1. Prior malignancy (other than the disease under study) within the past 2 years, except in situ malignancies that have been curatively resected, localized breast cancer treated with curative intent with no evidence of breast active disease for more than 3 years and receiving adjuvant hormonal therapy, localized Gleason score ≤ 6 prostate cancer undergoing observation or treatment with androgen depravation, or any other cancer treated with curative intent, not on adjuvant treatment, and in the opinion of the investigator is unlikely to recur. 2. Requires ongoing systemic treatment for any other malignancy 3. Requires ongoing systemic (defined as ≥ 10 mg/day of prednisone or equivalent) corticosteroid treatment. 4. Current or history of central nervous system involvement including the brain, spinal cord, leptomeninges, and cerebrospinal fluid (as documented by imaging, cytology, or biopsy) by B-cell malignancy, regardless of whether participants had received treatment for central nervous system disease 5. Known active plasma cell neoplasm, prolymphocytic leukemia, T-cell lymphoma, Burkitt lymphoma, acquired immunodeficiency syndrome (AIDS)-related B-cell lymphoma, Castleman disease, post-transplant lymphoproliferative disorders, hairy cell leukemia, germinal center B-cell (GCB), DLBCL, EBV+ DLBCL NOS, primary DLBCL of the central nervous system (CNS), primary cutaneous DLBCL - leg type, DLBCL associated with chronic inflammation, primary mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, ALK+ large B-cell lymphoma, primary effusion lymphoma, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, high-grade B-cell lymphoma - NOS, B-cell lymphoma unclassifiable with features intermediate between DLBCL and classical Hodgkin lymphoma, or history of or currently suspected transformation of an indolent lymphoma to an aggressive histology (except for participants with Richter Transformation to DLBCL are eligible for Part 1a, 1"
NCT06151574,"Beamion LUNG 2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered Zongertinib (BI 1810631) Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations",,PHASE3,"Argentina, Brazil, Chile, Mexico, Puerto Rico","Clinica Adventista Belgrano, CABA, Argentina, [NOT_YET_RECRUITING] | Instituto Medico Especializado Alexander Fleming, Ciudad Autónoma de Bs As, Argentina, [NOT_YET_RECRUITING] | Instituto Oncologico de Cordoba, Córdoba, Argentina, [NOT_YET_RECRUITING] | Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina, [NOT_YET_RECRUITING] | Instituto Médico de la Fundación Estudios Clínicos, Rosario, Argentina, [NOT_YET_RECRUITING] | Clinicas Viedma S.A., Viedma, Argentina, [NOT_YET_RECRUITING] | Associacao Dr. Bartholomeu Tacchini, Bento Gonçalves, Brazil, [NOT_YET_RECRUITING] | Hospital do Cancer de Londrina, Londrina, Brazil, [NOT_YET_RECRUITING] | Hospital Sao Lucas da PUCRS, Porto Alegre, Brazil, [RECRUITING] | OncoClinicas Rio de Janeiro, Rio de Janeiro, Brazil, [RECRUITING]","Lung Cancer, Non-squamous, Non-small Cell",2,[1] Experimental treatment arm (EXPERIMENTAL): zongertinib only || [2] Comparator arm (ACTIVE_COMPARATOR): pembrolizumab plus platinum-pemetrexed chemotherapy,"1. Signed and dated written informed consent form (ICF) in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial. 2. Patients ≥18 years of age or over the legal age of consent in countries where that is greater than 18 years at the time of signature of the ICF. 3. Histologically or cytologically confirmed diagnosis of an advanced and/or metastatic non-squamous Non-small cell lung cancer (NSCLC). 4. Documented Human epidermal growth factor receptor 2 (HER2) mutation in the Tyrosine kinase domain (TKD) as per local lab results. 5. An archival tumor tissue sample must be submitted to the central laboratory after inclusion of the patient to retrospectively confirm the HER2 status. If no archival tissue is available, this may be acceptable in exceptional cases after written agreement with the sponsor. 6. Patients who have not received any systemic treatment for unresectable, locally advanced or metastatic disease and are not eligible for curative therapy. 7. Presence of at least one measurable lesion according to Response evaluation criteria in solid tumors (RECIST) 1.1, as determined by the local site investigator/radiology assessment. 8. Eligible to receive treatment with the selected platinum-based doublet-chemotherapy (i.e. cisplatin/pemetrexed or carboplatin/pemetrexed) and pembrolizumab in accordance with the Summaries of Product Characteristics (SmPC)/Product Information. Further inclusion criteria apply.","1. Previous or concomitant malignancies other than the one treated in this trial within the last 5 years, except; * effectively treated non-melanoma skin cancers * effectively treated carcinoma in situ of the cervix * effectively treated ductal carcinoma in situ * other effectively treated malignancy that is considered cured by local treatment 2. Tumors with targetable alterations with approved available therapy. 3. Lung-specific intercurrent clinically significant severe illness based on investigators assessment. 4. Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial. 5. Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to randomization or planned within 6 months after screening, e.g. hip replacement. 6. Any history of or concomitant condition that, in the opinion of the investigator, would compromise the patient's ability to comply with the trial or interfere with the evaluation of the safety and efficacy of the test drug. 7. History or presence of cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of ≥ III or IV, unstable angina or poorly controlled arrhythmia which are considered as clinically relevant by the investigator. Myocardial infarction, stroke, or pulmonary embolism within 6 months prior to randomization. 8. Any clinically important abnormalities (as assessed by the investigator) in rhythm, conduction, or morphology of resting electrocardiograms, e.g. complete left bundle branch block, third degree heart block. Further exclusion criteria apply."
NCT06704724,A PHASE 1 OPEN-LABEL STUDY OF PF-07985045 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS,,PHASE1,Puerto Rico,"Pan American Center for Oncology Trials, LLC, Rio Piedras, Puerto Rico, [RECRUITING]","Carcinoma, Pancreatic Ductal | Colorectal Neoplasms | Carcinoma, Non-Small-Cell Lung",11,"[1] Part 1 Dose Escalation (EXPERIMENTAL): PF-07985045 monotherapy Dose Escalation at prescribed dose and frequency in 28-day cycles || [2] Part 1 Cohort A1 (EXPERIMENTAL): PF-07985045 monotherapy dose expansion in 2-3L PDAC at prescribed dose and frequency in 28-day cycles || [3] Part 1 Cohort B1 (EXPERIMENTAL): PF-07985045 monotherapy dose expansion in 2-3L CRC at prescribed dose and frequency in 28-day cycles || [4] Part 1 Cohort C1 (EXPERIMENTAL): PF-07985045 monotherapy dose expansion in 2-3L NSCLC at prescribed dose and frequency in 28-day cycles || [5] Part 1 Cohort D1 (EXPERIMENTAL): PF-07985045 monotherapy dose expansion in other tumor types at prescribed dose and frequency in 28-day cycles || [6] Part 2 Cohort A2 (EXPERIMENTAL): Combination (PF-07985045 + Gemcitabine + Nab-paclitaxel) dose escalation/expansion in 1L PDAC.

Prescribed dose and frequency in 28-day cycles || [7] Part 2 Cohort B2 (EXPERIMENTAL): Combination (PF-07985045 + Cetuximab) dose escalation/expansion in 2-3L CRC

Prescribed dose and frequency in 28-day cycles || [8] Part 2 Cohort B3 (EXPERIMENTAL): Combination (PF-07985045 + FOLFOX + Bevacizumab) dose escalation/ expansion in 1L CRC

Prescribed dose and frequency in 28-day cycles || [9] Part 2 Cohort C2 (EXPERIMENTAL): Combination (PF-07985045 + Pembro or sasanlimab) dose escalation/expansion in 1L NSCLC (TPS ≥ 50%)

Prescribed dose and frequency in 21-day (pembro) or 28-day (sasanlimab) cycles || [10] Part 2 Cohort C3 (EXPERIMENTAL): Combination (PF-07985045 + Pembro + Platinum Chemo) dose escalation/expansion in 1L NSCLC (any TPS)

Prescribed dose and frequency in 21-day cycles","* Histological or cytological diagnosis of advanced, unresectable, and/or metastatic or relapsed/refractory solid tumor. * Note for PDAC: Only participants with the histologic type of adenocarcinoma of the pancreas are allowed to enroll. For PDAC, if loco-regional disease is present, must also have metastatic disease. * Note for NSCLC: If a driver mutation is present, the participant was resistant or intolerant of precision medicine therapy (eg, inhibitors of EGFR, ALK, ROS1, or others). * ECOG PS 0 or 1 * Presence of at least 1 measurable lesion based on RECIST version 1.1 that has not been previously irradiated. * Documentation of mutated KRAS gene 1. KRAS mutations of any variant except previously treated G12C, present in tumor tissue or blood 2. If the participant received KRAS G12C inhibitor treatment previously, the KRAS mutation status must be other than G12C * Part 1: Participant must have progressed on standard treatment(s) for which no additional, effective therapy is available. 1. PDAC (2-3L): Participants must have received and radiologically progressed on prior lines of systemic therapy for metastatic pancreatic adenocarcinoma. If participants received prior neoadjuvant or adjuvant chemotherapy and progressed within 6 months of the last dose, then this should be considered as a prior line of systemic therapy. 2. NSCLC (2-3L): Participants must have received prior lines of anti-cancer treatment and progressed on at least a platinum-containing chemotherapy regimen and checkpoint inhibitor therapy; for participants with EGFR, ALK, or other genomic tumor alterations, participants must have progressed on approved therapy for these alterations. 3. CRC (2-3L): Participants must have had one or two prior systemic treatment regimens for mCRC. For either one or two prior treatments, these regimens must have included a fluoropyrimidine, oxaliplatin, or irinotecan; for one prior treatment, exposure to VEGF/VEGF receptor (VEGFR) inhibitor is optional. 4. other tumor","* Active or history of pneumonitis/ILD, pulmonary fibrosis requiring treatment with systemic steroid therapy, including evidence to suggest pneumonitis/ILD on baseline assessments including imaging. * Diagnosis of immunodeficiency or an active autoimmune disease that require systemic treatment with chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy in the past 2 years. * Sensory peripheral neuropathy ≥Grade 2 (Part 2 only) * Active or history of clinically significant gastrointestinal (GI) disease (including but not limited to inflammatory GI disease \[eg, ulcerative colitis, Crohn's disease, inflammatory bowel disease\], immune-mediated colitis, peptic ulcer disease, GI bleeding, chronic diarrhea) and other conditions that are unresolved and/or may increase the risk associated with study participation or study treatment administration. * Active bleeding disorder, including GI bleeding, as evidenced by hematemesis, significant hemoptysis or melena in the past 6 months. * Major surgery or completion of radiation therapy ≤4 weeks prior to enrollment/randomization or radiation therapy that included \>30% of the bone marrow. * Known sensitivity or contraindication to any component of study intervention (PF-07985045, gemcitabine, nab-paclitaxel, cetuximab, bevacizumab, FOLFOX, 5-FU, pembrolizumab, sasanlimab, cisplatin, carboplatin, pemetrexed, SHP2 inhibitor(s). * Hematologic abnormalities. * Renal impairment. * Hepatic abnormalities."
NCT05896189,Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial,,NA,Puerto Rico,"Cancer Center-Metro Medical Center Bayamon, Bayamón, Puerto Rico, [RECRUITING] | Puerto Rico Hematology Oncology Group, Bayamón, Puerto Rico, [RECRUITING] | Doctors Cancer Center, Manatí, Puerto Rico, [RECRUITING] | San Juan Community Oncology Group, San Juan, Puerto Rico, [RECRUITING] | Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico, [RECRUITING] | PROncology, San Juan, Puerto Rico, [RECRUITING] | San Juan City Hospital, San Juan, Puerto Rico, [RECRUITING]",Breast Cancer | Cognitive Impairments,2,"[1] Arm 1: Computerized Cognitive Training-Global Stimulation Games (ACTIVE_COMPARATOR): The global stimulation games active attention control intervention is composed of computerized games. These games are fully developed and are rated E (for everyone) by the Entertainment Software Ra... || [2] Arm 2: Computerized Cognitive Training-Neuroplasticity Games (EXPERIMENTAL): The neuroplasticity games provide core elements necessary for inducing neuroplasticity. The five core elements include the principles of speed of processing, accuracy of processing, adaptivity, gen...","* The participant must provide study-specific informed consent prior to any study specific procedures and authorization permitting release of personal health information. * The participant must have a first time diagnosis of non-metastatic breast cancer which is Stage I-III. * The participant must have a score of less than 12 on the PROMIS Adult v2.0 - Cognitive Function 4a. * Participants must be at least 6 months and no more than 5 years (after completion of initial surgery +/- adjuvant chemotherapy/radiation therapy) and targeted therapies (e.g., PARP inhibitors, CDK4/6, or immunotherapy). Participants may still be taking endocrine therapy and/or trastuzumab. * The participant must be able to understand, speak, read, and write in English or Spanish.","* Scoring less than or equal to 3 on the 6-item cognitive screen. * Patient Health Questionnaire-2 item (PHQ-2) score of greater than or equal to 3. * Definitive clinical or radiologic evidence of metastatic disease. * Current or past history of another cancer. Patients with history of only non-melanoma skin cancer or in situ cervical cancer without chemotherapy treatment would be eligible. * Previous exposure to chemotherapy treatment for another cancer or due to other medical condition (e.g. methotrexate exposure for treatment of rheumatoid arthritis). * Previous central nervous system (CNS) radiation, intrathecal therapy or CNS-involved surgery. * Participants with history of stroke, traumatic brain injury, brain surgery, Alzheimer's disease or other dementia. * Participants with active substance abuse and/or in treatment for substance abuse, or history of bipolar disorder, psychosis, schizophrenia, ADHD, or learning disability. * Participants who are enrolled in an active behavioral intervention (e.g., occupational therapy, physical therapy, etc.) or pharmaceutical intervention or who are in the follow-up phase of a cancer control trial or therapeutic trial that has extensive PRO follow-up after treatment ends. Participants who are enrolled in a therapeutic trial in which they have completed active treatment and require only minimal follow-up monitoring of toxicity and/or survival analysis (cancer-related mortality or all-cause mortality) would be eligible. * Hearing impairment unless adequately corrected with hearing aids to be able to hear over the phone for the neuropsychological testing."
NCT06624059,"A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients With Resectable Stage I-III Non-Small Cell Lung Cancer, Selected According to Biomarker Status",HORIZON 2,PHASE3,"Brazil, Chile, Mexico","Universidade de Caxias do Sul - Rio Grande do Sul, Caxias do Sul, Brazil, [RECRUITING] | Hospital Sao Lucas - PUCRS, Porto Alegre, Brazil, [RECRUITING] | Hospital de Clínicas de Porto Alegre X, Porto Alegre, Brazil, [RECRUITING] | Hospital de Cancer de Barretos, Barretos, Brazil, [RECRUITING] | Hospital de Base de Sao Jose do Rio Preto, São José do Rio Preto, Brazil, [RECRUITING] | Instituto do Cancer do Estado de Sao Paulo - ICESP, São Paulo, Brazil, [RECRUITING] | K2 Oncology, Providencia, Chile, [RECRUITING] | RedSalud Vitacura, Santiago, Chile, [RECRUITING] | Centro Oncologico Internacional, Mexico City, Mexico, [RECRUITING] | ARKE Estudios Clínicos S.A. de C.V., Mexico City, Mexico, [RECRUITING]",Non-Small Cell Lung Cancer,2,"[1] Cohort B1 (EXPERIMENTAL): Participants will receive alectinib in combination with platinum-based chemotherapy for up to 4 cycles (cycle length = 3 weeks), followed by alectinib monotherapy for up to 5 years. || [2] Cohort B2 (EXPERIMENTAL): Participants will receive alectinib and platinum-based chemotherapy for up to 3 cycles (cycle length = 3 weeks) prior to surgery, and alectinib monotherapy after surgery for up to 5 years after sur...",* Complete resection of the primary NSCLC with negative margins * Confirmed stage II to select stage IIIB (T3N2) NSCLC of non-squamous (adenocarcinoma) histology * Eastern cooperative oncology group (ECOG) performance status of 0 or 1 * Evaluation by the operating attending surgeon and involved medical oncologist prior to study enrollment to verify study eligibility for complete surgical resection with curative intent * Pathologically and/or histologically confirmed Stage II-IIIA and IIIB (T3N2 only) NSCLC of non-squamous (adenocarcinoma) histology * Documented ALK fusion,"* NSCLC of squamous or mixed histology regardless of the presence of an ALK mutation * Prior exposure to any systemic anti-cancer therapy * NSCLC of squamous or mixed histology regardless of the presence of an ALK mutation * Known sensitivity to any component of alectinib, pemetrexed, cisplatin, or carboplatin * Prior exposure to any systemic anti-cancer therapy * Pregnancy or breastfeeding, or intention of becoming pregnant during the study"
NCT06615479,"A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma",,PHASE3,"Argentina, Brazil","Hospital Italiano de Buenos Aires, ABB, Argentina, [RECRUITING] | Local Institution - 0214, ABB, Argentina, [WITHDRAWN] | Hospital Aleman, Buenos Aires, Argentina, [RECRUITING] | Local Institution - 0012, Nova Lima, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0013, São Paulo, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0103, São Paulo, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0031, São Paulo, Brazil, [NOT_YET_RECRUITING]",Relapsed or Refractory Multiple Myeloma (RRMM),2,[1] Arm A (EXPERIMENTAL): No description || [2] Arm B (ACTIVE_COMPARATOR): No description,"* Participants must have relapsed or refractory multiple myeloma (RRMM). * Participants must have received at least 1 but no greater than 3 prior multiple myeloma (MM) regimens which may include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody and have prior exposure to lenalidomide. * Participants must have a documented diagnosis of MM as per International Myeloma Working Group Criteria. * Participants must have measurable disease during screening. * Participants must have adequate organ function. * Participants must have an Eastern Cooperative Oncology group performance status 0 or 1.",* Participants must not have known active or history of central nervous system (CNS) involvement of Multiple Myeloma (MM). * Participants must not have solitary plasmacytomas or non-secretory myeloma without other evidence of measurable disease. * Participants must not need urgent treatment due to rapidly progressing MM. * Other protocol-defined Inclusion/Exclusion criteria apply.
NCT03340506,"Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study",,PHASE4,Argentina,"Novartis Investigative Site, Buenos Aires, Argentina, [COMPLETED]",Melanoma | Non Small Cell Lung Cancer | Solid Tumor | Rare Cancers | High Grade Glioma,3,"[1] dabrafenib monotherapy (EXPERIMENTAL): Patients in this study may receive:

\- monotherapy of dabrafenib || [2] trametinib monotherapy (EXPERIMENTAL): Patients in this study may receive:

\- monotherapy of trametinib || [3] Combination therapy (dabrafenib & trametinib) (EXPERIMENTAL): Patients in this study may receive:

\- the combination of dabrafenib and trametinib",* Patient is currently receiving treatment with dabrafenib/trametinib monotherapy or combination within a Novartis or former GSK sponsored study which has fulfilled the requirements for the primary objective. * In the opinion of the Investigator would benefit from continued treatment.,* Patient has been previously permanently discontinued from study treatment in the parent protocol. * Patient's indication is commercially available and reimbursed in the local country. * Patient currently has unresolved toxicities for which dabrafenib and/or trametinib dosing has been interrupted in the parent study.
NCT03785249,A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1,,"PHASE1, PHASE2",Puerto Rico,"PanOncology Trials - Rio Piedras Medical Center, San Juan, Puerto Rico, [RECRUITING]",Advanced Cancer | Metastatic Cancer | Malignant Neoplastic Disease,9,"[1] Phase 1 Dose Exploration (EXPERIMENTAL): Dose escalation of MRTX849 to determine maximum tolerated dose || [2] Phase 1b Expansion (EXPERIMENTAL): Expansion cohort to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 to recommend Phase 2 regimens || [3] Phase 2 (EXPERIMENTAL): Separate cohorts of patients stratified by histological diagnosis, prior treatment history or co-mutation status (e.g., STK11) for evaluation of clinical activity of MRTX849 || [4] Pilot Phase 1b Combination with Pembrolizumab (EXPERIMENTAL): Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with pembrolizumab in patients with NSCLC || [5] Pilot Phase 1b Combination with Cetuximab (EXPERIMENTAL): Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with cetuximab in patients with CRC || [6] Pilot Phase 1b Combination with Afatinib (EXPERIMENTAL): Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with afatinib in patients with NSCLC || [7] Phase 2 Combination with Cetuximab (EXPERIMENTAL): Phase 2 evaluation of the clinical activity of MRTX849 in combination with cetuximab in patients with CRC || [8] Pilot Phase 1b Combination with Cetuximab in NSCLC (EXPERIMENTAL): Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with cetuximab in patients with NSCLC || [9] Pilot Phase 1b Combination with Cetuximab in PDAC (EXPERIMENTAL): Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with cetuximab in patients with pancreatic adenocarcinoma (PDAC)",* Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation * Unresectable or metastatic disease * Standard treatment is not available or patient declines; first-line treatment for NSCLC for certain cohorts * Adequate organ function,* History of intestinal disease or major gastric surgery or inability to swallow oral medications * Other active cancer
NCT06112314,"A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301",PRISM-MEL-301,PHASE3,"Argentina, Brazil","Sanatorio Finochietto, Caba, Argentina, [RECRUITING] | Clínica Adventista Belgrano - Sector Investigación, Caba, Argentina, [RECRUITING] | Instituto Alexander Fleming, CABA, Argentina, [RECRUITING] | CEMAIC (Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica, Córdoba, Argentina, [RECRUITING] | Clinica Viedma, Viedma, Argentina, [RECRUITING] | Centro de Pesquisa Clinica em Oncologia - Oncosite, Ijuí, Brazil, [RECRUITING] | Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa Ltda, Porto Alegre, Brazil, [RECRUITING] | Fundacao Pio XII - Hospital de Cancer de Barretos - Hospital de Amor, Barretos, Brazil, [RECRUITING] | Hospital Sirio-Libanes (HSL) - Centro de Oncologia - Brasilia, Brasília, Brazil, [RECRUITING] | Centro de Pesquisas Oncologicas (CEPON), Florianópolis, Brazil, [RECRUITING]",Advanced Melanoma,3,"[1] Arm A: Brenetafusp Low Dose + Nivolumab (EXPERIMENTAL): Participants receive brenetafusp Low Dose once weekly (QW) for the first 13 weeks, then every 2 weeks (Q2W) through Week 51, and then every 4 weeks (Q4W). Nivolumab is given Q4W. || [2] Arm B: Brenetafusp High Dose + Nivolumab (EXPERIMENTAL): Participants receive brenetafusp High Dose once weekly (QW) for the first 13 weeks, then every 2 weeks (Q2W) through Week 51, and then every 4 weeks (Q4W). Nivolumab is given Q4W. || [3] Arm C: Nivolumab OR Nivolumab + Relatlimab (ACTIVE_COMPARATOR): Participants receive nivolumab 480 mg monotherapy, or nivolumab 480 mg + relatlimab 160 mg, Q4W.",* Participants must be HLA-A\*02:01-positive * Participants must have histologically confirmed Stage IV or unresectable Stage III melanoma * Archived or fresh tumor tissue sample that must be confirmed as adequate * Participants must have measurable disease per RECIST 1.1 * Participant must have BRAF V600 mutation status determined * Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 * Male and female participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control from the study screening date until 5 months after the final dose of study intervention,"* Participants with a history of a malignant disease other than those being treated in this study * Participants with untreated, active, or symptomatic central nervous system (CNS) metastases or carcinomatous meningitis * Hypersensitivity to IMC-F106C, nivolumab, relatlimab, or any associated excipients * Participants with clinically significant pulmonary disease or impaired lung function * Participants with clinically significant cardiac disease or impaired cardiac function * Participants with active autoimmune disease requiring immunosuppressive treatment * Participants with any medical condition that is poorly controlled or that would, in the Investigator's or Sponsor's judgment, adversely impact the participant's participation in the clinical study due to safety concerns, compliance with clinical study procedures, or interpretation of study results * Participants who received prior systemic anticancer therapy for unresectable or metastatic melanoma * Participants with a history of a life-threatening AE related to prior anti-PD-(L)1 or anti-LAG-3"
NCT05000697,Chemoradiation and Consolidation Chemotherapy With or Without Oxaliplatin for Distal Rectal Cancer and Watch and Wait. A Multi-center Prospective Randomized Controlled Trial. (CCHOWW),CCHOWW,NA,"Argentina, Brazil, Uruguay","Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, [RECRUITING] | Hospital Ramos Mejia: Hospital General de Agudos Dr. Jose Maria Ramos Mejia, Buenos Aires, Argentina, [RECRUITING] | Hospital de Gastroenterologia Udaondo Ciudad de Buenos Aires, Buenos Aires, Argentina, [RECRUITING] | Hospital Britanico de Buenos Aires - Asociacion Civil, Buenos Aires, Argentina, [RECRUITING] | Hospital Curruca: Superintendencia de Bienestar Policia Federal Argentina, Buenos Aires, Argentina, [RECRUITING] | Hospital Alemão Oswaldo Cruz, São Paulo, Brazil, [RECRUITING] | Hospital Felicio Rocho, Belo Horizonte, Brazil, [RECRUITING] | Hospital das Clínicas da Faculdade de Medicina de Botucatu, Botucatu, Brazil, [RECRUITING] | Complexo de Saude São João de Deus - Divinopolis, Divinópolis, Brazil, [RECRUITING] | Hospital das Clinicas de Passo Fundo, Passo Fundo, Brazil, [RECRUITING]",Rectal Cancer | Consolidation,2,"[1] Arm 1 - 5FU + Oxaliplatin (EXPERIMENTAL): 1\) RT (54Gy) plus daily concomitant capecitabine 825mg/m2 bid, followed by mFOLFOX6 or XELOX for 4 cycles (12 weeks), starting 1 week after radiotherapy ended; || [2] Arm 2 - 5FU Only (ACTIVE_COMPARATOR): 2\) RT (54Gy) plus daily concomitant capecitabine 825mg/m2 bid, followed by capecitabine 2000mg/m2/day for 14 days in a 21 days cycle for 4 cycles (12 weeks), starting 1 week after radiotherapy ended;","1. Age ≥18 years; 2. ECOG 0-2 or KPS≥70; 3. Primary rectal adenocarcinoma (biopsy confirmed) within the reach of digital rectal examination (at least lower tip/border) by the attending colorectal surgeon; 4. Endoscopic documentation; 5. Abdominal and chest CT scans showing no evidence of metastatic disease; 6. High-resolution magnetic resonance images performed at either 1.5T or 3.0T system using a phased array surface coil with: sagittal T2 images including the anal verge and the sacrum; axial oblique T2 weighted images acquired in a plane perpendicular to the long axis of the rectal wall guided by the sagittal images; coronal images acquired in parallel to the anal canal plane. Small field of view (16-18cm), 3mm section thickness, increased matrix size and increased number of signal averages are required; 7. Radiological defining criteria (centralized): 1. Lower edge of tumor at the level (max. 1cm distance) or below the anorectal ring defined at sagittal or coronal views; 2. mrT2, mrT3 (any subclassification) 3. mrN0-1 (≤3 radiologically positive lymph nodes) 4. mrEMVI: any status 5. mrMRF: any status",1. Pregnancy 2. ECOG ≥3 or KPS\<70 3. Unwilling to consent 4. Metastatic disease (any kind; internal iliac and obturator nodes are considered local disease and not metastatic disease and therefore will not be considered as exclusion criteria) 5. mrT4 or mrN2 6. Previous pelvic irradiation 7. Baseline neuropathy 8. Receiving treatment of other anti-cancer drug or methods 9. Presence of uncontrolled life threatening diseases
NCT06644768,"A Multicenter, Randomized, Open-Label, Phase 1b/2 Trial Of Valemetostat Tosylate Plus Pembrolizumab Vs Pembrolizumab Alone in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 With Tumor Proportion Score ≥50% Without Actionable Genomic Alterations",,"PHASE1, PHASE2","Argentina, Brazil","Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, [RECRUITING] | Instituto Alexander Fleming, Buenos Aires, Argentina, [RECRUITING] | Sanatorio Allende, Córdoba, Argentina, [NOT_YET_RECRUITING] | Fundacion Ars Medica, N Salvador de Jujuy, Argentina, [NOT_YET_RECRUITING] | Centro de Investigacion Pergamino Sa, Pergamino, Argentina, [NOT_YET_RECRUITING] | Instituto Medico de La Fundacion Estudios Clinicos, Rosario, Argentina, [NOT_YET_RECRUITING] | Clinica Viedma S.A., Viedma, Argentina, [RECRUITING] | Centro de Pesquisas Clinica Reichow, Blumenau, Brazil, [RECRUITING] | Clínica de Neoplasias Litoral Ltda., ItajaĂ-, Brazil, [NOT_YET_RECRUITING] | CINPAM Centro Integrado De Pesquisa Da Amazonia, Manaus, Brazil, [RECRUITING]",Non-small Cell Lung Cancer | Lung Cancer,3,"[1] Phase 1b: Pembrolizumab + Valemetostat Tosylate (EXPERIMENTAL): Participants will be provided with pembrolizumab at standard dose of 200 mg intravenously (IV) Q3W, and valemetostat will be provided per a dose escalation schedule, with an initial starting dose o... || [2] Phase 2: Pembrolizumab + Valemetostat Tosylate (EXPERIMENTAL): Participants will be provided with pembrolizumab at standard dose of 200 mg IV Q3W, and valemetostat will be provided per recommended phase 2 dose (RP2D) || [3] Phase 2: Pembrolizumab (ACTIVE_COMPARATOR): Participants will be provided with pembrolizumab at standard dose of 200 mg IV Q3W","1. Has signed and dated the ICF, prior to the start of any trial-specific qualification procedures. 2. Is an adult ≥18 years of age or the minimum legal age (whichever is greater) at the time of informed consent. (Follow local regulatory requirements if the legal age of adult voluntary consent for trial participation is \>18 years old). 3. Has histologically documented NSCLC that meets all of the following criteria: 1. Has no prior systemic therapy for advanced or metastatic disease. 2. Has Stage IIIB or IIIC disease and is not a candidate for surgical resection or definitive chemoradiation, or Stage IV NSCLC disease at the time of enrollment/randomization (based on the American Joint Committee on Cancer, Eighth Edition). Participants with early-stage NSCLC who have relapsed should be restaged during Screening to ensure their eligibility for the trial. 3. Has documented negative test results for EGFR, ALK, and ROS1 actionable genomic alterations based on analysis of tumor tissue. If test results for EGFR, ALK, and ROS1 are not available, participants are required to undergo testing performed locally for these genomic alterations. Participants with squamous NSCLC are only required to undergo EGFR, ALK, and ROS1 testing if they have no history of tobacco smoking or were diagnosed with NSCLC at \<40 years of age. 4. Has no known actionable genomic alterations in NTRK, BRAF, RET, MET, or other actionable oncogenic drivers with locally approved therapies (testing for genomic alterations besides EGFR, ALK, and ROS1 is not required prior to enrollment/randomization). Participants whose tumors harbor KRAS mutations are eligible for the trial. 4. Has measurable disease on CT or MRI based on local imaging assessment using RECIST v1.1 5. Has a tumor expressing PD-L1 TPS ≥50% as determined by local testing using 22C3 pharmDx PD-L1 IHC assay. In regions where PD-L1 (TPS ≥50%) testing by 22C3 pharmDx is not considered SOC, PD-L1 expression levels will be determined by central tes","1. Has received prior treatment with any of the following, including in the adjuvant/neoadjuvant setting: 1. Any anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX40, or CD137). 2. Has previously been treated with any enhancer of zeste homolog inhibitors. 2. Participants who received adjuvant or neoadjuvant therapy other than those listed in the exclusion criterion above are eligible if the adjuvant/neoadjuvant therapy was completed at least 6 months prior to the current diagnosis of advanced or metastatic disease. 3. Has received a live vaccine or live attenuated vaccine within 30 days prior to the first dose of trial intervention. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid vaccines. Note: Administration of killed vaccines is allowed. 4. Has an active, known, or suspected autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of systemic disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed. Inhaled, intranasal, intraocular, intra-articular, or topical steroids and adrenal replacement steroids are permitted in the absence of active autoimmune disease. 5. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (at doses exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial intervention. Note: Short-course systemic corticosteroids (eg, prevention of/treatment for transfusion reaction) or steroid use for a noncancer indication (eg, adrenal replacement) is permissible. 6. Has a kn"
NCT05929768,"Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study",,PHASE3,Puerto Rico,"Cancer Center-Metro Medical Center Bayamon, Bayamón, Puerto Rico, [RECRUITING] | Doctors Cancer Center, Manatí, Puerto Rico, [RECRUITING] | San Juan Community Oncology Group, San Juan, Puerto Rico, [RECRUITING] | Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico, [RECRUITING] | PROncology, San Juan, Puerto Rico, [RECRUITING] | San Juan City Hospital, San Juan, Puerto Rico, [RECRUITING]",Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Early Stage Triple-Negative Breast Carcinoma,2,"[1] Arm I (usual chemo-immunotherapy) (ACTIVE_COMPARATOR): Patients receive paclitaxel IV, carboplatin IV, and pembrolizumab IV on study. Patients then receive doxorubicin IV, cyclophosphamide IV, and pembrolizumab IV on study. Patients then undergo surger... || [2] Arm II (shorter chemo-immunotherapy) (EXPERIMENTAL): Patients receive docetaxel IV, carboplatin IV, and pembrolizumab IV on study. Patients then undergo surgery. Patients may receive pembrolizumab after surgery. Patients may optionally undergo collec...","* Participants must have histologically confirmed estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative breast cancer (TNBC) defined as ER \< 5%, PR \< 5%, and HER2 negative (per 2020 American Society of Clinical Oncology \[ASCO\] College of American Pathologists \[CAP\] guidelines) * NOTE: Participants with weakly ER or PR positive disease, defined as ER and/or PR between 1-4% by immunohistochemistry, are eligible if adjuvant endocrine therapy is not recommended/planned by the treating physician * Participants must have American Joint Committee on Cancer (AJCC) 8 anatomic tumor clinical stage either * T2-T4, N0, M0 or * T1-T3, N1-2, M0 * Note: All participants with clinically suspicious nodes must undergo core needle biopsy or fine needle biopsy per standard clinical practice to pathologically confirm nodal status * Participants must have breast and axillary imaging with mammogram and/or ultrasound and/or magnetic resonance imaging (MRI) within 49 days prior to randomization * Note: Participants with bilateral invasive breast cancer are eligible if both breast cancers are ER-negative, PR-negative, and HER2-negative provided they meet the other eligibility criteria * Participants must not have T4/N+, any N3, or inflammatory breast cancer * Participants must not have metastatic disease (M1) * Participants must not have received prior systemic therapy or radiation therapy with curative intent for the current breast cancer * Participants must not have had previous definitive ipsilateral breast surgery for the current breast cancer * Participants must not have current or anticipated use of other investigational agents while participating in this study * Participants must not have history of allergic reactions attributed to compounds of similar chemical or biologic composition as study agents * Participants must not have severe hypersensitivity (\>= grade 3) to pembrolizumab or any of its excipients * Participants must not have received ",
NCT06319820,"A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations",MoonRISe-1,PHASE3,"Argentina, Brazil","Hospital Sirio Libanes, Buenos Aires, Argentina, [RECRUITING] | Investigaciones Clinico Moleculares (ICM), CABA, Argentina, [RECRUITING] | Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica, Córdoba, Argentina, [RECRUITING] | Centro Urologico Profesor Bengio, Córdoba, Argentina, [RECRUITING] | Hospital Privado de la Comunidad, Mar del Plata, Argentina, [RECRUITING] | Sanatorio de la Mujer, Rosario, Argentina, [RECRUITING] | Fundacao Pio XII, Barretos, Brazil, [RECRUITING] | Universidade Estadual De Campinas, Campinas, Brazil, [RECRUITING] | Liga Norte Riograndense Contra O Cancer, Natal, Brazil, [RECRUITING] | Associacao Hospitalar Moinhos de Vento, Porto Alegre, Brazil, [RECRUITING]",Non-Muscle Invasive Bladder Cancer,2,[1] Group A: TAR-210 (EXPERIMENTAL): Participants in Group A will have TAR-210 inserted in the bladder on Day 1 and removed after 12 weeks. One TAR-210 will be inserted every 12 weeks over a treatment period of approximately 1 year. || [2] Group B: MMC or Gemcitabine (ACTIVE_COMPARATOR): Participants in Group B will receive intravesical mitomycin C (MMC) or gemcitabine (investigator's choice) once weekly for 4 to 6 induction doses followed by a maintenance phase for a minimum of 6 ...,"* Have a histologically confirmed diagnosis (within 90 days of randomization) of IR-NMIBC with at least one of the following criteria fulfilled: a. Ta low grade (LG)/ Grade 1 (G1): primary or recurrent, b. Ta LG/G2: primary or recurrent and c. Greater than or equal to (\>=) 1 of the following risk factors: i. Multiple Ta LG tumors, ii. Solitary LG tumor \>= 3 cm, iii. Early recurrence (less than \[\<\] 1 year), iv. Frequent recurrence (greater than \[\>\] 1 per year), v. Recurrence after prior adjuvant intravesical treatment (single perioperative dose of chemotherapy does not fulfill this risk factor) * Have a susceptible fibroblast growth factor receptor (FGFR) mutation or fusion either by urine testing or tumor tissue testing (from TURBT tissue), as determined by central or local testing * Participants must be willing to undergo all study procedures (e.g., multiple cystoscopies from Screening through the end of study and TURBT for assessment of recurrence/progression) and receive the assigned treatment, including intravesical chemotherapy if randomized into that arm. * Visible papillary disease must be fully resected prior to randomization and absence of disease must be documented at Screening cystoscopy * Can have a prior or concurrent second malignancy (other than the disease under study) which natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment * Have an Eastern Cooperative Oncology Group performance status of 0 to 2","* Known allergies, hypersensitivity, or intolerance to any study component or its excipients, including: a. Erdafitinib excipients; b.TAR-210 drug delivery system constituent materials ; c. urinary placement catheter materials; d. MMC or chemically related drugs; e. Gemcitabine or chemically related drugs * Presence of any bladder or urethral anatomic feature (that is, urethral stricture) that, in the opinion of the investigator, may prevent the safe insertion, indwelling use, removal of TAR-210 or passage of a urethral catheter for intravesical chemotherapy * Polyuria with recorded 24-hour urine volumes \> 4000 milliliters (mL) * Current indwelling urinary catheters, however, intermittent catheterization is acceptable * Had major surgery or had significant traumatic injury and/or not fully recovered within 4 weeks before first dose (TURBT is not considered major surgery)"
NCT05939414,"An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease Recurrence in Adult Male Patients With Prostate-specific Membrane Antigen (PSMA) Positive Oligometastatic Prostate Cancer (OMPC)",PSMA-DC,PHASE3,"Argentina, Brazil, Puerto Rico","Novartis Investigative Site, CABA, Argentina, [RECRUITING] | Novartis Investigative Site, Caba, Argentina, [RECRUITING] | Novartis Investigative Site, São Paulo, Brazil, [RECRUITING] | VA Caribbean Healthcare System, San Juan, Puerto Rico, [RECRUITING]",Oligometastatic Prostate Cancer (OMPC),2,[1] Investigational Arm: lutetium (177Lu) vipivotide tetraxetan (AAA617) (EXPERIMENTAL): All participants will be treated with Stereotactic Body Radiation Therapy (SBRT) to all metastatic lesions followed by a dose of 7.4 GBq (200 mCi) +/- 10% of AAA617 which will be administered once ... || [2] Control arm: observation (watchful waiting) (NO_INTERVENTION): All participants will be treated with Stereotactic Body Radiation Therapy (SBRT) to all metastatic lesions followed by observation only.,"1. Histologically confirmed prostate cancer prior to randomization 2. Participants must have biochemically recurrent disease after definitive treatment to prostate by Radical Prostatectomy ((RP), (alone or with post-operative radiation to prostate bed/pelvic nodes)) or External beam Radiation Therapy (EBRT), (prostate alone or prostate with seminal vesicle and/or pelvic nodes) and/or brachytherapy prior to randomization. Biochemical recurrence (BCR) is defined as: nadir PSA + 2 ng/mL post XRT (if participant received-radiation therapy to intact prostate) and PSA \> 0.2 ng/mL and rising post RP (with or without post-operation Radiation Therapy (RT)) 3. Participants must have OMPC with 1-5 PSMA -positive metastatic lesions on screening PSMA PET/CT scan (with either gallium (68Ga) gozetotide or piflufolastat (18F)) as visually assessed by BIRC. For definition of PSMA PET positivity, please refer to Section 8.1 and the Imaging Manual. Metastatic lesions may include regional/pelvic lymph nodes (N1), distant lymph nodes (M1a), bone (M1b), lung and others visceral (M1c) except liver and brain classified using American Joint Committee on Cancer (AJCC) 8. When counting the number of oligometastatic lesions, each lesion is counted as distinct metastasis irrespective of its anatomical location (e.g., one pelvic and one extra-pelvic lymph node will be counted as two metastatic lesions) 4. At least 1 PSMA-positive lesion must be a distant metastasis (M1) per AJCC8 classification at screening. For AJCC M staging, PSMA PET/CT information should be used 5. Participants must have a negative CI for M1 disease at screening. Note: * For a participant not to be eligible, CI positive M1 lesions should be unequivocal in CI scans, i.e., potentially not attributable to findings thought to represent something other than tumor (e.g., degenerative, or post-traumatic changes or Paget's disease in bone lesions). For CI assessments, bone lesions must be assessed by bone scan only and soft tissue ","1. Participants with de novo OMPC at screening 2. Unmanageable concurrent bladder outflow obstruction or urinary incontinence at screening. Note: participants with bladder outflow obstruction or urinary incontinence, which is manageable and controlled with best available standard of care (incl. pads, drainage) are allowed 3. Prior therapy with: 1. ADT (including bilateral orchiectomy) and ARPIs used for metastatic prostate cancer treatment * Participants who received AR-directed therapy, whether ADT or an ARPI or both, as neoadjuvant or adjuvant therapy as a component of their primary therapy, are eligible provided that they discontinued therapy ≥12 months prior to randomization for ADT (i.e., 12 months after the last day of the last injection) or ≥3 months if ARPI was given as monotherapy. ARPI's as a term includes both contemporary androgen synthesis inhibitors (e.g., abiraterone, galeterone, and orteneronel), and receptor inhibitors (enzalutamide, apalutamide and darolutamide). * Patients who biochemically relapsed after primary therapy may also have had treatment with AR directed therapy and participants who had SBRT with ADT are also eligible provided that the ARPI +/- ADT or ADT alone was terminated ≥12 months prior to randomization for ADT (i.e., 12 months after the last day of the last injection) or ≥3 months if ARPI was given as monotherapy. * Participants who received first generation anti-androgens (bicalutamide, flutamide, nilutamide, cyproterone) for biochemical recurrence or adjuvant/neoadjuvant therapy are eligible provided that they discontinued therapy ≥3 months prior to randomization. * Participants who have discontinued ADT due to disease progression are not eligible (i.e., Castration-Resistant Prostate Cancer (CRPC) participants) 2. Other hormonal therapy. e.g., •Use of estrogens, 5-α reductase inhibitors (finasteride, dutasteride), other steroidogenesis inhibitors (aminoglutethimide) if used in the context of prostate cancer treatment. Same medi"
NCT03513614,Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS). A Multicenter Randomized Phase III Trial (OPBC-03/ SAKK 23/16 /IBCSG 57-18 / ABCSG-53 / GBG-101),TAXIS,NA,Argentina,"Sanatorio Parque Breast Cancer Center, Rosario, Argentina, [RECRUITING] | Institute of Oncology ""Angel H. Roffo, Buenos Aires, Argentina, [RECRUITING]",Node-positive Breast Cancer,2,[1] ALND (ACTIVE_COMPARATOR): Tailored axillary surgery followed by axillary lymph node dissection (ALND) and regional nodal irradiation excluding the dissected axilla. || [2] No ALND (ACTIVE_COMPARATOR): Tailored axillary surgery followed by regional nodal irradiation including the full axilla.,"Inclusion criteria at pre-registration: * Written informed consent according to ICH/GCP regulations prior to any trial specific procedures. * Breast cancer, node positive detected by palpation or imaging (with or without planned neoadjuvant treatment) * Female or male aged ≥ 18 years * Ability to complete the Quality of Life questionnaires Inclusion criteria at registration: * Node-positive breast cancer (histologically or cytologically proven both in primary tumor and in lymph node) AJCC/UICC \[42\] stage II-III (all molecular subtypes allowed): * Node-positivity detected by imaging (iN+) and confirmed by pathology * Node-positivity detected by palpation (cN1-3) and confirmed by pathology * Occult breast cancer is allowed, if biopsy-proven axillary lymphatic metastasis is present * Eligible for primary ALND or sentinel lymph node (SLN) procedure with frozen section and either: * Newly diagnosed * Isolated in-breast recurrence or second ipsilateral breast cancer after previous breast conserving surgery and sentinel procedure and at least 3 years disease free and no prior axillary dissection or axillary RT * Most suspicious axillary lymph node clipped * Baseline Quality of Life questionnaire has been completed * WHO performance status 0-2 * Adequate condition for general anesthesia and breast cancer surgery * Women with child-bearing potential are using effective contraception, are not pregnant or lactating and agree not to become pregnant during trial treatment and thereafter during the time recommended by the guidelines for adjuvant systemic therapies. A negative pregnancy test before inclusion into the trial is required for all women with child-bearing potential. * Men agree not to father a child during trial treatment and thereafter during 6 months. Inclusion criteria at randomization (intraoperatively) * Node-positive breast cancer (histologically or cytologically proven both in primary tumor and in lymph node) AJCC/UICC stage II-III (all molecular subtypes allo","Exclusion criteria at pre-registration: Any potential patient who meets any of the following criteria has to be excluded from entering the trial. * Stage IV breast cancer * Clinical N3c breast cancer (clinical N3a and clinical N3b are allowed) * Clinical N2b breast cancer (clinical N2a is allowed) * Contralateral breast cancer within 3 years Note: Contralateral Ductal Carcinoma In Situ (DCIS) is allowed if prior treatment does not interfere with or compromise the trial treatment * Prior axillary surgery (except prior sentinel node procedure in case of in- breast recurrence) * Prior regional radiotherapy * History of hematologic or primary solid tumor malignancy, unless in remission for at least 3 years from pre-registration with the exception of adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer. * Treatment with any experimental drug within 30 days of pre-registration * Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications. Exclusion criteria at randomization (intraoperatively): Any potential patient who meets any of the following criteria has to be excluded from the trial. * Absence of clip in the specimen radiography * Palpable disease left behind in the axilla after Tailored Axillary Surgery (TAS) * No SLN identified in the axilla"
NCT02386800,"Open Label, Multi-center, Phase IV Study of Ruxolitinib or Ruxolitinib and Panobinostat Combination, for Patients Who Have Completed Prior Global Novartis or Incyte Sponsored Studies",,PHASE4,"Chile, Mexico","Novartis Investigative Site, Viña del Mar, Chile, [COMPLETED] | Novartis Investigative Site, Santiago, Chile, [COMPLETED] | Novartis Investigative Site, Santiago, Chile, [COMPLETED] | Novartis Investigative Site, Monterrey, Mexico, [COMPLETED]",Primary Myelofibrosis | Polycythemia Vera | Graft Versus Host Disease | Acute Myeloid Leukemia | Thalassemia,1,"[1] Ruxolitinib monotherapy or ruxolitinib plus panobinostat in combination (EXPERIMENTAL): All participants will receive either ruxolitinib monotherapy or ruxolitinib in combination with panobinostat, at the same dose/schedule that they were taking in the parent study.","1. Patient is currently enrolled in a Novartis GDD or GMA-sponsored or Incyte-sponsored clinical study, are receiving either ruxolitinib or combination of ruxolitinib and panobinostat, and fulfilled all of the requirements of the parent protocol. 2. Patient is currently benefiting from the treatment with ruxolitinib monotherapy or combination of ruxolitinib and panobinostat, as determined by the investigator 3. Patient has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements 4. Patient currently has no evidence of progressive disease, as determined by the investigator, following previous treatment with ruxolitinib or combination of ruxolitinib and panobinostat Key","1. Patient has been permanently discontinued from study treatment in the parent study due to any reason. 2. Patient's indication is currently approved and reimbursed in the corresponding country for ruxolitinib monotherapy or combination of ruxolitinib and panobinostat. 3. Pregnant or nursing (lactating) women. 4. Female patients of childbearing potential (e.g. are menstruating) who do not agree to abstinence or, if sexually active, do not agree to the use of highly effective contraception, throughout the study and for up to 30 days after stopping study treatment. Other protocol-defined Inclusion / Exclusion criteria may apply."
NCT04993014,Circulating Tumor Cells and Adjuvant Treatment De-escalation After Neoadjuvant Therapy With Trastuzumab and Pertuzumab for HER2 Positive Early Breast Cancer,HER2Cell,PHASE2,Brazil,"A.C. Camargo Cancer Center, São Paulo, Brazil, [RECRUITING]",Breast Neoplasms | HER2-positive Breast Cancer | Circulating Tumor Cell,4,"[1] Cohort 1, Arm A - trastuzumab (ACTIVE_COMPARATOR): Adjuvant trastuzumab for patients with HER2 positive CTCs at baseline || [2] Cohort 1, Arm B - Trastuzumab + pertuzumab (EXPERIMENTAL): Adjuvant trastuzumab + pertuzumab for patients with HER2 positive CTCs at baseline || [3] Cohort 2, Arm A - trastuzumab (ACTIVE_COMPARATOR): Adjuvant trastuzumab for patients with HER2 negative/absent CTCs at baseline || [4] Cohort 2, Arm B - Trastuzumab + pertuzumab (EXPERIMENTAL): Adjuvant trastuzumab + pertuzumab for patients with HER2 negative/absent CTCs at baseline",* HER2 positive breast cancer (hormone receptors positive or negative) * Stage I to III * Indication for neoadjuvant therapy with chemo (any regimen) + trastuzumab + pertuzumab * Breast surgery after neoadjuvant therapy * Preserved coagnition * ECOG 0-3 * For the randomization phase: pathological complete response (ypT0/ypTis and ypN0) * Agreement on participation and signature of de ICF,"* Contradindication for trastuzumab or pertuzumab * Adjuvant chemotherapy. Hormone therapy is allowed * Second primary tumor \< 5 years, with an exception for treated non-melanoma skin cancer, and in situ cervical cancer"
NCT03101995,A Phase II Clinical Trial to Evaluate the Potential of Concomitant Chemoradiotherapy With Gemcitabine in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease,,PHASE2,Mexico,"National Institute of Cancer, Mexico City, Mexico, [RECRUITING]",Cervical Cancer,1,[1] Gemcitabine (EXPERIMENTAL): Gemcitabine doses: 300 mg/m2/week for 6 weeks.,"1. Patients who give their written consent to participate in the study. 2. Women, 18-70 years of age, considering the following criteria: • In women of childbearing age: i. Negative serum pregnancy test at baseline (14 days prior to the start of QT-RT). ii. The patient must accept the use of any contraceptive method approved by the attending physician during the study and 12 weeks after the end of treatment. • Postmenopausal women must meet at least one of the following parameters for eligibility: i. Prior bilateral oophorectomy ii. Age ≥ 60 years iii. Age \< 60 years, with amenorrhea for at least 12 months and levels of follicle stimulating hormone and estradiol within postmenopausal parameters. 3. Diagnosed with CC IB2-IVA, with or without retroperitoneal lymph nodes (para-aortic), smaller than 2 cm. 4. With histologic confirmation of squamous carcinoma, adenosquamous carcinoma, adenocarcinoma or glassy cells carcinoma. 5. Without previous treatment and medically able to receive gemcitabine. 6. Disease measurable by CT and/or MRI according to RECIST (v1.1) criteria. 7. Functional status of 0-3 according to WHO criteria. 8. Renal dysfunction defined by glomerular filtration (GF) \<60 ml/min/1.73m2 calculated by the CKD-EPI formula. 9. Normal hematologic and liver function, as defined by the following parameters: * Hemoglobin \> 10g/L. (Transfusion prior to the treatment is allowed to reach this level of hemoglobin). * Leucocytes \> 4000/mm3. * Platelets \> 100,000/mm3. * Total Bilirubin ≤1.5 times the upper normal limit (UNL). * Transaminases \< 1.5 times the UNL. 10. Normal PA chest radiograph.","1. Patients with prior or concomitant malignancy, except non-melanoma skin carcinoma. 2. Patients with diabetes and/or hypertension with retinopathy or albuminuria \>300. 3. Patients with evidence of active TB infection. 4. Patients infected with Human Immunodeficiency Virus (HIV). 5. Patients with a history of Systemic Lupus Erythematosus and other rheumatologic diseases that cause kidney damage. 6. Patients with vesicovaginal or vesicorectal fistula at the time of diagnosis. 7. Patients with uncontrolled intercurrent diseases including active infections that contraindicate QT, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, decompensated diabetes, difficult control hypertension and psychiatric illness. 8. Concomitant treatment with other experimental drugs. 9. Social, family or geographical conditions that suggest a poor adherence to the study. Study discontinuation criteria. 1. Evidence of disease progression, if the researcher considers that the patient would benefit more with other therapy. 2. At the request of the patient. 3. By unacceptable toxicity. 4. Pregnancy. Violation of starting criteria. Criteria must be followed punctually. If a patient were inappropriately included, she must be discontinued from the study."
NCT06611553,NCI Cervical Cancer 'Last Mile' Initiative 'Self-Collection for HPV Testing to Improve Cervical Cancer Prevention' (SHIP) Trial,,NA,Puerto Rico,"University of Puerto Rico, San Juan, Puerto Rico, [RECRUITING]",Cervical Carcinoma | Human Papillomavirus Infection,1,[1] Prevention (self-collected and clinician-collected samples) (EXPERIMENTAL): Patients undergo self-collection of a vaginal sample and then undergo clinician-collection of a cervical test sample. Patients then undergo standard of care colposcopy with or without biopsy/endoce...,"* Willingness and ability to provide a documented informed consent * Is 25 years or older * Has an intact cervix * Has had a referral for colposcopy and/or cervical excisional procedure in which routine cervical cancer screening has included HPV testing (HPV primary screening, co-testing, or atypical squamous cell of undetermined significance \[ASC-US\] cytology triage) or abnormal cytology performed within the past 12 months preceding the referral visit * Willing and able to undergo colposcopy, and if clinically indicated for standard of care (SOC) purposes, a biopsy, endocervical curettage, and/or a cervical excisional procedure, as applicable","* Is pregnant when presenting for the referral visit or gave birth within the past 3 months * Has a known history of excisional or ablative therapy to the cervix (e.g., loop electrosurgical excision procedure \[LEEP\], cone biopsy, cervical laser surgery, cryotherapy, thermal ablation) in the last 12 months prior to the referral visit * Has had a complete or partial hysterectomy, either supracervical or involving removal of the cervix, via self-report or confirmation via medical records * Known medical conditions that, in the opinion of the investigator, preclude study participation * Previous participation in the SHIP Trial. Participation is defined as completing the self-collection * Is experiencing unusual bleeding or pelvic pain"
NCT06497556,"A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer",Krascendo 1,PHASE3,"Argentina, Brazil, Mexico","Hospital Britanico, Buenos Aires, Argentina, [ACTIVE_NOT_RECRUITING] | Centro Oncologico Korben, Ciudad Autonoma Buenos Aires, Argentina, [ACTIVE_NOT_RECRUITING] | Clinica Adventista Belgrano, Ciudad Autonoma Buenos Aires, Argentina, [WITHDRAWN] | Sanatorio Parque S.A., Rosario, Argentina, [WITHDRAWN] | Hospital Sao Rafael - HSR, Salvador, Brazil, [ACTIVE_NOT_RECRUITING] | Hospital Brasilia, Brasília, Brazil, [WITHDRAWN] | Clinica Onconeo, Campo Grande, Brazil, [WITHDRAWN] | Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil, [WITHDRAWN] | Hospital Nossa Senhora da Conceicao, Porto Alegre, Brazil, [WITHDRAWN] | Hospital Mae de Deus, Porto Alegre, Brazil, [WITHDRAWN]",Non-Small Cell Lung Cancer | KRAS G12C Lung Cancer,2,"[1] Divarasib (EXPERIMENTAL): Participants will receive divarasib orally, once daily (QD). || [2] KRAS G12C inhibitor (ACTIVE_COMPARATOR): Participants will receive Sotorasib orally QD or adagrasib orally twice a day (BID)","* Unequivocal histologically or cytologically confirmed diagnosis of metastatic or locally advanced NSCLC not amenable to treatment with surgical resection or combined chemoradiation * Disease progression during or after treatment with at least one prior systemic therapy but no more than three lines of prior systemic therapy in the advanced or metastatic setting * Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 * Documentation of the presence of a KRAS G12C mutation * Availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen in a paraffin block (preferred) or 10-15 (15 preferred) unstained, freshly cut, serial slides with an associated pathology report * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Life expectancy of \>= 12 weeks","* Known hypersensitivity to any of the components of divarasib, or sotorasib or adagrasib * Malabsorption syndrome or other condition that would interfere with enteral absorption * Known concomitant second oncogenic driver * Mixed small-cell lung cancer or large cell neuroendocrine histology * Known and untreated, or active central nervous system (CNS) metastases * Leptomeningeal disease or carcinomatous meningitis * Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures biweekly or more frequently * Any infection that, in the opinion of the investigator, could impact patient safety, or treatment with therapeutic oral or IV antibiotics within 14 days prior to Day 1 of Cycle 1 * Prior treatment with any KRAS G12C inhibitor or pan-KRAS/RAS inhibitor * More than 30 Gy of radiotherapy to the lung within 6 months of randomization * Uncontrolled tumor-related pain * Unresolved toxicities from prior anticancer therapy * History of malignancy within 5 years prior to screening, with the exception of the cancer under investigation in this study and malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate \>90%), such as adequately treated carcinoma in situ of the cervix, nonmelanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer"
NCT06299462,"Efficacy Evaluation of Post-transplant Cyclophosphamide-based Graft-versus-host Disease Prophylaxis with ATG, Calcineurin Inhibitor-free, for Matched-sibling or Matched-unrelated Transplantation",,"PHASE1, PHASE2",Brazil,"Instituto Nacional de Cancer, Rio de Janeiro, Brazil, [RECRUITING]",Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndromes | Hodgkin Lymphoma | Non-hodgkin Lymphoma,2,[1] Matched-sibling donor transplants (EXPERIMENTAL): Matched sibling transplants will receive PTCy + ATG4.0 || [2] Matched unrelated donor transplants (EXPERIMENTAL): Unrelated transplants will receive PTCy + ATG5.0,"* Patient with (1) acute leukemia in first or second remission; (2) myelodysplasia with less than 20% blasts; (3) Hodgkin's or non-Hodgkin's lymphoma, in partial remission after salvage therapy * Who will receive a related or unrelated, HLA-compatible transplant; * Who is a transplant candidate with FluMel, FluTBI, CyTBI, BuCy or BuFlu conditioning; * Peripheral blood source; * Age between 18 and 60 years.",\- Hepatic dysfunction (transaminases x2 the normal value)
NCT06328751,Study With Cancer Patients at the CECON Foundation's Pain Therapy and Palliative Care Service: Meditation With Immersive Virtual Reality for Pain Relief,,NA,Brazil,"Fundação Centro de Controle de Oncologia do Estado do Amazonas - FCECON, Manaus, Brazil, [RECRUITING]",Cancer Pain | Quality of Life | Palliative Medicine,3,"[1] Case Group (EXPERIMENTAL): The case group will watch a 7-minute immersive virtual reality video of mindfulness meditation with image and sound in the office of the Oncology Control Center Foundation (FCECON), using Samsung® ... || [2] Active Control Group (ACTIVE_COMPARATOR): The active control group will watch a 7-minute mindfulness meditation video presented via cell phone with image and sound in the office of the Oncology Control Center Foundation (FCECON), using a S... || [3] Passive Control Group (ACTIVE_COMPARATOR): The passive control group will perform meditation breathing exercises based on instructions and through an audio played from the health professional for 4 minutes in the office of the Oncology Cont...","* Be followed up at the Pain Therapy and Palliative Care Service (STDCP) to control symptoms resulting from any type of cancer at any stage; * Have a diagnosis of chronic pain, recorded in the medical records. * Be between 18 and 75 years old on the date of the first collection; * Be able to understand Portuguese (read and write); * Have normal vision and hearing; * Have a cell phone with an Android system; * Be able to make head movements and have sufficient motor control to make body movements; * Agree to take part in the study and sign the Informed Consent Form (ICF).","* Indigenous patients (due to cultural and linguistic peculiarities and special legislation); * Patients with records of serious psychiatric illnesses (DSM-5 - Diagnostic and Statistical Manual of Mental Disorders - schizophrenia, schizotypal disorders, delusional disorders, borderline and dementias); * Impairment of the ability to understand or communicate based on the researcher's assessment; * Report of discomfort with the use of Immersive Virtual Reality; * Progression of the disease with limitation in maintaining the proposed regular outpatient visits; * Patients with brain tumors, brain metastases or a previous history of seizures."
NCT04530565,A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults,,PHASE3,Puerto Rico,"Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico, [RECRUITING] | San Juan City Hospital, San Juan, Puerto Rico, [RECRUITING]",B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1,5,"[1] Arm A (steroid, TKI), Single Arm Pre-Induction (ACTIVE_COMPARATOR): Patients receive prednisone PO QD on days 1-21 and ponatinib PO QD or dasatinib PO QD on days 1-21 based on investigator's choice. || [2] Arm B (steroid, TKI, chemotherapy) (EXPERIMENTAL): See Detailed Description. || [3] Arm C (steroid, TKI, chemotherapy, immunotherapy) (EXPERIMENTAL): CYCLE 1: Patients receive ponatinib PO QD or dasatinib PO QD on days 1-28. Patients also receive dexamethasone PO or IV on day 1 and blinatumomab IV continuously on days 1-28, followed by methotrex... || [4] Arm D (steroid, TKI, chemotherapy, immunotherapy) (EXPERIMENTAL): Patients treated on Arm B who remain MRD positive at the end of induction therapy receive blinatumomab based re-induction identical to the regimen described for Arm C.

Patients whose molecular tes... || [5] Arm E (steroid, TKI, chemotherapy) (EXPERIMENTAL): Patients treated on Arm C who remain MRD positive at the end of induction therapy receive chemotherapy based re-induction which is identical to regimen described for Arm B according to patient's ag...","* ELIGIBILITY CRITERIA FOR PRE-REGISTRATION (TO STEP 0) * Patient must be \>= 18 and =\< 75 years of age * Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status between 0-3 * Patient must be newly diagnosed with B acute lymphoblastic leukemia (B-ALL) or is suspected to have acute lymphoblastic leukemia (ALL) * Patient must have BCR-ABL1 positive disease. The diagnosis of ALL and the presence of BCR-ABL translocation must be confirmed centrally. Patients can be registered and begin step 1 therapy while awaiting central laboratory eligibility confirmation * NOTE: Bone marrow aspirate and/or peripheral blood specimen must be submitted to the ECOG-American College of Radiology Imaging Network (ACRIN) Leukemia Laboratory at MD Anderson Cancer Center to determine patient's eligibility for registration to Step 1 or confirm patient evaluability. Centrally fluorescence-activated cell sorting (FACS) analysis will be performed to determine B-ALL and to exclude acute myeloid leukemia (AML) or acute bi-phenotypic leukemia and baseline BCR-ABL status will be determined by fluorescent in situ hybridization (FISH). The ECOG-ACRIN Leukemia Laboratory will forward results within 48 hours of receipt of the specimen to the submitting institution. Bone marrow aspirate is to be from first pull (initial or re-direct). Specimens must contain sufficient blast cells. In cases where the bone marrow aspiration may be inadequate, or the bone marrow examination has already been performed prior to study consent and enrollment on Step 0, peripheral blood may be submitted, with recommendation that adequate circulating blasts are present (\> 10%). If a diagnosis of BCR-ABL positive B-ALL has already been established by local Clinical Laboratory Improvement Act (CLIA) certified laboratories, the patient may be registered to step 1 without waiting for central confirmation * Patient must not have a diagnosis of BCR/ABL T-ALL * Patient must not have received chemotherapy for ","* ELIGIBILITY CRITERIA FOR REGISTRATION TO STEP 1 * Patient must have a diagnosis of Philadelphia chromosome positive (Ph+) ALL that has been determined locally and bone marrow and/or peripheral blood was sent and receipt confirmed for central confirmation or determined centrally by the ECOG-ACRIN Leukemia Laboratory at MD Anderson Cancer Center * Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy. A patient of childbearing potential is defined as any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) * Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse from the time of step 1 registration, while on study treatment, and until at least six months after the last dose of study treatment * Total bilirubin =\< 3 mg/dL (patients with Gilbert's syndrome must have a total bilirubin =\< 5 mg/dL) (obtained =\< 28 days prior to step 1 registration) * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 X the institutional upper limit of normal (ULN) (obtained =\< 28 days prior to step 1 registration) * Estimated creatinine clearance \> 45 mL/min (based on Cockcroft-Gault equation) (obtain"
NCT03067181,A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors,,PHASE3,Puerto Rico,"HIMA San Pablo Oncologic Hospital, Caguas, Puerto Rico, [ACTIVE_NOT_RECRUITING] | San Jorge Children's Hospital, San Juan, Puerto Rico, [ACTIVE_NOT_RECRUITING]",Childhood Extracranial Germ Cell Tumor | Extragonadal Embryonal Carcinoma | Germ Cell Tumor | Malignant Germ Cell Tumor | Malignant Ovarian Teratoma,5,"[1] Arm I (bleomycin, carboplatin, etoposide) (EXPERIMENTAL): Patients receive bleomycin IV over 10 minutes and carboplatin IV over 1 hour on day 1. Patients also receive etoposide IV over 1-2 hours on days 1-5. Treatment repeats every 21 days for up to 4 cyc... || [2] Arm II (bleomycin, etoposide, cisplatin) (EXPERIMENTAL): Patients receive bleomycin IV over 10 minutes on day 1. Patients also receive etoposide IV over 1-2 hours and cisplatin IV over 1-3 hours on days 1-5. Treatment repeats every 21 days for up to 4 cy... || [3] Arm III (bleomycin, etoposide, carboplatin) (EXPERIMENTAL): Patients receive bleomycin IV over 10 minutes on days 1, 8, and 15, etoposide IV over 1-2 hours on days 1-5, and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for up to 3 cyc... || [4] Arm IV (bleomycin, etoposide, cisplatin) (EXPERIMENTAL): Patients receive bleomycin IV over 10 minutes on days 1, 8, and 15, etoposide IV over 1-2 hours on days 1-5, and cisplatin IV over 1-3 hours on days 1-5. Treatment repeats every 21 days for up to 3... || [5] Low-Risk (observation) (EXPERIMENTAL): Patients with low-risk stage I grade 2, 3 ovarian immature teratoma or stage I non-seminoma or seminoma MGCTs undergo observation and can transfer to standard risk arm when eligibility criteria are...","* There is no age limit for the low risk stratum (stage I ovarian immature teratoma and stage I non-seminoma or seminoma malignant GCT \[all sites\]) * Standard risk 1: Patients must be \< 11 years of age at enrollment * Standard risk 2: Patients must be \>= 11 and \< 25 years of age at enrollment * Patients enrolling on one of the low risk arms must be newly diagnosed with a stage I germ cell tumor; for the standard risk arms, patients must be newly diagnosed with malignant germ cell tumor (stage II or higher). * Histologic confirmation of a primary extracranial germ cell tumor in any of the categories outlined below is required of all patients at enrollment , with the following exceptions: * Among patients were initially diagnosed with completely resected non-seminoma malignant GCT and later recur during observation post surgery, a diagnostic biopsy is not required for enrollment if elevated tumor markers rise to \> 5 x upper limit of normal (ULN) on at least 2 measurements taken at least 1 week apart. The pathology report of initial surgery should be provided * Patients may be enrolled without histologic or cytologic confirmation in the rare case where there are exceptionally raised tumor markers (alpha fetoprotein \[AFP- ≥ 500 ng/mL or HCG ≥ 500 IU/L) and radiologic features consistent with GCT. In addition, the treating clinician must deem that the patient's tumor is not suitable for upfront resection and that a biopsy is not in the patient's best interest; or that there is a need to start therapy urgently * Low risk immature teratoma (IT); site: ovarian; stage: any; grade: any; histology: pure immature teratoma, mixed immature and mature teratoma, (may contain microscopic foci of yolk sac tumor \[\< 3 mm\], but no other pathological evidence of MGCT); tumor markers: alpha-FP =\< 1,000 ng/mL, beta-HCG institutional normal; all ages * Low risk stage I non-seminoma MGCT; site: ovarian, testicular, or extragonadal; stage: COG stage I, FIGO stage IA and IB, America","* Patients with any diagnoses not listed including: * Stage I testicular cancer patients who have undergone primary RPLND (retroperitoneal lymph node dissection) * Pure ovarian or extragonadal dysgerminoma/seminoma * Pure mature teratoma * Pure immature teratoma with alpha-fetoprotein (AFP) \>= 1000 ng/mL * ""Poor risk"" GCT (age \>= 11 years old and COG stage IV ovarian, COG stage II- IV extragonadal, or IGCCC intermediate or poor risk testicular), or * Primary central nervous system (CNS) germ cell tumor * Germ cell tumor with somatic malignant transformation * Spermatocytic seminoma * Patients must have had no prior systemic therapy for the current cancer diagnosis * Patients must have had no prior radiation therapy with the exception of CNS irradiation of brain metastases; (this exception only applies to SR1 patients; any patients over age 11 with distant metastases to brain \[stage IV disease\] would be considered poor risk and therefore not eligible for this trial) * Patients with significant, pre-existing co-morbid respiratory disease that contraindicate the use of bleomycin are ineligible for the standard risk arms of the trial * Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs; a pregnancy test is required for female patients of childbearing potential; (this criteria applies ONLY to patients who will receive chemotherapy \[SR1 and SR2 patients\]) * Lactating females who plan to breastfeed their infants; (this criteria applies ONLY to patients who will receive chemotherapy \[SR1 and SR2 patients\]) * Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation; (this criteria applies ONLY to patients who will receive chemotherapy \[SR1 and SR2 patients\])"
NCT05705401,A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO),HERO,PHASE3,Puerto Rico,"Cancer Center-Metro Medical Center Bayamon, Bayamón, Puerto Rico, [RECRUITING] | Doctors Cancer Center, Manatí, Puerto Rico, [RECRUITING] | San Juan Community Oncology Group, San Juan, Puerto Rico, [RECRUITING] | Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico, [RECRUITING] | San Juan City Hospital, San Juan, Puerto Rico, [RECRUITING]",HER2-positive Breast Cancer,2,[1] Standard of Care Adjuvant Breast Radiation (ACTIVE_COMPARATOR): Patients continue to receive their current planned adjuvant breast radiation and systemic HER2-targeted therapies || [2] Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation (ACTIVE_COMPARATOR): Patients continue to receive their current systemic HER2-targeted therapy without breast adjuvant radiation,"* The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the U.S., authorization permitting release of personal health information. * female and male patients who have undergone breast conserving surgery and completed a minimum of 4 cycles (12 weeks) of neoadjuvant or adjuvant chemotherapy in combination with HER2-targeted therapy. -≥ 40 years of age * ECOG performance status of 0 ,1, or 2/Karnofsky performance status above 60 * Histologically or cytologically confirmed invasive breast carcinoma. * tumor must have been determined to be HER2-positive by current ASCO/CAP guidelines based on local testing results. * Patient must have undergone axillary staging, either sentinel node biopsy (SNB) or axillary lymph nodal dissection (ALND). In neoadjuvant patients, SNB following neoadjuvant therapy is strongly recommended. SNB prior to neoadjuvant therapy is discouraged, but patients are permitted if node negative (pN0). * The following staging criteria must be met according to AJCC 8th edition criteria: Adjuvant cohort : By pathologic evaluation, the patient's primary tumor must be \</= 2 cm and ipsilateral nodes must be pN0. Surgical lumpectomy margins must be negative for invasive cancer and ductal carcinoma in situ (no ink on tumor). Neoadjuvant cohort: Prior to neoadjuvant therapy, the patient's primary tumor must be \< 3 cm by imaging studies, with negative axillary nodes (cN0) based on axillary U/S, CT, PET or MRI. Physical examination is not sufficient documentation of cN0 status; • Must be ypT0N0 at surgery (lumpectomy); patients with residual non-invasive disease (DCIS) in the surgical specimen (ypTis), are NOT eligible. * For the Adjuvant cohort, adjuvant therapy must have consisted of a minimum of 4 cycles (12 weeks) of chemotherapy in combination with HER2-targeted therapy. * For the Neoadjuvant cohort, neoadjuvant therapy must have consisted of a minimum of 4 cycles (12","* Definitive clinical or radiologic evidence of metastatic disease. * On the Adjuvant cohort, patients with a primary tumor \>2 cm on pathologic examination of the surgical specimen. On the Neoadjuvant cohort, patients with a primary tumor \> 3 cm or with abnormal or suspicious ipsilateral axillary nodes by pretreatment imaging, unless demonstrated to be negative by cytologic or histologic examination. * Pathologically positive axillary nodes at any time including of pN0(i+) or pN0(mol+) ypN0(i+) or ypN0(mol+) disease. * Patient planning for or status-post mastectomy. * Radiographically suspicious ipsilateral or contralateral axillary, supraclavicular, infraclavicular, or internal mammary lymph nodes, unless there is histological confirmation that these nodes are negative for metastatic disease. * Suspicious microcalcifications, densities, or palpable abnormalities (in the ipsilateral or contralateral breast), or mass or non-mass enhancement on MRI (if performed) aside from the known cancer, unless biopsied and found to be benign. * Non-epithelial breast malignancies such as sarcoma or lymphoma. * Multicentric carcinoma (invasive cancer or DCIS) in more than one quadrant or separated by \> 4 centimeters. If multifocal, all foci should be confined to a maximum tumor bed of 3 cm determined by pathological assessment. * Paget's disease of the nipple. * Synchronous (unilateral or bilateral) invasive breast cancer or DCIS. (Patients with synchronous and/or previous contralateral LCIS are eligible.) * On the Adjuvant cohort, surgical margins that cannot be microscopically assessed or are positive at pathologic evaluation. (If surgical margins are rendered free of disease by re-excision, the patient is eligible). * Treatment plan that includes regional nodal irradiation. * Patients treated for a prior invasive breast malignancy are excluded. Contralateral DCIS ≥ 10 years prior to enrollment is permissible. * Patients with a prior or concurrent malignancy whose natural hist"
NCT06731478,"A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05)",,PHASE3,"Argentina, Brazil, Chile","CEMIC Ciudad Autonoma, Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Instituto Medico Especializado Alexander Fleming, Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Clinica Universitaria Privada Reina Fabiola, Córdoba, Argentina, [NOT_YET_RECRUITING] | Centro de Investigaciones Medicas Mar del Plata, Mar del Plata, Argentina, [NOT_YET_RECRUITING] | Instituto Medico de la Fundacion Estudios Clinicos, Rosario, Argentina, [NOT_YET_RECRUITING] | Centro de Oncologia - Unidade Brasilia - Hospital Sirio Libanes, Brasília, Brazil, [NOT_YET_RECRUITING] | ICESP - Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira Sao Paulo, Brazil, Brazil, [NOT_YET_RECRUITING] | CEPON - Centro de Pesquisas Oncológicas de Santa Catarina, Florianópolis, Brazil, [NOT_YET_RECRUITING] | Fundação Doutor Amaral Carvalho, Jaú, Brazil, [NOT_YET_RECRUITING] | Liga Norte-Rio-Grandense Contra o Câncer, Natal, Brazil, [NOT_YET_RECRUITING]",Gastric Cancer | Gastroesophageal Junction Cancer,4,[1] Main Cohort: Arm M1 (EXPERIMENTAL): Participants will receive T-DXd plus fluoropyrimidine (5-FU or capecitabine) plus pembrolizumab || [2] Main Cohort: Arm M2 (EXPERIMENTAL): Participants will receive Trastuzumab plus platinum-based chemotherapy (cisplatin plus 5-FU or oxaliplatin plus capecitabine) plus pembrolizumab || [3] Exploratory Cohort: Arm E1 (EXPERIMENTAL): Participants will receive T-DXd plus fluoropyrimidine (5-FU or capecitabine) || [4] Exploratory Cohort: Arm E2 (EXPERIMENTAL): Participants will receive Trastuzumab plus platinum-based chemotherapy (cisplatin plus 5-FU or oxaliplatin plus capecitabine),"1. Sign and date the Tissue Prescreening ICF, prior to HER2 and PD-L1 CPS central testing. Sign and date the Main Screening ICF, prior to the start of any trial-specific qualification procedures. Sign and date the Optional PGx ICF (included in the Main Screening ICF) prior to any PGx procedure. 2. Adults ≥18 years of age on the day of signing the ICF. Follow local regulatory requirements if the legal age of consent for trial participation is \>18 years old. 3. Previously untreated, unresectable, locally advanced or metastatic gastric or GEJ adenocarcinoma histologically confirmed by pathology report. Prior treatment in the perioperative and/or adjuvant setting is permissible, provided there is \>6 months between the end of perioperative or neoadjuvant treatment and the diagnosis of recurrent disease. Note: Prior use of IO (ie, anti-PD-1/PD-L1) therapy in the (neo)adjuvant setting is allowed as long as there is \>6 months between the end of IO therapy and the diagnosis of recurrent disease. 4. Centrally determined HER2-positive (IHC 3+ or IHC 2+/ISH-positive) gastric or GEJ cancer as classified by the American Society of Clinical Oncology-College of American Pathologists for GC on a tumor biopsy as detected by prospective central test on new (core, incisional, excisional biopsy) or existing tumor tissue taken at the time of diagnosis of locally advanced or metastatic disease. Note: Archival samples taken from a previous diagnostic or surgical biopsy not previously irradiated can be accepted. Details pertaining to tumor tissue submission can be found in the Study Laboratory Manual. 5. All participants must provide a tumor sample for tissue-based IHC staining to centrally determine HER2 expression, PD-L1 CPS, and other correlatives. The mandatory FFPE tumor sample can be from either the primary tumor or metastatic biopsy. Specimens with limited tumor content (as centrally determined) and cytology samples are inadequate for defining tumor HER2 and PD-L1 status. 6. At le","1. Prior exposure to other HER2-targeting therapies (including ADCs). 2. Lack of physiological integrity of the upper gastrointestinal tract (ie, severe Crohn disease that results in malabsorption) or malabsorption syndrome that would preclude feasibility of oral chemotherapy (ie, capecitabine). 3. Known DPD enzyme deficiency. Note: Screening for DPD enzyme deficiency is required only in regions/countries where DPD testing is SoC and with unknown DPD status. For regions/countries where DPD testing is not SoC, local practice should be followed. 4. Contraindications to trastuzumab, 5-FU, capecitabine, cisplatin, or oxaliplatin treatment as per local label. 5. Medical history of myocardial infarction within 6 months before randomization or symptomatic CHF (New York Heart Association Class II to IV). Participants with troponin levels above ULN at Screening (as defined by the manufacturer) and without any myocardial infarction -related symptoms should have a cardiologic consultation during the Screening Period to rule out myocardial infarction. 6. Has a corrected QT interval (QTcF) prolongation to \>470 ms (females) or \>450 ms (males) based on the average of the screening triplicate 12-lead ECG. 7. Has a history of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening 8. Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (eg, pulmonary emboli within 3 months of the trial randomization, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, pleural effusion, etc)."
NCT06311721,"A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda® (Pembrolizumab) in Subjects With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer",,PHASE3,"Argentina, Brazil, Chile, Peru","Instituto de Investigaciones Clinicas Mar del Plata, Mar del Plata, Argentina, [RECRUITING] | Centro de Investigacion Pregamino SA, Pergamino, Argentina, [RECRUITING] | Fundacion ARS Medica, San Salvador de Jujuy, Argentina, [RECRUITING] | Sanatorio Britanico De Rosario, Rosario, Argentina, [RECRUITING] | Hospital Provincial del Centenario, Rosario, Argentina, [RECRUITING] | IONC - Instituto Oncologico de Cordoba, Córdoba, Argentina, [RECRUITING] | CRIO - Centro Regional Integrado de Oncologia, Fortaleza, Brazil, [RECRUITING] | OC Oncoclinicas Oncovida, Brasília, Brazil, [RECRUITING] | Centro de Pesquisas Clinicas em Oncologia (CPCO)/HECI, Cachoeiro de Itapemirim, Brazil, [RECRUITING] | Associacao Feminina de Educacao e Combate ao Cancer(AFECC) - Hospital Santa Rita, Vitória, Brazil, [RECRUITING]",Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer,3,[1] ABP 234 (EXPERIMENTAL): Part 1: Participants will receive ABP 234 followed by pemetrexed administered with platinum-based chemotherapy (cisplatin or carboplatin). Part 2: Participants will receive ABP 234 followed by peme... || [2] Pembrolizumab (US) (EXPERIMENTAL): Part 1: Participants will receive FDA-licensed pembrolizumab followed by pemetrexed administered with platinum-based chemotherapy (cisplatin or carboplatin). Part 2: Participants will receive FDA-l... || [3] Pembrolizumab (EU) (EXPERIMENTAL): Part 1: Participants will receive EU-approved pembrolizumab followed by pemetrexed administered with platinum-based chemotherapy (cisplatin or carboplatin). Part 2: Participants will receive EU-app...,"1. At least 18 years of age. 2. Histologically or cytologically confirmed stage IV non-squamous Non-Small Cell Lung Cancer (NSCLC). 3. Participant has no prior systemic treatment for advanced disease. 4. Measurable disease according to RECIST v1.1. 5. Tumor tissue from the resected site of disease must be available for biomarker analyses in order to be randomized. 6. Eastern Cooperative Oncology Group performance status score 0 or 1. 7. Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and c-ros oncogene 1, receptor tyrosine kinase of the insulin receptor family (ROS-1) negative 8. Have a life expectancy of at least 3 months.","1. Small cell lung cancer (SCLC) or mixed SCLC/NSCLC histology or squamous cell carcinoma. 2. Participant has active central nervous system metastases not previously treated. 3. Participant has active or known immune-mediated disorders. 4. Participant has received prior systemic cytotoxic chemotherapy, immunotherapy (including PD-1/PD-L1), anti-neoplastic biological therapy, or targeted therapy for advanced/metastatic disease. 5. Known hypersensitivity to monoclonal antibodies or to any of the excipients of the study drug, or to any component of cisplatin, carboplatin, or pemetrexed."
NCT05849298,"An International Prospective Open-label, Multi-center, Randomized, Non-comparative Phase II Study of Lutetium [177Lu] Vipivotide Tetraxetan (AAA617) Alone and Lutetium [177Lu] Vipivotide Tetraxetan (AAA617) in Combination With Androgen Receptor Pathway Inhibitors in Patients With PSMA PET Scan Positive Castration-Resistant Prostate Cancer",PSMACare,PHASE2,Brazil,"Novartis Investigative Site, São Paulo, Brazil, [RECRUITING] | Novartis Investigative Site, São Paulo, Brazil, [RECRUITING]",Prostatic Neoplasm,2,[1] Arm A (EXPERIMENTAL): Participants will receive 7.4 GBq (+/- 10%) of AAA617 (Lutetium \[177Lu\] vipivotide tetraxetan) once every 6 weeks for 6 cycles. ADT must be ongoing; Best supportive care is allowed. || [2] Arm B (EXPERIMENTAL): Participants will receive 7.4 GBq (+/- 10%) of AAA617 (Lutetium \[177Lu\] vipivotide tetraxetan) once every 6 weeks for 6 cycles. In addition of SOC (ADT plus choice of ARPI as per physician's deci...,"* Participants must be adults ≥ 18 years of age with signed informed consent prior to participation to study * Histologically or cytologically confirmed prostate cancer * Participants must have ongoing androgen deprivation therapy with a GnRH agonist/antagonist or prior bilateral orchiectomy at the time of randomization. Intermittent administration of ADT is accepted before randomization if criterion for serum testosterone is met * Castrate level of serum testosterone (\< 1.7 nmol/l \[50 ng/dl\]) on GnRH agonist or antagonist therapy (continuous/intermittent) or after bilateral orchiectomy prior to randomization * Participants must have evidence of PSMA-positive disease (N1 or M1) as seen on a AAA517 or piflufolastat F 18 PET/CT scan at baseline as determined by Blinded Independent Central Review (BICR) based on the methodology proposed in the Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) (Eiber et al 2018). Participants with M1 disease only on PSMA PET scan are allowed to participate * Participants must have a negative conventional imaging for M1 disease. * Participants must have adequate organ functions: bone marrow reserve, hepatic \& renal Key","* Prior or present evidence of metastatic disease as assessed by CT/MRI locally for soft tissue disease and whole-body radionuclide bone scan for bone disease. Exception: Participants with pelvic disease may be eligible (e.g., participants with enlarged lymph nodes below the bifurcation of common iliac arteries (N1)) * Unmanageable concurrent bladder outflow obstruction or urinary incontinence. Note: participants with bladder outflow obstruction or urinary incontinence, which is manageable with best available standard of care (incl. pads, drainage) are allowed * Active clinically significant cardiac disease; history of seizure or condition that may pre-dispose to seizure which may require treatment with surgery or radiation therapy * Prior therapy with: second generation anti-androgens (e.g., enzalutamide, apalutamide and darolutamide) \< 3 months before randomization; CYP17 inhibitors (e.g., abiraterone acetate, orteronel, galeterone) \< 3 months before randomization; ketoconazole (short duration ketoconazole treatment (\<28 days) is permitted); radiopharmaceutical agents (e.g., Strontium-89) if wash-out period of at least 3 months is not completed, PSMA-targeted radioligand therapy; immunotherapy (e.g., sipuleucel-T); chemotherapy, except if administered in the adjuvant/neoadjuvant setting, completed \> 2 years before randomization; any other investigational agents for CRPC; use of estrogens, 5-α reductase inhibitors (finasteride, dutasteride), other steroidogenesis inhibitors (aminoglutethimide) or first-generation anti-androgens (bicalutamide, flutamide, nilutamide, cyproterone) within 28 days before randomization; radiation therapy (external beam radiation therapy \[EBRT\] and brachytherapy within 28 days before randomization * Other concurrent cytotoxicity chemotherapy, immunotherapy, radioligand therapy, poly adenosine diphosphate-ribose polymerase (PARP) inhibitor, biological therapy or investigational therapy Other protocol-defined inclusion/exclusion crite"
NCT06422806,"A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Dedifferentiated Liposarcoma (DDLPS), Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas",,PHASE3,Puerto Rico,"Pan American Center for Oncology Trials LLC, San Juan, Puerto Rico, [RECRUITING]",Metastatic Dedifferentiated Liposarcoma | Metastatic Undifferentiated Pleomorphic Sarcoma | Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Unresectable Dedifferentiated Liposarcoma,2,[1] Arm A (doxorubicin and pembrolizumab (EXPERIMENTAL): Patients receive doxorubicin IV over 3-10 minutes or up to 3 hours on day 1 of each cycle. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicit... || [2] Arm B (doxorubicin) (ACTIVE_COMPARATOR): Patients receive doxorubicin IV over 3-10 minutes or up to 3 hours on day 1 of each cycle. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicit...,"* Patient must be \>= 18 years of age * Patient must have a confirmed histopathologic diagnosis of dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma. Because UPS can sometimes exist in a spectrum among related diagnoses, the following additional diagnostic will be allowed, but not limited to: * Pleomorphic sarcoma with inflammation or with limited areas of differentiation * Pleomorphic sarcoma with giant cells * Malignant fibrous histiocytoma (including storiform-pleomorphic and inflammatory subtypes) * Myxofibrosarcoma * Poorly differentiated sarcoma not otherwise specified (NOS) * Undifferentiated spindle cell sarcoma * Poorly differentiated spindle cell sarcoma NOS Any of these subtypes may have areas of focal myogenic differentiation * Patient must have metastatic or unresectable sarcoma * Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: * Has achieved menarche at some point * Has not undergone a hysterectomy or bilateral oophorectomy; or * Has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) * Patient must not expect to conceive or father children by using an accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study. Contraception measures must continue for 6 months after the last dose of doxorubicin for patients of",
NCT05622136,Dose-escalation Strategy of Regorafenib in Patients With Advanced Hepatocellular Carcinoma,STRAT-aHCC,PHASE2,Brazil,"ICESP - Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil, [RECRUITING]",Liver Cancer | Hepatocellular Carcinoma,1,"[1] Regorafenib (EXPERIMENTAL): Cycles 1 and 2:

* Week 1: 80mg/day
* Week 2: 120mg/day
* Week 3: 160mg/day
* Week 4: off-treatment Cycles 3 on (up to treatment discontinuation)
* Weeks 1 to 3: Maximum dose tolerated daily, defin...","1. Age 18 years or older; 2. Hepatocellular carcinoma with histological or cytological confirmation or that meet radiological criteria for the diagnosis of HCC21; 3. BCLC-B stage not candidate for locoregional treatment or BCLC-C; 4. Have been previously treated with at least 1 line of systemic treatment with sorafenib, levantinib, atezolizumab plus bevacizumab or other immunotherapy-based regimen; 5. Have received the last dose of first-line systemic treatment between 2 and 6 weeks before starting study treatment; 6. Recovery to baseline or ≤ grade 1 from toxicities related to any previous treatments, unless the adverse event is not clinically significant as determined by the investigator (according to the Common Terminology Criteria for Adverse Events (CTCAE) v522); 7. Not having received previous treatment with regorafenib; 8. Child-Pugh A or B7 (in the absence of clinical ascites); 9. Measurable disease as defined by the RECIST 1.1 criteria. Target lesions must not have undergone previous local or locoregional treatment (example: ablation, transarterial chemoembolization, radiotherapy or selective internal radiotherapy) 10. Performance status: ECOG 0 or 1. 11. Adequate hematologic, hepatic and renal functions as defined below: i. Hemoglobin ≥ 8.5 g/dl ii. Absolute neutrophil count ≥ 1,000 /mm3 iii. Platelet count ≥ 50,000 /mm3 iv. Total bilirubin \< 2.0 x upper limit of normality (ULN) v. ALT or AST \<5 x LSN vi. Creatinine clearance (CrCI) ≥ 30 mL/min (according to Cockroft-Gault formula) vii. Serum albumin ≥ 2.8 mg/dl 12. Ability to understand informed consent and comply with the treatment protocol. 13. Informed consent form and clarification signed by the patient, impartial witness or legal representative. 14. Sexually active patients of childbearing potential and their partners must agree to use highly effective methods of contraception that result in a rate of less than 1% per year when used consistently and correctly throughout the study and 6 months after","1. Fibrolamellar carcinoma, sarcomatoid HCC or mixed hepatocellular cholangiocarcinoma; 2. Previous use of regorafenib; 3. Hepatic encephalopathy or medication requirement to control hepatic encephalopathy in the last 60 days before randomization; 4. Clinically significant ascites (ie, ascites that requires parcentesis or increased dose of diuretics) within 30 days prior to randomization. 5. Patients who have received local therapies (ablation, transarterial chemomebolization or surgery) within 28 days prior to randomization. Radiation treatments with the aim of pain control of bone metastases are allowed. 6. Known or suspected brain metastasis or cranial epidural disease unless adequately treated with surgery or radiotherapy and stable for at least 8 weeks from randomization. 7. Any participant who cannot be submitted neither to computed tomography (CT) nor magnetic resonance imaging (MRI) due to contra-indication to contrast media used. 8. The participant has an uncontrolled disease, or a significant complication in the last 28 days of randomization, such as: 1. Cardiovascular disorders: * i. Class III or IV congestive heart failure as defined by the New York Heart Association, unstable angina pectoris, or symptomatic arrhythmias; * ii. Uncontrolled hypertension (defined as systolic blood pressure greater than 160 mmgHg or diastolic pressure \> 95 mmHg despite antihypertensive therapy); * iii. Stroke, myocardial ischemia, or any ischemic event within the 6-month period prior to randomization; 2. Gastrointestinal disorders, including those associated with a high risk of perforation: * i: active peptic ulcer disease, inflammatory bowel disease, tumors invading the gastrointestinal tract, diverticulitis, cholecystitis, appendicitis, acute pancreatitis and cholangitis; * ii: Abdominal fistula, gastro-intestinal perforation or abdominal abscess in the last 6 months; * iii: Esophageal varices that have not been adequately treated or that have been incompletely treated w"
NCT04166409,A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1),,PHASE3,Puerto Rico,"HIMA San Pablo Oncologic Hospital, Caguas, Puerto Rico, [ACTIVE_NOT_RECRUITING]",Low Grade Astrocytoma | Low Grade Glioma | Metastatic Low Grade Astrocytoma | Metastatic Low Grade Glioma,2,"[1] Arm I (vincristine sulfate, carboplatin) (ACTIVE_COMPARATOR): INDUCTION: Patients receive vincristine sulfate IV on days 1, 8, 15, 22, 29, 36, 43, 50, 57, and 64, and carboplatin IV over 60 minutes on days 1, 8, 15, 22, 43, 50, 57, and 64 in the absence of di... || [2] Arm II (selumetinib sulfate) (EXPERIMENTAL): Patients receive selumetinib sulfate PO BID on days 1-28. Treatment repeats every 28 days for up to 27 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo c...","* Patients must be \>= 2 years and =\< 21 years at the time of enrollment * Patients must have a body surface area (BSA) of \>= 0.5 m\^2 at enrollment * Patients must have non-neurofibromatosis type 1 (non-NF1) low-grade glioma (LGG) without a BRAFV600E mutation as confirmed by Rapid Central Pathology and Molecular Screening Reviews performed on APEC14B1 (NCT02402244) Childhood Cancer Data Initiative (CCDI)-MCI, or accepted Clinical Laboratory Improvement Amendments (CLIA)-certified test and that has not been treated with any modality besides surgery. Note: Patients may be newly-diagnosed OR previously diagnosed, and there is no required time frame between biopsy/surgery and treatment initiation. * Patients with residual tumor after resection or progressive tumor after initial diagnosis (with or without surgery) who have not received treatment (chemotherapy and/or radiation) are eligible * Patients must have two-dimensional measurable tumor \>= 1 cm\^2 to be eligible * Patients with ependymoma are not eligible * Eligible histologies will include all tumors considered low-grade glioma or low-grade astrocytoma (World Health Organization \[WHO\] grade I and II) by 5th edition WHO classification of central nervous system (CNS) tumors with the exception of subependymal giant cell astrocytoma * Patients with metastatic disease or multiple independent primary LGG are eligible * Creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 70 mL/min/1.73 m\^2 OR a serum creatinine based on age/sex as follows (performed within 7 days prior to enrollment): * Age: Maximum Serum Creatinine (mg/dL) * 2 to \< 6 years: 0.8 mg/dL (male); 0.8 mg/dL (female) * 6 to \< 10 years: 1 mg/dL (male); 1 mg/dL (female) * 10 to \< 13 years: 1.2 mg/dL (male); 1.2 mg/dL (female) * 13 to \< 16 years: 1.5 mg/dL (male); 1.4 mg/dL (female) * \>= 16 years: 1.7 mg/dL (male); 1.4 mg/dL (female) * Total bilirubin =\< 1.5 x upper limit of normal (ULN) for age (performed within 7 days prior to","* Patients must not have received any prior tumor-directed therapy including chemotherapy, radiation therapy, immunotherapy, or bone marrow transplant. Prior surgical intervention (with the exclusion of laser interstitial thermal therapy \[LITT\]) is permitted * Patients with a concurrent malignancy or history of treatment (other than surgery) for another tumor within the last year are ineligible * Patients with diffuse intrinsic pontine tumors as seen on MRI (\> 2/3 of pons involvement on imaging) are not eligible even if biopsy reveals grade I/II histology * Patients may not be receiving any other investigational agents * Patients with any serious medical or psychiatric illness/condition, including substance use disorders or ophthalmological conditions, likely in the judgment of the investigator to interfere or limit compliance with study requirements/treatment * Patients who, in the opinion of the investigator, are not able to comply with the study procedures are not eligible * Female patients who are pregnant are not eligible since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential * Lactating females who plan to breastfeed their infants are not eligible * Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation and for 12 weeks after stopping study therapy are not eligible. * Note: Women of child-bearing potential and males with sexual partners who are pregnant or who could become pregnant (i.e., women of child-bearing potential) should use effective methods of contraception for the duration of the study and for 12 weeks after stopping study therapy to avoid pregnancy and/or potential adverse effects on the developing embryo * Known genetic disorder that increases risk for coronary artery disease. Note: The presence of dyslipidemia in a family with a "
NCT05319730,"A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06B",,"PHASE1, PHASE2","Brazil, Chile","Liga Norte Riograndense Contra o Câncer ( Site 4303), Natal, Brazil, [RECRUITING] | Hospital Nossa Senhora da Conceição ( Site 4301), Porto Alegre, Brazil, [RECRUITING] | ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 4300), São Paulo, Brazil, [RECRUITING] | FALP-UIDO ( Site 4400), Santiago, Chile, [RECRUITING] | Centro de Oncología de Precisión-Oncology ( Site 4404), Santiago, Chile, [RECRUITING] | Clínica las Condes ( Site 4403), Santiago, Chile, [COMPLETED] | Clínica UC San Carlos de Apoquindo ( Site 4405), Santiago, Chile, [RECRUITING]",Esophageal Squamous Cell Carcinoma,5,"[1] Paclitaxel or irinotecan (ACTIVE_COMPARATOR): Participants receive paclitaxel 80-100 mg/m\^2 intravenously (IV) on Days 1, 8, and 15 every 28-day cycle until progressive disease (PD) or discontinuation, or irinotecan 180 mg/m\^2 IV on day 1 of... || [2] Pembrolizumab + MK-4830 + paclitaxel or irinotecan (EXPERIMENTAL): Participants receive pembrolizumab 200 mg IV once every 3 weeks (Q3W) for up to 35 cycles (cycle=21 days) or until PD or discontinuation + MK-4830 800 mg IV Q3W up to 35 infusions + paclitaxel 80-1... || [3] Pembrolizumab + MK-4830 + lenvatinib (EXPERIMENTAL): Participants receive pembrolizumab 200 mg IV Q3W up to 35 cycles (cycle=21 days) until PD or discontinuation + MK-4830 800 mg IV Q3W up to 35 infusions + lenvatinib 20 mg oral administration every ... || [4] Sacituzumab tirumotecan 4 mg/kg (EXPERIMENTAL): Participants will receive 4 mg/kg of sacituzumab tirumotecan via IV infusion on Days 1, 15, and 29 of each 42-day cycle until discontinuation. || [5] Sacituzumab tirumotecan 5 mg/kg (EXPERIMENTAL): Participants will receive 5 mg/kg of sacituzumab tirumotecan via IV infusion on Days 1, 15, and 29 of each 42-day cycle until discontinuation.","* Histologically or cytologically confirmed diagnosis of metastatic or locally advanced unresectable esophageal squamous cell carcinoma (ESCC) * Has experienced investigator documented radiographic or clinical disease progression on one prior line of standard therapy, that includes a platinum agent and previous exposure to an anti-programmed cell death 1 (PD1)/programmed cell death ligand 1 (PD-L1) based immune oncology (IO) therapy * Has provided an archival or most recent tumor tissue sample obtained as part of clinical practice * Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement or participants who have ≤Grade 2 neuropathy are eligible","* Direct invasion into adjacent organs such as the aorta or trachea * Has experienced weight loss \>10% over approximately 2 months prior to first dose of study therapy * Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing * Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease * Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration * Known additional malignancy that is progressing or has required active treatment within the past 3 years, except basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ that has undergone potentially curative therapy * Known active central nervous system (CNS) metastases and/or carcinomatous meningitis * Participants with human immunodeficiency virus (HIV) with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * History of allogenic tissue/solid organ transplant * Clinically significant cardiovascular disease within 12 months from first dose of study intervention * Has risk for significant gastrointestinal (GI) bleeding such as a serious nonhealing wound, peptic ulcer, or bone fracture within 28 days prior to allocation/randomization, significant bleeding disorders, vasculitis, or has had a significant bleeding episode from the GI tract within 12 weeks prior to allocation/randomization"
NCT02981628,A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL),,PHASE2,Puerto Rico,"HIMA San Pablo Oncologic Hospital, Caguas, Puerto Rico, [ACTIVE_NOT_RECRUITING]",Recurrent B Acute Lymphoblastic Leukemia | Recurrent B Lymphoblastic Lymphoma | Refractory B Acute Lymphoblastic Leukemia | Refractory B Lymphoblastic Lymphoma,2,"[1] Cohort I (inotuzumab ozogamicin) (EXPERIMENTAL): Patients receive inotuzumab ozogamicin IV over 60 minutes on days 1, 8, and 15 of each cycle. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptabl... || [2] Cohort II (inotuzumab ozogamicin, mBFM chemotherapy) (EXPERIMENTAL): See Detailed Description","* Patients must be \>= 1 year and \< 22 years of age at the time of enrollment * Patients must have B-ALL, or previously diagnosed B lymphoblastic lymphoma (B-LL), with \>= 5% (M2 or M3) bone marrow blasts with or without extramedullary disease * NOTE: Relapsed patients previously diagnosed with B-lymphoblastic lymphoma (B-LL) are eligible if they have an M2 or M3 marrow at the time of enrollment on this study * Patients with ALL or B-LL who have M2 morphology must have local confirmatory testing showing \>= 5% blasts by flow cytometry, fluorescence in situ hybridization (FISH) testing or other molecular method * Leukemic blasts must demonstrate surface expression of CD22 at the time of relapse by local/institutional flow cytometry of a bone marrow aspirate sample; (assessment of CD22 using a bright fluorophore such as phycoerythrin \[PE\] is strongly recommended) * In the case of an inadequate aspirate sample (dry tap) or if bone marrow aspirate is unable to be performed due to patient clinical status, flow cytometry of peripheral blood specimen may be substituted if the patient has at least 1,000/uL circulating blasts; alternatively, CD22 expression may be documented by immunohistochemistry of a bone marrow biopsy specimen * Patients with one of the following: * Second or greater relapse; * Primary refractory disease with at least 2 prior induction attempts; * First relapse refractory to at least one prior re-induction attempt * Any relapse after HSCT (Cohort 1 ONLY) Patients with Down syndrome are eligible ONLY for Cohort 1 with: * Any of above disease status, OR * First relapse with no prior re-induction attempt NOTE: Patients with Down syndrome or prior HSCT are NOT eligible for Cohort 2 combination therapy * Patients with Philadelphia chromosome (Ph)+ ALL must have had two prior therapy attempts including two different tyrosine kinase inhibitors (TKIs) * Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy, defined a","* Patients with any prior history of SOS irrespective of severity * Patients with isolated central nervous system (CNS), testicular, or any other extramedullary site of relapse * Patients who have been previously treated with inotuzumab ozogamicin * Patients who have previously received HSCT (Cohort 2 only) * Patients with Down syndrome (Cohort 2 only) * History of allergic reaction attributed to compounds of similar or biologic composition to inotuzumab ozogamicin or other agents in the study * Note: Patients with history of allergy to pegaspargase/calaspargase pegol are eligible for enrollment on Cohort 2 if Erwinia formulation of asparaginase can be obtained * Patients with active optic nerve and/or retinal involvement are not eligible; patients who are presenting with visual disturbances should have an ophthalmologic exam and, if indicated, a magnetic resonance imaging (MRI) to assess optic nerve or retinal involvement * Patients who are currently receiving another investigational drug * Patients who are currently receiving or plan to receive other anti-cancer agents (except hydroxyurea, which may be continued until 24 hours prior to start of protocol therapy, and intrathecal chemotherapy) * Anti-GVHD or agents to prevent organ rejection post-transplant; patients who are receiving cyclosporine, tacrolimus, or other agents to prevent either graft-versus-host disease post bone marrow transplant or organ rejection post-transplant are not eligible for this trial; at least 3 half-lives must have elapsed after the last dose of GVHD or anti-rejection medications * Patients who are currently receiving or plan to receive corticosteroids except as described below * Systemic corticosteroids may be administered for cytoreduction up to 24 hours prior to the start of protocol therapy, (Cohort 1 only) for all patients, corticosteroids may be administered as a premedication for inotuzumab ozogamicin and as treatment for allergic reactions or for physiologic replacement/stress d"
NCT06578247,"Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial Of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients With Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia",QuANTUM-WILD,PHASE3,Brazil,"Cetus Hospital Dia Oncologia, Belo Horizonte, Brazil, [RECRUITING] | Unesp - Faculdade de Medicina Da Universidade Estadual Paulista - Campus Botucatu, Botucatu, Brazil, [RECRUITING] | Centro de Hematologia E Hemoterapia - Hemocentro de Campinas - Unicamp, Campinas, Brazil, [NOT_YET_RECRUITING] | Centro de Hematologia e Hemoterapia - Hemocentro de Campinas - UNICAMP, Campinas, Brazil, [RECRUITING] | Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer, Curitiba, Brazil, [RECRUITING] | Hospital Erasto Gaertner - Liga Paranaense de Combate Ao Că'Ncer, Curitiba, Brazil, [NOT_YET_RECRUITING] | Cepon - Centro De Pesquisas Oncolagicas de Santa Catarina, Florianópolis, Brazil, [RECRUITING] | HUWC - UFC - Hospital Universitário Walter Cantídio - Universidade Federal do Ceará, Fortaleza, Brazil, [RECRUITING] | HC-UFG - Hospital das Clínicas da Universidade Federal de Goiás, Goiânia, Brazil, [RECRUITING] | Hc-Ufg - Hospital Das Clă Nicas Da Universidade Federal de Goiă S, Goiânia, Brazil, [NOT_YET_RECRUITING]",Leukemia,3,"[1] Arm A: Quizartinib + Chemotherapy (EXPERIMENTAL): Participants will receive quizartinib at 60 mg/day orally once daily for 14 days starting after the completion of chemotherapy in Induction and Consolidation Phase. In the Maintenance Phase, partic... || [2] Arm B: Placebo + Chemotherapy (PLACEBO_COMPARATOR): Participants will receive placebo at 60 mg/day orally once daily for 14 days starting after the completion of chemotherapy in Induction and Consolidation Phase. In the Maintenance Phase, participan... || [3] Arm C: Quizartinib + Chemotherapy then Placebo Maintenance (EXPERIMENTAL): Participants will receive quizartinib at 60 mg/day orally once daily for 14 days starting after the completion of chemotherapy in Induction and Consolidation Phase. In the Maintenance Phase, partic...","* Must be competent and able to comprehend, sign, and date an Ethics Committee (EC)- or Institutional Review Board (IRB)-approved Informed Consent Form (ICF) before performance of any trial-specific procedures or tests. * ≥18 years or the minimum legal adult age (whichever is greater) and 70 years (at Screening). * Newly diagnosed, morphologically documented primary AML based on the World Health Organization (WHO) 2016 classification (at Screening) * Eastern Cooperative Oncology Group (ECOG) performance status (at the time the participant signs their ICF) of 0-2. * Participant is receiving standard ""7+3"" induction chemotherapy regimen as specified in the protocol Key","* Diagnosis of acute promyelocytic leukemia (APL), French-American-British classification M3 or WHO classification of APL with translocation, t(15;17)(q22;q12), or BCR-ABL positive leukemia (ie, chronic myelogenous leukemia in blast crisis); participants who undergo diagnostic workup for APL and treatment with all-trans retinoic acid (ATRA), but who are found not to have APL, are eligible (treatment with ATRA must be discontinued before starting induction chemotherapy). * Diagnosis of AML secondary to prior chemotherapy or radiotherapy for other neoplasms or autoimmune/rheumatologic conditions. * Diagnosis of AML secondary to myelodysplastic syndrome (MDS) or a myeloproliferative neoplasm (MPN) or MDS/MPNs including CMML, aCML, JMML and others. * Participants with newly diagnosed AML with FLT3-ITD mutations (FLT3-ITD \[+\]) present at ≥5% VAF (or ≥0.05 SR) based on a validated FLT3 mutation assay. * Prior treatment for AML, except for the following allowances: 1. Leukapheresis; 2. Treatment for hyperleukocytosis with hydroxyurea; 3. Cranial radiotherapy for central nervous system (CNS) leukostasis; 4. Prophylactic intrathecal chemotherapy; 5. Growth factor/cytokine support."
NCT05947851,"A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)",,PHASE3,"Argentina, Brazil, Chile, Colombia, Mexico, Puerto Rico","Instituto Alexander Fleming ( Site 1005), Ciudad Autónoma de Buenos Aires, Argentina, [RECRUITING] | Instituto de Investigaciones Clínicas Mar del Plata ( Site 1007), Mar del Plata, Argentina, [RECRUITING] | Sanatorio Parque ( Site 1003), Rosario, Argentina, [RECRUITING] | Centro Medico Fleischer ( Site 1006), Buenos Aires, Argentina, [RECRUITING] | Hospital Aleman-oncohematologic diseases ( Site 1001), Buenos Aires, Argentina, [RECRUITING] | ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO-Pesquisa Clinica ( Site 1308), São Paulo, Brazil, [ACTIVE_NOT_RECRUITING] | IC La Serena Research ( Site 1506), La Serena, Chile, [RECRUITING] | Centro de Estudios Clínicos SAGA-CECSAGA ( Site 1509), Santiago, Chile, [RECRUITING] | FALP-UIDO ( Site 1500), Santiago, Chile, [RECRUITING] | Clínica Inmunocel ( Site 1511), Santiago, Chile, [RECRUITING]","Leukemia, Lymphocytic, Chronic, B-Cell | Leukemia, Chronic Lymphocytic | Small-Cell Lymphoma | Lymphoma, Small Lymphocytic | CLL",2,[1] Nemtabrutinib + Venetoclax (EXPERIMENTAL): Participants will receive nemtrabrutinib oral tablets at specified doses daily starting at Cycle 1 Day 1 (C1D1) and venetoclax oral tablets at doses of 20 mg up to 400 mg daily starting at Cycle 2 ... || [2] Venetoclax + Rituximab (ACTIVE_COMPARATOR): Participants will receive venetoclax oral tablets at doses from 20 mg up to 400 mg daily starting at C1D1 on 4-week cycles up to 2 years and rituximab or biosimilar at 375 mg/m\^2 up to 500 mg/m2 i...,"* Confirmed diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and active disease clearly documented to initiate therapy. * Deletion (Del) (17p) status, tumor protein 53 (TP53) mutation status, immunoglobulin heavy chain gene (IGHV) mutation status and Bruton's tyrosine kinase (BTK)-C481 mutation status results required before randomization for Part 2 participants only. * Relapsed or refractory to at least 1 prior available therapy. * Have at least 1 marker of disease burden. * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before randomization. * Has a life expectancy of at least 3 months. * Has the ability to swallow and retain oral medication. * Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV deoxyribonucleic acid (DNA) viral load before randomization. * Participants with history of hepatitis C virus (HCV) infection are eligible if HCV ribonucleic acid (RNA) viral load is undetectable at screening. * Participants with human immunodeficiency virus (HIV) who meet ALL eligibility criteria. * Participants with adequate organ function with specimens collected within 7 days before the start of study intervention. * If capable of producing sperm, participant agrees to eliminate Nemtabrutinib: 12 days, Venetoclax: 1 month (30 days), Rituximab (rituximab biosimilar): not applicable; abstains from penile-vaginal intercourse as their preferred and usual lifestyle; OR uses prescribed contraception. * Participant assigned female sex at birth are eligible to participate if not pregnant or breastfeeding and are not a person of childbearing potential (POCBP) OR is a POCBP and uses a contraceptive method that is highly effective, has a negative highly sensitive pregnancy test, and abstains from breastfeeding.","* Has an active hepatitis B virus/ hepatitis C virus (HBV/HCV) infection. * Has gastrointestinal (GI) dysfunction that may affect drug absorption. * Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. * Has diagnosis of Richter Transformation or active central nervous system (CNS) involvement by CLL/SLL. * Has an active infection requiring systemic therapy, such as intravenous (IV) antibiotics, during screening. * HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease and/or acquired immune deficiency syndrome (AIDS)-defining opportunistic infection in the past 12 months before screening. * Has QT interval corrected (QTc) prolongation or other significant electrocardiogram (ECG) abnormalities. * Has a known allergy/sensitivity to nemtabrutinib or contraindication to venetoclax/rituximab (or rituximab biosimilar), or any of the excipients. * Has history of severe bleeding disorders (eg, hemophilia). * Has received prior systemic anticancer therapy within 5 half-lives or 4 weeks (if prior therapy was a monoclonal antibody) before randomization. * Has received prior B-cell lymphoma 2 inhibitor(s) (BCL2i) including venetoclax or Non-covalent Bruton's tyrosine kinase inhibitor (BTKi). * Is currently being treated with p-glycoprotein (P-gp) substrates with a narrow therapeutic index, cytochrome P450 3A (CYP3A) strong or moderate inducers or CYP3A strong inhibitors. * Has received a live or live attenuated vaccine within 30 days before the first dose of study intervention. * Has received an investigational agent or has used an investigational device within 4 weeks before study intervention administration. * Has a known psychiatric or substance use disorder that would interfere with the participant's ability to cooperate with the requirements of the study. * Participants who have not adequately recovered from major surgery or have ongoing surgical complications."
NCT06926868,"A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable,or Metastatic Triple-negative Breast Cancer (TNBC)or ER-low, HER2-negative BC Who Are Ineligible for Anti-PD1/PD-L1 Treatment",,"PHASE2, PHASE3","Argentina, Brazil, Chile, Colombia, Mexico","Local Institution - 0345, Buenas Aires, Argentina, [NOT_YET_RECRUITING] | Local Institution - 0011, Ciudad Autónoma de Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Local Institution - 0214, ABB, Argentina, [NOT_YET_RECRUITING] | Local Institution - 0143, Córdoba, Argentina, [NOT_YET_RECRUITING] | Local Institution - 0137, Río Cuarto, Argentina, [NOT_YET_RECRUITING] | Local Institution - 0142, Rosario, Argentina, [NOT_YET_RECRUITING] | Local Institution - 0012, Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Local Institution - 0317, Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Local Institution - 0346, Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Local Institution - 0187, Manaus, Brazil, [NOT_YET_RECRUITING]",Breast Neoplasms,3,[1] Arm A1 (EXPERIMENTAL): No description || [2] Arm A2 (EXPERIMENTAL): No description || [3] Arm B (ACTIVE_COMPARATOR): No description,"* Histologically or cytologically confirmed and documented locally-advanced, recurrent inoperable, or metastatic TNBC (ER \< 1%, PgR \< 1%, HER2 IHC 0, 1+, or 2+ with FISH negative for HER2 gene amplification) or ER-low, HER2-negative BC (ER and / or PgR 1% to 10%, HER2 IHC 0, 1+, or 2+ with FISH negative for HER2 gene amplification) per ASCO/CAP criteria, based on the most recently analyzed biopsy or other pathology specimen. * Patients with recurrent disease must have experienced disease relapse at least 6 months after finishing their last therapy with curative intent. * Patients with TNBC must be considered ineligible for 1L chemotherapy combination treatment with an anti-PD-1 or an anti-PD-L1 due to either one of the following criteria:. * Investigator-determined ineligibility based on PD-L1 negative disease determined and documented prior to trial screening as part of SoC. * Has experienced disease relapse between 6 to 12 months after the completion of (neo)adjuvant therapy with an anti-PD(L)1. * Has a severe auto-immune disease or other contraindication. * Patients with ER-low, HER2-negative BC must be ineligible, in the opinion of the Investigator, for endocrine therapy-based treatments. * No previous systemic therapy in the locally advanced, recurrent inoperable or metastatic setting (ie incurable setting). * Measurable disease by CT or MRI as per RECIST v1.1. * Other protocol-defined Inclusion/",
NCT05800834,Effectiveness of Topical Morphine Use in Patients With Painful Neoplastic Wounds in the Breast and Head and Neck: Double Blind Randomized Clinical Trial - MorphineGEL,MorphineGEL,PHASE2,Brazil,"National Cancer Institute, Rio de Janeiro, Brazil, [RECRUITING]","Wounds and Injuries | Cancer Pain | Cancer, Breast | Cancer Head Neck",2,[1] Morphine sulfate (EXPERIMENTAL): Topical morphine with hydrogel base. || [2] Lidocaine Hcl 2% jelly (ACTIVE_COMPARATOR): 2% lidocaine jelly,* Malignant neoplastic wound in breast or head and neck; * Malignant neoplastic wound with staging \>= II; * KPS \>=30% * Having at least 3 on the numerical pain rating scale (0-10); * Admission time equal to or greater than 48 hours. * Make use of systemic morphine.,* Wound with fistula; * Wound with extensive coagulation necrosis (\>50% of wound area; * Exuding wound \> 1 (PUSH Scale); * Bleeding wound \>1 (VIBe Scale) * Ongoing radiotherapy on the wound.
NCT03959085,"A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy",,PHASE3,Puerto Rico,"HIMA San Pablo Oncologic Hospital, Caguas, Puerto Rico, [ACTIVE_NOT_RECRUITING] | University Pediatric Hospital, San Juan, Puerto Rico, [RECRUITING]",B Acute Lymphoblastic Leukemia | B Lymphoblastic Lymphoma | Central Nervous System Leukemia | Mixed Phenotype Acute Leukemia | Testicular Leukemia,5,[1] Arm I (HR-FAV B-ALL) (EXPERIMENTAL): See detailed description for Arm I || [2] Arm II (HR B-ALL CONTROL) (ACTIVE_COMPARATOR): See detailed description for Arm II. || [3] Arm III (HR B-ALL EXPERIMENTAL) (EXPERIMENTAL): See detailed description for Arm III. || [4] Arm IV (MPAL) (EXPERIMENTAL): See detailed description for Arm IV. || [5] ARM V (B-LLY) (EXPERIMENTAL): See detailed description for Arm V.,"* B-ALL and MPAL patients must be enrolled on APEC14B1 and consented to eligibility studies (Part A) prior to treatment and enrollment on AALL1732. Note that central confirmation of MPAL diagnosis must occur within 22 days of enrollment for suspected MPAL patients. If not performed within this time frame, patients will be taken off protocol. * APEC14B1 is not a requirement for B-LLy patients but for institutional compliance every patient should be offered participation in APEC14B1. B-LLy patients may directly enroll on AALL1732. * Patients must be \> 365 days and \< 25 years of age * White blood cell count (WBC) criteria for patients with B-ALL (within 7 days prior to the start of protocol-directed systemic therapy): * Age 1-9.99 years: WBC \>= 50,000/uL * Age 10-24.99 years: Any WBC * Age 1-9.99 years: WBC \< 50,000/uL with: * Testicular leukemia * CNS leukemia (CNS3) * Steroid pretreatment. * White blood cell count (WBC) criteria for patients with MPAL (within 7 days prior to the start of protocol-directed systemic therapy): * Age 1-24.99 years: any WBC NOTE: Patients enrolled as suspected MPAL but found on central confirmatory testing to have B-ALL must meet the B-ALL criteria above (age, WBC, extramedullary disease, steroid pretreatment) to switch to the B-ALL stratum before the end of induction. * Patient has newly diagnosed B-ALL or MPAL (by World Health Organization \[WHO\] 2016 criteria) with \>= 25% blasts on a bone marrow (BM) aspirate; * OR If a BM aspirate is not obtained or is not diagnostic of acute leukemia, the diagnosis can be established by a pathologic diagnosis of acute leukemia on a BM biopsy; * OR A complete blood count (CBC) documenting the presence of at least 1,000/uL circulating leukemic cells if a bone marrow aspirate or biopsy cannot be performed. * Patient has newly diagnosed B-LLy Murphy stages III or IV. * Patient has newly diagnosed B-LLy Murphy stages I or II with steroid pretreatment. * Note: For B-LLy patients with tissue available","* Patients with Down syndrome are not eligible (patients with Down syndrome and B-ALL are eligible for AALL1731, regardless of NCI risk group). * With the exception of steroid pretreatment and steroid cytoreduction or the administration of intrathecal cytarabine, patients must not have received any prior cytotoxic chemotherapy for the current diagnosis of B-ALL, MPAL, or B-LLy or for any cancer diagnosed prior to initiation of protocol therapy on AALL1732. * Patients who have received \> 72 hours of hydroxyurea within one week prior to start of systemic protocol therapy. * Patients with B-ALL or MPAL who do not have sufficient diagnostic bone marrow submitted for APEC14B1 testing and who do not have a peripheral blood sample submitted containing \> 1,000/uL circulating leukemia cells. * Patients with acute undifferentiated leukemia (AUL) are not eligible. * For Murphy stage III/IV B-LLy patients, or stage I/II patients with steroid pretreatment, the following additional exclusion criteria apply: * T-lymphoblastic lymphoma. * Morphologically unclassifiable lymphoma. * Absence of both B-cell and T-cell phenotype markers in a case submitted as lymphoblastic lymphoma. * Patients with known Charcot-Marie-Tooth disease. * Patients with known MYC translocation associated with mature (Burkitt) B-cell ALL, regardless of blast immunophenotype. * Patients requiring radiation at diagnosis. * Female patients who are pregnant, since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential. * Lactating women who plan to breastfeed their infants while on study and for 2 months after the last dose of inotuzumab ozogamicin. * Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of study participation. For those patients randomized to inotuzumab ozogamicin, there is a minimum of 8 months after the last do"
NCT03937635,Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM),,PHASE3,Puerto Rico,"Cancer Center-Metro Medical Center Bayamon, Bayamón, Puerto Rico, [RECRUITING] | HIMA San Pablo Oncologic Hospital, Caguas, Puerto Rico, [SUSPENDED] | Doctors Cancer Center, Manatí, Puerto Rico, [RECRUITING] | San Juan Community Oncology Group, San Juan, Puerto Rico, [RECRUITING] | Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico, [RECRUITING] | San Juan City Hospital, San Juan, Puerto Rico, [RECRUITING]",Smoldering Plasma Cell Myeloma,2,"[1] Arm I (daratumumab, lenalidomide, dexamethasone) (EXPERIMENTAL): Patients receive daratumumab IV on days 1, 8, 15, and 22 of courses 1-2, days 1 and 15 of courses 3-6, and day 1 of courses 7-24. Patients also receive lenalidomide PO daily on days 1-21 and dexame... || [2] Arm II (lenalidomide, dexamethasone) (EXPERIMENTAL): Patients receive lenalidomide PO daily on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22 of courses 1-12. Treatment repeats every 28 days for up to 24 courses in the absence of disease pro...","* Patients must be diagnosed with asymptomatic high-risk smoldering multiple myeloma (SMM) within the past 12 months. High-risk is defined by the presence of 2 or more of the following factors: * Abnormal serum free light chain ratio of involved to uninvolved \>20, but less than 100 if the involved FLC is \>= 10 mg/dL by serum free light chain (FLC) assay * Serum M-protein level \>= 2 gm/dL * Presence of t(4;14) or del 17p, del 13q or 1q gain by conventional cytogenetics or fluorescence in situ hybridization (FISH) studies. * \>20% plasma cells on biopsy or aspirate * Bone marrow aspirate and/or biopsy is required to be performed within 42 days prior to randomization and must demonstrate 10-59% clonal plasma cells. * \>= 1 g/dL on serum protein electrophoresis (within 28 days prior to randomization). * \>= 200 mg of monoclonal protein on a 24 hour urine protein electrophoresis (within 28 days prior to randomization). * NOTE: In the rare situation where the serum protein electrophoresis (SPEP) is felt to be unreliable, then quantitative immunoglobulin levels on nephelometry or turbidometry can be accepted. * SPEP, urine protein electrophoresis (UPEP), and serum FLC are required to be performed within 28 days prior to randomization. * NOTE: UPEP (on a 24-hour collection) is required; no substitute method is acceptable. Urine must be followed monthly if the baseline urine M-spike is \>= 200 mg/24 hour (hr), and urine in addition to serum must be followed in order to confirm a very good partial response (VGPR) or higher response. * Patients must have no lytic lesions, no known plasmacytoma, and no unexplained hypercalcemia (i.e., \> 11 mg/dL or 1mg/dL above upper limit of normal \[ULN\]). * Hemoglobin \>= 11 g/dL (within 28 days prior to randomization). * Platelet count \>= 100,000 cells/mm\^3 (within 28 days prior to randomization). * Absolute neutrophil count \>= 1500 cells/mm\^3 (within 28 days prior to randomization). * Calculated creatinine clearance \>= 30 mL/min ",
NCT02332668,"A Phase I/II Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)",,"PHASE1, PHASE2",Brazil,"MSD Brasil, São Paulo, Brazil, [RECRUITING]",Melanoma | Lymphoma | Solid Tumor | Classical Hodgkin Lymphoma | Microsatellite-instability-high Solid Tumor,6,"[1] Melanoma (EXPERIMENTAL): Participants aged 6 months to \<18 years with melanoma receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), intravenously (IV) once every 3 weeks (Q3W). Enrollment of participants ag... || [2] Solid Tumors and Other Lymphomas (EXPERIMENTAL): Participants aged 6 months to \<18 years with solid tumors and other lymphomas receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), IV Q3W. Initial enrollment limited to programmed d... || [3] rrcHL (EXPERIMENTAL): Participants aged 3 years to \<18 years with rrcHL receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), IV Q3W. || [4] MSI-H (EXPERIMENTAL): Participants aged 6 months to \<18 years with microsatellite-instability-high (MSI-H) solid tumors receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), IV Q3W. || [5] TMB-H (EXPERIMENTAL): Participants aged 6 months to \<18 years with tumor-mutational burden-high ≥10 mutation/Mb (TMB-H) solid tumors receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), IV Q3W. || [6] Adjuvant Melanoma (EXPERIMENTAL): Participants aged 12 years to \<18 years with resected high-risk Stage IIB, IIC, III, or IV melanoma receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), intravenously (IV) once ever...","* Between 6 months and \<18 years of age on day of signing informed consent is documented. * Histologically- or cytologically-documented, locally-advanced, or metastatic solid malignancy or lymphoma that is incurable and has failed prior standard therapy, or for which no standard therapy exists, or for which no standard therapy is considered appropriate * Any number of prior treatment regimens * Tissue (or lymph node biopsy for rrcHL participants) available from an archival tissue sample or, if appropriate, a newly obtained core or excisional biopsy of a tumor lesion not previously irradiated * Advanced melanoma or PD-L1-positive advanced, relapsed, or refractory solid tumor or lymphoma * Measurable disease based on RECIST 1.1 (Or based on IWG \[Cheson, 2007\] \[i.e., measurement must be \>15 mm in longest diameter or \>10 mm in short axis\] for rrcHL participants) * Participants with neuroblastoma with only metaiodobenzylguanidine (MIBG)-positive evaluable disease may be enrolled * Lansky Play Scale ≥50 for participants from 6 months up to and including 16 years of age; or Karnofsky score ≥50 for participants \>16 years of age * Adequate organ function * Female participants of childbearing potential should have a negative urine or serum pregnancy test within 72 hours before the first dose of study medication * Female participant is not a woman of childbearing potential (WOCBP) or is a WOCBP who is abstinent from heterosexual intercourse or using contraception during the intervention period and for at least 120 days after the last dose of study intervention * Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. * Demonstrate adequate organ function.","* Currently participating and receiving study therapy in, or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the date of allocation/randomization * Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the date of allocation/randomization * Prior systemic anti-cancer therapy including investigational agent within 2 weeks prior to study Day 1 or not recovered from adverse events due to a previously administered agent * Prior radiotherapy within 2 weeks of start of study treatment * Known additional malignancy that is progressing or requires active treatment with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (eg, breast carcinoma, cervical carcinoma in situ) with potentially curative therapy, or in situ cervical cancer * Known active central nervous system (CNS) metastases and/or carcinomatous meningitis * Tumor(s) involving the brain stem * Severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients * Active autoimmune disease that has required systemic treatment in past 2 years; replacement therapy (such as thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is acceptable * Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis. * Active infection requiring systemic therapy * Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial through 120 days after the last dose of study medication * Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-ligand 1 (anti-PD-L1), anti-PD-L2 agent, or any agent directed to another stimulatory or inhibitory T-cell receptor (eg, cytotoxic lymphocyte associated protein-4 \[CTLA-4\], OX-40, CD137) * Human immunodeficiency vir"
NCT05277935,Wearable Enhanced Fitness Tracking for Metastatic Breast Cancer Patients Using Endocrine Treatment and Palbociclib,WEFITTER,NA,Brazil,"Oncoclínicas, Rio de Janeiro, Brazil, [RECRUITING] | A Beneficência Portuguesa de São Paulo, São Paulo, Brazil, [RECRUITING] | A.C.Camargo Cancer Center, São Paulo, Brazil, [RECRUITING] | Centro Paulista de Oncologia, São Paulo, Brazil, [RECRUITING]",Breast Neoplasm Female | Quality of Life,2,"[1] Use of the WeCancer app combined with the smartwatch (ACTIVE_COMPARATOR): The Wecancer app will be used in a way, combined with a smartwatch, similar to those used in professional fitness programs, with active measures, which may include, for example: notifications with ... || [2] Using the WeCancer app (NO_INTERVENTION): The Wecancer application similar to those used in professional fitness programs, with active measures, which may include, for example: notifications with personalized advice (via chat), patient fee...","* Female patients ≥ 18 years of age diagnosed with hormone receptor-positive/ human epidermal growth factor receptor 2- negative metastatic breast cancer undergoing treatment with Palbociclib combined with aromatase inhibitors (letrozole, exemestane or anastrozole) or fulvestrant as first-line therapy, or in treatment with Palbociclib and fulvestrant as second-line or posterior-line therapy in the metastatic setting; may be using ovarian suppression if the patient is premenopausal. * The patient must be on treatment for at least three (3) months with Palbociclib and endocrine therapy. * Evidence of a signed and dated informed consent document, physically or digitally, indicating that the research participant was informed about all relevant aspects of the study; * The patient agrees not to participate in another study with drug intervention while on treatment. * Have performance status according to the Eastern Cooperative Oncology Group * Have access to a compatible smartphone and 3G or 4G internet connection","* Patients considered to be at poor medical risk due to uncontrolled serious medical disorder, non-malignant systemic disease, or active uncontrolled infection. Examples: uncontrolled ventricular arrhythmia, recent myocardial infarction (within 6 months), stroke, gastrointestinal bleeding, or any psychiatric disorder that precludes informed consent; between others. * Patients who have a life expectancy of \< 3 months. * Treatment with any product under investigation during the last 28 days; * Another acute or chronic medical or psychiatric condition or severe laboratory abnormality that could increase the risk associated with participation in the study or that Page 10 de 21 Version 6.0 could interfere with the interpretation of the study results and, in the investigator's judgment, would make the research participant unsuitable for inclusion in the study. study. * Illiterate patients or those with a low level of education that may prevent the correct use of the Wecancer application and/or the watch with monitoring of physical activity."
NCT06058377,Phase III Trial Of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone For Adults With MammaPrint High 2 Risk (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer,,PHASE3,Puerto Rico,"Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico, [RECRUITING] | PROncology, San Juan, Puerto Rico, [RECRUITING]",Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | HER2-Negative Breast Carcinoma | Hormone Receptor-Positive Breast Carcinoma,3,"[1] Step 1 (MammaPrint testing) (EXPERIMENTAL): Patients without a known MP2 score undergo MammaPrint testing on a previously-collected tissue sample. Patients with MP2 score proceed to STEP 2 || [2] Step 2, Arm 1 (chemotherapy) (ACTIVE_COMPARATOR): Patients receive paclitaxel IV on days 1 and 8 of each cycle. Treatment repeats every 14 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive doxo... || [3] Step 2, Arm 2 (chemotherapy, durvalumab) (EXPERIMENTAL): Patients receive paclitaxel IV on days 1 and 8 of each cycle and durvalumab IV over 60 minutes on day 1 of cycles 1, 3, and 5. Treatment repeats every 14 days for 6 cycles in the absence of disease...","* STEP 1: REGISTRATION (SCREENING): Participants must have histologically confirmed estrogen receptor (ER) positive and/or progesterone receptor (PR) positive (hormone receptor positive) and HER2 negative breast cancer, as per American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines * NOTE: Participants with HER2 positive disease by ASCO CAP guidelines are ineligible. HER2 negative and HER2 low or equivocal cases as per ASCO CAP guidelines that do not receive HER2 targeted therapy are eligible * STEP 1: REGISTRATION (SCREENING): Participants must have clinical stage II or III breast cancer * NOTE: Participants with inflammatory breast cancer are eligible * NOTE: Participants with occult (i.e. undetectable) primary breast cancer with axillary nodal involvement are not eligible, as MammaPrint testing has not been validated on tissue obtained from an axillary lymph node * STEP 1: REGISTRATION (SCREENING): Participants must not have metastatic disease (i.e., must be clinically M0 or Mx) Systemic staging studies with imaging should follow routine practice as per National Comprehensive Cancer Network (NCCN) and ASCO guidelines * STEP 1: REGISTRATION (SCREENING): Participants must not have locally recurrent breast cancer * STEP 1: REGISTRATION (SCREENING): Participants with multifocal disease in the same breast or synchronous bilateral primary tumors are eligible, however, all tumors that are biopsied must be hormone receptor positive and HER2 negative per ASCO CAP guidelines and at least one of the tumors must be MammaPrint High-2. MammaPrint can be performed sequentially on biopsies as it is sufficient to have MammaPrint High 2 status on at least one of the lesions * NOTE: Biopsy of multiple lesions in the same breast is not required if the clinical presentation is consistent with a single disease process that is multifocal in nature. However, if there is clinical suspicion of two distinct primary breast malignancies, additional biop",
NCT06793137,Phase II Trial for Intestinal Microbiome Modulation With Antibiotics in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer,,PHASE2,Brazil,"A.C Camargo Cancer Center, São Paulo, Brazil, [RECRUITING]","Rectal Cancer, Adenocarcinoma",1,"[1] Antibiotic in neoadjuvant treatment of locally advanced rectal adenocarcinoma (EXPERIMENTAL): This study investigates the administration of an oral antibiotic, metronidazole, during the first seven days of radiotherapy for patients with locally advanced rectal adenocarcinoma undergoing tota...","* Patients over 18 years old with middle and lower rectal adenocarcinoma, classified as locally advanced or where the tumor´s location necessitates rectal amputation surgery; * Tumors located below the peritoneal reflection, as determined by MRI, will be defined as middle and lower rectum; * Patients eligible for rectal amputation will be those with tumor whose distal margin is less than 2,0cm from the pectineal line, as determined by rectoscopy, or less than 2,0cm from the anorectal ring by palpation or MRI. * Patients with middle rectum cancer candidates for radiotherapy as part of neoadjuvant treatment will be included according to the following criteria: mesorectal fascia compromised by direct extension of the primary tumor or by an affected lymph node; cT4 tumors.","* Patients without performance status for total neoadjuvant treatment; * Histologies other than adenocarcinoma; * Adenocarcinomas with a microsatellite instability phenotype, as determined by immunohistochemistry; * Patients with middle rectal tumors who are not indicated for radiotherapy in the neoadjuvant treatment regimen, according to the institutional protocol (tumors cT3N0, with free mesorectal fascia; cT1-3 N+, with free mesorectal fascia)."
NCT06162572,"A Phase 1b/2, Multicenter, Open-label Platform Study of Select Immunotherapy Combinations in Adult Participants With Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) With High PD-L1 Expression",,"PHASE1, PHASE2","Argentina, Brazil","Instituto Médico Especializado Alexander Fleming, Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Sanatorio Parque S.A., Santa Fe, Argentina, [NOT_YET_RECRUITING] | Hospital de Amor - Barretos, Barretos, Brazil, [NOT_YET_RECRUITING] | Supera Oncologia, Chapecó, Brazil, [RECRUITING] | CIONC, Curitiba, Brazil, [RECRUITING] | ONCOSITE, Ijuí, Brazil, [NOT_YET_RECRUITING] | Liga Contra O Cancer - Natal, Natal, Brazil, [RECRUITING] | Santa Casa de Porto Alegre, Porto Alegre, Brazil, [RECRUITING] | Hospital São Lucas Da Pucrs, Porto Alegre, Brazil, [RECRUITING] | Oncoclinicas Rj, Rio de Janeiro, Brazil, [RECRUITING]",Non-small Cell Lung Cancer (NSCLC),7,[1] S095018 (anti-TIM3 antibody) in combination with cemiplimab (EXPERIMENTAL): Part A: Combination-therapy safety lead-in || [2] S095024 (anti-CD73 antibody) in combination with cemiplimab (EXPERIMENTAL): Part A: Combination-therapy safety lead-in || [3] S095029 (anti-NKG2A antibody) in combination with cemiplimab (EXPERIMENTAL): Part A: Combination-therapy safety lead-in || [4] S095018 (anti-TIM3 antibody) RDE in combination with cemiplimab (EXPERIMENTAL): Part B: Randomized dose expansion || [5] S095024 (anti-CD73 antibody) RDE in combination with cemiplimab (EXPERIMENTAL): Part B: Randomized dose expansion || [6] S095029 (anti-NKG2A antibody) RDE in combination with cemiplimab (EXPERIMENTAL): Part B: Randomized dose expansion || [7] Cemiplimab (control arm) (ACTIVE_COMPARATOR): Part B: Randomized dose expansion,"* Adult patient aged ≥ 18 years * Written informed consent * Histologically (squamous or non-squamous) or cytologically documented locally advanced NSCLC not eligible for surgical resection and/or definitive chemoradiation, or metastatic NSCLC * No prior systemic treatment for locally advanced or metastatic NSCLC * High tumor cell PD-L1 expression \[Tumor Proportion Score (TPS) ≥50%\] based on documented status as determined by an approved test * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Measurable disease as determined by RECIST v1.1","* Tumors harboring driver mutations/genetic aberrations for which targeted therapies are approved as frontline treatment (e.g. EGFR mutation, ALK fusion oncogene, ROS1 aberrations) * Prior immune checkpoint inhibitor therapy * Active brain metastases * Participants with active and uncontrolled hepatitis B virus (HBV) or hepatitis C virus (HCV) infection * Uncontrolled HIV infection. Participants with HIV who have controlled infection (undetectable viral load and CD4 count above 350 either spontaneously or on a stable antiviral regimen) are allowed to enroll * Active, known or suspected autoimmune disease or immune deficiency * History of hypersensitivity reactions to any ingredient of the investigational medicinal product (IMP) and other monoclonal antibody (mAbs) and/or their excipients * History of interstitial lung disease, idiopathic pulmonary fibrosis, drug-induced pneumonitis, idiopathic pneumonitis or active pneumonitis ≥ grade 2 * History of inflammatory bowel disease or colitis ≥ grade 2 * History of hemophagocytic lymphohistiocytosis. * Systemic chronic steroid therapy (\>10mg/d prednisone or equivalent) * Active infection, including infection requiring systemic antibiotic therapy * Pregnant or breast-feeding (lactating) women * Participants with a history of allogeneic organ transplantation (e.g., stem cell or solid organ transplant) * Any medical condition that would in the investigator's judgement prevent the participant's participation in the clinical study"
NCT05123391,Technical Feasibility of a Randomized Pilot Study of Radiosurgery for the Treatment of Non-metastatic Prostate Cancer,,NA,Chile,"Pontificia Universidad Catolica de Chile, Santiago, Chile, [RECRUITING]",Prostatic Neoplasms | Radiosurgery | Quality of Life,6,"[1] Low-Intermediate favorable risk 5 Fraction SBRT arm (EXPERIMENTAL): 36.25 Gy in 5 fractions to the prostate weekly or every other day || [2] Low-Intermediate favorable risk 2 Fraction SBRT arm (EXPERIMENTAL): 26 Gy in 2 fractions to the prostate || [3] Intermediate unfavorable-high risk prostate only SBRT arm (EXPERIMENTAL): 36.25 Gy in 5 fractions to the prostate and seminal vesicles base, weekly or every other day || [4] Intermediate unfavorable-high risk prostate and pelvis SBRT arm (EXPERIMENTAL): 25 Gy in 5 fractions to the elective pelvic nodes and simultaneous integrated boost to 36.25 Gy in 5 fractions to the prostate and seminal vesicles base, weekly || [5] Pelvic node positive moderate hypofractionated radiotherapy (EXPERIMENTAL): 44 Gy in 20 daily fractions to the elective pelvic nodes and simultaneous integrated boost to 60 Gy to the prostate and seminal vesicles base and 54 Gy to positive lymph nodes || [6] Pelvic node positive moderate ultra-hypofractionated radiotherapy (EXPERIMENTAL): 25 Gy in 5 fractions to the elective pelvic nodes and simultaneous integrated boost to 36.25 Gy in 5 fractions to the prostate and seminal vesicles base and to 30 Gy to positive lymph nodes.","* Histology confirmed prostate cancer * Disease confined to the pelvis by imaging CT (CT scan of chest, abdomen and pelvis and bone scan or prostate specific membrane antigen positron emission tomography (PET-PSMA) if required according to local guidelines) * Eastern Cooperative Oncology Group (ECOG) performance 0-1 * Eligible for curative radiotherapy",* Metastasis beyond the pelvis * Poor performance ECOG 2-4 * Cannot follow directions to prepare for simulation (bladder filling and rectal emptying)
NCT06225596,A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2),,"PHASE2, PHASE3","Argentina, Brazil, Chile","Centro de Diagnostico Urologico S.R.L., Buenos Aires, Argentina, [RECRUITING] | Hospital Britanico de Buenos Aires, Buenos Aires, Argentina, [RECRUITING] | Hospital Sirio Libanes de Buenos Aires, Buenos Aires, Argentina, [RECRUITING] | Instituto Alexander Fleming, Buenos Aires, Argentina, [RECRUITING] | Fundacion Medica Rio Negro y Neuquen, Cipolletti, Argentina, [RECRUITING] | Centro Medico Privado (CEMAIC), Córdoba, Argentina, [RECRUITING] | Fundación CORI para la investigación y Prevención del Cancer, La Rioja, Argentina, [RECRUITING] | Centro De Investigacion Pergamino S.A., Pergamino, Argentina, [RECRUITING] | Instituto de Oncologia de Rosario, Santa Fe, Argentina, [RECRUITING] | Clinica Viedma S.A., Viedma, Argentina, [RECRUITING]",Metastatic Urothelial Cancer,6,[1] Cohort 1: BT8009 Arm 1 (EXPERIMENTAL): Participants will receive BT8009 and a standard dose of pembrolizumab. || [2] Cohort 1: BT8009 Arm 2 (EXPERIMENTAL): Participants will receive BT8009 and a standard dose of pembrolizumab. || [3] Cohort 1: Arm 3 (ACTIVE_COMPARATOR): Participants will receive Platinum-based combination chemotherapy +/- avelumab maintenance || [4] Cohort 2: BT8009 Arm 1 (EXPERIMENTAL): Participants will receive BT8009. || [5] Cohort 2: BT8009 Arm 2 (EXPERIMENTAL): Participants will receive BT8009. || [6] Cohort 2: Arm 3: BT8009 (Not Recruiting) (EXPERIMENTAL): Participants will receive BT8009 and a standard dose of pembrolizumab.,"* Life expectancy ≥ 12 weeks. * Measurable disease as defined by RECIST v1.1. * Histologically or cytologically confirmed locally advanced (unresectable) or metastatic UC of the renal pelvis, ureter, bladder, or urethra. * Archival or fresh tumor tissue comprising muscle-invasive UC or locally advanced or metastatic UC should be available for submission to central laboratory. * Negative pregnancy test for women of childbearing potential (WOCBP) (negative serum test at Screening and negative urine or serum test within 72 hours prior to the first dose). * Cohort 1: Previously Untreated: Eligible to receive platinum-based chemotherapy (either cisplatin- or carboplatin-based chemotherapy based on Investigator decision. * Cohort 1: Participants must not have received prior systemic therapy for locally advanced or metastatic UC with the following exceptions: 1. Prior local intravesical chemotherapy, local surgery when full resection is not achieved, local immunotherapy, and radiotherapy are permitted if completed at least 4 weeks prior to the initiation of study treatment and all acute toxicities have resolved. 2. Prior neoadjuvant/adjuvant chemotherapy or monomethyl auristatin E (MMAE)-based therapy with recurrence \>12 months from completion of therapy. 3. Prior neoadjuvant/adjuvant immune checkpoint inhibitor therapy with recurrence \>12 months from completion of therapy. * Cohort 2: Previously Treated: Participants must have received ≥ 1 prior systemic treatment for locally advanced or metastatic UC. This includes neoadjuvant/adjuvant platinum-based chemotherapy if recurrence occurred within 12 months of completing therapy. * Cohort 2: Progression or recurrence of UC during or following receipt of most recent therapy. Key","* Active keratitis or corneal ulcerations. * Requirement, while on study, for treatment with strong inhibitors or strong inducers of human cytochrome P450 3A (CYP3A) or inhibitors of P-glycoprotein (P-gp) including herbal- or food-based inhibitors. * Any condition requiring current treatment with high dose corticosteroids (\> 10 mg daily prednisone or equivalent). * Known hypersensitivity or allergy to any of the ingredients of any of the study interventions, or to MMAE. * Has not adequately recovered from recent major surgery (excluding placement of vascular access). * Receipt of live or attenuated vaccine within 30 days of first dose. * Cohort 1: Previously Untreated: Prior treatment with a checkpoint inhibitor (CPI) for any other malignancy within the last 12 months. * Cohort 2: Previously Treated: Received more than 1 prior platinum-based chemotherapy regimen for locally advanced or metastatic UC. This includes neoadjuvant/adjuvant platinum-based chemotherapy if recurrence occurred within 12 months of completing therapy. * Cohort 2: Prior treatment with enfortumab vedotin or any other MMAE-based therapy"
NCT06531460,Effect of Perioperative Nutrition Enriched With Omega-3 on the Incidence of Infections in Oncologic Patients Following Lung Resection,,NA,Mexico,"National Institute of Respiratory Diseases, Mexico City, Mexico, [RECRUITING]",Lung Cancer | Surgery,4,[1] Experimental enteral nutrition (EXPERIMENTAL): Patients admitted to the hospital at least three days before surgery Use of an enteral feeding tube to administer enriched enteral formula || [2] Experimental oral nutrition (EXPERIMENTAL): Patients admitted one day before surgery. Home-self administration of enriched enteral formula three days before surgery || [3] Standard enteral nutrition (OTHER): Patients admitted to the hospital at least three days before surgery Use of an enteral feeding tube to administer standard enteral formula || [4] Standard oral nutrition (OTHER): Patients admitted one day before surgery. Home-self administration of standard enteral formula three days before surgery,* Lung cancer diagnosis * Elective surgery for lung resection schedule at least four days before surgery * Signed informed consent.,* Acute or chronic organ failure as hepatic or renal insufficiency * Patients with fish-allergy * History of any surgery within 3 months * Immunocompromised patients
NCT06742996,A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma,,PHASE3,"Argentina, Brazil, Puerto Rico","Hospital Aleman, CABA, Argentina, [RECRUITING] | FUNDALEU, Caba, Argentina, [NOT_YET_RECRUITING] | Hospital Italiano de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Hospital Universitario de Cordoba, Córdoba, Argentina, [NOT_YET_RECRUITING] | Fundacao Pio Xii Hospital de Amor de Barretos, Barretos, Brazil, [RECRUITING] | Hospital Felicio Rocho, Belo Horizonte, Brazil, [RECRUITING] | Universidade de Campinas Centro de Hematologia E Hemoterapia, Campinas, Brazil, [RECRUITING] | Hospital Erasto Gaertner, Curitiba, Brazil, [RECRUITING] | Instituto Joinvilense de Hematologia E Oncologia, Joinville, Brazil, [RECRUITING] | Fundacao Universidade de Caxias Do Sul Instituto de Pesquisas Em Saude, Petrópolis, Brazil, [RECRUITING]",Mantle Cell Lymphoma | B Cell Lymphoma,2,[1] Arm A: sonrotoclax plus zanubrutinib (EXPERIMENTAL): Sonrotoclax and zanubrutinib will be administered in combination. || [2] Arm B: placebo plus zanubrutinib (PLACEBO_COMPARATOR): Placebo and zanubrutinib will be administered in combination.,"* Histologically confirmed diagnosis of MCL based on the World Health Organization 2022 classification of Haematolymphoid Tumors (WHO-HAEM5), or based on International Consensus Classification (ICC) * Received 1 to 5 prior lines of systemic therapy including an anti-CD20 monoclonal antibody (mAb)-based immunotherapy or chemoimmunotherapy and requiring treatment in the opinion of the investigator * Relapsed or refractory disease after the last line of therapy * Measurable disease defined as ≥ 1 nodal lesion that is \> 1.5 cm in longest diameter, or ≥ 1 extranodal lesion that is \> 1 cm in longest diameter * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2 * Adequate organ function",* Prior therapy with B-cell lymphoma-2 inhibitor * Prior therapy with covalent or non-covalent Bruton tyrosine kinase inhibitor (BTKi) unless the participant was intolerant of non-zanubrutinib covalent or non-covalent BTKi * Prior autologous stem cell transplantation or chimeric antigen receptor T-cell therapy within 3 months before first dose of study drug * Prior allogeneic stem cell transplant within 6 months of the first dose of the study drug * Known central nervous system involvement by lymphoma * Clinically significant cardiovascular disease * History of stroke or intracranial hemorrhage within 6 months before first dose of study drug Note: Other protocol defined Inclusion/Exclusion criteria may apply.
NCT05502237,"A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations",STAR-121,PHASE3,"Argentina, Brazil, Chile, Mexico","Investigaciones CORI S.R.L., Capital, Argentina, [RECRUITING] | Centro Médico Privado Centro de Especialidades Médicas Ambulatorias e Investigación Clínica, Cardoba, Argentina, [RECRUITING] | Centro Medico Barrio Parque, Ciudad Autanoma Buenos Aires, Argentina, [WITHDRAWN] | Sanatorio Allende, Córdoba, Argentina, [RECRUITING] | Sanatorio Britanico de Rosario, Rosario, Argentina, [RECRUITING] | Sanatorio Parque de Rosario, Rosario, Argentina, [RECRUITING] | Hospital Provincial del Centenario, Rosario, Argentina, [RECRUITING] | Instituto Medico de la Fundacion Estudios Clinicos, Rosario, Argentina, [RECRUITING] | CAIPO - Centro para la Atención Integral del Paciente Oncológico, San Miguel de Tucumán, Argentina, [WITHDRAWN] | Clínica Viedma, Viedma, Argentina, [RECRUITING]",Non-small Cell Lung Cancer,3,"[1] Zimberelimab (ZIM) +Domvanalimab (DOM) + Chemotherapy (EXPERIMENTAL): Participants will receive ZIM 360 mg + DOM 1200 mg (up to 35 doses) with chemotherapy every 3 weeks (Q3W) on Day 1 of each 21-day cycle.

Choice of chemotherapy is dependent on histology.

* Partic... || [2] Pembrolizumab (PEMBRO) + Chemotherapy (ACTIVE_COMPARATOR): Participants will receive PEMBRO 200 mg (up to 35 doses) with chemotherapy Q3W on Day 1 of each 21-day cycle.

Choice of chemotherapy is dependent on histology.

* Participants with nonsquamous his... || [3] Zimberelimab (ZIM) + Chemotherapy (EXPERIMENTAL): Participants will receive ZIM 360 mg (up to 35 doses) with chemotherapy Q3W on Day 1 of each 21-day cycle.

Choice of chemotherapy is dependent on histology.

* Participants with nonsquamous histol...","* Life expectancy ≥ 3 months. * Pathologically documented NSCLC that meets both of the criteria below: * Have documented evidence of Stage IV NSCLC disease at the time of enrollment (based on American Joint Committee on Cancer (AJCC), Eighth Edition). * Have documented negative test results for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations. * Have no actionable genomic alterations such as ROS proto-oncogene 1 (ROS1), neurotrophic tyrosine receptor kinase (NTRK), proto-oncogene B-raf (BRAF), RET mutations, or other driver oncogenes with approved frontline therapies. * Have not received prior systemic treatment for metastatic NSCLC. * Measurable disease per RECIST v1.1 criteria by investigator assessment. * Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1. * Have adequate organ functions. Key","* Have mixed small-cell lung cancer (SCLC) and NSCLC histology. * Positive serum pregnancy test or individuals who are breastfeeding or have plans to breastfeed during the study period. * Received prior treatment with any anti-PD-1, anti-PD-L1, or any other antibody targeting an immune checkpoint. * Known hypersensitivity to the study drug, its metabolites, or formulation excipient. * Have an active second malignancy or have had an active second malignancy within 3 years prior to enrollment. * Have an active autoimmune disease that required systemic treatment in past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). * Are receiving chronic systemic steroids. * Have significant third-space fluid retention. * Have untreated central nervous system (CNS) metastases and/or carcinomatous meningitis. * Active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or gastrointestinal perforation within 6 months of enrollment. * Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease. * Has had an allogenic tissue/solid organ transplant. * Have received a live-virus vaccination within 30 days of planned treatment start. Seasonal flu and COVID-19 vaccines that do not contain live virus are permitted. * Have known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Note: Other protocol defined Inclusion/Exclusion criteria may apply."
NCT06881784,"RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC",RASolve 301,PHASE3,Puerto Rico,"Pan American Center for Oncology Trials, San Juan, Puerto Rico, [RECRUITING]",NSCLC (Non-small Cell Lung Cancer) | Non-Small Cell Lung Cancer | NSCLC | NSCLC (Non-small Cell Lung Carcinoma) | NSCLC (Advanced Non-small Cell Lung Cancer),2,[1] daraxonrasib (EXPERIMENTAL): study drug || [2] docetaxel (ACTIVE_COMPARATOR): Patients randomized to the comparator control arm will receive docetaxel as the standard of care therapy.,"* At least 18 years old and has provided informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Histologically confirmed NSCLC, either locally advanced or metastatic, not amenable to curative surgery or radiotherapy. * Measurable disease per RECIST v1.1. * Adequate organ function (bone marrow, liver, kidney, coagulation). * One to two prior lines of therapy including an anti-PD-1/anti-PD(L)-1 agent and platinum-based chemotherapy. * Documented RAS mutation status, defined as Nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61). * Able to take oral medications.","* Prior therapy with direct RAS-targeted therapy or docetaxel. * Untreated central nervous system (CNS) metastases. * Medically significant comorbidities (significant cardiovascular disease, lung disease, or impaired GI function). * Ongoing anticancer therapy. * Pregnancy and/or breastfeeding."
NCT03486873,"A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab",,PHASE3,"Argentina, Brazil, Chile, Colombia, Costa Rica, Guatemala, Mexico, Peru, Puerto Rico","Centro de Oncología e Investigación de Buenos Aires ( Site 1357), Berazategui, Argentina, [RECRUITING] | Fundacion Favaloro ( Site 1367), CABA, Argentina, [RECRUITING] | Instituto Alexander Fleming ( Site 1364), Ciudad Autónoma de Buenos Aires, Argentina, [RECRUITING] | IDIM - Instituto de Investigaciones Metabólicas ( Site 1362), Ciudad de Buenos Aires, Argentina, [RECRUITING] | Instituto de Investigaciones Clínicas Mar del Plata ( Site 1363), Mar del Plata, Argentina, [RECRUITING] | Clinica Viedma ( Site 1353), Viedma, Argentina, [RECRUITING] | Fundacion Estudios Clinicos ( Site 1369), Rosario, Argentina, [RECRUITING] | Sanatorio Parque ( Site 1355), Rosario, Argentina, [RECRUITING] | Instituto de Oncologia de Rosario ( Site 1350), Rosario, Argentina, [RECRUITING] | Hospital Provincial del Centenario ( Site 1359), Rosario, Argentina, [RECRUITING]",Solid Tumors | Hematologic Malignancies,15,[1] Pembrolizumab 200 mg (EXPERIMENTAL): Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations or more for First Course participants and up to 17 administrations... || [2] Pembrolizumab 400 mg (EXPERIMENTAL): Participants receive pembrolizumab 400 mg via intravenous (IV) infusion on Day 1 of each 6-week cycle for up to 17 administrations or more for First Course participants and up to 8 administrations ... || [3] Pembrolizumab 200 mg + SOC: Per Parent Study) (EXPERIMENTAL): Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle PLUS standard of care (SOC) treatment (or per parent study if there is no SOC) for up to 35 administrations o... || [4] Pembrolizumab 400 mg + SOC (Per Parent Study) (EXPERIMENTAL): Participants receive pembrolizumab 400 mg via IV infusion on Day 1 of each 6-week cycle PLUS SOC treatment (or per parent study if there is no SOC) for up to 17 administrations or more for First Co... || [5] SOC (Per Parent Study) (ACTIVE_COMPARATOR): Participants receive the dose matched non-pembrolizumab SOC treatment (e.g. chemotherapy) they were receiving as per parent study protocol. || [6] Lenvatinib 20 mg (EXPERIMENTAL): Participants with body weight (BW)\>60kg receive Lenvatinib 20mg orally once daily on a 21 or 42 day cycle. It is taken 0-4 hours after completion of pembrolizumabd administration in the clinic on ... || [7] Lenvatinib 24 mg (EXPERIMENTAL): Participants with body weight (BW)\>60 kg receive Lenvatinib 24 mg orally once daily on a 21 or 42 day cycle. It is taken 0-4 hours after completion of pembrolizumabd administration in the clinic o... || [8] Lenvatinib 12 mg (EXPERIMENTAL): Participants with body weight (BW)\>60 kg receive Lenvatinib 12 mg orally once daily on a 21 or 42 day cycle. It is taken 0-4 hours after completion of pembrolizumabd administration in the clinic o... || [9] Lenvatinib 8 mg (EXPERIMENTAL): Participants with bo,"* Treated on the parent pembrolizumab studies established by the Sponsor as MK-3475-587 ready. * Currently receiving pembrolizumab, pembrolizumab based combinations or lenvatinib from parent studies or in a follow-up phase. Additional eligibility criteria for participants who enter Second Course Phase once they are enrolled on MK-3475-587: * Has not received any anticancer systemic treatment since the last dose of pembrolizumab or a pembrolizumab-based combination in First Course Phase. * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Demonstrates adequate organ function. * Have resolution of any toxic effect(s) of First Course Phase trial treatment with pembrolizumab or a pembrolizumab-based combination to Grade 1 or less (except alopecia) before trial treatment in Second Course Phase is started. If participant received major surgery or radiation therapy of \>30 Gray (Gy), they must have recovered from the toxicity and/or complications of the intervention. * A female participant is eligible to enroll if she is not pregnant, not breastfeeding, and ≥1 of the following conditions applies: A woman of childbearing potential (WOCBP) who agrees to use contraception during the study treatment period and for ≥120 days (corresponding to time needed to eliminate any study combination treatment(s) plus 30 days (a menstruation cycle) for study treatments with risk of genotoxicity. Additional eligibility criteria for participants who enter dosing with Lenvatinib: * Adequately controlled blood pressure (BP) to \<150/90 mmHg, with or without antihypertensive medications. * For male agrees to be abstinent from penile-vaginal intercourse OR agrees to use a highly effective contraceptive method while receiving study drug and for 7 days after the last dose of lenvatinib. * Is female and not pregnant/breastfeeding and at least one of the following applies during the study and for ≥4 days after: is not a woman of childbearing potential (WOCBP), is a WOC","-There are no exclusion criteria to participate in MK-3475-587. Participants are excluded from entering Second Course trial treatment once they are enrolled on MK-3475-587 if any of the following criteria applies: * Has severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients. * Has received a live vaccine within 30 days prior to the first dose of Second Course Phase trial treatment. * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the Cycle 1 Day 1 of Second Course Phase. * Has a known additional malignancy that is progressing or requires active treatment. Exceptions include early stage cancers (carcinoma in situ or Stage 1) treated with curative intent, melanoma (non-ulcerated, thin primary), basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ cervical cancer, or in situ breast cancer that has undergone potentially curative therapy. * Has known active central nervous system metastases and/or carcinomatous meningitis. * Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed. * Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis. Note: Participants that experienced pneumonitis during First Course that did not meet the criteria for permanent discontinuation are eligible. * Non-small cell lung cancer (NSCLC) participants only: Has interstitial lung disease. * Has an active infection requiring systemic therapy. * Has a known history of human immunodeficiency virus (HIV) infection. * Has a known hist"
NCT06624813,Partial Robot-assisted Laparoscopic Prostatectomy for Intermediate Risk Prostate Cancer,P-RALP,NA,Brazil,"Insituto do Câncer do Estado de São Paulo, São Paulo, Brazil, [RECRUITING]",Prostate Cancer,1,[1] Partial prostatectomy (EXPERIMENTAL): Robot-assisted partial prostatectomy in patients with prostate cancer,"Patients with prostate cancer that presents an institutional (ICESP) fusion biopsy (cognitive or target) that presents 1. Fusion-guided prostate biopsy with mpMRI performed at the São Paulo State Cancer Institute, which 2. Present fragments for ISUP group grade (GG) ≤ 3 in only one of the prostate lobes 3. Multiparametric prostate resonance with PIRADS 3 - 5 and which is in agreement with the laterality of the tumor in the prostate biopsy 4. Life expectancy ≥ 10 years according to the Charlson score 5. Absence of second primary cancer under active treatment. Patients treated for cancer from other sites for more than 5 years and without evidence of disease will be allowed 6. Able to read, understand and complete the informed consent related to the research, as well as the research questionnaires on quality of life and functional parameters on erection and urinary continence",1. Patients with prostate cancer with an histology different from adenocarcinoma 2. Suspicion of lymph node metastasis on mpMRI or distant bone scintigraphy 3. definitive signs of extraprostatic extension on mpMRI 4. history of pelvic/prostatic radiotherapy 5. ISUP grade group ≥ 4 6. Laterality of prostate biopsy discordant with mpMRI findings
NCT04756713,"Impact of Second Uterine Evacuation in Women With Non-metastatic, Low-risk Gestational Trophoblastic Neoplasia: A Phase III Trial",ReCure,PHASE3,Brazil,"Paulista State University UNESP, Botucatu, Brazil, [NOT_YET_RECRUITING] | Campinas State University UNICAMP, Campinas, Brazil, [RECRUITING] | University of Caxias do Sul, Caxias do Sul, Brazil, [RECRUITING] | Federal University of Ceará, Ceará, Brazil, [RECRUITING] | Medical School of Santa Casa da Misericórdia de Porto Alegre, Porto Alegre, Brazil, [RECRUITING] | Maternidade Escola da Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, [RECRUITING] | Federal University of São Paulo UNIFESP, São Paulo, Brazil, [RECRUITING]","Gestational Trophoblastic Neoplasia | Molar Pregnancy | Gestational Trophoblastic Tumor, Non-Metastatic",2,"[1] Chemotherapy (ACTIVE_COMPARATOR): Patients allocated to receive conventional chemotherapy will be treated with methotrexate (1 mg/kg intramuscular) with rescue of folinic acid (15mg orally). In cases of chemoresistance, second-line... || [2] Uterine evacuation (EXPERIMENTAL): Patients randomized to undergo a second curettage will undergo manual or electronic vacuum aspiration under ultrasound guidance. Following discharge after the second curettage patients will return ...","* Histopathological diagnosis of molar pegnancy according to the morphological criteria described by Sebire et al., who meet the diagnostic criteria for low-risk non-metastatic GTN according to FIGO 2000 criteria","1. High risk GTN (FIGO risk score ≥ 7) or metastatic disease at diagnosis of GTN (stage II, III or IV); 2. Histopathological diagnosis of choriocarcinoma, placental site trophoblastic or epithelioid trophoblastic tumor at the second curettage; 3. Previous chemotherapy treatment; 4. Level of hCG at the time of GTN diagnosis less than 20 IU/L (to minimize the risk of inclusion of patients with false positive hCG, either by cross-reaction with pituitary hormones or by the presence of circulating heterophilic antibodies); 5. Relapsed GTN; 6. Incomplete medical records. 7. Loss to follow-up; 8. Voluntary desire to stop participating in the study."
NCT03866382,"A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)",,PHASE2,Puerto Rico,"Pan American Center for Oncology Trials LLC, San Juan, Puerto Rico, [ACTIVE_NOT_RECRUITING]",Bladder Adenocarcinoma | Bladder Clear Cell Adenocarcinoma | Bladder Mixed Adenocarcinoma | Bladder Neuroendocrine Carcinoma | Bladder Small Cell Neuroendocrine Carcinoma,1,"[1] Treatment (cabozantinib, nivolumab, ipilimumab) (EXPERIMENTAL): Patients receive cabozantinib PO QD on days 1-21 of cycles 1-4 and on days 1-28 of subsequent cycles. Patients also receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 90 minutes o...","* Metastatic disease defined as new or progressive lesions on cross-sectional imaging or bone scan. Patients must have at least: * One measurable site of disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 * One bone lesion on bone scan (tec99 or sodium fluoride \[NaF\] PET/CT, CT or MRI) for the bone-only cohort. * Histologically confirmed diagnosis of one of the following metastatic cohorts: * Small cell/ neuroendocrine carcinoma of the bladder (Cohort A)- All urothelial carcinomas with any amount of neuroendocrine differentiation (including small cell differentiation) will be included. If the tumor is purely neuroendocrine, metastasis from another site of origin should be clinically excluded * Adenocarcinoma of the bladder, or urachal adenocarcinoma, or bladder/urethra clear cell adenocarcinoma (Cohort B) - must be pure (per World Health Organization \[WHO\] definition), (i.e. urothelial carcinoma with glandular differentiation is not considered a pure adenocarcinoma * Squamous cell carcinoma of the bladder (Cohort C) - must be pure (i.e. urothelial carcinoma with squamous differentiation is not considered a pure squamous cell carcinoma) * Plasmacytoid urothelial carcinoma (Cohort D) - Tumor should show predominantly \> or equal \~ 50% plasmacytoid histology (including all types of discohesive growth, such as tumors with signet-ring and/or rhabdoid features as well) * Any penile cancer (Cohort E) * Sarcomatoid renal cell carcinoma (Cohort F) - Tumor should be predominantly sarcomatoid \~ 50% (including rhabdoid differentiation) is also unclassified renal cell carcinomas (RCCs): all (assuming they are high grade with metastasis) malignant angiomyolipomas are allowed * Other miscellaneous histologic variants of the urothelial carcinoma, such as, but not limited to (Cohort G) : Micropapillary (Tumor should show predominantly \> or equal 50% micropapillary architecture), giant cell, lipid-rich, clear cell and nested variants (Tumor sh","* Women of childbearing potential must have a negative pregnancy test =\< 7 days prior to registration * Women of childbearing potential include women who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal. Post menopause is defined as amenorrhea \>= 12 consecutive months. Note: women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, ovarian suppression or any other reversible reason * Pregnant women may not participate in this study because with cabozantinib, nivolumab, and ipilimumab have potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with cabozantinib, nivolumab, and ipilimumab, breastfeeding should be discontinued if the mother is treated with these agents * The patient has received no cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within 2 weeks before the first dose of study treatment * The patient has received no radiation therapy: * To the lungs and mediastinum or abdomen within 4 weeks before the first dose of study treatment, or has ongoing complications, or is healing from prior radiation therapy * To brain metastasis within 3 weeks for whole-brain radiotherapy (WBXRT), and 2 weeks for stereotactic body radiation therapy (SBRT) before the first dose of study treatment * To the abdomen within 4 weeks before the first dose of study treatment, or has ongoing complications, or is healing from prior radiation therapy * To any other site(s) within 2 weeks before the first dose of study treatment * The patient has received no radionuclide treatment within 6 weeks of the first dose of study treatment * The patient"
NCT03899155,Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies,,PHASE2,"Argentina, Brazil, Chile, Mexico, Peru, Puerto Rico","Local Institution - 0199, Berazategui, Argentina, [COMPLETED] | Local Institution - 0415, Río Cuarto, Argentina, [NOT_YET_RECRUITING] | Centro de Investigaciones Clinicas. Clinica Viedma S.A., Viedma, Argentina, [RECRUITING] | Local Institution - 0407, Rosario, Argentina, [NOT_YET_RECRUITING] | CAIPO Centro para la Atencion Integral del Paciente Oncologico, San Miguel de Tucumán, Argentina, [RECRUITING] | Local Institution - 0191, San Miguel de Tucumán, Argentina, [COMPLETED] | Local Institution - 0201, Buenos Aires, Argentina, [WITHDRAWN] | Instituto Fleming, Buenos Aires, Argentina, [RECRUITING] | Local Institution, CABA, Argentina, [WITHDRAWN] | Fundacion Richardet Longo - IONC, Córdoba, Argentina, [RECRUITING]",Cancer,32,[1] A1: Nivolumab Monotherapy Dose 1 (EXPERIMENTAL): No description || [2] A2: Nivolumab Monotherapy Dose 2 (EXPERIMENTAL): No description || [3] B1: Nivolumab + Ipilimumab (EXPERIMENTAL): No description || [4] B2: Nivolumab + Ipilimumab + Cabozantinib (EXPERIMENTAL): No description || [5] B3: Nivolumab + Ipilimumab + Trametinib (EXPERIMENTAL): No description || [6] C1: Relatlimab + Nivolumab Fixed Dose Combination Dose 1 (EXPERIMENTAL): No description || [7] C3: Relatlimab + Nivolumab Fixed Dose Combination Dose 2 (EXPERIMENTAL): No description || [8] C2: Relatlimab + Nivolumab Single Agent Vial (SAV) Dose 1 (EXPERIMENTAL): No description || [9] C4: Relatlimab + Nivolumab SAV Dose 2 (EXPERIMENTAL): No description || [10] C5: Relatlimab + Nivolumab + Ipilimumab (EXPERIMENTAL): No description,"* Signed Written Informed Consent. * Eligible to receive continued study treatment per the Parent Study, including treatment beyond progression per investigator assessment in the Parent Study. * On treatment hold in the Parent Study following long-lasting response or are eligible for treatment rechallenge as defined in the Parent Study. * WOCBP and male participants who are sexually active must agree to follow instructions for method(s) of contraception as described below and included in the ICF.","* Participant is not eligible for study treatment per the Parent Study eligibility criteria. * Participants not receiving clinical benefit as assessed by the Investigator. * Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness which, in the opinion of the Investigator, indicates that participation in the study is not in the best interest of the participant. * Other protocol-defined Inclusion/Exclusion Criteria apply"
NCT04510714,"A Prospective, Phase III Study to Assess the Efficacy and Safety of Microwave Ablation of Metastatic Lung Sarcoma Lesions.",BORIS,NA,Brazil,"Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil, [RECRUITING]",Sarcoma,1,[1] Microwave ablation arm (EXPERIMENTAL): Single arm patients with lung sarcoma metastasis that will be treated with microwave ablation,"* Patients over 18 years; * Patients with lung metastases arising from sarcoma; * Patients who are not eligible for surgery for medical reasons, including limited cardiopulmonary reserve. In this cases we will perform a pulmonary function test (PFT) to determine if the patient can withstand ablation; * Patients with recurrent metastases after pneumectomy or metastases after surgical resection. In this cases we will perform a PFT to determine if the patient can withstand ablation; * Patients with pulmonary lesions with dimensions up to 3,0 cm in the largest axial diameter; * Patients with four or fewer lesions. In cases of bilateral metastases, we will evaluate the treatment of only one lung at a time, with an interval of at least two weeks for the treatment of the contralateral lung, respecting the clinical evolution of the patient. * Patients with no extrapulmonary metastases or just indolent extrapulmonary disease; * Patients with prior histopathological confirmation of pulmonary lesions.","* Patients with primary disease without clinical control; * Presence of uncontrolled extrapulmonary disease, including lymph node progression; * Presence of hilar lesions or near the main bronchi; * Presence of five or more lung lesions and/or lesions larger than 3,0 cm in greatest axial length; * Presence of tumors infiltrating the chest wall, mediastinal and/or pleural dissemination; * Patients with severe coagulopathy (international normalized ratio (INR) \> 1,5 or lower platelet count to 50000/mm³); * Patients with chronic obstructive pulmonary disease (COPD) stage III/ IV; * Patients with septicemia; * Patients refusing ablation treatment or participation in the study."
NCT06447662,A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene,,PHASE1,Puerto Rico,"Pan American Center for Oncology Trials, LLC, Rio Piedras, Puerto Rico, [RECRUITING]","Carcinoma, Pancreatic Ductal | Colorectal Neoplasms | Carcinoma, Non-Small-Cell Lung",9,"[1] Part 1 (EXPERIMENTAL): PF-07934040 Monotherapy Dose Escalation PF-07934040 monotherapy at prescribed dose and frequency in 28-day cycles || [2] Part 2a Cohort A1 (EXPERIMENTAL): Monotherapy dose expansion in 2-3L PDAC. PF-07934040 at prescribed dose and frequency in 28-day cycles || [3] Part 2a Cohort B1 (EXPERIMENTAL): Monotherapy dose expansion in 2-3L CRC. PF-07934040 at prescribed dose and frequency in 28-day cycles || [4] Part 2a Cohort C1 (EXPERIMENTAL): Monotherapy dose expansion in 2-3L NSCLC. PF-07934040 at prescribed dose and frequency in 28-day cycles || [5] Part 2b Cohort A2 (EXPERIMENTAL): Combination (PF-07934040 + Gemcitabine + Nab-paclitaxel) dose escalation/expansion in 1L PDAC.

Prescribed dose and frequency in 28-day cycles || [6] Part 2b Cohort B2 (EXPERIMENTAL): Combination (PF-07934040 + Cetuximab) dose escalation/expansion in 2-3L CRC

Prescribed dose and frequency in 28-day cycles || [7] Part 2b Cohort B3 (EXPERIMENTAL): Combination (PF-07934040 + FOLFOX + Bevacizumab) dose escalation/expansion in 1L CRC

Prescribed dose and frequency in 28-day cycles || [8] Part 2b Cohort C2 (EXPERIMENTAL): Combination (PF-07934040 + Pembro) dose escalation/expansion in 1L NSCLC (TPS ≥ 50%)

Prescribed dose and frequency in 21-day cycles || [9] Part 2b Cohort C3 (EXPERIMENTAL): Combination (PF-07934040 + Pembro + Platinum Chemo) dose escalation/expansion in 1L NSCLC (any TPS)

Prescribed dose and frequency in 21-day cycles","* Histological or cytological diagnosis of advanced, unresectable, and/or metastatic or relapsed/refractory solid tumor. ECOG PS 0 or 1 * Presence of at least 1 measurable lesion based on RECIST version 1.1 that has not been previously irradiated. * Documentation of mutated KRAS gene 1. PDAC, CRC, Other tumor types: Confirmed KRAS mutation, any variant 2. NSCLC: Confirmed KRAS mutation, any variant except previously treated G12C. If driver mutation, must have failed precision medicine therapy \[eg, inhibitors of epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), and others\]. * Part 1 and Part 2a: Participant must have progressed on standard treatment(s) for which no additional, effective therapy is available. 1. PDAC (2-3L): Participants must have received and radiologically progressed on prior lines of systemic therapy for metastatic pancreatic adenocarcinoma. If participants received prior neoadjuvant or adjuvant chemotherapy and progressed within 6 months of the last dose, then this should be considered as a prior line of systemic therapy. 2. NSCLC (2-3L): Participants must have received prior lines of anti-cancer treatment and progressed on at least a platinum-containing chemotherapy regimen and checkpoint inhibitor therapy; for participants with EGFR, ALK, or other genomic tumor alterations, participants must have progressed on approved therapy for these alterations. 3. CRC (2-3L): Participants must have had one or two prior systemic treatment regimens for mCRC. For either one or two prior treatments, these regimens must have included a fluoropyrimidine, oxaliplatin, or irinotecan; for one prior treatment, exposure to VEGF/VEGF receptor (VEGFR) inhibitor is optional; 4. Other tumors: Participants, in the judgment of the investigator, must have progressed or become intolerant to all available standard therapies, or have refused such therapy. * Part 2b: 1. PDAC (1L) Cohort A2: Participants must not have received p","* Active or history of pneumonitis/ILD, pulmonary fibrosis requiring treatment with systemic steroid therapy, including evidence to suggest pneumonitis/ILD on baseline assessments including imaging. * Diagnosis of immunodeficiency or an active autoimmune disease that require systemic treatment with chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy in the past 2 years. * Sensory peripheral neuropathy ≥Grade 2 * Active or history of clinically significant gastrointestinal (GI) disease (including but not limited to inflammatory GI disease \[eg, ulcerative colitis, Crohn's disease, inflammatory bowel disease\], immune-mediated colitis, peptic ulcer disease, GI bleeding, chronic diarrhea) and other conditions that are unresolved and/or may increase the risk associated with study participation or study treatment administration. * Active bleeding disorder, including GI bleeding, as evidenced by hematemesis, significant hemoptysis or melena in the past 6 months. * Major surgery or completion of radiation therapy ≤4 weeks prior to enrollment/randomization or radiation therapy that included \>30% of the bone marrow. * Known sensitivity or contraindication to any component of study intervention (PF 07934040, gemcitabine, nab-paclitaxel, cetuximab, bevacizumab, FOLFOX, 5-FU, pembrolizumab, cisplatin, carboplatin, pemetrexed, SHP2 inhibitor(s), cyclin-dependent kinase (CDK) inhibitor(s), antibody drug conjugates (ADCs) or EGFR inhibitor(s)). * Hematologic abnormalities. * Renal impairment. * Hepatic abnormalities."
NCT04698252,Local Therapy for Hormone Receptor-positive Oligometastatic Breast Cancer - a Phase II Randomized Trial,LARA,PHASE2,Brazil,"ICESP, São Paulo, Brazil, [RECRUITING]",Breast Cancer,2,"[1] Systemic therapy (NO_INTERVENTION): Patients will receive standard of care with systemic therapy alone. || [2] Local therapy + systemic therapy (EXPERIMENTAL): In addition to systemic therapy, patients will receive local therapy for all oligometastatic sites. Options of local therapy will be radiotherapy, radiofrequency ablation, and/ or surgery.","* Female sex * ≥ 18 years of age * Histologically confirmed invasive breast cancer, with oligometastatic disease defined as one of the following criteria: 1) One to four bone lesions; 2) One to four lung and/ or hepatic lesions; 3) Distant metastasis limited to ipsilateral cervical lymph nodes; 4) Distant metastasis limited to contralateral axillary lymph nodes * Oligometastatic sites amenable to treatment with a local therapy modality, including surgical resection, stereotactic radiotherapy, or radiofrequency ablation * Estrogen receptor-positive and/ or progesterone receptor-positive breast cancer * Partial response or stable disease after at least six months of systemic therapy for breast cancer * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Measurable or non-measuble disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 * Life expectancy of at least 12 weeks * For women in childbearing age, negative pregnancy test until 21 days before the date of study enrollment. * Signed informed consent form * Disposition and aptitude to fulfill the study protocol during the study duration","* HER2-positive breast cancer * Progressive disease during the last systemic treatment received for metastatic disease * Previous local therapy for distant metastasis * Current or previous history of severe diseases, such as clinically relevant heart failure, acute myocardium infarction in the last six months, chronic obstructive lung disease, HIV infection, chronic active hepatitis B or C infection, current serious uncontrolled infections or other severe diseases that may impact patients' expected survival) * Current or previous history of other invasive malignancy within the last five years, excluding non-melanoma skin cancer"
NCT06952504,"A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)",TroFuse-033,PHASE3,"Argentina, Brazil, Chile, Colombia, Peru, Puerto Rico","Instituto Alexander Fleming ( Site 0105), Ciudad Autónoma de Buenos Aires, Argentina, [RECRUITING] | Instituto de Investigaciones Clínicas Mar del Plata ( Site 0108), Mar del Plata, Argentina, [RECRUITING] | Fundación Respirar ( Site 0101), Buenos Aires, Argentina, [RECRUITING] | Hospital Británico de Buenos Aires ( Site 0103), CABA, Argentina, [RECRUITING] | Instituto San Marcos ( Site 0106), San Juan, Argentina, [RECRUITING] | IBCC - Instituto Brasileiro de Controle do Câncer ( Site 0525), São Paulo, Brazil, [RECRUITING] | Centro de Estudios Clínicos SAGA ( Site 0708), Santiago, Chile, [RECRUITING] | FALP ( Site 0702), Santiago, Chile, [RECRUITING] | Pontificia Universidad Catolica de Chile ( Site 0705), Santiago, Chile, [RECRUITING] | Bradfordhill ( Site 0703), Santiago, Chile, [RECRUITING]",Endometrial Cancer,4,"[1] Maintenance Treatment Arm A: Pembrolizumab + Sacituzumab Tirumotecan (EXPERIMENTAL): During the Induction Phase, participants receive pembrolizumab 200 mg, carboplatin area under the curve (AUC) 5 (mg/mL/min), and paclitaxel 175 mg/m2 or docetaxel 75 mg/m2 on Day 1 of each 3-week c... || [2] Maintenance Treatment Arm B: Pembrolizumab Monotherapy (ACTIVE_COMPARATOR): During the Induction Phase, participants receive pembrolizumab 200 mg, carboplatin AUC 5 (mg/mL/min), and paclitaxel 175 mg/m2 or docetaxel 75 mg/m2 on Day 1 of each 3-week cycle for 6 cycles (up t... || [3] Subsequent Treatment Arm A: Pembrolizumab + Sacituzumab Tirumotecan (EXPERIMENTAL): During the Induction Phase, participants receive pembrolizumab 200 mg, carboplatin AUC 5 (mg/mL/min), and paclitaxel 175 mg/m2 or docetaxel 75 mg/m2 on Day 1 of each 3-week cycle for 6 cycles (up t... || [4] Subsequent Treatment Arm B: Sacituzumab Tirumotecan Monotherapy (ACTIVE_COMPARATOR): During the Induction Phase, participants receive pembrolizumab 200 mg, carboplatin AUC 5 (mg/mL/min), and paclitaxel 175 mg/m2 or docetaxel 75 mg/m2 on Day 1 of each 3-week cycle for 6 cycles (up t...","* Has a histologically confirmed diagnosis of primary advanced or recurrent endometrial carcinoma that has been confirmed as proficient mismatch repair (pMMR) * Has radiographically evaluable disease, with measurable Stage III or either measurable or non-measurable Stage IV or recurrent disease per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1), as assessed by the investigator. * Has received no prior systemic therapy for endometrial carcinoma except the following conditions as pre-specified by the protocol: 1 prior line of systemic platinum-based adjuvant and/or neoadjuvant chemotherapy in the setting of curative-intent, prior radiation with or without radiosensitizing chemotherapy if \>2 weeks before the start of induction treatment, or prior hormonal therapy for treatment of endometrial carcinoma that was discontinued ≥1 week before the start of induction treatment","* Has carcinosarcoma, neuroendocrine tumors or endometrial sarcoma, including stromal sarcoma, leiomyosarcoma, adenosarcoma, or other types of sarcomas * Has endometrial carcinoma of any histology that is mismatch repair deficient (dMMR) * Is a candidate for curative-intent surgery or curative-intent radiotherapy at the time of enrollment * Has a history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing * Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease * Has uncontrolled, significant cardiovascular disease or cerebrovascular disease * Human Immunodeficiency Virus-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Received prior therapy in any setting with any of the following: anti-programmed cell death 1 protein, anti-programmed cell death ligand 1, anti-programmed cell death ligand 2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor; trophoblast cell surface antigen 2-targeted antibody drug conjugate; or topoisomerase I inhibitor-containing antibody drug conjugate"
NCT05920356,"A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)",,PHASE3,"Argentina, Brazil, Chile, Colombia, Mexico, Peru","Hospital Britanico de Buenos Aires, CABA, Argentina, [RECRUITING] | Instituto Alexander Fleming, Capital Federal, Argentina, [RECRUITING] | Instituto Argentino de Diagnostico y Tratamiento IADT, Ciudad Autónoma de Buenos Aires, Argentina, [RECRUITING] | Hospital Italiano de La Plata, La Plata, Argentina, [RECRUITING] | Fundacion Ars Medica, San Salvador de Jujuy, Argentina, [RECRUITING] | Clinica Viedma, Viedma, Argentina, [RECRUITING] | Sanatorio Parque SA, Rosario, Argentina, [RECRUITING] | Centro Oncologico Korben, Buenos Aires, Argentina, [RECRUITING] | Fundacion Centro Oncológico Riojano Integral para la Investigación y Prevención del Cáncer, La Rioja, Argentina, [RECRUITING] | Centro de Diagnostico Investigacion y Tratamiento, Salta, Argentina, [RECRUITING]",Non-Small Cell Lung Cancer (NSCLC),2,[1] Sotorasib combined with carboplatin and pemetrexed (EXPERIMENTAL): Sotorasib administered in combination with carboplatin and pemetrexed. || [2] Pembrolizumab combined with carboplatin and pemetrexed (ACTIVE_COMPARATOR): Pembrolizumab administered in combination with carboplatin and pemetrexed.,* Histologically or cytologically confirmed diagnosis of nonsquamous stage IV or advanced Stage IIIB or IIIC NSCLC with KRAS p. G12C mutation and negative for PD-L1 expression by central testing or local laboratory testing confirmed through central testing * No history of systemic anticancer therapy in metastatic/non-curable settings * Eastern Cooperative Oncology Group (ECOG) ≤ 1,"* Mixed histology NSCLC with either small-cell or large-cell neuroendocrine cell component or predominant squamous cell histology * Participants with tumors known to harbor molecular alterations for which targeted therapy is locally approved as a front-line therapy * Symptomatic (treated or untreated) brain metastases * Gastrointestinal (GI) tract disease causing the inability to take oral medication * Myocardial infarction within 6 months of randomization, unstable arrhythmias, or unstable angina * Prior therapy with a KRAS G12C inhibitor"
NCT07063745,A Randomized Phase 2/3 Study of BMS-986504 in Combination With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion,MountainTAP-29,"PHASE2, PHASE3","Brazil, Colombia, Mexico","Local Institution - 0088, Vitória, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0079, Natal, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0346, Porto Alegre, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0085, Blumenau, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0081, Barretos, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0076, Bauru, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0094, Campinas, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0355, São Caetano do Sul, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0351, São José do Rio Preto, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0095, São Paulo, Brazil, [NOT_YET_RECRUITING]",Metastatic Non-small Cell Lung Cancer With MTAP Deletion,6,[1] Arm A: BMS-986504 + Pembrolizumab + Chemotherapy (ACTIVE_COMPARATOR): No description || [2] Arm B: BMS-986504 + Pembrolizumab + Chemotherapy (ACTIVE_COMPARATOR): No description || [3] Arm C: Placebo + Pembrolizumab + Chemotherapy (PLACEBO_COMPARATOR): No description || [4] Arm D: Placebo + Pembrolizumab + Chemotherapy (PLACEBO_COMPARATOR): No description || [5] Arm E: BMS-986504 + Pembrolizumab + Chemotherapy (ACTIVE_COMPARATOR): No description || [6] Arm F: Placebo + Pembrolizumab + Chemotherapy (PLACEBO_COMPARATOR): No description,"* Participants must have Metastatic (Stage IV or recurrent) non-small cell lung cancer (NSCLC) (as defined by the American Joint Committee on Cancer, Ninth Edition) with no prior systemic anti-cancer therapy for metastatic disease. * Participants must have histologically confirmed diagnosis of NSCLC and homozygous methylthioadenosine phosphorylase (MTAP) deletion or MTAP loss. * Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. * Participants must have at least 1 measurable lesion as per RECIST v1.1.","* Nonsquamous participants must not have documented targetable oncogenic mutation or actionable genetic alterations (AGAs) for which there is a standard of care (SoC) available as first-line (1L) therapy. * Participants must not have symptomatic brain metastases or spinal cord compression. * Participants must not have any prior systemic therapy (chemotherapy, immunotherapy, targeted therapy, or biological therapy) for metastatic non-small cell lung cancer (mNSCLC). Note: One cycle of SoC treatment prior to randomization will be allowed for participants who require immediate treatment if clinically indicated. * Participants must not have any known or suspected impairment of gastrointestinal function that may prohibit the ability to absorb or swallow an oral medication without chewing or crushing. * Other protocol-defined Inclusion/Exclusion criteria apply."
NCT05668650,"Randomized, Multicenter, Multinational, Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) Versus Keytruda® in Subjects With Stage IV NSCLC",,PHASE3,Argentina,"Clínica Viedma, Viedma, Argentina, [RECRUITING]",Non Small Cell Lung Cancer Metastatic,2,"[1] Medical Reference Product (ACTIVE_COMPARATOR): Keytruda® will be administered as monotherapy, on Day 1 of every 3-week cycle (21 days), during the Main Study Period (6 cycles) unless there is disease progression, intolerance to the study drug, ... || [2] Investigational Product (EXPERIMENTAL): MB12 will be administered as monotherapy, on Day 1 of every 3-week cycle (21 days), during the Main Study Period (6 cycles) unless there is disease progression, intolerance to the study drug, or tr...","Individuals must meet all of the following criteria to be included in the study: 1. Willing and able to provide written informed consent for the study before the initiation of any study-specific procedures. 2. Greater than or equal to 18 years of age at the time of signing the ICF. 3. Body weight ≥50 kg at Screening. 4. Having newly diagnosed stage IV (defined by the eighth edition of the TNM classification) non-squamous NSCLC, without prior systemic treatment for the disease. For those subjects in whom the pleural or pericardial effusion is the only location of metastatic disease, confirmation of its malignant etiology is required. 5. At least 1 radiographically measurable lesion per RECIST version 1.1, locally assessed. 6. Programmed death-ligand 1 (PD-L1) expression ≥50%, locally determined by immunohistochemistry, as determined by a Food and Drug Administration (FDA) validated method. 7. Life expectancy of at least 3 months. 8. ECOG performance status of 0 to 1. 9. Adequate hepatic, renal, hematologic, endocrine, and coagulation function, defined as: 1. Liver function: bilirubin level ≤1.5 × the upper limit of normal (ULN) (≤3 × ULN for subjects with Gilbert's syndrome), albumin level ≥ lower limit of normal (LLN), aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤2.5 × ULN in subjects without liver metastases or ≤5 × ULN in subjects with liver metastases. 2. Renal function: serum creatinine level ≤1.5 × ULN, calculated creatinine clearance ≥50 mL/min (Cockcroft-Gault formula). 3. Hematologic function: absolute neutrophil count ≥1.5 × 109/L; platelet count ≥100 × 109/L, hemoglobin ≥9 g/dL. 4. Endocrine function: thyroid stimulating hormone (TSH) within normal limits. If TSH is not within normal limits, the subject may still be eligible if T3 and free T4 are within normal limits. 5. Coagulation: international normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN unless subject is receiving anticoagulant therapy. Subjec","1. Unwilling or unable to comply with scheduled visits, drug administration plan, laboratory tests, or other study procedures and study restrictions. 2. Predominantly squamous cell histology NSCLC. Mixed tumors will be categorized by the predominant cell type; if small cell elements are present, the subject is ineligible. 3. Participation in another clinical trial or treatment with another investigational agent within 4 weeks or 5 half-lives before randomization, whichever is longer. 4. Known actionable mutations for which there is an approved and available therapy. 5. Known central nervous system metastases and/or carcinomatous meningitis. 6. Previous systemic steroid therapy (prednisone at a dose of 10 mg or equivalent) within 3 days before the first dose of the study drug or receiving any other form of immunosuppressive medication. Subjects receiving daily steroid replacement therapy (daily prednisone at a dose of 5 to 7.5 mg or equivalent) could be included in the study. 7. Subject who requires any other form of localized or systemic antineoplastic therapy during the study. 8. Prior anti-programmed cell death-1 (anti-PD-1), anti-PD-L1, anti programmed death-ligand 2 (anti-PD-L2), anti-CD137, or anti cytotoxic T lymphocyte antigen (CTLA)-4 therapy (including ipilimumab or any other antibody or drug that specifically targets co stimulation of T cells or immune checkpoints). 9. Prior systemic cytotoxic chemotherapy, biological therapy, or major surgery within 3 weeks before the first dose of the study drug; have received thoracic radiation therapy of \>30 gray (Gy) within 6 months before the first dose of the study drug. Palliative radiotherapy is allowed if completed \>14 days before the first dose of the study drug. 10. Known history of severe hypersensitivity to another monoclonal antibody. 11. Active autoimmune disease which has required systemic treatment in the last 2 years before the first dose of the study drug (eg, disease modifying agents, corticosteroids"
NCT06146231,Motiva Flora® Tissue Expander as a Support for the Creation of an Autologous Adipose Matrix for Hybrid Breast Reconstruction: a Pivotal Study,,NA,"Colombia, Costa Rica","Hospital Universitario San Ignacio, Bogotá, Colombia, [NOT_YET_RECRUITING] | Hospital UNIBE, San José, Costa Rica, [NOT_YET_RECRUITING]",Mammaplasty | Breast Cancer | Poland Syndrome,0,,"1. Genetically female, aged 18 years or older. 2. Subjects who had provided written informed consent form. 3. The participant needs tissue expansion as part of breast reconstruction treatment, which may include immediate reconstruction. 4. Clinical condition to allow reverse expansion breast reconstruction, at the investigator's discretion. 5. Sufficient fat in donor sites (abdomen, gluteus, hips, and thighs) per plastic surgeon criteria. 6. Complete radiotherapy and chemotherapy at least one year before surgery. 7. BMI between 18.5 and 30.0 (average classified weight). 8. Physical and cognitive capacity to understand and follow the surgeon's recommendations. 9. To be able and willing to comply with all study requirements, including attending follow-up appointments. Only Sub study participants 10. Provide additional consent to undergo an MRI with contrast.","1. Current pregnancy or lactation, or full-term pregnancy or lactation at any point during the clinical investigation. 2. Abnormal hematological and biochemical values after chemotherapy. 3. High surgical risk according to the investigator. 4. Breast width larger than 18 cm 5. Tumor residues in or near the area where tissue expansion is performed. 6. Subjects with metastatic breast cancer 7. Significant Breast ptosis or poor skin quality 8. Participants who do not have adequate tissue at the intended site for expansion, at the surgeon's discretion, due to previous radiotherapy, ulceration, vascular involvement, history of impaired wound healing, or mastectomy scar deformity. 9. Inadequate chest wall tissue due to damage caused by radiotherapy, tight skin grafts, or radical resection of the pectoralis major muscle. 10. Current or previous infection in the area where the expansion occurs. 11. Any condition that impedes magnetic resonance imaging (MRI), including implanted metal device, claustrophobia, or other ailments that would prohibit MRI scan. 12. Presence of autoimmune diseases such as lupus or scleroderma, or immunocompromised participants due to immunosuppressive or steroid therapy. 13. History of silicone sensitivity. 14. Active smokers 15. Previous attempts of breast reconstruction 16. Subjects who, in the opinion of the investigator, are considered part of any vulnerable population 17. Subjects with affiliation to the Sponsor, sites or investigators, including relatives. 18. Participants who do not live in the procedure's country make it impossible to assist in follow-up visits. 19. Subjects who are participating in other investigation(s) which may affect the outcomes or ability to comply follow-up requirements of this study"
NCT06780137,A Phase 1b/2 Open-Label Clinical Study to Evaluate the Safety and Efficacy of MK-6070 and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer,,"PHASE1, PHASE2",Chile,"FALP ( Site 2100), Santiago, Chile, [RECRUITING] | Bradfordhill ( Site 2101), Santiago, Chile, [RECRUITING]",Small Cell Lung Cancer,8,[1] Part 1 Arm 1: Gocatamig and I-DXd (EXPERIMENTAL): Participants will receive gocatamig and I-DXd at a determined dose until documented disease progression or discontinuation criteria are met. || [2] Part 1 Arm 2: Gocatamig and I-DXd (EXPERIMENTAL): Participants will receive gocatamig and I-DXd at a determined dose until documented disease progression or discontinuation criteria are met. || [3] Part 1 Arm 3a: I-DXd Monotherapy (EXPERIMENTAL): Participants will receive I-DXd until documented disease progression or discontinuation criteria are met. || [4] Part 1 Arm 3b: Gocatamig and I-DXd (EXPERIMENTAL): Participants will receive gocatamig and I-DXd at a determined dose until documented disease progression or discontinuation criteria are met. || [5] Part 2 Arm 4: Gocatamig Monotherapy in Japan (EXPERIMENTAL): Participants in Japan will receive escalating doses of gocatamig until documented disease progression or discontinuation criteria are met. || [6] Part 2 Arm 5: Gocatamig Monotherapy in China (EXPERIMENTAL): Participants in China will receive escalating doses of gocatamig until documented disease progression or discontinuation criteria are met. || [7] Part 2 Arm 6: Gocatamig (EXPERIMENTAL): Participants will receive gocatamig at a determined dose until documented disease progression or discontinuation criteria are met. || [8] Part 3 Arm 7: Gocatamig and Durvalumab (EXPERIMENTAL): Participants will receive gocatamig and durvalumab at a determined dose until documented disease progression or discontinuation criteria are met.,"* Has histologically or cytologically confirmed SCLC that is extensive stage (defined as Stage IV (T any, N any, M1a/b/c) following at least 1 prior line of systemic therapy that included platinum-based chemotherapy * Must be able to provide archival tumor tissue sample or fresh biopsy tissue sample * Human immunodeficiency virus (HIV) infected participants must have well controlled HIV on antiretroviral therapy (ART)","* Pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedure * History of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids or has current pneumonitis/ILD, and or suspected ILD/pneumonitis * Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses * Active or history of immune deficiency with the exception of HIV-infected participants with well controlled HIV on ART * History within 6 months before the first dose of study intervention of coronary/peripheral artery bypass graft and/or any coronary/peripheral angioplasty or clinically significant cardiovascular disease such as myocardial infarction, symptomatic congestive heart failure (CHF) (New York Heart Association \> class II), and/or uncontrolled cardiac arrhythmia * History of arterial thrombosis (eg, stroke or transient ischemic attack) within 6 months before the first dose of study intervention * Active clinically significant infection requiring systemic therapy * History of allogeneic tissue/solid organ transplant * History of leptomeningeal disease * Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids * Receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of chronic immunosuppressive therapy within 7 days prior to the first dose of study intervention * Known additional malignancy that is progressing or has required active treatment within the past 3 years * Untreated or symptomatic brain metastases * Active viral hepatitis, defined as hepatitis A (hepatitis A virus immunoglobulin M \[IgM\] positive in the setting of associated signs/symptoms), hepatitis B (hepatitis B virus surface antigen \[HbsAg\] positive and/or detectable hepatitis B virus \[HBV\] deoxyribonucleic acid \[DNA\]), or hepatitis C (hepatitis C virus \[HCV\] antibody positive and detectable HCV "
NCT06096779,"A Phase II, Open-Label, Multi-Cohort, Multicenter Study in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis",Kirros,PHASE2,Puerto Rico,"Pan American Center for Oncology Trials, LLC, Rio Piedras, Puerto Rico, [RECRUITING]",Hepatocellular Carcinoma,2,[1] Cohort A: Atezolizumab+Bevacizumab (EXPERIMENTAL): Participants will receive Atezolizumab plus Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator. || [2] Cohort B: Atezolizumab (EXPERIMENTAL): Participants will receive Atezolizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.,"* Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic participants * Disease that is not amenable to curative surgical and/or locoregional therapies * No prior systemic treatment (including systemic investigational agents) for locally advanced or metastatic and/or unresectable HCC * Measurable disease (at least one untreated target lesion) according to RECIST v1.1 * ECOG Performance Status of 0-2 within 7 days prior to initiation of study treatment * Child-Pugh B7 or B8 cirrhosis at screening and within 7 days prior to study treatment * Adequate hematologic and end-organ function * Life expectancy of at least 12 weeks * Female participants of childbearing potential must be willing to avoid pregnancy and egg donation * Absolute neutrophil count ≥1.0 x 109/L (≥1000/μL) without granulocyte colony-stimulating factor support * Platelet count ≥ 50 × 109/L (50,000/μL) without transfusion * Hemoglobin ≥ 80 g/L (8 g/dL) AST and ALT ≤ 5 × upper limit of normal (ULN) * Serum bilirubin ≤ 3 × ULN * Creatinine clearance ≥ 50 mL/min (calculated using the Cockcroft-Gault formula) * Serum albumin ≥ 20 g/L (2.0 g/dL) without transfusion in the prior 3 months * INR ≤2.3 General","* Pregnancy or breastfeeding * Prior treatment with CD137 agonists or immune checkpoint blockade therapies * Treatment with investigational therapy within 28 days prior to initiation of study treatment * Treatment with locoregional therapy to liver within 28 days prior to initiation of study treatment, or non-recovery from side effects of any such procedure * Treatment with systemic immunostimulatory agents * Treatment with systemic immunosuppressive medication * Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment * Inadequately controlled hypertension * Active or history of autoimmune disease or immune deficiency * History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan * Participants who have a known concurrent malignancy that is progressing or requires active treatment, who have not completely recovered from treatment, or who have a significant malignancy history that, in the opinion of the investigator, should preclude participation. * Participants on preventative hormonal therapies (i.e., tamoxifen and other hormonal inhibitors) are not excluded. * Known fibrolamellar HCC, sarcomatoid HCC, other rare HCC variant, or mixed cholangiocarcinoma and HCC * Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases * Prior allogeneic stem cell or solid organ transplantation * Actively listed for liver transplantation * Co-infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) * Untreated or incompletely treated esophageal and/or gastric varices with bleeding or that are at high risk for bleeding * A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment * Grade ≥3 hemorrhage or bleeding event within 6 months prior to initiation of study treatment * Hepatic encephalopathy is allowed "
NCT06611540,NCI Cervical Cancer 'Last Mile' Initiative 'Self-Collection for HPV Testing to Improve Cervical Cancer Prevention' (SHIP) Trial,,NA,Puerto Rico,"University of Puerto Rico, San Juan, Puerto Rico, [NOT_YET_RECRUITING]",Cervical Carcinoma | Human Papillomavirus Infection,1,[1] Prevention (self-collected and clinician-collected samples) (EXPERIMENTAL): Patients undergo self-collection of a vaginal sample and then undergo clinician-collection of a cervical test sample. Patients then undergo SOC colposcopy with cervical biopsy/endocervical curettag...,"* Willingness and ability to provide a documented informed consent. * Is 25 years or older. * Has an intact cervix. * Has had a referral for colposcopy and/or cervical excisional procedure in which routine cervical cancer screening has included HPV testing (HPV primary screening, co-testing, or atypical squamous cells of undetermined significance \[ASC-US\] cytology triage) or abnormal cytology performed within the past 12 months preceding the referral visit. * Willing and able to undergo colposcopy, and if clinically indicated for SOC purposes, a biopsy, endocervical curettage, and/or a cervical excisional procedure, as applicable.","* Is pregnant when presenting for the referral visit or gave birth within the past 3 months. * Has a known history of excisional or ablative therapy to the cervix (e.g., loop electrosurgical excision procedure \[LEEP\], cone biopsy, cervical laser surgery, cryotherapy, thermal ablation) in the last 12 months prior to the referral visit. * Has had a complete or partial hysterectomy, either supracervical or involving removal of the cervix, via self-report or confirmation via medical records. * Known medical conditions that, in the opinion of the investigator, preclude study participation. * Previous participation in the SHIP Trial. Participation is defined as completing the self-collection. * Is experiencing unusual bleeding or pelvic pain."
NCT04322318,Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT),,PHASE2,Puerto Rico,"HIMA San Pablo Oncologic Hospital, Caguas, Puerto Rico, [ACTIVE_NOT_RECRUITING] | University Pediatric Hospital, San Juan, Puerto Rico, [RECRUITING]",Anaplastic Kidney Wilms Tumor | Recurrent Kidney Wilms Tumor | Stage II Kidney Wilms Tumor | Stage III Kidney Wilms Tumor | Stage IV Kidney Wilms Tumor,2,"[1] Arm I (Regimen UH-3) (EXPERIMENTAL): See outline in detailed description section. || [2] Arm II (Regimen ICE/Cyclo/Topo) (EXPERIMENTAL): CYCLES 1, 2, 4, 5, 7, AND 9: Patients receive carboplatin IV over 15-60 minutes on day 1. Patients also receive etoposide IV over 1-2 hours and ifosfamide IV over 2-4 hours on days 1-3. Treatment r...","* Patients with newly diagnosed stages 2 - 4 diffuse anaplastic Wilms tumor must be enrolled on APEC14B1, consented to Part A - Eligibility Screening, and have received an initial stratum assignment showing DAWT (if anaplasia first identified at diagnostic, pre-treatment nephrectomy or biopsy) or a final stratum assignment showing DAWT (if anaplasia first noted at delayed nephrectomy) prior to enrollment on AREN1921. Prior enrollment on APEC14B1 is not an eligibility requirement for patients with relapsed favorable histology Wilms tumor. * Patients must be =\< 30 years old at study enrollment * Patients with the following diagnoses are eligible for this study: * Newly diagnosed stages 2 - 4 diffuse anaplastic Wilms tumor as confirmed by central review * Favorable histology Wilms tumor at first relapse. Relapsed FHWT patients must have previously achieved remission for their initial FHWT diagnosis to be eligible for this study. The relapse risk groups are defined as follows, regardless of radiation therapy: * Standard-Risk relapse: Patients who received two chemotherapy agents for frontline therapy; primarily actinomycin D and vincristine * High-Risk relapse: Patients who received three chemotherapy agents for frontline therapy; primarily vincristine, actinomycin D and doxorubicin or vincristine, actinomycin D and irinotecan * Very High-Risk relapse: Patients who received four or more chemotherapy agents as part of initial therapy; primarily regimen M or its variations * Patients with newly diagnosed DAWT must have had histologic verification of the malignancy. For relapsed FHWT patients, biopsy to prove recurrence is encouraged, but not required * Note: For relapsed FHWT patients, an institutional pathology report confirming favorable histology Wilms tumor (from relapse, if available, or from original diagnosis) must be available for upload prior to initiation of protocol therapy * Patients with newly diagnosed Stages 2 - 4 diffuse anaplastic Wilms tumor must be enr","* Patients with a history of bilateral Wilms tumor (synchronous or metachronous) * Patients with any uncontrolled, intercurrent illness including, but not limited to, ongoing or active infection, or symptomatic congestive heart failure (defined as grade 2 or higher heart failure per Common Terminology Criteria for Adverse Events \[CTCAE\] version 5.0) * Relapsed FHWT patients who did not receive frontline chemotherapy (e.g., very low risk FHWT initially observed without chemotherapy) or received only one chemotherapy agent for frontline therapy * For patients with high-risk or very high-risk relapsed FHWT: * Patients with renal tubular acidosis (RTA) as evidenced by serum bicarbonate \< 16 mmol/L and serum phosphate =\< 2 mg/dL (or \< 0.8 mmol/L) without supplementation * For stages 2-4 DAWT and standard-risk relapsed FHWT patients: * Chronic inflammatory bowel disease and/or bowel obstruction * Concomitant use of St. John's wort, which cannot be stopped prior to the start of trial treatment * Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential * Lactating females who plan to breastfeed their infants * Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation"
NCT04379596,"A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants With HER2-expressing Gastric Cancer (DESTINY-Gastric-03)",DG-03,PHASE2,Brazil,"Research Site, Florianópolis, Brazil, [WITHDRAWN] | Research Site, Londrina, Brazil, [RECRUITING] | Research Site, Natal, Brazil, [WITHDRAWN] | Research Site, Porto Alegre, Brazil, [WITHDRAWN] | Research Site, Ribeirão Preto, Brazil, [ACTIVE_NOT_RECRUITING] | Research Site, Rio de Janeiro, Brazil, [WITHDRAWN] | Research Site, Santa Maria, Brazil, [RECRUITING] | Research Site, São Jose Do Rio Preto, Brazil, [RECRUITING] | Research Site, São Paulo, Brazil, [WITHDRAWN] | Research Site, São Paulo, Brazil, [WITHDRAWN]",Gastric Cancer,16,"[1] Arm 1A (EXPERIMENTAL): T-DXd and 5-fluorouracil (5-FU) || [2] Arm 1B (EXPERIMENTAL): T-DXd and capecitabine || [3] Arm 1C (EXPERIMENTAL): T-DXd and durvalumab || [4] Arm 1D(b) (EXPERIMENTAL): T-DXd, capecitabine, and oxaliplatin || [5] Arm 1E(a) (EXPERIMENTAL): T-DXd, 5-FU, and durvalumab || [6] Arm 1E(b) (EXPERIMENTAL): T-DXd, capecitabine, and durvalumab || [7] Arm 2A (ACTIVE_COMPARATOR): Trastuzumab, 5-FU or capecitabine, and cisplatin or oxaliplatin || [8] Arm 2B (EXPERIMENTAL): T-DXd monotherapy || [9] Arm 2C (EXPERIMENTAL): T-DXd, 5-FU or capecitabine || [10] Arm 2D (EXPERIMENTAL): T-DXd, pembrolizumab and 5-FU or capecitabine","1. Male and female participants must be at least 18 years of age. Other age restrictions may apply as per local regulations 2. Disease Characteristics: 1. Locally advanced, unresectable, or metastatic disease based on most recent imaging 2. For Part 1, 2, 3a, 4a pathologically documented adenocarcinoma of the stomach/GEJ/esophagus, HER2-positive (IHC 3+ or IHC 2+/ISH+) based on local tissue testing results 3. For Part 3b and 4b, pathologically documented adenocarcinoma of the stomach/GEJ/esophagus, HER2-low (IHC 2+/ISH-negative or IHC 1+) based on local tissue testing results 3. For Part 1, progression on or after at least one prior trastuzumabcontaining regimen For Part 2, Part 3 and Part 4, previously untreated for unresectable or metastatic adenocarcinoma of the stomach/GEJ/ esophagus with with HER2-positive (Part 2 and Part 3 \[Arm 3A\] and Part 4 \[Arm 4A\]) or HER2-low (Part 3 \[Arm 3B\] and Part 4 \[Arm 4B\])) status 4. Has measurable target disease assessed by the Investigator based on RECIST version 1.1 5. Has protocol defined adequate bone marrow and organ function including cardiac, renal and hepatic function 6. If of reproductive potential, agrees to use a highly effective form of contraception or avoid intercourse during and upon completion of the study.","1. History of active primary immunodeficiency, known HIV, active chronic, or past hepatitis B infection, or hepatitis C infection. 2. Uncontrolled intercurrent illness 3. History of non-infectious pneumonitis/ILD, current ILD, or where suspected ILD that cannot be ruled out by imaging at screening. 4. Lung-specific intercurrent clinically significant severe illnesses. 5. Uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or antifungals. 6. Pleural effusion, ascites or pericardial effusion that requires drainage, peritoneal shunt, or Cell-free and Concentrated Ascites Reinfusion Therapy (CART). 7. Has spinal cord compression or clinically active central nervous system metastases."
NCT06757634,"VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study of Fulvestrant and CDK4/6 Inhibitors With or Without Gedatolisib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer",,PHASE3,"Argentina, Brazil, Mexico","Centro de Oncologia e Investigacion Buenos Aires COIBA, Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Pergamino Clinic, Buenos Aires, Argentina, [NOT_YET_RECRUITING] | CENIT Foundation, Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Fleischer Medical Center (Centro Medico Fleischer), Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Fundacion Respirar, Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Centro Oncológico Korben, Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Alexander Fleming Institute, Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Center for Medical Education and Clinical Research (CEMIC), Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Cordoba Oncology Institute (IONC), Córdoba, Argentina, [NOT_YET_RECRUITING] | Centro Oncologico de Excelencia, La Plata, Argentina, [NOT_YET_RECRUITING]",Breast Cancer,2,"[1] Arm A: Gedatolisib + Palbociclib or Ribociclib + Fulvestrant (EXPERIMENTAL): Drug: Gedatolisib Participants will receive intravenous (IV) gedatolisib once weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off || [2] Arm B: Palbociclib or Ribociclib + Fulvestrant (ACTIVE_COMPARATOR): Drug: Palbociclib Participants will receive oral palbociclib on Days 1-21 of each 28-day cycle","1. Histologically or cytologically confirmed diagnosis of metastatic or locally advanced HR+/HER2- breast cancer 2. Adult females, pre- and/or post-menopausal, and adult males. Pre-menopausal (and peri-menopausal) women can be enrolled if amenable to treatment with an LHRH agonist. Patients are to have commenced concomitant treatment with LHRH agonist prior to or on Cycle 1, Day 1 and must be willing to continue for the duration of the study. 3. Negative pregnancy test for females of childbearing potential. Female subjects who are not surgically sterile must use a medically effective contraceptive method from screening until 2 years after the last dose of study treatment. 4. Progression of disease during or within 12 months of completing (neo)adjuvant ET. 5. Adequate archival, fresh tumor tissue, or liquid biopsy for the analysis of PIK3CA mutational status. 6. Permitted prior therapies: 1. (neo)adjuvant fulvestrant or any selective ER degrader only if the treatment duration \< 6 months 2. (neo)adjuvant chemotherapy 3. (neo)adjuvant CDK4/6 inhibitor, unless PD was on or within 6 months of discontinuation of CDK4/6i 7. Subject has radiologically measurable disease according to RECIST v1.1, per local assessment. Patients with evaluable bone-only disease are not eligible. Patients with bone-only disease that has lytic or mixed lytic/blastic lesions and at least one measurable soft tissue component per RECIST v1.1 may be eligible. 8. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. 9. Life expectancy of at least \>6 months. 10. Adequate bone marrow, hepatic, renal and coagulation function.","1. Concurrent malignancies other than adequately treated non-melanoma skin cancer. Previous malignancies in remission but curatively treated with no evidence of disease progression and judged by local Investigator to be at low risk of impacting health or survival while on study. 2. Prior treatment with a phosphoinositide 3-kinase (PI3K) inhibitor, a protein kinase B (Akt) inhibitor, or a mechanistic target of rapamycin (mTOR) inhibitor 3. Prior treatment with systemic anticancer therapy for ABC 4. Subjects with type 1 diabetes 5. Known and untreated, or active, brain or leptomeningeal metastases 6. History of clinically significant cardiovascular abnormalities 7. History of drug-induced symptomatic interstitial lung disease (pneumonitis) or hepatitis"
NCT06233942,"Phase 1a/1b Study of BG-C9074, an Antibody Drug Conjugate Targeting B7H4, as Monotherapy and in Combination With Tislelizumab in Participants With Advanced Solid Tumors",,PHASE1,Brazil,"Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira, São Paulo, Brazil, [NOT_YET_RECRUITING]",Advanced Solid Tumor,5,"[1] Phase 1a: Part A (Monotherapy Dose Escalation) (EXPERIMENTAL): BG-C9074 monotherapy dose escalation || [2] Phase 1a: Part B (Monotherapy Safety Expansion) (EXPERIMENTAL): BG-C9074 dose levels that have been determined to be safe and tolerable in Part A will be investigated. || [3] Phase 1a: Part C (Combination Therapy Dose Escalation) (EXPERIMENTAL): BG-C9074 plus tislelizumab combination at the recommended dose for expansion (RDFE). || [4] Phase 1b: Monotherapy Dose Expansion (EXPERIMENTAL): The monotherapy dose expansion phase will begin once the BG-C9074 monotherapy RDFE and dosing schedule have been determined from Parts A and B in Phase 1a. || [5] Phase 1b: Combination Therapy Dose Expansion (BG-C9074 plus tislelizumab) (EXPERIMENTAL): Combination therapy will begin post-completion of combination dose escalation (Part C, Phase 1a).","1. Able to provide a signed and dated written informed consent prior to any study-specific procedures, sampling, or data collection. 2. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1. 3. Participants with selected histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors who have been previously treated. 4. ≥ 1 measurable lesion per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) 5. Able to provide an archived tumor tissue sample. 6. Adequate bone marrow and organ function. 7. Females of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study, and for ≥ 7 months after the last dose of study drug(s). 8. Nonsterile males must be willing to use a highly effective method of birth control for the duration of the study treatment period and for ≥ 4 months after the last dose of study drug(s).","1. Prior treatment with a B7 homolog 4 (B7H4)-targeting antibody-drug conjugate (ADC) or an ADC with a topoisomerase 1 inhibitor (TOP1i) payload. 2. Active leptomeningeal disease or uncontrolled, untreated brain metastasis 3. Any malignancy ≤ 2 years before the first dose of study treatment(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast). 4. History of interstitial lung disease, ≥ Grade 2 noninfectious pneumonitis, oxygen saturation at rest \< 92%, or requirement for supplemental oxygen (including intermittent use) at baseline. 5. Uncontrolled diabetes. 6. Infection (including tuberculosis infection) requiring systemic (oral or intravenous) antibacterial, antifungal, or antiviral therapy ≤ 14 days before the first dose of study treatment(s). Note: Other protocol defined Inclusion/Exclusion criteria may apply."
NCT01804686,"A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study",CAN3001,PHASE3,"Argentina, Brazil, Colombia, Mexico, Puerto Rico","CEMIC Saavedra, Ciudad Autonoma Buenos Aires, Argentina, [ACTIVE_NOT_RECRUITING] | Fundaleu, Ciudad de Buenos Aires, Argentina, [COMPLETED] | Ministerio da Saude Instituto Nacional do Cancer, Rio de Janeiro, Brazil, [COMPLETED] | Santa Casa da Misericórdia da Bahia - Hospital Santa Isabel, Salvador, Brazil, [COMPLETED] | Instituto de Ensino e Pesquisa São Lucas, São Paulo, Brazil, [COMPLETED] | Fundacion Santa Fe, Bogotá, Colombia, [COMPLETED] | Fundacion Oftalmologica de Santander - FOSCAL, Floridablanca, Colombia, [COMPLETED] | Oaxaca Site Management Organization S.C., Oaxaca City, Mexico, [COMPLETED] | Auxilio Mutuo Cancer Center, San Juan, Puerto Rico, [RECRUITING]",Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Mantle Cell Lymphoma | Follicular Lymphoma | Diffuse Large B-cell Lymphoma,1,[1] Ibrutinib (EXPERIMENTAL): No description,"* Participants must be currently participating in an ibrutinib clinical study considered complete and have received at least 6 months of treatment with ibrutinib. At study entry, participants must be actively receiving treatment with single-agent ibrutinib; or participants must have participated in an ibrutinib randomized clinical study in which they initially received comparator treatment and now cross-over to ibrutinib. Note: A minimum of 6 months requirement for prior ibrutinib treatment will not be mandatory in this case and participants with less than 6 months will be required to have more frequent initial safety assessments; or participants must be currently participating in study PCI-32765LYM1002. At study entry, participants must be actively receiving combination treatment with ibrutinib and nivolumab or single-agent ibrutinib * Investigator's assessment that the benefit of continued ibrutinib therapy as a single agent or in combination with nivolumab will outweigh the risks * Agrees to protocol-defined use of effective contraception * Negative blood or urine pregnancy test at screening","* Requires anticoagulation with warfarin or equivalent vitamin K antagonists * Requires treatment with strong cytochrome P450 (CYP)3A4/5 inhibitors, unless previously approved by sponsor * Any condition or situation which, in the opinion of the investigator, may put the participant at significant risk, may confound the study results, or may interfere significantly with volunteer's participation in the study"
NCT06209190,Safety and Feasibility of Total Marrow and Total Lymphoid Irradiation as Conditioning Regimen in Allogeneic Hematopoietic Stem-cell Transplantation,,NA,Mexico,"Andres Gomez, Monterrey, Mexico, [RECRUITING]",Acute Lymphoblastic Leukemia,1,"[1] Total marrow and lymphoid irradiation (TMLI) (EXPERIMENTAL): TMLI will be added in doses of 12 Gy on days -3 to -1 divided into 6 fractions of 2 Gy every 12 hours for 3 days, which will be administered through a computed tomography tomotherapy system.","* Diagnosis of ALL confirmed by flow cytometry. * Patients between age 16 and 45 years with ALL in first remission, refractory, or relapsing * Patients who have an identical or haploidentical allogeneic donor by high resolution HLA","* Patients who do not meet the age previously mentioned. * Patient with comorbidities that rule them out for HSCT, with a Hematopoietic cell transplantation-specific comorbidity index (HCT-CI) greater than 2. * Poor performance status or Karnofsky less than 70% * Transthoracic echocardiogram with alteration in myocardial function with left ventricular ejection fraction (LVEF) less than 50% * Patients who previously and for another reason have already received radiotherapy or who refuse to receive it"
NCT05048797,"An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)",,PHASE3,"Brazil, Mexico","Research Site, Barretos, Brazil, [RECRUITING] | Research Site, Blumenau, Brazil, [RECRUITING] | Research Site, Brasília, Brazil, [RECRUITING] | Research Site, Florianópolis, Brazil, [RECRUITING] | Research Site, Natal, Brazil, [RECRUITING] | Research Site, Salvador, Brazil, [RECRUITING] | Research Site, São Paulo, Brazil, [RECRUITING] | Research Site, São Paulo, Brazil, [RECRUITING] | Research Site, Uberlândia, Brazil, [RECRUITING] | Research Site, Culiacán, Mexico, [WITHDRAWN]",Locally Advanced or Metastatic Non-Small Cell Lung Cancer,2,"[1] Arm 1 (EXPERIMENTAL): Trastuzumab Deruxtecan (T-DXd) || [2] Arm 2 (ACTIVE_COMPARATOR): Standard of Care Treatment (platinum, pemetrexed and pembrolizumab)","* Participants at least 18 years of age * Locally advanced and unresectable NSCLC, not amenable to curative therapy, or metastatic disease * Histologically documented non-squamous NSCLC with HER2 mutation in exons 19 or 20 by tissue NGS or ctDNA * Treatment-naïve for palliative intent systemic therapy for locally advanced or metastatic disease * Left ventricular ejection fraction (LVEF) ≥ 50% * Measurable disease assessed by Investigator based on RECIST 1.1 * Protocol-defined adequate organ function including cardiac, renal, hepatic function * ECOG 0-1 * Having tumour tissue available for central testing","* Tumors with targetable alterations to EGFR (or other targetable mutations including but not limited to ALK, if routinely tested as a targetable alteration with approved available therapy) * Any untreated brain metastases, including asymptomatic or clinically inactive brain metastases * Active autoimmune or inflammatory disorders * Medical history of myocardial infarction within 6 months prior to randomization * History of non-infectious pneumonitis/ILD, current or suspected ILD * Lung-specific intercurrent clinical significant severe illness * Contraindication to platinum-based doublet chemotherapy or pembrolizumab"
NCT06858813,"A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV 324 in Adults With Hepatocellular Cancer or Squamous Cell Non-Small Cell Lung Cancer",,PHASE1,Puerto Rico,"Fdi Clinical Research /ID# 272960, San Juan, Puerto Rico, [RECRUITING]",Hepatocellular Cancer | Squamous-Cell Non-Small Cell Lung Cancer,5,[1] Part 1 Dose Escalation: ABBV-324 (EXPERIMENTAL): Participants will receive escalating doses of ABBV-324 as part of the approximately 6.5 year study duration. || [2] Part 2 Dose Optimization Arm 1: ABBV-324 Dose 1 (EXPERIMENTAL): Participants will receive ABBV-324 dose 1 as part of the approximately 6.5 year study duration. || [3] Part 2 Dose Optimization Arm 1: ABBV-324 Dose 2 (EXPERIMENTAL): Participants will receive ABBV-324 dose 2 as part of the approximately 6.5 year study duration. || [4] Part 2 Dose Optimization Arm 1: ABBV-324 Dose 3 (EXPERIMENTAL): Participants will receive ABBV-324 dose 3 as part of the approximately 6.5 year study duration. || [5] Part 2 Comparator Arm 4: Lenvatinib (ACTIVE_COMPARATOR): Participants will receive lenvatinib as part of the approximately 6.5 year study duration.,"* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Hepatocellular cancer (HCC) only: Child-Pugh A classification within 7 days before Cycle 1, Day 1 dosing. * Laboratory values meeting the criteria outlined in the protocol. * QT interval corrected for heart rate (QTc) \< 470 msec (using Fridericia's correction), no Grade 3 arrythmia, and no other clinically significant cardiac abnormalities. * Measurable disease per RECIST version 1.1. * Part 1 and Part 2 - participants with HCC meeting the following disease activity criteria: * Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology or cytology. Participants with fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma/HCC are not eligible to enroll. * Disease that is not amenable to surgical and/or locoregional therapies, or progressive disease after surgical and/or locoregional therapies. For participants who progressed after locoregional therapy for HCC, locoregional therapy must have been completed \>= 28 days prior to baseline scan for the current study. * Part 1: Failure of at least 1 prior systemic treatment for HCC. * Part 2: Failure of at least 1 prior systemic treatment consisting of an immune checkpoint inhibitor (CPI) containing regimen for HCC, including but not limited to, atezolizumab in combination with bevacizumab or tremelimumab in combination with durvalumab. Note: Participants who have received prior lenvatinib will not be eligible for Part 2. * Part 1 only - participants with squamous-cell non-small cell lung cancer (LUSC) meeting the following disease activity criteria: * Advanced or metastatic LUSC that is not amenable to surgical resection. * Must have failed at least 1 prior line of therapy that included at least platinum-based chemotherapy and an immune CPI, and/or an appropriate targeted therapy (if applicable), or is not suitable for other approved therapeutic options that have demonstrated clinical benefit at the judgm","* Unresolved clinically significant adverse events (AEs) \> Grade 1 from prior anticancer therapy except for alopecia. * Untreated brain or meningeal metastases (i.e., participants with history of metastases are eligible provided they do not require ongoing steroid treatment for cerebral edema and have shown clinical and radiographic stability for at least 14 days after definitive therapy). Participants may continue with antiepileptic therapy if required. * History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, nor any evidence of active ILD or pneumonitis on screening chest computed tomography (CT) scan. * History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis. * History of clinically significant, intercurrent lung-specific illnesses including, but not limited to: * Underlying pulmonary disorder (i.e., pulmonary emboli within 3 months of the study enrollment, severe asthma, severe COPD, restrictive lung disease, pleural effusion, dependence on supplemental oxygen, etc.). * Any autoimmune, connective tissue or inflammatory disorders with documented or suspicious pulmonary involvement at Screening. * Must have discontinued anticancer therapy with antineoplastic intent including chemotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy within 14 days or 5 half lives of the drug (whichever is shorter) prior to the first dose of ABBV-324. Palliative radiation therapy for bone, skin or subcutaneous metastases with 10 fractions or less is permitted and not participant to a washout period."
NCT06496178,"A Phase 3 Open-label, Randomized Controlled Study to Evaluate the Efficacy and Safety of Petosemtamab Compared With Investigator's Choice Monotherapy Treatment in Previously Treated Patients With Incurable, Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma",,PHASE3,"Argentina, Brazil, Chile","Site 37, Buenos Aires, Argentina, [RECRUITING] | Site 80, Buenos Aires, Argentina, [RECRUITING] | Site 58, Caba, Argentina, [RECRUITING] | Site 45, Córdoba, Argentina, [RECRUITING] | Site 110, Rosario, Argentina, [RECRUITING] | Site 57, Viedma, Argentina, [RECRUITING] | Site 154, Brasília, Brazil, [RECRUITING] | Site 145, Porto Alegre, Brazil, [RECRUITING] | Site 150, Porto Alegre, Brazil, [RECRUITING] | Site 146, Recife, Brazil, [RECRUITING]",Head and Neck Squamous Cell Carcinoma,2,[1] MCLA-158 (EXPERIMENTAL): No description || [2] Investigator's Choice (ACTIVE_COMPARATOR): No description,"* Signed ICF before initiation of any study procedures. * Age ≥ 18 years at signing of ICF. * Histologically previously confirmed HNSCC with evidence of metastatic or locally advanced disease not amenable to standard therapy with curative intent. * HNSCC patients progressed on or after anti-PD-1 therapy and platinum-containing therapy. * The eligible HNSCC primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx. * Documentation of p16 status (positive or negative) by local laboratory IHC for patients with primary oropharyngeal cancer. * A baseline new tumor sample unless the patient has an available tumor sample as an FFPE block with sufficient material. * Measurable disease as defined by RECIST v1.1 by radiologic methods. * ECOG PS of 0 or 1 * Life expectancy ≥ 12 weeks, as per investigator * Adequate organ function (as per protocol)","* Central nervous system metastases that are untreated or symptomatic, or require radiation, surgery, or continued steroid therapy to control symptoms within 14 days of study entry. * Known leptomeningeal involvement * Any systemic anticancer therapy within 4 weeks of the first dose of study treatment. * Major surgery or radiotherapy within 3 weeks of the first dose of study treatment. * Persistent Grade \>1 clinically significant toxicities related to prior antineoplastic therapies * History of hypersensitivity reaction to any of the excipients of treatment required for this study. * Unstable angina; history of congestive heart failure of Class II-IV New York Heart Association (NYHA) criteria, or serious cardiac arrhythmia requiring treatment or history of myocardial infarction within 6 months of study entry * History of prior malignancies with the exception of excised cervical intraepithelial neoplasia or nonmelanoma skin cancer, or curatively treated cancer deemed at low risk for recurrence with no evidence of disease * Current dyspnea at rest of any origin, or other diseases requiring continuous oxygen therapy * Current serious illness or medical conditions including, but not limited to, uncontrolled active infection, clinically significant pulmonary, metabolic or psychiatric disorders * Patients with known infectious diseases (as per protocol) * Pregnant or breastfeeding patients * Patient has a primary tumor site of nasopharynx (any histology)."
NCT04726241,Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias,,"PHASE1, PHASE2",Puerto Rico,"HIMA San Pablo Oncologic Hospital, Caguas, Puerto Rico, [ACTIVE_NOT_RECRUITING]",Acute Lymphoblastic Leukemia | Acute Myeloid Leukemia | Acute Myeloid Leukemia Post Cytotoxic Therapy | Juvenile Myelomonocytic Leukemia | Mixed Phenotype Acute Leukemia,1,"[1] Screening (biospecimen collection) (EXPERIMENTAL): Patients undergo collection of blood and/or bone marrow samples at baseline, end of treatment cycle(s), and at relapse/refractory disease status (if applicable).","* Patients must be less than 22 years of age at the time of study enrollment * Patient must have one of the following at the time of study enrollment: * Patient has known or suspected relapsed/refractory (including primary refractory) AML as defined in protocol * This includes isolated myeloid sarcoma * Patient has known or suspected relapsed/refractory (including primary refractory) myeloid leukemia of Down syndrome (ML-DS) * Patient has known or suspected relapsed ALL as defined in protocol that meets one of the following criteria: * Second or greater B-ALL medullary relapse, excluding KMT2Ar * Any first or greater B-ALL medullary relapse involving KMT2Ar * Any first or greater T-ALL medullary relapse with or without KMT2Ar * Patient has known or suspected relapsed/refractory (including primary refractory) mixed phenotype acute leukemia (MPAL) as defined in protocol * Patient has known or suspected de novo or relapsed/refractory (including primary refractory) treatment-related AML (t-AML) * Patient has known or suspected de novo or relapsed/refractory (including primary refractory) myelodysplastic syndrome (MDS) or treatment-related myelodysplastic syndrome (t-MDS) * Note: Relapsed/refractory disease includes stable disease, progressive disease, and disease relapse. * Patient has known or suspected de novo or relapsed/refractory (including primary refractory) juvenile myelomonocytic leukemia (JMML) * Note: Relapsed/refractory disease includes stable disease, progressive disease, and disease relapse. * All patients and/or their parents or legal guardians must sign a written informed consent * All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met",
NCT04534205,"An Open-label Phase II/III Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1",AHEAD-MERIT,"PHASE2, PHASE3","Argentina, Brazil, Chile, Mexico","Centro de Oncología e Investigación Buenos Aires COIBA, Berazategui, Argentina, [RECRUITING] | Hospital Britanico de Buenos Aires, Ciudad de Buenos Aires, Argentina, [RECRUITING] | Instituto de Oncologia de Cordoba, Córdoba, Argentina, [RECRUITING] | Centro Oncologico Riojano Integral, La Rioja, Argentina, [RECRUITING] | Centro de Investigacion Pergamino SA - Clinica Pergamino, Pergamino, Argentina, [RECRUITING] | Instituto de Oncologia de Rosario, Rosario, Argentina, [RECRUITING] | Sanatorio Britanico, Rosario, Argentina, [RECRUITING] | CAIPO Centro para la Atencion Integral del Paciente Oncologico, San Miguel de Tucumán, Argentina, [RECRUITING] | Clinica Viedma, Viedma, Argentina, [WITHDRAWN] | Fundação PIO XII - Hospital de Amor Barretos, Barretos, Brazil, [ACTIVE_NOT_RECRUITING]",Unresectable Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Cancer | Recurrent Head and Neck Cancer,3,[1] Part A (Safety Run-In) - BNT113 + Pembrolizumab (EXPERIMENTAL): Safety Run-In Phase to confirm the safety and tolerability at the selected dose range level of BNT113 in combination with pembrolizumab. || [2] Part B (Randomized phase) - BNT113 + Pembrolizumab (EXPERIMENTAL): BNT113 in combination with pembrolizumab. || [3] Part B (Randomized phase) - Pembrolizumab monotherapy (ACTIVE_COMPARATOR): Pembrolizumab monotherapy.,"* Patients must sign the written pre-screening informed consent form (ICF) before any pre-screening procedures. * Patients who present histologically confirmed recurrent or metastatic HPV16+ HNSCC that is considered incurable by local therapies. * Patients who have a tumor that expresses PD-L1 \[CPS ≥1\] as determined by the European Conformity (CE)-marked/Food and Drug Administration-approved CDx PD-L1 immunohistochemistry 22C3 pharmDx performed according to the manufacturer's instructions for use. * Patients must not have had prior systemic anticancer therapy administered in the incurable recurrent or metastatic setting. Systemic therapy which was completed more than 180 days prior to randomization, if given as part of multimodal treatment for locally advanced disease, is allowed. * Patients who have measurable disease based on RECIST 1.1 as determined by the site and confirmed by BICR. Tumor lesions situated in a previously irradiated area may be considered measurable, if progression has been demonstrated in such lesions disease by RECIST 1.1. * All patients must provide a tumor tissue sample (formalin fixed paraffin embedded \[FFPE\] blocks or both slides and curls) from archival tissue. Alternatively, a fresh biopsy sample could be provided if a biopsy sample is performed as part of the patient's standard clinical practice before the first dose of trial treatment. The sample should be preferably derived from a current site of metastatic or recurrent disease. Otherwise, a sample from the primary tumor can be submitted. Key","Medical conditions: * Patients present primary tumor site of nasopharynx (any histology). * Patients with another primary malignancy that has not been in complete remission for at least 2 years, with the exception of those with a negligible risk of metastasis or death (such as adequately treated carcinoma in situ of the cervix, non-invasive basal or non-invasive squamous cell skin cancer, localized prostate cancer, non-invasive superficial bladder cancer or breast ductal carcinoma in situ). Prior/concomitant therapy: * Patients who have received or currently receive the following therapy/medication: 1. Chronic systemic immunosuppressive treatment including corticosteroid treatment (prednisone \>10 mg daily orally \[PO\] or intravenously \[IV\], or equivalent) in the 7 days prior to the first dose of trial treatment. 2. Prior treatment with other immune-modulating agents that was (a) within fewer than 4 weeks (28 days) or five half-lives of the agent (whichever is longer) prior to the first dose of BNT113, or (b) associated with immune-mediated AEs that have not resolved prior to the first dose of BNT113 or that pose an additional risk of on-trial complications, per investigator's assessment, or c) associated with toxicity that resulted in discontinuation of the immune-modulating agent and that poses an additional risk of on-trial complications, per investigator's assessment. 3. Prior treatment with live attenuated vaccines within 4 weeks before the first dose of BNT113. 4. Prior treatment with an investigational drug (including investigational vaccines) within 4 weeks or five half-lives of the agent (whichever is longer) before the planned first dose of BNT113. 5. Ongoing treatment with therapeutic PO or IV antibiotics. Note: Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) may be enrolled. * Prior treatment with anti-cancer immunomodulating agents, such as blockers of programmed"
NCT05730036,"An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)",LINKER-MM3,PHASE3,"Brazil, Chile","IDOR - Sao Rafael Salvador Bahia, Salvador, Brazil, [ACTIVE_NOT_RECRUITING] | Hospital Erasto Gaertner, Curitiba, Brazil, [ACTIVE_NOT_RECRUITING] | Associacao Dr Bartholomeu Tacchini, Bento Gonçalves, Brazil, [ACTIVE_NOT_RECRUITING] | Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil, [ACTIVE_NOT_RECRUITING] | Centro Gaucho Integrado, Porto Alegre, Brazil, [ACTIVE_NOT_RECRUITING] | Animi Unidade de Tratamento Oncologico, Centro, Brazil, [ACTIVE_NOT_RECRUITING] | Instituto Americas de Ensino e Pesquisa, Rio de Janeiro, Brazil, [ACTIVE_NOT_RECRUITING] | Hospital A Beneficencia Portuguesa de Sao Paulo, São Paulo, Brazil, [ACTIVE_NOT_RECRUITING] | Instituto DOr de Pesquisa e Ensino, São Paulo, Brazil, [ACTIVE_NOT_RECRUITING] | AC Camargo Cancer Center, São Paulo, Brazil, [ACTIVE_NOT_RECRUITING]",Relapsed Refractory Multiple Myeloma (RRMM),2,[1] Linvoseltamab (EXPERIMENTAL): Randomization 1:1 || [2] Elotuzumab/Pomalidomide/Dexamethasone (EPd) (ACTIVE_COMPARATOR): Randomization 1:1,"1. Age 18 years or older (or legal adult age in the country) at the time of the screening visit. 2. Eastern Cooperative Oncology Group (ECOG) performance status ≤1. Patients with ECOG 2 solely due to local symptoms of myeloma (eg. pain) may be allowed after discussion with the Medical Monitor. 3. Received at least 1 and no more than 4 prior lines of anti-neoplastic MM therapies, including lenalidomide and a proteasome inhibitor and demonstrated disease progression on or after the last therapy as defined by the 2016 IMWG criteria. Participants who have received only 1 line of prior line of antimyeloma therapy must be lenalidomide refractory, as described in the protocol. Note: Participants in Israel also must have previously received a CD38 antibody. Participants in the EU and the UK must have previously received 2 to 4 prior lines of therapy, including a CD38 antibody. 4. Patients must have measurable disease for response assessment as per the 2016 IMWG response assessment criteria, as described in the protocol 5. Adequate hematologic function and hepatic function within 7 days of randomization, as well as adequate renal and cardiac function and corrected calcium 6. Life expectancy of at least 6 months Key","1. Diagnosis of plasma cell leukemia, amyloidosis, Waldenström macroglobulinemia, or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes). 2. Prior treatment with elotuzumab and/or pomalidomide 3. Participants with known MM brain lesions or meningeal involvement 4. Treatment with any systemic anti-cancer therapy within 5 half-lives or within 28 days before first administration of study drug, whichever is shorter 5. History of allogeneic stem cell transplantation within 6 months, or autologous stem cell transplantation within 12 weeks of the start of study treatment. Participants who have received an allogeneic transplant must be off all immunosuppressive medications for 6 weeks without signs of graft-versus-host disease. Steroids at doses equivalent to suppletion doses may be acceptable. 6. Prior treatment with B-cell maturation antigen (BCMA) directed immunotherapies Note: BCMA antibody-drug conjugates are allowed. 7. History of progressive multifocal leukoencephalopathy (PML), known or suspected PML, or history of a neurocognitive condition or central nervous system (CNS) movement disorder (Parkinson's disease or Parkinsonism). 8. Any infection requiring hospitalization or treatment with IV anti-infectives within 2 weeks of first administration of study drug 9. Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); or another uncontrolled infection, as defined in the protocol 10 Cardiac ejection fraction \<40%. NOTE: Other protocol defined inclusion/exclusion criteria apply"
NCT06346392,"A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared With Investigator's Choice of Therapy in Second- or Later-Line Adult Participants With Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (CLARITY Gastric 01)",,PHASE3,Brazil,"Research Site, Porto Alegre, Brazil, [NOT_YET_RECRUITING] | Research Site, Ribeirão Preto, Brazil, [RECRUITING] | Research Site, São Paulo, Brazil, [RECRUITING] | Research Site, Vitória, Brazil, [RECRUITING]",Gastric Cancer | Gastroesophageal Junction Cancer,3,"[1] AZD0901 arm 1 (EXPERIMENTAL): Participants in the AZD0901 arm 1 will receive AZD0901 dose level 1 intravenous infusion treatment. || [2] AZD0901 Arm 2 (EXPERIMENTAL): Participants in the AZD0901 arm 2 will receive AZD0901 dose level 2 intravenous infusion treatment. (Enrolment was closed) || [3] Investigator's choice arm (ACTIVE_COMPARATOR): Participants in the Investigator's choice arm will receive a regimen of Investigator's choice, including regionally accepted chemotherapies or targeted therapies.","1. Capable of giving signed informed consent prior to any study procedure. 2. Participant must be at least 18 years or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the ICF. 3. Histologically confirmed unresectable, locally advanced or metastatic adenocarcinoma of gastric, GEJ, or distal esophagus (distal third of the esophagus) and the following requirement: (a) Participants with positive CLDN18.2 expression from archival tumor collected within past 24 months or from a fresh biopsy. 4. Disease progression on or after at least one prior line of treatment (LoT) for advanced or metastatic disease, which included a fluoropyrimidine and a platinum, for advanced or metastatic disease. 5. Must have at least one measurable or evaluable lesion assessed by the Investigator based on RECIST 1.1. 6. ECOG performance status of 0 or 1 with no deterioration over the previous 2 weeks prior to baseline or day of first dosing. 7. Predicted life expectancy of ≥ 12 weeks. 8. Adequate organ and bone marrow function 9. Body weight of ≥ 35 kg. 10. Sex and Contraceptive Requirements","1. Participants with known HER2 positive status as defined as IHC 3+ or IHC 2+/ISH + (Cases with HER2: CEP17 ratio ≥ 2 or an average HER2 copy number ≥ 6.0 signals/cell are considered positive by ISH). Participants must undergo local (or have had) HER2 testing by IHC/ISH, and the most recent result of HER2 status will be used to determine the eligibility. 2. Participant has significant or unstable gastric bleeding and/or untreated gastric ulcers. 3. CNS metastases or CNS pathology including: epilepsy, seizures or aphasia within 3 months prior to consent, severe brain injury, dementia, Parkinson's disease, neurodegenerative diseases, cerebellar disease, severe uncontrolled mental illness, psychosis, CNS involvement of autoimmune diseases. 4. Participant has known clinically significant corneal disease (eg, active keratitis or corneal ulcerations). 5. Persistent toxicities (CTCAE Grade ≥ 2) caused by previous anticancer therapy, excluding alopecia. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention may be included (eg, hearing loss). 6. Prior exposure to any ADC with MMAE payload or any CLDN18.2 targeting treatment other than naked monoclonal antibody (eg, CLDN18.2 targeting CAR-T cell therapy, multi-specific antibody including targeting CLDN18.2, etc). 7. History of thromboembolic events: 1. Participants with venous thromboembolism within the past 6 months prior to randomization: participants with venous port or catheter thrombosis or superficial venous thrombus that do not require treatment or are stable on treatment with anticoagulants are excepted 2. History of arterial thromboembolism within the past 12 months prior to randomization 8. As judged by the Investigator, any evidence of diseases which in the Investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol."
NCT06090747,Efecto de Una intervención Multidisciplinaria de Estilo de Vida Sobre el Exposoma de Pacientes premenopáusicas Con cáncer de Mama Estadios I-III.,,NA,Mexico,"Dr. Marlid Cruz Ramos, México, Mexico, [RECRUITING]",Breast Neoplasm,2,"[1] Evaluate the effect of hybrid educational intervention in Lifestyle behavior. (ACTIVE_COMPARATOR): Group 1: hybrid educational intervention || [2] Evaluate the effect of hybrid personalized intervention in Lifestyle behavior (EXPERIMENTAL): Group 2: hybrid personalized lifestyle intervention delivered by a multidisciplinary team of specialists in oncology, nutrition, psychology, rehabilitation and mindfulness.","* Women diagnosed with stage I-III BC, confirmed by pathology and image at the INCAN * Candidates for multidisciplinary treatment including surgery, chemotherapy, and/or hormonal treatments. * Signed the informed consent form * Have access to a mobile phone or any electronic device with an active internet connection to receive the program information.","* Patients with inflammatory cancer * Those with cardiomyopathy or ventricular dysfunction (NYHA \>II), arrythmia secondary to left ventricular ejection alterations that requires medication, previous myocardial infarction, or angina pectoris in the last six months * Receiving treatment for cardiovascular or cerebrovascular disease, inflammatory bowel disease, malabsorption syndrome, rheumatoid arthritis, lupus, thyroid diseases, or Cushing syndrome * Unable to walk for at least 1 km * Have cardiovascular, respiratory, or musculoskeletal diseases that impede physical activity * Pregnant or breastfeeding * Have psychiatric conditions impeding active participation in this protocol * Do not understand Spanish"
NCT04224493,"Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma",SYMPHONY-1,PHASE3,Brazil,"Association Hospital de Caridade de Iju, Ijuí, Brazil, [RECRUITING] | Liga Norte Riograndense Contra o Cancer, Natal, Brazil, [RECRUITING] | Hospital de Clinicas de Porto Alegre - Centro de Pesquisa Clinica, Porto Alegre, Brazil, [RECRUITING] | Instituto de Psiquiatria - UFRJ, Rio de Janeiro, Brazil, [RECRUITING] | Instituto Nacional de Câncer - INCA, Rio de Janeiro, Brazil, [RECRUITING] | Irmandade Santa Casa de Misericordia de Sao Paulo, São Paulo, Brazil, [RECRUITING]",Relapsed/Refractory Follicular Lymphoma | Follicular Lymphoma | Refractory Follicular Lymphoma,2,"[1] Tazemetostat + R2 arm (EXPERIMENTAL): Stage 1 (Phase 1b): This phase is now completed.

* Tazemetostat was escalated from a starting dose of 400 mg PO twice daily to 600 mg PO twice daily to 800 mg PO twice daily in 28-day cycles.
* Ri... || [2] Placebo + R2 Arm (PLACEBO_COMPARATOR): Stage 2:

* Placebo administered PO twice daily in continuous 28-day cycles.
* Rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1; then on day 1 of cycles 2 to 5.
* Lenalidomide 20 mg or 10...","1. Have voluntarily agreed to provide written informed consent and demonstrated willingness and ability to comply with all aspects of the protocol. 2. Males or females are ≥18 years of age at the time of providing voluntary written informed consent. 3. Life expectancy ≥3 months before enrollment. 4. Meet requirement for hepatitis and human immunodeficiency virus (HIV) infection as follows * Negative serologic or polymerase chain reaction (PCR) test results for acute or chronic hepatitis B virus (HBV) infection Note: Participants whose HBV infection status could not be determined by serologic test results have to be negative for HBV-DNA by PCR to be eligible for study participation. Participants seropositive for HBV with undetectable HBV DNA by PCR are permitted with appropriate antiviral prophylaxis. * Negative test results for hepatitis C virus (HCV) Note: Participants who are positive for HCV antibody must be negative for HCV RNA by PCR to be eligible for study participation * If HIV positive, HIV infection is controlled 5. Have histologically confirmed FL, Grades 1 to 3A. 6. Must have been previously treated with at least 1 prior systemic chemotherapy, immunotherapy, or chemoimmunotherapy: a. Systemic therapy includes treatments such as: i. Rituximab monotherapy ii. Chemotherapy given with or without rituximab iii. Radioimmunoconjugates such as 90Y-ibritumomab tiuxetan and 131I-tositumomab. b. Systemic therapy does not include, for example: i. Local involved field radiotherapy for limited-stage disease ii. Helicobacter pylori eradication c. Prior investigational therapies will be allowed provided the subject has received at least 1 prior systemic therapy as discussed in Inclusion Criterion #6a. d. Prior autologous/allogeneic hematopoietic stem cell transplant (HSCT) will be allowed. e. Prior chimeric antigen receptor T-cell therapy (CAR T) will be allowed. 7. Must have documented relapsed, refractory, or PD after treatment with systemic therapy (refractory define","All Subjects 1. Prior exposure to tazemetostat or other inhibitor(s) of EZH2. 2. Prior exposure to lenalidomide or drugs of the same class. 3. Grade 3b, mixed histology, or FL that has histologically transformed to diffuse large B-cell lymphoma (DLBCL) (subjects transformed from DLBCL to FL may be enrolled). 4. Has thrombocytopenia, neutropenia, or anemia of Grade ≥3 (per CTCAE Version 5.0 criteria) or any prior history of myeloid malignancies, including myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or myeloproliferative neoplasm (MPN). 5. Has a prior history of T-cell lymphoblastic lymphoma (T-LBL)/T-cell acute lymphoblastic leukemia (T-ALL) or B-cell acute lymphoblastic leukemia (B-ALL). 6. Subjects with uncontrolled leptomeningeal metastases or brain metastases or history of previously treated brain metastases. 7. Subjects taking medications that are known strong CYP3A inhibitors and strong or moderate CYP3A inducers (including St. John's wort). 8. Are unwilling to exclude grapefruit juice, Seville oranges, and grapefruits from the diet and/or consumed within 1 week of the first dose of study drug and for the duration of the study. 9. Major surgery within 4 weeks before the first dose of study drug. a. Note: Minor surgery (eg, minor biopsy of extracranial site, central venous catheter placement, shunt revision) is permitted within 3 weeks prior to enrollment. 10. Are unable to take oral medication OR have malabsorption syndrome or any other uncontrolled gastrointestinal condition (eg, nausea, diarrhea, vomiting) that might impair the bioavailability of tazemetostat. 11. Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, uncontrolled arterial hypertension, unstable angina, myocardial infarction, or stroke within 6 months of the first dose of study drug; or cardiac ventricular arrhythmia. 12. Prolongation of corrected QT interval using Fridericia's formula (QTcF) to ≥480 "
NCT06348199,"A Phase III Randomised, Double-blind, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 (Proposed Pembrolizumab Biosimilar) and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer",,PHASE3,"Brazil, Mexico","SB Investigative Site, Curitiba, Brazil, [ACTIVE_NOT_RECRUITING] | SB Investigative Site, Florianópolis, Brazil, [ACTIVE_NOT_RECRUITING] | SB Investigative Site, Ijuí, Brazil, [ACTIVE_NOT_RECRUITING] | SB Investigative Site, Natal, Brazil, [ACTIVE_NOT_RECRUITING] | SB Investigative Site, Pelotas, Brazil, [ACTIVE_NOT_RECRUITING] | SB Investigative Site, Porto Alegre, Brazil, [ACTIVE_NOT_RECRUITING] | SB Investigative Site, Rio de Janeiro, Brazil, [ACTIVE_NOT_RECRUITING] | SB Investigative Site, Santo André, Brazil, [RECRUITING] | SB Investigative Site, Aguascalientes, Mexico, [ACTIVE_NOT_RECRUITING] | SB Investigative Site, Guadalajara, Mexico, [RECRUITING]",Non-small Cell Lung Cancer Stage IV,2,[1] SB27 (EXPERIMENTAL): SB27 will be administered followed by Pemetrexed and Carboplatin (Carboplatin will be administered for the first 4 cycles). || [2] Keytruda (ACTIVE_COMPARATOR): Keytruda will be administered followed by Pemetrexed and Carboplatin (Carboplatin will be administered for the first 4 cycles).,* Male or female ≥ 18 years of age * Have been diagnosed with stage IV non-squamous NSCLC * Have not received any prior systemic anti-cancer therapy for metastatic NSCLC * Agree to use adequate methods of contraception,"* Unable or unwilling to take folic acid and vitamin B12 supplementation * Severe hypersensitivity to treatment with another monoclonal antibody, any ingredient contained in SB27 or Keytruda, or any component of platinum-containing compounds or pemetrexed."
NCT06129864,"A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)",eVOLVE-HNSCC,PHASE3,"Brazil, Puerto Rico","Research Site, Barretos, Brazil, [RECRUITING] | Research Site, Florianópolis, Brazil, [RECRUITING] | Research Site, Fortaleza, Brazil, [RECRUITING] | Research Site, Ijuí, Brazil, [RECRUITING] | Research Site, Ipatinga, Brazil, [RECRUITING] | Research Site, Londrina, Brazil, [RECRUITING] | Research Site, Natal, Brazil, [RECRUITING] | Research Site, Porto Alegre, Brazil, [RECRUITING] | Research Site, Ribeirão Preto, Brazil, [RECRUITING] | Research Site, Rio de Janeiro, Brazil, [RECRUITING]",Locally Advanced Head and Neck Squamous Cell Carcinoma,2,[1] Study Arm (EXPERIMENTAL): Participants in this arm will receive volrustomig. || [2] Observation Arm (NO_INTERVENTION): Patients in this arm will undergo observation.,"* Histologically or cytologically documented locally advanced squamous cell carcinoma of the oropharynx, hypopharynx, oral cavity, or larynx with no evidence of metastatic disease (i.e. M0). * Confirmed unresected Stage III, Stage IVA or IVB according to the eighth edition of the American Joint Committee on Cancer (AJCC) staging manual (tumor, node, metastasis (TNM) staging system). * Participants will have completed definitive concurrent chemoradiotherapy (cCRT) with curative intent prior to randomization.","* Histologically/cytologically confirmed head and neck cancer of any other primary anatomic location in the head and neck not specified in the inclusion criteria including participants with squamous cell carcinoma of unknown primary or non-squamous histologies (eg, nasopharynx or salivary gland). Participants with \>1 primary tumors are not eligible for the study. * Participants with any of the following: 1. LA-HNSCC that was resected before definitive cCRT 2. LA-HNSCC that was treated and is recurrent at the time of screening * Participants who have received radiotherapy (RT) alone as definitive local therapy for LA-HNSCC."
NCT05554406,"A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who Are Considered High-Risk (Adverse) Acute Myeloid Leukemia As Determined by MYELOMATCH; A MYELOMATCH Clinical Trial",,PHASE2,Puerto Rico,"Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico, [RECRUITING] | San Juan City Hospital, San Juan, Puerto Rico, [RECRUITING]","Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Acute Myeloid Leukemia Post Cytotoxic Therapy | Acute Myeloid Leukemia, Myelodysplasia-Related",5,"[1] Arm I (cytarabine, daunorubicin) (ACTIVE_COMPARATOR): Patients receive cytarabine IV continuously on days 1-7 and daunorubicin IV on days 1-3 per standard approach of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progre... || [2] Arm II (cytarabine, daunorubicin, venetoclax) (EXPERIMENTAL): Patients receive cytarabine IV continuously on days 2-8 and daunorubicin IV on days 2-4 with venetoclax PO on days 1-11 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of dise... || [3] Arm III (azacitidine, venetoclax) (EXPERIMENTAL): Patients receive azacitidine SC or IV on days 1-7 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 cycles in the absence of disease progression or unacceptable toxici... || [4] Arm IV (daunorubicin and cytarabine liposome) (EXPERIMENTAL): Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days 1, 3, and 5 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unaccept... || [5] Arm V (daunorubicin and cytarabine liposome, venetoclax) (EXPERIMENTAL): Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days 1, 3, and 5 and venetoclax PO on days 1-14 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of ...","* STEP 1 REGISTRATION: * Participants must have been registered to Master Screening and Re-Assessment Protocol, MYELOMATCH, prior to consenting to this study. Participants must have been assigned to this clinical trial, via MATCHBox, prior to registration to this study. * Note: Pre-enrollment/diagnosis labs must have already been performed under the MYELOMATCH * Participants must have newly diagnosed, untreated acute myeloid leukemia (AML) per World Health Organization (WHO) criteria * Participants must have high-risk (adverse) AML per European LeukemiaNet (ELN) 2017 criteria * Participants with therapy-related AML (t-AML), or with AML evolving from an antecedent hematologic disorder (such as myeloproliferative neoplasm), or AML with myelodysplasia-related changes (AML-MRC) are eligible * Acute promyelocytic leukemia is excluded * Participants with favorable or intermediate risk disease are excluded * Participants with FLT3 mutations (ITD or TKD) are excluded * Participants with t(9;22) translocation are excluded * A single dose of intrathecal chemotherapy is allowed prior to study entry * Prior anthracycline therapy is allowed but must not exceed a cumulative lifetime dose of 200 mg/m\^2 daunorubicin or equivalent. Prior hypomethylating agent (HMA) exposure is allowed, as long as not for AML diagnosis * Participants must not have received or be currently receiving any prior therapy for acute myeloid leukemia. Hydroxyurea to control the white blood cells (WBC) is allowed prior to registration and initiation of protocol-defined therapy. All trans retinoic acid (ATRA) given until a diagnosis of acute promyelocytic leukemia is ruled out is also allowed. * Participants must not be receiving or planning to receive any other investigational agents before completing protocol therapy * Participants must be between 18 and 59 years of age * Participants must have Zubrod performance status =\< 3 as determined by a history and physical (H\&P) completed within 14 days prior to r",
NCT06943755,"A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors",STELLAR-311,"PHASE2, PHASE3",Puerto Rico,"Exelixis Clinical Site #2, San Juan, Puerto Rico, [RECRUITING] | Exelixis Clinical Site # 4, San Juan, Puerto Rico, [RECRUITING]",Pancreatic Neuroendocrine Tumor (pNET) | Extra-Pancreatic Neuroendocrine Tumor (epNET),2,[1] Zanzalintinib (EXPERIMENTAL): Participants will receive zanzalintinib oral tablets once daily. || [2] Everolimus (ACTIVE_COMPARATOR): Participants will receive everolimus oral tablets once daily.,"* Histologically confirmed, locally advanced/unresectable or metastatic, well-differentiated Grade 1, 2, or 3 NETs of pancreatic origin or extra-pancreatic origin. * Allowed prior lines of therapy, based on the site of NET and functional status. * Documented radiographic disease progression per RECIST 1.1, as assessed by the Investigator based on imaging assessments (computed tomography \[CT\] or magnetic resonance imaging \[MRI\]) within 12 months before randomization. * Measurable disease according to RECIST 1.1 as determined by the Investigator. * Archival tumor tissue is required, if available. If archival tumor tissue is not available, a fresh biopsy may be submitted if it can be safely and feasibly obtained. Every attempt should be made to provide tumor tissue. Key","* Histologically confirmed neuroendocrine carcinomas (including small cell lung cancer), medullary thyroid cancer, pheochromocytoma, paraganglioma, Merkel cell carcinoma, and mixed neuroendocrine non-neuroendocrine neoplasm (MiNEN). * Prior treatment with a vascular endothelial growth factor receptor (VEGFR) -targeting tyrosine kinase inhibitor or a mammalian target of rapamycin (mTOR) inhibitor. * Systemic chemotherapy and any liver-directed or other ablative therapy within 4 weeks before randomization. * Systemic radionuclide therapy within 6 weeks before randomization. * Radiation therapy for bone metastases within 2 weeks, any other radiation therapy, except as indicated above, within 4 weeks before randomization. Note: Other protocol defined Inclusion/Exclusion criteria may apply."
NCT05890677,The LYMPH Trial - Comparing Microsurgical With Conservative Treatment of Chronic Breast Cancer Associated Lymphedema: Study Protocol of a Pragmatic Randomized International Multicentre Superiority Trial,LYMPH,NA,Brazil,"Hospital Erasto Gaertner, Paraná, Brazil, [NOT_YET_RECRUITING]","Lymphedema, Breast Cancer",2,"[1] Group A : Surgical Group (EXPERIMENTAL): According to the pragmatic study design, neither the diagnostic workup nor the surgery will be standardized in order to offer surgeons considerable leeway on how to perform lymphatic surgery, which... || [2] Group B: Conservative Complex Physical Decongestion Therapy (control group) (ACTIVE_COMPARATOR): CDT (Conservative Complex Physical Decongestion Therapy) will be performed as in usual care, following the pragmatic study design. The key aspects like frequency of lymphatic drainage, time when ly...","* Written informed consent. * Patients ≥ 18 years of age. * Former diagnosis of breast cancer. * Clinical diagnosis of chronic Breast Cancer-Related Lymphedema (BCRL) (persisting for more than 3 months) classified as ≥ Stage 1, according to ISL. * Minimum of 3 months Conservative Complex Physical Decongestion Therapy. * Ability to complete the QoL questionnaires. * Willingness to undergo surgery.",* No indication for lymphatic surgery according to clinical judgment of the treating surgeon (individual reasons will be specifically documented). * Primary congenital Lymphedema or non-BCRL. * Previous surgical BCRL treatment on the side intended for intervention.
NCT04643002,Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol,,"PHASE1, PHASE2",Puerto Rico,"Puerto Rico Medical Research Center- Site Number : 8400005, HATO REY, Puerto Rico, [RECRUITING]",Plasma Cell Myeloma Refractory,6,"[1] Control Arm: isatuximab + pomalidomide + dexamethasone (Substudy 01) (ACTIVE_COMPARATOR): * Isatuximab, intravenous (IV) doseweekly (QW) × 4 weeks (Cycle 1), followed by every two weeks (Q2W) (subsequent cycles).
* Pomalidomide dose by mouth daily Day 1 to Day 21.
* Dexamethasone dose b... || [2] isatuximab + SAR439459 + dexamethasone (Substudy 02) (EXPERIMENTAL): SAR439459 in combination with isatuximab and dexamethasone

Part 1:

2 dose levels (DLs) of IV SAR439459:

* DL1 SAR439459 dose Q2W.
* DL2 SAR439459 dose Q2W.
* Isatuximab dose IV QW × 5 weeks (Cyc... || [3] isatuximab + dexamethasone + belantamab mafodotin (Substudy 03) (EXPERIMENTAL): Belantamab mafodotin in combination with isatuximab and dexamethasone

Part 1:

1 DL of IV belantamab mafodotin in Part 1 and de-escalation dose DL-1:

* DL1 belantamab mafodotin IV dose QW4 or de-... || [4] Isatuximab + pegenzileukin (Substudy 04) (EXPERIMENTAL): Pegenzileukin in combination with isatuximab

Part 1- dose escalation:

* Up to 3 DLs of IV pegenzileukin are planned to be evaluated:

  * DL1 will explore pegenzileukin at Q2W.
  * DL2 will explo... || [5] Experimental: Isatuximab + Dexamethasone + Belumosudil (Substudy 05) (EXPERIMENTAL): Isatuximab in combination with belumosudil and dexamethasone Part 1- dose escalation: During the first cycle, belumosudil will be evaluated in monotherapy during 2 to 4 weeks, then isatuximab and d... || [6] Isatuximab + evorpacept + dexamethasone (Substudy 06) (EXPERIMENTAL): Isatuximab in combination with evorpacept and dexamethasone

Part 1- dose escalation:

* Evorpacept IV dose Q2W
* Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)
* Dexamethason...","* Participant must be 18 years of age inclusive or older. * Eastern Cooperative Oncology Group (ECOG) performance status 0-1. * Participants with relapsed or refractory MM who have received at least 2 prior lines of therapy for MM, including PIs and IMiDs (eg, Induction regimen with autologous stem cell transplant followed by maintenance is considered one line). * RRMM with measurable disease: * Serum M protein ≥0.5 g/dL measured using serum protein immunoelectrophoresis and/or * Urine M protein ≥200 mg/24 hours measured using urine protein immunoelectrophoresis and/or * Serum free light chain (sFLC) MM without measurable M protein in serum or urine per previous criteria (serum Ig free light chain ≥10 mg/dL and abnormal serum Ig kappa lambda free light chain ratio \<0.26 or \>1.65). * Men or woman or childbearing potential should agree to use contraception. * Substudy 01, 06: Anti-CD38 therapy naïve or prior exposure to such drugs with a wash out of at least 12 months after the last dose. ""Exposure"" is defined as at least 2 cycles of therapy. * Substudies 02, 03: Anti-CD38 therapy naïve or prior exposure to such drugs without being refractory but with a wash out of at least 6 months after the last dose. ""Refractory"" is defined as progressing within 60 days of last dose of anti-CD38 targeting therapy. * Substudy 04: Anti-CD38 and anti-B cell maturation antigen (BCMA) therapy (if available) prior exposed participants with RRMM. For anti-CD38, ""Exposure"" is defined as at least 2 cycles of therapy. For anti-BCMA therapy if available, exposure is defined by at least 2 cycles of therapy. * Substudy 05: Participants with RRMM with at least 2 cycles of prior exposure to anti-CD38 therapy. For participants to whom BCMA targeted therapy is available (ie, approved in their region and can be reimbursed), at least 2 cycles of prior exposure to a BCMA targeted agent is mandatory.","* Primary systemic amyloid light chain amyloidosis, plasma cell leukemia, monoclonal gammopathy of undetermined significance, or smoldering myeloma. * Uncontrolled infection within 14 days prior to first study intervention administration. * Clinically significant cardiac (including valvular) or vascular disease within 3 months prior to first study intervention administration., eg, myocardial infarction, unstable angina, coronary (eg, coronary artery bypass graft, percutaneous coronary intervention) or peripheral artery revascularization, left ventricular ejection fraction \<40%, heart failure New York Heart Association Classes III and IV, stroke, transient ischemic attack, pulmonary embolism, other thromboembolic event, or cardiac arrhythmia (Grade 3 or higher by NCI CTCAE Version 5.0). * Known acquired immunodeficiency syndrome-related illness or known human immunodeficiency virus (HIV) disease requiring antiviral treatment or active hepatitis A. * Uncontrolled or active hepatitis B virus (HBV) infection. * Active hepatitis C virus (HCV) infection. * Any of the following within 3 months prior to first study intervention administration: treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease. * Second malignancy other than basal cell or squamous cell carcinoma of the skin or in situ carcinoma, unless they are successfully treated with curative intent for more than 3 years before first study intervention administration. * Any anti-MM drug treatment within 14 days before first study intervention administration, including dexamethasone. * Participants with a contraindication to treatment. * Vaccination with a live vaccine 4 weeks before the start of the study. * Seasonal flu and COVID-19 vaccines that do not contain live virus are permitted. * Hemoglobin \<8 g/dL. * Platelets \<50 × 10\^9/L. * Absolute neutrophil count \<1.0 × 10\^9/L. * Creatinine clearance \<30 mL/min/1.73m2. * Total bilirubin \>1.5 × ULN, "
NCT06525181,Evaluation of AI-Enhanced Symptom Summarization in Weekly Radiotherapy Consultations: A Comparative Study,,NA,Brazil,"Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA, Rio de Janeiro, Brazil, [RECRUITING]",Radiotherapy Side Effect | Pelvic Cancer | Patient,2,[1] Standard weekly symptom assessment by physicians (ACTIVE_COMPARATOR): No description || [2] AI-assisted symptom intake (EXPERIMENTAL): No description,All patients undergoing radiotherapy in the pelvic region.,Cases of pelvic reirradiation or operated cases.
NCT06428019,"A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination With Obinutuzumab or Acalabrutinib With Different Ramp- Up Periods in Previously Untreated Subjects With CLL",,PHASE3,Puerto Rico,"Pan American Center for Oncology Trials /ID# 266243, Rio Piedras, Puerto Rico, [RECRUITING]",Chronic Lymphocytic Leukemia,4,"[1] Arm A: Venetoclax + Obinutuzumab (EXPERIMENTAL): Participants will receive venetoclax in combination with obinutuzumab, with a 5 week venetoclax ramp up. || [2] Arm B: Venetoclax + Acalabrutinib (EXPERIMENTAL): Participants will receive venetoclax in combination with acalabrutinib, with a 5 week venetoclax ramp up. || [3] Arm C: Venetoclax + Acalabrutinib (EXPERIMENTAL): Participants will receive venetoclax in combination with acalabrutinib, with a modified venetoclax ramp up A. || [4] Arm D: Venetoclax + Acalabrutinib (EXPERIMENTAL): Participants will receive venetoclax in combination with acalabrutinib, with a modified venetoclax ramp up B.","* Diagnosis of documented, previously untreated, chronic lymphocytic leukemia (CLL) requiring treatment according to the 2018 international workshop on chronic lymphocytic leukemia (iwCLL) criteria and have a life expectancy of \> 6 months. * Previously untreated small lymphocytic lymphoma (SLL) meeting the 2018 iwCLL criteria for treatment will also be equally considered as CLL for eligibility, screening, treatment and evaluation. * Eastern Cooperative Oncology Group (ECOG) performance status \<= 2. * Adequate marrow function independent of growth factor or transfusion support within 2 weeks of screening, unless cytopenia is due to marrow involvement of CLL as listed in the protocol. * Creatinine clearance (CrCl) \>= 30 mL/min using the Cockcroft-Gault formula are eligible for inclusion.","\- Active/uncontrolled infection, no Richter's transformation, no active immune thrombocytopenia."
NCT06350097,"A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer",TROPION-Lung14,PHASE3,"Brazil, Puerto Rico","Research Site, Barretos, Brazil, [RECRUITING] | Research Site, Natal, Brazil, [RECRUITING] | Research Site, Porto Alegre, Brazil, [RECRUITING] | Research Site, Salvador, Brazil, [RECRUITING] | Research Site, São Paulo, Brazil, [RECRUITING] | Research Site, Rio Piedras, Puerto Rico, [RECRUITING] | Research Site, San Juan, Puerto Rico, [NOT_YET_RECRUITING]",Non-small Cell Lung Cancer,2,[1] Arm 1: Osimertinib in combination with Datopotamab Deruxtecan (EXPERIMENTAL): Participants in this group will receive osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion q3w of Day 1 of every 21-day cycle. || [2] Arm 2: Osimertinib monotherapy (ACTIVE_COMPARATOR): Participants in this group will receive osimertinib 80 mg QD as oral tablet.,"Age 1. Participant must be ≥ 18 years. Type of Participant and Disease Characteristics 2. Histologically or cytologically documented nonsquamous NSCLC. NSCLC of mixed histology is allowed if adenocarcinoma is the predominant histology. Mixed small-cell lung cancer and NSCLC histology, and sarcomatoid variant of NSCLC is ineligible. 3. Stage IIIB or IIIC or Stage IV metastatic NSCLC or recurrent NSCLC (based on the American Joint Committee on Cancer Edition 8) not amenable to curative surgery or definitive chemoradiation at the time of randomisation. 4. Participants must not have received prior EGFR TKIs or other systemic therapy for Stage IIIB, IIIC or IV NSCLC. 5. The tumour harbors at least 1 of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del or L858R), either alone or in combination with other genomic alterations, which may include EGFR T790M, assessed by a CLIA-certified (US sites) or an accredited (outside of the US) local laboratory or by central prospective tissue testing. 6. For participants enrolled in randomisation period, mandatory provision of an unstained, archival tumour tissue sample in a quantity sufficient to allow for central confirmation of the EGFR mutation status. 7. WHO performance status of 0 or 1. 8. At least one lesion not previously irradiated that qualifies as a RECIST 1.1 TL at baseline and can be accurately measured at baseline as ≥10 mm in the longest diameter (except lymph nodes, which must have short axis ≥15 mm) with CT or MRI and is suitable for accurate repeated measurements. 9. Adequate bone marrow reserve and organ function within 7 days before the first dose of study intervention. Sex and Contraceptive/Barrier Requirements 10. Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Other Inclusion Criteria 11. All races, gender and ethnic groups are eligible for this study.","1. As judged by the investigator, any evidence of diseases (such as severe or uncontrolled systemic diseases, including active bleeding diseases, psychiatric illness/social situations), history of allogenic organ transplant, and/or substance abuse which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardise compliance with the protocol. 2. Refractory nausea and vomiting, chronic gastrointestinal disease, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of osimertinib. 3. History of another primary malignancy. 4. Spinal cord compression and unstable brain metastases, as defined by Protocol. 5. Clinically significant corneal disease. 6. Has active or uncontrolled hepatitis B or C virus infection, as defined by Protocol. 7. Known HIV infection that is not well controlled, as defined by Protocol. 8. Uncontrolled infection requiring i.v. antibiotics, antivirals or antifungals; suspected infections (eg, prodromal symptoms); or inability to rule out infections (participants with localised fungal infections of skin or nails are eligible). 9. Resting ECG with clinically abnormal findings, as defined by Protocol. 10. Uncontrolled or significant cardiac disease, as defined by Protocol. 11. Past medical history of ILD/penumonitis, including radiation pneumonitis (apart from radiation pneumonitis that did not require steroids), or drug-induced ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening. 12. Pulmonary embolism within 3 months of the study enrolment or has severe pulmonary function compromise. Prior/Concomitant Therapy 13. Prior exposure to any agent including an ADC containing a chemotherapeutic agent targeting topoisomerase I, TROP2-targeted therapy. Prior/Concurrent Clinical Study Experience 14. Participants with a known history of severe "
NCT04065399,"A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients With Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation",AUGMENT-101,"PHASE1, PHASE2",Puerto Rico,"Hospital Centro Comprensivo de Cancer UPR, San Juan, Puerto Rico, [RECRUITING]",Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Mixed Lineage Acute Leukemia | Mixed Phenotype Acute Leukemia | Acute Leukemia of Ambiguous Lineage,1,"[1] Revumenib (EXPERIMENTAL): Phase 1: Oral revumenib; sequential cohorts of escalating dose levels of revumenib to identify the MTD and RP2D. Participants will be enrolled in 1 of 6 dose-escalation arms:

* Arm A: Participants...","Participants must have active acute leukemia (bone marrow blasts ≥5% or reappearance of blasts in peripheral blood) as defined by the National Comprehensive Cancer Network (NCCN) in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia (Version 1.2020) and Acute Myeloid Leukemia (Version 3.2020), or acute leukemia harboring KMT2A rearrangement, NUP98 rearrangement, or NPM1 mutation that have detectable disease in the bone marrow. 1. Phase 1: * Arm A: Participants not receiving any strong CYP3A4 inhibitor/inducers or fluconazole. * Arm B: Participants receiving itraconazole, ketoconazole, posaconazole, or voriconazole (strong CYP3A4 inhibitors) for antifungal prophylaxis. * Arm C: Participants receiving revumenib in combination with cobicistat. * Arm D: Participants receiving fluconazole (moderate CYP3A4 inhibitor). * Arm E: Participants not receiving any weak, moderate, or strong CYP3A4 inhibitors/inducers. * Arm F: Participants receiving isavuconazole (moderate CYP3A4 inhibitor) for antifungal prophylaxis. 2. Phase 2: Documented R/R active acute leukemia (bone marrow blasts ≥5% or reappearance of blasts in peripheral blood) as defined by the NCCN Guidelines® for Acute Lymphoblastic Leukemia (Version 1.2020) and Acute Myeloid Leukemia (Version 3.2020). * Cohort 2A: Documented R/R ALL/MPAL with KMT2A rearrangement. * Cohort 2B: Documented R/R AML with KMT2A rearrangement. * Cohort 2C: Documented R/R AML with NPM1m. 3. White blood cell count below 25,000/ microliter at time of enrollment. Participants may receive cytoreduction prior to enrollment per protocol-specified criteria. 4. Male or female participants aged ≥30 days old. 5. Eastern Cooperative Oncology Group (ECOG) performance status score 0-2 or Karnofsky/Lansky score ≥50. 6. Any prior treatment-related toxicities resolved to ≤Grade 1 prior to enrollment, with the exception of ≤Grade 2 neuropathy or alopecia. 7. Radiation Therapy: At least 60 days from prior tota","Participants meeting any of the following criteria are not eligible for study participation: 1. Diagnosis of active acute promyelocytic leukemia. 2. Isolated extramedullary relapse (Phase 2 only). 3. Active central nervous system disease (cytologic, such as any blasts on cytospin, or radiographic). 4. Detectable human immunodeficiency virus (HIV) viral load within the previous 6 months. Participants with a known history of HIV 1/2 antibodies must have viral load testing prior to study enrollment. 5. Hepatitis B or C. 6. Pregnant or nursing women. 7. Cardiac Disease: * Any of the following within the 6 months prior to study entry: myocardial infarction, uncontrolled/unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), life-threatening, uncontrolled arrhythmia, cerebrovascular accident, or transient ischemic attack. * Corrected QT interval (QTc) \>450 milliseconds. 8. Gastrointestinal Disease: * any gastrointestinal issue of the upper GI tract that might affect oral drug absorption or ingestion (that is, gastric bypass, gastroparesis, etc). * Cirrhosis with a Child-Pugh score of B or C. 9. Graft-Versus-Host Disease (GVHD): Signs or symptoms of acute or chronic GVHD \>Grade 0 within 4 weeks of enrollment. All transplant participants must have been off all systemic immunosuppressive therapy and calcineurin inhibitors for at least 4 weeks prior to enrollment. Participants may be on physiological doses of steroids. 10. Concurrent malignancy in the previous 2 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (for example, breast carcinoma, cervical cancer in situ, melanoma in situ) treated with potentially curative therapy, or concurrent low-grade lymphoma, that is asymptomatic and lacks bulky disease and shows no evidence of progression, and for which the participant is not receiving any systemic therapy or radiation. 11. In Phase 1 and Phase 2: Participants r"
NCT05296798,"A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant in Combination With Phesgo Versus Phesgo After Induction Therapy With Phesgo + Taxane in Patients With Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally-Advanced or Metastatic Breast Cancer",,PHASE3,"Argentina, Brazil, Colombia, Mexico","Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Argentina, [RECRUITING] | Centro Oncologico Korben, Ciudad Autonoma Buenos Aires, Argentina, [ACTIVE_NOT_RECRUITING] | Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina, [RECRUITING] | Fundacion Centro Oncologico de Integracion Regional (COIR), Mendoza, Argentina, [RECRUITING] | Instituto de Oncología de Rosario, Rosario, Argentina, [RECRUITING] | Hospital Provincial del Centenario, Rosario, Argentina, [ACTIVE_NOT_RECRUITING] | CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica, San Juan, Argentina, [RECRUITING] | Pronutrir - suporte nutricional e quimioterapia ltda., Fortaleza, Brazil, [RECRUITING] | Hospital Sao Rafael - HSR, Salvador, Brazil, [RECRUITING] | Hospital Araujo Jorge, Goiânia, Brazil, [RECRUITING]",Locally Advanced or Metastatic Breast Cancer,3,"[1] Induction Therapy: Phesgo plus Taxane-Based Chemotherapy (OTHER): No description || [2] Arm A, Maintenance Therapy: Phesgo (ACTIVE_COMPARATOR): No description || [3] Arm B, Maintenance Therapy: Giredestrant plus Phesgo (EXPERIMENTAL): No description","* Histologically or cytologically confirmed and documented human epidermal growth factor receptor 2 (HER2)-positive/estrogen receptor (ER)-positive adenocarcinoma of the breast with metastatic or locally-advanced disease not amenable to curative resection * At least one measurable lesion and/or non-measurable disease evaluable according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 * Disease-free interval from completion of adjuvant or neoadjuvant systemic non-hormonal treatment to recurrence of ≥6 months * Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 * Left ventricular ejection fraction (LVEF) of at least (≥)50% measured by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA) * Adequate hematologic and end-organ function * For women of childbearing potential: Participants who agree to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agree to refrain from donating eggs, during the treatment period and for 7 months after the final dose of Phesgo * For men: participants who agree to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agree to refrain from donating sperm, during the treatment period and for 7 months after the final dose of Phesgo to avoid exposing the embryo Maintenance Phase Inclusion Criteria * Complete a minimum of four cycles to a maximum of eight cycles of induction therapy; the minimum cycles are defined as either: Phesgo injections + 4 docetaxel infusions, or Phesgo injections + 12 paclitaxel infusions * Achieve a minimum of stable disease (SD) (or Non-complete response \[CR\]/Non-progressive disease \[PD\] for participants with non-measurable disease) (i.e., did not experience PD) according to RECIST v1.1 at the last tumor assessment during the induction therapy phase * LVEF of ≥50% at the last assessment during the induction therapy phase","* Previous systemic non-hormonal anti-cancer therapy in the metastatic breast cancer (MBC) or advanced breast cancer (ABC) setting. Note: Up to one line of single-agent endocrine therapy given in the metastatic or locally advanced setting will be allowed. * Prior treatment with a selective estrogen receptor degrader (SERD) * Previous treatment with approved or investigative anti-HER2 agents in any breast cancer treatment setting, except Phesgo (or trastuzumab SC with pertuzumab IV, or pertuzumab and trastuzumab IV), single-agent trastuzumab IV or SC, ado-trastuzumab emtansine, lapatinib, and neratinib in the neoadjuvant or adjuvant setting * Disease progression within 6 months of receiving adjuvant anti-HER2 therapy (such as trastuzumab, with or without pertuzumab \[IV, SC, or fixed-dose combination\], or ado-trastuzumab emtansine, or neratinib) * Non-resolution of all acute toxic effects of prior anti-cancer therapy or surgical procedures to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0) Grade 1 or better * History of persistent Grade ≥2 (NCI-CTC, Version 5.0) hematological toxicity resulting from previous adjuvant or neo-adjuvant therapy * History of exposure to the following cumulative doses of anthracyclines; Doxorubicin \>360 mg/m2; Liposomal doxorubicin \>500 mg/m2; Epirubucin \>720 mg/m2; Mitoxantrone \>120 mg/m2; Idarubicin \>90 mg/m2. * Known active uncontrolled or symptomatic central nervous system (CNS) metastases, carcinomatous meningitis, or leptomeningeal disease * Dyspnea at rest due to complications of advanced malignancy, or other disease requiring continuous oxygen therapy * Pregnant or breastfeeding, or intending to become pregnant during the study or within 7 months after the final dose of Phesgo (Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of induction therapy). * Treated with investigational therapy within 28 days prior"
NCT05074264,Optimization of Screening Algorithms for Cervical and Anal High-Grade Squamous Intraepithelial Lesions in People Living With HIV in Mexico and Puerto Rico,CAMPO-101,NA,"Mexico, Puerto Rico","Condesa Specialized Clinic, Mexico City, Mexico, [RECRUITING] | Condesa Iztapalapa Specialized Clinic, Mexico City, Mexico, [RECRUITING] | Instituto Nacional de Cancerologia (INCan), Mexico City, Mexico, [NOT_YET_RECRUITING] | University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico, [RECRUITING]",AIDS-Related Anal Carcinoma | AIDS-Related Cervical Carcinoma | High Grade Anal Intraepithelial Neoplasia | High Grade Cervical Intraepithelial Neoplasia | HIV Infection,1,"[1] Imaging, biospecimen collection, anoscopy and/or colposcopy (EXPERIMENTAL): Patients undergo collection of cervical images (if applicable), 3 cervical anal swabs (if applicable) and 3 anal swabs for real-time testing of HPV or hrHPV over 90 minutes. Patients with a positiv...","* Documentation of HIV-1 infection by means of any one of the following: * Documentation of HIV diagnosis in the medical record by a licensed health care provider * Documentation of receipt of antiretroviral therapy (ART) by a licensed health care provider (Documentation may be a record of an ART prescription in the participant's medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant's name. Receipt of at least two agents is required; each component agent of a multi-class combination ART regimen will be counted toward the 2-agent requirement, excepting receipt of a pre-exposure prophylaxis (PrEP) regimen alone \[e.g., Truvada\], which is","* Participants who have undergone hysterectomy * History of anal cancer, penile, vulvar, vaginal, or cervical cancer * Potential participants who received prior treatment of anal, cervical, penile, vaginal, or vulvar lesions within 18 months of study enrollment * Inability in the opinion of the study investigator of the participant to comply with study requirements * Participants who are pregnant (a urine pregnancy test will be provided to participants aged 60 years or less) or within 2 months being post-partum"
NCT07099898,"Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), Compared With Topotecan in Participants With Relapsed Small Cell Lung Cancer (SCLC)",,PHASE3,Argentina,"GSK Investigational Site, Buenos Aires, Argentina, [RECRUITING] | GSK Investigational Site, Ciudad Autonoma de Buenos Aire, Argentina, [RECRUITING]","Neoplasms, Lung",2,[1] GSK5764227 (EXPERIMENTAL): No description || [2] Topotecan (ACTIVE_COMPARATOR): No description,"Participants are eligible to be included in the study only if all of the following criteria apply: * Adults \>18 or the minimum legal adult age at the time the informed consent form is signed * Has histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC). * Has received 1 prior platinum-based systemic therapy with a PD- (L)1 inhibitor with at least 2 cycles of therapy and a chemotherapy free-interval of \>30 days, with documented progression * Has at least 1 target lesion per RECIST 1.1, as determined by the investigator. * Is capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the ICF and in the protocol. * Has an ECOG performance status of 0 or 1","Participants are excluded from the study if any of the following criteria apply: * Pathological diagnosis of complex SCLC or transformed SCLC. * Has received any prior therapy with an Antibody-drug conjugate (ADC) with a Topoisomerase-1 (TOPO1)-inhibitor payload or treatments targeting B7-H3. * Has known sensitivity to study intervention components or excipients or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study. * Has severe, uncontrolled or active cardiovascular disorders. * Has clinically significant bleeding symptoms or significant bleeding tendency within 1 month prior to the first dose. * Known active infectious diseases requiring systemic treatment or known Human immunodeficiency virus (HIV). * Has symptomatic brain metastases or untreated progression exclusively due to brain metastasis during or after the last treatment prior to screening, evidence of leptomeningeal/meningeal/brainstem metastasis or evidence of spinal cord metastases. * Has any evidence of current interstitial lung disease or pneumonitis or a prior history of ILD or non-infectious pneumonitis requiring high dose steroids. * Has documented Hepatitis B or Hepatitis C"
NCT06330064,"A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)",,PHASE2,"Argentina, Brazil, Chile, Mexico","DIABAID, Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Hospital Aleman, Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Hospital Sirio Libanes, Caba, Argentina, [RECRUITING] | Centro de Investigaciones Medicas Mar Del Plata, Mar del Plata, Argentina, [RECRUITING] | Hospital de Câncer de Barretos - Fundação Pio XII, Barretos, Brazil, [RECRUITING] | Cepon - Centro de Pesquisas Oncolă""Gicas de Santa Catarina, Florianópolis, Brazil, [RECRUITING] | Centro de Pesquisas Clinicas da Fundação Doutor Amaral Carvalho, Jaú, Brazil, [RECRUITING] | Hospital de Clă Nicas de Porto Alegre, Porto Alegre, Brazil, [NOT_YET_RECRUITING] | Hospital São Lucas Da Pucrs, Porto Alegre, Brazil, [RECRUITING] | Biocenter, Concepción, Chile, [RECRUITING]",Recurrent or Metastatic Solid Tumors,13,"[1] Cohort 1: Endometrial Cancer (EXPERIMENTAL): Participants with recurrent or metastatic endometrial cancer who were previously treated with 1 or more systemic therapy who received an intravenous infusion of I-DXd 12 mg/kg. || [2] Cohort 2: Head and Neck Squamous Cell Carcinoma (EXPERIMENTAL): Participants with recurrent or metastatic head and neck squamous carcinoma who were previously treated with 1 or more systemic therapy who received an intravenous infusion of I-DXd 12 mg/kg. || [3] Cohort 3: Pancreatic Ductal Adenocarcinoma (EXPERIMENTAL): Participants with recurrent or metastatic pancreatic ductal adenocarcinoma who were previously treated with 1 or more systemic therapy who received an intravenous infusion of I-DXd 12 mg/kg. || [4] Cohort 4: Colorectal Cancer (EXPERIMENTAL): Participants with recurrent or metastatic colorectal cancer who were previously treated with 1 or more systemic therapy who received an intravenous infusion of I-DXd 12 mg/kg. || [5] Cohort 5: Hepatocellular Carcinoma (EXPERIMENTAL): Participants with recurrent or metastatic hepatocellular carcinoma who were previously treated with 1 or more systemic therapy who received an intravenous infusion of I-DXd at the determined dose. || [6] Cohort 6: Adenocarcinoma of esophagus, gastroesophageal junction, and stomach (EXPERIMENTAL): Participants with recurrent or metastatic adenocarcinoma of esophagus, gastroesophageal junction, and stomach who were previously treated with 1 or more systemic therapy who received an intravenous... || [7] Cohort 7: Urothelial carcinoma (EXPERIMENTAL): Participants with recurrent or metastatic urothelial carcinoma who were previously treated with 1 or more systemic therapy who received an intravenous infusion of I-DXd 12 mg/kg. || [8] Cohort 8: Ovarian cancer (EXPERIMENTAL): Participants with recurrent or metastatic non-squamous ovarian cancer who were previously treated with 1 or more systemic therapy who received an intravenous infusion of I-DXd 12 mg/kg. || [","Participants must meet all of the following criteria to be included in the study: 1. Participant must have at least 1 lesion, not previously irradiated, amenable to core biopsy and must consent to provide a pretreatment biopsy tissue sample. An archival tumor tissue sample obtained within 6 months of consent and after progression during/after treatment with the participant's most recent cancer therapy regimen is also acceptable. 2. Participants ages ≥18 years (follow local regulatory requirements if the legal age of consent for study participation is \>18 years). 3. At least 1 measurable lesion on computed tomography (CT) or magnetic resonance imaging (MRI) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), as assessed by the investigator. 4. Documentation of radiological disease progression on or after the previous standard-of-care regimen in the advanced/metastatic setting. 5. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 1. Pathologically or cytologically documented EC of any histological carcinoma subtype or endometrial carcinosarcoma, irrespective of microsatellite instability or mismatch repair status. 2. Relapse or progression after a platinum-containing systemic treatment and an immune checkpoint inhibitor (ICI)-containing regimen (combined or sequential). Subjects with actionable target tumor mutation should have been previously treated with targeted therapy, with a maximum of 3 prior lines of therapy for endometrial carcinoma or carcinosarcoma. Neoadjuvant/adjuvant therapy may count as 1 line of therapy if the subject progressed within 6 months after completion of therapy. 1. Pathologically or cytologically documented unresectable or metastatic squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx, excluding nasopharynx, nasal cavity and paranasal sinuses, and unknown primary. 2. Has disease progression after platinum-based and ICI treatment, whether administered in",
NCT06852222,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy",cAMeLot-2,PHASE3,Brazil,"Fundacao Pio XII, Barretos, Brazil, [RECRUITING] | Instituto D Or de Pesquisa e Ensino, São Paulo, Brazil, [RECRUITING] | Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein, São Paulo, Brazil, [RECRUITING]","Leukemia, Myeloid, Acute",2,"[1] Arm A: Bleximenib and Venetoclax (VEN) + Azacitidine (AZA) (EXPERIMENTAL): Participants with acute myeloid leukemia (AML) will receive bleximenib in combination with venetoclax (VEN) and azacitidine (AZA) for 28-days treatment cycles and treatment will continue until prog... || [2] Arm B: Placebo and Venetoclax (VEN) + Azacitidine (AZA) (PLACEBO_COMPARATOR): Participants with AML will receive placebo in combination with VEN and AZA for 28-days treatment cycles, and treatment will continue until progression or unacceptable toxicity.","* Be 18 years of age or older at the time of informed consent * Previously untreated lysine N-methyltransferase 2A gene rearranged (KMT2Ar) or nucleophosmin 1 gene mutated (NPM1m) acute myeloid leukemia (AML) with greater than or equal to (\> or =) 10% bone marrow blasts per 2022 international Consensus Classification criteria * Ineligible for intensive chemotherapy based on the following criteria: a) \>= 75 years of age and ineligible per physician's discretion, with Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, b) \>=18 to \<75 years of age with \>= 1 of the following comorbidities: i) ECOG performance status of 2, ii) Severe cardiac disorder, iii) Severe pulmonary disorder, iv) Renal impairment, v) Comorbidity that, in the investigator's opinion, makes the participant unsuitable for intensive chemotherapy, which must be documented before enrollment as defined in the protocol. Ineligibility for intensive chemotherapy should be explicitly approved by a multidisciplinary team in countries in which this process is standard of care. * Participants must have adequate hepatic and renal function * A female participant must agree not to be pregnant, breast-feed, plan to become pregnant and use protocol-specified contraception while enrolled in this study and for 6 months after the last dose of study treatment * A male participant must agree to use protocol-specified contraception while enrolled in this study for at least 90 days after the last dose of study treatment * Must sign an informed consent form indicating that the participant understands the purpose of, and procedures required for, the study and is willing to participate in the study","* Diagnosis of acute promyelocytic leukemia (APL) * Known active leukemic involvement of the central nervous system (CNS) * Recipient of solid organ transplant * Any cardiac disorders such as heart attack, uncontrolled/unstable chest pain, congestive heart failure, uncontrolled or symptomatic irregular heartbeat, blockage of a blood vessel to brain, or transient ischemic (decreased oxygen in tissue) attack within 6 months of randomization * Active infectious hepatitis * Live, attenuated vaccine within 4 weeks of randomization * Known allergies, hypersensitivity, or intolerance of bleximenib, azacitidine, or venetoclax excipients"
NCT02960022,A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study,,PHASE2,"Argentina, Brazil, Chile","Site AR54005, Buenos Aires, Argentina, [COMPLETED] | Site AR54007, Rosario, Argentina, [ACTIVE_NOT_RECRUITING] | Site AR54008, Buenos Aires, Argentina, [ACTIVE_NOT_RECRUITING] | Site AR54003, Cordorba, Argentina, [COMPLETED] | Site AR54006, San Miguel de Tucumán, Argentina, [ACTIVE_NOT_RECRUITING] | Site AR54002, San Miguel de Tucumán, Argentina, [COMPLETED] | Site BR55007, Porto Alegre, Brazil, [ACTIVE_NOT_RECRUITING] | Site BR55009, Bahia, Brazil, [ACTIVE_NOT_RECRUITING] | Site BR55008, Campinas, Brazil, [ACTIVE_NOT_RECRUITING] | Site BR55004, Ijuí, Brazil, [RECRUITING]",Prostate Cancer,3,"[1] enzalutamide (EXPERIMENTAL): Subjects will receive enzalutamide orally once daily at the same time each day || [2] enzalutamide plus abiraterone acetate and prednisone (EXPERIMENTAL): Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide once daily || [3] Enzalutamide plus leuprolide acetate (EXPERIMENTAL): Subjects enrolling from study MDV3100-13 (EMBARK) study may receive leuprolide acetate once every 12 weeks in addition to enzalutamide once daily","* Subject must currently be receiving enzalutamide for prostate cancer in a study sponsored by Astellas or Medivation and, based on the investigator's assessment, benefit from continued treatment. Subjects participating in investigator-initiated trials are not eligible. * Subject is able to continue on the treatment regimen that the subject was receiving in the prior study. If in the investigator's assessment, a change is needed to the subject's regimen (e.g., dose change in Androgen deprivation therapy (ADT) or dropping of a combination therapy) approval from a medical monitor is required prior to enrollment. * Subject is able to swallow enzalutamide capsules and comply with study requirements. * Subject and female partner who is of childbearing potential must continue to use 2 forms of birth control, of which 1 must be highly effective and 1 must be a barrier method throughout the study and for 3 months after final enzalutamide administration. * Subject agrees to avoid sperm donation during the study and for at least 3 months after final enzalutamide administration. * Subject agrees not to participate in another interventional study while on treatment. Canada Specific: * Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written Informed Consent and privacy language as per national regulations (e.g., Health Insurance Portability and Accountability Act authorization for the United States sites) must be obtained from the subject prior to any study-related procedures. * Subject must currently be receiving enzalutamide for breast cancer in a study sponsored by Astellas or Medivation/Pfizer and based on the investigator's assessment, benefit from continued treatment. Subjects participating in investigator-initiated trials are not eligible. * Subject is able to continue on the treatment regimen that they were receiving in the prior study. If in the investigator's assessment, a change is needed to the subject's regimen (e.g., dropping of a combi","* Subject met any of the discontinuation criteria or whose cancer progressed on the current enzalutamide clinical study in which subject is enrolling from. * Subject requires treatment with or plans to use either of the following: * New systemic therapy for subjects cancer (palliative radiation therapy is allowed). The treatment with agents administered during previous studies which was stopped and then restarted during this study does not represent new treatment. * Investigational therapy other than enzalutamide. * Subject is currently participating in an investigator-initiated interventional trial and receiving enzalutamide. * Subject has any concurrent disease, infection, or comorbid condition that interferes with the ability of the subject to participate in the study, which places the subject at undue risk or complicates the interpretation of data. Canada Specific: Subject will be excluded from participation if any of the following apply: * Subject met any of the discontinuation criteria or whose cancer progressed on the current enzalutamide clinical study in which they are enrolling from. * Subject requires treatment with or plans to use any of the following: * New systemic therapy for their cancer (palliative radiation therapy is allowed). The treatment with agents administered during previous studies which was stopped and then restarted during this study does not represent new treatment. * Investigational therapy other than enzalutamide. * Subject is currently participating in an investigator-initiated interventional trial and receiving enzalutamide. * Subject has any concurrent disease, infection, or comorbid condition that interferes with the ability of the subject to participate in the study, which places the subject at undue risk or complicates the interpretation of data in the opinion of the investigator."
NCT06211036,"A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)",DeLLphi-305,PHASE3,"Argentina, Brazil, Mexico","Hospital Britanico de Buenos Aires, CABA, Argentina, [RECRUITING] | Instituto Alexander Fleming, Capital Federal, Argentina, [RECRUITING] | Fundacion Medica de Rio Negro y Neuquen, Cipolletti, Argentina, [RECRUITING] | Exelsus Oncologia Clinica, San Miguel de Tucumán, Argentina, [RECRUITING] | Fundacion Centro Oncológico Riojano Integral para la Investigación y Prevención del Cáncer, La Rioja, Argentina, [RECRUITING] | Hospital Sao Rafael-Idor, Salvador, Brazil, [RECRUITING] | Cenantron Centro Avançado de Tratamento Oncologico Ltda, Belo Horizonte, Brazil, [RECRUITING] | Santa Casa de Misericordia de Passos, Passos, Brazil, [RECRUITING] | Hospital Uopeccan, Cascavel, Brazil, [RECRUITING] | Hospital de Clinicas de Ijui, Ijuí, Brazil, [RECRUITING]",Extensive-Stage Small-Cell Lung Cancer | Small-Cell Lung Cancer,2,[1] Tarlatamab in Combination With Durvalumab (EXPERIMENTAL): Participants will receive tarlatamab once every 2 weeks (Q2W) and durvalumab once every 4 weeks (Q4W). || [2] Durvalumab Alone (ACTIVE_COMPARATOR): Participants will receive durvalumab Q4W alone.,"* Participant has provided informed consent prior to initiation of any study specific activities/procedures. * Age \>= 18 years (or \>= legal adult age within the country if it is older than 18 years). * Completed 3-4 cycles of platinum-etoposide chemotherapy with concurrent durvalumab as first-line treatment of extensive-stage (ES)-SCLC prior to enrollment, without disease progression (ongoing response or stable disease) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1. * Minimum life expectancy \> 12 weeks. * Toxicities attributed to prior anti-cancer therapy resolved to grade ≤ 1, unless otherwise specified, excluding alopecia or fatigue. * Adequate organ function. * Histologically or cytologically documented extensive-stage disease (American Joint Committee on Cancer, 2017, IV small-cell lung cancer (SCLC) \[T any, N any, M1 a/b/c\]), or T3 to T4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan. Participants with prior limited-stage (LS)-SCLC are allowed if the interval is \> 6 months since the end of previous therapy and progression, in discussion with the medical monitor.","* Symptomatic central nervous system (CNS) metastases, or leptomeningeal disease. Participants with treated brain metastases are eligible as per protocol. * Prior history of severe or life-threatening events from any immune-mediated therapy. * History of other malignancy within the past 2 years, with some exceptions as per protocol. * Active or prior documented autoimmune or inflammatory disorders as per protocol. * Myocardial infarction and/or symptomatic congestive heart failure (New York Heart Association \> class II) within 6 months of first dose of study treatment. * History of arterial thrombosis (e.g., stroke or transient ischemic attack) within 6 months of first dose of study treatment. * Evidence of interstitial lung disease (ILD) or active, non-infectious pneumonitis. * History of solid organ transplant. * Major surgical procedures within 28 days of first dose of study treatment. * Known human immunodeficiency virus (HIV) infection (participants with HIV infection on antiviral therapy and undetectable viral load are permitted with a requirement for regular monitoring for reactivation for the duration of treatment on study), hepatitis C infection (participants with hepatitis C that achieve a sustained virologic response after antiviral therapy are allowed), or hepatitis B infection (participants with hepatitis B surface antigen \[HBsAg\] or core antibody that achieve sustained virologic response with antiviral therapy are permitted with a requirement for regular monitoring for reactivation for the duration of treatment on the study). * Receiving systemic corticosteroid therapy or any other form of immunosuppressive therapy within 14 days prior to first dose of study treatment. * History of allergic reactions or acute hypersensitivity reaction to antibody therapies, platinum chemotherapy, or etoposide. * Participant with symptoms and/or clinical signs and/or radiographic signs that indicate an acute and/or uncontrolled active systemic infection within 7 days"
NCT06839001,Cryoablation Versus Breast Surgery in the Local Treatment of Early-Stage Breast Cancer - Six Trial,CRYSTAL - SIX,PHASE3,Brazil,"Research Institute - Hospital do Coracao, São Paulo, Brazil, [NOT_YET_RECRUITING] | Research Institute - Hospital do Coracao, São Paulo, Brazil, [RECRUITING]",Breast Cancer | Breast Neoplasm,2,"[1] Cryoablation (EXPERIMENTAL): Patients will be treated with cryoablation using a Cryoprobe under real-time ultrasound guidance and local anesthesia. The cryoablation procedure consists of a freezing phase followed by passive th... || [2] Breast Surgery (Lumpectomy or Mastectomy) (ACTIVE_COMPARATOR): Surgery will be performed under general anesthesia according to standard operative procedures at the hospital of origin. Surgery may be performed as either a lumpectomy or a mastectomy, along with ...","* Unifocal primary invasive breast carcinoma * Tumor size ≤ 2.0 cm (T1) * Complete pathological report (including results for ER, PR, HER2, Ki-67, and FISH report for the ERBB2 gene, if necessary) * Lesion visible on ultrasound * Surgical treatment would be the first option, regardless of immunohistochemistry results","* Multifocal or multicentric invasive breast carcinoma * Ductal carcinoma in situ * Breast cancer with skin involvement * Clinically positive axilla (N1, N2 or N3) * Distance from lesion and skin less than 5 mm * Prior neoadjuvant systemic therapy for breast cancer * Distant metastasis"
NCT05256225,"A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma",,PHASE3,Puerto Rico,"Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico, [RECRUITING]",Endometrial Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma,3,"[1] Arm I (paclitaxel, carboplatin) (ACTIVE_COMPARATOR): Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacc... || [2] Arm II (paclitaxel, carboplatin, Herceptin Hylecta) (EXPERIMENTAL): Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30-60 minutes, and trastuzumab/hyaluronidase-oysk SC over 2-5 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 ... || [3] Arm III (paclitaxel, carboplatin, Phesgo) (EXPERIMENTAL): Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30-60 minutes, and pertuzumab/trastuzumab/hyaluronidase-zzxf SC over 5-8 minutes on day 1 of each cycle. Treatment repeats every 3 w...","* Federation of Gynecology and Obstetrics (FIGO) 2009 stage IA-IVB, non-recurrent, chemotherapy (chemo)-naive, HER2-positive endometrial cancer. The following endometrial cancer types are eligible: * Serous * Other endometrial cancers (including clear cell, endometrioid, mixed epithelial, dedifferentiated/undifferentiated) * Carcinosarcoma * NOTE: Endometrial cancers that are mismatch repair deficient (dMMR) by IHC are not eligible * Histologic confirmation of the original primary tumor is required. Submission of surgical pathology report (or endometrial biopsy pathology report in patients who never undergo hysterectomy) is required * Patients must be within 8 weeks of primary surgery (or endometrial biopsy in patients who never undergo hysterectomy) at the time of study registration * Patients may have measurable disease, non-measurable disease, or no measurable disease. In patients with measurable disease, lesions will be defined and monitored by RECIST v 1.1. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be \>= 10 mm when measured by CT or magnetic resonance imaging (MRI). Lymph nodes must be \>= 15 mm in short axis when measured by CT or MRI * For patients with uterine-confined (stage I) disease, the tumor must be invasive into the myometrium. Any amount of myoinvasion is acceptable for eligibility. Patients with non-invasive disease, endometrial intraepithelial carcinoma alone, or disease confined to a polyp will be excluded * All patients must have tumors that are HER2 positive as defined by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) 2018 Breast Cancer guidelines (https://documents.cap.org/documents/algorithim-evaluation-her2.pdf.) IHC and ISH testing will be done locally, at each participating institution and interpreted by local pathologists. In general HER2 positivity is defined as any of the following","* Prior Therapy: * Patients must NOT have received prior chemotherapy, biologic therapy, or targeted therapy for treatment of endometrial carcinoma * Patients must NOT have received prior radiation therapy for treatment of endometrial carcinoma. Prior radiation includes external beam pelvic radiation therapy, external beam extended field pelvic/para-aortic radiation therapy, and/or intravaginal brachytherapy * NOTE: Vaginal brachytherapy for treatment of endometrial cancer is permitted during study treatment. Planned use of vaginal brachytherapy must be declared at time of registration * Patients may have received prior hormonal therapy for treatment of endometrial carcinoma. All hormonal therapy must be discontinued at least one week prior to registration * Patients may not have a planned interval cytoreduction or hysterectomy, prior to documentation of progression, after study registration * Patients may not have planned external beam radiotherapy, prior to documentation of progression, after study registration * Significant cardiovascular disease including: * Uncontrolled hypertension, defined as systolic \> 150 mm Hg or diastolic \> 90 mm Hg despite antihypertensive medications * Myocardial infarction or unstable angina within 6 months prior to registration * New York Heart Association functional classification II, III or IV * Serious cardiac arrhythmia requiring medication. This does not include asymptomatic, atrial fibrillation with controlled ventricular rate * Significant lung disease: dyspnea at rest grade 2 or greater (resulting from extensive tumor involvement or other causes), pneumonitis grade 2 or greater, interstitial lung disease grade 2 or greater, idiopathic pulmonary fibrosis, cystic fibrosis, Aspergillosis, active tuberculosis, or history of opportunistic infections (pneumocystis pneumonia or cytomegalovirus pneumonia) * Patients with uncontrolled intercurrent illness including, but not limited to: ongoing or active infection (except for uncompli"
NCT06634589,"A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies",,"PHASE1, PHASE2",Brazil,"Hospital Sirio Libanes Brasilia, Brasília, Brazil, [NOT_YET_RECRUITING] | Ensino E Terapia de Inovacao Clinica Amo Etica, Salvador, Brazil, [NOT_YET_RECRUITING] | Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto, São José do Rio Preto, Brazil, [NOT_YET_RECRUITING] | Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein, São Paulo, Brazil, [NOT_YET_RECRUITING]",B-cell Malignancy | Relapsed Cancer | Refractory Cancer | B-cell Lymphoma,8,[1] Substudy 1 Part 1a: Dose Escalation (EXPERIMENTAL): Sequential cohorts of increasing dose level combinations of BGB-16673 and sonrotoclax will be evaluated in participants with selected B-cell malignancies. || [2] Substudy 1 Part 1b: Safety Expansion (EXPERIMENTAL): Cohorts of select dose level combinations of BGB-16673 and sonrotoclax will be evaluated in participants with selected B-cell malignancies. || [3] Substudy 2 Part 1a: Dose Escalation (EXPERIMENTAL): Sequential cohorts of increasing dose level combinations of BGB-16673 and zanubrutinib will be evaluated in participants with selected B-cell malignancies. || [4] Substudy 2 Part 1b: Safety Expansion (EXPERIMENTAL): Cohorts of select dose level combinations of BGB-16673 and zanubrutinib will be evaluated in participants with selected B-cell malignancies. || [5] Substudy 3 Part 1a: Dose Escalation (EXPERIMENTAL): Sequential cohorts of increasing dose level combinations of BGB-16673 and mosunetuzumab will be evaluated in participants with selected B-cell malignancies. || [6] Substudy 3 Part 1b: Safety Expansion (EXPERIMENTAL): Cohorts of select dose level combinations of BGB-16673 and mosunetuzumab will be evaluated in participants with selected B-cell malignancies. || [7] Substudy 4 Part 1a: Dose Escalation (EXPERIMENTAL): Sequential cohorts of increasing dose level combinations of BGB-16673 and glofitamab will be evaluated in participants with selected B-cell malignancies. Participants will receive obinutuzumab as p... || [8] Substudy 4 Part 1b: Safety Expansion (EXPERIMENTAL): Cohorts of select dose level combinations of BGB-16673 and glofitamab will be evaluated in participants with selected B-cell malignancies.,"* Must sign the informed consent form (ICF) and be capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the ICF * Confirmed diagnosis of a R/R B-cell malignancy * Protocol-defined measurable disease * Stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2 * Adequate organ function * Female participants of childbearing potential must be willing to use a highly effective method of birth control and refrain from egg donation for the duration of the study and for 30 days after the last dose of BGB-16673 or zanubrutinib, 60 days after the last dose of glofitamab, or 90 days after the last dose of sonrotoclax or mosunetuzumab. A negative urine or serum pregnancy test result must be provided 10-14 days before the first dose of study treatment * Nonsterile male participants must be willing to use a highly effective method of birth control and refrain from sperm donation for the duration of the study and for 30 days after the last dose of BGB-16673 or zanubrutinib, 60 days after the last dose of glofitamab, or 90 days after the last dose of sonrotoclax or mosunetuzumab * Substudies 1, 3, and 4 Inclusion Criterion: * Adequate renal function as indicated by estimated glomerular filtration rate (eGFR) of ≥ 50 mL/min * Substudy 2 Inclusion Criteria: * Bruton tyrosine kinase (BTK) inhibitor-naive, or previously received treatment with a covalent BTK inhibitor and discontinued for reasons other than clinical progression * Adequate renal function as indicated by eGFR of ≥ 30 mL/min Key","* Treatment-naive B-cell malignancies * Unable to comply with the requirements of the protocol * Active leptomeningeal disease or uncontrolled, untreated brain metastasis * Any malignancy ≤ 2 years before first dose of study treatment except for the specific cancer under investigation in this study or any locally recurring cancer that has been treated curatively * Autologous stem cell transplant ≤ 3 months prior to screening or chimeric antigen T-cell therapy ≤ 3 months prior to screening * Substudies 1 and 2: Prior allogeneic stem cell transplant with active graft-versus-host disease (GVHD), or requiring immunosuppressive drugs for treatment of GVHD, or who have taken calcineurin inhibitors within 4 weeks prior to consent * Participants who have a history of severe allergic reactions or hypersensitivity to the active ingredient and excipients of BGB-16673, sonrotoclax, zanubrutinib, mosunetuzumab, or glofitamab * Substudy 1 Exclusion Criterion: * Prior treatment with a B-cell lymphoma-2 (Bcl-2) inhibitor (with exception for participants who relapsed ≥ 24 months after completion of a full course of a prior Bcl-2 inhibitor containing regimen) * Substudy 2 Exclusion Criterion: * Participants who discontinued prior zanubrutinib treatment due to intolerance * Substudies 3 and 4 Exclusion Criteria: * Prior exposure to a CD20 x CD3 T-cell engager antibody treatment * All participants with a prior allogeneic stem cell transplant Note: Other protocol defined Inclusion/Exclusion criteria may apply."
NCT04680442,"Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction: A Randomized, Controlled Trial",SCHOLAR-2,PHASE2,Brazil,"Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, [RECRUITING] | Irmandade Da Santa Casa De Misericórdia De Porto Alegre, Porto Alegre, Brazil, [RECRUITING] | Hospital Alemão Oswaldo Cruz, São Paulo, Brazil, [RECRUITING] | Clínica de Pesquisa e Centro de Estudos em Oncologia Ginecológica e Mamária Ltda, São Paulo, Brazil, [RECRUITING]",Breast Cancer | Heart Failure,2,"[1] Control Group (ACTIVE_COMPARATOR): Recommendations for continuing or holding trastuzumab, pertuzumab, or trastuzumab-emtansine (T-DM1) for the control group are guided by an adaptation of the 2008 Canadian recommendations. || [2] Intervention Group (EXPERIMENTAL): The intervention group will continue to receive trastuzumab, pertuzumab, or trastuzumab-emtansine (T-DM1) in the setting of asymptomatic decline in LVEF up to an LVEF of 40% as outlined in the crit...","1. Stage I-III HER-2 positive breast cancer 2. Receiving adjuvant or neoadjuvant therapy with trastuzumab, pertuzumab, or trastuzumab-emtansine (T-DM1) 3. Evidence of left ventricular dysfunction, as defined by at least one of: a) LVEF \< 54% or b) LVEF ≥54% and either i) fall in LVEF of ≥15% from prior to trastuzumab, pertuzumab, or trastuzumab-emtansine (T-DM1) exposure, or ii) New York Heart Association (NYHA) class II heart failure symptoms within the past 6 months",1. Current use of both angiotensin converting enzyme inhibitor (ACEI) /angiotensin receptor blocker (ARB) and beta-blocker 2. Contra-indication to both ACE-I/ARB and beta-blockers 3. NYHA class III or IV heart failure 4. LVEF \<40% 5. Systolic blood pressure \<100mmHg 6. Current or planned pregnancy or breastfeeding
NCT06018337,"A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02)",,PHASE3,Argentina,"Research Site 5411-0, Bahía Blanca, Argentina, [RECRUITING] | Research Site 5414-0, CABA, Argentina, [RECRUITING] | Research Site 5405-0, La Plata, Argentina, [RECRUITING] | Research Site 5413-0, Mar del Plata, Argentina, [RECRUITING] | Research Site 5408-0, Quilmes, Argentina, [RECRUITING] | Research Site 5403-0, CABA, Argentina, [RECRUITING] | Research Site 5402-0, Viedma, Argentina, [RECRUITING] | Research Site 5401-0, Rosario, Argentina, [RECRUITING] | Research Site 5406-0, Rosario, Argentina, [RECRUITING] | Research Site 5404-0, San Miguel de Tucumán, Argentina, [RECRUITING]",Metastatic Breast Cancer,2,"[1] DB-1303/BNT323 (EXPERIMENTAL): Enrolled Subjects will be randomized to receive a 8 mg/kg IV dose of DB-1303/BNT323 on Day 1 of each cycle Q3W || [2] investigator's choice single agent chemotherapy (ACTIVE_COMPARATOR): Enrolled Subjects will be randomized to receive investigator's choice single agent chemotherapy (capecitabine:1000 or 1250 mg/m2, Oral, Twice daily orally for 2 weeks followed by a 1-week rest peri...","1\. Male or female adults (defined as ≥ 18 years of age or acceptable age according to local regulations at the time of voluntarily signing of informed consent). 2\. Pathologically documented breast cancer that: 1. Is advanced or metastatic 2. Has HER2-low expression (IHC 1+ or IHC 2+/ISH-) as determined by the central laboratory result. 3. Was never previously reported as HER2-positive (IHC 3+ or ISH+) as per American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines. 4. Is documented as HR+ (either estrogen receptor \[ER\] and/or progesterone receptor \[PgR\] positive \[ER or PgR ≥1%\]) per ASCO/CAP guidelines (Allison et al 2020). 3\. Must have an adequate tumor tissue sample available for assessment of HER2 by central laboratory, in formalin fixation and paraffin embedding (FFPE) blocks based on a mandatory FFPE tumor sample preferably obtained at the time of metastatic disease or later; 4\. Eastern Cooperative Oncology Group performance status of 0 or 1. 5\. Must have had either: 1. Disease progression on endocrine therapy + CDK4/6 inhibitor within 6 months of starting first line treatment for metastatic disease and considered appropriate for chemotherapy as the next treatment by the investigator, OR 2. Disease progression on at least 2 previous lines of ET with or without a targeted therapy (such as CDK4/6, mammalian target of rapamycin \[mTOR\] or phosphoinositide 3-kinase \[PI3-K\] inhibitors) administered for the treatment of metastatic disease. 6\. No prior chemotherapy for advanced or metastatic breast cancer. Subjects who have received chemotherapy in the neo-adjuvant or adjuvant setting are eligible, as long as they have had a disease-free interval (defined as completion of systemic chemotherapy to diagnosis of advanced or metastatic disease) of \>12 months. 7\. Life expectancy ≥12 weeks at screening. 8\. Subjects must have at least one measurable lesion as defined per RECIST v1.1 (For bone only disease, subjects with l","1. Ineligible for all options in the investigator's choice chemotherapy arm. 2. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, uncontrolled or significant cardiovascular disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring adverse events or compromise the ability of the subject to give written informed consent. 3. Clinically uncontrolled pleural effusion, ascites or pericardial effusion requiring repeated drainage, peritoneal shunt or cell-free concentrated ascites reinfusion therapy within 2 weeks prior to the randomization. 4. Uncontrolled or significant cardiovascular disease 5. Has a medical history of interstitial lung diseases (e.g., non-infectious interstitial pneumonia, pneumonitis, pulmonary fibrosis, and radiation pneumonitis which needs glucocorticoids and antibiotics) or current interstitial lung diseases or who are suspected to have these diseases by imaging at screening. 6. Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤ 1 or baseline or Grade ≤ 2 anemia. 7. Previous treatment with anti-HER2 therapy. 8. Prior treatment with antibody-drug conjugate that comprised an exatecan derivative that is a topoisomerase I inhibitor. 9. Prior randomization or treatment in a previous DB-1303/BNT323 study regardless of treatment assignment. 10. Has substance abuse or any other medical conditions such as psychological conditions, that may, in the opinion of the Investigator, interfere with the subject's participation in the clinical study or evaluation of the clinical study results. 11. Individuals who are dependent on the Sponsor, clinical site, or Investigator (e.g., is an employee of the Sponsor or the clinical trial site, a dependent of the Investigator, or any site staff member"
NCT05812807,OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy,,PHASE3,Puerto Rico,"Doctors Cancer Center, Manatí, Puerto Rico, [RECRUITING] | Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico, [RECRUITING] | PROncology, San Juan, Puerto Rico, [RECRUITING] | San Juan City Hospital, San Juan, Puerto Rico, [RECRUITING]",Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Early Stage Triple-Negative Breast Carcinoma,2,"[1] Arm I (pembrolizumab) (ACTIVE_COMPARATOR): Patients receive pembrolizumab IV on study. Patients also undergo tumor biopsy on study, and collection of blood on study and during follow-up. || [2] Arm II (observation) (EXPERIMENTAL): Patients undergo observation on study. Patients also undergo tumor biopsy on study, and collection of blood on study and during follow-up.","* Age \>= 18 years * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2 * Triple Negative Breast Cancer: * Patients with a history of stage T1cN1-2 or T2-4N0-2 breast cancer according to the primary tumor-regional lymph node anatomic staging criteria of the American Joint Committee on Cancer (AJCC), 8th edition as determined by the investigator in radiologic assessment, clinical assessment or both * Patients must have no residual invasive disease in the breast or lymph nodes after the completion of neoadjuvant therapy. Residual ductal carcinoma in situ (DCIS) is allowed. Isolated tumor cells are considered node-negative * Estrogen (ER) and progesterone (PR) =\< 10%; HER2-negative by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines (immunohistochemistry \[IHC\] and fluorescence in situ hybridization \[FISH\]) * If invasive disease was present in both breasts, participation in the study is permitted as long as the eligibility criteria are met for both tumors/breasts * Patients must have received neoadjuvant chemotherapy in combination with pembrolizumab for a minimum of 6 cycles. All systemic chemotherapy and ICI therapy should have been completed preoperatively * An interval of no more than 12 weeks between the completion date of the final surgery and the date of randomization \* Note: Adjuvant radiation can be given on study. If given, it is encouraged to be given concurrently with pembrolizumab, per investigator discretion. Treatment with adjuvant pembrolizumab is strongly discouraged prior to participation in this trial, but if administered (e.g., if patients are awaiting pathology results), pembrolizumab may be administered for up to 6 weeks post-surgery and must be completed prior to registration * Use of investigational anti-cancer agents must be discontinued at time of registration * Adequate excision: Surgical removal of all clinically evident disease in the breast and lymph nodes as follows: * Breas","* No stage IV (metastatic) breast cancer * No history of any prior (ipsi- or contralateral) invasive breast cancer. Prior DCIS is allowed * No evidence of recurrent disease following preoperative therapy and surgery * No known active liver disease, e.g. due to hepatitis B virus (HBV), hepatitis C virus (HCV), autoimmune hepatic disorders, or sclerosing cholangitis * No history of intolerance, including Grade 3 or 4 infusion reaction or hypersensitivity to pembrolizumab or murine proteins or any components of the product \* Note: Prior immune-related adverse events (irAEs) are allowed if they resolved and the patient tolerated subsequent therapy without requiring chronic steroids for the irAE * No medical conditions that require chronic systemic steroids (\>10 mg prednisone daily or equivalent) or any other form of immunosuppressive medications and has required such therapy in the last two years. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic therapy * Patients who are unable or unwilling to comply with the requirements of the protocol per investigator assessment are not eligible"
NCT05710328,Interim FDG-PET/CT for PreDIcting REsponse of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT Trial,,PHASE2,Puerto Rico,"Cancer Center-Metro Medical Center Bayamon, Bayamón, Puerto Rico, [SUSPENDED] | Doctors Cancer Center, Manatí, Puerto Rico, [SUSPENDED] | San Juan Community Oncology Group, San Juan, Puerto Rico, [SUSPENDED] | Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico, [SUSPENDED] | San Juan City Hospital, San Juan, Puerto Rico, [SUSPENDED]",Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | HER2-Positive Breast Carcinoma | Invasive Breast Carcinoma,1,"[1] Diagnostic (FDG-PET/CT scan) (EXPERIMENTAL): Patients receive FDG IV, undergo PET/CT, receive standard of care chemotherapy, and undergo standard of care surgery on study.","* Patients (all genders) must be \>= 18 years of age. * Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible. * Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. * Patient must have histologically confirmed HER2-positive primary invasive breast carcinoma by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines that has been determined by local testing. * Patient must have known (either positive or negative) hormone receptor (estrogen receptor \[ER\] or progesterone receptor \[PR\]) status by local testing, per ASCO/CAP guidelines. Patients with either hormone receptor-positive or hormone receptor- negative HER2-positive breast cancer are eligible. * Patient must have American Joint Committee on Cancer (AJCC) 8th Edition stage IIa-IIIc according to anatomic staging table at diagnosis and below criteria. * Patients without nodal involvement (cN0) are eligible if T size \> 2.0 cm (T2-4) * Patients with nodal involvement (cN1-3) are eligible if T2-4 * Patients with clinical T4d are not eligible * Patients with bilateral invasive breast cancers are eligible if both cancers are HER2-positive and at least one meets all protocol eligibility criteria and neither cancer renders the patient ineligible. * Patients with multiple ipsilateral invasive tumors are eligible as long as all tumors are HER2-positive and at least one tumor focus meets all eligibility criteria. Multiple lesions that appear part of the same index tumor do not require additional biopsy/HER2 testing. * Patient must plan to start a standard neoadjuvant pertuzumab (or other biosimilars) based regimen. * Patients with a prior or concurrent malignancy whose natural history or treatment does not hav","* Patient must not have any prior treatment for the current breast cancer, including surgery, chemotherapy, hormonal therapy, radiation or experimental therapy. * Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the teratogenic effects of FDG in addition to the radiation exposure during PET/CT. All patients of childbearing potential must have a blood test or urine study within 7 days prior to registration to rule out pregnancy. * NOTE: A pregnancy test within 7 days prior to the T0 scan is also required but will only need to be done if a) the T0 scan is completed after study registration and b) if the pregnancy test done prior to registration is completed outside of the 7-day window. A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months). * Patient must not have any contraindication to FDG-PET/CT imaging which includes routine glucose values \> 200 mg/dL and severe claustrophobia."
NCT06333951,"A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)",,PHASE1,"Argentina, Brazil","Instituto Argentino de Diagnóstico y Tratamiento, Ciudad Automona de Buenos Aires, Argentina, [RECRUITING] | Cemic, Ciudad Autonoma Buenos Aires, Argentina, [RECRUITING] | Oncosite Centro de Pesquisa Clinica Em Oncologia Ltda, Ijuí, Brazil, [RECRUITING] | Fund Fac Reg Med Sao Jose Rio Preto, São José do Rio Preto, Brazil, [RECRUITING] | Beneficencia Portuguesa de Sao Paulo - Bp, São Paulo, Brazil, [RECRUITING] | Instituto Cancer Sao Paulo Icesp, São Paulo, Brazil, [RECRUITING]",Thoracic Tumors | Non-small Cell Lung Cancer,5,"[1] Subprotocol A: Non-Small Cell Lung Cancer (NSCLC) Arm A (EXPERIMENTAL): Participants with MTAP-deleted NSCLC will receive a regimen of AMG 193 orally (PO) and carboplatin, paclitaxel, and pembrolizumab intravenously (IV) || [2] Subprotocol A: NSCLC Arm B (EXPERIMENTAL): Participants with MTAP-deleted NSCLC will receive a regimen of AMG 193 PO and carboplatin, pemetrexed, and pembrolizumab IV || [3] Subprotocol A: NSCLC Arm C (EXPERIMENTAL): Participants with MTAP-deleted NSCLC will receive a combination of AMG 193 PO and pembrolizumab IV || [4] Subprotocol B: NSCLC With KRasG12C Mutation (EXPERIMENTAL): Participants with MTAP-deleted NSCLC and KRasG12C mutation will receive a combination of AMG 193 and sotorasib PO || [5] Subprotocol C: NSCLC With Brain Metastases (EXPERIMENTAL): Participants with MTAP-deleted NSCLC with brain metastases will receive AMG 193 PO","Subprotocol A, B, and C * Age ≥ 18 years (or ≥ legal age within the country if it is older than 18 years). * Tumor tissue (formalin-fixed, paraffin-embedded sample) or an archival block must be available. Participants without archived tumor tissue available may be allowed to enroll by undergoing tumor biopsy before AMG 193 dosing. * Homozygous MTAP-deletion * Able to swallow and retain PO administered study treatment. * Disease measurable as defined by RECIST v1.1. Subprotocol A - Histologically or cytologically confirmed diagnosis of NSCLC. Arm A (AMG 193 + carboplatin + paclitaxel + pembrolizumab): \- Predominantly squamous histology. Arm B (AMG 193 + carboplatin + pemetrexed + pembrolizumab): \- Predominantly non-squamous histology. Arm C (AMG 193 + pembrolizumab): \- PD-L1 positive. Subprotocol B - Histologically confirmed NSCLC with homozygous MTAP-deletion and KRAS p.G12C mutation. Subprotocol C * Histologically or cytologically confirmed diagnosis of NSCLC with brain metastases. * Brain lesion meeting RANO-BM criteria for measurable disease.","Subprotocol A, B, and C * Cardiovascular and pulmonary exclusion criteria as defined in the protocol. * Gastrointestinal tract disease causing the inability to take PO medication, malabsorption syndrome, requirement for IV alimentation, gastric/jejunal tube feeds, uncontrolled inflammatory gastrointestinal disease (eg, Crohn's disease, ulcerative colitis). * History of solid organ transplant. * Major surgery within 28 days of first dose of AMG 193. * Prior treatment with a MAT2A inhibitor or a PRMT5 inhibitor. * Radiation therapy within 28 days of first dose. Subprotocol A \- Autoimmune disease or immunodeficiency disease as defined in the protocol'"
NCT05498428,"A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer",PALOMA-2,PHASE2,Brazil,"Fundacao Pio XII, Barretos, Brazil, [RECRUITING] | PERSONAL Oncologia de Precisao e Personalizada, Belo Horizonte, Brazil, [RECRUITING] | Instituto do Cancer de Londrina Hospital do Cancer de Londrina, Londrina, Brazil, [RECRUITING] | Associacao Hospitalar Moinhos de Vento, Porto Alegre, Brazil, [RECRUITING] | Instituto D Or de Pesquisa e Ensino IDOR, Rio de Janeiro, Brazil, [RECRUITING] | Instituto D Or de Pesquisa e Ensino IDOR, Salvador, Brazil, [RECRUITING] | Hospital Alemao Oswaldo Cruz, São Paulo, Brazil, [RECRUITING] | Impar Servicos Hospitalares SA Hospital Nove de Julho, São Paulo, Brazil, [RECRUITING] | Fundacao Antonio Prudente A C Camargo Cancer Center, São Paulo, Brazil, [RECRUITING]","Carcinoma, Non-small-Cell Lung",8,"[1] Cohort 1(Exon19del/Exon21 L858R NSCLC, 1L, Previously Untreated): Amivantamab (Q2W) + Lazertinib (EXPERIMENTAL): Participants with treatment-naive locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) exon 19 deletion (exon19del) or exon 21 leuc... || [2] Cohort 2(Exon20 NSCLC,1L, Previously Untreated): Amivantamab (Q3W) + Chemotherapy (EXPERIMENTAL): Participants with treatment-naive locally advanced or metastatic NSCLC harboring an EGFR exon20ins mutation will receive Amivantamab SC-CF injection 1600 mg or 2240 mg if body weight is \>=80 kg on... || [3] Cohort 3(Exon19del/Exon21 L858R NSCLC,2L,Post Osimertinib):Amivantamab(Q3W)+Lazertinib+Chemotherapy (EXPERIMENTAL): Participants with locally advanced or metastatic NSCLC harboring an EGFR exon19del or exon 21 L858R mutation who have experienced disease progression on or after treatment with a third-generation E... || [4] Cohort 3b(Exon19del/Exon21 L858R NSCLC, 2L, Post Osimertinib): Amivantamab (Q3W)+Chemotherapy (EXPERIMENTAL): Participants with locally advanced or metastatic NSCLC harboring an EGFR exon19del or exon 21 L858R mutation who have experienced disease progression on or after treatment with a third-generation E... || [5] Cohort 4(Previously Treated with Amivantamab IV): Switch from Amivantamab IV to SC-CF (Q2W) (EXPERIMENTAL): Participants who were previously on amivantamab IV once every 2 weeks (Q2W) regimen as part of standard of care, for at least 8 weeks, either as monotherapy or combination with lazertinib, will rec... || [6] Cohort 5(Exon19del/Exon21 L858R NSCLC, 1L, Previously Untreated): Amivantamab (Q4W) + Lazertinib (EXPERIMENTAL): Participants with treatment-naïve locally advanced or metastatic NSCLC harboring an EGFR Exon19del or Exon 21 L858R mutation will receive amivantamab SC-CF induction with 1,600 mg (or 2,240 mg if B... || [7] Cohort6(Exon19del/Exon21L858R,NSCLC1L,PreviouslyUntreated):Amivantamab(Q2W)+Lazertinib+Ant","* Participant must have histologically or cytologically confirmed, locally advanced or metastatic, non-small cell lung cancer (NSCLC) that is not amenable to curative therapy including surgical resection or chemoradiation. Additional Cohort specific disease requirements include: Cohorts 1, 3, 3b, 5, 6 and 7: epidermal growth factor receptor (EGFR) exon 19 deletion (Exon19del) or Exon 21 L858R mutation; Cohort 2: EGFR Exon 20ins mutation. Cohorts 1,5,and6: Participant should not have received any prior systemic therapy for locally advanced or metastatic NSCLC. Cohort 2: Participant should not have received any prior systemic therapy for locally advanced or metastatic NSCLC. Cohorts 3and3b: Participant must have progressed on or after osimertinib monotherapy as the most recent line of treatment. Osimertinib must have been administered as either the first-line treatment for locally advanced or metastatic disease or in the second-line setting after prior treatment with first- or second-generation EGFR tyrosine kinase inhibitor (TKI) as a monotherapy. Cohort 4: Participants need to currently be on an amivantamab IV Q2W regimen (1,050 mg or 1,400 mg depending on weight) for at least 8 weeks, as part of standard of care, an expanded access program, or as a rollover from a long-term extension, without any amivantamab dose reduction. Cohort 7: Participants must have progressed on or after the combination of amivantamab and lazertinib as the most recent line of treatment. The combination of amivantamab and lazertinib must have been administered as the first-line treatment for locally advanced or metastatic disease. Cohort 2, 3, 3b, and 7 only: Squamous NSCLC are excluded. EGFR mutation must have been identified as determined by Food and Drug Administration (FDA) approved or other validated test of either circulating tumor deoxyribonucleic acid (ctDNA) or tumor tissue in a clinical laboratory improvement amendments (CLIA) certified laboratory (sites in the United states \[US\]","* Participant has a medical history of interstitial lung disease (ILD), including drug induced ILD or radiation pneumonitis * Participant has a history of hypersensitivity to any excipients of the investigational products to be used in their enrollment cohort * Participant has received a live or live attenuated vaccine within 3 months before Cycle 1 Day 1. The seasonal influenza vaccine and non-live vaccines against Coronavirus disease 19 (COVID-19) are not exclusionary * For all cohorts (with regimens potentially including lazertinib): Participant is currently receiving medications or herbal supplements known to be potent Cytochrome (CYP3A4/5) inducers and is unable to stop use for an appropriate washout period prior to Cycle 1 Day 1 * Other clinically active liver disease of infectious origin * Participant has a history of clinically significant cardiovascular disease including, but not limited to: a) All cohorts: diagnosis of deep vein thrombosis or pulmonary embolism within 1 month prior to the first dose of study treatment(s), or any of the following within 6 months prior to the first dose of study treatment(s): myocardial infarction, unstable angina, stroke, transient ischemic attack, coronary/peripheral artery bypass graft, or any acute coronary syndrome. Clinically non-significant thrombosis, such as non-obstructive catheter-associated clots, are not exclusionary; b) All cohorts (with regimens potentially including lazertinib): Participant has a significant genetic predisposition to venous thromboembolic events (VTE; such as Factor V Leiden); c) All cohorts (with regimens potentially including lazertinib): Participant has a prior history of VTE and is not on appropriate therapeutic anticoagulation as per NCCN or local guidelines; d) prolonged corrected QT interval by Fridericia (QTcF) interval greater than (\>) 480 milliseconds (msec) or clinically significant cardiac arrhythmia or electrophysiologic disease (example, placement of implantable cardioverter de"
NCT03556228,"An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma",,PHASE1,Puerto Rico,"PanOncology Trials, Hospital Oncologico - Puerto Rico Medical Center, Río Piedras (site 200), San Juan, Puerto Rico, [RECRUITING]",Head and Neck Carcinoma | Adenoid Cystic Carcinoma | Lung Cancer | Non-Small Cell Lung Cancer | Breast Cancer,1,[1] VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete) (EXPERIMENTAL): No description,"* Histologically or cytologically confirmed diagnosis of any type of solid tumor malignancy or lymphoma that is not responsive to standard therapies or had progressed following standard therapy and for which there is no approved or curative therapy. Additionally, patients must not be candidates for or have exhausted regimens known to provide clinical benefit, including hematopoietic stem cell transplantation in lymphoma patients if they are deemed transplant eligible. * Eastern Cooperative Oncology Group (ECOG) Performance Status: 0 or 1. * Able to swallow and retain oral medication. * Adequate organ system function. * Subjects must either have available archival tumor tissue samples, or consent to tumor tissue sampling prior to the first dose, that is sufficient for IHC analysis of TrkA expression, except with prior documented NTRK+. * Subjects must have a tumor: (i). with TrkA protein overexpression (TrkA+) in the validated TrkA IHC assay, OR (ii). with documented NTRK1 gene fusion (NTRK1+) including a tumor which has progressed due to NTRK1 mutation after treatment of a pan-Trk inhibitor (e.g. larotrectinib \[Vitrakvi®\] or entrectinib \[Rozlytrek®\]) * Adequate organ system function as defined as follows: 1. Absolute neutrophil count ≥1.5x10\^9/L 2. Hemoglobin ≥9g/dL 3. Platelets ≥100x10\^9/L 4. PT/INR, PTT ≤1.5xULN 5. Total bilirubin ≤1.5x ULN 6. AST, ALT ≤2.5xULN 7. Creatinine ≤1.2xULN for age, weight 8. Calculated creatinine clearance or 24h urine creatinine clearance ≥60mL/min Key","1. Received chemotherapy having delayed toxicity within the last 14 days (six weeks for prior nitrosourea or mitomycin C). 2. Received anticancer therapy with radiation, immunotherapy, and a biologic, surgery and/or tumor embolization within the past 2 weeks. 3. Received an investigational anticancer drug within 14 days or 5 half-lives of the investigational agent, whichever is longer, prior to the first dose of VMD-928. Any exceptions to the above must be approved by the Sponsor Medical Monitor. 4. Unresolved toxicity from previous anticancer therapy \&amp;amp;amp;gt; CTCAE Grade 1 (except alopecia or anemia) unless agreed to by both the Sponsor Medical Monitor and the Investigator. 5. Negative result on TrkA immunohistochemistry (IHC) assay (if enrolled in dose expansion cohorts). 6. Known active infections including HIV disease. 7. Patients with a history of chronic viral hepatitis (HBV/HCV), even if treated, or a history of cirrhotic liver secondary to any etiology (i.e. alcoholism, non-alcoholic steatohepatitis). 8. Currently pregnant, nursing, or planning to become pregnant during the course of the study. 9. QTcF interval ≥ 480 msec. 10. Class II, III, or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system. 11. Acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting within the past 24 weeks. 12. Unstable or uncompensated respiratory, hepatic, renal, or cardiac disease that would compromise the patient's safety or interfere with assessment of the drug. 13. Psychological, familial, sociological, geographical, or other concurrent conditions that would interfere with safety evaluation, limit the patient's ability to follow the procedures in the protocol or otherwise jeopardize compliance with the protocol. Patients with uncontrolled major depression, bipolar disorder, or severe anxiety disorder are excluded. 14. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to "
NCT06305767,A Phase 1/2 Study of V940 Plus Pembrolizumab With or Without Enfortumab Vedotin in Muscle-Invasive Urothelial Carcinoma (MIUC) (INTerpath-005),,"PHASE1, PHASE2","Chile, Colombia, Peru","Bradfordhill-Clinical Area ( Site 1501), Recoleta, Santiago, Chile, [RECRUITING] | FALP ( Site 1500), Santiago, Chile, [RECRUITING] | Pontificia Universidad Catolica de Chile ( Site 1503), Santiago, Chile, [RECRUITING] | CIDO SpA ( Site 1509), Temuco, Chile, [RECRUITING] | ONCOCENTRO APYS-ACEREY ( Site 1506), Viña del Mar, Chile, [RECRUITING] | Clínica Universitaria Colombia ( Site 1600), Bogotá, Colombia, [RECRUITING] | Sociedad De Oncologia Y Hematologia Del Cesar-Oncology ( Site 1605), Valledupar, Colombia, [RECRUITING] | Instituto Nacional De Cancerologia-Oncología Clínica ( Site 1606), Bogota, Colombia, [RECRUITING] | Fundacion Valle del Lili- CIC-Oncology CIC ( Site 1608), Santiago de Cali, Colombia, [RECRUITING] | IPOR Instituto Peruano de Oncología & Radioterapia ( Site 1702), Lima, Peru, [RECRUITING]",Bladder Cancer,3,"[1] Adjuvant Cohort: Pembrolizumab + Intismeran autogene (EXPERIMENTAL): Adjuvant Cohort participants receive adjuvant treatment with up to 9 cycles of pembrolizumab plus up to a total of 9 doses of intismeran autogene. Intismeran autogene doses may begin as soon as Day... || [2] Adjuvant Cohort: Pembrolizumab + Placebo (ACTIVE_COMPARATOR): Adjuvant Cohort participants receive adjuvant treatment with up to 9 cycles of pembrolizumab plus up to a total of 9 doses of placebo. Placebo doses may begin as soon as Day 22 of Cycle 1. The tota... || [3] Perioperative Cohort: Pembrolizumab + Intismeran autogene + EV and Surgery (EXPERIMENTAL): Participants will receive neoadjuvant treatment with up to 4 cycles of pembrolizumab plus EV and 1 to 4 doses of intismeran autogene, followed by radical cystectomy \[RC\] plus pelvic lymph node di...","The main inclusion criteria include but are not limited to the following: * Has a histological diagnosis of urothelial carcinoma (UC) * Must provide blood samples per protocol, to enable intismeran autogene production, and circulating tumor deoxyribonucleic acid testing * Has an Eastern Cooperative Oncology Group performance status of 0 to 2 assessed within 7 days before randomization * Must provide a formalin-fixed paraffin-embedded tumor tissue sample for next generation sequencing Adjuvant Cohort: * Has MIUC * Has high-risk pathologic disease after radical resection * For participants who have not received cisplatin-based neoadjuvant chemotherapy, are ineligible to receive cisplatin according to protocol pre-defined criteria Perioperative Cohort: * Has MIBC * Is deemed eligible for RC and PLND and agrees to undergo curative intent standard RC and PLND and neoadjuvant and adjuvant treatment per protocol * Is ineligible to receive cisplatin according to protocol pre-defined criteria","The main exclusion criteria include but are not limited to the following: * Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention * Has known additional malignancy that is progressing or has required active treatment ≤3 years prior to study randomization * Has current pneumonitis/interstitial lung disease * Has active infection requiring systemic therapy * Has active hepatitis B and hepatitis C virus infection Adjuvant Cohort: * Has received prior systemic anticancer therapy * Has received prior neoadjuvant therapy, with the exception of neoadjuvant cisplatin-based chemotherapy for MIUC * Has severe hypersensitivity to either intismeran autogene or pembrolizumab (MK-3475) and/or any of their excipients Perioperative Cohort: * Has received any prior systemic treatment, cancer vaccine treatment, chemoradiation, and/or radiation therapy treatment for MIBC * Has severe hypersensitivity to either intismeran autogene, pembrolizumab, or EV and/or any of their excipients * Has ongoing sensory or motor neuropathy * Has active keratitis or corneal ulcerations"
NCT05542030,Accuracy of CAD Eye in the Detection of Colonic Remaining Lesions After Endoscopic Mucosal Resection: a Pilot Study,,NA,Ecuador,"Carlos Robles-Medranda, Guayaquil, Ecuador, [RECRUITING]",Colorectal Dysplasia | Colorectal Neoplasms,2,"[1] Endoscopic mucosal resection + CAD-Eye™ (EXPERIMENTAL): This group constitutes patients with lesions suggestive of high-grade dysplasia or early invasive cancer approached with endoscopic mucosal resection, subjected to colonoscopy + CAD-Eye™ system eva... || [2] Endoscopic mucosal resection without CAD Eye (ACTIVE_COMPARATOR): This group constitutes patients with lesions suggestive of high-grade dysplasia or early invasive cancer approached with endoscopic mucosal resection and subjected to colonoscopy. The detection of ...",* Patients referred to our center with an indication of colonoscopy and EMR for the treatment of lesions suspicious of high-grade dysplasia and early invasive cancer. * Patients who authorize EMR and colonoscopy. * Signed informed consent,* Any clinical condition which makes EMR inviable. * Poor bowel preparation score defined as the total Boston bowel preparation score (BBPS) \<6 and the right-segment score \<2 * Patients with more than one previous EMR * Lost on a three-month follow-up after EMR * Pregnancy or nursing
NCT06758375,Low-dose Teclistamab As Consolidation in the First-line Treatment of Patients with Newly Diagnosed Multiple Myeloma.,,PHASE2,Mexico,"Hospital Universitario Dr. Jose E. Gonzalez, Monterrey, Mexico, [RECRUITING]","Multiple Myeloma, Newly Diagnosed",1,[1] Arm 1 (EXPERIMENTAL): Patients receiving 3 cycles of VRd followed by low-dose teclistamab.,"* ≥18 years of age. * Newly diagnosed multiple myeloma. * Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0 or 1. * Women of childbearing potential must have a negative serum pregnancy test prior to starting treatment and agree to use a highly effective method of contraception, such as a hormonal method that inhibits ovulation, an intrauterine device, or a vasectomy partner. * Males: agree to use a highly effective contraceptive method, such as a male condom or vasectomy.","* History of previous treatment for MM. * Active central nervous system (CNS) involvement or clinical signs of meningeal involvement of multiple myeloma. * Plasma cell leukemia, Waldenström's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes) or AL amyloidosis. * Severe active infection secondary to viruses, bacteria or fungi. * Pulmonary disease requiring supplemental oxygen. * History of allogeneic or autologous hematopoietic cell transplantation. * Vaccination with live attenuated virus in the 4 weeks prior to teclistamab administration. * Major surgery during the 2 weeks prior to the first dose or absence of complete recovery from surgery. * Presence of other concomitant malignancy. * Hepatitis B and C virus infection or human immunodeficiency virus (HIV) infection. * Cerebrovascular events or seizures in the last 6 months. * Congestive heart failure class III-IV according to NYHA (New York Heart Association Stage). * Acute myocardial infarction or history of coronary revascularization surgery in the last 6 months. * Women of childbearing age: active pregnancy prior to the first administration of treatment."
NCT06312137,A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery,TroFuse-019,PHASE3,"Argentina, Brazil, Chile, Mexico, Peru","Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0213), Ciudad Autonoma de Buenos Aires, Argentina, [RECRUITING] | Hospital Británico de Buenos Aires-Oncology ( Site 0207), Ciudad Autónoma de Buenos Aires, Argentina, [RECRUITING] | Sanatorio Británico-Clinical Oncology Department ( Site 0206), Rosario, Argentina, [RECRUITING] | Sanatorio Parque ( Site 0205), Rosario, Argentina, [RECRUITING] | Clínica Mayo de Urgencias Médicas Cruz Blanca S.R.L ( Site 0217), San Miguel de Tucumán, Argentina, [RECRUITING] | Hospital Aleman-Oncology ( Site 0202), Buenos Aires, Argentina, [RECRUITING] | Hospital Privado Universitario de Córdoba-Hematology and Oncology ( Site 0204), Córdoba, Argentina, [RECRUITING] | Liga Norte Riograndense Contra o Câncer ( Site 0301), Natal, Brazil, [RECRUITING] | Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 0303), Porto Alegre, Brazil, [RECRUITING] | Hospital Nossa Senhora da Conceição ( Site 0302), Porto Alegre, Brazil, [RECRUITING]",Non Small Cell Lung Cancer,2,[1] Pembrolizumab + Sacituzumab tirumotecan (EXPERIMENTAL): Participants will receive pembrolizumab 200 mg intravenous (IV) infusion every 3 weeks (Q3W) for up to 12 weeks + double-platinum chemotherapy per neoplasm histology classification at the investiga... || [2] Pembrolizumab (ACTIVE_COMPARATOR): Participants will receive pembrolizumab 200 mg intravenous (IV) infusion Q3W for up to 12 weeks + double-platinum chemotherapy per neoplasm histology classification at the investigator's discretion...,"* Has histological or cytological confirmation of squamous or nonsquamous non-small cell lung cancer (NSCLC), resectable clinical Stage II, IIIA or IIIB (with nodal involvement \[N2\]) per AJCC eighth edition guidelines * Has confirmation that either epidermal growth factor receptor (EGFR)-directed or anaplastic lymphoma kinase (ALK)-directed therapy is not indicated as primary therapy * Is able to undergo surgery based on opinion of investigator after consultation with surgeon * Is able to receive neoadjuvant pembrolizumab and platinum-based doublet chemotherapy * Applies to screening for the adjuvant period only, before randomization: Has not achieved pathological complete response (pCR) at surgery by local review of pathology. * Applies to screening for the adjuvant period only, before randomization: Tumor tissue sample from surgical resection has been provided for determination of programmed cell death ligand 1 (PD-L1) and trophoblast cell surface antigen 2 (TROP2) status by central vendor before randomization into the adjuvant period * Applies to screening for the adjuvant period only, before randomization: Confirmed to be disease-free based on re-baseline radiological assessment as documented by contrast enhanced chest/abdomen/pelvis computed tomography (CT) (or magnetic resonance imaging (MRI)) within 28 days before randomization * Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement are eligible * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART) * Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load at screening * Participants with history of hepatitis C virus (HCV) infection are eligible if HCV vir","* Has one of the following tumor locations/types: * NSCLC involving the superior sulcus * Large cell neuro-endocrine cancer (LCNEC) * Sarcomatoid tumor * Diagnosis of SCLC or, for mixed tumors, presence of small cell elements * Has Grade ≥2 peripheral neuropathy * Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing * Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease * Has uncontrolled, significant cardiovascular disease or cerebrovascular disease, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QT corrected for heart rate by Fridericia's cube root formula (QTcF) interval to \>480 ms, and/or other serious cardiovascular and cerebrovascular diseases within the 6 months preceding study intervention * Has received prior neoadjuvant therapy for their current NSCLC diagnosis * Has received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study intervention * Has received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids * Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed * Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication * Has a known additional malignancy that is progressing or has required active treatmen"
NCT06960577,"A Phase IIIb, Open-label, Single-arm, Global Study of Perioperative Durvalumab With Neoadjuvant ddMVAC or Gem/Cis in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)",,PHASE3,Brazil,"Research Site, Barretos, Brazil, [NOT_YET_RECRUITING] | Research Site, Porto Alegre, Brazil, [NOT_YET_RECRUITING] | Research Site, Santo André, Brazil, [NOT_YET_RECRUITING] | Research Site, São Paulo, Brazil, [NOT_YET_RECRUITING]",Urinary Bladder Neoplasms | Immune Checkpoint Inhibitors | Methotrexate | Vinblastine | Doxorubicin,2,[1] ddMVAC cohort (EXPERIMENTAL): Durvalumab + chemotherapy || [2] gem/cis cohort (EXPERIMENTAL): Durvalumab + chemotherapy,* Participants with clinical tumour stage T2-T4aN0/1M0 or T1N1M0 with transitional or mixed transitional cell histology * Patients must be planning to undergo radical cystectomy * Patients who have not received prior systemic chemotherapy or immunotherapy for treatment of muscle-invasive bladder cancer * ECOG performance status of 0 or 1 * Minimum life expectancy of 12 weeks at first dose of study medication,"* Evidence of lymph node (N2-N3) or metastatic (M1) disease * Inoperable tumour(s) with fixation to the pelvic wall on clinical examination * Prior exposure to immune-mediated therapy including, but not limited to, other anti CTLA-4, anti-PD 1, anti-PD L1 and anti-PD-L2 antibodies, excluding Bacillus Calmette-Guérin * Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab * Any concomitant medication known to be contraindicated to the chemotherapy (ddMVAC or gem/cis). * Uncontrolled intercurrent illness."
NCT05238922,"A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors",,PHASE1,Puerto Rico,"Panoncology Trials Pan American Center For Oncology Trials, Llc, Rio Piedras, Puerto Rico, [RECRUITING]",Solid Tumors,21,"[1] Phase 1a Dose Escalation (EXPERIMENTAL): INCB123667 will be administered at a protocol defined starting regimen once daily (QD) orally in 28-day cycles.

Subsequent dose regimens will be determined during study conduct. || [2] Phase 1b: Dose Expansion Cohort Disease Group 1 (EXPERIMENTAL): INCB123667 will be administered at the recommended dose or doses for expansion (RDE\[s\]) for advanced or metastatic solid tumors. Participants with gynecologic tumors (epithelial ovarian/fallopian... || [3] Phase 1b: Dose Expansion Cohort Disease Group 2 (EXPERIMENTAL): INCB123667 will be administered at the recommended dose or doses for expansion (RDE\[s\]) for advanced or metastatic solid tumors. Participants with Endometrial/Uterine cancer will enroll in this g... || [4] Phase 1b: Dose Expansion Cohort Disease Group 3 (EXPERIMENTAL): INCB123667 will be administered at the recommended dose or doses for expansion (RDE\[s\]) for advanced or metastatic solid tumors. Participants with gastric, Gastro Esophageal Junction (GEJ), and e... || [5] Phase 1b: Dose Expansion Cohort Disease Group 4 (EXPERIMENTAL): INCB123667 will be administered at the recommended dose or doses for expansion (RDE\[s\]) for advanced or metastatic solid tumors. Participants with Triple Negative Breast Cancer(TNBC) will enroll ... || [6] Phase 1b: Dose Expansion Cohort Disease Group 5 (EXPERIMENTAL): INCB123667 will be administered at the recommended dose or doses for expansion (RDE\[s\]) for advanced or metastatic solid tumors. Participants with HR+/HER2- breast cancer who have had disease pro... || [7] Phase 1b: Dose Expansion Cohort Disease Group 6 (EXPERIMENTAL): INCB123667 will be administered at the recommended dose or doses for expansion (RDE\[s\]) for advanced or metastatic solid tumors will enroll in this group. || [8] Phase 2a Dose Escalation Treatment Group A (TGA) (EXPERIMENTAL): INCB123667 administered in combination with palbociclib at the recommended doses in participants with HR+/HER2- brea","* Adults aged 18 years or older at the time of the signing of the ICF. * Life expectancy greater than 12 weeks. * ECOG performance status score of 0 or 1. * Disease progression on prior standard treatment, intolerance to or ineligibility for standard treatment, or no available treatment to improve the disease outcome. * Availability of a baseline archival tumor specimen or willingness to undergo a pretreatment and an on-treatment tumor biopsy. For Part 1: Participants in Part 1A (dose escalation): Histologically or cytologically confirmed advanced or metastatic solid tumors. Participants in Part 1B (dose expansion): * Disease Group 1: Ovarian/Fallopian/Primary Peritoneal Cancer * Disease Group 2: Endometrial/Uterine Cancer * Disease Group 3: Gastric, GEJ, and esophageal carcinomas * Disease Group 4: TNBC * Disease Group 5: HR+/HER2- breast cancer * Disease Group 6: Other tumor indications excluding bone cancers For Part 2: Participants in Part 2A (dose escalation): Histologically or cytologically confirmed advanced or metastatic solid tumors. * TGA, TGC, TGE, TGF, and TGG: Participants with HR+/HER2- breast cancer or participants with a different tumor. * TGB and TGD: Participants with HR+/HER2- breast cancer. Participants in Part 2b (dose expansion): * TGH and TGJ: * Participants with HR+/HER2- breast cancer. * Participants with any other advanced or metastatic solid tumor. * TGI and TGK: • Participants with HR+/HER2- breast cancer. * TGL, TGM and TGN: • Participants with advanced or metastatic epithelial ovarian/fallopian/primary peritoneal carcinoma. * Measurable lesions by CT or MRI based on RECIST v1.1 criteria.","* History of clinically significant or uncontrolled cardiac disease. * History or presence of an ECG abnormality that, in the investigator's opinion, is clinically meaningful. * Presence of chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment. * Untreated brain or central nervous system (CNS) metastases or brain or CNS metastases that have progressed. * Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of the first dose of study drug. * Specific laboratory values. * Significant concurrent, uncontrolled medical conditions, including but not limited to Hepatic and Gastrointestinal. * Has not recovered to ≤ Grade 1 from toxic effects of prior therapy and/or complications from prior surgical intervention before starting study drug. * Prior treatment with any CDK2 inhibitor. * Any change in endocrine therapy within 5 half-lives or 28 days (whichever is shorter) before the first dose of study drug or any administration of targeted therapy, antibody, or hypomethylating agent to treat the participant's disease within 5 half-lives or 28 days (whichever is shorter) before the first dose of study drug. * Any major surgery within 28 days before the first dose of study drug. * Any prior radiation therapy within 28 days before the first dose of study drug. * Undergoing treatment with another investigational medication or having been treated with an investigational medication within 5 half-lives or 28 days (whichever is shorter) before the first dose of study drug. * Active HBV or HCV infection that requires treatment. * Known history of HIV. * Known hypersensitivity or severe reaction to any component of study treatment or formulation components. Other protocol-defined Inclusion/Exclusion Criteria may apply."
NCT06750094,"A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy",OrigAMI-3,PHASE3,"Brazil, Mexico, Puerto Rico","Fundacao Pio XII, Barretos, Brazil, [RECRUITING] | Fundacao Universidade de Caxias do Sul, Caxias do Sul, Brazil, [RECRUITING] | Fundacao Doutor Amaral Carvalho, Jaú, Brazil, [RECRUITING] | Hospital Nossa Senhora da Conceicao S A, Porto Alegre, Brazil, [RECRUITING] | Hospital Santa Izabel Santa Casa de Misericordia da Bahia, Salvador, Brazil, [RECRUITING] | Fundacao Faculdade Regional De Medicina S Jose Rio Preto Hospital De Base, São José do Rio Preto, Brazil, [RECRUITING] | Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo, São Paulo, Brazil, [RECRUITING] | Fundacao Antonio Prudente A C Camargo Cancer Center, São Paulo, Brazil, [RECRUITING] | Associacao Feminina de Educacao e Combate ao Cancer Hospital Santa Rita de Cassia, Vitória, Brazil, [RECRUITING] | Centro Oncologico de Chihuahua, Chihuahua City, Mexico, [RECRUITING]",Colorectal Neoplasms,2,"[1] Arm A: Amivantamab + FOLFIRI (EXPERIMENTAL): Participants will receive amivantamab along with FOLFIRI (consisting of 5-fluorouracil, leucovorin calcium \[folinic acid\] or levoleucovorin, and irinotecan) as a chemotherapy regimen for 28-days ... || [2] Arm B: Cetuximab or Bevacizumab + FOLFIRI (ACTIVE_COMPARATOR): Participants will receive either cetuximab or bevacizumab along with FOLFIRI as a chemotherapy regimen for 28-days treatment cycles and will continue to receive the treatment until radiographic dis...","* Have histologically or cytologically confirmed adenocarcinoma of the colon or rectum. Participants must have recurrent, unresectable or metastatic disease * Determined to have kirsten rat sarcoma viral oncogene/neuroblastoma RAS viral oncogene homolog (KRAS/NRAS), G12, G13 and v-raf murine sarcoma viral oncogene homolog B (BRAF) V600X (X represents any single amino acid change from the original amino acid) wild type status by local and/or central next-generation sequencing (NGS) testing * Must agree to the submission of fresh or archival tumor tissue post progression from the most recent therapy, if clinically feasible * Have measurable disease according to response evaluation criteria in solid tumors (RECIST) version (v) 1.1 * Have an eastern cooperative oncology group (ECOG) performance status (PS) of 0 or 1 * Participant must have received 1 line of systemic therapy (fluoropyrimidine-based and oxaliplatin-based) for metastatic colorectal cancer (mCRC), with documented radiographic disease progression on or after this line of therapy. Participants can receive anti-VEGF as prior line of therapy","* Has medical history of (noninfectious) interstitial lung disease (ILD) /pneumonitis/pulmonary fibrosis or has current ILD/pneumonitis/pulmonary fibrosis, or where suspected ILD/pneumonitis/pulmonary fibrosis cannot be ruled out by imaging at screening * Has known allergies, hypersensitivity, or intolerance to excipients of any of the following: amivantamab, cetuximab or bevacizumab or any component of FOLFIRI * Has a prior or concurrent second malignancy other than the disease under study or one whose natural history or treatment is likely to interfere with any study endpoints of safety or the efficacy of the study treatment(s) * Participant with known mismatch repair deficiency (dMMR)/ high microsatellite instability (MSI-H) status who has not received immunotherapy treatments * Participant with known human epidermal growth factor receptor 2 (HER2)- positive/amplified tumor * Has prior exposure to irinotecan, any agents that target epidermal growth factor receptor (EGFR) or mesenchymal epithelial transition (MET)"
NCT06109272,"A Phase 2/3, Randomized Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab in Subjects With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment",LIVIGNO-2,"PHASE2, PHASE3",Puerto Rico,"Puerto Rico Medical Research Center /ID# 262362, Hato Rey, Puerto Rico, [RECRUITING]",Hepatocellular Carcinoma,6,[1] Stage 1: Cohort 1 (EXPERIMENTAL): Participants will receive livmoniplimab Dose 1 in combination with budigalimab every 3 weeks until disease progression or until discontinuation criteria are met. || [2] Stage 1: Cohort 2 (EXPERIMENTAL): Participants will receive livmoniplimab Dose 2 in combination with budigalimab every 3 weeks until disease progression or until discontinuation criteria are met. || [3] Stage 1: Cohort 3 - Group 1 (Control) (ACTIVE_COMPARATOR): Participants will receive atezolizumab in combination with bevacizumab every 3 weeks until disease progression or until discontinuation criteria are met. || [4] Stage 1: Cohort 3 - Group 2 (Control) (ACTIVE_COMPARATOR): Participants will receive a single dose of tremelimumab in combination with durvalumab every four weeks until disease progression or until discontinuation criteria are met. || [5] Stage 2: Arm 1 (EXPERIMENTAL): Participants will receive livmoniplimab (optimized dose) in combination with budigalimab every 3 weeks until disease progression or until discontinuation criteria are met. || [6] Stage 2: Arm 2 (Control) (ACTIVE_COMPARATOR): Participants will receive a single dose of tremelimumab in combination with durvalumab every 4 weeks until disease progression or until discontinuation criteria are met.,"* Locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC) with diagnosis confirmed by histology or cytology or clinically by American Association for the Study of Liver Diseases criteria for participants with cirrhosis. * Barcelona Clinic Liver Cancer (BCLC) Stage B or C. * Child-Pugh A or B7 classification (i.e., total Child-Pugh score of 5, 6, or 7). * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.","* Prior systemic therapy for HCC. * Symptomatic, untreated, or actively progressing CNS metastases. * History of malignancy other than HCC."
NCT06982274,Combination of Oral Arsenic With ATRA and Minimal-Dose Chemotherapy for Newly Diagnosed Patients With Acute Promyelocytic Leukemia: a Study by the International Consortium on APL,IC-APL2020,PHASE2,Brazil,"Instituto do Cancer do Estado de Sao Paulo, São Paulo, Brazil, [RECRUITING]",Acute Promyelocytic Leukemia (APL),1,[1] Proposed protocol (EXPERIMENTAL): Oral Arsenic + ATRA with low-dose daunorubicin for high-risk patients,"* Informed consent * New diagnosis of APL by cytomorphology, confirmed for molecular analysis * Age ≥18 and ≤75 years * Serum total bilirubin ≤ 3.0 mg/dl (≤ 51 μmol/l) * Serum creatinine ≤ 3.0 mg/dl (≤ 260 μmol/l) * Women must meet at least one of the following criteria to be eligible for inclusion in the study: Postmenopausal (12 months of amenorrhea or 6 months of amenorrhea with serum FSH \> 40 U/ml); After undergoing hysterectomy or bilateral oophorectomy; Continuous and correct use of a contraceptive method with a Pearl Index \<1% (e.g., implants, oral contraceptives, intrauterine devices); Sexual abstinence; Vasectomy of sexual partner.","* High-risk patients who are not eligible for chemotherapy according to the judgment of the treating physician; * Age \<18 or \>75 years * Other active malignancy at the time of study entry * Lack of diagnostic confirmation at the genetic level * Significant arrhythmias, ECG abnormalities, or neuropathy: Congenital long QT syndrome; History or presence of significant ventricular or atrial tachyarrhythmia; Clinically significant resting bradycardia (\<50 beats per minute); QTc \> 500 ms on ECG screening for both sexes; Right bundle branch block with left anterior hemiblock or bifascicular block * High-risk patients with other cardiac contraindications for intensive chemotherapy (LVEF \< 50%) * Uncontrolled and potentially fatal infections * Severe uncontrolled pulmonary or cardiac disease * Severe hepatic or renal dysfunction * Known HIV and/or hepatitis C infection * Pregnant or breastfeeding women * Allergy to the study drug or excipients in the study medication * Substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study or the assessment of study outcomes * Use of other investigational drugs at the time of enrollment or within 30 days before study entry."
NCT05315154,Sentinel Lymph Node Biopsy Versus No Axillary Surgery in Early Breast Cancer Clinically and Ultrasonographically Node-negative,VENUS,NA,Brazil,"Hospital Geral de Fortaleza, Fortaleza, Brazil, [RECRUITING] | Maternidade Dona Iris, Goiânia, Brazil, [RECRUITING] | Universidade Federal de Goiás, Goiânia, Brazil, [RECRUITING] | Hospital de Clínica da Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, [RECRUITING] | Hospital do Câncer de Muriaé da Fundação Cristiano Varella, Muriaé, Brazil, [RECRUITING] | Universidade Federal do Paraná, Curitiba, Brazil, [RECRUITING] | Hospital Barão de Lucena, Recife, Brazil, [RECRUITING] | Oncocenter, Teresina, Brazil, [RECRUITING] | Universidade Federal do Piauí, Teresina, Brazil, [RECRUITING] | Hospital Federal da Lagoa, Rio de Janeiro, Brazil, [RECRUITING]",Breast Cancer,2,[1] No axillary surgery (EXPERIMENTAL): No description || [2] Sentinel lymph node biopsy (ACTIVE_COMPARATOR): No description,"* Women * Aged 18 years or older * Histologically confirmed invasive breast carcinoma (core or open biopsy), independent of hormone receptor and HER2 status * Tumor smaller than 5 cm (T1 or T2) in clinical and radiological exams * Clinically negative axilla * Sonographically negative axilla or negative core biopsy/ fine needle biopsy (FNB) when ultrasound is suspect (lymph node tissue is required in core/FNB sample) * Planned breast conservative surgery or mastectomy * Written informed consent",* Previous diagnostic of any invasive neoplasia (excluded skin cancer no melanoma) * Metastatic disease in biopsy or image before treatment * Withdrawal from participating of the study * Initiated treatment for current breast cancer prior to study enrollment * Pregnancy * Breastfeed
NCT05564390,Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials,,PHASE2,Puerto Rico,"Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico, [RECRUITING] | San Juan City Hospital, San Juan, Puerto Rico, [RECRUITING]",Acute Myeloid Leukemia | Myelodysplastic Syndrome,34,"[1] MM1MDS-A01 Arm A (ASTX727) (ACTIVE_COMPARATOR): Patients receive ASTX727 PO QD on days 1-5 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR, CRL, or CRh a... || [2] MM1MDS-A01 Arm B (ASTX727, enasidenib) (EXPERIMENTAL): Patients receive ASTX727 PO QD on days 1-5 and enasidenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who ... || [3] MM1OA-EA02 Regimen 1 (azacitidine, venetoclax) (EXPERIMENTAL): INDUCTION: Patients receive azacitidine IV or SC on days 1-7 of each cycle and venetoclax PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until patient achieves... || [4] MM1OA-EA02 Regimen 2 (azacitidine, venetoclax, gilteritinib) (EXPERIMENTAL): INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax and gilteritinib PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until patient achie... || [5] MM1OA-EA02 Regimen 3 (azacitidine, venetoclax, gilteritinib) (EXPERIMENTAL): INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days 1-28, and gilteritinib PO on days 8-21 of each cycle. Treatment repeats every 28 days for up to 2 cycles or un... || [6] MM1OA-MDS-A05 Cohort A, Arm 1 (ASTX727, venetoclax) (ACTIVE_COMPARATOR): Patients receive ASTX727 PO QD on days 1-5 of each cycle and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for 4 cycles in the absence of disease progression or unaccepta... || [7] MM1OA-MDS-A05 Cohort A,Arm 2 (ASTX727,venetoclax,olutasidenib) (EXPERIMENTAL): Patients receive ASTX727 PO QD on days 1-5 of each cycle, venetoclax PO QD on days 1-28 of each cycle, and olutasidenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 4 cycles i... || [8] MM1OA-MDS-A05 Cohort B, Arm 3 (ASTX727, olutasidenib) (EXPERIMENTAL)","* Participants must be suspected to have previously untreated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Participants with AML cannot have a history of previously treated myeloproliferative neoplasms (MPN) or MDS. * Participants must be \>= 18 years of age. * Participants must not have received prior anti-cancer therapy for AML or MDS. * Note: Hydroxyurea to control the white blood cell count (WBC) is allowed. * Note: Prior erythroid stimulating agent (ESA) is not considered prior therapy for the purposes of eligibility. Participants must not be currently receiving any cytarabine-containing therapy other than up to 1 g/m\^2 of cytarabine, which is allowed for urgent cytoreduction. * Participants are allowed prior use of hydroxyurea, all-trans retinoic acid (ATRA), BCR-ABL directed tyrosine kinase inhibitor, erythropoiesis-stimulating agent, thrombopoietin receptor agonist and lenalidomide, with a maximum limit of 1 month of exposure. * Note: Participants receiving hydroxyurea prior to treatment substudy or TAP assignment must agree to discontinue hydroxyurea within 24 hours before beginning substudy or TAP treatment. * Participants must not have a prior or concurrent malignancy that requires concurrent anti-cancer therapy * Note: active hormonal therapy is allowed * Participants must have a Zubrod Performance Status evaluation within 28 days prior to registration. * Participants must agree to have translational medicine specimens submitted. * Participants must be offered the opportunity to participate in specimen banking. * Note: Specimens must be collected and submitted following the initial paper-based process and subsequently via the Precision Medicine Specimen Tracking Forms in Medidata Rave instance for the MyeloMATCH MSRP. * Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines. * Note: As a part of the Oncology Patient Enrol",
NCT04811560,"A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia (cAMeLot-1)",cAMeLot-1,"PHASE1, PHASE2",Brazil,"Instituto D Or de Pesquisa e Ensino, Brasília, Brazil, [RECRUITING] | Liga Norte Riograndense Contra O Cancer, Natal, Brazil, [RECRUITING] | Ministerio da Saude Instituto Nacional do Cancer, Rio de Janeiro, Brazil, [RECRUITING] | Instituto D Or de Pesquisa e Ensino IDOR, São Paulo, Brazil, [RECRUITING]",Acute Leukemias | Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia,1,[1] Bleximenib (EXPERIMENTAL): Participants in Phase 1 Part 1 (dose escalation) will receive bleximenib orally. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by Study Evaluation Team (S...,"Phase 1: * Age 2 years and above (pediatric cohort only), all other cohorts 18 years and above * Relapsed or refractory (R/R) acute leukemia and has exhausted, or is ineligible for, available therapeutic options * Acute leukemia harboring histone-lysine N-methyltransferase 2A (KMT2A), nucleophosmin 1 gene (NPM1) or nucleoporin 98 gene or nucleoporin 214 gene (NUP98 or NUP214) alterations Phase: 2 * Participants greater than 18 years are eligible * Must have had an initial diagnosis of acute myeloid leukemia (AML) per the WHO 2022 classification criteria and have relapsed/refractory disease * AML harboring KMT2A-r (gene rearrangement/translocation) or NPM1 mutations only For Both Phase 1 and 2: * Pretreatment clinical laboratory values meeting the following criteria: (a) Hematology: white blood cell (WBC) count less than or equal to (\<=) 20\*10\^9/liter (L) and (b) renal function; For adult participants, estimated or measured glomerular filtration rate greater than equal (\>=) 30 milliliter per minute (mL/min) per four variable MDRD equation. For pediatric participants an estimated or measured glomerular filtration rate \>40 mL/min per the CKiD (Chronic Kidney Disease in Children) Schwartz formula * Eastern Cooperative Oncology Group (ECOG) performance status grade of 0, 1 or 2. Pediatric participants only: Performance status \>=70 by Lansky scale (for participants less than \[\<\]16 years of age) or \>=70 Karnofsky scale (for participants \>=16 years of age) * A female of childbearing potential must have a negative highly sensitive serum beta-human chorionic gonadotropin at screening and within 48 hours prior to the first dose of study treatment * Participant must agree to all protocol required contraception requirements and avoid sperm or egg donations or freezing for future reproductive use while on study and for 90 days (males) or 6 months (females) after the last dose of study treatment","* Acute promyelocytic leukemia, diagnosis of Down syndrome associated leukemia or juvenile myelomonocytic leukemia according to World Health Organization (WHO) 2016 criteria * Active central nervous system (CNS) disease * Prior solid organ transplantation * QTc according to Fridericia's formula (QTcF) for males \>= 450 millisecond (msec) or for females \>= 470 msec. Participants with a family history of Long QT syndrome are excluded * Exclusion criteria related to stem cell transplant: a. Received prior treatment with allogenic bone marrow or stem cell transplant \<=3 months before the first dose of study treatment; b. Has evidence of graft versus host disease; c. Received donor lymphocyte infusion \<=1 month before the first dose of study treatment; d. Requires immunosuppressant therapy (exception: daily doses \<=10 milligrams (mg) prednisone or equivalent are allowed for adrenal replacement) * Prior cancer immunotherapy within 4 weeks prior to enrollment or blinatumomab within 2 weeks prior to enrollment. Additional prior cancer therapies must not be given within 4 weeks prior to enrollment or 5 half-lives of the agent (whichever is shorter)"
NCT06946797,"A Phase 2, Open-label, Randomized Trial to Evaluate Two Dosing Regimens of Subcutaneous Formulation of Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent NSCLC",CheckMate-1533,PHASE2,"Brazil, Chile, Mexico","Local Institution - 0041, Brasília, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0043, Belo Horizonte, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0038, Porto Alegre, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0037, Barretos, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0034, São Paulo, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0068, Antofagasta, Chile, [NOT_YET_RECRUITING] | Local Institution - 0069, Viña del Mar, Chile, [NOT_YET_RECRUITING] | Local Institution - 0067, Santiago, Chile, [NOT_YET_RECRUITING] | Local Institution - 0025, Guadalajara, Mexico, [NOT_YET_RECRUITING] | Local Institution - 0058, Monterrey, Mexico, [NOT_YET_RECRUITING]",Non-Small Cell Lung Cancer,2,[1] Arm A (EXPERIMENTAL): No description || [2] Arm B (EXPERIMENTAL): No description,"* Participants must have histologically confirmed stage IV or recurrent non-small cell lung cancer (NSCLC) (as defined by the 9th edition of the IASLC Lung Cancer Staging Guidelines) of squamous or non-squamous histology. * Participants must have no prior systemic anti-cancer treatment (including EGFR, ALK, ROS-1, BRAF, RET, and NTRK inhibitors) given as primary therapy for advanced or metastatic disease. * Participants with prior definitive chemoradiation for locally advanced disease is permitted as long as the last administration of chemotherapy or radiotherapy (whichever was given last) occurred at least 6 months prior to randomization. Participants with locally advanced disease with recurrence after chemoradiation therapy (stage III disease, specifically refers to patients with no curative options) are eligible to enroll. * Participants with prior adjuvant or neoadjuvant chemotherapy for early-stage lung cancer are permitted if completed at least 6 months prior to randomization. * Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1 at screening and confirmed prior to randomization. * Participants must have measurable disease by CT or MRI per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria with radiographic tumor assessment performed within 28 days of randomization.","* Participants must not have any prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways. * Participants must not have any known driver mutations with available targeted therapy (including but not limited to EGFR mutations, ALK translocations, ROS-1 translocations and known BRAFV600E, that are sensitive to available targeted inhibitor therapy; participants with a known activating RET mutations and NTRK fusion gene alterations). * Participants must not have any untreated central nervous system (CNS) metastases * Participants must not have leptomeningeal metastases (carcinomatous meningitis). * Participants must not have any active, known or suspected autoimmune disease. Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. * Participants with previous malignancies (except non-melanoma skin cancers, and in situ cancers such as the following: bladder, gastric, colon, cervical/dysplasia, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to randomization and no additional therapy is required or anticipated to be required during the study period. * Participants must not have a condition requiring systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalent) within 14 days or other immunosuppressive medications within 30 days of randomization. Inhaled or topical steroids, and adrenal replacement steroid \> 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease. * Participants must not have any history of interstitial lung disease or pneumonitis that required oral or IV glucocorticoids to assist with management. * Other"
NCT06230224,"A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Versus Standard of Care Therapy in Participants With Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma (OLYMPIA-4)",OLYMPIA-4,PHASE3,"Argentina, Brazil, Chile","Instituto Alexander Fleming, Ciudad Autonoma de Buenos Aires, Argentina, [RECRUITING] | Hospital Santa Izabel - Santa Casa de Misericordia da Bahia, Salvador, Brazil, [RECRUITING] | Hospital Sao Rafael, Salvador, Brazil, [RECRUITING] | Ensino e Terapia de Inovacao Clinica Amo (Etica), Salvador, Brazil, [RECRUITING] | Hospital Sirio Libanes Brasilia, Brasília, Brazil, [RECRUITING] | Uopeccan Hospital do Cancer de Cascavel, Cascavel, Brazil, [RECRUITING] | Hospital Erasto Gaertner, Curitiba, Brazil, [RECRUITING] | Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil, [RECRUITING] | Centro Gaucho Integrado, Porto Alegre, Brazil, [RECRUITING] | Amaral Carvalho Hospital, Jaú, Brazil, [RECRUITING]",B-Cell Non-Hodgkin Lymphoma (B-NHL),2,"[1] Odronextamab (EXPERIMENTAL): Participants will receive odronextamab monotherapy. || [2] Standard Of Care (ACTIVE_COMPARATOR): Participants will receive salvage therapy (ifosfamide, carboplatin, etoposide ± rituximab \[ICE ± R\], or dexamethasone, cisplatin, cytarabine ± rituximab \[DHAP ± R\], or gemcitabine, dexamethason...","1. Histologically proven aggressive B-NHL, as described in the protocol. Availability of tumor tissue for submission to central laboratory is required for study enrollment. Archival tumor tissue for histological assessment prior to enrollment is allowed 2. Have primary refractory or relapse 12 months or less (≤) from initiation of frontline therapy Only patients who received 1 prior line of therapy containing an anti-Cluster of Differentiation 20 (CD20) antibody and anthracycline are allowed for enrollment 3. Have measurable disease with at least one nodal lesion with longer diameter (LDi) greater than 1.5 cm or at least one extranodal lesion with LDi greater than 1.0 cm, documented by diagnostic imaging (computed tomography \[CT\] or magnetic resonance imaging \[MRI\]) 4. Intent to proceed to autologous stem cell transplant (ASCT), as described in the protocol 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 6. Adequate hematologic and organ function. Key","1. Primary central nervous system (CNS) lymphoma or known involvement by non-primary CNS NHL, as described in the protocol 2. History of or current relevant CNS pathology, as described in the protocol 3. A malignancy other than NHL unless the participant is adequately and definitively treated and is cancer free for at least 3 years, with the exception of localized prostate cancer, cervical carcinoma in situ, breast cancer in situ, or nonmelanoma skin cancer that was definitively treated 4. Any other significant active disease or medical condition that could interfere with the conduct of the study or put the participant at significant risk, as described in the protocol 5. Wash-out period from prior anti-lymphoma treatments and infections, as described in the protocol 6. Allergy/hypersensitivity to study drug, or excipients. NOTE: Other protocol defined inclusion / exclusion criteria apply"
NCT04613596,A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation,,"PHASE2, PHASE3","Argentina, Brazil, Chile, Colombia, Mexico, Peru","Local Institution - 007-5001, Belgrano, Argentina, [NOT_YET_RECRUITING] | Local Institution - Unk043, Ciudad Autonoma de Buenos Aires, Argentina, [ACTIVE_NOT_RECRUITING] | Local Institution - 007-435, Ciudad Autonoma de Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Local Institution - 007-5003, San Pedro, Argentina, [NOT_YET_RECRUITING] | Local Institution - 007-5004, Rosario, Argentina, [NOT_YET_RECRUITING] | Local Institution - Unk053, Buenos Aires, Argentina, [ACTIVE_NOT_RECRUITING] | Local Institution - Unk033, Porto Alegre, Argentina, [ACTIVE_NOT_RECRUITING] | Local Institution - Unk020, Río Cuarto, Argentina, [ACTIVE_NOT_RECRUITING] | Local Institution - 007-458, Natal, Brazil, [NOT_YET_RECRUITING] | Local Institution - Unk050, Lajeado, Brazil, [ACTIVE_NOT_RECRUITING]",Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer,5,[1] Phase 2 Cohort 1a: PD-L1 TPS <1% (EXPERIMENTAL): Cohort 1a: Adagrasib twice daily (BID) in combination with pembrolizumab || [2] Phase 2 Cohort 1b: PD-L1 TPS <1% (EXPERIMENTAL): Cohort 1b: Adagrasib BID monotherapy || [3] Phase 2 Cohort 2: PD-L1 TPS ≥1% (EXPERIMENTAL): Cohort 2: Adagrasib BID in combination with pembrolizumab || [4] Phase 3 Cohort 3 Investigational Arm (EXPERIMENTAL): Adagrasib BID in combination with pembrolizumab || [5] Phase 3 Cohort 4 Comparator Arm (ACTIVE_COMPARATOR): Pembrolizumab,"* Phase 2: Histologically confirmed diagnosis of unresectable or metastatic NSCLC with KRAS G12C mutation and any PD-L1 TPS * Phase 3: Histologically confirmed diagnosis of unresectable or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS \>=50% * Phase 3: Presence of evaluable or measurable disease per RECIST * Phase 3: CNS Inclusion - Based on screening brain imaging, patients must have one of the following: 1. No evidence of brain metastases 2. Untreated brain metastases not needing immediate local therapy 3. Previously treated brain metastases not needing immediate local therapy","* Phase 2 and Phase 3: Prior systemic treatment for locally advanced or metastatic NSCLC including chemotherapy, immune checkpoint inhibitor therapy, or a therapy targeting KRAS G12C mutation (e.g., AMG 510). * Phase 2: Active brain metastases * Phase 3: Patients with known central nervous system (CNS) lesions must not have any of the following: 1. Any untreated brain lesions \> 1.0 cm in size 2. Any brainstem lesions 3. Ongoing use of systemic corticosteroids for control of symptoms of brain lesions at a total daily dose of \> 10 mg of prednisone (or equivalent) prior to randomization. 4. Have poorly controlled (\> 1/week) generalized or complex partial seizures, or manifest neurologic progression due to brain lesions notwithstanding CNS-directed therapy * Phase 3: Radiation to the lung \> 30 Gy within 6 months prior to the first dose of study treatment"
NCT04958239,"An Open Label, Phase I Dose-finding and Expansion Study of BI 765179 as Monotherapy and in Combination With Ezabenlimab (BI 754091) in Patients With Advanced Solid Cancers, and BI 765179 in Combination With Pembrolizumab in First-line PD-L1-positive Metastatic or Incurable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)",,PHASE1,"Brazil, Mexico","ICESP - Instituto do Cancer do Estado de Sao Paulo, São Paulo, Brazil, [RECRUITING] | Hospital Sírio Libanês-São Paulo-68088, São Paulo, Brazil, [NOT_YET_RECRUITING] | Beneficência Portuguesa - Real e Benemérita Associação Portuguesa de Beneficência, São Paulo, Brazil, [RECRUITING] | Centro Oncologico Internacional, Mexico City, Mexico, [NOT_YET_RECRUITING] | ARKE SMO S.A. de C.V, Mexico City, Mexico, [NOT_YET_RECRUITING] | Instituto Nacional de Cancerologia, México, Mexico, [RECRUITING] | Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Mexico, [NOT_YET_RECRUITING] | Fundación Santos y de la Garza Evia, I.B.P, Monterrey, Mexico, [NOT_YET_RECRUITING] | Investigacion Biomedica para el Desarrollo de Farmacos, S.A. de C.V., Zapopan, Mexico, [NOT_YET_RECRUITING]",Neoplasms,4,[1] Phase 1 Arm A: BI 765179 (EXPERIMENTAL): No description || [2] Phase 1a Arm B: BI 765179 + ezabenlimab (EXPERIMENTAL): No description || [3] Phase 1b Cohort 1: pembrolizumab + low dose of BI 765179 (EXPERIMENTAL): No description || [4] Phase 1b Cohort 2: pembrolizumab + high dose of BI 765179 (EXPERIMENTAL): No description,"All cohorts: * Patients with locally advanced, unresectable or metastatic solid tumors who are either refractory after standard therapy for the disease or for whom standard therapy is not appropriate * Tumor with expected high expression of Fibroblast activation protein (FAP) of the following histologies: * Non-small cell lung carcinoma (NSCLC) * Gastric cancer * Esophageal adenocarcinoma or squamous cell carcinoma * Urothelial bladder carcinoma * Head and neck squamous cell carcinoma * Cutaneous malignant melanoma * Cutaneous squamous cell carcinoma * Hepatocellular carcinoma * Pancreatic adenocarcinoma * Colorectal cancer * Malignant pleural mesothelioma * Cervical squamous cell cancer * Ovarian carcinoma * Triple-negative breast cancer * At least 18 years of age at the time of the consent or over the legal age of consent in countries where that is greater than 18 years * Signed and dated, written informed consent (IC) in accordance with ICH-GCP and local legislation prior to admission to the trial * At least one measurable lesion outside of central nervous system (CNS) as defined per modified Response evaluation criteria in solid tumors (RECIST) v1.1 * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Adequate liver, bone marrow and renal organ function * Male or female patients. Women of childbearing potential (WOCBP) and men able to father a child must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. These methods must be used during the study and for at least 6 months after the last dose of the study medication. A list of contraception methods meeting these criteria is provided in the patient information. * Patients with brain metastases are eligible provided they meet all of the following criteria: * Brain metastases have adequately been treated and are considered stable by the Investigator * Radiotherapy or","Phase 1a * Currently enrolled in another investigational device or drug trial * Previous or concomitant malignancies other than the one treated in this trial within the last 2 years except: * Effectively treated non-melanoma skin cancers * Effectively treated carcinoma in situ of the cervix * Effectively treated ductal carcinoma in situ * Other effectively treated malignancy that is considered cured by 'local treatment' * Previous treatment with agents targeting CD137 * Known leptomeningeal disease or spinal cord compression due to disease * Anticoagulant treatment that cannot be safely interrupted if medically needed (e.g., biopsy) based on the opinion of the Investigator * Persistent toxicity from previous treatments that has not resolved to ≤ Common terminology criteria for adverse events (CTCAE) Grade 1 (except for alopecia, CTCAE Grade 2 neuropathy, asthenia/fatigue or grade 2 endocrinopathies controlled by replacement therapy) * Patient has a diagnosis of immunodeficiency * Patient with history of immunosuppressive medication within 14 days prior to the first dose of BI 765179. The following are exceptions to this criterion: * Use of intranasal, inhaled, or topical corticosteroids, local steroid injections (e.g., intra-articular injections) * Systemic corticosteroids at physiologic doses ≤10 mg/day (prednisone or equivalent) * Physiological replacement dose of corticosteroids Further exclusion criteria apply. Phase Ib * Disease suitable for local therapy administered with curative intent * Participants must not have a primary tumor site of nasopharynx or sino-nasal cancer or salivary gland cancers (any histology) * Currently enrolled in another investigational device or drug trial * Life expectancy of \<3 months and/or has rapidly progressing disease * Diagnosed and/or treated additional malignancy within 2 years prior to randomization with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or curativ"
NCT05211895,"A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab Plus Domvanalimab(AB154) in Participants With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease Has Not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy",PACIFIC-8,PHASE3,"Brazil, Chile, Mexico","Research Site, Barretos, Brazil, [RECRUITING] | Research Site, Londrina, Brazil, [RECRUITING] | Research Site, Porto Alegre, Brazil, [RECRUITING] | Research Site, Porto Velho, Brazil, [RECRUITING] | Research Site, Rio de Janeiro, Brazil, [RECRUITING] | Research Site, Santo André, Brazil, [RECRUITING] | Research Site, São Paulo, Brazil, [RECRUITING] | Research Site, São Paulo, Brazil, [WITHDRAWN] | Research Site, São Paulo, Brazil, [WITHDRAWN] | Research Site, São Paulo, Brazil, [WITHDRAWN]",Non-Small Cell Lung Cancer,2,"[1] Arm A: Durvalumab + Domvanalimab (EXPERIMENTAL): Durvalumab and domvanalimab as an IV infusion q4w, starting on Day 1 for up to a maximum of 12 months || [2] Arm B: Durvalumab + Placebo (ACTIVE_COMPARATOR): Durvalumab + placebo as an IV infusion q4w starting on Day 1 for up to a maximum of 12 months","1. Participant must be ≥ 18 years at the time of screening. 2. Histologically- or cytologically-documented NSCLC and have been treated with concurrent CRT for locally advanced, unresectable (Stage III) disease 3. Provision of a tumour tissue sample obtained prior to CRT 4. Documented tumour PD-L1 status ≥ 1% by central lab 5. Documented EGFR and ALK wild-type status (local or central). 6. Patients must not have progressed following definitive, platinum-based, concurrent chemoradiotherapy 7. Participants must have received at least 2 cycles of platinum-based chemotherapy concurrent with radiation therapy 8. Participants must have received a total dose of radiation of 60 Gy ±10% (54 Gy to 66 Gy) as part of the chemoradiation therapy, to be randomised. Radiation therapy should be administered by intensity modulated RT (preferred) or 3D-conforming technique. 9. WHO performance status of 0 or 1 at randomization 10. Adequate organ and marrow function","1. History of another primary malignancy, except for: * Malignancies treated with curative intent and adequate follow-up with no known active disease and have not required active treatment within the past 3 years before the first dose of study intervention and of low potential risk of recurrence. * Adequately resected non melanoma skin cancer or lentigo maligna without evidence of disease . * Adequately treated carcinoma in situ, including Ta tumors without evidence of disease. 2. Mixed small cell and non-small cell lung cancer histology. 3. Participants who receive sequential (not inclusive of induction) chemoradiation therapy for locally advanced (Stage III) unresectable NSCLC. 4. Participants with locally advanced (Stage III) unresectable NSCLC who have progressed during platinum-based cCRT. 5. Any unresolved toxicity CTCAE \>Grade 2 from the prior chemoradiation therapy (excluding alopecia). 6. Participants with ≥ grade 2 pneumonitis from prior chemoradiation therapy. 7. History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, or idiopathic pneumonitis - regardless of time of onset prior to randomisation. Evidence of active non-CRT induced pneumonitis (≥ Grade 2), active pneumonia, active ILD, active or recently treated pleural effusion, or current pulmonary fibrosis 8. Active or prior documented autoimmune or inflammatory disorders (with exceptions) 9. Active EBV infection, or known or suspected chronic active EBV infection at screening 10. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab."
NCT06380751,"A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)",EvoPAR-BR01,PHASE3,"Argentina, Brazil, Chile, Peru, Puerto Rico","Research Site, Ciudad Autónoma Buenos Aires, Argentina, [RECRUITING] | Research Site, Ciudad de Buenos Aires, Argentina, [RECRUITING] | Research Site, Ciudad de Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Research Site, Córdoba, Argentina, [NOT_YET_RECRUITING] | Research Site, Rosario, Argentina, [NOT_YET_RECRUITING] | Research Site, Salta, Argentina, [RECRUITING] | Research Site, San Miguel de Tucumán, Argentina, [NOT_YET_RECRUITING] | Research Site, Cachoeira de Itapemirim, Brazil, [RECRUITING] | Research Site, Curitiba, Brazil, [RECRUITING] | Research Site, Fortaleza, Brazil, [RECRUITING]",Advanced Breast Cancer,3,"[1] Arm 1: saruparib (AZD5305) plus camizestrant (EXPERIMENTAL): participants will receive saruparib (AZD5305) orally and camizestrant orally || [2] Arm 2: Physician's choice CDK4/6i plus physician's choice ET (ACTIVE_COMPARATOR): agents are indicated below and should follow local guidelines:

* Physician's Choice CDK4/6i:

  * abemaciclib orally, or
  * ribociclib orally, or
  * palbociclib orally.
* Physician's Choice ET:
... || [3] Arm 3: Physician's choice CDK4/6i plus camizestrant (EXPERIMENTAL): participants will receive camizestrant orally. Agents for CDK4/6i treatment are indicated above and should follow local guidelines","* Adult females, pre/peri-menopausal and/or post-menopausal, and adult males * Histologically or cytologically documented diagnosis of HR-positive, HER2-negative breast cancer * Advanced breast cancer with either locally advanced disease not amenable to curative treatment or metastatic disease * ECOG performance status of 0 or 1 with no deterioration over the previous 2 weeks * FFPE tumour tissue from each participant * Documented germline tumour loss of function mutation in BRCA1, BRCA2, or PALB2 * Adequate organ and marrow function","* Participants with history of MDS/AML or with features suggestive of MDS/AML * Participants with any known predisposition to bleeding * Any history of persisting severe cytopenia * Any evidence of severe or uncontrolled systemic diseases or active uncontrolled infections * Refractory nausea and vomiting, chronic GI disease, inability to swallow the formulated product, or previous significant bowel resection * History of another primary malignancy * Persistent toxicities (CTCAE Grade ≥ 2) caused by previous anti-cancer therapy excluding alopecia * Spinal cord compression, brain metastases, carcinomatous meningitis, or leptomeningeal disease * Evidence of active and uncontrolled hepatitis B and/or hepatitis C * Evidence of active and uncontrolled HIV infection * Active tuberculosis infection * Cardiac criteria, including history of arrythmia and cardiovascular disease * Concurrent exogenous reproductive hormone therapy or non-topical hormonal therapy for non-cancer-related conditions * Major surgical procedure or significant traumatic injury within 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study * Palliative radiotherapy with a limited field of radiation within 2 weeks or with wide field of radiation or to more than 30% of the bone marrow within 4 weeks before the first dose of study treatment * Prior treatment with systemic anti-cancer therapy for locoregionally recurrent or metastatic disease is not permitted, apart from treatment with ET up to 28 days before randomisation * Prior treatment within 28 days with blood product support or growth factor support * Any systemic concurrent anti-cancer treatment * Concomitant use of the following types of medications or herbal supplements within 21 days or at least 5 half-lives of randomisation: 1. Strong and moderate CYP3A4 inducers/inhibitors 2. Sensitive CYP2B6 substrates 3. Substrates of CYP2C9 and/or CYP2C19 which have a narrow therapeutic index, eg, warfarin (a"
NCT04669873,"Clinical Trial, Randomized, Open Label, With an Active Comparator to Assess the Efficacy and Safety of Using Accelerated Partial Irradiation Versus Standard or Hypofractionated Irradiation of the Entire Breast in Patients With Initial Breast Cancer After Conservative Surgery",LAPIDARY,NA,Brazil,"IBCC Oncologia, São Paulo, Brazil, [RECRUITING]",Malignant Neoplasm of Breast,3,"[1] Active Comparator: Standard (ACTIVE_COMPARATOR): Whole breast Radiotherapy, 40 Gray (40Gy) fractions || [2] Experimental 1: Hypofractionated radiotherapy (EXPERIMENTAL): Whole breast Radiotherapy, 26 Gray (26Gy) in 5 fractions || [3] Experimental 2: Accelerated Partial Breast Irradiation (EXPERIMENTAL): Partial Breast Irradiation 26 Gray (26Gy) to the tumor bed in 5 fractions.",* Information to the patient and signed informed consent; * Women aged ≥50 years * Breast conserving surgery * Pathologic tumor size \< 3 cm (maximum microscopic diameter of the invasive component) * Invasive adenocarcinoma (except classic invasive lobular carcinoma) * Unifocal disease * Histopathologic grades I or II * Eastern Cooperative Oncology Group (ECOG) 0-1 * Lymphovascular invasion absent * Negative axillary lymph nodes * Minimum microscopic margins of non-cancerous tissue of 2mm (excluding deep margin when in deep fascia) * No prior breast or mediastinal radiotherapy * No hematogenous metastases,"* Previous malignancy (except non-melanomatous skin cancer) * Mastectomy * Classical-Type Invasive Lobular Carcinoma * Neoadjuvant chemotherapy * Human Epidermal growth factor Receptor-type 2 positive (HER2+) * Triple-negative breast cancers * Intravascular lymphoma present * Contraindications to radiotherapy. * No geographical, social or psychologic reasons that would prevent study follow"
NCT05894239,"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer",INAVO122,PHASE3,"Argentina, Brazil, Colombia, Mexico","Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Argentina, [ACTIVE_NOT_RECRUITING] | Centro Oncologico Korben, Ciudad Autonoma Buenos Aires, Argentina, [RECRUITING] | Instituto de Oncología de Rosario, Rosario, Argentina, [RECRUITING] | Hospital Provincial del Centenario, Rosario, Argentina, [RECRUITING] | CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica, San Juan, Argentina, [RECRUITING] | Clínica Viedma, Viedma Rio Negro, Argentina, [WITHDRAWN] | Crio - Centro Regional Integrado de Oncologia, Fortaleza, Brazil, [RECRUITING] | Hospital Sao Rafael - HSR, Salvador, Brazil, [RECRUITING] | Hospital Araujo Jorge, Goiânia, Brazil, [RECRUITING] | Hospital do Câncer de Londrina, Londrina, Brazil, [RECRUITING]",Metastatic Breast Cancer,3,[1] Induction Therapy: Phesgo plus Taxane-Based Chemotherapy (OTHER): Participants will be administered the treatments as outlined in the interventions section. || [2] Maintenance Therapy: Inavolisib plus Phesgo (EXPERIMENTAL): Participants will be administered the treatments as outlined in the interventions section. || [3] Maintenance Therapy: Placebo plus Phesgo (ACTIVE_COMPARATOR): Participants will be administered the treatments as outlined in the interventions section.,* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 * Histologically or cytologically confirmed and documented adenocarcinoma of the breast with metastatic or locally advanced disease not amenable to curative resection * Confirmation of HER2 biomarker eligibility based on valid results from central testing of tumor tissue documenting HER2-positivity * Confirmation of PIK3CA-mutation biomarker eligibility based on valid results from central testing of tumor tissue documenting PIK3CA-mutated tumor status * Disease-free interval from completion of adjuvant or neoadjuvant systemic non-hormonal treatment to recurrence of \>= 6 months * LVEF (left ventricular ejection fraction) of at least 50% measured by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA) * Adequate hematologic and organ function prior to initiation of study treatment,"* Prior treatment in the locally advanced or metastatic setting with any PI3K, AKT, or mTOR inhibitor or any agent whose mechanism of action is to inhibit the PI3K-AKT-mTOR pathway * Any prior systemic non-hormonal anti-cancer therapy for locally advanced or metastatic HER2-positive breast cancer prior to initiation of induction therapy * History or active inflammatory bowel disease * Disease progression within 6 months of receiving any HER2-targeted therapy * Type 2 diabetes requiring ongoing systemic treatment at the time of study entry; or any history of Type 1 diabetes * Participants with active HBV infection * Clinically significant and active liver disease, including severe liver impairment, viral or other hepatitis, current alcohol abuse, or cirrhosis * Symptomatic active lung disease, including pneumonitis or interstitial lung disease * Any history of leptomeningeal disease or carcinomatous meningitis * Serious infection requiring IV antibiotics within 7 days prior to Day 1 of Cycle 1 * Any concurrent ocular or intraocular condition that, in the opinion of the investigator, would require medical or surgical intervention during the study period to prevent or treat vision loss that might result from that condition * Active inflammatory or infectious conditions in either eye or history of idiopathic or autoimmune-associated uveitis in either eye"
NCT05533775,"A Phase I/II, Open-Label, Single-Arm, Two-Part Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination With Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma",iMATRIX GLO,"PHASE1, PHASE2",Brazil,"Hospital Erasto Gaertner, Curitiba, Brazil, [RECRUITING] | Graacc-Grupo de Apoio ao adolescente e a crianca com cancer, São Paulo, Brazil, [RECRUITING]",Mature B-Cell Non-Hodgkin Lymphoma,2,[1] Arm A (EXPERIMENTAL): Participants will receive glofitamab + R-ICE chemoimmunotherapy for up to 3 cycles (cycle length = 21 days). || [2] Arm B (EXPERIMENTAL): Participants will receive glofitamab monotherapy for up to 12 cycles (cycle length = 21 days).,"* Age 6 months to \< 18 years at the time of signing Informed Consent for Part 1 and Cohort B of the study, and age 6 months to ≤ 30 years old at the time of signing Informed Consent for Part 2 of the study * Histologically re-confirmed diagnosis, via tissue biopsy, or bone marrow aspirate, pleural effusion, or ascites, prior to study entry of aggressive mature B-NHL that expresses CD20 (reconfirmed by IHC or flow cytometry if IHC is not possible), including BL, BAL (mature B-cell leukemia FAB L3), DLBCL, and PMBCL, at the time of first R/R disease for Cohort A and second or greater R/R disease for Cohort B * Refractory or relapsed disease (i.e., prior treatment was ineffective or intolerable) following first-line standard-of-care chemoimmunotherapy for Cohort A and following at least two prior systemic chemoimmunotherapy regimens and who have exhausted all available established therapies for Cohort B * Measurable disease, defined as: At least one bi-dimensionally measurable nodal lesion, defined as \> 1.5 cm in its longest dimension, or at least one bi dimensionally measurable extranodal lesion, defined as \> 1.0 cm in its longest dimension; or percentage of bone marrow involvement with lymphoma cells defined by cytomorphological analysis of bone marrow aspirates * Adequate performance status, as assessed according to the Lansky or Karnofsky Performance Status scales: Participants \< 16 years old: Lansky Performance Status ≥ 50%; Participants ≥ 16 years old: Karnofsky Performance Status ≥ 50% * Adequate bone marrow, liver, and renal function * Negative test results for acute or chronic hepatitis B virus (HBV), hepatitis C virus (HCV) * Negative HIV test at screening, with the following exception: Individuals with a positive HIV test at screening are eligible provided they are stable on anti-retroviral therapy for at least 4 weeks, have a CD4 count ≥200/uL, have an undetectable viral load, and have not had a history of opportunistic infection attributable to AIDS wi","* Isolated CNS disease of mature B-NHL without systemic involvement, and primary CNS lymphoma * Receipt of glofitamab prior to study enrollment * Ongoing adverse events from prior anti-cancer therapy that were not resolved to Grade ≤ 1 (exceptions: alopecia, Grade 2 peripheral neuropathy) * Grade ≥ 3 adverse events, with the exception of Grade 3 endocrinopathy managed with replacement therapy * Participants with active infections which are not resolved prior to Day 1 of Cycle 1 * Prior solid organ transplantation * Known or suspected history of hemophagocytic lymphohistiocytosis (HLH), or chronic active Epstein-Barr viral infection (CAEBV) * Active autoimmune disease requiring treatment * History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins) or known sensitivity or allergy to murine products, except if the participant was able to safely receive it after initial administration (consider consultation with Medical Monitor) * History of confirmed progressive multifocal leukoencephalopathy * Current or past history of uncontrolled non-malignant CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease * Evidence of significant and uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results * Major surgery or significant traumatic injury \< 28 days prior to the obinutuzumab pretreatment infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment * Administration of a live, attenuated vaccine within 4 weeks before the start of study treatment (obinutuzumab pretreatment) or at any time during the study treatment period and within 12 months after end of study treatment * Participants with any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that would contraindicate the use of an "
NCT06662786,"A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer",OrigAMI-2,PHASE3,"Brazil, Puerto Rico","Fundacao Pio XII, Barretos, Brazil, [RECRUITING] | Fundacao Universidade de Caxias do Sul, Caxias do Sul, Brazil, [RECRUITING] | Fundacao Doutor Amaral Carvalho, Jaú, Brazil, [RECRUITING] | Hospital Nossa Senhora da Conceicao S A, Porto Alegre, Brazil, [RECRUITING] | Hospital Santa Izabel Santa Casa de Misericordia da Bahia, Salvador, Brazil, [RECRUITING] | Clinica de Hematologia e Oncologia Viver Ltda, Santa Maria, Brazil, [RECRUITING] | Fundacao Faculdade Regional De Medicina S Jose Rio Preto Hospital De Base, São José do Rio Preto, Brazil, [RECRUITING] | Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo, São Paulo, Brazil, [RECRUITING] | Fundacao Antonio Prudente A C Camargo Cancer Center, São Paulo, Brazil, [RECRUITING] | Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein, São Paulo, Brazil, [RECRUITING]",Colorectal Neoplasms,2,"[1] Arm A: Amivantamab in Combination With Chemotherapy (EXPERIMENTAL): Participants will receive amivantamab in combination with chemotherapy (mFOLFOX6 \[chemotherapy consisting of 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and oxaliplatin\] ... || [2] Arm B: Cetuximab in Combination With Chemotherapy (ACTIVE_COMPARATOR): Participants will receive cetuximab in combination with chemotherapy (mFOLFOX6 or FOLFIRI) for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progres...","* Have histologically or cytologically confirmed adenocarcinoma of the left-sided colorectal cancer. Participants must have unresectable or metastatic disease * Determined to have Kirsten rat sarcoma viral oncogene (KRAS), neuroblastoma RAS viral oncogene homolog (NRAS), and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type (WT) tumor by local and/or central testing (if available) * Must agree to the submission of fresh tumor tissue * Have measurable disease according to RECIST v1.1 * Have an eastern cooperative oncology group (ECOG) performance status (PS) of 0 or 1","* Has medical history of (noninfectious) interstitial lung disease (ILD) /pneumonitis/pulmonary fibrosis or has current ILD/pneumonitis/pulmonary fibrosis, or where suspected ILD/pneumonitis/pulmonary fibrosis cannot be ruled out by imaging at screening * Has known allergies, hypersensitivity, or intolerance to excipients of any of the following: (a) amivantamab or cetuximab, (b) any component of mFOLFOX6 and, (c) any component of FOLFIRI * Has a prior or concurrent second malignancy other than the disease under study or one whose natural history or treatment is likely to interfere with any study endpoints of safety or the efficacy of the study treatment(s) * Participant with known mismatch repair deficiency (dMMR)/ high microsatellite instability (MSI-H) status and human epidermal growth factor receptor 2 (HER2)-positive/amplified tumor * Has prior exposure to any agents that target epidermal growth factor receptor (EGFR) or mesenchymal epithelial transition (MET)"
NCT04879329,"A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination With Pembrolizumab in Subjects With Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2",,PHASE2,"Argentina, Chile","Clinica Viedma, Viedma, Argentina, [RECRUITING] | Hospital Aleman, Buenos Aires, Argentina, [RECRUITING] | Fundacion CENIT para la lnvestigacion en Neurociencias, Buenos Aires, Argentina, [RECRUITING] | Instituto Medico Especializado Alexander Fleming, Buenos Aires, Argentina, [RECRUITING] | Hospital Sirio Libanes - Buenos Aires, Buenos Aires, Argentina, [RECRUITING] | Centro Medico Austral, CABA, Argentina, [RECRUITING] | Centro Oncologico Korben, Caba, Argentina, [RECRUITING] | Instituto Oncologico de Cordoba, Córdoba, Argentina, [RECRUITING] | Oncovida SA, Santiago, Chile, [RECRUITING] | Pontificia Universidad Catolica de Chile, Santiago, Chile, [RECRUITING]",Urothelial Carcinoma,8,[1] Cohort A - DV monotherapy for HER2-positive tumor types (EXPERIMENTAL): Disitamab vedotin monotherapy || [2] Cohort B - DV monotherapy for HER2-low tumor types (EXPERIMENTAL): Disitamab vedotin monotherapy || [3] Cohort C - Non-randomized combination therapy (EXPERIMENTAL): Disitamab vedotin + pembrolizumab || [4] Cohort C - Randomized combination therapy (EXPERIMENTAL): Disitamab vedotin + pembrolizumab || [5] Cohort C - Randomized monotherapy (EXPERIMENTAL): Disitamab vedotin monotherapy || [6] Cohort D - DV monotherapy (Japan only) (EXPERIMENTAL): Disitamab vedotin monotherapy || [7] Cohort E - DV combination therapy (Japan only) (EXPERIMENTAL): Disitamab vedotin + pembrolizumab || [8] Cohort G - DV monotherapy (EXPERIMENTAL): Disitamab vedotin,"Cohorts A and B * Histopathologically-confirmed, locally-advanced, unresectable or metastatic urothelial cancer (LA/mUC), including UC originating from the renal pelvis, ureters, bladder, or urethra * Participants must have received only 1 or 2 lines of prior systemic treatment for LA/mUC, including 1 line of platinum-containing chemotherapy * At least one measurable lesion by investigator assessment based on RECIST version 1.1. * HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, in the provided tumor sample * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 Cohort C * Histopathologically-confirmed LA/mUC, including UC originating from the renal pelvis, ureters, bladder, or urethra * No prior systemic therapy for LA/mUC * Neoadjuvant or adjuvant therapy, including PD-(L)1 inhibitors, is acceptable, if disease recurrence/progression occurred more than 12 months after the last dose of systemic therapy * At least one measurable lesion by investigator assessment based on RECIST v1.1. * Participant is eligible to receive cisplatin- or carboplatin- containing chemotherapy per investigator evaluation * HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, on the provided tumor tissue sample * ECOG performance status of 0, 1, or 2 Cohort D * Histopathologically-confirmed LA/mUC, including UC originating from the renal pelvis, ureters, bladder, or urethra * Based on a participant's eligibility to receive treatment with standard of care therapies in Japan, participants must have received all of the following lines of therapy for LA/mUC: * a. One prior line of platinum-containing chemotherapy. * b. Prior therapy with PD-(L)1 inhibitors as (neo)adjuvant therapy, first-line maintenance therapy or as second line treatment. * c. Prior enfortumab vedotin therapy. * At least one measurable lesion by investigator assessment based on RECIST v1.1. * ECOG performance status of 0 or 1 Cohort E * H","Cohorts A and B * Known hypersensitivity to disitamab vedotin or any of their components * Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study (defined as Cycle 1 Day 1 for Cohorts A and B) * Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia) * Prior MMAE-based ADCs (eg, enfortumab vedotin) or HER2-directed therapy * Major surgery that has not fully recovered within 4 weeks prior to dose administration * Peripheral sensory or motor neuropathy ≥ Grade 2 at baseline Cohort C * Known hypersensitivity to disitamab vedotin, pembrolizumab, or any of their components * Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study defined as Cycle 1 Day 1 for the single-arm part of Cohort C and as randomization date for the randomized part of Cohort C) * Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia) * Prior MMAE-based ADCs (eg, enfortumab vedotin) or HER2-directed therapy * Major surgery that has not fully recovered within 4 weeks prior to dose administration * Peripheral sensory or motor neuropathy ≥ Grade 2 at baseline * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug * Participants who have previously received any prior treatment with an agent directed to another stimulatory or co-inhibitory T cell receptor (including but not limited to CD137 agonists, CAR-T cell therapy, CTLA-4 inhibitors, or OX-40 agonists) are excluded. Cohort D * Known hypersensitivity to disitamab vedotin or any of their components * Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of star"
NCT03448757,Determination of Autonomic Responses to the Exposure of Low Energy Electromagnetic Fields With Frequency Modulation in Patients With Advanced Hepatocellular Carcinoma and Healthy Individuals.,,NA,Brazil,"Hospital Sírio-Libanês, São Paulo, Brazil, [RECRUITING]",Hepatocellular Carcinoma,1,"[1] Autonomic response (EXPERIMENTAL): Group for determination of biofeedback response - 40 individuals. For the formation of this study group of subjects, 20 healthy volunteers and 20 patients with advanced hepatocellular carcinoma wil...","* Healthy volunteers * Must be considered healthy, with no known relevant comorbidity. * Patients must not be carriers of active malignant neoplasm or have a history of malignant neoplasm. * Must be over 18 years old. * Must have the ability to understand and provide written Informed Consent. Patients with hepatocellular carcinoma * Patients must be diagnosed with inoperable HCC. * Presence of the primary or metastatic tumor at the time of the procedure. * Patients diagnosed with hepatic cirrhosis must be restricted to Child-Pugh A or B. * Patients with AFP\> 400 ng/ml and characteristic image do not need histopathological confirmation. However, in patients with serology for active B virus, this AFP value must be greater than 4000 ng/ml. The remaining patients must have histological confirmation of HCC. * Patients may be in observation or in the course of systemic or intra-hepatic treatment. * Must have the ability to understand and provide written Informed Consent.","* Individuals selected for this study will be excluded if they meet the following exclusion criteria: * They cannot stop antihypertensive drugs or beta blockers for at least 24 hours. * Have a pacemaker or other implantable device. * Pregnant or breastfeeding. * Under the age of 18. * Patients undergoing radiotherapy or up to 2 weeks after its suspension. * Inability to understand and provide written Informed Consent. * Child Pugh C hepatic cirrhosis. * Patient without definite diagnosis. * Absence of primary or metastatic tumor at the time of the procedure. Potentially eligible participants will be previously guided by the researcher on the objectives and risks of the study in question and will be presented and informed about the Free, Prior and Informed Consent document. Only after all doubts related to the study have been clarified and the Free, Prior and Informed Consent document has been signed, will the study participant be invited and scheduled to attend the Oncology Center clinic of Hospital Sírio Libanês. Patients must be informed that they may not drink alcohol up to 12 hours before the procedure, as there may be interference during the procedure. They will also be advised not to use antihypertensive drugs like beta-blockers or calcium channel inhibitors 24 hours before the procedure, without resulting in a risk to the participant's health. In this study, following or follow-up of patients is not foreseen."
NCT05020236,"AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR",MAGNETISMM-5,PHASE3,"Argentina, Brazil, Mexico","Alexander Fleming S.A (Instituto Medico Especializado Alexander Fleming), Ciudad Autonoma de Buenos Aires, Argentina, [ACTIVE_NOT_RECRUITING] | FUNDALEU - Fundacion para combatir la Leucemia, Ciudad Autonoma de Buenos Aires, Argentina, [ACTIVE_NOT_RECRUITING] | FUNDALEU -Fundación para combatir la leucemia, Ciudad Autónoma de Buenos Aires, Argentina, [ACTIVE_NOT_RECRUITING] | FUNDALEU, Ciudad Autónoma de Buenos Aires, Argentina, [ACTIVE_NOT_RECRUITING] | Hospital Italiano de La Plata, La Plata, Argentina, [ACTIVE_NOT_RECRUITING] | Hospital Universitario Austral, Presidente Derqui, Argentina, [ACTIVE_NOT_RECRUITING] | Sanatorio de La Mujer, Rosario, Argentina, [ACTIVE_NOT_RECRUITING] | Instituto D'Or de Pesquisa e Ensino (IDOR) - Filial Salvador, Salvador, Brazil, [ACTIVE_NOT_RECRUITING] | Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa, Porto Alegre, Brazil, [ACTIVE_NOT_RECRUITING] | Centro de Pesquisa Clínica - Área Administrativa, Porto Alegre, Brazil, [ACTIVE_NOT_RECRUITING]",Multiple Myeloma,6,[1] Part 1 Safety Lead-In Dose Escalation: Elranatamab + Daratumumab (EXPERIMENTAL): No description || [2] Part 2 Randomized Arm A: Elranatamab (EXPERIMENTAL): No description || [3] Part 2 Randomized Arm B: Elranatamab + Daratumumab (EXPERIMENTAL): No description || [4] Part 2 Randomized Arm C: Daratumumab + Pomalidomide + Dexamethasone (ACTIVE_COMPARATOR): No description || [5] Part 3 Arm D: Elranatamab (EXPERIMENTAL): No description || [6] Part 3 Arm E: Elranatamab + Daratumumab (EXPERIMENTAL): No description,"* Prior diagnosis of multiple myeloma as defined by IMWG criteria (Rajkumar et al, 2014). * Measurable disease based on IMWG criteria as defined by at least 1 of the following: * Serum M-protein ≥0.5 g/dL. * Urinary M-protein excretion ≥200 mg/24 hours. * Serum immunoglobulin FLC ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (\<0.26 or \>1.65). * Prior anti-multiple myeloma therapy including treatment with lenalidomide. * ECOG performance status ≤2. * Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1. * Not pregnant and willing to use contraception.","* Smoldering multiple myeloma. * Plasma cell leukemia. * Amyloidosis. * POEMS Syndrome. * Stem cell transplant within 12 weeks prior to enrolment, or active graft versus host disease. * Active HBV, HCV, SARS-CoV2, HIV, or any active, uncontrolled bacterial, fungal, or viral infection. * Any other active malignancy within 3 years prior to enrolment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ. * Previous treatment with a BCMA-directed therapy. * Live attenuated vaccine within 4 weeks of the first dose of study intervention. * Administration with an investigational product (e.g. drug or vaccine) concurrent with study intervention or within 30 days preceding the first dose of study intervention used in this study."
NCT03574571,Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC),,PHASE3,Brazil,"Hospital de Amor de Barretos (Fundação Pio XII) / Barretos Cancer Hospital, Barretos, Brazil, [RECRUITING] | Instituto de Medicina Integral Professor Fernando Figueira (IMIP), Boa Vista, Brazil, [RECRUITING] | Instituto Brasileiro de Controle do Câncer/IBCC, São Paulo, Brazil, [RECRUITING] | Hospital Sírio Libanês, Brasília, Brazil, [RECRUITING] | Hospital Erasto Gaertner, Curitiba, Brazil, [RECRUITING] | CPORS - Centro de Pesquisa em Oncologia do Hospital São Lucas da PUCRS, Porto Alegre, Brazil, [RECRUITING] | Hospital Moinhos de Vento (HMV), Porto Alegre, Brazil, [RECRUITING] | Hospital Israelita Albert Einstein, São Paulo, Brazil, [RECRUITING] | Beneficência Portuguesa, São Paulo, Brazil, [RECRUITING] | Centro de Pesquisas São Lucas - Sociedade Campineira de Educação e Instrução (SCEI), São Paulo, Brazil, [RECRUITING]",Prostate Cancer,2,"[1] Docetaxel (EXPERIMENTAL): Docetaxel 75 mg/m2 will be administered IV every three weeks for 10 doses. Prednisone will be given at a dose of 5mg orally twice daily. || [2] Docetaxel with Radium-223 (EXPERIMENTAL): Docetaxel 60 mg/m2 will be administered IV every 3 weeks for 10 doses. Radium-223 will be administered at 55 kBq/kg, 6 injections at 6 weeks intervals.","* Willing and able to provide written informed consent (ICF) and HIPAA authorization for the release of personal health information. A signed informed consent must be obtained before screening procedures are performed. NOTE: HIPAA authorization may be either included in the informed consent or obtained separately. * Males 18 years of age and above * Histological or cytological proof of prostate cancer * Documented progressive mCRPC based on at least one of the following criteria: 1. PSA progression defined as 25% increase over baseline value with an increase in the absolute value of at least 1.0 ng/mL that is confirmed by another PSA level with a minimum of a 1 week interval and a minimum PSA of 1.0 ng/mL. 2. Soft-tissue progression defined as an increase ≥ 20% in the sum of the LD of all target lesions based on the smallest sum LD since treatment started or the appearance of one or more new lesions. 3. Progression of bone disease (evaluable disease) or two or more new bone lesions by bone scan. * Two or more bone lesions * ECOG 0- 1 * Normal organ function with acceptable initial laboratory values within 14 days of randomization: * Albumin \> 30 g/L * ANC ≥ 1.5 x 10\^9/L * Hemoglobin ≥ 10 g/dL * Platelet count ≥ 100 x 10\^9/L * Creatinine ≤ 1.5 x the institutional upper limit of normal (ULN) * Bilirubin ≤ ULN (unless documented Gilbert's disease) * SGOT (AST) ≤ 1.5 x ULN * SGPT (ALT) ≤ 1.5 x ULN * WBC count ≥ 3 x 10\^9/L * Subjects must agree to use a medically acceptable method of birth control (e.g., spermicide in conjunction with a barrier such as a condom) or sexual abstinence for the duration of the study, including 30 days after the last dose of study drug. Sperm donation is prohibited during the study and for 30 days after the last dose of study drug. Female partners must use hormonal or barrier contraception unless postmenopausal or abstinent. * Serum testosterone \< 50 ng/dL. Subjects must continue primary androgen deprivation with an LHRH analogue (agonis","* Received any other investigational therapeutic agents or other anticancer therapies within 4 weeks prior to randomization. °Note: If this requirement to have a washout of 2 weeks or 5 half-lives prior to randomization causes potential treatment delay due to Radium-223 importation timelines, the PCCTC must be contacted at pcctc@mskcc.org to request approval to randomize the subject prior to the completion of the washout. Requests for early randomization must be accompanied by written assurance by the site that the washout will be completed prior to treatment start. * Received external beam radiotherapy within the 4 weeks prior to randomization. ° Note: If prolonging randomization to complete EBRT washout causes potential treatment delay due to Radium-223 importation timelines, the PCCTC must be contacted at pcctc@mskcc.org to request approval to randomize the subject prior to the completion of the washout. Requests for early randomization must be accompanied by written assurance by the site that the washout will be completed prior to treatment start. * Has an immediate need for external beam radiotherapy. * Has received any systemic bone-seeking radiopharmaceutical in the past. * Has received any prostate cancer directed chemotherapy in the castration resistant setting. Subjects who have received up to 6 prior doses of docetaxel in the castration sensitive setting are permitted if they have not experienced disease progression within 36 weeks of last treatment with docetaxel. * Has received four or more systemic anticancer regimens for mCRPC. * Treatment with docetaxel or abiraterone for non-castrate metastatic disease is permissible and does not count towards the lines of therapy for mCRPC * A 'line' is a regimen. Combinations of hormones and other types of therapies count as single lines. * Has known Grade ≥3 docetaxel-related toxicities or docetaxel toxicity related dose interruption or discontinuation. * Has received blood transfusions or growth factors within t"
NCT04015609,Adaptation and Pilot Feasibility of a Psychotherapy Intervention for Latinos With Advanced Cancer,,NA,Puerto Rico,"Ponce Health Sciences University, Ponce, Puerto Rico, [RECRUITING]","Solid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, Adult",2,[1] Meaning Centered Psychotherapy for Latinos (MCP-L) (EXPERIMENTAL): No description || [2] Control (ACTIVE_COMPARATOR): No description,"Phase I: Quantitative * Diagnosed with stages III or IV solid tumor cancer \*(as per self report for ICCAN patients) * Age 18 or older * As per self report, Latino/a or Hispanic ethnicity * As per self report, fluent in oral Spanish (monolingual) or fluent in oral Spanish and English (bilingual) Phase 2: Qualitative * Enrolled in the quantitative phase of study (as seen above) * Completes the quantitative phase questionnaire package * Scores above or below the threshold for the Distress Thermometer (DT≥4 or ≤3) * In the judgment of the investigator, willing and able to be interviewed in Spanish only * Agrees to be audio- recorded Phase 3: Provider Feedback * Professionals working in the mental health field; * Have a caseload of five or more Latino cancer patients per month * Able to communicate and read in Spanish * Agrees to be audio or video-recorded Phase 4: Patient Feedback * Diagnosed with stages III or IV solid tumor cancer \*(as per self report for ICCAN patients) * Age 18 or older * As per self report, Latino/a or Hispanic ethnicity * In the judgment of the investigator, willing and able to be interviewed in Spanish only * Agrees to be audio-recorded","Phase 1: Quantitative * In the judgment of the treating physician and/or the consenting professional, presence of significant cognitive impairment (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection * In the judgment of the consenting professional, significant or major disabling medical or psychiatric condition sufficient to preclude meaningful informed consent, interview, or completion of assessment measures (patients whose psychiatric disorder is well controlled by treatment will be eligible) Phase 2: Qualitative * In the judgment of the treating physician and/or the consenting professional, presence of significant cognitive impairment (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection * In the judgment of the consenting professional, significant or major disabling medical or psychiatric condition sufficient to preclude meaningful informed consent, interview, or completion of assessment measures (patients whose psychiatric disorder is well controlled by treatment will be eligible) Phase 4: Patient Feedback * Diagnosed with a major disabling medical or psychiatric condition * Unable to understand the consent procedure * Too ill to participate, all as reported by the patient and/or determined by the investigator's judgment."
NCT05226871,A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED PALBOCICLIB CLINICAL STUDIES,,PHASE2,Mexico,"Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"", Monterrey, Mexico, [RECRUITING]",Breast Cancer | Head and Neck Cancer,4,[1] Arm 1 (OTHER): Cetuximab || [2] Arm 2 (EXPERIMENTAL): Palbociclib plus Cetuximab || [3] Arm 3 (OTHER): Palbociclib plus Fulvestrant || [4] Arm 4 (OTHER): Palbociclib plus Letrozole,"* Any participant who is receiving study treatment and deriving clinical benefit as determined by the investigator in a Pfizer-sponsored palbociclib Parent Study * Participants must agree to follow the reproductive criteria * Participants who are willing and able to comply with all scheduled visits, treatment plans, and other study procedures * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent document and protocol","* Any medical reason that, in the opinion of the investigator or sponsor, precludes the participant from inclusion in the study"
NCT05794906,"A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer",ARASTEP,PHASE3,Brazil,"Oncocentro - Fortaleza, Fortaleza, Brazil, [RECRUITING] | Hospital Evangélico de Cachoeiro de Itapemirim, Vitória, Brazil, [NOT_YET_RECRUITING] | Hospital São Rafael, Salvador, Brazil, [RECRUITING] | Assistência Multidisciplinar em Oncologia (AMO), Salvador, Brazil, [RECRUITING] | Liga Paranaense de Combate ao Cancer-Hosp Erasto Gaertner, Curitiba, Brazil, [RECRUITING] | Real Hospital Português, Recife, Brazil, [WITHDRAWN] | Instituto D'Or Pesquisa e Ensino (IDOR) (D'Or Institute for Research & Education) - Rio de Janeiro, Rio de Janeiro, Brazil, [RECRUITING] | Liga Norte Riograndense Contra o Cancer | Centro de Pesquisa Clínica, Natal, Brazil, [RECRUITING] | Hospital Moinhos de Vento-Centro Clínico, Porto Alegre, Brazil, [RECRUITING] | Hospital Mae de Deus, Porto Alegre, Brazil, [RECRUITING]",Biochemically Recurrent Prostate Cancer,2,[1] Darolutamide+ADT (EXPERIMENTAL): Participants will receive darolutamide plus ADT twice daily with food for a pre-specified duration of 24 months. || [2] Placebo+ADT (PLACEBO_COMPARATOR): Participants will receive Placebo plus ADT twice daily with food for a pre-specified duration of 24 months.,"* Capable of giving signed informed consent as described which includes compliance with the requirements, restrictions listed in the informed consent form (ICF), and in this protocol. * Male ≥18 years of age at the time of signing the informed consent. * Histologically or cytologically confirmed adenocarcinoma of prostate. * Prostate cancer initially treated by: radical prostatectomy (RP) followed by adjuvant radiotherapy (ART), or salvage radiotherapy (SRT), or RP in participants who are unfit for (or refused) ART or SRT, or primary radiotherapy (RT). * High-risk biochemical recurrence (BCR), defined as Prostate-specific antigen doubling time (PSADT) \<12 months calculated using the formula provided by the Sponsor, and PSA ≥0.2 ng/mL after ART or SRT post RP or after RP in participants who are unfit for ART or SRT (local or central values accepted), or PSA ≥2 ng/mL above the nadir after primary RT only (local or central values accepted). * Participants must undergo prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) within the 42-day Screening period using either 18F-DCFPyL (piflufolastat F 18) or 68Ga-PSMA-11 which will be assessed by blinded independent central review (BICR) to identify at least one PSMA PET/CT lesion of prostate cancer. * Serum testosterone ≥150 ng/dL (5.2 nmol/L) (local assessment is allowed whenever central assessment cannot be done). * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Blood counts at screening: Hemoglobin ≥9.0 g/dL (participant must not have received blood transfusion within 7 days prior to sample being taken); Absolute neutrophil count (ANC) ≥1.5x10\^9/L (participant must not have received any growth factor within 4 weeks prior to sample being taken); Platelet count ≥100x10\^9/L. * Screening values of: Alanine aminotransferase (ALT) ≤1.5 x upper limit of normal (ULN); Aspartate aminotransferase (AST) ≤1.5 x ULN; Total bilirubin (TBL) ≤1.5 ULN, (except part","* Pathological finding consistent with small cell, ductal or ≥50 % component of neuroendocrine carcinoma of the prostate. * History of bilateral orchiectomy. * Metastases or recurrent /new malignant lesions in prostate gland/bed seminal vesicles, lymph nodes below the CIA bifurcation on conventional imaging (CI) as assessed by BICR during screening. * Brain metastasis on PSMA PET /CT by BICR at screening. * High-risk BCR after primary radiotherapy with new loco-regional lesions on screening PSMA PET/CT who are eligible for curative salvage prostatectomy. Note: Participants treated with curative salvage prostatectomy after primary RT who meet the PSA criteria (inclusion criteria 5) may be considered for the study. * Prior treatment with second generation (e.g. enzalutamide, apalutamide) androgen receptor inhibitors (ARIs) and CYP 17 inhibitors (e.g., abiraterone) within 18 months prior to signing of the ICF. * Prior treatments with PSMA-radiotherapeutics within 12 months prior to randomization. * Prior radiotherapy (including image-guided radiotherapy) as primary, adjuvant or salvage treatment completed within 8 weeks prior to signing of the ICF. * Any prior malignancy (other than adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or any other cancer in situ currently in complete remission) within 5 years. * History of pelvic radiotherapy for other malignancy."
NCT06065748,"A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy",,PHASE3,"Argentina, Brazil, Chile, Colombia, Costa Rica, Guatemala, Mexico, Peru, Puerto Rico","Inst. de Oncologia Angel H. Roffo, Buenos Aires, Argentina, [RECRUITING] | Fundación CENIT para la Investigación en Neurociencias, Ciudad Autonoma Buenos Aires, Argentina, [RECRUITING] | Centro Oncologico Korben, Ciudad Autonoma Buenos Aires, Argentina, [RECRUITING] | Sanatorio Allende, Córdoba, Argentina, [RECRUITING] | Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina, [RECRUITING] | Hospital Alemán, Recoleta, Argentina, [RECRUITING] | Instituto de Oncología de Rosario, Rosario, Argentina, [RECRUITING] | Sanatorio Parque S.A., Rosario, Argentina, [RECRUITING] | Hospital Provincial del Centenario, Rosario, Argentina, [RECRUITING] | Centro Oncológico de Excelencia, San Juan, Argentina, [RECRUITING]","Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer",2,"[1] Giredestrant + Investigator's Choice of CDK4/6i (EXPERIMENTAL): Participants in the experimental arm will receive giredestrant plus the investigator's choice of CDK4/6 inhibitor (CDK4/6i): palbociclib, ribociclib, or abemaciclib. || [2] Fulvestrant + Investigator's Choice of CDK4/6i (ACTIVE_COMPARATOR): Participants in the control arm will receive fulvestrant plus the investigator's choice of CDK4/6 inhibitor (CDK4/6i): palbociclib, ribociclib, or abemaciclib.","* Locally advanced or metastatic adenocarcinoma of the breast, not amenable to treatment with curative intent * Documented estrogen receptor-positive (ER+), HER2-negative (HER2-) tumor assessed locally on the most recent tumor biopsy (or an archived tumor sample if a recent tumor sample is not available for testing) * Confirmed ESR1 mutation status (ESR1m versus ESR1nmd) in baseline circulating tumor DNA (ctDNA) through central laboratory testing * Resistance to prior adjuvant endocrine therapy (ET), which is defined as having relapsed with prior standard adjuvant ET, on-treatment after \>/=12 months or off-treatment within 12 months of completion. Prior use of adjuvant CDK4/6i is allowed (if relapse occurred \>/=12 months since completion). * No prior systemic anti-cancer therapy for advanced disease * Measurable disease as defined per RECIST v.1.1 or non-measurable (including bone-only) disease * Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1 * For pre/perimenopausal women and for men: willing to undergo and maintain treatment with approved LHRH agonist therapy (as per local guidelines) for the duration of study treatment","* Prior systemic therapy (e.g., prior chemotherapy, immunotherapy, or biologic therapy) for locally advanced unresectable or metastatic breast cancer * Prior treatment with another SERD (e.g., fulvestrant, oral SERDs) or novel ER-targeting agents * Advanced, symptomatic, visceral spread that is at risk of life-threatening complications in the short term * Active cardiac disease or history of cardiac dysfunction * Clinically significant history of liver disease"
NCT05477576,"Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy",ACTION-1,PHASE3,Brazil,"Research Facility, Brasília, Brazil, [RECRUITING] | Research Facility, Rio de Janeiro, Brazil, [RECRUITING] | Research Facility, São Paulo, Brazil, [RECRUITING]",GEP-NET | Gastroenteropancreatic Neuroendocrine Tumor | Gastroenteropancreatic Neuroendocrine Tumor Disease | Neuroendocrine Tumors | Carcinoid,3,"[1] Phase 1b - RYZ101 (EXPERIMENTAL): Part 1 is an uncontrolled dose de-escalation study to confirm the safety and determine the RP3D of RYZ101 based on Bayesian optimal interval design. || [2] Phase 3 - RYZ101 (ACTIVE_COMPARATOR): Actinium 225 radiolabeled somatostatin analog (SSA) for injection || [3] Phase 3 - Standard of Care (ACTIVE_COMPARATOR): Investigator's choice of standard of care between everolimus, sunitinib, octreotide, or lanreotide.","* Histologically proven, Grade 1-2 well differentiated, inoperable, advanced GEP-NETs (Ki67 ≤20%) Eastern Cooperative Oncology Group (ECOG) status 0-2 * Progressive, SSTR-PET positive (i.e., Krenning score 3 or 4) GEP-NET (GI or pancreas) following 2-4 cycles of treatment with 177Lu-labeled SSA. Must have achieved disease control for at least 6 months following Lu-177 SSA. No time limit is defined between 177Lu-SSA treatment and randomization. There must be at least 1 SSTR-PET imaging-positive measurable site of disease (according to RECIST v1.1) and no RECIST v1.1 measurable metastatic lesions that are SSTR imaging-negative. * Adequate renal function, as evidenced by estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m2 (calculated using the Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\]) (Levey et al. 2009) * Adequate hematologic function, defined by the following laboratory results: * Part 2: Hemoglobin concentration ≥5.0 mmol/L (≥8.0 g/dL); ANC ≥1000 cells/µL (≥1000 cells/mm3); platelets ≥75 x 109/L (75 x 103/mm3). * Total bilirubin ≤3 x upper limit normal (ULN) * Serum albumin ≥3.0 g/dL unless prothrombin time is within the normal range","* Prior radioembolization * Significant cardiovascular disease, such as New York Heart Association (NYHA) Class ≥II heart failure, left ventricular ejection fraction (LVEF) \<40% or QT interval corrected for heart rate using Fridericia's formula (QTcF) \>450 ms for males and \>470 ms for females. * Resistant hypertension, defined as uncontrolled blood pressure (BP) \>140/90 mmHg while on optimal doses of at least 3 antihypertensive medications with 1 being a diuretic (Whelton et al. 2018) * Uncontrolled diabetes mellitus as defined by hemoglobin A1C (HgB A1C) ≥8% * PRRT other than Lu-177 SSA * Any condition requiring systemic treatment with high-dose glucocorticoids within 14 days prior to first dose of study treatment and/or which cannot be stopped while on study. Inhaled or topical steroids are permitted. * Prior history of liver cirrhosis or liver transplantation"
NCT06075810,"A Phase 1 Open-Label, First-in-Human Trial of Oral MBQ-167 as Single Agent in Participants With Advanced Breast Cancer",,PHASE1,Puerto Rico,"FDI Clinical Research, San Juan, Puerto Rico, [RECRUITING]",Breast Cancer | Breast Neoplasm | Breast Cancer Stage IV,1,[1] MBQ-167 oral capsule (EXPERIMENTAL): A dose ranging from 10mg to 400mg BID following a standard 3+3 cohort design,"* The investigator will evaluate these and other criteria to determine whether a participant can be included in this study. * Histologically and/or cytologically confirmed advanced breast cancer which has progressed after treatment with approved therapies or for which there are no standard therapies available. * Participants with known brain metastases may be eligible if specific conditions are met. * Life expectancy ≥6 months, in the opinion of the investigator, after starting MBQ-167. * Are able to swallow capsules twice daily with a meal. Key","* The investigator will evaluate these and other criteria to determine whether a participant should be excluded from this study. * Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea, or vomiting) that might impair the bioavailability of MBQ-167. * Females who are pregnant or breastfeeding. * Participants who have received any anticancer treatment within 4 weeks or any investigational agent within 28 days prior to the first dose of trial drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment. * Participants who have received any anticancer treatment within 4 weeks or any investigational agent within 28 days prior to the first dose of trial drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment. * Active malignancies other than advanced breast cancer will be excluded from the study."
NCT07128199,"A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Adjuvant Chemotherapy Versus Placebo Plus Adjuvant Chemotherapy in Stage IB-IIIA NSCLC Patients With Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)",REZILIENT4,PHASE3,"Argentina, Brazil, Mexico, Peru","Instituto Argentino de Diagnóstico y Tratamiento, Ciudad Autónoma de Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Centro de Investigación Pergamino SA, Pergamino, Argentina, [NOT_YET_RECRUITING] | Hospital Universitario Austral, Pilar, Argentina, [NOT_YET_RECRUITING] | CEMAIC - Centro de Especialidades Médicas Ambulatorias e Investigación Clínica, Córdoba, Argentina, [NOT_YET_RECRUITING] | NOHC - Núcleo de Oncologia e Hematologia do Ceará - José Lourenço, Fortaleza, Brazil, [NOT_YET_RECRUITING] | Centro Regional Integrado de Oncologia, Fortaleza, Brazil, [NOT_YET_RECRUITING] | Centro de Pesquisas Clínicas Em Oncologia - CPCO, Cachoeiro de Itapemirim, Brazil, [NOT_YET_RECRUITING] | Hospital Santa Rita, Vitória, Brazil, [NOT_YET_RECRUITING] | Núcleo de Oncologia da Bahia Ondina - NOB, Salvador, Brazil, [NOT_YET_RECRUITING] | Oncoclinicas Oncovida - Brasilia, Brasília, Brazil, [NOT_YET_RECRUITING]","NSCLC, Stage IB-IIIA | Lung Cancer | Adjuvant | Post-surgical | EGFR",2,"[1] Zipalertinib (EXPERIMENTAL): Participants will receive adjuvant platinum-based chemotherapy consisting of cisplatin 75 milligrams per square meter (mg/m\^2) or carboplatin (area under concentration \[AUC\] 5 milligrams per mil... || [2] Placebo (PLACEBO_COMPARATOR): Participants will receive adjuvant platinum-based chemotherapy consisting of cisplatin 75 mg/m\^2 or carboplatin AUC 5 mg/mL/min plus pemetrexed 500 mg/m\^2, administered via IV infusion, on 21-day...","1. Histologically confirmed diagnosis of primary NSCLC on predominantly non-squamous histology. 2. Documented EGFRmt status as determined by local testing performed at a clinical laboratory improvement amendment (CLIA) certified (United States \[US\]) or accredited (outside of the US) local laboratory, defined as either one of the following EGFRmt: 1. exon20 insertion mutations (ex20ins) or 2. other uncommon, non-ex20ins EGFRmt (eg, G719X, L861Q, or S768I) 3. Magnetic resonance imaging (MRI) or computed tomography (CT) scan of the brain done prior to surgery. Participants in whom this was not done prior to surgery may still be enrolled if appropriate imaging (i.e., MRI or CT of the brain) is performed prior to randomization. 4. Complete surgical resection of the primary NSCLC is mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for tumor. Resection may be accomplished by open thoracotomy or video associated thoracic surgery (VATS) techniques. 5. Classified post-operatively as either Stage IB, IIA, IIB, or IIIA according to the tumor nodes metastasis (TNM) staging system for lung cancer (American Joint Committee on Cancer \[AJCC\] 9th edition). 6. Complete recovery from surgery at the time of randomization. 7. Eastern cooperative oncology group performance status (ECOG PS) of 0 or 1. 8. Archival tumor tissue available for submission, with minimum quantity sufficient to evaluate EGFRmt status and, where possible, other biomarkers.","1. Is currently receiving an investigational drug in a clinical trial or participating in any other type of medical research judged not to be scientifically or medically compatible with this study. 2. Treatment with any of the following within the time frame specified: 1. Zipalertinib (TAS6417/CLN-081) or any other EGFR inhibitor at any time. 2. Pre-operative or post-operative or planned radiation therapy for the current lung cancer. 3. Any prior systemic anticancer therapy (e.g., neoadjuvant chemotherapy), including investigational therapy, for treatment of NSCLC. 4. Major surgery (including primary tumor surgery, excluding placement of vascular access) within 4 weeks of the first dose of study treatment. 5. All prescribed medication, over-the-counter medication, vitamin preparations and other food supplements, or herbal medications that are strong or moderate cytochrome p450 (CYP) 3A4 inducers or inhibitors within 7 days prior to first dose. 6. Treatment with an investigational drug within five half-lives of the compound or any of its related material, if known. 3. Has received only segmentectomies or wedge resections. 4. Past medical history of interstitial lung disease (ILD)/pneumonitis, drug-induced ILD/pneumonitis or any evidence of clinically active ILD/pneumonitis. 5. Impaired cardiac function or clinically significant cardiac disease. 6. Unable to swallow tablets or has any disease or condition that may significantly affect gastrointestinal (GI) absorption of zipalertinib (such as inflammatory bowel disease, malabsorption syndrome, or prior significant bowel resection). 7. Participants with a history of any other cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer, other cancers curatively treated with no evidence of disease for \>5 years following the end of treatment and which, in the opinion of the treating physician, do not have a substantial risk of recurrence of the prior malignancy. 8. Known history of hepat"
NCT04862663,"A Phase Ib/III, Open-label, Randomised Study of Capivasertib Plus CDK4/6 Inhibitors and Fulvestrant Versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)",CAPItello-292,PHASE3,"Argentina, Brazil","Research Site, Buenos Aires, Argentina, [ACTIVE_NOT_RECRUITING] | Research Site, Buenos Aires, Argentina, [ACTIVE_NOT_RECRUITING] | Research Site, CABA, Argentina, [ACTIVE_NOT_RECRUITING] | Research Site, CABA, Argentina, [ACTIVE_NOT_RECRUITING] | Research Site, CABA, Argentina, [SUSPENDED] | Research Site, Chivilcoy, Argentina, [ACTIVE_NOT_RECRUITING] | Research Site, Rosario, Argentina, [ACTIVE_NOT_RECRUITING] | Research Site, Santa Fe, Argentina, [WITHDRAWN] | Research Site, Alfenas, Brazil, [ACTIVE_NOT_RECRUITING] | Research Site, Blumenau, Brazil, [ACTIVE_NOT_RECRUITING]",Locally Advanced (Inoperable) or Metastatic Breast Cancer,5,[1] Capivasertib Plus Palbociclib and Fulvestrant (EXPERIMENTAL): Capivasertib Plus Palbociclib and Fulvestrant (Ph 1b) || [2] Capivasertib Plus Ribociclib and Fulvestrant (EXPERIMENTAL): Capivasertib Plus Ribociclib and Fulvestrant (Ph 1b) || [3] Capivasertib Plus Abemaciclib and Fulvestrant (EXPERIMENTAL): Capivasertib Plus Abemaciclib and Fulvestrant (Ph 1b) || [4] Capivasertib Plus Fulvestrant and Investigator's choice of CDK4/6i (palbociclib or ribociclib) (EXPERIMENTAL): Capivasertib Plus Fulvestrant and Investigator's choice of CDK4/6i (palbociclib or ribociclib) (Ph III) || [5] Fulvestrant and Investigator's choice of CDK4/6i (palbociclib or ribociclib) (ACTIVE_COMPARATOR): Fulvestrant and investigator's choice of CDK4/6i (palbociclib or ribociclib) (Ph III),"1. Adult females (pre-/peri-/ and post-menopausal), and adult males. 2. Histologically confirmed HR+/ HER2- breast cancer determined from the most recent tumour sample (primary or metastatic) per the American Society of Clinical Oncology and College of American Pathologists guideline. To fulfil the requirement of HR+ disease, a breast cancer must express ER with or without co-expression of progesterone receptor. 3. Eligible for fulvestrant therapy and at least one of the following: palbociclib, ribociclib, or abemaciclib, as per local investigator assessment. Previous tolerance to specific CDK4/6 inhibitors and dose levels required. 4. Adequate organ and bone marrow functions. 5. Consent to provide a mandatory FFPE tumour sample. 1. Previous treatment with an ET (tamoxifen, AI, or oral SERD) as a single agent or in combination, with radiological evidence of breast cancer recurrence or progression while on, or within 12 months of, completing a (neo)adjuvant ET regimen. 2. Provision of mandatory blood samples at screening for central testing using an investigational ctDNA test to be stratified based on PIK3CA/AKT1/PTEN status. 3. Be eligible for fulvestrant and at least one out of palbociclib or ribociclib (depending on the available CDK4/6i options at time of enrolment), as per local investigator assessment. 4. Have measurable lesion(s) according to Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST v1.1) or, in the absence of measurable disease, lytic or mixed bone lesions that can be assessed by computed tomography (CT) or magnetic resonance imaging (MRI).","1. History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥ 2 years before the first dose of study intervention and of low potential risk for recurrence. 2. Radiotherapy within 2 weeks prior to study treatment initiation. 3. Major surgery or significant traumatic injury within 4 weeks of the first dose of study treatment. 4. Persistent toxicities (CTCAE Grade \>1) caused by previous anticancer therapy, excluding alopecia. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention may be included (eg, hearing loss or peripheral sensory neuropathy) after consultation with the AstraZeneca study physician. 5. Spinal cord compression, brain metastases or leptomeningeal metastases unless these lesions are definitively treated (eg. radiotherapy, surgery) and clinically stable off steroids for management of symptoms for at least 4 weeks prior to study treatment initiation. 6. Any of the following cardiac criteria at screening: (a). Mean resting corrected QT interval (QTcF): (i) Participants to be treated with palbociclib:: QTcF ≥ 470 ms obtained from the average of 3 consecutive (triplicate) ECGs (ii) Participants to be treated with ribociclib: QTcF ≥ 450 ms obtained from the average of 3 consecutive (triplicate) ECGs (iii) Participants to be treated with abemaciclib (Phase Ib only): QTcF ≥ 470 ms obtained from the average of 3 consecutive (triplicate) ECGs (b). Any clinically important abnormalities in cardiac rhythm, conduction or morphology of resting ECG (eg, complete left bundle branch block, third-degree heart block) (c). Any factors that increase the risk of QTc prolongation or risk of arrhythmic events (d). Experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, unstable angina pectoris, congestive heart failure New York Heart Association (N"
NCT04589845,Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial,,PHASE2,"Brazil, Puerto Rico","Hospital Moinhos de Vento, Porto Alegre, Brazil, [WITHDRAWN] | Hospital Sírio-Libanês, São Paulo, Brazil, [WITHDRAWN] | Hospital Sírio-Libanês, São Paulo, Brazil, [RECRUITING] | Hospital A. C. Camargo, São Paulo, Brazil, [ACTIVE_NOT_RECRUITING] | Clínica Onco Star - Rede D'Or, São Paulo, Brazil, [RECRUITING] | PanOncology Trials, San Juan, Puerto Rico, [COMPLETED]",Solid Tumors,13,"[1] Cohort A: ROS Proto-oncogene 1 (ROS1) Fusion-positive Tumors (Excluding NSCLC) (EXPERIMENTAL): Participants with metastatic or advanced solid tumors, with the exception of non-small cell lung cancer (NSCLC), will receive entrectinib once daily (QD) in repeated 28-day cycles at a dose of 600 ... || [2] Cohort B: Neurotrophic Tyrosine Receptor Kinase (NTRK) 1/2/3 Fusion-positive Tumors (EXPERIMENTAL): Participants with metastatic or advanced solid tumors will receive entrectinib, QD in repeated 28-day cycles at a dose of 600 mg/day for adults and pediatric participants with a BSA ≥ 1.51 m\^2. Th... || [3] Cohort C: Anaplastic Lymphoma Kinase (ALK) Fusion-positive Tumors (Excluding NSCLC) (EXPERIMENTAL): Participants with metastatic or advanced solid tumors, with the exception of NSCLC, will receive alectinib at a dosage of 600 mg, orally, twice a day (BID), taken with food, in repeated 28-day cycles. || [4] Cohort D: TMB-high Tumors (EXPERIMENTAL): Participants with metastatic or advanced solid tumors will receive atezolizumab intravenously (IV) at a fixed dose for participants aged ≥ 18 years, and 15 milligrams per kilogram (mg/kg) (maximum ... || [5] Cohort E: Protein Kinase B (AKT) 1/2/3 Mutant-positive Tumors (EXPERIMENTAL): Participants with metastatic or advanced solid tumors will receive ipatasertib orally, QD at the starting dose of 400 mg in repeated 28-day cycles until the participant experiences disease progress... || [6] Cohort F: Human Epidermal Growth Factor Receptor 2 (HER2) Mutant-positive Tumors (EXPERIMENTAL): Participants with metastatic or advanced solid tumors will receive trastuzumab emtansine IV at a dose of 3.6 mg/kg every 21 days.

Note: Cohort F has been closed as of protocol version 7 because en... || [7] Cohort H: PIK3CA Multiple Mutant-positive Tumors (EXPERIMENTAL): Participants with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) multiple mutant-positive tumors will receive inavolisib (GDC-0077) QD at ","* Histologically or cytologically confirmed diagnosis of advanced and unresectable or metastatic solid malignancy * Measurable disease as defined by RECIST v1.1, RANO, or INRC * Performance status as follows: Participants aged ≥ 18 years: Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2; Participants aged 16 to \< 18 years: Karnofsky score ≥ 50%; Participants aged \< 16 years: Lansky score ≥ 50% * For participants aged ≥ 18 and \< 18 years: adequate hematologic and end-organ function * Disease progression on prior treatment, or previously untreated disease with no available acceptable treatment * Adequate recovery from most recent systemic or local treatment for cancer * Life expectancy ≥ 8 weeks * Ability to comply with the study protocol, in the investigator's judgment * For female participants of childbearing potential: Negative serum pregnancy test ≤ 14 days prior to initiating study treatment, agreement to remain abstinent or use single or combined contraception methods that result in a failure rate of \< 1% per year for the period defined in the cohort-specific inclusion criteria; and agreement to refrain from donating eggs during the same period * For male participants: Willingness to remain abstinent or use acceptable methods of contraception as defined in the cohort-specific inclusion criteria * In addition to the general inclusion criteria above, participants must meet all of the cohort-specific inclusion criteria for the respective cohort","* Current participation or enrollment in another therapeutic clinical trial * Any anticancer treatment within 2 weeks or 5 half-lives prior to start of study treatment * Whole brain radiotherapy within 14 days prior to start of study treatment * Stereotactic radiosurgery within 7 days prior to start of study treatment * Pregnant or breastfeeding, or intending to become pregnant during the study * History of or concurrent serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study or confounds the ability to interpret data from the study * Incomplete recovery from any surgery prior to the start of study treatment that would interfere with the determination of safety or efficacy of study treatment * Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or higher), myocardial infarction, or cerebrovascular accident within 3 months prior to enrollment, unstable arrhythmias, or unstable angina * History of another active cancer within 5 years prior to screening that may interfere with the determination of safety or efficacy of study treatment with respect to the qualifying solid tumor malignancy * In addition to the general exclusion criteria above, in order to be enrolled in a treatment cohort of the study, participants must not meet any of the cohort-specific exclusion criteria"
NCT06784986,"Impact of Using the Airseal System with Ultra-low Pneumoperitoneum in Patients Undergoing Robot-assisted Radical Prostatectomy: a Prospective, Comparative, Randomized Clinical Study.",ARCO2,PHASE4,Brazil,"Instituto Brasileiro de Cirurgia Robotica, Salvador, Brazil, [RECRUITING] | Hospital Mater Dei Salvador, Salvador, Brazil, [RECRUITING]",Prostate Carcinoma | Prostate Neoplasm | Pain Intensity Assessment | Quality of Life (QOL),2,"[1] Conventional Insufflator and Trocar (OTHER): Subjects enrolled in this study arm will undergo robot-assisted radical prostatectomy using a conventional CO2 insufflation system. This system maintains standard intra-abdominal pressure (12-15 mm... || [2] AirSeal® System-Interventional (EXPERIMENTAL): Subjects enrolled in this study arm will undergo robot-assisted radical prostatectomy using the AirSeal® System. The device enables stable pneumoperitoneum at ultra-low pressures (6-8 mmHg), aiming...",* Patients with prostate cancer who will undergo robotic prostatectomy;,"* Patients over 65 and under 18 years of age; * Patients allergic to NSAIDs and/or Morphine and/or Tramadol; * Patients with chronic renal failure; * Patients with recurrence, metastasis and other existing neoplasms."
NCT06158841,"A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)",CERVINO,PHASE3,Puerto Rico,"Hematology And Oncology Institute /ID# 272531, Manatí, Puerto Rico, [RECRUITING] | Auxilio Mutuo Cancer Center /ID# 272565, San Juan, Puerto Rico, [RECRUITING]",Multiple Myeloma,2,"[1] Etentamig (EXPERIMENTAL): Participants will receive etentamig as a monotherapy. || [2] Standard Available Therapy (SAT) (EXPERIMENTAL): Participants will receive SAT, in accordance with the local (or applicable) approved label, package insert, summary of product characteristics, and/or the institutional guidelines, as applicable. S...","* Eastern Cooperative Oncology Group (ECOG) performance of \<= 2. * Diagnosis of relapsed/refractory (R/R) multiple myeloma (MM) during or after the participant's last treatment as stated in the protocol. * Must have measurable disease with at least 1 of the following assessed within 28 days of enrollment: * Serum M-protein \>= 0.5 g/dL (\>= 5 g/L). * Urine M-protein \>= 200 mg/24 hours. * In participants without measurable serum or urine M protein, serum free light chain (FLC) \>= 100 mg/L (10 mg/dL) (involved light chain)and an abnormal serum kappa lambda ratio. * Must have received at least 2 or more lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory imide (IMiD), and an anti-CD38 monoclonal antibody (mAb). * Must be eligible to receive the Investigator's choice standard available therapy (SAT) based on approved prescribing information, previous MM treatment history, and institutional guidelines.","* Clinically significant (per Investigator's judgment) drug or alcohol abuse within the last 6 months. * Clinically significant conditions such as but not limited to the following: neurologic, psychiatric, endocrine, metabolic, immunologic, cardiovascular, pulmonary, or hepatic disease within the last 6 months that would adversely affect the participant's participation in the study. * Central nervous system involvement of MM. * Has received B-cell maturation antigen (BCMA)-targeted therapy."
NCT05253651,An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer,MOUNTAINEER-03,PHASE3,"Argentina, Brazil, Chile","Centro de Investigacion Pergamino SA, Pergamino, Argentina, [RECRUITING] | Instituto Medico de la Fundacion Estudios Clinicos, Rosario, Argentina, [RECRUITING] | Instituto Medico Especializado Alexander Fleming, Buenos Aires, Argentina, [RECRUITING] | Hospital Britanico de Buenos Aires, CABA, Argentina, [RECRUITING] | IONC Instituto Oncologico de Cordoba Fundacion Richardet Longo, Córdoba, Argentina, [RECRUITING] | CEMAIC - Centro Medico Privado, Córdoba, Argentina, [RECRUITING] | CIONC-Centro Integrado de Oncologia de Curitiba, Curitiba, Brazil, [RECRUITING] | Institute de Educacao, Pesquisa e Gestao em Saude - Instituto COI, Rio de Janeiro, Brazil, [RECRUITING] | Institute de Educacao, Pesquisa e Gestao em Saude - Instituto COI, Rio de Janeiro, Brazil, [RECRUITING] | Centro Integrado de Pesquisa em Oncologia CIPO-GHC / Hospital Nossa Senhora da Conceicao, Porto Alegre, Brazil, [RECRUITING]",Colorectal Neoplasms,2,"[1] Tucatinib Arm (EXPERIMENTAL): Tucatinib + trastuzumab + mFOLFOX6 || [2] Standard of Care Arm (ACTIVE_COMPARATOR): Either (1) mFOLFOX6, (2) mFOLFOX6 and bevacizumab, or (3) mFOLFOX6 and cetuximab","* Histologically and/or cytologically confirmed adenocarcinoma of the colon or rectum which is locally advanced unresectable or metastatic * Able to provide the most recently available formalin-fixed paraffin-embedded (FFPE) tumor tissue blocks (or freshly sectioned slides) obtained prior to treatment initiation to a central laboratory * If archival tissue is not available, a newly-obtained baseline biopsy of an accessible tumor lesion is required within 35 days prior to start of study treatment * HER2+ disease as determined by a tissue based assay performed at a central laboratory. * Participant has rat sarcoma viral oncogene homolog wild-type (RAS WT) disease as determined by local or central testing. For central RAS analysis, tissue sample must be analyzed within 1 year of biopsy date. * Radiographically measurable disease per RECIST v1.1 with: * At least one site of disease that is measurable and that has not been previously irradiated, or * If the participant has had previous radiation to the target lesion(s), there must be evidence of progression since the radiation * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * CNS Inclusion - based on contrast brain magnetic resonance imaging, participants may have any of the following: * No evidence of brain metastases * Previously treated brain metastases which are asymptomatic",* Prior systemic anticancer therapy for colorectal cancer (CRC) in the locally advanced unresectable or metastatic setting; note that participants may have received a maximum of 2 doses of mFOLFOX6 in the locally advanced/unresectable or metastatic setting prior to randomization. * Note: May have received chemotherapy for CRC in the adjuvant setting if it was completed \>6 months prior to enrollment * Radiation therapy within 14 days prior to enrollment (or within 7 days in the setting of stereotactic radiosurgery) * Previous treatment with anti-HER2 therapy * Ongoing Grade 3 or higher neuropathy * Active or untreated gastrointestinal (GI) perforation at the time of screening.
NCT07084610,Metabolic Signatures Predictive of Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer,,PHASE2,Brazil,"Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (HC-FMRP-USP), Ribeirão Preto, Brazil, [RECRUITING]",Non-Small Cell Lung Cancer,1,[1] Neoadjuvant Nivolumab Plus Platinum-Based Chemotherapy (EXPERIMENTAL): Patients with resectable non-small cell lung cancer (NSCLC) clinical stage IB-IIIA (AJCC 8th edition) will receive two cycles of neoadjuvant nivolumab at 3 mg/kg combined with platinum-based double...,"* Histologically confirmed non-small cell lung cancer (NSCLC), clinical stage IB to IIIA (according to AJCC 8th edition) * Tumor deemed resectable by the multidisciplinary thoracic oncology team * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Adequate organ and bone marrow function * Ability to understand and willingness to sign a written informed consent","* Prior systemic therapy, radiotherapy, or immunotherapy for lung cancer * Known EGFR mutations or ALK rearrangements * Active autoimmune disease requiring systemic therapy within the past 2 years * Uncontrolled comorbidities or active infections * Pregnant or breastfeeding women * Contraindications to surgery or anesthesia * Known history of other malignancies within the last 3 years, except for adequately treated basal or squamous cell skin cancer, or carcinoma in situ of the cervix"
NCT05150691,"A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients With Advanced/Metastatic Solid Tumors",,"PHASE1, PHASE2",Puerto Rico,"BRCR Global Puerto Rico LLC., Mayagüez, Puerto Rico, [WITHDRAWN]",HER2-positive Advanced Solid Tumor,24,[1] DB-1303/BNT323 Dose Level 1 (EXPERIMENTAL): Enrolled Subjects will receive a single-dose of DB-1303/BNT323 at Dose Level 1 on Day 1 of each cycle Q3W || [2] DB-1303/BNT323 Dose Level 2 (EXPERIMENTAL): Enrolled Subjects will receive a single-dose of DB-1303/BNT323 at Dose Level 2 on Day 1 of each cycle Q3W || [3] DB-1303/BNT323 Dose Level 3 (EXPERIMENTAL): Enrolled Subjects will receive a single-dose of DB-1303/BNT323 at Dose Level 3 on Day 1 of each cycle Q3W || [4] DB-1303/BNT323 Dose Level 4 (EXPERIMENTAL): Enrolled Subjects will receive a single-dose of DB-1303/BNT323 at Dose Level 4 on Day 1 of each cycle Q3W || [5] DB-1303/BNT323 Dose Level 5 (EXPERIMENTAL): Enrolled Subjects will receive a single-dose of DB-1303/BNT323 at Dose Level 5 on Day 1 of each cycle Q3W || [6] DB-1303/BNT323 Dose Expansion 1 (EXPERIMENTAL): Enrolled Subjects will be randomized to receive a single-dose of DB-1303/BNT323 on a selected dose level 1 or dose level 2 Day 1 of each cycle Q3W || [7] DB-1303/BNT323 Dose Expansion 2 (EXPERIMENTAL): Enrolled Subjects will receive a single-dose of DB-1303/BNT323 on a selected dose level (RP2D) Day 1 of each cycle Q3W || [8] DB-1303/BNT323 Dose Expansion 3 (EXPERIMENTAL): Enrolled Subjects will receive a single-dose of DB-1303/BNT323 on a selected dose level (RP2D) Day 1 of each cycle Q3W || [9] DB-1303/BNT323 Dose Expansion 4 (EXPERIMENTAL): Enrolled Subjects will receive a single-dose of DB-1303/BNT323 on a selected dose level (RP2D) Day 1 of each cycle Q3W || [10] DB-1303/BNT323 Dose Expansion 5 (EXPERIMENTAL): Enrolled Subjects will receive a single-dose of DB-1303/BNT323 on a selected dose level (RP2D) Day 1 of each cycle Q3W,"* Has a pathologically documented HER2-positive or HER2-expressing (except for cohort 2h where the requirement is HER2-null), advanced/unresectable, recurrent, or metastatic malignant solid tumor that is refractory to or intolerable with standard treatment, or for which no standard treatment is available. * At least 1 measurable lesion (per RECIST 1.1) * Provide signed informed consent * ECOG performance status (PS) of 0-1. * LVEF ≥ 50% by ECHO or MUGA * Adequate organ functions * Provide pre-existing diagnosis of HER2 status or resected tumor samples or undergo fresh tumor biopsy for HER2 testing. * Life expectancy of ≥ 3 months. Additional Inclusion Criteria for Part 2 Expansion Group 9: 1\. Has pathologically documented advanced/unresectable, recurrent, or metastatic EC (including UCS and USPC) and has progressed on or after at least 1 line of systemic treatment including platinum-based therapy and exposure to ICI but no more than prior 3 lines of therapy for advanced/unresectable, or metastatic disease. Note: endocrine therapy will not qualify as a systemic therapy line.","* History of symptomatic CHF (New York Heart Association \[NYHA\] classes II-IV) or serious cardiac arrhythmia requiring treatment. * History of myocardial infarction or unstable angina within 6 months before Day 1. * Average QTcF \> 450 ms in males and \> 470 ms in females * History of clinically significant lung diseases * Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals. * HIV infection with AIDS defining illness or active viral hepatitis. * Clinically active brain metastases * Unresolved toxicities from previous anticancer therapy, defined as toxicities not yet resolved to NCI-CTCAE version 5.0, Grade ≤ 1 or baseline. * A known hypersensitivity to either the drug substances or inactive ingredients in the drug product. * Part 2 (expansion) Only:Multiple primary malignancies within 3 years, except adequately resected non- melanoma skin cancer, curatively treated in-situ disease, other solid tumors curatively treated, or contralateral breast cancer."
NCT06646276,"A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).",,PHASE3,"Argentina, Brazil, Chile, Mexico","Instituto Alexander Fleming, Ciudad Autónoma de Buenos Aires, Argentina, [RECRUITING] | Hospital Italiano de Buenos Aires, ABB, Argentina, [RECRUITING] | Local Institution - 0100, Buenos Aires, Argentina, [WITHDRAWN] | Clinica Adventista Belgrano, CABA, Argentina, [RECRUITING] | Instituto Médico Río Cuarto, Río Cuarto, Argentina, [RECRUITING] | Local Institution - 0166, Fortaleza, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0165, Porto Alegre, Brazil, [NOT_YET_RECRUITING] | Hospital São Lucas da PUCRS, Porto Alegre, Brazil, [RECRUITING] | Local Institution - 0170, Santa Cruz do Sul, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0163, Itajaí, Brazil, [NOT_YET_RECRUITING]",Extensive-Stage Small Cell Lung Cancer,2,[1] Arm A (EXPERIMENTAL): No description || [2] Arm B (ACTIVE_COMPARATOR): No description,* Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). * Participants must be Healthy enough to do their normal activities with little or no help based on the ECOG performance scale. * Participants must have at least one tumor that can be measured using special imaging techniques like a CT scan or MRI at a site other than the brain and nervous system,"* Participants have already received certain types of treatment for extensive stage small cell lung cancer * Participants have certain health conditions, like spread of small cell lung cancer to the brain that are causing symptoms, certain lung diseases, heart diseases, infections, autoimmune diseases, other cancers, or a type of nerve damage called peripheral sensory neuropathy * Other protocol-defined Inclusion/Exclusion criteria apply."
NCT05492123,"Randomized Phase II Study to Evaluate Induction Nivolumab-Ipilimumab, Followed by Nivolumab With Chemoradiotherapy Versus Chemoradiotherapy for Advanced Cervical Cancer",,PHASE2,Brazil,"CRIO -Centro Regional Integrado de Oncologia, Fortaleza, Brazil, [RECRUITING] | Clinica AMO, Salvador, Brazil, [RECRUITING] | Hospital das Clinicas da UFMG, Belo Horizonte, Brazil, [NOT_YET_RECRUITING] | Hospital Erasto Gaertner, Curitiba, Brazil, [NOT_YET_RECRUITING] | Multi Oncoclinicas Recife, Recife, Brazil, [RECRUITING] | Hospital São Lucas - PUCRS, Porto Alegre, Brazil, [NOT_YET_RECRUITING] | Universidade Federal de Roraima, Boa Vista, Brazil, [RECRUITING] | CEPON - Florianópolis, Florianópolis, Brazil, [NOT_YET_RECRUITING] | Hospital de Amor, Barretos, Brazil, [NOT_YET_RECRUITING] | Hospital De Base de São José do Rio Preto - CIP São José, São José do Rio Preto, Brazil, [NOT_YET_RECRUITING]",Uterine Cervical Neoplasms,2,[1] Standard Chemoradiation (ACTIVE_COMPARATOR): Traditional radiation therapy with a target of 45 Gy in 25 1.8Gy fractions with concurrent weekly cisplatin 40mg/m2/week or carboplatin AUC 2/week || [2] Immunotherapy (EXPERIMENTAL): 4 cycles of induction therapy with nivolumab 1mg/kg and ipilimumab 3mg/kg every 3 weeks followed by traditional radiation therapy with a target of 45 Gy in 25 1.8Gy fractions with concurrent weekly...,"* Female participants older than 18 years * Documented evidence of cervical adenocarcinoma or squamous carcinoma FIGO Stage IB2-IB3 node positive or Stage IIB-IVA * No prior chemotherapy, immune checkpoint inhibitors or radiotherapy for cervical cancer * WHO/ECOG performance status of 0-1 * At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 Target Lesion at baseline.","* Diagnosis of small cell (neuroendocrine) histology cervical cancer * Intent to administer a fertility-sparing treatment regimen * Undergone a previous hysterectomy * Evidence of metastatic disease per RECIST 1.1 including lymph nodes ≥15 mm (short axis) above the L1 cephalad body or outside the planned radiation field. * History of allogeneic organ transplantation * Active or prior documented autoimmune or inflammatory disorders * Uncontrolled intercurrent illness * History of another primary malignancy and active primary immunodeficiency * Patients with active infection Laboratory values that fall into: 1. WBC count (WBC) \< 2000/μL ; 2. Neutrophil count \< 1500/μL; 3. Platelet count \< 100 x 103/μL; 4. Hemoglobin level \< 9.0 g/dL; 5. Serum creatinine \> 1.5 x upper limit of normal (ULN) unless creatinine clearance is ≥ 40 mL/min (measured or calculated using the Cockcroft-Gault formula); 6. Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT): \> 3.0 x ULN; 7. Total bilirubin \> 1.5 x ULN (except participants with Gilbert Syndrome who must have a total bilirubin level of \< 3.0 x ULN); 8. Any positive test result for hepatitis B virus or hepatitis C virus that indicates the presence of the virus, for example, positive Hepatitis B surface antigen (HBsAg, Australia antigen) or Hepatitis C antibodies (anti- HCV) positive (unless the HCV-RNA is negative). * Participants with a condition requiring systemic treatment or with corticosteroids (\>10 mg daily of a prednisone equivalent) or other immunosuppressive drugs within 14 days of initiating study treatment. * Pregnant or breastfeeding woman"
NCT05563220,"A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer",ELEVATE,"PHASE1, PHASE2","Argentina, Brazil","Centro Medico Austral, Buenos Aires, Argentina, [RECRUITING] | Hospital Britanico De Buenos Aires, Buenos Aires, Argentina, [RECRUITING] | Cemaic - Centro De Especialidades Medicas Ambulatorias E Investigacion Clinica, Córdoba, Argentina, [RECRUITING] | Centro Oncologico Riojano Integral (Cori), La Rioja, Argentina, [RECRUITING] | ACCG - Hospital Araujo Jorge, Goiânia, Brazil, [RECRUITING] | Clinica Neoplasias Litoral, Itajaí, Brazil, [RECRUITING] | Hospital Sao Lucas da PUCRS, Porto Alegre, Brazil, [RECRUITING] | Centro Gaucho Integrado de Oncologia; Hematologia; Ensino e Pesquisa - Hospital Mae de Deus/AESC, Porto Alegre, Brazil, [RECRUITING] | Hospital Sirio-Libanes (HSL) - Centro De Oncologia - Sao Paulo, São Paulo, Brazil, [RECRUITING]",Breast Cancer | Metastatic Breast Cancer,5,"[1] Phase 1b Arm A: elacestrant with alpelisib (EXPERIMENTAL): Elacestrant Dihydrochloride 300 milligrams (mg) or 400 mg + Alpelisib 150 mg to 250 mg || [2] Phase 1b Arm B: elacestrant with everolimus (EXPERIMENTAL): Elacestrant Dihydrochloride 300 mg or 400 mg + Everolimus 5.0 mg, 7.5 mg or possibly 10 mg || [3] Phase 1b Arm C: elacestrant with abemaciclib or ribociclib: (EXPERIMENTAL): Elacestrant Dihydrochloride 100 mg, 200 mg, 300 mg + Ribociclib 400 mg or possibly 600 mg

The RP2D for the combination of elacestrant and abemaciclib is evaluated in the ongoing ELECTRA trial (Cli... || [4] Phase 1b Arm D: elacestrant with either palbociclib, abemaciclib, or ribociclib (no prior CDK4/6i) (EXPERIMENTAL): Elacestrant Dihydrochloride 300 mg or 400 mg + Palbociclib 100 mg,125 mg or the RP2D for the combination of elacestrant and abemaciclib is evaluated in the ongoing ELECTRA trial (ClinicalTrials.gov... || [5] Phase 1b Arm E: (EXPERIMENTAL): Elacestrant Dihydrochloride 300 mg, 400 mg + Capivasertib 200 mg, 320 mg, 400 mg","1. Participant has signed the informed consent before all study specific activities are conducted. 2. Women or men aged ≥18 years (or the minimum age of consent in accordance with the local law), at the time of informed consent signature. Female participants may be of any menopausal status. * Postmenopausal status is defined as follows or in accordance with local regulations: 1. Age ≥60 years or 2. Age \<60 years and amenorrhea for 12 or more months (without an alternative cause) and follicle-stimulating hormone value and an estradiol level within the postmenopausal range per local laboratory reference or 3. Documentation of bilateral oophorectomy, at least 1 month before first dose of trial therapy. * Premenopausal and perimenopausal women (who do not fit postmenopausal criteria) and men must be receiving a luteinizing hormone-releasing hormone (LHRH) agonist and must be initiated at least 3 weeks (4 depending on local label) before the start of trial therapy and are planning to continue LHRH agonist treatment during the study treatment. 3. Histopathological or cytological confirmed ER+, HER2-, breast cancer, per local laboratory, as per the American Society of Clinical Oncology/College of American Pathologists guidelines. Note: In the context of this trial, ER status will be considered positive if ≥10% of tumor cells demonstrate positive nuclear staining by immunohistochemistry, with or without progesterone positivity. 4. Documented radiological disease progression during or after the most recent therapy. 5. At least 1 measurable lesion as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). Tumor lesions previously irradiated or subjected to any locoregional treatment will only be considered measurable if there is clear, documented progression at the treated site. For participants with bone only disease, lesions: must be lytic or mixed (lytic + blastic / sclerotic), confirmed and accurately assessed by computed tomography or magnetic resona","1. Active or newly diagnosed central nervous system metastases, or meningeal carcinomatosis. Note: Participants with stable brain or subdural metastases are allowed if the participant has completed local therapy and was on a stable or decreasing dose of corticosteroids at baseline for management of brain metastasis for at least 4 weeks before starting treatment in this study. The dose must be ≤2.0 mg/day of dexamethasone or equivalent. Any signs (for example, radiologic) or symptoms of brain metastases must be stable for at least 4 weeks before starting study treatment. 2. Participants with advanced, symptomatic visceral spread, who are at risk of life-threatening complications in the short term, including massive uncontrolled effusions (peritoneal, pleural, pericardial), pulmonary lymphangitis, or liver involvement \>50%. 3. Prior chemotherapy or elacestrant in the advanced/metastatic setting. 4. Participants with known germline BRCA mutation without prior treatment with a PARP inhibitor before study entry. 5. Prior therapy with elacestrant or other investigational selective estrogen receptor degraders, or investigational alike agents such as selective estrogen receptor modulators, selective estrogen receptor covalent antagonists, complete estrogen receptor antagonists, and proteolysis-targeting chimeras, in the metastatic setting. Prior treatment with fulvestrant is not exclusionary, except for Arm E, as it is an approved medication. 6. Participant has a concurrent malignancy or history of invasive malignancy within 3 years of enrollment, except basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix that has completed curative therapy. Other malignancies with low risk of recurrence may be considered eligible with Sponsor approval. 7. Uncontrolled significant active infections. * Participants with hepatitis B virus and/or hepatitis C virus infection must have undetectable viral load during screening. * Participants known "
NCT06818643,A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors,,"PHASE1, PHASE2",Chile,"Centro de Estudios Clínicos SAGA ( Site 0033), Santiago, Chile, [RECRUITING] | FALP ( Site 0031), Santiago, Chile, [RECRUITING] | Pontificia Universidad Catolica de Chile ( Site 0032), Santiago, Chile, [RECRUITING] | Bradford Hill Centro de Investigaciones Clinicas ( Site 0030), Santiago, Chile, [RECRUITING]",Advanced Solid Tumors | Malignant Neoplasm,2,[1] Arm 1 Dose level 1 (EXPERIMENTAL): Participants receive MK-3120 at dose level 1 as per the schedule specified in the arm. || [2] Arm 2 Dose level 2 (EXPERIMENTAL): Participants receive MK-3120 at dose level 2 as per the schedule specified in the arm.,"* Has a confirmed advanced (unresectable and/or metastatic) solid tumor * Has measurable disease by RECIST 1.1 as assessed by the local site investigator/radiology. Lesions situated in a previously irradiated area are considered measurable if progression has been shown in such lesions * Has archival tumor tissue sample or newly obtained biopsy of a tumor lesion not previously irradiated has been provided * Who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement or participants who have ≤Grade 2 neuropathy are eligible * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART) * Hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to randomization. * Who has history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening * Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 3 days before intervention allocation/randomization * Has adequate organ function","* Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea) * Has uncontrolled significant cardiovascular disease or cerebrovascular disease * Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or corneal disease that prevents/delays corneal healing * Has pleural effusion, ascites, and/or pericardial effusion that are symptomatic or require repeated drainage * HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Has received prior systemic anticancer therapy including investigational agents within 4 weeks before the start of study intervention * Has received prior radiotherapy within 2 weeks of start of study intervention * Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention * Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis * Has active infection requiring systemic therapy * Has concurrent active Hepatitis B (defined as hepatitis B surface antigen (HBsAg) positive and/or detectable HBV deoxyribonucleic acid (DNA) and Hepatitis C virus (defined as anti-HCV antibody (Ab) positive and detectable HCV ribonucleic acid (RNA) infection"
NCT06120140,"A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib",COCOON,PHASE2,"Argentina, Brazil","Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, [RECRUITING] | IADT Instituto Argentino de Diagnostico y Tratamiento, CABA, Argentina, [RECRUITING] | Centro Medico Austral, Capital Federal, Argentina, [RECRUITING] | Hospital Italiano de La Plata, La Plata, Argentina, [COMPLETED] | Hospital Privado de la Comunidad, Mar del Plata, Argentina, [RECRUITING] | CTO Centro De Tratamento Oncologico LTDA, Belém, Brazil, [RECRUITING] | Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, Brazil, [RECRUITING] | Liga Paranaense de Combate ao Cancer, Curitiba, Brazil, [RECRUITING] | Fundacao Doutor Amaral Carvalho, Jaú, Brazil, [RECRUITING] | Hospital Nossa Senhora da Conceicao S A, Porto Alegre, Brazil, [RECRUITING]","Carcinoma, Non-Small-Cell Lung",5,"[1] Arm A: Enhanced Dermatologic Management (EXPERIMENTAL): Participants will receive enhanced dermatologic management to reduce toxicities in skin and nail with doxycycline tablet or minocycline capsule, clindamycin topical lotion, chlorhexidine topical so... || [2] Arm B: Standard-of-Care Dermatologic Management (ACTIVE_COMPARATOR): Participants will receive standard care for dermatologic management according to local practice to reduce dermatologic toxicities in skin and nail during background anticancer treatment of advanced... || [3] Sub-study: Cohort A: Ruxolitinib (EXPERIMENTAL): Participants enrolled in Arms A and B of the main study who experience new-onset or persistent specific DAEIs (Grade greater than or equal to \[\>=\] 2, as defined by National Cancer Institute Comm... || [4] Sub-study: Cohort B: Tacrolimus (EXPERIMENTAL): Participants enrolled in Arms A and B of the main study who experience new-onset or persistent specific DAEIs (Grade \>= 2, as defined by NCI-CTCAE v5.0) will be enrolled and receive reactive treat... || [5] Amivantamab Subcutaneous (SC) Expansion Cohort: Modified Enhanced Dermatologic Management (EXPERIMENTAL): Participants will receive modified enhanced dermatologic management with oral doxycycline or minocycline, zinc gluconate and noncomedogenic skin moisturizer during background anticancer treatment o...","* Have histologically or cytologically confirmed, locally advanced or metastatic non-small cell lung cancer (NSCLC); Is treatment naive and not amenable to curative therapy including surgical resection or (chemo) radiation. Adjuvant or neoadjuvant therapy for Stage I, Stage II or Stage IIIA disease is allowed if last dose administered more than 12 months prior to the development of locally advanced or metastatic disease * Have a tumor that harbors an epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R substitution, as detected by an Food and Drug Administration (FDA)-approved or other validated test in a clinical laboratory improvement amendments (CLIA)-certified laboratory (sites in the United States) or an accredited local laboratory (sites outside of the United States) in accordance with site standard-of-care * A participant with asymptomatic or previously treated and stable brain metastases may participate in this study. Participants with a history of symptomatic brain metastases must have had all lesions treated as clinically indicated (that is, no current indication for further definitive local therapy). Any definitive local therapy to brain metastases must have been completed at least 14 days prior to randomization, and the participant can be receiving no greater than 10 milligram (mg) prednisone or equivalent daily for the treatment of intracranial disease * Can have prior or concurrent second malignancy (other than the disease under study) which natural history or treatment is unlikely to interfere with any study endpoints, safety, or the efficacy of the study treatment(s). For the amivantamab SC expansion cohort: Due to the increased risk of skin cancer with ruxolitinib, participants with any prior or concurrent skin malignancies will be excluded * Sub-study: Participants must have new-onset or persistent (defined as non-responsive to standard of care \[SoC\]) Grade \>=2 specific DAEIs of the scalp, face, or body, as defined by NCI-CTCAE Gr","* History of uncontrolled illness, including but not limited to uncontrolled diabetes; ongoing or active infection (includes infection requiring treatment with antimicrobial therapy \[participants will be required to complete antibiotics 1 week prior to starting background anticancer treatment\] or diagnosed or suspected viral infection). For the amivantamab SC expansion cohort, this includes active localized serious infections; active bleeding diathesis; impaired oxygenation requiring continuous oxygen supplementation; refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of background anticancer treatment or doxycycline/minocycline; psychiatric illness, social situation, or any other circumstances that would limit compliance with study requirements; any ophthalmologic condition that is clinically unstable; pre-existing skin condition that would prevent adequate evaluations of dermatologic toxicity, as determined by the investigator * Medical history of interstitial lung disease (ILD), including drug-induced ILD or radiation pneumonitis * Known allergy, hypersensitivity, or intolerance to the excipients of amivantamab, lazertinib, or to tetracyclines, doxycycline, minocycline, timolol\*, ruxolitinib\*, zinc\*, corticosteroids\* or their excipients or to any component of the enhanced dermatologic management (\*for the amivantamab SC expansion cohort) * Participant has received any prior systemic treatment at any time for locally advanced stage III B/C or metastatic stage IV disease (adjuvant or neoadjuvant therapy for stage I, II or IIIA disease is allowed if last dose administered more than 12 months prior to the development of locally advanced or metastatic disease) * Participant has an active or past medical history of leptomeningeal disease * Sub-study: Participants who have received prior treatment for epidermal growth factor"
NCT02185443,"Stereotactic Body Radiation Therapy for the Treatment of Unresectable Liver Metastases in Patients With Colorectal Adenocarcinoma, Carcinoma of the Anal Canal and Gastrointestinal Neuroendocrine Tumors",,PHASE2,Brazil,"Instituto do Cancer do Estado de São Paulo, São Paulo, Brazil, [RECRUITING]",Liver Metastases | Colorectal Cancer | Anal Canal Cancer | Gastrointestinal Neuroendocrine Tumors,1,[1] SBRT (EXPERIMENTAL): No description,"* Karnofsky Performance Scale (KPS) equal or greater than 70 * 1 to 4 liver metastases with an individual maximum diameter of up to 5 cm * Lesions considered unresectable or patients considered unfit for surgery * Histology of the primary tumor: colorectal adenocarcinoma, carcinoma of the anal canal or gastrointestinal neuroendocrine tumors. * Absence of evidence of extra-hepatic disease or extra-hepatic disease to be treated with curative intent. * Minimum interval of 2 weeks between systemic chemotherapy and SBRT. * Adequate bone marrow function defined as: * absolute neutrophils count \> 1,800 cells / mm 3 * platelets \> 100,000 cells / mm 3 * hemoglobin \> 8.0 g / dl ( transfusion or other intervention accepted)","* Concomitant chemotherapy * Prior radiotherapy to the upper abdomen * Pregnancy * Underlying Cirrhosis * Active hepatitis or clinically significant liver failure * Prior invasive neoplasm except for non-melanoma skin cancer, or unless more than five years without evidence of disease * Severe Comorbidity * Current anticoagulant treatment"
NCT05862285,"An Open-Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Study",UmbrellaMAX,PHASE3,"Costa Rica, Mexico","Clinica CIMCA, San José, Costa Rica, [ACTIVE_NOT_RECRUITING] | ICIMED Instituto de Investigación en Ciencias Médicas, San José, Costa Rica, [ACTIVE_NOT_RECRUITING] | Centro Medico Culiacan SA de CV, Culiacán, Mexico, [ACTIVE_NOT_RECRUITING] | Medical Care & Research, Mérida, Mexico, [RECRUITING] | Consultorio de Especialidad en Urologia Privado, Durango, Mexico, [ACTIVE_NOT_RECRUITING]",Cancer,2,"[1] Roche IMP(s) Monotherapy (EXPERIMENTAL): Participants will continue to receive Roche IMP(s) monotherapy as per parent protocol, until disease progression, loss of clinical benefit as judged by the investigator, death, withdrawal of study ... || [2] Roche Combined Agents (EXPERIMENTAL): Participants will continue to receive Roche IMP(s) in combination with other agent(s) as per parent protocol, until disease progression, loss of clinical benefit as judged by the investigator, deat...","* Eligible for continuing Roche IMP-based therapy at the time of roll-over from the parent study, as per the parent study protocol OR * Eligible for continuing the comparator agent(s) in a Genentech- or Roche-sponsored study as per the parent study protocol, with no access to commercially available comparator agent * First dose of study treatment in this extension study will be received within 7 days of the treatment interruption window allowed by the parent study * Continue to benefit from the Roche IMP-based therapy or comparator at the time of roll-over from the parent study as assessed by the investigator * Ability to comply with the extension study protocol, per Investigator's judgement",* Meet any of the study treatment discontinuation criteria specified in the parent study at the time of enrollment in this extension study * Study treatment or comparator agent is commercially marketed in the participant's country for the participant-specific disease and is accessible to the participant * Treatment with any anti-cancer treatment (other than treatment permitted in the parent study) during the time between last treatment in the parent study and the first dose of study treatment in this extension study * Permanent discontinuation of all study treatment(s) or comparator agent(s) for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in this extension study (if applicable) * Ongoing SAE(s) that has not resolved to baseline level or Grade ≤1 from the parent study or during the time between the last treatment in the parent study and the first dose of study treatment in this extension study * Concurrent participation in any therapeutic clinical trial (other than the parent study)
NCT06459180,"A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)",,PHASE3,"Argentina, Brazil, Chile, Colombia, Puerto Rico","Hospital Británico de Buenos Aires-Oncology ( Site 0102), Ciudad Autónoma de Buenos Aires, Argentina, [RECRUITING] | Instituto de Investigaciones Clínicas Mar del Plata ( Site 0107), Mar del Plata, Argentina, [RECRUITING] | Instituto de Oncología Angel H. Roffo ( Site 0103), Buenos Aires, Argentina, [RECRUITING] | Instituto Alexander Fleming ( Site 0108), Buenos Aires, Argentina, [RECRUITING] | Sanatorio Allende - Cerro-Oncology ( Site 0106), Córdoba, Argentina, [RECRUITING] | Hospital Aleman-Oncology ( Site 0100), Buenos Aires, Argentina, [RECRUITING] | Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0109), CABA, Argentina, [RECRUITING] | Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0104), La Rioja, Argentina, [RECRUITING] | Instituto do Câncer e Transplante de Curitiba ( Site 0205), Curitiba, Brazil, [RECRUITING] | Hospital Moinhos de Vento-Centro de Pesquisa Clínica ( Site 0204), Porto Alegre, Brazil, [RECRUITING]",Cervical Cancer,2,"[1] Sacituzumab Tirumotecan (EXPERIMENTAL): Participants will receive 4 mg/kg of sacituzumab tirumotecan once every 2 weeks (Q2W) via intravenous (IV) infusion until progressive disease or discontinuation. || [2] Treatment of Physician's Choice (TPC) (ACTIVE_COMPARATOR): At the physician's discretion, participants will receive 500 mg/m\^2 of pemetrexed on day 1 of every 3-week cycle via IV infusion OR 2 mg/kg of tisotumab vedotin on day 1 of every 3-week cycle via ...","* Has histologically-confirmed diagnosis of squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix * Must have recurrent or metastatic cervical cancer that has progressed on or after treatment with 1 prior line of systemic platinum doublet chemotherapy (with or without bevacizumab) AND must have received anti-PD-1/anti-PD-L1 therapy as part of prior cervical cancer regimens * Has measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, as assessed by the investigator. Lesions situated in a previously irradiated area are considered measurable if progression has been shown in such lesions * Is assigned female sex at birth, at least 18 years of age at the time of providing the informed consent * Has ECOG performance status of 0 or 1 within 7 days before allocation for the Sacituzumab Tirumotecan Run-in or within 7 days before randomization for the Phase 3 portion * Has provided tumor tissue (most recent sample is preferred) from a core or excisional biopsy of a tumor lesion not previously irradiated * HIV-infected participants must have well controlled human immunodeficiency virus (HIV) on antiretroviral therapy (ART) * Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to allocation (Sacituzumab Tirumotecan Run-in) or randomization (Phase 3 portion) * Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening * Has adequate organ function","* Has Grade ≥2 peripheral neuropathy * Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing * Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea) * Has uncontrolled, significant cardiovascular disease or cerebrovascular disease. * Received prior systemic anticancer therapy * Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids * Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed * Has histological subtypes of cervical cancer other than squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma (eg, carcinosarcoma) or nonepithelial cancer (eg, sarcoma, neuroendocrine tumors) * Known additional malignancy that is progressing or has required active treatment within the past 3 years * Known active central nervous system (CNS) metastases and/or carcinomatous meningitis * Active infection requiring systemic therapy * HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Concurrent active Hepatitis B and active Hepatitis C virus infection * Severe hypersensitivity (≥Grade 3) to sacituzumab tirumotecan or treatment of physician's choice (TPC) and/or any of their excipients, or other biologic therapy * Participants who have not adequately recovered from major surgery or have ongoing surgical complications * Has a history of (noninfectious) pneumonitis/ILD that required steroids or has current pneumonitis/ILD"
NCT06953193,Intraoperative Hypotension in Pancreatoduodenectomy: A Randomized Trial of General Versus Combined Anesthesia,,NA,Mexico,"Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, [RECRUITING]",Pancreatic Neoplasms | Hypotension | Pancreatoduodenectomy,2,"[1] General Anesthesia (ACTIVE_COMPARATOR): Patients will receive general anesthesia for pancreatoduodenectomy. Standardized anesthetic technique will be used with induction and maintenance based on institutional protocols, including intrave... || [2] Combined General Anesthesia (Thoracic Epidural) (EXPERIMENTAL): Patients will receive combined general anesthesia (thoracic epidural) for pancreatoduodenectomy. Standardized general anesthesia will be administered as in the general anesthesia group, with the ad...","* Signed written informed consent. * Patients scheduled for elective pancreatoduodenectomy at National Institute of Medical Sciences and Nutrition Salvador Zubirán. * No contraindications for neuroaxial anesthesia (epidural catheter placement), including: * Generalized or localized infection at the puncture site. * Thrombocytopenia. * Coagulation disorders. * Intracranial hypertension. * Patient refusal.","* Age under 18 years. * Pregnancy. * Inability to randomize the case due to specific circumstances (such as contraindications to epidural use), resulting in non-eligibility based on participation criteria."
NCT03646955,The DBCG RT Natural Trial: Partial Breast Versus no Irradiation for Women >=60 Years Operated With Breast Conservation for an Early Breast Cancer: a Clinically Controlled Randomized Phase III Trial,,NA,Chile,"Ponticia Universidad Catolica de Chile, Santiago, Chile, [RECRUITING]",Local Neoplasm Recurrence | Distantly Metastatic Malignant Neoplasm | Death | Fibrosis Breast | Depigmentation/Hyperpigmentation of Skin,2,"[1] Partial breast irradiation (ACTIVE_COMPARATOR): External beam irradiation 40 Gy / 15 fractions, 5 fractions per week, 3 weeks || [2] No partial breast irradiation (NO_INTERVENTION): No radiation therapy",Female patient \>=60 years Primary tumour characteristics by conventional histopathology * unilateral and unifocal non-lobular histology grade 1-2 * maximum microscopic size \<=20mm * node negative determined by sentinel node or axillary lymph node dissection * estrogen receptor \>=10% positive * HER2 negative (by IHC and/or in situ hybridization) * resection margin \>=2 mm for invasive carcinoma and any ductal carcinoma in situ associated with the cancer Surgical type is breast conservation Performance status ECOG 0-2 No evidence of distant metastasis,"* multifocal or multicentric invasive carcinoma or ductal carcinoma in situ * evidence of clinical or pathological T4 breast cancer * grade 3 malignancy * previous breast cancer or DCIS irrespective of disease-free interval * previous radiation therapy to the breast or thorax, * previous neoplasm within 5 years except carcinoma in situ of the cervix, endometrium or coli, melanoma in situ. * comorbidity precluding the patient from radiation therapy (e.g. cardiovascular or pulmonary disease, scleroderma, systemic lupus erythematosus). * mental/psychiatric disorder which precludes the patient from understanding the randomization and the follow up. * documented hereditary breast cancer or with high genetic risk of breast cancer * life expectancy \<10 years"
NCT06562543,A Single Arm Phase 4 Trial to Evaluate the Safety and Efficacy of Oral Fruquintinib in the Treatment of Refractory Metastatic Colorectal Cancer in Patients From Minority Populations Underrepresented in Prior Fruquintinib Studies,,PHASE4,Puerto Rico,"Fundacion de Investigacion de Diego (FDI Clinical Research), San Juan, Puerto Rico, [RECRUITING]",Colorectal Cancer,1,"[1] Fruquintinib 5 mg (EXPERIMENTAL): Participants will receive fruquintinib capsule at a dose of 5 mg, orally (PO), once daily (QD), for the first 21 days of each 28-day treatment cycle until progressive disease (PD), unacceptable tox...","1. Provide written (or electronic) informed consent. 2. Male or female aged more than or equal to (≥)18 years. 3. Presence of histologically and/or cytologically documented metastatic colorectal adenocarcinoma. Rat sarcoma virus (RAS) status for each participant must be documented. 4. Have been previously treated with standard approved therapies: * Fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, * An anti-vascular endothelial growth factor (VEGF) biological therapy (e.g., bevacizumab, aflibercept, ramucirumab \[regorafenib is NOT an anti-VEGF biologic\]), and * If RAS wild-type and medically appropriate, an anti-epidermal growth factor receptor (EGFR) therapy (e.g., cetuximab, panitumumab). * If known microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) tumor and medically appropriate, a programmed cell death protein 1 (PD1) inhibitor. 5. Self-identify as Black and/or African American or Hispanic and/or Latino or as both. 6. Body weight ≥40 kilograms (kg). 7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at screening. 8. Have assessable disease according to RECIST version 1.1, assessed locally. 9. In participants of childbearing potential, agreement to use highly effective form(s) of contraception, which results in a low failure rate (less than \[\<\]1 percent \[%\] per year) when used consistently and correctly, starting during the screening period, continuing throughout the entire trial period, and for 2 weeks after taking the last dose of the trial intervention. Such methods include oral (PO) hormonal contraception (combined estrogen/progestogen or progestogen-only) associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system (IUS), bilateral tubal ligation, vasectomized partner, or true sexual abstinence in line with the preferred and usual lifestyle of the participant. Those assigned male sex at birth must always use a condom.","1. Absolute neutrophil count (ANC) \<1.5 times 10\^9 per liter (10\^9/L), platelet count \<100 times 10\^9/L, or hemoglobin \<9.0 grams per deciliter (g/dL). Blood transfusion within 1 week prior to enrollment for the purpose of increasing the likelihood of eligibility is not allowed. 2. Serum total bilirubin more than (\>)1.5 times the upper limit of normal range (ULN). Participants with previously documented Gilbert syndrome and bilirubin \<2 times ULN are eligible. 3. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2.5 times ULN in participants without hepatic metastases; ALT or AST \>5 times ULN in participants with hepatic metastases. 4. Creatinine clearance \<30 milliliters per minute (mL/min). Creatinine clearance can either be measured in a 24-hour urine collection or estimated by the Cockcroft-Gault equation. Where available and appropriate, other formulae may be used to estimate clearance after consultation with the trial medical monitor. 5. Urine dipstick or urinalysis with protein ≥2 positive or 24-hour urine protein ≥1.0 gram per 24 hours (g/24 hours). Participants with 1+ positive proteinuria must undergo a 24-hour urine collection to assess urine protein level. 6. Uncontrolled hypertension, defined as systolic BP ≥140 millimeter of mercury (mmHg) and/or diastolic blood pressure (BP) ≥90 mmHg despite optimal medical management. The participant must have BP below both limits. Repeated assessments are permitted. 7. International normalized ratio (INR) \>1.5 times ULN or activated partial thromboplastin time (aPTT) \>1.5 times ULN, unless the participant is currently receiving or intended to receive anticoagulants for prophylactic purposes. 8. History of or active gastric/duodenal ulcer or ulcerative colitis, active hemorrhage of an unresected gastrointestinal tumor, history of perforation or fistulas, or any other condition that could, in the investigator's judgment, result in gastrointestinal hemorrhage or perforation within the 6 m"
NCT06070376,Comparative Study Between Fully Covered Esophageal Prosthesis (FC-SEMS) and Partially Covered Esophageal Prosthesis (PC-SEMS) in the Palliation of Dysphagia Due to Malignant Neoplasm of Esophagus.,,NA,Brazil,"Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil, [RECRUITING]",Esophageal Neoplasms | Dysphagia,2,[1] Group A (ACTIVE_COMPARATOR): placement of the esophageal prostheses fully covered in the palliative treatment of malignant esophageal obstructions. || [2] Group B (ACTIVE_COMPARATOR): placement of the partially covered esophageal prostheses in the palliative treatment of malignant esophageal obstructions.,"* Patients with advanced malignant neoplasm of the esophagus, whether or not undergoing chemotherapy or radiotherapy; * Dysphagia score greater than 2 or presence of malignant esophagorespiratory fistula; * Indication of palliation of dysphagia through the placement of esophageal prostheses in a multidisciplinary meeting.",* Patients under 18 years; * Extraesophageal neoplasms; * Lesions with longitudinal extension less than 30 mm; * Previous treatment with esophageal prosthesis; * Tumors easily transposed to standard endoscope (9.8mm).
NCT06062420,"A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck",,PHASE2,"Argentina, Brazil","GSK Investigational Site, Buenos Aires, Argentina, [RECRUITING] | GSK Investigational Site, Capital Federal, Argentina, [RECRUITING] | GSK Investigational Site, Capital Federal, Argentina, [RECRUITING] | GSK Investigational Site, Ciudad Autonoma de Bueno, Argentina, [RECRUITING] | GSK Investigational Site, Córdoba, Argentina, [RECRUITING] | GSK Investigational Site, Florida, Argentina, [RECRUITING] | GSK Investigational Site, Mendoza, Argentina, [RECRUITING] | GSK Investigational Site, San Juan, Argentina, [RECRUITING] | GSK Investigational Site, Santa Fe, Argentina, [RECRUITING] | GSK Investigational Site, Santo André, Brazil, [RECRUITING]","Neoplasms, Head and Neck",5,[1] Dostarlimab Monotherapy (EXPERIMENTAL): No description || [2] Sub study 1: Dostarlimab and Belrestotug (EXPERIMENTAL): No description || [3] Sub study 2: Dostarlimab and nelistotug (EXPERIMENTAL): No description || [4] Sub study 3: Dosarlimab and Belrestotug and nelistotug (EXPERIMENTAL): No description || [5] Sub study 4: Dostarlimab and GSK4381562 (EXPERIMENTAL): No description,"* Have histologically or cytologically-confirmed HNSCC that is R/M and is considered incurable by local therapies. A) Subjects must not have had prior systemic therapy administered in the R/M setting. Chemoradiation therapy which was completed more than 4 months prior to signing consent if given as part of multimodal treatment for locally advanced disease is allowed B) The eligible primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx C) Subjects may not have a primary tumor site of nasopharynx (any histology) * Has measurable (target) disease based on RECIST 1.1 as determined by the investigator. * Has an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 * Provides a tumor tissue sample obtained at the time of or after the initial diagnosis of R/M HNSCC. A fresh tumor tissue sample obtained within 90 days of screening is highly preferred, If fresh biopsy is not possible, an archival tumor specimen is acceptable unless it was obtained prior to administration of chemoradiation for the treatment of a participant's tumour. Needle or excisional biopsies or resected tissue is required. Cytological specimens such as fine needle aspirates, bone marrow samples, or cell blocks are not acceptable. Bone specimen is not acceptable. * Has tumor Programmed death ligand 1 (PD-L1) expression * If the primary tumor site is oropharyngeal carcinoma, the participant must have Human papillomavirus (HPV) results","* Has received prior therapy with any immune checkpoint inhibitors, including antibodies or drugs targeting Programmed death protein 1 (PD-1), PD-L1, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine based inhibitory motif domains (TIGIT), Cluster of differentiation (CD) 96, or other immune checkpoint pathways. * Participants with previous malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, esophageal, colon, endometrial, cervical/dysplasia, melanoma, or breast) unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period. * Have active tumor bleeding or a high risk of bleeding (examples include but are not limited to radiographic evidence of major blood vessel invasion/infiltration or tumor demonstrates \>90 degree abutment or encasement of a major vessel \[carotid, jugular, bronchial artery\] and/or exhibits other high-risk features such as arteriovenous fistula). * Has PD within 4 months of completion of curatively intended treatment for locoregionally advanced HNSCC * Participants with any carcinomatous meningitis or leptomeningeal spread and those with uncontrolled or symptomatic Central Nervous System (CNS) metastases * Active autoimmune disease that has required systemic disease-modifying or immunosuppressive treatment within the last 2 years. (Stable, medically managed autoimmune endocrinopathies are acceptable if participant otherwise meets entry criteria.)"
NCT06577025,"A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination With Daratumumab SC (Tal-D) and Teclistamab SC in Combination With Daratumumab SC (Tec-D) Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants With Standard-risk Newly Diagnosed Multiple Myeloma",aMMbition,PHASE2,Brazil,"Instituto D Or de Pesquisa e Ensino, Salvador, Brazil, [RECRUITING] | Fundacao Antonio Prudente A C Camargo Cancer Center, São Paulo, Brazil, [RECRUITING] | Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein, São Paulo, Brazil, [RECRUITING]",Multiple Myeloma,2,[1] Cohort A: DVRd Induction + Tal-D Consolidation + Cilta-cel (EXPERIMENTAL): Participants will undergo apheresis followed by 4 cycles of DVRd induction (each cycle is of 28 days) and cilta-cel will be generated from the participants' T-cells selected from the apheresis prod... || [2] Cohort B: DVRd Induction + Cilta-cel + Tal-D and Tec-D Consolidation (EXPERIMENTAL): Participants will undergo apheresis followed by 4 cycles of DVRd induction and Cilta-cel will be generated from the participants' T-cells selected from the apheresis product. Upon completion of cil...,"* Participants with documented new diagnosis of multiple myeloma (MM) according to international myeloma working group (IMWG) diagnostic criteria and with no prior myeloma-directed therapy * Participants must have standard-risk MM (stage I and II) based on revised International Staging System (R-ISS) * Participants must be considered fit (score equals to \[=\] 0) or intermediate-fit (score=1) according to IMWG Frailty Index assessment (based on the Charlson Comorbidity Index, the Katz Activity of Daily Living and the Lawson Instrumental Activities of Daily Living) * Measurable disease defined as: Serum monoclonal paraprotein (M-protein) level greater than or equal to (\>=) 1.0 gram per deciliter (g/dL) (\>=10 gram per liter \[g/L\] for institutions using alternative units) or urine M-protein level \>= 200 milligrams per 24 hours (mg/24 hours); Light chain MM without measurable disease in the serum or the urine: Serum immunoglobulin free light chain \>=10 milligrams per deciliter (mg/dL) (\>=100 mg/L for institutions using alternative units) and abnormal serum immunoglobulin kappa lambda free light chain ratio * Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1","* Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM). Any history of malignancy, other than MM, which is considered at high risk of recurrence requiring systemic therapy * Peripheral neuropathy or neuropathic pain of Grade \>= 2, as defined by National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 * Known active or prior history of central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM * Stroke or seizure within 6 months of signing the informed consent form (ICF) * Plasma cell leukemia at the time of diagnosis or any time thereafter through apheresis (\>= 5 percent \[%\] circulating plasma cells in peripheral blood smears), Waldenstrom macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes(POEMS) syndrome, or primary amyloid light chain amyloidosis with associated organ dysfunction * Presence of high-risk disease features: (a) Cytogenetic high risk lesions by MM fluorescence in situ hybridization (FISH) including deletion 17p (del\[17p\])/, t(4;14), t(14;16), amplification 1q (amp\[1q21\]) (\>= 4 copies); (b) Presence of 1 or more extramedullary plasmacytomas * Seropositive for human immunodeficiency virus (HIV)"
NCT06875310,"A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)",,PHASE3,"Argentina, Brazil, Chile, Colombia, Mexico","Instituto Alexander Fleming, Ciudad Autónoma de Buenos Aires, Argentina, [RECRUITING] | IDIM - Instituto de Investigaciones Metabólicas, Ciudad de Buenos Aires, Argentina, [RECRUITING] | Local Institution - 0584, Pilar, Argentina, [NOT_YET_RECRUITING] | Hospital Italiano de Buenos Aires, ABB, Argentina, [RECRUITING] | Local Institution - 0571, Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Clinica Adventista Belgrano, CABA, Argentina, [RECRUITING] | Sanatorio Plaza, Rosario, Argentina, [RECRUITING] | Local Institution - 0242, Vitória, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0257, Salvador, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0244, Belo Horizonte, Brazil, [NOT_YET_RECRUITING]","Carcinoma, Non-Small-Cell Lung",2,[1] Adagrasib (EXPERIMENTAL): No description || [2] Placebo (PLACEBO_COMPARATOR): No description,"* Histologically or cytologically confirmed diagnosis of non-squamous NSCLC with evidence of KRAS G12C mutation via tumor sample and/or circulating tumor deoxyribonucleic acid (ctDNA). * Locally advanced or metastatic disease. * Measurable disease via computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1 criteria of at least 1 lesion. * No prior systemic anti-cancer therapy given for advanced or metastatic disease. * Not a candidate for definitive therapy (eg, chemoradiation or complete surgical resection). * Participants with brain metastases are eligible for enrollment, including those with untreated brain metastases. Brain metastases must be asymptomatic and not in need of immediate local therapy. Any untreated brain metastases must be ≤ 20 mm in diameter. * Any PD-L1 expression (0 to 100%) as determined by VENTANA PD-L1 (SP263) assay, Agilent PD-L1 IHC 22C3 pharmDx, or Agilent PD-L1 IHC 28-8 pharmDx.","* Participants with an active autoimmune or inflammatory disease requiring systemic treatment within 2 years. * Uncontrolled or significant cardiovascular conditions within 6 months prior to enrollment that are ongoing or with risk of recurrence. * Inadequate bone marrow or liver function or electrocardiogram (ECG) abnormalities. * Ongoing treatment with concomitant medication known to cause prolonged QTc interval and that cannot be switched to alternative treatment prior to study entry. * Treatment targeting KRAS G12C mutation (eg, sotorasib, adagrasib) in any setting. * Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration. * Other protocol-defined Inclusion/Exclusion criteria apply."
NCT06077760,"A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (INTerpath-002)",INTerpath-002,PHASE3,"Argentina, Brazil, Chile, Costa Rica, Mexico","Clinica Adventista Belgrano-Oncology ( Site 2901), Caba., Argentina, [RECRUITING] | Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 2912), Ciudad Autonoma de Buenos Aires, Argentina, [RECRUITING] | Instituto Alexander Fleming ( Site 2911), Ciudad Autónoma de Buenos Aires, Argentina, [RECRUITING] | Instituto de Investigaciones Clínicas Mar del Plata ( Site 2908), Mar del Plata, Argentina, [RECRUITING] | Fundacion Estudios Clinicos-Oncology ( Site 2907), Rosario, Argentina, [RECRUITING] | Sanatorio Parque ( Site 2904), Rosario, Argentina, [RECRUITING] | CRIO - CENTRO REGIONAL INTEGRADO DE ONCOLOGIA-Pesquisa Clínica ( Site 3007), Fortaleza, Brazil, [RECRUITING] | Liga Norte Riograndense Contra o Câncer ( Site 3001), Natal, Brazil, [RECRUITING] | Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 3003), Porto Alegre, Brazil, [RECRUITING] | Hospital Nossa Senhora da Conceição ( Site 3002), Porto Alegre, Brazil, [RECRUITING]",Non-small Cell Lung Cancer,2,[1] Intismeran autogene + Pembrolizumab (EXPERIMENTAL): Participants will receive 1 mg of intismeran autogene via intramuscular (IM) injection once every 3 weeks for 9 doses PLUS 400 mg of pembrolizumab via intravenous (IV) infusion once every 6 weeks f... || [2] Placebo + Pembrolizumab (ACTIVE_COMPARATOR): Participants will receive intismeran autogene-matched placebo via IM injection once every 3 weeks for 9 doses PLUS 400 mg of pembrolizumab via IV infusion once every 6 weeks for up to 9 doses until...,"The main inclusion criteria include but are not limited to the following: * Has undergone margin negative, completely resected non-small cell lung cancer (NSCLC), and has pathological Stage II, IIIA, IIIB (N2) squamous or nonsquamous tumor, node, metastasis (TNM) staging per American Joint Committee on Cancer (AJCC) Eighth Edition guidelines. * Has no evidence of disease before randomization. * Has received at least one dose of adjuvant treatment with standard of care platinum doublet chemotherapy. * No more than 24 weeks have elapsed between surgical resection of curative intent and the first dose of pembrolizumab. * Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization. * Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening. * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART).","The main exclusion criteria include but are not limited to the following: * Diagnosis of small cell lung cancer (SCLC) or, for mixed tumors, presence of small cell elements, or has a neuroendocrine tumor with large cell components or a sarcomatoid carcinoma. * HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease. * Received prior neoadjuvant therapy for their current NSCLC diagnosis. * Received or is a candidate to receive radiotherapy for their current NSCLC diagnosis. * Received prior therapy with an anti-programmed cell death 1 protein (PD-1), anti-PD-ligand 1 (L1), or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor. * Received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization. * Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed. * Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration. * Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication. * Known additional malignancy that is progressing or has required active treatment within the past 5 years. * Active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed. * History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease. * Active infection requiring systemic therapy."
NCT03571568,"Phase 1/2a Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab",,"PHASE1, PHASE2",Brazil,"Hospital São Rafael, Salvador, Brazil, [RECRUITING] | Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, [RECRUITING] | Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer, Curitiba, Brazil, [NOT_YET_RECRUITING] | Ruschel Medicina e Pesquisa Clínica, Rio de Janeiro, Brazil, [NOT_YET_RECRUITING] | A.C. Camargo Cancer Center, São Paulo, Brazil, [RECRUITING] | Hospital Amaral Carvalho, São Paulo, Brazil, [NOT_YET_RECRUITING] | Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, [NOT_YET_RECRUITING] | Hospital Israelita Albert Einstein, São Paulo, Brazil, [RECRUITING] | Hospital Samaritano, São Paulo, Brazil, [NOT_YET_RECRUITING] | Hospital Sírio-Libanês, São Paulo, Brazil, [NOT_YET_RECRUITING]",Indolent B-Cell Non-Hodgkin Lymphoma,5,"[1] BI-1206 IV Dose Escalation (EXPERIMENTAL): Standard 3+3 Dose-Escalation of BI-1206 IV in combination with Rituximab || [2] BI-1206 SC Dose Escalation (EXPERIMENTAL): Adaptive Dose Escalation of BI-1206 SC (Bayesian logistic regression model (BLRM) in combination with Rituximab || [3] Phase 2a IV Dose expansion (EXPERIMENTAL): BI-1206 IV in Combination with Rituximab || [4] Phase 2a SC Signal seeking (EXPERIMENTAL): SC Arm, BI-1206 in Combination with Rituximab and Acalabrutinib || [5] Phase 2a IV Signal Seeking (EXPERIMENTAL): IV Arm, BI-1206 in Combination with Rituximab and Acalabrutinib","1. Are ≥ 18 years of age by initiation of study treatment. 2. Have B-cell NHL proven by histology, with histological subtypes limited to follicular lymphoma (FL) (except FL grade 3B), MCL and marginal zone lymphoma (MZL) 3. Have measurable nodal disease 4. Are willing to undergo lymph node biopsies or biopsies of other involved tissue 5. Have relapsed disease or disease refractory to conventional treatment or for which no standard therapy exists 6. Have received at least one line of conventional previous therapy which must include at least one rituximab-based regimen 7. Have a life expectancy of at least 12 weeks 8. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 9. Have CD20+ malignancy 10. Have hematological and biochemical indices within prespecified ranges","1. Have had an allogenic bone marrow or stem cell transplant within 12 months 2. Have presence of active chronic graft versus host disease 3. Have current leptomeningeal lymphoma or compromise of the central nervous system 4. Have transformed lymphoma from a pre-existing indolent lymphoma 5. Have Waldenstrom's Macroglobulinemia or FL grade 3B, 6. Need systemic doses of prednisolone \>10 mg daily (or equipotent doses of other corticosteroids) while on the study trial other than as pre-medication. 7. Have known or suspected hypersensitivity to rituximab or BI-1206 8. Have cardiac or renal amyloid light-chain amyloidosis 9. Have received any of the following: 1. Chemotherapy or small molecule products with 2 weeks of first dose of BI-1206 2. Radiotherapy (except for focal symptomatic control of lymphadenopathy) within 4 weeks 3. Immunotherapy within 8 weeks 4. Previous lines of treatment containing BTK inhibitors for Subjects receiving BI-1206 in combination with rituximab and acalabrutinib 10. Have ongoing toxic manifestations of previous treatments. 11. Have the ability to become pregnant (or already pregnant or lactating/breastfeeding). 12. Have had major surgery from which the subject has not yet recovered. 13. Are at high medical risk because of non-malignant systemic disease including active infection on treatment with antibiotics, antifungals or antivirals. 14. Are serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV). 15. Have an active, known or suspected autoimmune disease. 16. Have concurrent congestive heart failure, prior history of class III/ IV cardiac disease (New York Heart Association \[NYHA\]) 17. Have current malignancies of other types"
NCT03678025,Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer,,PHASE3,"Chile, Colombia, Mexico","Instituto Nacional del Cancer, Independence, Chile, [RECRUITING] | Instituto Nacional De Cancerologia, Bogotá, Colombia, [RECRUITING] | Instituto Nacional De Cancerologia de Mexico, Mexico City, Mexico, [RECRUITING]",Castration Levels of Testosterone | Metastatic Prostatic Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8,3,"[1] Arm I (SST) (ACTIVE_COMPARATOR): Participants receive 1 acceptable form of SST as in Induction except for treatment with docetaxel and prednisone. || [2] Arm II (SST, prostatectomy or radiation therapy) (EXPERIMENTAL): Participants receive 1 acceptable form of SST as in Induction except for treatment with docetaxel and prednisone. Participants undergo prostatectomy within 8 weeks after randomization or radiation ... || [3] Step 1 (pre-randomization) (ACTIVE_COMPARATOR): Standard treatment data collection prior to randomization","* STEP 1 REGISTRATION: DISEASE-RELATED CRITERIA: All patients must have a histologically or cytologically proven diagnosis of adenocarcinoma of the prostate. Patients with pure small cell carcinoma\* (SCC), sarcomatoid, or squamous cell carcinoma are not eligible. (\*morphology must be consistent with SCC; synaptophysin or chromogranin positive by immunohistochemical staining is insufficient to diagnose SCC). * STEP 1 REGISTRATION: DISEASE-RELATED CRITERIA: Patients must have an intact prostate. No prior local therapy for prostate adenocarcinoma is allowed (e.g., brachytherapy, high-intensity focused ultrasound \[HIFU\], cryotherapy, laser ablative therapies). Any prior therapy for benign conditions, such as obstruction, are acceptable (e.g., transurethral resection of the prostate, greenlight laser ablation, microwave ablation). * STEP 1 REGISTRATION: DISEASE-RELATED CRITERIA: Patients must have evidence of metastatic disease on technetium bone scan and computed tomography (CT) or magnetic resonance imaging (MRI) within 42 days prior to starting standard systemic therapy. Metastatic disease that is detected by positron emission tomography (PET) scan only (sodium fluoride \[NaF\], prostate-specific membrane antigen \[PSMA\], anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid \[FACBC\], carbon \[C\]11) but not conventional imaging (technetium \[Tc\]99 bone scan, CT or MRI) or solitary metastases by conventional imaging, must be confirmed histologically or cytologically. * STEP 1 REGISTRATION: DISEASE-RELATED CRITERIA: Patients with known brain metastases are not eligible. Brain imaging studies are not required for eligibility if the patient has no neurologic signs or symptoms suggestive of brain metastasis. If brain imaging studies are performed, they must be negative for disease. * STEP 1 REGISTRATION: PRIOR/CONCURRENT THERAPY CRITERIA: Patients must have received no more than 28 weeks of standard systemic therapy (SST). SST is defined as current National Compre",
NCT06764485,"A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge",rechARge,PHASE3,"Argentina, Brazil, Chile, Puerto Rico","Hospital Británico de Buenos Aires, CABA, Argentina, [RECRUITING] | Instituto Alexander Fleming, Ciudad Autónoma de Buenos Aires, Argentina, [RECRUITING] | Hospital Italiano de Buenos Aires, ABB, Argentina, [RECRUITING] | Hospital Italiano de Córdoba, Córdoba, Argentina, [RECRUITING] | Local Institution - 0130, Río Cuarto, Argentina, [NOT_YET_RECRUITING] | Clinica Viedma S. A, Viedma, Argentina, [RECRUITING] | Asociación de Beneficencia Hospital Sirio Libanés, Buenos Aires, Argentina, [RECRUITING] | Local Institution - 0430, Córdoba, Argentina, [NOT_YET_RECRUITING] | Local Institution - 0039, Vitória, Brazil, [NOT_YET_RECRUITING] | Local Institution - 0025, Belo Horizonte, Brazil, [NOT_YET_RECRUITING]",Metastatic Castration-resistant Prostate Cancer,7,[1] Part 1: Dose 1 (EXPERIMENTAL): No description || [2] Part 1: Dose 2 (EXPERIMENTAL): No description || [3] Part 1: Comparator 1 (ACTIVE_COMPARATOR): Enzalutamide or Abiraterone Acetate + Prednisone/Prednisolone || [4] Part 1: Comparator 2 (ACTIVE_COMPARATOR): No description || [5] Part 2: Dose Selected (EXPERIMENTAL): No description || [6] Part 2: Comparator 1 (ACTIVE_COMPARATOR): Enzalutamide or Abiraterone Acetate + Prednisone/Prednisolone || [7] Part 2: Comparator 2 (ACTIVE_COMPARATOR): No description,"* Participants must have histologic or cytologic confirmation of adenocarcinoma of the prostate without small cell or neuro-endocrine features. * Participants must have current evidence of metastatic disease documented by either bone lesions on radionuclide bone scan and/or soft tissue lesions on computed tomography/magnetic resonance imaging (CT/MRI). * Participants must be asymptomatic or mildly symptomatic from prostate cancer with score on Brief Pain Inventory - Short Form (BPI-SF) that must be \< 4. * Participants must have had previous treatment with an androgen receptor pathway inhibitor (abiraterone, enzalutamide, apalutamide, or darolutamide).",* Participants must not have impaired cardiac function or clinically significant cardiac disease. * Participants must not have any brain metastasis. * Participants must not have any liver metastasis. * Participants with superscan on technetium-99m (Tc-99m) radionuclide bone scans. * Other protocol-defined Inclusion/Exclusion criteria apply.
NCT06148077,"Effects of Manual Therapy on Oral Opening, Swallow Function, and Upper Quarter Mobility in Chilean Survivors of Head and Neck Cancer: A Study Protocol for a Controlled, Randomized Study (MATEO Study, MAnual ThErapy for Oral Opening).",MaTeO,NA,Chile,"Barbara Burgos Mansilla, Temuco, Chile, [RECRUITING] | Universidad de La Frontera, Temuco, Chile, [RECRUITING]",Head and Neck Cancer | Trismus | Dysfunction,2,"[1] Manual Therapy (EXPERIMENTAL): Manual Therapy-based intervention: the session will be performed with the patient in a supine position. If they cannot reach this position, it can be done with the patient sitting in a chair to rec... || [2] Motor Control (ACTIVE_COMPARATOR): Motor control (exercise): the session will focus on strengthening and stretching exercises for the cervical, masticatory, and shoulder muscles .",* individuals with HNC * individuals over 18 years of age * individuals who have undergone oncological surgery of the head and neck and/or radiotherapy * having finished oncological medical treatment between 3 and 36 months before inclusion * having a medical diagnosis of trismus and/or TMD and/or cervical or shoulder dysfunction * Spanish native speakers,"* sequelae of previous stroke * structural instability and/or osteoporosis of the cervical spine, spondylosis, cervical herniated discs * active osteoradionecrosis or open wounds (fistulas, soft tissue necrosis) in the anatomical treatment area * tracheostomized individuals * metastasis or active cancer * refuse to participate."
NCT06824168,"A Phase 2, Multicenter, Randomized, Open-label Trial to Evaluate Safety and Efficacy of Two Dose Levels of Quizartinib as Maintenance for Adult Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia in Complete Remission",,PHASE2,Brazil,"Hospital Erasto Gaertner - Liga Paranaense de Combate ao Cancer, Curitiba, Brazil, [NOT_YET_RECRUITING] | Cetus Hospital Dia Oncologia, Minas Gerai, Brazil, [NOT_YET_RECRUITING] | Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, [NOT_YET_RECRUITING] | Irmandade da Santa Casa de Misericórdia de Porto Alegre Centro Multidisciplinar de Pesquisa, Porto Alegre, Brazil, [RECRUITING] | INCA - Instituto Nacional de Câncer, Rio de Janeiro, Brazil, [NOT_YET_RECRUITING] | ""Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto CIP - Centro Integrado de Pesquisa"", San Jose Rio Preto, Brazil, [NOT_YET_RECRUITING] | Hospital Santa Marcelina, São Paulo, Brazil, [NOT_YET_RECRUITING] | ICESP - Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira, São Paulo, Brazil, [NOT_YET_RECRUITING]",Acute Myeloid Leukemia | Leukemia,2,[1] Arm 1 (EXPERIMENTAL): Participants will receive higher dose of quizartinib || [2] Arm 2 (EXPERIMENTAL): Participants will receive lower dose of quizartinib,"1. Adults ≥18 years of age or the minimum legal adult age (whichever is greater) on the day of signing the ICF (no upper limit of age). 2. Newly diagnosed, morphologically documented primary AML or AML secondary to myelodysplastic syndrome or a myeloproliferative neoplasm based on the World Health Organization (WHO) 2008/2016 classification. 3. Participant has confirmed FLT3-ITD-positive (≥0.05 SR or ≥5% VAF) activating mutation from initial diagnosis in bone marrow or peripheral blood as determined by a local institution's validated molecular testing. 4. Participants must have confirmed, morphologically documented CR1, on the most recent BMA, based on the local laboratory results, performed within 28 days prior to C1D1 of maintenance therapy. Complete remission will be defined as \<5% blasts in the bone marrow with no morphologic characteristics of acute leukemia (e.g., Auer Rods), no evidence of extramedullary disease, and no leukemic blasts in the peripheral blood. Complete blood count recovery is required with absolute neutrophil count of more than 1.000 × 109/L and platelets more than 100 × 109/L (IWG criteria).27 5. Participant must meet the following prior therapy requirements: 1. Has received at least one cycle of induction therapy but no more than two to achieve CR1. The induction cycles can be the same regimen or different regimens and may contain conventional agents only (e.g., cytarabine + daunorubicin or idarubicin: ""7 + 3"" or ""5 + 2""), or a combination with FLT3 inhibitors. 2. Has not received more than four cycles of consolidation therapy. Regimens may contain conventional agents only. 3. FLT3 inhibitors are permitted as part of the induction or consolidation treatment. Participants who received FLT3 inhibitors before enrollment in the trial will need a washout period of 14 days. 6. Able to begin the maintenance phase within 60 days of D1 of the last consolidation cycle received. 7. Eastern Cooperative Oncology Group (ECOG) PS of 0 to 2. Key","1. Diagnosis of acute promyelocytic leukemia (APL), French-American-British classification M3 or WHO classification of APL with translocation, t(15;17)(q22;q12), or BCR-ABL positive leukemia (i.e., chronic myelogenous leukemia in blast crisis); participants who undergo diagnostic workup for APL and treatment with all-trans retinoic acid (ATRA), but who are found not to have APL, are eligible (treatment with ATRA must be discontinued before starting induction chemotherapy). 2. Diagnosis of AML secondary to prior chemotherapy or radiotherapy for other neoplasms. 3. Prior treatment for AML, except for the following allowances: 1. Induction and consolidation therapy, as previously described (inclusion criterion #5) 2. Leukapheresis 3. Hydroxyurea to treat hyperleukocytosis 4. Cranial radiotherapy for central nervous system (CNS) leukostasis 5. Prophylactic intrathecal chemotherapy 6. Growth factor/cytokine support 4. Participant had received allo-HSCT as part of AML treatment. 5. Treatment with any strong or moderate CYP3A inducers within 2 weeks or 5 half-lives of randomization whichever is longer 6. Uncontrolled or significant cardiovascular disease, including the following: 1. QTcF interval \>450 ms (based on average of triplicate ECG at Screening) 2. Diagnosed or suspected congenital long QT syndrome or known family history of congenital long QT syndrome 3. History of clinically relevant ventricular arrhythmias, such as ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes 4. Participant has bradycardia of less than 50 beats per minute (bpm; as determined by central reading), unless the participant has a pacemaker 5. History of second- or third-degree heart block. Candidates with a history of heart block may be eligible if they currently have pacemakers and have no history of fainting or clinically relevant arrhythmia with pacemakers. 6. Myocardial infarction within 6 months prior to screening 7. Uncontrolled angina pectoris within 6 months prior "
NCT06112613,Improving Medication Adherence in Metastatic Breast Cancer Using a Connected Customized Treatment Platform (CONCURxP),,NA,Puerto Rico,"Cancer Center-Metro Medical Center Bayamon, Bayamón, Puerto Rico, [RECRUITING] | Puerto Rico Hematology Oncology Group, Bayamón, Puerto Rico, [RECRUITING] | Doctors Cancer Center, Manatí, Puerto Rico, [RECRUITING] | San Juan Community Oncology Group, San Juan, Puerto Rico, [RECRUITING] | Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico, [RECRUITING] | PROncology, San Juan, Puerto Rico, [RECRUITING] | San Juan City Hospital, San Juan, Puerto Rico, [RECRUITING]",Anatomic Stage IV Breast Cancer AJCC v8 | Breast Carcinoma | HER2-Negative Breast Carcinoma | Hormone Receptor-Positive Breast Carcinoma,3,"[1] ARM A (Enhanced usual care) (EXPERIMENTAL): Patients use the WiseBag medication dispenser and receive access to educational materials every 4 weeks over 12 months. || [2] ARM B (CONCURxP program) (EXPERIMENTAL): Patients use the WiseBag medication dispenser and receive personalized text message reminders, medication tracking and healthcare provider follow ups as part of the CONCURxP platform over 12 months... || [3] ARM C (Non-patient interview) (EXPERIMENTAL): Participants complete an interview over 20-30 minutes 15-39 months post-first patient enrollment.","* NON-PATIENT: Participants must be an oncology healthcare provider (i.e., oncologist, advanced practice provider, or oncology nurse) * NON-PATIENT: Participants must have taken care of at least one patient randomized to Arm B (CONCURxP) who had less than 85% adherence rate at 12 months as measured by the WiseBag * NON-PATIENT: Participant must speak English * NON-PATIENT: Participant must be employed at an National Cancer Institute Community Oncology Research Program (NCORP) site for at least 6 months * NON-PATIENT: Participant must be able to provide informed consent to participate in this study * PATIENT STEP 0: Patient must be \>= 18 years of age * PATIENT STEP 0: Patient must be fluent in written and spoken English OR patient must be fluent in written and spoken Spanish * PATIENT STEP 0: Patient must present with new or established pathologically proven hormone receptor (HR)+ HER2- metastatic breast cancer at the time of Step 0 * PATIENT STEP 0: Patient must have initiated any of the CKD4/6 inhibitors (palbociclib or Ibrance, ribociclib or Kisqali, abemaciclib or Verzenio) within 30 days prior to consenting to Step 0 or have received a prescription order with stated intent to initiate within 30 days following Step 0 consent * NOTE: Patients who have been treated previously with anticancer treatments other than CDK4/6 inhibitors are eligible * NOTE: CDK4/6 inhibitors must be provided/supplied as a single agent blister pack. If the medication is supplied as capsules in a pill bottle (e.g., Ibrance capsules), patient is not eligible * NOTE: Ribociclib (Kisqali) and abemaciclib (Verzenio) are only available in blister packs. Palbociclib (Ibrance) is the only CDK4/6 inhibitor that might be available in a capsule formulation. However, this is an outdated formulation and is rarely prescribed as a new start. The format of ordered palbociclib can be determined based on the prescription order * PATIENT STEP 0: Patients must not have been previously treated with any of th","* NOTE: Ribociclib (Kisqali) and abemaciclib (Verzenio) are only available in blister packs. Palbociclib (Ibrance) is the only CDK4/6 inhibitor that might be available in a capsule formulation. However, this is an outdated formulation and is rarely prescribed as a new start. The format of ordered palbociclib can be determined based on the prescription order * PATIENT STEP 0: Patients must not have been previously treated with any of the following CDK4/6 inhibitors: Palbociclib or Ibrance, ribociclib or Kisqali, and abemaciclib or Verzenio * PATIENT STEP 0: Patients must not already be enrolled in a therapeutic clinical trial that monitors CDK4/6 inhibitors * PATIENT STEP 0: Patient must confirm that they intend to receive their care or monitoring at an NCORP site * PATIENT STEP 0: Patient must have a personal mobile phone in which they are able and willing to send and receive text messages * NOTE: The restriction to those with mobile phone access with text messaging is based on the primary intention of the study which involves the use of text messaging to improve adherence * PATIENT STEP 0: Patient must have an email address * NOTE: The restriction to those with an email address is based on the primary intention of the study which involves patients responding to questions regarding their reasons for non-adherence after every missed dose to improve adherence * PATIENT STEP 0: Patient must have the ability to understand and the willingness to sign a written informed consent document * NOTE: Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available are not eligible * PATIENT STEP 0: Patient must not have an Eastern Cooperative Oncology Group (ECOG) performance status \>= 3 OR patient must not be deemed medically unable to participate in the study by the study investigators or an oncology clinician (i.e., referral to hospice) * PATIENT STEP 0: Patient must not be enrolled in othe"
NCT06551324,"A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)",MEVPRO-1,PHASE3,"Argentina, Brazil","Centro de Urología (CDU), CABA, Argentina, [RECRUITING] | Hospital Sirio Libanes, Capital Federal, Argentina, [RECRUITING] | Instituto Alexander Fleming, Ciudad Autónoma de Buenos Aires, Argentina, [RECRUITING] | Imagenes Mdq, Mar del Plata, Argentina, [RECRUITING] | Instituto de Investigaciones Clínicas Mar del Plata, Mar del Plata, Argentina, [RECRUITING] | Centro Medico Privado CEMAIC, Capital, Argentina, [RECRUITING] | IMAXE, Buenos Aires, Argentina, [RECRUITING] | Asociación de Beneficencia Hospital Sirio Libanés, Buenos Aires, Argentina, [RECRUITING] | Centro de Educación Médica e Investigaciones clínicas ""Dr. Norberto Quirno"" (CEMIC), Buenos Aires, Argentina, [RECRUITING] | Hospital São Carlos, Fortaleza, Brazil, [RECRUITING]",Metastatic Castrate Resistant Prostate Cancer (mCRPC),2,[1] Arm A (EXPERIMENTAL): Investigational Arm A: PF-06821497 875 mg twice daily (BID) + enzalutamide 160 mg every day (QD) || [2] Arm B (ACTIVE_COMPARATOR): Comparator Arm B: Physician's choice of enzalutamide 160 mg QD or docetaxel 75 mg/m2 intravenous (IV) every 21 days,"* Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features. * Metastatic disease in bone documented on bone scan, or in soft tissue documented on CT/MRI scan. * Progressive disease in the setting of surgical or medical castration with evidence of disease progression on treatment with abiraterone acetate in the mCSPC setting or first line mCRPC setting is required. * Eastern Cooperate Oncology Group (ECOG) performance status 0 - 2, with life expectancy of at least 6 months as assessed by the investigator.","* Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may make the participant inappropriate for the study. * Know history of active inflammatory gastrointestinal disease, chronic diarrhea, or previous gastric resection or lap-band surgery. * Clinically significant cardiovascular disease. * Known or suspected brain metastasis or active leptomeningeal disease or clinically significant history of seizure. * Prior treatment for prostate cancer at any stage with any cytotoxic chemotherapy, radioligand therapy (i.e. 177Lu-PSMA-617, radium 223), androgen receptor signaling inhibitors (ARSi) including enzalutamide, apalutamide, darolutamide, poly ADP-ribose polymerase (PARP) monotherapy or other systemic anti-cancer treatment, with the following exceptions: 1. Treatment with first-generation antiandrogen agents, if discontinued prior to first dose of study intervention. 2. Docetaxel treatment is allowed for mCSPC, as long as no signs of failure, or disease progression occurred during treatment or within 3 months of treatment completion. * Previous administration with an investigational product within 30 days or 5 half-lives preceding the first dose of study intervention (whichever is shorter). * Inadequate organ function."
NCT06395103,LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors,,"PHASE1, PHASE2","Brazil, Chile, Colombia","Hospital Erasto Gaertner-CEPEP - Pesquisa Clínica ( Site 1268), Curitiba, Brazil, [RECRUITING] | Hospital de Clinicas de Porto Alegre ( Site 1265), Porto Alegre, Brazil, [RECRUITING] | Fundação Pio XII - Hospital de Câncer de Barretos ( Site 1264), Barretos, Brazil, [RECRUITING] | Fundação Faculdade Regional de Medicina de São José do Rio Preto-Centro Integrado de Pesquisa ( Site 1267), São José do Rio Preto, Brazil, [RECRUITING] | Hospital Carlos Van Buren ( Site 1880), Valparaíso, Chile, [RECRUITING] | Hospital Pablo Tobon Uribe ( Site 1923), Medellín, Colombia, [RECRUITING] | Clinica de la Costa S.A.S.-Clinical Research Oncology & Hematology -Pediatric ( Site 1924), Barranquilla, Colombia, [RECRUITING] | IMAT S.A.S ( Site 1921), Montería, Colombia, [RECRUITING]",B-cell Acute Lymphoblastic Leukemia | Diffuse Large B-cell Lymphoma | Burkitt Lymphoma | Neuroblastoma | Ewing Sarcoma,1,[1] Zilovertamab vedotin (EXPERIMENTAL): Participants receive escalating doses of zilovertamab vedotin via intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks).,* For hematological malignancies: Confirmed diagnosis of B-precursor B-ALL or DLBCL/Burkitt lymphoma according to World Health Organization (WHO) classification of neoplasms of the lymphoid tissues. * For solid tumor malignancies: Histologically confirmed diagnosis of neuroblastoma or Ewing sarcoma.,"* History of solid organ transplant. * Clinically significant (ie, active) cardiovascular disease. * Known history of liver cirrhosis. * Ongoing Grade \>1 peripheral neuropathy. * Demyelinating form of Charcot-Marie-Tooth disease. * Diagnosed with Down syndrome. * Ongoing graft-versus-host disease (GVHD) of any grade or receiving systemic GVHD treatment or prophylaxis. * History of human immunodeficiency virus (HIV) infection. * Contraindication or hypersensitivity to any of the study intervention components. * Received prior radiotherapy within 4 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities. * Ongoing, chronic corticosteroid therapy (exceeding 10 mg daily of prednisone equivalent). Prednisone equivalent dosing must have been stable for at least 4 weeks before Cycle 1 Day 1 (C1D1). * Received a strong cytochrome P450 3A4 (CYP3A4) inhibitor within 7 days or a strong CYP3A4 inducer within 14 days before the start of study intervention or expected requirement for chronic use of a strong CYP3A4 inhibitor or inducer during the study intervention period and for 30 days after the last dose of study intervention * Received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study intervention (except for prophylactic intrathecal chemotherapy and/or cytoreductive therapy with steroids/hydroxyurea. * Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed. * Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration. * Known additional malignancy that is progressing or has required active treatment within the past 1 year. * Active infection requiring systemic therapy. * Known history of Hepatitis B or known active Hepatitis C virus infection. * Participants who have not adequately recovered from"
NCT04928846,"A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer",,PHASE3,"Argentina, Brazil, Chile, Colombia, Mexico","Cemic /Id# 231486, Ciudad Autonoma Buenos Aires, Argentina, [RECRUITING] | Hospital Britanico de Buenos Aires /ID# 231495, Ciudad Autonoma de Buenos Aire, Argentina, [RECRUITING] | Centro Médico Austral /ID# 239860, Ciudad Autonoma Buenos Aires, Argentina, [RECRUITING] | Cenit /Id# 239880, Ciudad Autonoma de Buenos Aire, Argentina, [RECRUITING] | Centro de Investigaciones Clinicas Clinica Viedma S.A. /ID# 232339, Viedma, Argentina, [RECRUITING] | Ensino e Terapia de Inovacao - Clinica AMO /ID# 231604, Salvador, Brazil, [RECRUITING] | Irmandade da Santa Casa de Misericordia de Porto Alegre /ID# 233249, Porto Alegre, Brazil, [RECRUITING] | Fundacao Pio XII - Hospital de Cancer de Barretos /ID# 233247, Barretos, Brazil, [RECRUITING] | Hospital Sírio Libanês /ID# 261827, São Paulo, Brazil, [RECRUITING] | OC Oncoclínicas SP /ID# 261828, São Paulo, Brazil, [RECRUITING]",Non Small Cell Lung Cancer,2,[1] Telisotuzumab Vedotin (EXPERIMENTAL): Participants will receive telisotuzumab vedotin every 2 weeks until meeting study drug discontinuation criteria. || [2] Docetaxel (ACTIVE_COMPARATOR): Participants will receive docetaxel every 3 weeks until meeting study drug discontinuation criteria.,"* Projected life expectancy of at least 12 weeks. * Participants must have c-Met overexpressing non-small cell lung cancer (NSCLC) as assessed by an AbbVie designated immunohistochemistry (IHC) laboratory using the VENTANA MET (SP44) RxDx assay. * Archival or fresh tumor material must be submitted for assessment of c-Met levels during the Pre-Screening period. Tumor material from the primary tumor site and/or metastatic sites are allowed. * If a participant was prescreened for Study M14-239 but did not enroll, tumor material previously submitted for Study M14-239 may be used for Study M18-868 Pre-Screening upon confirmation from AbbVie that sufficient evaluable tumor material is available (Except China). * A histologically or cytologically documented non-squamous cell NSCLC that is locally advanced or metastatic. * A known epidermal growth factor receptor (EGFR) activating mutation status. * Actionable alterations in genes other than EGFR . * Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. * An Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1. * Have received no more than 1 line of prior systemic cytotoxic chemotherapy in the locally advanced or metastatic setting. * Neoadjuvant and adjuvant systemic cytotoxic chemotherapy will count as a prior line for eligibility purposes if progression occurred within 6 months of the end of therapy. * Have progressed on at least 1 line of prior therapy for locally advanced/metastatic NSCLC: * Participants WITHOUT an actionable gene alteration: must have progressed on (or be considered ineligible for) platinum-based chemotherapy and immune checkpoint inhibitor (as monotherapy or in combination with chemotherapy). * Participants WITH an actionable gene alteration for which immune checkpoint inhibitor therapy is not standard of care (e.g., anaplastic lymphoma kinase \[ALK\] translocation): must have progressed on (or be considered ineligible for) anti-cancer therapy tar","* Evidence of new, untreated CNS metastases. * Evidence of leptomeningeal disease. * Participants with adenosquamous or neuroendocrine histology, nor sarcomatoid features. * Actionable epidermal growth factor receptor (EGFR) activating mutations. * Participants who have received prior c-Met-targeted antibodies, prior telisotuzumab vedotin, or prior antibody-drug conjugates either targeting c-Met or consisting of monomethylauristatin E.. * Participants who have received prior docetaxel therapy. * A history of other malignancies except: * Malignancy treated with curative intent and with no known active disease present for \>=2 years before the first dose of study drug and felt to be at low risk for recurrence by investigator. * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease. * Adequately treated carcinoma in situ without current evidence of disease. * A history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. A history of prior radiation pneumonitis in the radiation field (fibrosis) is permitted. * Unresolved or neuroendocrine histology, nor sarcomatoid features adverse event (AE) \>= Grade 2 from prior anticancer therapy, except for alopecia or anemia. Participants with hormone deficiencies caused by prior anticancer therapy who are asymptomatic and on a stable dose of replacement hormone are eligible for study. * Major surgery within 21 days prior to randomization. * Clinically significant condition(s) as listed in the protocol."
NCT06500884,"A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity",Talisman,PHASE2,"Brazil, Puerto Rico","Fundacao Universidade de Caxias do Sul, Caxias do Sul, Brazil, [RECRUITING] | Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer, Curitiba, Brazil, [RECRUITING] | Instituto D Or de Pesquisa e Ensino, Salvador, Brazil, [RECRUITING] | Clinica Medica Sao Germano S/S LTDA, São Paulo, Brazil, [RECRUITING] | Instituto D Or de Pesquisa e Ensino IDOR, São Paulo, Brazil, [RECRUITING] | Hospital Espanol Auxilio Mutuo Auxilio Mutuo Cancer Center, San Juan, Puerto Rico, [RECRUITING]",Relapse Multiple Myeloma | Refractory Multiple Myeloma,4,"[1] Cohort A: Talquetamab (ACTIVE_COMPARATOR): Participants with relapsed or refractory multiple myeloma (RRMM) who are triple-class exposed (previously exposed to at least 1 proteasome inhibitor \[PI\], 1 immunomodulatory drug(s) \[IMiD\]), an... || [2] Cohort B: Prophylaxis A and Talquetamab (EXPERIMENTAL): Participants with RRMM who are triple-class exposed (previously exposed to at least 1 PI, 1 IMiD, and an anti-CD38 mAb) will receive prophylaxis A along with talquetamab therapy. Participants will ... || [3] Cohort C: Prophylaxis B and Talquetamab (EXPERIMENTAL): Participants with RRMM who are triple-class exposed (previously exposed to at least 1 PI, 1 IMiD, and an anti-CD38 mAb) will receive prophylaxis B along with talquetamab therapy. Participants will ... || [4] Cohort D: Prophylaxis C and Talquetamab (EXPERIMENTAL): Participants with RRMM who are triple-class exposed (previously exposed to at least 1 PI, 1 IMiD, and an anti-CD38 mAb) will receive prophylaxis C along with talquetamab therapy. Participants will ...","* Multiple myeloma (MM) according to IMWG diagnostic criteria * Were triple-class exposed (received prior treatment with a PI, an IMiD, and anti CD38 mAb) * Documented evidence of progressive disease based on investigator's determination of response by IMWG criteria on or after their last regimen * Have an Eastern Cooperative Oncology Group-performance status (ECOG-PS) of 0 or 1 at screening. Participants with ECOG-PS 2 or 3 are eligible for the study if the ECOG-PS score is related to stable physical limitations (e.g., wheelchair-bound due to prior spinal cord injury) and not related to multiple myeloma or associated therapy * Be willing and able to adhere to the lifestyle restrictions specified in the protocol","* Contraindications or life-threatening known allergies, hypersensitivity, or intolerance to any study drug or its excipients * Stroke, transient ischemic attack, or seizure within 6 months prior to screening * Any of the following within 6 months prior to the first dose of study treatment: severe or unstable angina, myocardial infarction; major thromboembolytic event (e.g., pulmonary embolism, cerebrovascular accident), clinically significant ventricular arrythmia or heart failure New York Heart Association functional classification Class III or IV. Uncomplicated deep vein thrombosis is not considered exclusionary * Major surgery or had significant traumatic injury within 2 weeks prior to the start of administration of talquetamab, or will not have fully recovered from surgery, or has major surgery planned during the time the participant is expected to be treated in the study or within 2 weeks after administration of the last dose of study treatment * A WETT score suggesting severe dysgeusia at screening. Also unresolved/severe dysgeusia referred by the participant or a finding in the physical examination/oral cavity inspection. Some examples include leukoplakia, prior mouth cancers, extensive dental caries, severe periodontitis, active oral infections, candidiasis, parotic gland removal, or radiotherapy with resultant xerostomia"
NCT06711185,Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy,DAPA-MYOCANCER,PHASE3,Brazil,"Hospital de Clinicas da Unicamp, Campinas, Brazil, [RECRUITING]",Breast Cancer,2,[1] Dapagliflozin (EXPERIMENTAL): Standard chemotherapy treatment + Dapagliflozin 10mg/day. || [2] Placebo Group (PLACEBO_COMPARATOR): Standard chemotherapy treatment + Placebo.,* Female * Over 18 years old * Breast cancer * Chemotherapy as treatment planning and programmed cumulative dose equivalent to 240 mg/m2 of doxorubicin.,"* Contraindications for performing CMR exams, such as patients with pacemakers or cardiac defibrillators of any type, metal clips for cerebral aneurysms, cochlear implants, and ventriculoperitoneal bypass valves. * Inability to perform CMR due to claustrophobia. * Renal failure with a glomerular filtration rate \< 30 ml/min/1.73 m2. * Previous history of myocardial infarction, congestive heart failure, or myocardial revascularization, whether percutaneous or surgical. * Previous history of significant valvular heart disease. * Previous history of cardiomyopathies."
NCT06535607,"A Phase II, Multi-Center Study to Evaluate the Efficacy and Safety of Volrustomig as Monotherapy or in Combination With Anti-cancer Agents in Participants With Advanced/Metastatic Solid Tumors",eVOLVE-02,PHASE2,Brazil,"Research Site, Ijuí, Brazil, [NOT_YET_RECRUITING] | Research Site, Londrina, Brazil, [NOT_YET_RECRUITING] | Research Site, São Caetano do Sul, Brazil, [NOT_YET_RECRUITING] | Research Site, Vitória, Brazil, [NOT_YET_RECRUITING]",Cervical Cancer | Head and Neck Squamous Cell Carcinoma,3,[1] Sub-study 1 (EXPERIMENTAL): Volrustomig monotherapy || [2] Sub-study 2 (EXPERIMENTAL): Volrustomig monotherapy || [3] Sub-study 3 (EXPERIMENTAL): Volrustomig in combination with carboplatin plus paclitaxel or 5-FU plus platinum,"For inclusion in the study, patients should fulfill the following criteria: 1. Age ≥18 at the time of signing the ICF. 2. Provision of tumor sample to assess the PD-L1 expression. 3. Measurable disease according to RECIST 1.1. 4. ECOG performance status of 0 or 1. 5. Life expectancy ≥ 12 weeks. 6. Adequate organ and bone marrow function. 7. Body weight \> 35 kg. 8. Capable of giving signed informed consent. 9. For sub-study 1, participants with R/M cervical cancer with squamous cell, adenocarcinoma or adenosquamous histology, that: have experienced disease progression during or after treatment with standard systematic therapy per local guideline; have received at least 1 line but no more than 2 lines of prior systemic treatment regimens for R/M cervical cancer. 10. For sub-study 2, for participants with OPC must have documented HPV status. 11. For sub-study 2, participants with R/M HNSCC, that: (a) Are histologically or cytologically documented R/M HNSCC of the OP, OC, HP, and LX that is considered incurable by local therapies; (b) Participants that have not been treated in R/M setting must have: (i) a documented PD-L1 positive result, (ii) with no prior systemic anti-cancer therapy for R/M HNSCC; (c) Platinum refractory participants must have relapsed from or are refractory to the first line of prior platinum-containing regimen. 12. For sub-study 3, participants with R/M HNSCC, that: (a) Are histologically or cytologically documented R/M HNSCC of the OP, OC, HP, and LX that is considered incurable by local therapies; (b) Participants that have not been treated in R/M setting","Patients should not enter the study if any of the following exclusion criteria are fulfilled: 1. Spinal cord compression. 2. Brain metastases unless asymptomatic, stable, and not requiring steroids for at least 14 days prior to start of study intervention. 3. Participants with primary neuroendocrine, mesenchymal, sarcomatoid histologies, or other histologies not mentioned as part of the inclusion criteria. 4. Have not recovered (ie, ≤ Grade 1 or at baseline) from an AE due to a previously administered anti-cancer therapy. 5. For sub-study 2, have had radiotherapy within 2 weeks prior to enrollment. 6. For sub-study 3, Participants have contraindications to any of the following drugs: 5-FU, paclitaxel and carboplatin 7. History of another primary malignancy except for a) Malignancy treated with curative intent with no known active disease ≥2 years before the first dose of study intervention and of low potential risk for recurrence; b) Adequately treated nonmelanoma skin cancer or lentigo maligna, or carcinoma in situ without evidence of disease. 8. Any evidence of diseases, and/or history of organ transplant or allogenic stem cell transplant, which makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol. 9. Evidence of the following infections: active infection including tuberculosis; known HIV infection. that is not well controlled; active or uncontrolled HBV or HCV; or active hepatitis A. 10. Active or prior documented autoimmune or inflammatory disorders. 11. Participants who are candidates for curative therapy. 12. Prior exposure to any immune-mediated therapy. 13. Current or prior use of immunosuppressive medication within 14 days before the first dose of the study intervention is excluded. The following are exceptions to this criterion: a) Intranasal, inhaled, topical steroids, or local steroid injections (eg, intraarticular injection); b) Steroids as premedication for hypersensitivity reactions"
NCT04070976,"Phase II Randomized Controlled Trial of Concomitant Chemoradiotherapy With Standard Fractionation Compared to Hypofractionated Concomitant Chemoradiotherapy Followed by Brachytherapy, for Clinical Stage III Cervical Cancer Patients",,NA,Mexico,"David Cantu de Leon, Mexico City, Mexico, [RECRUITING]",Cervical Cancer,2,"[1] Standard treatment (ACTIVE_COMPARATOR): Cisplatin 40mg/m2 weekly and concomitant pelvic radiotherapy (45 Gray/25 fractions) followed by brachytherapy 28Gray at point A. || [2] Experimental treatment (EXPERIMENTAL): Cisplatin 40mg/m2 weekly and hypofractionated concomitant external radiotherapy (37,50 Gray/15 fractions) followed by brachytherapy 28 Gray at point A.","* Women over 18 years old * Cervical Cancer at IIIA, IIIB y IIIC1 FIGO´s clinical stages * Histology: squamous, adenosquamous or adenocarcinoma * No previous treatment * No distance metastases, discard by Positron Emission Tomography (PET)/CT * Functional State ECOG (Eastern Cooperative Oncology Group) 0-2 * Complete Blood count obtained at least 14 days before admission to the study with adequate bone marrow function defined as: * Absolute neutrophil count ≥ 1,500 cell/mm3 * Platelets ≥ 100,000 cell/mm3 * Hemoglobin ≥ 10.0 g/dl * Leukocyte count ≥ 4000 cell/mm3 * Adequate Renal Function defined as: * Serum Creatinine ≤ 1.5 mg/dl within 14 days before admission to the study * Patients with HIV infection (human immunodeficiency virus) must have a CD4 cell count ≥ 350 cells / mm3 measured within 14 days prior to study entry (no HIV test is required) * The patient must understand the protocol and provide the specific informed consent of the study before admission * Negative pregnancy test","* Patients who had chemotherapeutic, surgical and/or radiotherapy treatment for female reproductive tract pathologies * Previous invasive neoplasia (except non-melanoma skin cancer) unless there is complete remission of the disease of 3 years minimum (For example, breast cancer or oral cavity cancer) * Previous systemic chemotherapy for current cervical cancer, take into account that prior chemotherapy for a different cancer is accepted, as long as they have been at least 3 years * Severe active or non-controlled co-morbidities, defined as: * Unstable angina and/or congestive heart failure that required hospitalization in the last 6 months. * Transmural myocardial infarction in the last 6 months. * Acute bacterial or fungal infection requiring intravenous antibiotics at the beginning of the study. * Chronic obstructive pulmonary disease exacerbation or another respiratory disease that requires hospitalization or that contraindicates the trial therapy at the time of admission. * Crohn's disease or ulcerative colitis. * Prior allergic reaction to cisplatin or other drugs based on platinum. * Other factors that contraindicate experimental therapy."
NCT06692738,"A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)",,PHASE3,"Argentina, Brazil, Peru, Puerto Rico","Research Site, Buenos Aires, Argentina, [RECRUITING] | Research Site, CABA, Argentina, [RECRUITING] | Research Site, La Plata, Argentina, [WITHDRAWN] | Research Site, Pilar, Argentina, [RECRUITING] | Research Site, Rosario, Argentina, [RECRUITING] | Research Site, Barretos, Brazil, [RECRUITING] | Research Site, Florianópolis, Brazil, [RECRUITING] | Research Site, Ijuí, Brazil, [RECRUITING] | Research Site, Londrina, Brazil, [RECRUITING] | Research Site, Porto Alegre, Brazil, [RECRUITING]",Non-small Cell Lung Cancer,2,[1] Arm A (EXPERIMENTAL): Rilvegostomig in combination with carboplatin and paclitaxel or nab-paclitaxel followed by rilvegostomig || [2] Arm B (ACTIVE_COMPARATOR): Pembrolizumab in combination with carboplatin and paclitaxel or nab-paclitaxel followed by pembrolizumab,"* Histologically or cytologically documented squamous NSCLC. * Stage IV mNSCLC (based on the American Joint Committee on Cancer Edition 8) not amenable to curative treatment. * Absence of documented tumor genomic mutation results from tests conducted as part of standard local practice in any actionable driver oncogenes for which there are locally approved targeted 1L therapies. * Provision of acceptable tumor sample to confirm tumor PD-L1 expression TC ≥ 1%. * At least one lesion not previously irradiated that qualifies as a RECIST 1.1 TL at baseline and can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have short axis ≥ 15 mm) with CT or MRI and is suitable for accurate repeated measurements. * Adequate organ and bone marrow function.","* Presence of small cell and neuroendocrine histology components. * Brain metastases unless asymptomatic, stable, and not requiring steroids or anticonvulsants for at least 7 days prior to randomization. A minimum of 2 weeks must have elapsed between the end of local therapy (brain radiotherapy or surgery) and randomization. Participants must have recovered from the acute toxic effect of radiotherapy (eg, dizziness and signs of increased intracranial pressure) or surgery prior to randomization. * Any prior systemic therapy received for advanced or mNSCLC. * Any prior treatment with an anti-PD-1 or anti-PD-L1 agent. * Any prior exposure to an anti-TIGIT therapy or any other anticancer therapy targeting immune-regulatory receptors or mechanisms. * History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥ 2 years before the first dose of study intervention and of low potential risk for recurrence. * Active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment. * Active primary immunodeficiency/active infectious disease(s). * Active tuberculosis infection."
NCT06432426,"The Effect of Virtual Exercise on Elderly Breast Cancer Survivors on Functionality, Muscular Strength, and Quality of Life Effecto-B):",,NA,Chile,"Complejo Asistencial Dr. Sótero del Río, Santiago, Chile, [RECRUITING]",Breast Cancer,2,"[1] Virtual Reality Training Group (EXPERIMENTAL): Participants will undergo a postural balance rehabilitation program, utilizing a probed protocol for the elderly population with virtual reality via the Nintendo Wii Fit® and its peripheral Balance... || [2] Standard physical exercise Group (ACTIVE_COMPARATOR): Participants will undergo a standardized physical exercise program based on a validated protocol designed for elderly breast cancer survivors","* Women between 60 and 80 years old. * Diagnosis of primary breast carcinoma. * Treated with at least two of the following treatments: surgery, radiotherapy, chemotherapy, hormone therapy, biological therapy. * Minimum of 2 years and a maximum of 10 years after finishing treatments (surgery, chemotherapy, and radiotherapy). * Being able to walk at least 4 meters independently or with a cane as assistive technology","* Stage IV breast cancer. * Previous cancer treatment for any type of cancer other than breast cancer (chemotherapy, radiotherapy, or endocrine therapy). * Cognitive impairment measured by the abbreviated Mini-Mental State Examination with a score \< 13 points. * Medical contraindication to perform physical exercise. * Self-reported of physical activity equivalent to the recent American College of Sports Medicine Exercise Guidelines for Cancer Patients and Survivors (150 min/week of moderate aerobic exercise and strength exercise twice a week). * Body mass index \< 18.5 kg/m2 or \> 40 kg/m2."
NCT05704049,"A Randomized, Phase 2, Open Label Study Evaluating Subcutaneous Administration of Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)",IZALCO,PHASE2,Brazil,"Hospital Mae de Deus Site Number : 0760002, Porto Alegre, Brazil, [ACTIVE_NOT_RECRUITING] | Clínica São Germano Site Number : 0760003, São Paulo, Brazil, [ACTIVE_NOT_RECRUITING] | Hospital das Clinicas de Sao Paulo Site Number : 0760001, São Paulo, Brazil, [RECRUITING]",Relapsed/Refractory Multiple Myeloma,8,"[1] Cohort 1: manual administration (EXPERIMENTAL): Isatuximab will be administered manually for 8 minutes on Day 1 of Cycle 1 followed by 6 minutes from Day 8 of Cycle 1 and thereafter, in combination with carfilzomib and dexamethasone. Participant... || [2] Part 1 Cohort 2: manual administration (EXPERIMENTAL): Isatuximab will be administered manually for 6 minutes on Day 1 of Cycle 1 and thereafter, in combination with carfilzomib and dexamethasone. Participants may receive other treatments as rescue med... || [3] Part 2 Cohort 3 Randomized Cohort: OBDS to manual (EXPERIMENTAL): Isatuximab will be administered in combination with carfilzomib and dexamethasone. Isatuximab will be administered via OBDS from Cycle 1 to 3. For Cycle 4 to 6, the method of administration will be... || [4] Part 2 Cohort 3 Randomized Cohort: Manual to OBDS (EXPERIMENTAL): Isatuximab will be administered in combination with carfilzomib and dexamethasone. Isatuximab will be administered manually from Cycle 1 to 3. For Cycle 4 to 6, the method of administration will be... || [5] Part 3 Cohort 4 Randomized Cohort: OBDS to manual (EXPERIMENTAL): Isatuximab will be administered in combination with carfilzomib and dexamethasone. Isatuximab will be administered via OBDS from Cycle 1 to 3. For Cycle 4 to 6, the method of administration will be... || [6] Part 3 Cohort 4: Randomized Cohort: manual to OBDS (EXPERIMENTAL): Isatuximab will be administered in combination with carfilzomib and dexamethasone. Isatuximab will be administered manually from Cycle 1 to 3. For Cycle 4 to 6, the method of administration will be... || [7] Part 3 Cohort 5 Randomized Cohort: OBDS to manual administration in Chinese participants (EXPERIMENTAL): Isatuximab will be administered in combination with carfilzomib and dexamethasone. Isatuximab will be administered via OBDS from Cycle 1 to 3. For Cycle 4 to 6, the method of administration will be... || [8] Part 3 Cohort 5 Randomized Cohort: manual to OBDS administration in","Participants must have a documented diagnosis of multiple myeloma (MM) * Participants with measurable disease defined as at least one of the following: * Serum M-protein ≥0.5 g/dL measured using serum protein immunoelectrophoresis and/or * Urine M-protein ≥200 mg/24 hours measured using urine protein immunoelectrophoresis and/or * Serum free light chain (FLC) assay: Involved FLC assay ≥10 mg/dL (≥100 mg/L) and an abnormal serum FLC ratio (\<0.26 or \>1.65). * Participant with relapsed and/or refractory MM with at least 1 prior line of therapy and no more than 3 prior lines of therapy. * A female participant is eligible to participate if she is not pregnant, not breastfeeding, and either is not a female of childbearing potential (FCBP) or agrees to practice complete abstinence or use approved contraception methods. * Male participants agree to practice true abstinence or agree to use approved contraception methods while receiving study treatment, during dose interruptions and at least 5 months following study treatment discontinuation, even if has undergone a successful vasectomy. * Capable of giving signed informed consent.","* Primary refractory MM defined as participants who have never achieved at least a minimal response (MR) with any treatment during the disease course * Participants with prior anti-CD38 treatment if: a) administered \<9 months before first isatuximab administration or randomization as applicable or, b) Intolerant to the anti-CD38 previously received * Prior treatment with carfilzomib * Known history of allergy to captisol (a cyclodextrin derivative used to solubilize carfilzomib), prior hypersensitivity to sucrose, histidine (as base and hydrochloride salt), polysorbate 80, or any of the components (active substance or excipient) of study treatment that are not amenable to premedication with steroids, or intolerance to arginine and Poloxamer 188 that would prohibit further treatment with these agents * Uncontrolled or active infection with hepatitis A, B, and C virus; known acquired immunodeficiency syndrome (AIDS)-related illness; active primary amyloid light chain (AL) amyloidosis * Any severe acute or chronic medical condition which could impair the ability of the participant to participate in the study or interfere with interpretation of study results (eg, systemic infection unless specific anti-infective therapy is employed) or participant unable to comply with the study procedures. The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial."
NCT06974734,AN OPEN-LABEL PHASE 1 STUDY TO EVALUATE PF-08046037 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES,,PHASE1,Puerto Rico,"Pan American Center for Oncology Trials, LLC, Rio Piedras, Puerto Rico, [NOT_YET_RECRUITING]","Carcinoma, Non Small Cell Lung | Carcinoma, Pancreatic Ductal | Malignant Melanoma | Squamous Cell Carcinoma of the Head and Neck (SCCHN)",6,[1] Part 1a (EXPERIMENTAL): PF-08046037 monotherapy dose escalation || [2] Part 2a (EXPERIMENTAL): PF-08046037 monotherapy dose optimization || [3] Part 3a (EXPERIMENTAL): PF-08046037 monotherapy dose expansion || [4] Part 1b (EXPERIMENTAL): PF-08046037 +sasanlimab dose escalation || [5] Part 2b (EXPERIMENTAL): PF-08046037 + sasanlimab dose optimization || [6] Part 3b (EXPERIMENTAL): PF-08046037 + sasanlimab dose expansion,"This study is seeking participants who have the following tumor types and can provide tumor tissue samples as per below. 1. Tumor types * Monotherapy Dose Escalation (Part 1a) and Optimization (Part 2a) cohorts * Advanced or metastatic NSCLC, HNSCC, melanoma, or PDAC * Must have progressive disease following at least 1 prior approved systemic therapy * Monotherapy Dose Expansion (Part 3a) • Advanced or metastatic NSCLC or PDAC * Combination Safety Evaluation (Part 1b) and Dose Optimization (Part 2b) * Advanced or metastatic NSCLC or HNSCC * May be either a) not received prior immunotherapy for the tumor type OR b) relapse/ refractory after prior immunotherapy * Combination Dose Expansion (Part 3b) * Unresectable locally advanced or metastatic HNSCC or NSCLC * Must not have received prior systemic cytotoxic therapy in the locally advanced or metastatic setting (first-line setting) * Must be treatment naïve to any immunotherapy * NSCLC must have PD-L1 expression TPS \>=50% * HNSCC must have PD-L1 expression CPS \>=1 2. Tissue requirement * Part 1 at lower doses: sufficient archival tissue collected within 12 months of enrollment for submission to central laboratory * Part 1 at higher doses: de novo baseline tumor biopsy or archival tissue within 12 months of enrollment * Part 1 backfill: de novo baseline and on-treatment tumor biopsies are required * Part 2 and 3: de novo baseline or archival tissue within 6 months of enrollment * Part 2 and 3: mandatory on-treatment tumor biopsy, if required by sponsor 3. Measurable disease per RECIST v1.1 Participants who meet the following might not be able to participate. 1. History of Grade \>=3 immune mediated AE related to prior immune modulatory therapy and required immunosuppressive therapy 2. Active or prior autoimmune disease that might deteriorate when receiving an immunostimulatory agent 3. History of uveitis within the preceding 6 months 4. Clinically significant Grade \>=3 neurodegenerative disease 5. Grade 3 or higher ",
NCT04596800,Prehabilitation Plus Enhanced Recovery After Surgery Versus Enhanced Recovery After Surgery in Gynecologic Oncology: a Randomized Clinical Trial,PROPER,PHASE3,Brazil,"Instituto Brasileiro de Controle do Cancer - IBCC, São Paulo, Brazil, [RECRUITING]",Gynecologic Cancer | Enhanced Recovery After Surgery,2,"[1] Prehabilitation + Enhanced Recovery After Surgery (EXPERIMENTAL): Patients allocated to the intervention group will undergo prehabilitation protocol (nutrition + exercise + psychological counselling), with individualized monitoring by the multidisciplinary team. || [2] Enhanced Recovery After Surgery (ACTIVE_COMPARATOR): Patients allocated to the control group will not undergo any pre-surgical intervention, except for preoperative counselling, already implicated in ERAS®.","* Patients who sign the Informed Consent Form, indicating that they understand the study procedures and their purpose; * Women aged between 18 and 80 years old; * Gynecological surgery performed by laparotomy; * Patients with Eastern Cooperative Oncology Group Performance Status of at least 2 (ECOG ≤2); * Preoperative schedule that allows prehabilitation intervention for 2 to 3 weeks","* Patients under 18 or older than 80 years old; * ECOG ≥3; * Significant comorbidities, such as: neurological or musculoskeletal disorder, heart disease and / or respiratory failure that prohibit physical exercise; * Limitation of ambulation preventing the patient to perform physical exercises; * Cognitive deterioration or patients with psychiatric disorder that prevents adherence to the program; * Emergency or urgency surgeries; * Surgeries by minimally invasive approach (laparoscopy or robotics); * Vulvectomy or soft tissue surgery without abdominal approach; * Minor gynaecological surgeries such as conizations; * Surgeries performed together with other specialties, in which the gynecology team is not primarily responsible for postoperative care; * If surgery is performed 21 days after the last day of the prehabilitation program, for any reason"
NCT06428409,A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers,,"PHASE1, PHASE2",Chile,"FALP-UIDO ( Site 0041), Providencia, Chile, [RECRUITING] | Clínica UC San Carlos de Apoquindo ( Site 0043), Santiago, Chile, [RECRUITING] | Bradfordhill-Clinical Area ( Site 0047), Santiago, Chile, [RECRUITING] | James Lind Centro de Investigacion del Cancer ( Site 0048), Temuco, Chile, [RECRUITING]",Colorectal Cancer | Pancreatic Ductal Adenocarcinoma | Biliary Tract Cancer,3,"[1] Sacituzumab tirumotecan + Chemotherapy (EXPERIMENTAL): Participants will receive sacituzumab tirumotecan in one of two dose levels and chemotherapy every 2 weeks (Day 1 and Day 15 of every 4-week cycle). Participants will continue to receive the treatm... || [2] Sacituzumab tirumotecan (EXPERIMENTAL): Participants will receive sacituzumab tirumotecan every 2 weeks (Day 1 and Day 15 of every 4-week cycle). Participants will continue to receive the treatment until the cancer gets worse or they don... || [3] Sacituzumab tirumotecan + Cisplatin + Pembrolizumab (EXPERIMENTAL): Participants will receive sacituzumab tirumotecan in one of two dose levels on Day 1 and Day 8 of every 3-week cycle until the cancer gets worse or they don't tolerate treatment, cisplatin on Day 1...",The main inclusion criteria include but are not limited to the following: * Has one of the following cancers: * Unresectable or metastatic colorectal cancer and has received prior therapy for the cancer * Advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) and has received prior therapy for the cancer * Advanced and/or unresectable biliary tract cancer (BTC) and has received prior therapy for the cancer * Advanced and/or unresectable BTC and has not received prior therapy for the cancer * For participants who have received prior therapy for cancer: Has recovered from any side effects due to previous cancer treatment,The main exclusion criteria include but are not limited to the following: * History of severe eye disease * For participants who have received prior therapy for cancer: Received prior systemic anticancer therapy including investigational agents within 4 weeks before starting study intervention * History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
NCT06054555,"A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Treatment-Naïve Unresectable or Metastatic Melanoma",,PHASE3,"Argentina, Chile, Mexico","Fundación CENIT, Buenos Aires, Argentina, [RECRUITING] | Centro De Investigaciones Medicas Mar Del Plata (CIMMDP) - Rheumatology, Mar Del Plata, Argentina, [RECRUITING] | Clínica Viedma, Viedma, Argentina, [RECRUITING] | Instituto de Oncologia de Rosario, Rosario, Argentina, [RECRUITING] | ISIS Clinica Especializada, Santa Fe, Argentina, [RECRUITING] | IC La Serena Research, La Serena, Chile, [RECRUITING] | Centro de Investigacion y Desarrollo Oncologico, Temuco, Chile, [RECRUITING] | Oncocentro APYS, Valparaíso, Chile, [RECRUITING] | Icegclinic Research & Care, Estacion Central, Chile, [RECRUITING] | Preparaciones Oncologicas SC, León, Mexico, [RECRUITING]",Melanoma,2,[1] ABP 206 (EXPERIMENTAL): Subjects will receive Dose A of ABP 206 via intravenous (IV) infusion. || [2] Nivolumab (ACTIVE_COMPARATOR): Subjects will receive Dose A of Nivolumab via IV infusion.,* At least 18 years of age. * Histologically confirmed unresectable or metastatic melanoma. * Subject has no prior systemic treatment for advanced disease. * Subject must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST version 1.1). * Tumor tissue from site of unresectable or metastatic melanoma must be available for biomarker analyses in order to be randomized. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1. Key,"* Subject has had any prior systemic anti-cancer therapy for the treatment of advanced melanoma. * Known hypersensitivity to monoclonal antibodies or to any of the excipients of the study drug. * Subject has active central nervous system (CNS) metastases not previously treated. * Ocular melanoma. * Subject has active or known immune-mediated disorders. * Subject has had prior treatment with PD-1/PD-L1 and cytotoxic T lymphocyte- associated protein 4 inhibitors, or other antibodies targeting immune checkpoint pathways. * Subject has medical conditions requiring systemic immunosuppression with either corticosteroids or other immunosuppressive medications within 14 days of the first dose of investigational product. Other protocol-defined inclusion/exclusion criteria apply."
NCT05675410,A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma,,PHASE3,Puerto Rico,"University Pediatric Hospital, San Juan, Puerto Rico, [RECRUITING]",Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8,8,"[1] Arm A (ABVD) (ACTIVE_COMPARATOR): Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at le... || [2] Arm B (ABVD, brentuximab vedotin, nivolumab) (EXPERIMENTAL): Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at le... || [3] Arm C (ABVD, eBEACOPP or eBPDac, ISRT) (EXPERIMENTAL): See Detailed Description. || [4] Arm D (ABVD, brentuximab vedotin, nivolumab, ISRT) (EXPERIMENTAL): Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at le... || [5] Arm E (ABVD, AVD) (EXPERIMENTAL): Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at le... || [6] Arm F (ABVD, brentuximab vedotin, nivolumab) (EXPERIMENTAL): Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at le... || [7] Arm G (ABVD, eBEACOPP or eBPDac, ISRT) (EXPERIMENTAL): Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at le... || [8] Arm H (ABVD, brentuximab vedotin, nivolumab, ISRT) (EXPERIMENTAL): Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at le...","* Patients must be 5 to 60 years of age at the time of enrollment * Patients with newly diagnosed untreated histologically confirmed classic Hodgkin lymphoma (cHL) (nodular sclerosis, mixed cellularity, lymphocyte-rich, or lymphocyte-depleted, or not otherwise specified \[NOS\]) with stage I or II disease * Patients must have bidimensionally measurable disease (at least one lesion with longest diameter \>= 1.5 cm) * Patients must have a whole body or limited whole body PET scan performed within 42 days prior to enrollment. PET-CT is strongly preferred. PET-MRI allowed if intravenous contrast enhanced CT is also obtained * Pediatric patients (age 5-17 years) with known or suspected mediastinal disease must have an upright posteroanterior (PA) chest X-ray (CXR) for assessment of bulky mediastinal disease. * Note: Pediatric patients who have received both a CT chest and upright PA CXR may meet the definition of bulk through either modality. * Patients \>= 18 years must have a performance status corresponding to Zubrod scores of 0, 1 or 2 * Patients =\< 17 years of age must have a Lansky performance score of \>= 50 * Pediatric patients (age 5-17 years): A serum creatinine based on age/gender as follows (within 28 days prior to enrollment): * 2 to \< 6 years (age): 0.8 mg/dL (male), 0.8 mg/dL (female) * 6 to \< 10 years (age): 1 mg/dL (male), 1 mg/dL (female) * 10 to \< 13 years (age): 1.2 mg/dL (male), 1.2 mg/dL (female) * 13 to \< 16 years (age): 1.5 mg/dL (male), 1.4 mg/dL (female) * \>= 16 years (age): 1.7 mg/dL (male), 1.4 mg/dL (female) OR a 24 hour urine creatinine clearance \>= 50 mL/min/1.73 m\^2 (within 28 days prior to enrollment) OR a glomerular filtration rate (GFR) \>= 50 mL/min/1.73 m\^2 (within 28 days prior to enrollment). GFR must be performed using direct measurement with a nuclear blood sampling method OR direct small molecule clearance method (iothalamate or other molecule per institutional standard) * Note: Estimated GFR (eGFR) from serum or plasma ","* Patients with nodular lymphocyte predominant Hodgkin lymphoma * Patients with a history of active interstitial pneumonitis or interstitial lung disease * Patients with a diagnosis of inherited or acquired immunodeficiency that is poorly controlled or requiring active medications, such as primary immunodeficiency syndromes or organ transplant recipients * Patients with any known uncontrolled intercurrent illness that would jeopardize the patient's safety such as infection, autoimmune conditions, cardiac arrhythmias, angina pectoris, and gastrointestinal disorders affecting swallowing and/or absorption of pills * Patients with a condition requiring systemic treatment with either corticosteroids (defined as equivalent to \> 10 mg daily predniSONE for patients \>= 18 years or \> 0.5 mg/kg \[up to 10 mg/day\] for patients \< 18 years) or other immunosuppressive medications within 14 days prior to enrollment * Note: Replacement therapy such as thyroxine, insulin, or physiologic corticosteroid for adrenal or pituitary insufficiency is not considered a form of systemic treatment. Inhaled or topical steroids, and adrenal replacement doses (=\< 10 mg daily for patients \>= 18 years or =\< 0.5 mg/kg \[up to 10 mg/day\] predniSONE equivalents) are permitted in the absence of active autoimmune disease * Note: Steroid use for the control of Hodgkin lymphoma symptoms is allowable, but must be discontinued by cycle 1, day 1 * Short term use of corticosteroids for premedication or treatment of an allergy or hypersensitivity is considered an acceptable use of corticosteroids. * Patients with peripheral neuropathy \> grade 1 at the time of enrollment or patients with known Charcot-Marie-Tooth syndrome * Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen * Administration of prior chemotherapy, radiation, or antibody-based treatment for cHL * Prior solid "
NCT06077123,Differential Effects of a Telemonitoring Platform in the Development of Chemotherapy-Associated Toxicity: A Randomised Trial,DETECT,NA,Chile,"Centro del Cáncer, Pontificia Universidad Católica de Chile, Santiago, Chile, [RECRUITING] | Complejo Asistencial Dr. Sotero del Río, Santiago, Chile, [NOT_YET_RECRUITING]",Cancer | Chemotherapeutic Agent Toxicity,2,[1] Telemonitoring Platform (EXPERIMENTAL): Patients allocated to the active intervention group will receive a smartphone application called Contigo. This tool aims to detect signs and symptoms of oncology drug toxicity and delivering educat... || [2] Traditional Follow-Up (NO_INTERVENTION): Those assigned to the traditional follow-up group will receive standard care and in-person check-ups as determined by their attending physician.,"* Adult patients (\>18 years) * Histologically confirmed diagnosis of lung, gastric, gallbladder, colon, breast, or cervical carcinoma in any of its forms and stages * Initiating an outpatient curative intent chemotherapy regimen within the facilities of UC-Christus Health Network or Hospital Sotero del Río during the months of November 2023 to July 2024 * Proficient in the Spanish language * Possess a smartphone, regardless of the native operating system (iOS® or Android®)",* Individuals undergoing concomitant radiotherapy * Those with any form of sensory impairment hindering the use of the application * Those with cognitive impairment or psychiatric pathology preventing the use of the application * Those who do not wish to participate in the study
NCT05996367,Prospective Cohort Assessing the Impact of Single-dose Radiotherapy in the Treatment of Painful Bone Lesions in Patients With Multiple Myeloma,,NA,Brazil,"University of Sao Paulo, São Paulo, Brazil, [RECRUITING]",Multiple Myeloma,1,[1] Single Arm (EXPERIMENTAL): Single-dose radiation to involved-site,* Biopsy of plasma cell neoplasm with bone lesion treatable with radiotherapy; * Age between 18 and 85 years old; * Performance on the ECOG scale less than or equal to 2. * Not using systemic therapies for 4 weeks OR being on maintenance therapy with the same drug for at least 4 weeks before radiotherapy.,"* Refusing to sign or inability to understand the consent term; * Pain less than 2/10 on the numeric pain rating scale; * Change in systemic treatment scheme, including use of bone metabolism modulation drugs, up to 4 weeks before radiotherapy treatment; * Technical incapacity for the treatment, including, but not limited to, weight greater than 115Kg, inability to abduct the limb to be treated in appendicular bones, intolerable pain to remain in the treatment position; * Previous cancer and previous oncological treatments; * Previous autoimmune diseases, even if controlled; * Current pregnancy."
NCT06670911,"A Phase II Trial of Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer - ACCESS I",ACCESS-I,PHASE2,Brazil,"Instituto Nacional de Cancer, Rio de Janeiro, Brazil, [RECRUITING]","Persistent, Recurrent, or Metastatic Cervical Cancer",1,[1] Low-dose Pembrolizumab Plus Chemotherapy (EXPERIMENTAL): pembrolizumab 100mg intravenous infusion plus chemotherapy every 3 weeks. Chemotherapy may consist of paclitaxel 175 mg/m² + carboplatina AUC 5 or paclitaxel 175 mg/m² + cisplatin 50 mg/m² for pati...,"1. ) Female participants aged 18 years and older 2. ) Patients with persistent, recurrent, or metastatic squamous cell, adenocarcinoma, or adenosquamous cervical cancer, with PD-L1 CPS ≥ 1 expression, who have not received prior chemotherapy and are ineligible for curative surgery and/ or radiotherapy. Prior chemotherapy used as a radiosensitizer and completed at least 2 weeks before the scheduled date for C1D1 with resolution of all treatment-related toxicities is allowed. Adverse events due to prior treatments must be resolved to ≤ grade 1 or the participant's baseline. Neuropathy ≤ grade 2 or alopecia of grade ≤ 2 are eligible. 3. ) Not pregnant or breastfeeding a ) Fertile-age women with the potential to become pregnant must agree to follow contraceptive guidance during treatment and for at least 120 days after the last dose of pembrolizumab and 210 days after the last dose of chemotherapy. Abstinence is acceptable if it is the participant's usual lifestyle and preferred contraception. 4. ) The participant (or legal representative, if applicable) must provide written informed consent for the study. The participant may also provide consent for future biomarker research. However, the participant may participate in the main study without participating in future biomarker research. 5. ) Have measurable disease according to RECIST 1.1 criteria, as assessed by the local investigator/radiologist. Lesions located in a previously irradiated area are considered measurable only if progression has been demonstrated. 6. ) Have an archived tumor tissue sample (recurrent or metastatic cervical cancer) no older than 4 years or provide a biopsy of a previously unirradiated tumor lesion for prospective PD-L1 status determination, since only participants with PD-L1 expression CPS ≥ 1 will be included in the study. 7. ) Performance Status/Eastern Cooperative Oncology Group (ECOG) of 0 to 1 within 7 days prior to C1D1 8. ) Have adequate organ function, as indicated by the following ","1. ) Positive urine pregnancy test within 72 hours prior to C1D1. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; 2. ) Presence of known active central nervous system metastases and/or carcinomatous meningitis. Participants with known brain metastases may be included provided that the brain metastases have been previously treated (except with chemotherapy) and are radiographically stable. To demonstrate radiographic stability of previously treated brain metastases, a minimum of two post-treatment brain imaging evaluations are required: 1) The first brain image should be acquired after completion of the treatment of brain metastases. 2) The second image should be obtained during screening (i.e., within 28 days prior to the scheduled C1D1 date) and \>4 weeks after the prior post-treatment brain image.Known brain metastases are considered active if any of the following criteria apply: a ) The brain image obtained during screening shows progression of existing metastases or the appearance of new lesions compared to brain images taken at least 4 weeks earlier b ) The neurological symptoms attributed to brain metastases have not returned to baseline; c) Steroid doses exceeding 10 mg of prednisone daily (or equivalent) were used to treat symptoms related to brain metastases within 28 days prior to the scheduled C1D1 date. 3. ) Presence of other known malignancies within the past 3 years. Participants with basal cell carcinoma or squamous cell carcinoma of the skin who have undergone potentially curative therapy are not excluded. 4. ) Having a diagnosis of immunodeficiency or being on chronic systemic steroid therapy (at doses greater than 10 mg daily prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the scheduled C1D1 date. 5. ) Having an active autoimmune disease that has required systemic treatment within the past 2 years (i.e., with the use of disease-modifying agents, "
NCT04152109,Evaluation of Integrative and Complementary Practices in Health (PICS),PICS,NA,Brazil,"Núcleo de Praticas Integrativas e Complementares, Uberaba, Brazil, [RECRUITING]",Neoplasms | Epilepsy,3,"[1] Without laying on of hands (OTHER): The patients will remain in bed supine with blindfolds. A volunteer will move close to the patient with hands behind and mentally repeat the alphabet or do count math during 5 minutes, around 8 weeks. || [2] Laying on of hands with healing intent and without Spiritual connection (SHAM_COMPARATOR): Participants included in this subgroup will be exposed to the laying on of hands with healing intent by volunteers. The patients will be blindfold in the supine bed during 5 minutes, 8 weeks. || [3] Laying on of hands with healing intent and Spiritual connection by Spiritual ""Passe"" (EXPERIMENTAL): The participants will be subjected application of the laying on of hands by the passistas who will give the Spiritist ""passe"". Patients remain in the supine bed blindfolded for 5 minutes, around 8 ...",* Cancer patients: diagnosis of neoplasia receiving parenteral chemotherapy. * Epileptic patients: clinical diagnosis of focal epilepsy,"* Cancer patients: pregnant women, unable to understand the questionnaires; non-attendance of 3 sessions of therapy application and refusal to sign the consent form. * Epileptic patients: people unable to understand the questionnaires; non-attendance of 3 sessions of therapy application and refusal to sign the consent form, as well as special groups (pregnant women, newly diagnosed epilepsy)."
NCT06731907,"KEYMAKER-U01 Substudy 01G: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab With or Without Platinum-based Chemotherapy in Treatment-Naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)",,PHASE2,Chile,"Centro de Estudios Clínicos SAGA ( Site 0162), Santiago, Chile, [RECRUITING] | FALP ( Site 0161), Santiago, Chile, [RECRUITING] | Bradfordhill ( Site 0160), Santiago, Chile, [RECRUITING]",Non-small Cell Lung Cancer,2,[1] Pembrolizumab and Chemotherapy (ACTIVE_COMPARATOR): Pembrolizumab will be administered as a 200mg IV infusion on Day 1 of every three weeks (Q3W) for up to 35 cycles (\~ 2 years). The doublet platinum-based chemotherapy treatments used in this subst... || [2] Pembrolizumab and HER3-DXd (EXPERIMENTAL): Pembrolizumab will be administered as a 200mg IV infusion on Day 1 Q3W for up to 35 cycles (\~ 2 years). HER3-Dxd will be administered as 5.6mg/kg IV infusion on Day 1 Q3W until discontinuation cri...,"The main inclusion criteria include but are not limited to the following: * Histologically or cytologically confirmed diagnosis of Stage IV squamous or non-squamous non-small cell lung cancer (NSCLC) per American Joint Committee on Cancer (AJCC) Staging Manual Version 8. * Has an Eastern Cooperative Oncology Group (ECOG) performance status of either 0 or 1 as assessed within 7 days before randomization. * Has archival tumor tissue sample or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated has been provided. * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on ART. * Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to treatment randomization.","The main exclusion criteria include but are not limited to the following: * Has a diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements. * Participants with squamous histology are excluded if there is a known tumor-activating epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) or c ros oncogene 1 (ROS1) gene rearrangement. * Is HIV-infected with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder, or any autoimmune, connective tissue, or inflammatory disorders with pulmonary involvement. * Has evidence of any leptomeningeal disease. * Has known history of, or active, neurologic paraneoplastic syndrome. * Has clinically significant corneal disease. * Has myocardial infarction within 6 months. * Has New York Heart Association (NYHA) Classes 3 or 4 congestive heart failure. * Has uncontrolled angina pectoris within 6 months. * Has cardiac arrhythmia requiring ongoing antiarrhythmic treatment. * Has history of clinically relevant ventricular arrhythmias, such as ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes. * Has bradycardia of less than 50 beats per minute (bpm) unless the participant has a pacemaker. * Has history of second- or third-degree heart block. Candidates with a history of heart block may be eligible if they currently have pacemakers and have no history of fainting or clinically relevant arrhythmia with pacemakers. * Has coronary/peripheral artery bypass graft within 6 months. * Has complete left bundle branch block. * Has inadequate washout period from prior concomitant therapy as specified in protocol before randomization. * Has received prior treatment with a topoisomerase I inhibitor or an anti-HER3 antibody and/or ADC that consists of an exatecan derivative that is a topoisomerase I inhibit"
NCT05554393,"A Measurable Residual Disease (MRD) Driven, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients With Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial",,PHASE2,Puerto Rico,"Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico, [RECRUITING] | San Juan City Hospital, San Juan, Puerto Rico, [RECRUITING]",Acute Myeloid Leukemia,3,"[1] ARM I (daunorubicin, cytarabine, venetoclax) (EXPERIMENTAL): Patients receive daunorubicin IV on days 2-4, cytarabine IV continuously on days 2-8, and venetoclax PO QD on days 1-11. Cycle is 28 days and treatment is given in the absence of disease progressio... || [2] ARM II (azacitidine, venetoclax) (EXPERIMENTAL): Patients receive azacitidine IV or SC on days 1-7 or days 1-5 and 8-9 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for a total of 2 cycles, in the absence of disease pr... || [3] ARM III (daunorubicin, cytarabine) (ACTIVE_COMPARATOR): Patients receive daunorubicin IV on days 1-3 and cytarabine IV, continuously, on days 1-7. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Ba...","* Patient must have enrolled onto MYELOMATCH and must have been given a treatment assignment to MyeloMATCH to MM1YA-CTG01 based on the presence of an actionable mutation as defined in MYELOMATCH * Participants must have been registered to master screening and re-assessment protocol (myeloMATCH MSRP) prior to consenting to this study. Participants must have been assigned to this clinical trial, via MATCHBox, prior to registration to this study. Participants must have agreed to have specimens submitted for translational medicine (MRD) and must be offered the opportunity to submit biosamples for banking for future research as per the myeloMATCH MSRP * Note: Pre-enrollment/diagnosis labs must have already been performed under the MSRP * Previously untreated, de novo acute myeloid leukemia (AML) defined by \> 20% myeloblasts in the peripheral blood or bone marrow (refer to the 2016 updated World Health Organization \[WHO\] classification of myeloid neoplasms and acute leukemia) excluding all the following categories of AML: * Favorable cytogenetics: (t(8;21)q22;q22.1); RUNX1-RUNX1T1, inversion 16(p13.1;q22), t(16;16)(p13.1;q22); CBFB-MYH11 * CEBPA biallelic mutations * NPM1 mutation * AML with PML-RARalpha * AML with any adverse cytogenetics, TP53 mutation, RUNX1 mutation, ASXL1, 11q23/KMT2 rearrangements * AML with FLT3-ITD or FLT3-TKD mutations * Therapy related AML, or AML following a diagnosis of myelodysplasia or myeloproliferative neoplasm Participants with central nervous system (CNS) disease are eligible for this trial and will be treated according to institutional guidelines with intrathecal chemotherapy for this aspect of their disease * Age 18-59 years at time of induction therapy * Eastern Cooperative Oncology Group (ECOG) performance status =\< 3 * Total bilirubin =\< 2 x institutional upper limit of normal (ULN) (must be done within 7 days of enrollment) * Aspartate aminotransferase (AST) (serum glutamate pyruvate transaminase \[SGPT\]) +/or alanine aminotr","* Prior therapy for AML except for hydroxyurea and leukapheresis to control blood counts. The use of all-trans retinoic acid (ATRA) is permitted until a diagnosis of acute promyelocytic leukemia, if suspected, is ruled out * Patients who are receiving any other investigational agents * History of allergic reactions attributed to compounds of similar chemical or biologic composition to cytarabine, daunorubicin, azacitidine, venetoclax * Pregnant women are excluded from this study because venetoclax, cytarabine and azacitidine have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with venetoclax, cytarabine and azacitidine breastfeeding should be discontinued if the mother is treated with venetoclax, cytarabine and azacitidine. These potential risks may also apply to other agents used in this study * Patients with isolated myeloid sarcoma are not eligible * Any other serious intercurrent illness, life threatening condition, organ system dysfunction, or medical condition judged by the local investigator to compromise the subject's safety (for example): * Active, uncontrolled bacterial, fungal, or viral infection"
NCT06618287,"A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors",,"PHASE1, PHASE2",Chile,"Local Institution - 0048, Santiago, Chile, [NOT_YET_RECRUITING] | Local Institution - 0049, Santiago, Chile, [NOT_YET_RECRUITING] | Local Institution - 0047, Santiago, Chile, [NOT_YET_RECRUITING]",Lung Cancer | Breast Cancer,3,[1] Group A (EXPERIMENTAL): No description || [2] Group B (EXPERIMENTAL): No description || [3] Group C (EXPERIMENTAL): No description,"* Participants must have at least one measurable lesion per response evaluation criteria in solid tumors. * Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Participants must have a life expectancy of at least 3 months at the time of the first dose. * Group A: Participants must have pathologically confirmed locally advanced or metastatic NSCLC with an EGFR exon 19 deletion or L858R mutation in exon 21, either alone or in combination with other EGFR mutations, which may include T790M in exon 20. Participants with other EGFR mutations (including but not limited to, exon 21 L861Q, exon 18 G719X, and exon 20 S768I mutations, etc.) will also be allowed * Group B: Participants must have pathologically confirmed locally advanced or metastatic NSCLC. * Group C: Participants must have pathologically confirmed locally-advanced, recurrent inoperable, or metastatic TNBC or ER-low, HER2-negative BC.",* Participants must not have any mixed Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) histology. * Participants with known mutations in EGFR will be excluded (Group B). * Participants must not have a history of serious recurrent infections. * Participants must not have a history of severe heart disease. * Other protocol-defined Inclusion/Exclusion criteria apply.
NCT05572515,"A Phase 3 Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide",MajesTEC-9,PHASE3,Brazil,"Hospitais Integradaos da Gavea S/A - DF Star, Brasília, Brazil, [COMPLETED] | Fundacao Universidade de Caxias do Sul, Caxias do Sul, Brazil, [COMPLETED] | Liga Paranaense de Combate ao Cancer, Curitiba, Brazil, [ACTIVE_NOT_RECRUITING] | Instituto Joinvilense de Hematologia e Oncologia Ltda Centro de Hematologia e Oncologia, Joinville, Brazil, [ACTIVE_NOT_RECRUITING] | Liga Norte Riograndense Contra O Cancer, Natal, Brazil, [COMPLETED] | Complexo Hospitalar de Niteroi, Niterói, Brazil, [ACTIVE_NOT_RECRUITING] | Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI), Rio de Janeiro, Brazil, [COMPLETED] | Hospital Sao Rafael, Salvador, Brazil, [ACTIVE_NOT_RECRUITING] | Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto Hospital de Base, São José do Rio Preto, Brazil, [ACTIVE_NOT_RECRUITING] | Sociedade Beneficente de Senhoras Hospital Sirio Libanes, São Paulo, Brazil, [COMPLETED]",Relapsed or Refractory Multiple Myeloma,2,"[1] Teclistamab (EXPERIMENTAL): Participants will receive teclistamab monotherapy in Part 1 and an alternative dosing regimen of teclistamab in Part 2. || [2] Pomalidomide, Bortezomib and Dexamethasone (PVd) or Carfilzomib and Dexamethasone (Kd) (EXPERIMENTAL): Participants will receive either PVd or Kd based on principal investigator's choice during Part 1 of the study.","* Documented diagnosis of multiple myeloma as defined by the criteria below: (a)Multiple myeloma diagnosis according to International Myeloma Working Group (IMWG) diagnostic criteria (b) Measurable disease at screening as defined by any of the following: (1) Serum M-protein level greater than or equal to (\>=)0.5 grams per deciliter (g/dL) (central laboratory); or (2) Urine M-protein level \>=200 milligrams (mg)/24 hours (central laboratory); or (3) Serum immunoglobulin free light chain \>=10 milligrams per deciliter (mg/dL) (central laboratory) and abnormal serum immunoglobulin kappa lambda free light chain ratio * Received 1 to 3 prior lines of antimyeloma therapy including a minimum of 2 consecutive cycles of an anti- cluster of differentiation 38 (CD38) monoclonal antibody at the approved dosing regimen in any prior line and 2 consecutive cycles of lenalidomide in any prior line * Documented evidence of progressive disease or failure to achieve a response to last line of therapy based on investigator's determination of response by International myeloma working group (IMWG) criteria * Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2 * A female participant must agree not to be pregnant, breast-feeding, or plan to become pregnant while enrolled in this study or within 6 months after the last dose of study treatment * Must be willing and able to adhere to the lifestyle restrictions specified in this protocol","* Received any prior B cell maturation antigen (BCMA)-directed therapy * A participant is not eligible to receive PVd as control therapy if any of the following are present: (1) Received prior pomalidomide therapy, (2) Does not meet criteria for bortezomib retreatment (3) Contraindications or life-threatening allergies, hypersensitivity, or intolerance to pomalidomide or bortezomib, (4) Grade 1 peripheral neuropathy with pain or Grade greater than or equal to (\>=) 2 peripheral neuropathy as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0, (5) Received a strong cytochrome P (CYP) 3A4 inducer within 5 half-lives prior to randomization; A participant is not eligible to receive Kd as control therapy if any of the following are present:(1) Received prior carfilzomib therapy, (2) Uncontrolled hypertension, defined as an average systolic blood pressure greater than (\>)159 millimeters of mercury (mmHg) or diastolic blood pressure \>99 mmHg despite optimal treatment (3) Grade 2 peripheral neuropathy with pain or Grade \>=3 peripheral neuropathy as defined by NCI-CTCAE Version 5.0, (4) Contraindications or life-threatening allergies, hypersensitivity, or intolerance to carfilzomib (intolerance defined as prior therapy discontinued due to any adverse event \[AE\] related to carfilzomib) * Received a maximum cumulative dose of corticosteroids of \>=140 mg of prednisone or equivalent within 14 days prior to randomization * Received a live, attenuated vaccine within 4 weeks before randomization * Central nervous system (CNS) involvement or clinical signs of meningeal involvement of multiple myeloma * Plasma cell leukemia at the time of screening, Waldenstrom's macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, M-protein (POEMS) syndrome and skin changes, or primary amyloid light chain amyloidosis"
NCT06345729,"A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic NSCLC With PD-L1 TPS ≥50% (KANDLELIT-004)",,PHASE3,"Argentina, Brazil, Chile, Mexico","AUSTRAL MEDICAL CENTER ( Site 0302), CABA, Argentina, [COMPLETED] | Centro Oncologico Korben ( Site 0304), CABA, Argentina, [RECRUITING] | Instituto de Investigaciones Clínicas Mar del Plata ( Site 0300), Mar del Plata, Argentina, [RECRUITING] | Fundacion Estudios Clinicos ( Site 0306), Rosario, Argentina, [RECRUITING] | Sanatorio Parque ( Site 0301), Rosario, Argentina, [RECRUITING] | Hospital Mario Penna ( Site 0436), Belo Horizonte, Brazil, [RECRUITING] | Hospital de Câncer de Recife ( Site 0447), Recife, Brazil, [RECRUITING] | Oncoclínica Oncologistas Associados ( Site 0441), Teresina, Brazil, [RECRUITING] | Liga Norte Riograndense Contra o Câncer ( Site 0439), Natal, Brazil, [RECRUITING] | Irmandade da Santa Casa de Misericórdia de Porto Alegre-Centro Multidisciplinar de Pesquisa Clínica ( Site 0435), Porto Alegre, Brazil, [RECRUITING]",Non-small Cell Lung Cancer,2,[1] MK-1084 with Pembrolizumab (EXPERIMENTAL): Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles and MK-1084 by oral tablets once daily until discontinuation criterio... || [2] Placebo with Pembrolizumab (ACTIVE_COMPARATOR): Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles and placebo by oral tablets once daily until discontinuation criterio...,"* Has histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC) * Has newly diagnosed Stage IIIB/IIIC NSCLC, not eligible for curative resection or curative chemotherapy/radiation as determined by a multidisciplinary tumor board and/or by radiation oncologist, surgeon, and medical oncologist or Stage IV (M1a, M1b, or M1c) by American Joint Committee on Cancer (AJCC) Staging Manual, Version 8 * Provides an archival tumor tissue sample (≤5 years) or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated to enable central laboratory testing of kirsten rat sarcoma (KRAS) G12C mutation status, PD-L1 status, and biomarker research * If have had adverse events (AEs) due to previous anticancer therapies, must have recovered to \< Grade 1 or baseline * If human immunodeficiency virus (HIV)-infected, must have well controlled HIV on antiretroviral therapy (ART) * If Hepatitis B surface antigen (HBsAg) positive, have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load * If a participant has a history of Hepatitis C virus (HCV) infection, HCV viral load is undetectable","* Has diagnosis of small cell lung cancer. For mixed tumors, if small cell elements are present, the participant is ineligible * Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease * Has known history of, or active, neurologic paraneoplastic syndrome * Has an active infection requiring systemic therapy, with exceptions * Has uncontrolled, significant cardiovascular disease or cerebrovascular disease * Has one or more of the following ophthalmological findings/conditions: intraocular pressure \>21 mmHg and/or any diagnosis of glaucoma, diagnosis of central serous retinopathy, retinal vein occlusion, or retinal artery occlusion, diagnosis of retinal degenerative disease * Has received prior systemic anticancer therapy for their locally advanced or metastatic NSCLC * Has received radiation therapy to the lung that is \>30 Gray within 6 months of start of study intervention * Has received radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not required corticosteroids, and not have had radiation pneumonitis * Has known active central nervous system metastases and/or carcinomatous meningitis * Known additional malignancy that is progressing or has required active treatment within the past 3 years * Has active autoimmune disease that has required systemic treatment in the past 2 years * Has history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease * Is HIV-infected and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Has history of allogenic tissue/solid organ transplant * Has not fully recovered from any effects of major surgical procedure"
NCT06504394,"A Phase 2 Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)",,PHASE2,"Chile, Mexico","IC La Serena Research ( Site 0204), La Serena, Chile, [RECRUITING] | FALP ( Site 0207), Santiago, Chile, [RECRUITING] | Clínica Inmunocel ( Site 0201), Santiago, Chile, [RECRUITING] | Bradfordhill-Clinical Area ( Site 0202), Santiago, Chile, [RECRUITING] | Biocenter ( Site 0203), Concepción, Chile, [RECRUITING] | Health Pharma Professional Research S.A. de C.V: ( Site 0403), Mexico City, Mexico, [RECRUITING] | Centro de Investigacion Clinica de Oaxaca ( Site 0405), Oaxaca City, Mexico, [RECRUITING]",Classical Hodgkin Lymphoma Recurrent | Classical Hodgkin Lymphoma Refractory | Primary Mediastinal Large B-cell Lymphoma Recurrent | Primary Mediastinal Large B-cell Lymphoma Refractory,1,[1] Pembrolizumab Coformulated With Hyaluronidase (EXPERIMENTAL): Participants with rrCHL and rrPMBCL receive pembrolizumab coformulated with hyaluronidase subcutaneous (SC) injection on Day 1 of each 6-week cycle (Q6W) for up to 18 cycles (approximately 2 years)...,"The main inclusion criteria include but are not limited to the following: * Histologically confirmed diagnosis of classical Hodgkin lymphoma (cHL) or primary mediastinal B-cell lymphoma (PMBCL) * Radiographically measurable cHL or PMBCL disease assessed by investigator as per Lugano classification * Have a life expectancy of \>3 months * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART) * Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load before enrollment * Participants with history of hepatitis C virus (HCV) infection are eligible if they have completed curative antiviral therapy at least 4 weeks before enrollment and HCV viral load is undetectable at screening * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 7 days before or on the day of the first dose of study intervention","The main exclusion criteria include but are not limited to the following: * Has clinically significant (i.e., active) cardiovascular disease * Has pericardial effusion or clinically significant pleural effusion * Has known additional malignancy that is progressing or has required active treatment within the past 2 years * Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention * Received prior monoclonal antibody within 4 weeks prior to first dose of study intervention or has not recovered (i.e., ≤Grade 1 or at baseline) from adverse events (AEs) due to agents administered more than 4 weeks earlier * Received prior therapy with an anti-programmed cell death 1 protein (anti-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), or anti-programmed cell death ligand 2 (anti-PD-L2) agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor * Received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study intervention * Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids * Received a live or live-attenuated vaccine within 30 days before first dose of study intervention * Is receiving systemic antineoplastic chemotherapy, immunotherapy, or biological therapy not specified in this protocol * Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis * Active autoimmune disease that has required systemic treatment in the past 2 years * History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease * Active infection requiring systemic therapy except certain protocol-specified therapies * Concurrent active hepatitis B and hepatitis C virus infection * Has undergone solid organ "
NCT05833997,Safety Analysis and Oncological Outcomes in Endoscopic Bladder Tumor Resection With Laser Holmium Compared With Transurethral Resection: a Prospective and Randomized Study,,NA,Brazil,"Instituto do Cancer do Estado de São Paulo (ICESP), São Paulo, Brazil, [RECRUITING]",Bladder Urothelial Carcinoma | Bladder Cancer,2,[1] Holmium Laser En-bloc Resection of Bladder Tumors (HoLERBT) arm (EXPERIMENTAL): Patients randomized to HoLERBT group will have their tumor resected using the Megapulse 70w (Richard Wolf). || [2] Control arm (ACTIVE_COMPARATOR): Patients randomized to control arm will undergo a monopolar transurethral resection of bladder tumor.,"* Patients aged between 18 and 80 years old; * Presence of bladder tumor \> 3cm without signals of MIBC or advanced disease (US, CT scan or MRI 3 months before surgery) * Able to understand and willing to sign a written informed consent document * Satisfactory clinical pre operatory conditions for surgery with regional or general anesthesia.","* Previous diagnosis of muscle-invasive bladder cancer; * Tumor's Invasive aspect (T2 or more) on image (US, TC or RNM); * Previous TURBT in the last 5 years; * Urethral stenosis; * Previous intra-vesical os systemic chemotherapy or radiotherapy; * Previous treatment with intravesical BCG * No clinical conditions for regional or general anesthesia; * Any other significant disease or disorder which, in the opinion of the investigator may either put the participant at risk because of trial participation or may influence the trial result, or the participant's ability ti participate in the trial."
NCT03127631,The Role of Androgen Deprivation Therapy In Cardiovascular Disease - A Longitudinal Prostate Cancer Study (RADICAL PC1) & A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICAL PC2),RADICALPC,NA,"Brazil, Colombia","Centro de Pesquisa Clínica do Brasil, Brasília, Brazil, [RECRUITING] | Hospital Felício Rocho, Belo Horizonte, Brazil, [RECRUITING] | Universidade Federal do Triângulo Mineiro, Uberaba, Brazil, [RECRUITING] | Sociedade Hospitalar Angelina Caron, Campina Grande do Sul, Brazil, [RECRUITING] | Nucleo de Pesquisa Clinica Hospital do Rocio, Campo Largo, Brazil, [RECRUITING] | Centro Médico São Francisco, Curitiba, Brazil, [RECRUITING] | Instituto De Medicina Integral Prof. Fernando Figueira - IMIP, Recife, Brazil, [RECRUITING] | Instituto Nacional de Cardiologia, Rio de Janeiro, Brazil, [RECRUITING] | Hospital de Caridade de Ijuí, Ijuí, Brazil, [RECRUITING] | Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, [RECRUITING]",Prostate Cancer | Cardiovascular Disease,2,"[1] Randomized - Intervention (ACTIVE_COMPARATOR): The intervention will consist of a systematic cardiovascular and lifestyle risk factor modification strategy, including dietary and exercise advice, advice to quit smoking, and the prescription of ... || [2] Randomized - Control (NO_INTERVENTION): The control will consist of usual clinical care, which may include a referral to a cardiologist or internist, or the use of treatments included in the intervention as clinically indicated, if part ...","1\. A man with a diagnosis of prostate cancer that is either: * new (i.e. the diagnosis was made within 1 year of the enrolment visit) or * treated with Androgen Deprivation Therapy for the first time within 6 months prior to the enrolment visit, or * to be treated with Androgen Deprivation Therapy for the first time within 1 month after the enrolment visit","1. Patients will be excluded if they fulfill any of the following: 1. are unwilling to provide consent or 2. are \<45 years of age, or 3. prostate cancer was found incidentally following cystectomy for bladder cancer 2. Patients will be eligible for RADICAL PC1, but will not be eligible for RADICAL PC2 if they: 1. see a cardiologist every year, or 2. both take a statin and have systolic blood pressure ≤130mmHg"
NCT06312176,"An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer",,PHASE3,"Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, Peru, Puerto Rico","Instituto Alexander Fleming-Alexander Fleming ( Site 0382), Buenos Aires, Argentina, [RECRUITING] | Fundacion Estudios Clinicos-Oncology ( Site 0384), Rosario, Argentina, [RECRUITING] | Hospital Aleman-Oncology ( Site 0386), Buenos Aires, Argentina, [RECRUITING] | Centro de Educación Médica e Investigaciones clínicas ""Dr. Norberto Quirno"" (CEMIC) ( Site 0383), Buenos Aires, Argentina, [RECRUITING] | Hospital Italiano de Córdoba ( Site 0385), Córdoba, Argentina, [RECRUITING] | Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0387), La Rioja, Argentina, [RECRUITING] | Oncoclínica Oncologistas Associados-Clinical Research ( Site 0407), Teresina, Brazil, [RECRUITING] | Hospital Moinhos de Vento ( Site 0403), Porto Alegre, Brazil, [RECRUITING] | Hospital do Câncer Mãe de Deus ( Site 0404), Porto Alegre, Brazil, [RECRUITING] | Instituto de Oncologia Saint Gallen ( Site 0412), Santa Cruz do Sul, Brazil, [RECRUITING]",Breast Neoplasms,3,"[1] Arm A: Sacituzumab tirumotecan (EXPERIMENTAL): Participants receive 4 mg/kg of sacituzumab tirumotecan once every 2 weeks (Q2W) via intravenous (IV) infusion until progressive disease or discontinuation. || [2] Arm B:Pembrolizumab + Sacituzumab tirumotecan (EXPERIMENTAL): Participants receive 4 mg/kg of sacituzumab tirumotecan Q2W via IV infusion until progressive disease or discontinuation PLUS 400 mg of pembrolizumab once every 6 weeks (Q6W) via IV infusion for up... || [3] Arm C: Treatment of Physician's Choice (TPC) (ACTIVE_COMPARATOR): At the physician's discretion, participants receive chemotherapy of 80 mg/m\^2 of paclitaxel once every week (Q1W) via IV infusion OR 90 mg/m\^2 of paclitaxel once every 4 weeks (Q4W) via IV infusi...","* Has unresectable locally advanced or metastatic centrally-confirmed hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer * Has radiographic disease progression on one or more lines of endocrine therapy for unresectable locally advanced/metastatic HR+/HER2- breast cancer, with one in combination with a CDK4/6 inhibitor * Is a chemotherapy candidate * Has an eastern cooperative oncology group (ECOG) performance status of 0 to 1 assessed within 7 days before randomization * Has adequate organ function * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy * Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable HBV viral load * Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable","* Has breast cancer amenable to treatment with curative intent * Has experienced an early recurrence (\<6 months after completing adjuvant/neoadjuvant chemotherapy) and therefore is eligible to receive second-line (2L) treatment * Has symptomatic advanced/metastatic visceral spread at risk of rapidly evolving into life-threatening complications * Has received prior chemotherapy for unresectable locally advanced or metastatic breast cancer * Active autoimmune disease that has required systemic treatment in the past 2 years * History of (noninfectious) pneumonitis/interstitial lung disease that requires steroids, or has current pneumonitis/interstitial lung disease * Has an active infection requiring systemic therapy"
NCT06764875,"A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)",,PHASE3,"Argentina, Brazil, Chile, Peru, Puerto Rico","Research Site, Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Research Site, Ciudad Autónoma Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Research Site, Ciudad de Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Research Site, Rosario, Argentina, [NOT_YET_RECRUITING] | Research Site, Rosario, Argentina, [NOT_YET_RECRUITING] | Research Site, Viedma, Argentina, [NOT_YET_RECRUITING] | Research Site, Barretos, Brazil, [RECRUITING] | Research Site, Brasília, Brazil, [RECRUITING] | Research Site, Campo Grande, Brazil, [RECRUITING] | Research Site, Natal, Brazil, [WITHDRAWN]",HER2-positive Gastric Cancer | Gastroesophageal Junction Adenocarcinoma,3,[1] Arm A (EXPERIMENTAL): T-DXd + Rilvegostomig + Fluoropyrimidine (Capecitabine OR 5-FU) || [2] Arm B (ACTIVE_COMPARATOR): Pembrolizumab + Trastuzumab + FP (5-FU plus cisplatin) or CAPOX (capecitabine plus oxaliplatin) || [3] Arm C (ACTIVE_COMPARATOR): Rilvegostomig + Trastuzumab + FP (5-FU plus cisplatin) or CAPOX (capecitabine plus oxaliplatin),"* HER2 positive for gastric cancer on a tumor biopsy. * PD-L1 combined positive score (CPS) ≥ 1. * Provision of tumor tissue sample from recent biopsy adequate for HER2 and PD-L1 testing. * Previously untreated, unresectable, locally advanced or metastatic gastric or GEJ adenocarcinoma. * WHO or Eastern Cooperative Oncology Group performance status of 0 or 1. * Have measurable target disease assessed by the Investigator based on RECIST v1.1. * Have adequate organ and bone marrow function within 14 days before randomization. * LVEF ≥ 55% within 28 days before randomization. * Adequate treatment washout period before randomization.","* Lack of physiological integrity of the upper gastrointestinal tract. * Known dihydropyrimidine dehydrogenase enzyme deficiency. * Contraindication to pembrolizumab or trastuzumab, contraindications to fluoropyrimidine (5-FU and capecitabine) or platinum (cisplatin and oxaliplatin) treatment as per local label. * History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 3 years before the first dose of study intervention and of low potential risk for recurrence. * Persistent toxicities caused by previous anti-cancer therapy. * Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring corticosteroid or anticonvulsant may be included in the study if they have recovered from the acute toxic effect of radiotherapy. * Uncontrolled infection including tuberculosis and active hepatitis A infection. * Uncontrolled infection requiring intravenous (IV) antibiotics, anti-virals, or antifungals. * Recent receipt of live, attenuated vaccine. * Chronic/active HBV or HCV infection unless controlled. * Clinically significant cardiac or psychological conditions. * Active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment. * History of (non-infectious) ILD/pneumonitis, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. * Lung-specific intercurrent clinically significant illnesses. * Any active non-infectious skin disease requiring systemic treatment. * A pleural effusion, ascites or pericardial effusion that requires drainage, peritoneal shunt, or cell-free and concentrated ascites reinfusion therapy (CART). * History of any of the following: drug-induced severe cutaneous adverse reaction. * Any concurrent antic-ancer treatment with the exception of receptor activator of nuclear factor kappa-B ligand inhibitors. * Have had major surg"
NCT06393374,"A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery",,PHASE3,"Argentina, Brazil, Mexico","Hospital Aleman-Oncology ( Site 0501), Capital Federal, Argentina, [RECRUITING] | Hospital Británico de Buenos Aires-Oncology ( Site 0502), Ciudad Autónoma de Buenos Aires, Argentina, [RECRUITING] | Instituto Alexander Fleming-Alexander Fleming ( Site 0509), Buenos Aires, Argentina, [RECRUITING] | Instituto de Oncología Angel H. Roffo ( Site 0503), Buenos Aires, Argentina, [RECRUITING] | Sanatorio Parque ( Site 0512), Rosario, Argentina, [RECRUITING] | Sanatorio Finochietto ( Site 0513), Buenos Aires, Argentina, [RECRUITING] | Centro de Educación Médica e Investigaciones clínicas ""Dr. Norberto Quirno"" (CEMIC) ( Site 0508), Buenos Aires, Argentina, [RECRUITING] | PRONUTRIR-CLINICAL RESEARCH ( Site 0609), Fortaleza, Brazil, [RECRUITING] | Oncoclínica Oncologistas Associados-Clinical Research ( Site 0607), Teresina, Brazil, [RECRUITING] | Hospital do Câncer Mãe de Deus ( Site 0604), Porto Alegre, Brazil, [RECRUITING]",Triple-Negative Breast Cancer,2,"[1] Pembrolizumab + sacituzumab tirumotecan (EXPERIMENTAL): Participants receive pembrolizumab every 6 weeks (q6w) in combination with sacituzumab tirumotecan every 2 weeks (q2w) for 24 weeks. In addition, participants receive an antihistamine, an H2 antago... || [2] Treatment of Physician's Choice (ACTIVE_COMPARATOR): Participants receive pembrolizumab q6w or pembrolizumab q6w in combination with capecitabine (twice daily \[BID\] on Days 1 to 14 and 22 to 35 every 42 days x 4 \[2 weeks 1, 1 week off\]) for 24 we...","* Has centrally confirmed TNBC, as defined by the most recent American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines * Has no evidence of locoregional or distant relapse, as assessed by the treating physician * Had neoadjuvant treatment based on the KEYNOTE-522 regimen (pembrolizumab with carboplatin/taxanes and pembrolizumab with anthracycline-based chemotherapy) followed by surgery according to National Comprehensive Cancer Network (NCCN) treatment guidelines for TNBC * Had adequate excision and surgical removal of all clinically evident disease in the breast and/or lymph nodes and have adequately recovered from surgery * Has non-pathologic complete response at surgery * Is able to continue on adjuvant pembrolizumab * Randomization must be conducted within 16 weeks from surgical resection * Completed adjuvant radiation therapy (if indicated) and recovered before randomization * Has provided tissue from the surgical resection for central laboratory determination of trophoblast cell surface antigen 2 (TROP2) status * If capable of producing sperm, the participant agrees to the following during the intervention period and for at least the time needed to eliminate each study intervention after the last dose of study intervention (120 days for sacituzumab tirumotecan and 95 days for capecitabine \[no restriction for pembrolizumab\]): agrees to refrain from donating sperm AND is either abstinent and agrees to remain abstinent or uses highly effective contraception * For females (assigned at birth), is not pregnant or breastfeeding and ≥1 of the following applies: is not a participant of childbearing potential (POCBP) OR is a POCBP and uses highly effective contraception after the last dose of study intervention (210 days for sacituzumab tirumotecan, 120 days for pembrolizumab, and 185 days for capecitabine). Abstains from breastfeeding during the study intervention period and for at least 120 days after study intervention * Particip","* Has a known germline breast cancer gene (BRCA) mutation (deleterious or suspected deleterious) and is eligible for adjuvant therapy with olaparib where olaparib is approved and available * Has Grade \>2 peripheral neuropathy * History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing * Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea) * Has uncontrolled, significant cardiovascular disease or cerebrovascular disease including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QTcF interval to \>480 ms, and/or other serious cardiovascular and cerebrovascular diseases within 6 months prior to study intervention * Received prior treatment with a trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) or a topoisomerase I inhibitor-containing ADC * Received anticancer therapy in the adjuvant phase including but not limited to chemotherapy, small molecule anticancer drugs, poly (adenosine diphosphate ribose) polymerase (PARP) inhibitors, ADCs, and/or immunotherapy, with the exception of adjuvant radiation therapy * Is currently receiving a strong inducer/inhibitor of cytochrome P450 3A4 (CYP3A4) that cannot be discontinued for the duration of the study. The required washout period before starting sacituzumab tirumotecan is 2 weeks * Except for pembrolizumab as neoadjuvant therapy for early-stage TNBC: received prior therapy with an anti-programmed cell death 1 protein (anti-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein-4 \[CTLA-4\], OX-40 \"
NCT06161441,A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination With Chemotherapy Versus Cemiplimab in Combination With Chemotherapy in Patients With Resectable Early Stage (Stage II to IIIB [N2]) NSCLC,,PHASE2,Chile,"Orlandi Oncologia, Providencia, Chile, [RECRUITING] | Clinica Santa Maria, Santiago, Chile, [RECRUITING] | Centro de Oncologia de Precision, Las Condes, Chile, [RECRUITING] | Oncocentro APYS, Viña del Mar, Chile, [RECRUITING]",Resectable Non-small Cell Lung Cancer,3,"[1] Arm A (EXPERIMENTAL): Randomized 1:1:1

Neoadjuvant period:

placebo + cemiplimab + platinum doublet chemotherapy

Adjuvant period:

placebo + cemiplimab || [2] Arm B (EXPERIMENTAL): Randomized 1:1:1

Neoadjuvant period:

fianlimab high dose + cemiplimab + platinum doublet chemotherapy

Adjuvant period:

fianlimab high dose + cemiplimab || [3] Arm C (EXPERIMENTAL): Randomized 1:1:1

Neoadjuvant period:

fianlimab low dose + cemiplimab + platinum doublet chemotherapy

Adjuvant Period:

fianlimab low dose + cemiplimab","1. Patients with newly diagnosed, histologically confirmed, fully resectable stage II to IIIB (N2) NSCLC as per American Joint Committee on Cancer (AJCC) version 8 2. For patients with evidence of mediastinal adenopathy on imaging, mediastinal lymph node sampling is required as defined in the protocol 3. All patients must have disease status showing no evidence of distant metastases documented by a complete physical examination and imaging studies performed within 4 weeks prior to randomization as defined in the protocol 4. A patient must have an evaluable Programmed cell death ligand-1 (PD-L1) immunohistochemistry (IHC) result as defined in the protocol 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 6. Adequate bone marrow, hepatic and kidney function as defined in the protocol Key","1. Any evidence of locally advanced unresectable or metastatic disease as defined in the protocol 2. Patients with tumors with known Epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene translocations as defined in the protocol 3. Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B (HBV) or hepatitis C virus (HCV) infection as defined in the protocol 4. Treatment with anti-cancer therapy including immunotherapy, chemotherapy, radiotherapy, or biological therapy in the 3 years prior to randomization. Adjuvant hormonotherapy used for breast cancer or other hormone-sensitive cancers in long term remission is allowed. 5. Patients with a history of myocarditis Note: Other protocol-defined Inclusion/ Exclusion Criteria apply"
NCT06215027,Os Efeitos da dança Como Recurso terapêutico em Pacientes Com câncer de Mama Submetidas a Tratamento cirúrgico,,NA,Brazil,"AC Camargo Cancer Center, São Paulo, Brazil, [RECRUITING]",Breast Cancer,1,[1] Dance (EXPERIMENTAL): Dance,* patients diagnosed with breast cancer * undergone surgical resection * after medical referral for physiotherapy * and physiotherapeutic assessment,* patients with another previous oncological diagnosis * previous neuromuscular diseases * patients who do not agree to take part in the study * or the impossibility of carrying out the muscle strength assessment and/or other assessments
NCT03549273,Evaluation of the Effect of the Combination of the Natural Products Glizigen® and Ocoxin®-Viusid® in the Treatment of High-grade Cervical Intraepithelial Lesions. Phase II,,PHASE2,Cuba,"Our Lady of Rule No. 52 &/Remedios and Quiroga, Luyano, Havana, Cuba, [RECRUITING]","Carcinoma | Neoplasia; Intraepithelial, Cervix | Glandular Neoplasms | Epithelial Neoplasm | Neoplasms",1,[1] Treatment (EXPERIMENTAL): Glizigen® spray + Ocoxin-Visuid® oral solution,"1. Patients that meet the diagnostic criteria. 2. Patients with age ≥18 years. 3. Patients with residual lesion greater than 3 mm after the initial punch, measurable by video colposcopy and with major changes (Criteria from Rio 2011). 4. Patients that have a positive test to the oncogenic virus of the human papilloma (16, 18, 31, 33, 45, 52 and 58). 5. Patients who give their informed consent to participation in writing. 6. Patients who consent to perform the conization according to the study schedule. 7. Patients with normal laboratory parameters within the limits established in the institution (complete blood count, platelets and erythrosedimentation. In the case of male sex (vasectomy, use of condoms) while the treatment lasts.","1. Patients who have received surgical, ablative, radiant, immunomodulatory or chemotherapy treatment 30 days before recruitment. 2. Patients pregnant or breastfeeding. 3. Patients with acute cervico-vaginal infections. 4. Patients with positive serology known to HIV and/or syphilis. 5. Patients with diseases that compromise the state of consciousness or their possibility of collaboration. 6. Patients with a history of severe allergic history. 7. Patients who are participating in another research."
NCT06925737,"A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)",,PHASE3,"Argentina, Brazil, Chile, Guatemala","Instituto de Investigaciones Clinicas Mar del Plata ( Site 0129), Mar del Plata, Argentina, [RECRUITING] | Instituto Alexander Fleming ( Site 0125), Mar del Plata, Argentina, [RECRUITING] | Sanatorio Parque ( Site 0126), Rosario, Argentina, [RECRUITING] | Centro Medico Dra De Salvo ( Site 0132), CABA, Argentina, [RECRUITING] | Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0131), La Rioja, Argentina, [RECRUITING] | Centro Oncologico de Integracion Regional. COIR ( Site 0130), Mendoza, Argentina, [RECRUITING] | Centro de Diagnostico Investigación y Tratamiento Oncológico (CeDIT) ( Site 0135), Salta, Argentina, [RECRUITING] | Instituto San Marcos ( Site 0137), San Juan, Argentina, [RECRUITING] | Hospital de Base de São José do Rio Preto ( Site 0176), São José do Rio Preto, Brazil, [RECRUITING] | Bradfordhill ( Site 0200), Santiago, Chile, [RECRUITING]",Prostate Cancer | Prostatic Neoplasms,2,[1] I-DXd (EXPERIMENTAL): Participants receive I-DXd 12mg/kg every 3 weeks (q3w) || [2] Docetaxel (ACTIVE_COMPARATOR): Participants receive docetaxel 75 mg//m\^2 q3w and prednisone 10 mg/day or per approved product label,The main inclusion criteria include but are not limited to the following: * Has diagnosis of metastatic castration-resistant prostate cancer (mCRPC) * Has prostate cancer progression while on androgen deprivation therapy (ADT) (or post bilateral orchiectomy) within 6 months prior to entering the study * Has received prior treatment with 1 or 2 androgen receptor pathway inhibitor (ARPI) and progressed during or after at least 8 weeks of treatment,The main exclusion criteria include but are not limited to the following: * History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids * Has uncontrolled or significant cardiovascular disease * Has received prior treatment with a taxane-based chemotherapy agent for mCRPC
NCT06547853,Effect of an Exercise Program on Physical Performance and Health Outcomes in Cancer Survivors,POWERSurviv,NA,Brazil,"Federal University of Alagoas Institute of Physical Education and Sports, Alagoas, Brazil, [RECRUITING]",Breast Cancer Female | Exercise,1,"[1] Combined exercise training (EXPERIMENTAL): In the combined exercise training regimen, participants will perform two hospital-based sessions with 45 minutes of aerobic dance and resistance training. The intensity of the aerobic dance will be...","1. Women; 2. Adults; 3. confirmed diagnostic of breast cancer and with treatment completed (surgery, radiotherapy, or chemotherapy) within the previous six months.",1. present metastatic breast cancer; 2. any clinical condition that would make participating in the exercise intervention impossible.
NCT06282575,An Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer,,PHASE3,"Argentina, Brazil, Chile, Puerto Rico","Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires (caba), Argentina, [RECRUITING] | Fundación ARS Médica, San Salvador de Jujuy, Argentina, [RECRUITING] | Centro de Investigaciónes Clínicas - Clínica Viedma, Viedma, Argentina, [RECRUITING] | Hospital Provincial Del Centenario, Rosario, Argentina, [RECRUITING] | Instituto Médico de la Fundación Estudios Clínicos, Rosario, Argentina, [RECRUITING] | CAIPO Centro para la Atención Integral del Paciente Oncológico, San Miguel de Tucumán, Argentina, [RECRUITING] | Centro Médico en Oncología Clínica EXELSUS S.R.L, San Miguel de Tucumán, Argentina, [RECRUITING] | Centro Médico Privado CEMAIC, Córdoba, Argentina, [RECRUITING] | Liga Norte Riograndense Contra O Cancer, Natal, Brazil, [RECRUITING] | Hospital de Clinicas de Porto Alegre - HCPA, Porto Alegre, Brazil, [RECRUITING]",Biliary Tract Cancer,2,"[1] Zanidatamab with Standard-of-care Therapy Arm (EXPERIMENTAL): Zanidatamab plus standard of care treatment of CisGem with or without a PD-1/L1 inhibitor. PD-1/L1 inhibitor will be physician's choice of either Durvalumab or Pembrolizumab, where approved under l... || [2] Standard-of-care Therapy Arm (ACTIVE_COMPARATOR): Standard of care treatment of CisGem with or without a PD-1/L1 inhibitor. PD-1/L1 inhibitor will be physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations.","1. Histologically- or cytologically-confirmed Biliary Tract Cancer (BTC), including Gallbladder Cancer (GBC), Intrahepatic Cholangiocarcinoma (ICC), or Extrahepatic Cholangiocarcinoma (ECC). 2. Locally advanced unresectable or metastatic BTC and not eligible for curative resection, transplantation, or ablative therapies. 3. Received no more than 2 cycles of systemic therapy which is limited to Cisplatin and Gemcitabine (CisGem) with or without a PD-1/L1 inhibitor (physician's choice of durvalumab or pembrolizumab, where approved under local regulations) for advanced unresectable or metastatic disease. 4. HER2-positive disease (defined as IHC 3+; or IHC 2+/ ISH+) by IHC and in situ Hybridization (ISH) assay (in participants with IHC 2+ tumors) at a central laboratory on new biopsy tissue or archival tissue from the most recent biopsy. 5. Assessable (measurable or non-measurable) disease as defined by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), per investigator assessment. 6. Male or female ≥ 18 years or age (or the legal age of adulthood per country-specific regulations). 7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 8. Adequate organ function 9. Females of childbearing potential must have a negative pregnancy test result. 10. Females of childbearing potential and males with a partner of childbearing potential must be willing to use 2 methods of birth control.","1. Prior treatment with a HER2-targeted agent 2. Prior treatment with checkpoint inhibitors, other than durvalumab or pembrolizumab 3. The following BTC histologic subtypes are excluded: small cell cancer, neuroendocrine tumors, lymphoma, sarcoma, mixed tumor histology, and mucinous cystic neoplasms detected in the biliary tract region. 4. Use of systemic corticosteroids. 5. Brain metastases 6. Severe chronic or active infections 7. History of allogeneic organ transplantation. 8. Active or prior autoimmune inflammatory conditions 9. History of interstitial lung disease or non-infectious pneumonitis. 10. Participation in another clinical trial with an investigational medicinal product within the last 3 months. 11. Females who are breastfeeding 12. Any other medical, social, or psychosocial factors that, in the opinion of the investigator, could impact safety or compliance with study procedures. 13. Use of phenytoin"
NCT05419375,Master Screening Study to Determine Biomarker Status and Potential Trial Eligibility for Patients With Malignant Tumors,,PHASE2,"Brazil, Chile, Colombia, Costa Rica, Mexico","Crio - Centro Regional Integrado de Oncologia, Fortaleza, Brazil, [WITHDRAWN] | Hospital Sao Rafael - HSR, Salvador, Brazil, [WITHDRAWN] | Oncocentro Belo Horizonte, Belo Horizonte, Brazil, [ACTIVE_NOT_RECRUITING] | COT - Centro Oncologico do Triangulo, Uberlândia, Brazil, [COMPLETED] | Universidade de Caxias do Sul - Rio Grande do Sul, Caxias do Sul, Brazil, [RECRUITING] | Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil, [ACTIVE_NOT_RECRUITING] | Hospital Sao Lucas - PUCRS, Porto Alegre, Brazil, [RECRUITING] | Hospital Nossa Senhora da Conceicao, Porto Alegre, Brazil, [RECRUITING] | Hospital de Clínicas de Porto Alegre X, Porto Alegre, Brazil, [RECRUITING] | Clínica de Oncologia Reichow, Blumenau, Brazil, [ACTIVE_NOT_RECRUITING]",Solid Tumors,1,[1] Non-Small Cell Lung Cancer (NSCLC) (OTHER): Participants with NSCLC will be screened for biomarker eligibility for a linked Roche study.,"* Confirmed availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen meeting criteria defined in the protocol * Considered by principal investigator (PI) to be a candidate for a linked clinical trial with an investigational medicinal product, and that the participant has the awareness and willingness to participate in said trial Inclusion Criteria for Participants with Stage III NSCLC * Locally advanced, unresectable Stage III NSCLC of either squamous or non-squamous histology based on 8th edition of the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control (UICC) cancer staging system * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 Inclusion Criteria for Participants with Stage II, IIIA, or Select IIIB (T3N2 only) NSCLC Requiring Adjuvant Treatment * Stage II, IIIA, or select IIIB (T3N2 only) NSCLC based on the 8th edition of the AJCC and UICC cancer staging system (Amin et al. 2017) * Considered eligible for curative intent surgery (complete resection with all surgical margins testing negative for tumor) * Screening within Study BX43361, using a pretreatment biopsy, is encouraged to be performed as early in the participant treatment pathway as possible to ensure the participant is potentially eligible for all cohorts, and should meet guidelines as defined by the protocol * Representative FFPE tumor specimen obtained prior to the start of any treatment * ECOG Performance Status of 0 or 1 General","* History of malignancy other than NSCLC within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death * Any condition that may affect the interpretation of study results * Significant liver or cardiovascular disease * Prior allogenic stem-cell or solid-organ transplantation"
NCT05445778,"Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab",GLORIOSA,PHASE3,Argentina,"Sanatorio De La Mujer /ID# 269352, Rosario, Argentina, [RECRUITING] | Hospital Italiano de Buenos Aires /ID# 269356, Buenos Aires, Argentina, [RECRUITING] | Sociedad de Beneficiencia Hospital Italiano /ID# 269090, Córdoba, Argentina, [RECRUITING] | Isis Centro Especializado De Luce /ID# 269353, Santa Fe, Argentina, [RECRUITING]",Ovarian Cancer | Peritoneal Cancer | Fallopian Tube Cancer,2,[1] Arm 1 (EXPERIMENTAL): Mirvetuximab Soravtansine (MIRV) plus Bevacizumab || [2] Arm 2 (ACTIVE_COMPARATOR): Bevacizumab monotherapy,"1. Adult women \>/=18 years old 2. Confirmed diagnosis of high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer 3. Confirmed high FRα expression by regulatory-agency approved Ventana FOLR1 (FOLR1-2.1) 4. Relapsed disease after frontline (first-line) platinum-based chemotherapy and must be plantinum-sensitive 5. Willing and able to sign the informed consent form (ICF) and adhere to protocol requirements 6. Negative pregnancy test and willing to use highly effective contraceptive method(s) while on study medication and for at least 7 months after the last dose of MIRV and 6 months after the last dose of bevacizumab","1. Endometrioid, clear cell, mucinous, or sarconmatous histology; mixed tumors containing any of the above or low grade/borderline ovarian tumor 2. More than one line of prior chemotherapy before current/planned triplet therapy 3. PD (progressive disease) while on or following platinum-based therapy 4. Prior or whole-pelvis or wide-field radiotherapy 5. \> Grade 1 peripheral neuropathy 6. History of or concurrent ocular disorders 7. Grade 4 thromboembolic events 8. Not appropriate for bevacizumab treatment 9. Requiring use of folate-containing supplements 10. Prior hypersensitivity to monoclonal antibodies 11. Pregnant or breatfeeding women 12. Received prior MIRV or other FRα-targeting agents 13. Untreated or symptomatic central nervous system metastases 14. History of other malignancy within 3 years prior to signing study consent"
NCT04892173,A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With LA-HNSCC,,PHASE3,Brazil,"Fundacao Pio Xii - Hospital De Cancer De Barretos, Barretos, Brazil, [RECRUITING] | Nucleo de Ensino e Pesquisa do Instituto Mario Penna, Belo Horizonte, Brazil, [RECRUITING] | Centro Regional Integrado de Oncologia CRIO, Fortaleza, Brazil, [RECRUITING] | Hospital Haroldo Juaçaba - Instituto do Câncer do Ceará, Fortaleza, Brazil, [RECRUITING] | Fundacao Sao Francisco Xavier, Ipatinga, Brazil, [RECRUITING] | Hospital Amaral Carvalho, Jaú, Brazil, [RECRUITING] | Hospital do Cancer de Londrina, Londrina, Brazil, [RECRUITING] | Hospital Sao Lucas da PUCRS, Porto Alegre, Brazil, [RECRUITING] | Hospital Nossa Senhora da Conceicao, Porto Alegre, Brazil, [RECRUITING] | Grupo Oncoclinicas - Botafogo, Rio de Janeiro, Brazil, [RECRUITING]",Locally Advanced Head and Neck Squamous Cell Carcinoma | Aged,2,"[1] Arm A (EXPERIMENTAL): JNJ-90301900 (NBTXR3), as an intratumoral/intranodal injection, activated by investigator's choice of RT alone or RT in combination with cetuximab. JNJ-90301900 (NBTXR3) is given as a dose of 33% o... || [2] Arm B (ACTIVE_COMPARATOR): Investigator's choice of RT alone or RT in combination with cetuximab.","* Age greater than or equal to (\>=) 60 years old * Squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or supraglottic larynx and a candidate for definitive radiation therapy with or without cetuximab * Clinical stage T3-4 NX or T2 N2-3 disease according to the 8th edition of AJCC * One primary tumor lesion amendable for intratumoral injection * Ineligible to receive platinum-based chemotherapy with radiation (at least one of the following): 1. Estimated creatinine clearance \>= 30 and less than (\<) 50 milliliters/minute (mL/min) (per Cockcroft-Gault equation), Grade \>= 2 hearing loss or tinnitus, Grade \>= 2 peripheral neuropathy, Eastern Cooperative Oncology Group (ECOG) Performance Status 2 or New York Heart Association Class 3 2. Age 70-74 years old with Geriatric 8 (G8) score less than or equal to (\<=) 14 3. Age \>= 75 years old","* Carcinoma of the nasopharynx, paranasal sinus(es), salivary gland, thyroid gland, or unknown primary * Non-squamous cell histology * Clinical stage T1-2 N0, T2 N1, or M1 disease according to the 8th edition of AJCC * Loco-regionally recurrent head \& neck cancer that has been previously treated with surgery, radiation therapy, and/or chemotherapy * Prior or concurrent primary malignancy (including second synchronous head \& neck cancer) within the last 2 years of informed consent and whose natural history has the potential to interfere with the safety and efficacy assessment of the investigational agent * Ongoing or active infection requiring treatment with antimicrobial therapy within 2 weeks of randomization"
NCT06128551,"Phase 1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors",,PHASE1,Puerto Rico,"Pan American Center for Oncology Trials, San Juan, Puerto Rico, [RECRUITING]",Non-Small Cell Lung Cancer (NSCLC) | Colorectal Cancer | Pancreatic Ductal Adenocarcinoma,1,[1] RMC-6291 and RMC-6236 (EXPERIMENTAL): Dose escalation and Dose expansion,"* 18 years of age * Histology: pathologically documented, KRAS G12C-mutated, advanced or metastatic solid tumors not amendable to curative therapy 1. Part 1. Dose Escalation: solid tumors, previously treated 2. Part 2. Dose Expansion: i. NSCLC, previously treated with immunotherapy, chemotherapy, and KRAS G12C (OFF) inhibitors, ii. NSCLC, previously treated with immunotherapy and chemotherapy, naïve to KRAS G12C (OFF) inhibitors, iii. NSCLC, previously treated with immunotherapy, chemotherapy, with untreated, asymptomatic central nervous system (CNS) metastases \<2 cm in size iv. Solid tumors, previously treated, naïve to KRAS G12C (OFF) inhibitors. * ECOG performance status 0 or 1 * Adequate organ function",* Primary central nervous system (CNS) tumors * Active brain metastases * Known impairment of GI function that would alter the absorption * Major surgical procedures within 28 days or non-study related minor procedures within 7 days of treatment
NCT04686305,"A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression (OE) (DESTINY-Lung03)",DL03,PHASE1,Brazil,"Research Site, Barretos, Brazil, [NOT_YET_RECRUITING] | Research Site, Porto Alegre, Brazil, [NOT_YET_RECRUITING] | Research Site, São Paulo, Brazil, [NOT_YET_RECRUITING]",Locally Advanced or Metastatic Non-Small Cell Lung Cancer,8,"[1] Arm 1A: T-DXd, Durvalumab and Cisplatin (EXPERIMENTAL): T-DXd, Durvalumab and Cisplatin || [2] Arm 1B: T-DXd, Durvalumab and Carboplatin (EXPERIMENTAL): T-DXd, Durvalumab and Carboplatin || [3] Arm 1C: T-DXd, Durvalumab and Pemetrexed (EXPERIMENTAL): T-DXd, Durvalumab and Pemetrexed (Arm not initiated) || [4] Arm 1D: T-DXd (EXPERIMENTAL): T-DXd || [5] Arm 3A: T-DXd and Volrustomig (EXPERIMENTAL): Drug: T-DXd and Volrustomig T-DXd: administered as an IV infusion Other Name: DS-8201a, Trastuzumab deruxtecan Biological/Vaccine: Volrustomig Volrustomig: administered as an IV infusion Other Name... || [6] Arm 3B: T-DXd, Volrustomig and Carboplatin (EXPERIMENTAL): Drug: T-DXd, Volrustomig and Carboplatin T-DXd: administered as an IV infusion Other Name: DS-8201a, Trastuzumab deruxtecan Biological/Vaccine: Volrustomig Volrustomig: administered as an IV infusi... || [7] Arm 4A: T-DXd and Rilvegostomig (EXPERIMENTAL): T-DXd and Rilvegostomig Drug: T-DXd, Rilvegostomig T-DXd: administered as an IV infusion Other Name: DS-8201a, Trastuzumab deruxtecan Biological/Vaccine: Rilvegostomig Rilvegostomig: administered a... || [8] Arm 4B T-DXd and Rilvegostomig with Carboplatin (EXPERIMENTAL): Drug: T-DXd, Rilvegostomig and Carboplatin T-DXd: administered as an IV infusion Other Name: DS-8201a, Trastuzumab deruxtecan Biological/Vaccine: Rilvegostomig Rilvegostomig: administered as an IV ...","* Histologically documented unresectable locally advanced/metastatic non-squamous NSCLC * Part 1: Progression after 1 or 2 lines of systemic therapy for recurrent or metastatic setting. * Part 3 and 4: Patients must have tumors that do not harbor known genomic alterations or actionable driver kinases, for which approved therapies are available are allowed. * Part 3 and 4: Patient must be treatment-naïve for advanced or metastatic NSCLC. Patients who have received prior adjuvant, or neoadjuvant chemotherapy, or definitive chemoradiation for advanced disease are eligible, provided that progression has occurred \> 6 months from end of last therapy * HER2overexpression status as determined by central review of tumor tissue * WHO / ECOG performance status of 0 or 1 * Measurable target disease assessed by the investigator using RECIST 1.1 * Has protocol defined adequate organ and bone marrow function * Part 3 and part 4: Minimum body weight of 35 kg.","* HER2 mutation if previously known * Has a history of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening * Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder and prior pneumonectomy * Active primary immunodeficiency known HIV infection, or active chronic and resolved hepatitis B (positive hepatitis B virus surface antigen \[HBsAg+ve\] or hepatitis B virus core antibody (anti-HBc +ve) regardless of HBV DNA level)) or hepatitis C infection. Patients positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA. Patients should be tested for HIV prior to treatment assignment if required by local regulations or IRB/EC * Active infection including tuberculosis and uncontrolled infection requiring IV antibiotics, antivirals, or antifungals * Spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms * Medical history of myocardial infarction within 6 months before treatment assignment, symptomatic CHF (New York Heart Association Class II to IV), clinically important cardiac arrhythmias, or a recent (\< 6 months) cardiovascular event including stroke * For Part 3 and Part 4: Cardiomyopathy of any etiology, symptomatic CHF (as defined by New York Heart Association Class \> II), unstable angina pectoris, history of MI within the past 12 months, or cardiac arrhythmia are to be excluded. Patients with troponin levels above ULN at screening (as defined by the manufacturer), and without any myocardial related symptoms, should have a cardiologic consultation before treatment assignment to rule out acute cardiopulmonary events. * Ascites or pericardial effusion that requires drainage, peritoneal shunt, Pleuroperi"
NCT05789082,"A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation",KRAScendo 170,"PHASE1, PHASE2","Argentina, Brazil","Hospital Britanico, Buenos Aires, Argentina, [RECRUITING] | Clinica Adventista Belgrano, Ciudad Autonoma Buenos Aires, Argentina, [RECRUITING] | Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina, [RECRUITING] | Hospital de Cancer de Barretos, Barretos, Brazil, [RECRUITING] | Instituto do Cancer do Estado de Sao Paulo - ICESP, São Paulo, Brazil, [RECRUITING]",Non-Small Cell Lung Cancer,2,[1] Cohort A - Combination Dose Finding + Dose Expansion (EXPERIMENTAL): Participants will be enrolled in different cohorts to receive divarasib (different dose levels will be evaluated) once a day (QD) combined with pembrolizumab 200 mg intravenous (IV) infusion every ... || [2] Cohort B - Combination Dose Finding + Dose Expansion (EXPERIMENTAL): Participants enrolled in this cohort will receive divarasib (different dose levels will be evaluated) QD combined with pembrolizumab 200 mg IV Q3W plus investigator's choice of platinum-based chemo...,"* Confirmation of Biomarker eligibility * Pre-treatment tumor tissue along with an associated pathology report is required for all participants enrolled on study. Representative tumor specimens must be in formalin-fixed, paraffin embedded (FFPE) blocks (preferred) or 15 unstained, freshly cut, serial slides. Although 15 slides are required, if only 10 slides are available, the participant may be eligible for the study following consultation with the Sponsor. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 * Histologically or cytologically documented locally advanced unresectable or metastatic NSCLC that is not eligible for curative surgery and/or definitive chemoradiotherapy * No prior systemic treatment for advanced unresectable or metastatic NSCLC * Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1","* Known concomitant second oncogenic driver with available targeted treatment * Squamous cell histology NSCLC * Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases * Prior treatment with a KRAS G12C inhibitor * Known hypersensitivity to any of the components of divarasib or pembrolizumab; or known hypersensitivity to pemetrexed, carboplatin, or cisplatin (Cohort B only) * History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis, active tuberculosis, significant cardiovascular disease within 3 months prior to initiation of study treatment * History of malignancy other than NSCLC within 5 years prior to initiation of study treatment, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate more \>90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal breast carcinoma in situ, or Stage I uterine cancer * Uncontrolled tumor related pain, pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures, uncontrolled or symptomatic hypercalcemia * Co-morbid condition that is an absolute contraindication to treatment with corticosteroids * Inability or unwillingness to take prophylactic treatments such as corticosteroids, anti-emetics, folic acid, or vitamin B12 supplementation."
NCT06356129,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)",GOLSEEK-1,PHASE3,"Argentina, Brazil, Chile, Colombia, Mexico, Puerto Rico","Hospital Aleman, Buenos Aires, Argentina, [RECRUITING] | Local Institution - 0421, Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Clínica Zabala, Buenos Aires, Argentina, [RECRUITING] | Instituto Alexander Fleming, Buenos Aires, Argentina, [RECRUITING] | Centro de Educación Médica e Investigaciones clínicas ""Dr. Norberto Quirno"" (CEMIC), Buenos Aires, Argentina, [RECRUITING] | Hospital Privado Universitario de Córdoba, Córdoba, Argentina, [RECRUITING] | Núcleo de Oncologia e Hematologia do Ceará, Fortaleza, Brazil, [RECRUITING] | Hospital Brasilia, Lago Sul, Brazil, [RECRUITING] | Universidade Federal de Goias, Goiânia, Brazil, [RECRUITING] | Hospital Erasto Gaertner, Curitiba, Brazil, [RECRUITING]",Large B-cell Lymphoma,2,"[1] Golcadomide + R-CHOP (Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone) (EXPERIMENTAL): No description || [2] Placebo + R-CHOP (PLACEBO_COMPARATOR): No description","\- Histologically confirmed (per local evaluation) diagnosis of de novo, previously untreated large B-cell lymphoma (LBCL) according to 2022 world health organization (WHO) classification including: i) Diffuse large B-cell lymphoma (DLBCL), not otherwise specified \[including germinal center B-cell (GCB) and activated B-cell (ABC) types\] ii) High-grade B-cell lymphoma, with MYC and BCL2 rearrangements (HGBL-MYC/BCL2 double-hit lymphomas) iii) High-grade B-cell lymphoma, not otherwise specified iv) T-cell/histiocyte/rich large B-cell lymphoma (THRLBCL) v) Epstein-Barr virus + DLBCL * International Prognostic Index (IPI) score 1 or 2 with lactate dehydrogenase (LDH) \> 1.3 x upper limit of normal (ULN) and/or bulky disease defined as single lesion of ≥ 7 cm OR IPI ≥ 3. * Measurable disease defined by at least 1 fluorodeoxyglucose (FDG)-avid lesion for FDG-avid subtype and 1 bi-dimensionally measurable (\> 1.5 cm in longest diameter) disease by computed tomography (CT) or magnetic resonance imaging (MRI), as defined by the Lugano classification. * Must have Ann Arbor Stage II-IV disease.","* Any significant medical condition, active infection, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study. * Any other subtype of lymphoma. Cases of primary mediastinal (thymic) large B-cell lymphoma (PMBCL), primary cutaneous DLBCL-leg type, Grade 3b FL, indolent lymphoma transformed to large B-cell lymphoma (LBCL), Anaplastic lymphoma kinase (ALK) positive large B-cell lymphoma, primary effusion lymphoma, and Burkitt lymphoma. * Documented or suspected central nervous system (CNS) involvement by lymphoma. * Other protocol-defined Inclusion/Exclusion criteria apply."
NCT05950945,"A Phase 3b, Multicenter, Global, Interventional, Open-label Study of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2-Antibody Drug Conjugate (ADC), in Subjects Who Have Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer (DESTINY-Breast15)",,PHASE3,Brazil,"Centro de Oncologia - Unidade Brasília - Hospital Sírio Libanês, Brasília, Brazil, [RECRUITING] | CIONC-Centro Integrado de Oncologia de Curitiba, Curitiba, Brazil, [RECRUITING] | Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer, Curitiba, Brazil, [RECRUITING] | CEPON - Centro de Pesquisas Oncológicas de Santa Catarina, Florianópolis, Brazil, [RECRUITING] | Oncosite - Centro de Pesquisa Clinica e Oncologia, Ijuí, Brazil, [RECRUITING] | Fundação Doutor Amaral Carvalho, Jaú, Brazil, [RECRUITING] | Instituto de Cancer de Londrina, Londrina, Brazil, [RECRUITING] | Hospital das Clínicas FMRP-USP, Riberão Preto, Brazil, [RECRUITING] | Hospital Nossa Senhora da Conceicao, Rio Grande, Brazil, [RECRUITING] | Ensino e Terapia de Inovação Clínica AMO-ETICA, Salvador, Brazil, [RECRUITING]",Breast Cancer,4,"[1] Cohort 1: HR-negative, HER2-low (EXPERIMENTAL): Participants with HR-negative HER2-low unresectable and/or metastatic breast cancer who have received at least one and at most two prior lines of therapy in the metastatic setting will receive T-DXd. || [2] Cohort 2: HR-negative, HER2 IHC 0 (EXPERIMENTAL): Participants with HR-negative HER2 IHC 0 unresectable and/or metastatic breast cancer who have received at least one and at most two prior lines of therapy in the metastatic setting will receive T-... || [3] Cohort 3: HR-positive, HER2-low (EXPERIMENTAL): Participants with HR-positive HER2-low unresectable and/or metastatic breast cancer who have received at least one and at most two prior lines of therapy in the metastatic setting will receive T-DX... || [4] Cohort 4: HR-positive, HER2 IHC 0 (EXPERIMENTAL): Participants with HR-positive HER2 IHC 0 unresectable and/or metastatic breast cancer who have received at least one and at most two prior lines of therapy in the metastatic setting will receive T-...","* Sign and date the main informed consent form * Must agree to provide a newly obtained or archival baseline biopsy from primary and/or metastatic lesion. * Pathologically documented Breast Cancer (BC) tumor * Is unresectable and/or metastatic. * Is hormone receptor-negative or hormone receptor-positive. * Must include percentage of positively stained cells to characterize if hormone receptor-positive or -negative. * Has confirmed HER2 IHC 1+ or IHC 2+/ISH- (HER2-low) status or HER2 IHC 0 status as determined according to ASCO CAP 2018 guidelines1 based on sample collected during Tissue Screening as described above. * Was never previously HER2-positive (IHC 3+ or IHC 2+/ISH+) on prior pathology testing (per ASCO CAP guidelines). * Was never previously treated with anti-HER2 therapy in the metastatic setting. * Has had at least one and up to two prior lines of therapy in the metastatic setting. * In participants with hormone receptor-positive HER2-low metastatic BC (Cohort 3): * Has recurrent disease \<2 years from the initiation of adjuvant ET OR * Has disease progression on CDK4/6 inhibitor-based regimen within 12 months of completion of adjuvant therapy with a CDK4/6 inhibitor OR * Has disease progression within the first 12 months of CDK4/6 in the first line metastatic setting * Presence of at least one measurable lesion based on computed tomography or magnetic resonance imaging. * Participants with brain metastases are allowed in the study. The brain lesion(s) should be small (\<2 cm), untreated, asymptomatic, not requiring urgent medical intervention, and are asymptomatic and clinically stable. * Has an Eastern Cooperative Oncology Group performance status of 0 or 1. * Has a minimum life expectancy of 12 weeks at Screening. * Has a left ventricular ejection fraction ≥50% within 28 days before enrollment. * Has adequate organ and bone marrow function within 28 days before enrollment. * Has adequate treatment washout period before enrollment. * Male and female su","* Prior treatment with an antibody drug conjugate (ADC). * Uncontrolled or significant cardiovascular disease. * Has a corrected QT interval prolongation. * Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening. * Has spinal cord compression or clinically active central nervous system metastases. * Has multiple primary malignancies within 3 years, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, other solid tumors curatively treated, or contralateral BC. * Has a history of severe hypersensitivity reactions to either the drug substances or inactive ingredients in the drug product. * Has a history of severe hypersensitivity reactions to other monoclonal antibodies. * Has an uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or antifungals. * Active primary immunodeficiency, known uncontrolled active human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection. * Has history of receiving a live, attenuated vaccine (messenger RNA and replication-deficient adenoviral vaccines are not considered attenuated live vaccines) within 30 days prior to the first exposure to study drug. * Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤1 or baseline. * Is pregnant or breastfeeding or planning to become pregnant. * Lung-specific intercurrent clinically significant illnesses. * Any autoimmune, connective tissue, or inflammatory disorders. * Prior complete pneumonectomy."
NCT05502367,"An Open-Label Single and Multiple-dose, Study to Evaluate Safety, Tolerability and Efficacy of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Squamous Intraepithelial Lesions",,"PHASE1, PHASE2",Peru,"CerviCusco, Cusco, Peru, [RECRUITING] | Ginobs S.A., Lima, Peru, [RECRUITING]",Cervical Intraepithelial Neoplasia,9,[1] Cohort A1: Single and multiple doses of ABI-2280 (EXPERIMENTAL): No description || [2] Cohort A2: Multiple doses of ABI-2280 (EXPERIMENTAL): No description || [3] Cohort A3: Multiple doses of ABI-2280 (EXPERIMENTAL): No description || [4] Cohort A4: Multiple doses of ABI-2280 (EXPERIMENTAL): No description || [5] Cohort A5: Multiple doses of ABI-2280 (EXPERIMENTAL): No description || [6] Cohort A6: Multiple doses of ABI-2280 (EXPERIMENTAL): No description || [7] Cohort A7: Multiple doses of ABI-2280 (EXPERIMENTAL): No description || [8] Cohort A8: Intermittent multiple doses of ABI-2280 (EXPERIMENTAL): No description || [9] Cohort A9: Multiple doses of ABI-2280 (EXPERIMENTAL): No description,"* Women, 25 to 55 years old. * For Cohorts A1 and A2 in Part A, participants with biopsy-confirmed CIN (with visible lesions) regardless of p16 positivity may be enrolled upon consultation with PI and Medical Monitor. These participants will not be required to get LLETZ if not medically necessary, as determined by the PI in consultation with the Medical Monitor. * For Cohorts A3 and above in Part A and Part B POC cohorts, biopsy-confirmed cHSIL that is p16+ (p16INK4a expressed) within 60 days of enrollment (dosing) with no evidence of invasive cancer in any specimen. If biopsy was performed ≥ 60 days before planned enrollment, participants must agree to have another biopsy performed at the Screening visit, unless approved by the Medical Monitor. * A positive high-risk HPV (hrHPV) result by provider-obtained cervical swab at screening or previously obtained and documented within the past 3 months. * No prior treatment for Cervical intraepithelial neoplasia (CIN). * Generally, in good health with no clinically significant pulmonary, cardiac, gastro-enterologic, neurologic, renal, musculoskeletal, rheumatologic, metabolic, neoplastic, or endocrine disease.","* Women who are pregnant, plan to become pregnant in the next 4 months, or lactating females. * Unwilling to use stringent methods of contraception (including barrier method, as well as another acceptable method) throughout the course of the study. * History of cancer, except basal cell or squamous cell carcinoma of the skin. * History of genital herpes with outbreak within prior 12 months. * Have an active pelvic or non-HPV (Human papillomavirus) vaginal infection (e.g., that was detected by a positive urine screen for gonorrhea or chlamydial infection, bimanual exam consistent with pelvic inflammatory disease, positive bedside testing criteria for bacterial vaginosis, candida vaginitis or trichomonal vaginitis, etc). * Current or recent abnormal vaginal discharge and /or abnormal vaginal bleeding. * Had a therapeutic abortion or miscarriage less than 3 months prior. * Any clinically significant immune suppressing condition. * Participants with a significant acute condition or any other condition that in the opinion of the Investigator might interfere with the evaluation of the study objectives. * Women who, in the PI's judgment, would be harmed by the delay in undergoing definitive treatment as a result of study participation and the ABI-2280 Vaginal Tablet dosing schedule. * Vaccination (even 1 dose) with a prophylactic HPV vaccine (i.e., Gardasil®, Gardasil®-9 or Cervarix®) in the last 3 months. * Vaccination with a therapeutic HPV vaccine. * Other inclusion/exclusion criteria may apply"
NCT06966453,"A Phase 1b/2, Open-Label, Multicohort Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer",,"PHASE1, PHASE2",Puerto Rico,"Pan American Center for Oncology Trials, LLC, Rio Piedras, Puerto Rico, [NOT_YET_RECRUITING]",Breast Cancer | Breast Neoplasms,3,"[1] Cohort 1: HER2+ locally advanced or metastatic breast cancer (EXPERIMENTAL): disitamab vedotin monotherapy || [2] Cohort 2: HR+, HER2-low locally advanced or metastatic breast cancer (EXPERIMENTAL): disitamab vedotin monotherapy || [3] Cohort 3: HR+, HER2 ultra-low or HR-negative, HER2-low locally advanced or metastatic breast cancer (EXPERIMENTAL): disitamab vedotin monotherapy","* Histologically or cytologically confirmed diagnosis of locally-advanced, unresectable, or metastatic breast carcinoma. * Human epidermal growth factor receptor 2 (HER2) and hormone receptor (HR) status appropriate for enrollment in cohort. * HER2 status determined by most recent local assessment based on American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP) guidelines for assessment of HER2 in BC for interpretation of HER2 expression and amplification * HER2+: immunohistochemistry (IHC) 3+ or IHC 2+/in situ hybridization (ISH)+ * HER2-low: IHC 1+/ISH-negative or untested or IHC 2+/ISH-negative * HER2-ultralow: IHC 0 with membrane staining (any staining of the membrane in \>0 and ≤10% of cancer cells) o HR+ disease is determined as either estrogen receptor (ER) and/or progesterone receptor (PgR) positive \[ER or PgR ≥1%\]) and HR negative disease is determined as both ER and PR negative \[ER and PgR \<1%\]) per ASCO/CAP guidelines in the advanced disease setting. If a patient has had multiple ER/PgR results for advanced disease, the most recent test result will be used to confirm eligibility. Prior therapy requirements for Cohort 1 (HER2+, HR+ or HR- participants): * Received prior trastuzumab, pertuzumab and a taxane if available as local first line standard of care therapy for advanced disease. * Prior tucatinib based therapy is allowed. * Must have progression on or after, or be intolerant to, T-DXd in any line advanced disease setting. * No more than 3 prior systemic cytotoxic therapy regimens (including antibody drug conjugates \[ADCs\]) for Locally Advanced (LA)/metastatic breast cancer (mBC). Participants previously treated with (neo)adjuvant cytotoxic therapy and have disease relapsed within 6 months of cytotoxic treatment is considered to have received 1 line of cytotoxic therapy for LA/mBC. Prior therapy requirements for Cohort 2 (HR+/HER2-low participants): * No more than 3 prior systemic cytotoxic therapy regimens (incl","* Known hypersensitivity to any excipient contained in the drug formulation of disitamab vedotin. * Active central nervous system (CNS) and/or leptomeningeal metastasis. * Participants with a history of other invasive malignancy within 3 years before the Cycle 1 Day 1 (C1D1) of study intervention, or any evidence of residual disease from a previously diagnosed malignancy. * Prior therapy with ADCs with MMAE payload. * Participants who have received prior systemic anticancer treatment or radiotherapy within 2 weeks, or 5 half-lives, whichever is shorter, prior to C1D1 of study intervention. Note: If the last immediate anticancer treatment contained an antibody-based agent(s), then an interval of 28 days or 5 half-lives (whichever is shorter) of the agent(s) prior to receiving the study intervention treatment is required. * Participants must have recovered from all adverse events due to previous therapies."
NCT06623422,A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009),,PHASE3,"Argentina, Brazil, Chile, Colombia, Peru","CEMIC ( Site 2454), Caba., Argentina, [RECRUITING] | Fundacion Intecnus ( Site 2456), Bariloche, Argentina, [RECRUITING] | Centro Médico IPAM ( Site 2452), Rosario, Argentina, [RECRUITING] | Instituto Medico Especializado Alexander Fleming ( Site 2457), Buenos Aires, Argentina, [RECRUITING] | Instituto Oncologico de Cordoba -IONC ( Site 2455), Córdoba, Argentina, [RECRUITING] | CRIO - CENTRO REGIONAL INTEGRADO DE ONCOLOGIA ( Site 2502), Fortaleza, Brazil, [RECRUITING] | Liga Norte Riograndense Contra o Cancer ( Site 2513), Natal, Brazil, [RECRUITING] | Hospital Tacchini ( Site 2506), Bento Gonçalves, Brazil, [RECRUITING] | Hospital de Clínicas de Passo Fundo ( Site 2504), Passo Fundo, Brazil, [RECRUITING] | Hospital Moinhos de Vento ( Site 2510), Porto Alegre, Brazil, [RECRUITING]","Carcinoma, Non-Small-Cell Lung",2,"[1] Pembrolizumab + Intismeran autogene (EXPERIMENTAL): For neoadjuvant treatment, participants will receive pembrolizumab 200 mg via intravenous (IV) infusion every 3-week cycle for up to 4 cycles PLUS background chemotherapy via IV infusion (cisplatin... || [2] Pembrolizumab + Placebo (ACTIVE_COMPARATOR): For neoadjuvant treatment, participants will receive pembrolizumab 200 mg via IV infusion every 3-week cycle for up to 4 cycles PLUS background chemotherapy via IV infusion (cisplatin 75 mg/m\^2 or...","The main inclusion criteria include but are not limited to the following: * Has histologically/cytologically confirmed diagnosis of previously untreated and pathologically confirmed resectable Stage II, IIIA, or IIIB (N2) non-small cell lung cancer (NSCLC) \[American Joint Committee on Cancer (AJCC) 8th Edition\] * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before the first dose of study intervention * Participants who have not achieved a pathological complete response (pCR) following completion of neoadjuvant chemotherapy and pembrolizumab followed by surgery will be eligible * Confirmation that epidermal growth factor receptor (EGFR)-directed therapy is not indicated as primary therapy (documentation of absence of tumor-activating EGFR mutations \[eg, DEL19 or L858R\]) * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART) * Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization * Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening","The main exclusion criteria include but are not limited to the following: * Diagnosis of SCLC or, for mixed tumors, presence of small cell elements, or has a neuroendocrine tumor with large-cell components, or a sarcomatoid carcinoma, or a pancoast tumor * Documentation by local test report indicating presence of anaplastic lymphoma kinase (ALK) gene rearrangements * Received prior neoadjuvant therapy for their current NSCLC diagnosis * Received prior therapy with an anti-programmed cell death 1 (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti-programmed cell-death ligand 2 (PD-L2) agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein \[CTLA-4\], OX-40, CD137) * Received prior systemic anticancer therapy including investigational agents other than what is specified in this protocol * Received prior treatment with a cancer vaccine * Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids * Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention"
NCT06417814,"A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants With EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib Treatment (TROPION-Lung15)",TROPION-Lung15,PHASE3,Brazil,"Research Site, Barretos, Brazil, [NOT_YET_RECRUITING] | Research Site, Betim, Brazil, [NOT_YET_RECRUITING] | Research Site, Blumenau, Brazil, [NOT_YET_RECRUITING] | Research Site, Florianópolis, Brazil, [NOT_YET_RECRUITING] | Research Site, Itajaí, Brazil, [NOT_YET_RECRUITING] | Research Site, Pelotas, Brazil, [NOT_YET_RECRUITING] | Research Site, Porto Alegre, Brazil, [NOT_YET_RECRUITING] | Research Site, Porto Alegre, Brazil, [NOT_YET_RECRUITING] | Research Site, Porto Alegre, Brazil, [NOT_YET_RECRUITING] | Research Site, Rio de Janeiro, Brazil, [NOT_YET_RECRUITING]",Metastatic Non-small Cell Lung Cancer,3,"[1] Group 1: Dato-DXd + Osimertinib Combination Therapy (EXPERIMENTAL): Participants will receive Dato-DXd 6 mg/kg as IV infusion Q3W on Day 1 of every 21-day cycle, and osimertinib 80 milligrams (mg) once daily (QD) orally, until RECIST v1.1-defined radiological progr... || [2] Group 2: Dato-DXd Monotherapy (EXPERIMENTAL): Participants will receive Dato-DXd 6 milligrams per kilogram (mg/kg) as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of every 21-day cycle, until RECIST v1.1-defined radiological progress... || [3] Group 3: Platinum-based Doublet Chemotherapy (EXPERIMENTAL): Participants will receive pemetrexed 500 milligrams per meter square (mg/m2) in combination with carboplatin (AUC5) or cisplatin 75 mg/m2 as IV infusion Q3W for 4 cycles followed by pemetrexed main...","* Histologically or cytologically confirmed non-squamous NSCLC. * Must have evidence of documented pre-existing EGFRm information (EGFRm known to be associated with (epidermal growth factor receptor \[EGFR\] tyrosine kinase inhibitor \[TKis\] sensitivity \[Ex19del, L858R, G719X, S768I, or L861Q\], either alone or in combination with other EGFR mutations, which may include T790M). * Documented extra-cranial radiologic progression on prior osimertinib monotherapy (as most recent line of treatment) in the adjuvant, locally advanced, or metastatic setting. * Less than or equal to (\<=2) prior lines of EGFR TKIs (osimertinib is the only permitted prior third generation EGFR TKI). * At least one lesion, not previously irradiated, that qualifies as a RECIST v1.1 TL at baseline and can be accurately measured at baseline. * World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Adequate bone marrow reserve and organ function within 7 days before randomization.","* Use of chemotherapy, vascular endothelial growth factor inhibitor, immunotherapy or any anti-cancer therapy in the metastatic setting. Platinum-based chemotherapy in non-metastatic setting within 12 months prior to randomization. * History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 2 years before the first dose of study intervention. * Any evidence of severe or uncontrolled systemic diseases, including, but not limited to active bleeding diseases, active infection, active ILD/pneumonitis, cardiac disease. * Has significant third-space fluid retention (example \[eg.\], ascites or pleural effusion) as judged by the investigator and is not amenable for required repeated drainage. * History of non-infectious ILD/pneumonitis including radiation pneumonitis that required steroids or drug-induced ILD, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening. * Has severe pulmonary function compromise resulting from intercurrent pulmonary illnesses. * Unstable spinal cord compression and/or unstable brain metastases. * Participants with symptomatic brain metastases (including leptomeningeal involvement). * Clinically significant corneal disease. * Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals, suspected infections or inability to rule out infections. * Has known human immunodeficiency virus (HIV) infection that is not well controlled."
NCT02715284,"A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors",GARNET,PHASE1,"Argentina, Brazil, Mexico","GSK Investigational Site, Ciudad Autonoma de Buenos Aire, Argentina, [RECRUITING] | GSK Investigational Site, Córdoba, Argentina, [RECRUITING] | GSK Investigational Site, Córdoba, Argentina, [RECRUITING] | GSK Investigational Site, Barretos, Brazil, [RECRUITING] | GSK Investigational Site, Porto Alegre, Brazil, [RECRUITING] | GSK Investigational Site, Ribeirão Preto, Brazil, [RECRUITING] | GSK Investigational Site, Rio de Janeiro, Brazil, [RECRUITING] | GSK Investigational Site, São José do Rio Preto, Brazil, [RECRUITING] | GSK Investigational Site, São Paulo, Brazil, [RECRUITING] | GSK Investigational Site, São Paulo, Brazil, [RECRUITING]",Neoplasms,7,"[1] Part 1: Participants receiving dostarlimab (EXPERIMENTAL): Part 1 will evaluate dostarlimab at ascending weight-based doses 1 mg/kg, 3 mg/kg and 10 mg/kg. Higher dose levels 15 mg/kg and/or 20 mg/kg may also be explored. Dostarlimab will be administered in... || [2] Part 2A: Participants receiving dostarlimab (EXPERIMENTAL): In Part 2A, participants will receive fixed dose of 500 mg administered Q3W or 1000 mg administered Q6W dose on Day 1 of each cycle. Cycle duration for Q3W dosing is 21 days and Q6W dosing is 42 da... || [3] Part 2B: Cohort A1 dMMR/MSI-H endometrial cancer (EXPERIMENTAL): Part 2B: Cohort A1 will include participants with mismatch repair deficient microsatellite instability high (dMMR/MSI-H) endometrial cancer who have progressed on or after platinum doublet therapy.... || [4] Part 2B: Cohort A2 MMR-proficient/MSS endometrial cancer (EXPERIMENTAL): Part 2B: Cohort A2 will include participants with MMR-proficient/MSS endometrial cancer who have progressed on or after platinum doublet therapy. These participants will receive dostarlimab 500 mg ... || [5] Part 2B: Cohort E NSCLC (EXPERIMENTAL): Part 2B: Cohort E NSCLC will include participants with non-small cell lung cancer (NSCLC) who progressed after at least 1 prior platinum-based systemic chemotherapy regimen for recurrent or advance... || [6] Part 2B:Cohort F non-endometrial dMMR/MSI-H & POLE-Mut cancers (EXPERIMENTAL): Participants with recurrent or advanced dMMR/MSI-H solid tumors except endometrial cancers, and gastrointestinal cancers, who have received prior systemic therapy and, who have no alternative treat... || [7] Part 2B: Cohort G PROC without known BRCA (EXPERIMENTAL): Participants with advanced, relapsed, high-grade serous, endometrioid, or clear cell ovarian, fallopian tube, or primary peritoneal cancer without known breast cancer susceptibility gene (BRCA) mut...","* Participant is at least 18 years of age. * Participant has proven recurrent or advanced solid tumor and has disease progression after treatment with available anti cancer therapies, or is intolerant to treatment that meets the following requirements for the part of the study they will participate in: * a. Part 1: Any histologically or cytologically proven recurrent advanced solid tumor * b. Part 2A: : Any histologically or cytologically proven recurrent advanced solid tumor * c. Part 2B: Histologically of cytologically proven recurrent or advanced solid tumor with measurable lesion(s) per RECIST version 1.1 and meets one of the following disease types: * The criteria below should be met for participant participating in: Cohort A1 (dMMR/MSI-H endometrial cancer) and Cohort A2 (MMR-proficient/MSS endometrial cancer) * Participants who have progressed on or after platinum doublet therapy * Participants have received no more than 2 lines of anti-cancer therapy for recurrent or advanced (\>=Stage IIIB) disease. Prior treatment with hormone therapies is acceptable and does not count towards the number of anti-cancer therapies noted in the criterion above for this cohort. * All endometrial cancer histologies are allowed except endometrial sarcoma (including carcinosarcoma). * Participants must submit 2 scans demonstrating increase in tumor measurement that meet criteria for PD on or after the latest systemic anti-cancer therapy based on RECIST Version 1.1 to Central Radiology prior to the first dose of dostarlimab. * Presence of at least 1 measurable lesion on Baseline scan will be confirmed by central radiology review. * Status of tumor MMR/MSI: Participants can be screened based on local MMR/MSI testing results using immunohistochemistry (IHC), polymerase chain reaction (PCR), or next generation sequencing (NGS) performed in a certified local laboratory, but participant eligibility needs to be determined by MMR IHC results. For participant with available local MMR IHC ","* Participant has received prior therapy with an anti- programmed death receptor 1 (anti-PD-1), anti-PD-1- ligand-1 (anti-PD-L1), or anti-PD-1 ligand-2 (anti-PD- L2) agent. * Participant has a known uncontrolled central nervous system (CNS) metastases and/or carcinomatous meningitis. * Participant has a known additional malignancy that progressed or required active treatment within the last 2 years. Exceptions include basal cell carcinoma of the skin, squamous cell cancer (SqCC) of the skin that has undergone potentially curative therapy, or in situ cervical cancer, or other neoplastic condition which has undergone curative therapy and is considered cured by the investigator. * Participant is considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease or active infection requiring systemic therapy. Specific examples include, but are not limited to, active, non-infectious pneumonitis; uncontrolled ventricular arrhythmia; recent (within 90 days) myocardial infarction; uncontrolled major seizure disorder; unstable spinal cord compression; superior vena cava syndrome; or any psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study (including obtaining informed consent). * Participant is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the study, starting with the Screening Visit through 150 days after the last dose of study treatment. * Participant has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment. * Participant has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies). * Participant has a known active hepatitis B (eg, hepatitis B surface antigen \[HBsAg\] reactive) or hepatitis C (eg, hepatitis C virus ribonucleic acid (HCV RNA) (qualitative) is detected). * Participant "
NCT05609578,A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation,,PHASE2,"Brazil, Chile","Local Institution - 017-458, Natal, Brazil, [WITHDRAWN] | Local Institution - 017-446, Ijuí, Brazil, [WITHDRAWN] | Local Institution - 017-453, Itajaí, Brazil, [WITHDRAWN] | Local Institution - 017-457, Barretos, Brazil, [WITHDRAWN] | Local Institution - 017-442, Curitiba, Brazil, [WITHDRAWN] | Local Institution - 017-452, Fortaleza, Brazil, [WITHDRAWN] | Local Institution - 017-455, Jaú, Brazil, [WITHDRAWN] | Local Institution - 017-454, Rio de Janeiro, Brazil, [WITHDRAWN] | Local Institution - 017-456, São Paulo, Brazil, [WITHDRAWN] | Local Institution - 017-695, Viña del Mar, Chile, [WITHDRAWN]",Advanced NSCLC | Metastatic Lung Cancer,3,"[1] Cohort A: PD-L1 TPS≥ 1% (Closed) (EXPERIMENTAL): Adagrasib 400 mg BID for 2 cycles followed by adagrasib 400 mg BID + pembrolizumab 200 mg every 3 weeks (Q3W) up to 35 cycles || [2] Cohort C (EXPERIMENTAL): Adagrasib 400 mg BID + pemetrexed 500 mg/m2 Q3W + pembrolizumab 200 mg Q3W up to 31 cycles || [3] Cohort E (EXPERIMENTAL): Adagrasib 400 mg BID + pembrolizumab 200 mg Q3W + pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 Q3W OR carboplatin AUC 5 Q3W for 4 cycles, followed by adagrasib 400 mg BID + pemetrexed 500 mg/m2 Q3W + ...",,"* All Cohorts: Any prior therapy targeting KRASG12C mutation in any setting * Cohorts A \& E: Prior systemic therapy for locally advanced or metastatic NSCLC, including chemotherapy, immune checkpoint inhibitor therapy or chemoimmunotherapy (note: prior systemic therapy or chemoradiation given in the adjuvant or neoadjuvant setting are allowed if last dose of prior systemic treatment was \>1 year prior to first dose of study treatment) * Cohort C: received maintenance therapy (e.g, pembrolizumab and/or pemetrexed following completion of 4-6 cycles of a platinum-based regimen administered in the first-line setting * Radiation to the lung \> 30 Gy within 6 months prior to first dose of study treatment * Active brain metastases"
NCT06472388,Randomized Phase II Trial of Everolimus 5 mg vs 10 mg/Daily for Patients With Advanced Neuroendocrine Tumors,EVENET,PHASE2,Brazil,"AC Camargo Cancer Center, São Paulo, Brazil, [RECRUITING] | AC Camargo Cancer Center, São Paulo, Brazil, [RECRUITING]",Neuroendocrine Tumors | Progression | Neuroendocrine Tumor Grade 1 | Neuroendocrine Tumor Grade 2 | Neuroendocrine Tumor of Pancreas,2,[1] Everolimus 5 (EXPERIMENTAL): oral everolimus 5 mg/daily continuously until progression or intolerance or consent withdrawal. dose reduction for toxicity is allowed. || [2] Everolimus 10 (ACTIVE_COMPARATOR): oral everolimus 10 mg/daily continuously until progression or intolerance or consent withdrawal. dose reduction for toxicity is allowed.,"* Histological confirmation of well-differentiated Grade 1/Grade 2 NET from gastrointestinal, pancreatic, pulmonary or unknown primary sites. * Metastatic or locally advanced and unresectable disease, measurable by images * Disease progression by RECIST 1.1 in the last 6 months assessed by local investigators * At least one previous line of systemic treatment (suspended for more than 3 weeks). * Eastern Cooperative Oncology Group (ECOG) 0-2 o Good organ function: * Hemoglobin \> 8 g/dL * Neutrophils ≥ 1,500/mm³ * Platelets \> 90,000/mm³ * Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 x ULN \[upper limit of normal\] or ≤ 5 x ULN for patients with liver metastases * Bilirubin ≤ 1.5 x ULN, creatinine \< 1.5 mg/dL","* Aggressive disease requiring cytotoxic therapy * Severe/uncontrolled comorbid conditions that deem participant unfit for everolimus therapy, as per investigators' judgement. * MiNEN"
NCT06425302,"A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma",GOLSEEK-2,PHASE2,"Brazil, Chile","Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil, [RECRUITING] | Centro de Tratamento de Tumores Botafogo para Oncoclinicas Rio de Janeiro SA, Rio de Janeiro, Brazil, [RECRUITING] | Instituto D'Or de Pesquisa e Ensino (IDOR), São Paulo, Brazil, [RECRUITING] | Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein, São Paulo, Brazil, [RECRUITING] | Fundacion Arturo Lopez Perez (FALP), Santiago, Chile, [RECRUITING] | Clínica Inmunocel, Santiago, Chile, [RECRUITING]","Lymphoma, Follicular",3,"[1] Rituximab + Chemotherapy (EXPERIMENTAL): R-CHOP (Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone) or Rituximab + Bendamustine || [2] Golcadomide Dose 1 + Rituximab (EXPERIMENTAL): No description || [3] Golcadomide Dose 2 + Rituximab (EXPERIMENTAL): No description","* Participant has histologically confirmed Grade 1, 2 or 3a follicular lymphoma (FL) or classic FL. Formalin-fixed paraffin embedded (FFPE) archival tissue from 1 year prior to screening is allowed. If more than 1 year has passed, then a fresh biopsy must be obtained to confirm the diagnosis. * Have no prior systemic treatment for follicular lymphoma. Prior radiation therapy or surgery for previously diagnosed stage I disease is acceptable. * Stage II to IV disease. * Deemed to need treatment by treating investigator. Reasons for treatment can include, but are not limited to, the following:. i) Bulky disease defined as:. A. A nodal or extra nodal (except spleen) mass \> 7cm in its greater diameter or, involvement of at least 3 nodal or extra nodal sites (each with a diameter greater than \>3 cm). ii) Presence of at least one of the following B symptoms:. A. Fever (\>38°C) of unclear etiology. B. Night sweats. C. Weight loss greater than 10% within the prior 6 months. iii) Splenomegaly with inferior margin below the umbilical line. iv) Any one of the following cytopenia due to lymphoma:. A. Platelets \<100,000 cells/mm3 (100 x 109/L). B. Absolute neutrophil count (ANC) \< 1,000 cells/mm3 (1.0 x 109/L). C. Hemoglobin \< 10g/dL (6.25 mmol/L). v) Pleural or peritoneal serous effusion (irrespective of cell content). vi) Any compressive syndrome (for example, but not restricted to ureteral, orbital, gastrointestinal).","* Clinical evidence of transformed lymphoma by investigator assessment. * Follicular Large Cell as per WHO 5th classification or Grade 3b follicular lymphoma as per WHO 4th classification. * Participant has any significant medical condition, active infection, laboratory abnormality, or psychiatric illness that would prevent the participation in the study. * Other protocol-defined Inclusion/Exclusion criteria apply."
NCT05578092,A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients With Advanced Solid Tumors Harboring Mutations in the KRAS MAPK Pathway,,"PHASE1, PHASE2",Puerto Rico,"Pan American Center for Oncology Trials, LLC, Rio Piedras, Puerto Rico, [RECRUITING]",Solid Tumor | Advanced Solid Tumor | Non Small Cell Lung Cancer | Colo-rectal Cancer,3,"[1] Phase 1/1B Monotherapy (EXPERIMENTAL): Dose Escalation/Evaluation || [2] Phase 1/1B Combination Therapy (EXPERIMENTAL): Dose Escalation/Evaluation and Food Effect Assessment || [3] Phase 2 (EXPERIMENTAL): MRTX0902 and adagrasib combination RP2D administered to separate cohorts of patients with selected solid tumor malignancies with KRAS G12C mutation to include the following: NSCLC, CRC, Other Solid...","* Histologically confirmed diagnosis of a solid tumor malignancy with any of the following oncogenic mutations detected in tumor tissue or ctDNA by a sponsor-approved test: 1. MRTX0902 monotherapy: known KRAS mutations, known annotated recurrent activating SOS1, PTPN11, class III BRAF, or EGFR mutation, or known annotated recurrent inactivating NF1 mutation; 2. MRTX0902 and adagrasib combination therapy: KRAS G12C mutation. * Unresectable or metastatic disease * No available treatment with curative intent; standard treatment is not available or patient declines * Presence of tumor lesions to be evaluated per RECIST 1.1: 1. Phase 1 dose escalation, RECIST 1.1 measurable or evaluable disease 2. Phase 1b and Phase 2 cohorts, RECIST 1.1 measurable disease * Presence of a tumor lesion amenable to mandatory biopsy for pharmacodynamic evaluation at baseline and on-study unless Sponsor-confirmed as medically unsafe or infeasible. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Adequate organ function","* Active brain metastases or carcinomatous meningitis * Prior treatment with a KRAS G12C inhibitor (for Phase 1b expansion for MRTX0902 and adagrasib combination, and Phase 2 cohorts only) * History of significant hemoptysis or hemorrhage within 4 weeks of the first dose of study treatment. * Major surgery within 4 weeks of first dose of study treatment * History of pneumonitis or interstitial lung disease * Ongoing need for medication with following characteristics: substrate of CYP3A; strong inducer or inhibitor or CYP3A and/or P-gp; strong inhibitors of BRCP and proton pump inhibitors * Cardiac abnormalities * History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications"
NCT06357533,"A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)",TROPION-Lung10,PHASE3,"Brazil, Puerto Rico","Research Site, Barretos, Brazil, [RECRUITING] | Research Site, Curitiba, Brazil, [RECRUITING] | Research Site, Florianópolis, Brazil, [RECRUITING] | Research Site, Ipatinga, Brazil, [RECRUITING] | Research Site, Natal, Brazil, [RECRUITING] | Research Site, Porto Alegre, Brazil, [RECRUITING] | Research Site, Rio de Janeiro, Brazil, [RECRUITING] | Research Site, Santa Maria, Brazil, [RECRUITING] | Research Site, São Paulo, Brazil, [RECRUITING] | Research Site, Taubaté, Brazil, [RECRUITING]",Non-Small Cell Lung Cancer,3,[1] Arm 1: Datopotamab Deruxtecan in Combination With Rilvegostomig (EXPERIMENTAL): Participants in the Datopotamab Deruxtecan (Dato-DXd) in combination with Rilvegostomig group will receive Dato-DXd plus rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of e... || [2] Arm 2: Rilvegostomig Monotherapy (EXPERIMENTAL): Participants in the rilvegostomig monotherapy group will receive rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle. || [3] Arm 3: Pembrolizumab Monotherapy (ACTIVE_COMPARATOR): Participants in the pembrolizumab group will receive pembrolizumab as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.,"* Histologically or cytologically documented non-squamous NSCLC. * Stage IIIB or IIIC or Stage IV metastatic NSCLC (according to Edition 8 of the AJCC staging manual) not amenable to curative surgery or definitive chemoradiation. * Absence of sensitising EGFR mutations, and ALK and ROS1 rearrangements, and absence of documented local test result for any other known genomic alteration for which there are locally approved and available targeted first-line therapies. * Must provide tumor sample to determine PD-L1 status, TROP2 status and other biomarkers. * Known tumour PD-L1 expression status defined as TC ≥ 50% * At least one lesion, not previously irradiated that qualifies as a RECIST 1.1 target lesion at baseline * ECOG performance status of 0 or 1 * Adequate bone marrow reserve and organ function within 7 days before the first dose of study intervention","* Prior systemic therapy for advanced/metastatic NSCLC. * Squamous cell histology, or predominantly squamous cell histology NSCLC; mixed small cell lung cancer; NSCLC histology, sarcomatoid variant. * History of another primary malignancy within 3 years * Active or prior documented autoimmune or inflammatory disorders (with exceptions) * Any evidence of severe or uncontrolled systemic diseases, including, but not limited to active bleeding diseases, active infection, active ILD/pneumonitis, cardiac disease. * Has clinically significant third-space fluid retention (for example pleural effusion) and is not amenable for repeated drainage. * History of non-infectious ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening * Has significant pulmonary function compromise, as determined by the investigator * Spinal cord compression, or brain metastases unless participant treated and no longer symptomatic, radiologically stable, and who require no treatment with corticosteroids or anticonvulsants. * History of leptomeningeal carcinomatosis * Known clinically significant corneal disease * Active infection with TB, HBV, HCV, Hepatitis A, or known HIV infection that is not well controlled * History of active primary immunodeficiency"
NCT05163028,"A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients With Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations",,PHASE1,Puerto Rico,"Pan American Center for Oncology Trials (PanOncology Trials), Rio Piedras, Puerto Rico, [RECRUITING]",Non Small Cell Lung Cancer | Colorectal Cancer | Pancreatic Cancer | Solid Tumor | Cancer,1,"[1] Dose Escalation and Expansion (EXPERIMENTAL): HBI-2376 will be given orally in ascending doses (escalation cohort), until the maximum tolerated dose or recommended Phase 2 dose is reached. Up to 6 patients will then be enrolled in the expansio...","* Male or female at least 18 years of age at the time of signing the ICF prior to initiation of any study specific activities/procedures * Advanced malignant solid tumors with KRAS or EGFR mutations diagnosed by histology or cytology * Relapsed or refractory to, or intolerant of, or refuse approved or standard of care established therapy known to provide clinical benefit for disease * At least 1 measurable target lesion that meets the definition of RECIST v1.1 * ECOG Performance Status of 0 or 1 * Demonstrate adequate organ function * Must be able to swallow oral medications and must not have gastrointestinal abnormalities that significantly affect drug absorption Key","* History of another concurrent malignancy within 3 years prior to study entry, unless the malignancy was treated with curative intent and the likelihood of relapse is \<5% in 2 years Note: Subjects with a history of squamous or basal cell carcinoma of the skin or carcinoma in the situ of the cervix may be enrolled * Untreated or symptomatic central nervous system (CNS) metastases Note: Subjects with asymptomatic treated CNS metastases are eligible provided they have been clinically stable and not requiring steroids for at least 4 weeks * Clinically significant cardiovascular disease, including stroke or myocardial infarction within 6 months * Any unresolved Grade 2 or greater toxicity from previous anti-cancer therapy, except alopecia, within 4 weeks of first study treatment administration * Active autoimmune diseases or history of autoimmune diseases that may relapse * Pregnant or nursing * Prior treatment with any SHP2 inhibitors * Any condition that required systemic treatment with either corticosteroids (\>10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤14 days before the first study treatment administration * Treatment with other investigational drugs/devices within 4 weeks prior to first study treatment administration"
NCT05100862,"A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma",MAHOGANY,PHASE3,"Argentina, Brazil, Puerto Rico","Hospital Aleman, CABA, Argentina, [ACTIVE_NOT_RECRUITING] | Hospital Italiano de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina, [ACTIVE_NOT_RECRUITING] | Hospital de Amor Barretos, Barretos, Brazil, [ACTIVE_NOT_RECRUITING] | Clinica de Oncologia Reichow, Blumenau, Brazil, [ACTIVE_NOT_RECRUITING] | Unesp Faculdade de Medicina Da Universidade Estadual Paulista Campus Botucatu, Botucatu, Brazil, [ACTIVE_NOT_RECRUITING] | Instituto Dor de Pesquisa E Ensino Distrito Federal, Brasília, Brazil, [ACTIVE_NOT_RECRUITING] | Universidade de Campinas Centro de Hematologia E Hemoterapia, Campinas, Brazil, [ACTIVE_NOT_RECRUITING] | Fundacao Universidade de Caxias Do Sul, Caxias do Sul, Brazil, [ACTIVE_NOT_RECRUITING] | Centro Integrado de Oncologia de Curitiba Ss Cionc, Curitiba, Brazil, [ACTIVE_NOT_RECRUITING] | Hospital Erasto Gaertner, Curitiba, Brazil, [ACTIVE_NOT_RECRUITING]",Relapsed/Refractory Follicular Lymphoma | Marginal Zone Lymphoma,4,"[1] Follicular Lymphoma Arm A: Zanubrutinib plus Obinutuzumab (EXPERIMENTAL): Participants will receive zanubrutinib and Obinutuzumab. Following the completion of the combination treatment, participants will continue receiving zanubrutinib monotherapy until confirmed disease... || [2] Follicular Lymphoma Arm B: Lenalidomide plus Rituximab (ACTIVE_COMPARATOR): Participants will receive lenalidomide and rituximab. || [3] Marginal Zone Lymphoma Arm C: Zanubrutinib plus Rituximab (EXPERIMENTAL): Participants will receive zanubrutinib and rituximab. Following the completion of the combination treatment, participants will continue receiving zanubrutinib monotherapy until confirmed disease pr... || [4] Marginal Zone Lymphoma Arm D: Lenalidomide plus Rituximab (ACTIVE_COMPARATOR): Participants will receive lenalidomide and rituximab.","* Histologically confirmed grade 1-3a FL or MZL * Previously treated with ≥ 1 line of systemic therapy including anti-CD20 agent. Must have a documented failure to achieve at least partial response during the most recent systemic therapy or documented progressive disease after the most recent systemic therapy * Need for systemic therapy for FL or MZL * Measurable disease by computed tomography or magnetic resonance imaging * Adequate bone marrow, liver and renal function Key","* Transformation to aggressive lymphoma * Requiring ongoing need for corticosteroid treatment * Clinically significant cardiovascular disease * Prior malignancy within the past 2 years * Active fungal, bacterial, and/or viral infection that requires systemic therapy * Prior treatment with lenalidomide or drug from same class, if without response (partial or complete) or short remission duration (\< 24 months) Note: Other protocol defined Inclusion/Exclusion criteria may apply."
NCT03275194,Hyperthermic Intraperitoneal Chemotherapy in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy. Phase II Study,,PHASE2,Mexico,"National Cancer Institute of Mexico, Mexico City, Mexico, [RECRUITING]",HPEC | Ovarian Cancer | Women's Health: Neoplasm of Ovary | Chemotherapy Effect,2,"[1] Control group (NO_INTERVENTION): After achieving a complete cytoreductive surgery (no visible residual disease), the patient will be randomised and if is assigned to this arm does not receive additional treatment and the procedure... || [2] HIPEC group (EXPERIMENTAL): After achieving a complete cytoreductive surgery (no visible residual disease), the patient will be randomised and if is assigned to this arm receive a HIPEC procedure with cisplatin and doxorubicin.","1. Patients younger than 70 years 2. Patient with a diagnosis of high grade serous carcinoma of the ovary and low-grade endometrioid corroborated by histopathological study. 3. Clinical stage IIIC and IVA (cytology-positive pleural effusion) who have received induction chemotherapy 3 or 4 cycles of CARBOPLATIN and PACLITAXEL. 4. Partial response to treatment with chemotherapy and evaluated by computed tomography (RECIST-see below) and response of at least 50% by serum determination of CA-125 antigen. 5. Signature of informed consent. 6. Optimal cytoreduction with residual tumor less than 2.5 mm during interval surgery 7. ECOG less than or equal to 1 8. Adequate renal, cardiac, hepatic, bone marrow and lung function evaluated preoperatively with the following parameters: a) Hb equal to or greater than 10 g / L (pre-treatment transfusion is permitted to achieve this hemoglobin level) b) Leukocytes Greater than 3000 / mm3 (c) Platelets equal to or greater than 100 000 / mm3 (d) total bilirubin less than 1.5 times greater than the normal value e) Hepatic transaminases less than 1.5 times higher than normal value f) Creatinine \<1.2 g / dl. In case of being elevated the measured purification should be greater than 60mL / min according to Cockroft's formula. g) Albumin greater than 3gr / dl. h) Left Ventricle Ejection fraction per cardiac echography greater than 55% 9). Sugarbaker carcinomatosis index less than 20","1. Patients with heart failure, ischemic heart disease 2. Previous history of treatment with chemotherapy for some other neoplasia 3. History of neuropsychiatric disease 4. Patients with intra operative bleeding that condition hemodynamic instability. 5. Patient requiring more than 2 intraoperative anastomosis"
NCT05677490,Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma,,PHASE3,Puerto Rico,"Cancer Center-Metro Medical Center Bayamon, Bayamón, Puerto Rico, [RECRUITING] | Puerto Rico Hematology Oncology Group, Bayamón, Puerto Rico, [RECRUITING] | Doctors Cancer Center, Manatí, Puerto Rico, [RECRUITING] | San Juan Community Oncology Group, San Juan, Puerto Rico, [RECRUITING] | Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico, [RECRUITING] | PROncology, San Juan, Puerto Rico, [RECRUITING] | San Juan City Hospital, San Juan, Puerto Rico, [RECRUITING]",Advanced Esophageal Adenocarcinoma | Advanced Gastric Adenocarcinoma | Advanced Gastroesophageal Junction Adenocarcinoma | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Gastric Cancer AJCC v8,2,"[1] Arm I (mFOLFIRINOX, nivolumab) (EXPERIMENTAL): Patients receive fluorouracil IV, leucovorin calcium IV, oxaliplatin IV, and irinotecan IV on study and nivolumab IV as clinically indicated. Patients undergo MRI and a CT scan throughout the trial... || [2] Arm II (mFOLFOX, nivolumab) (ACTIVE_COMPARATOR): Patients receive fluorouracil IV, leucovorin calcium IV, and oxaliplatin IV on study and nivolumab IV as clinically indicated. Patients undergo MRI and a CT scan throughout the trial. Patients may ...","* Histologic documentation: HER2 negative adenocarcinoma as defined by American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines (Bartley et al., Journal of Clinical Oncology \[JCO\] 2017) with known PD-L1 CPS (Any CPS is allowed, but should be known prior to registration) * Stage: unresectable or metastatic * Tumor site: esophagus, gastroesophageal junction, or stomach * Measurable disease or non-measurable but evaluable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 * No prior treatment for unresectable or metastatic disease * Prior neoadjuvant or adjuvant cytotoxic chemotherapy or adjuvant immunotherapy is allowed as long as it was completed at least 1 year prior to registration * Age \>= 18 years * Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 * Absolute neutrophil count (ANC) \>= 1,500/mm\^3 * Platelet count \>= 100,000/mm\^3 * Creatinine =\< 1.5 x upper limit of normal (ULN) OR calculated (calc.) creatinine clearance \>= 30 mL/min * Total bilirubin =\< 1.5 x ULN * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 3 x ULN (in patients with liver metastasis: =\< 5 x ULN if clearly attributable to liver metastases) * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Patients positive for human immunodeficiency virus (HIV) are eligible only if they meet all of the following: * On effective anti-retroviral therapy * Undetectable HIV viral load by standard clinical assay =\< 6 months of registration * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should b","* Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects \* Therefore, for women of childbearing potential only, a negative serum or urine pregnancy test done =\< 7 days prior to registration is required * No known Gilbert's syndrome or known homozygosity for UGAT1A1\*28 polymorphism * No baseline grade \>= 2 peripheral neuropathy, neurosensory toxicity, or neuromotor toxicity per CTCAE version (v) 5.0 regardless of causality * No medical condition such as uncontrolled infection or uncontrolled diabetes mellitus which, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient * No untreated, symptomatic brain metastasis. Patients with treated brain metastases are eligible if the following criteria are met: 1) follow-up brain imaging done at least in 4 weeks after central nervous system (CNS)-directed therapy shows no evidence of progression and 2) the patient no longer requires steroids, or is on a stable steroid dose for more than four weeks * No allogeneic tissue/organ transplant"
NCT06136559,"A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)",,PHASE3,"Brazil, Chile, Colombia, Mexico, Peru","Hospital 9 De Julho ( Site 2206), São Paulo, Brazil, [RECRUITING] | Instituto Nacional de Câncer - INCA ( Site 2201), Rio de Janeiro, Brazil, [RECRUITING] | Hospital Paulistano-Americas Oncologia ( Site 2202), São Paulo, Brazil, [RECRUITING] | FALP-UIDO ( Site 2300), Santiago, Chile, [RECRUITING] | Clínica Alemana de Santiago-Unidad de Investigaciones ( Site 2306), Santiago, Chile, [RECRUITING] | Bradfordhill-Clinical Area ( Site 2310), Santiago, Chile, [RECRUITING] | Sociedad De Oncología y Hematología Del Cesar SAS-Oncology ( Site 2405), Valledupar, Colombia, [RECRUITING] | IMAT S.A.S ( Site 2401), Montería, Colombia, [RECRUITING] | Fundacion Valle del Lili- CIC-Oncology CIC ( Site 2402), Santiago de Cali, Colombia, [RECRUITING] | Centro de Infusion Superare ( Site 2602), Mexico City, Mexico, [RECRUITING]",Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma,2,"[1] Nemtabrutinib (EXPERIMENTAL): Participants will receive nemtabrutinib at specified dose until disease progression, unacceptable toxicity or until discontinuation criteria are met. || [2] Ibrutinib/Acalabrutinib (ACTIVE_COMPARATOR): Participants will receive investigator's choice of ibrutinib or acalabrutinib at specified dose until disease progression, unacceptable toxicity or until discontinuation criteria are met.",The main inclusion criteria include but are not limited to the following: * Confirmed diagnosis of CLL/SLL and active disease clearly documented to have a need to initiate therapy. * Has at least 1 marker of disease burden. * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before randomization. * Has the ability to swallow and retain oral medication. * Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV deoxyribonucleic acid (DNA) viral load before randomization. * Participants with history of hepatitis C virus (HCV) infection are eligible if HCV ribonucleic acid (RNA) viral load is undetectable at screening. * Participants with human immunodeficiency virus (HIV) who meet ALL eligibility criteria.,"The main exclusion criteria include but are not limited to the following: * Has an active hepatitis B virus/ hepatitis C virus (HBV/HCV) infection. * Has gastrointestinal (GI) dysfunction that may affect drug absorption. * Has diagnosis of Richter Transformation or active central nervous system (CNS) involvement by CLL/SLL. * Has had acquired immune deficiency syndrome (AIDS)-defining opportunistic infection in the past 12 months before screening. * Has clinically significant cardiovascular disease. * Has hypersensitivity to nemtabrutinib or contraindication to ibrutinib or acalabrutinib, or any of the excipients. * Has history of severe bleeding disorder. * Has history of second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years. * Has received any systemic anticancer therapy for CLL/SLL. * Is currently being treated with p-glycoprotein (P-gp) substrates with a narrow therapeutic index, cytochrome P450 3A (CYP3A) strong or moderate inducers or CYP3A strong inhibitors. * Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids. * Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed. * Has received an investigational agent or has used an investigational device within 4 weeks before study intervention administration. * Has active infection requiring systemic therapy. * Participants who have not adequately recovered from major surgery or have ongoing surgical complications."
NCT06431594,"A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subjects With Advanced Solid Tumors",BEHOLD-1,PHASE1,Argentina,"GSK Investigational Site, Cipoletti Rio Negro, Argentina, [RECRUITING] | GSK Investigational Site, Ciudad de Buenos Aires, Argentina, [RECRUITING] | GSK Investigational Site, Rosario, Argentina, [RECRUITING]",Solid Tumors | Neoplasms,2,[1] Part 1: Dose Escalation (EXPERIMENTAL): Participants with advanced solid tumors who are refractory or intolerant to established standard therapies || [2] Part 2: Dose Expansion (EXPERIMENTAL): Participants with platinum-resistant ovarian cancer (PROC) and endometrial cancer (EC),"* Males or females aged 18 years or older (≥18 years). * Participants with pathologically confirmed advanced solid tumor (who have failed or are intolerant to standard of care). * PROC cohort 1. Histologically documented, advanced (metastatic and/or unresectable) high-grade serous/endometrioid ovarian, primary peritoneal, or fallopian tube cancer. 2. Must have received or are intolerant to 1 but no more than 3 lines of prior systemic therapy. 3. Platinum-resistant disease, defined as progression or relapse within 6 months after the completion of platinum-based therapy. 4. Must have had prior bevacizumab if the participant was considered a candidate for this regimen and the regimen is locally available. 5. Participants with known Folate receptor-α (FR-α) expressing tumors must have received mirvetuximab soravtasine if the participants was considered a candidate for this regimen and the regimen is locally available. 6. Participants with known Breast cancer susceptibility gene (BRCA) mutated tumors should have received a Poly adenosine diphosphate-ribose polymerase (PARP) inhibitor if the participant was considered a candidate for this regimen and the regimen is locally available. * Endometrial cancer cohort 1. Histologically documented, advanced (metastatic and/or unresectable) or recurrent endometrial cancer. 2. Must have received or are intolerant to 1 but no more than 3 lines of prior systemic therapy. 3. Must have had prior platinum and PD(L)-1 inhibitor (in same regimen or in separate regimens), if considered a candidate for this regimen and the regimen is locally available. 4. All epithelial histologies are permitted including carcinosarcoma. * Participants have at least one target lesion as assessed per the RECIST 1.1 * Tumor tissue from a newly obtained biopsy or archival tumor tissue is required for retrospective detection of B7 homolog 4 (B7-H4) expression by Immunohistochemistry (IHC) in central laboratory and other biomarker analysis. Tissue from a newly o","* Have received any of B7-H4-targeted therapies. * Have received any of cytotoxic chemotherapy drugs, anti-tumor traditional Chinese medicines or other anti-tumor drugs within 28 days prior to the first dose of study drug; or need to continue these drugs during the study. * Have received locoregional radiation therapy within 2 weeks prior to the first dose of study drug; more than 30% of bone marrow irradiation or wide-field radiation therapy within 4 weeks prior to the first dose of study treatment. * Presence of pleural/abdominal effusion/ascites requiring clinical intervention; presence of pericardial effusion * Major surgery within 28 days prior to the first dose of study treatment. * Evidence of brain metastasis unless asymptomatic. * Has inadequate bone marrow reserve or hepatic/renal functions. * Mean Fridericia-corrected QT interval (QTcF) \> 470 millisecond (msec) on resting ECG. * Evidence of current clinically significant arrhythmias or ECG abnormalities * Risk factors of prolonged QTc or arrhythmia events, * Left ventricular ejection fraction (LVEF) \< 50%. * Have severe, uncontrolled or active cardiovascular disorders, serious or poorly controlled hypertension, clinically significant bleeding symptoms or serious arteriovenous thromboembolic events * Any evidence of current Interstitial lung disease (ILD) or pneumonitis or a prior history of ILD or pneumonitis requiring high-dose systemic glucocorticoids. * Have received prior therapy with topoisomerase inhibitors or topoisomerase inhibitor Antibody-drug conjugate (ADCs) * PROC 1. Primary platinum refractory disease defined as those who have progressed on or within 12 weeks of last dose of first line platinum therapy not permitted. 2. Non-epithelial carcinoma, clear-cell, mucinous, germ-cell, low-grade serous, or low-grade endometrioid carcinoma not permitted. * Endometrial cancer a. Mesenchymal tumors of the uterus (uterine sarcomas) not permitted."
NCT04924075,"A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations",,PHASE2,Chile,"FALP ( Site 2200), Santiago, Chile, [RECRUITING] | Centro de Oncología de Precisión ( Site 2203), Santiago, Chile, [RECRUITING]",Pheochromocytoma/Paraganglioma | Pancreatic Neuroendocrine Tumor | Von Hippel-Lindau Disease | Advanced Gastrointestinal Stromal Tumor | HIF-2α Mutated Cancers,1,"[1] Belzutifan (EXPERIMENTAL): Belzutifan, 120 mg, oral, once daily (QD) until progressive disease or discontinuation.","* Male and female participants at least 12 years of age (at least 18 years of age for Cohort B1) * Diagnosis of one of the following: Advanced/metastatic pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumors (pNET), von Hippel-Lindau (VHL) disease associated localized tumors, or advanced wild-type gastrointestinal stromal tumor (wt GIST) or advanced solid tumors with Hypoxia Inducible Factor- 2 alpha subunit (HIF-2α) related genetic alterations * Cohort BI: VHL Disease-associated tumors: * Have a diagnosis of VHL disease as determined by a germline test locally and/or clinical diagnosis * Must be ≥18 years of age * Has a life expectancy of at least 3 months","* Unable to swallow orally administered medication or has a disorder that might affect the absorption of belzutifan * History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years * Any of the following: A pulse oximeter reading \<92% at rest, or requires intermittent supplemental oxygen, or requires chronic supplemental oxygen * Clinically significant cardiac disease, including unstable angina, acute myocardial infarction, or arterial bypass (CABG) or Percutaneous transluminal coronary angioplasty (PTCA) ≤6 months from study entry, or New York Heart Association Class III or IV congestive heart failure * Received prior treatment (except somatostatin analogs) with chemotherapy, targeted therapy, biologics, or other investigational therapy within the past 4 weeks of first dose of study intervention"
NCT05223036,"A Phase IIa, Placebo-Controlled, Randomized Study of Daily Obeticholic Acid (OCA) to Reduce Intestinal Polyp Burden in Familial Adenomatous Polyposis (FAP)",,PHASE2,Puerto Rico,"University of Puerto Rico, San Juan, Puerto Rico, [RECRUITING]",Attenuated Familial Adenomatous Polyposis | Colorectal Carcinoma | Duodenal Carcinoma | Familial Adenomatous Polyposis,2,[1] Arm I (OCA) (EXPERIMENTAL): Patients receive OCA PO QD for 6 months in the absence of unacceptable toxicity. Patients also undergo GI endoscopy with biopsy and collection of blood samples at screening and on study. || [2] Arm II (placebo) (PLACEBO_COMPARATOR): Patients receive placebo PO QD for 6 months in the absence of unacceptable toxicity. Patients also undergo GI endoscopy with biopsy and collection of blood samples at screening and on study.,"* Participants must have a diagnosis of phenotypic FAP with disease involvement of the duodenum and rectum as defined by: * Genetic diagnosis: APC germline mutation (with or without family history) or obligate carrier * Clinical diagnosis: FAP phenotype with \> 100 adenomas in large intestine and participant has a family history of FAP * Clinical diagnosis: FAP phenotype who are status post colectomy for polyposis, participant has a family history of FAP, and 2 FAP experts agree to the diagnosis * Attenuated FAP diagnosis: APC germline mutation required * Participants must have no evidence of active or recurrent invasive cancer for 6 months prior to screening and must be at least 6 months from any prior cancer-directed treatment (such as surgical resection, chemotherapy, immunotherapy, hormonal therapy or radiation) * Age \>= 18 years. Because no dosing or adverse event (AE) data are currently available on the use of OCA in participants \< 18 years of age, children are excluded from this study but will be eligible for future pediatric trials, if applicable * Eastern Cooperative Oncology Group (ECOG) performance status =\< 1 (Karnofsky \>= 70%) * Hemoglobin \>= 10 g/dL or hematocrit \>= 30% * Leukocyte count \>= 3,500/microliter * Platelet count \>= 100,000/microliter * Absolute neutrophil count \>= 1,500/microliter * Creatinine clearance (calculated if measured is not available) \>= 30 mL/min/1.73m\^2 * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 1.5 x the institutional upper limit of normal (ULN) * Total bilirubin =\< 1.0 x ULN * Alkaline phosphatase =\< 1.5 x ULN * Gamma-glutamyl transferase (GGT) =\< 1.5 x ULN * Presence of Spigelman stage II or III duodenal polyposis at screening * Presence of intact rectum or ileo-rectal anastomosis (IRA) or ileal pouch-anal anastomosis (IPAA) or end ileostomy * Participants must have a negative test resul","* Prior use of study drug * Duodenal or rectal/pouch polyp burden that is not quantifiable * Histologically-confirmed high-grade dysplasia or cancer on biopsy at screening * Individuals with active, known or suspected chronic liver disease including cirrhosis, nonalcoholic steatohepatitis (NASH) with liver fibrosis, NASH with cirrhosis, primary sclerosing cholangitis, biliary atresia * Individuals with acute cholecystitis (defined by a syndrome of right upper quadrant pain, fever, and leukocytosis associated with gallbladder inflammation) * Individuals with a history of pancreatitis or presence of pancreatic abnormalities suggestive of increased risk of pancreatitis * Individuals with hepatic steatosis and velocity \> 1.7 meters/second (m/s) as determined by liver ultrasound elastography * Individuals with hyperlipidemia not well controlled with the use of pharmacotherapy and/or dietary modifications * History of severe, progressive, or uncontrolled renal, genitourinary, hepatic, hematologic, endocrine, cardiac, vascular, pulmonary, rheumatologic, neurologic, psychiatric, or metabolic disturbances, or signs and symptoms thereof * Pregnant, breast-feeding, or women of childbearing potential unwilling to use a reliable contraceptive method. Pregnant women are excluded from this study because OCA is an agent with unknown effects on the developing human fetus. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with OCA, breastfeeding should be discontinued if the mother is treated with OCA * Known hypersensitivity, allergies, or intolerance to the study drug or compounds of similar chemical or biologic composition * Any serious and/or unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with participant's safety, obtaining informed consent, or compliance to the study procedures * Participants may not be receivin"
NCT06211764,"A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy",SunRISe-5,PHASE3,"Argentina, Brazil","Clinica Santa Isabel, Buenos Aires, Argentina, [ACTIVE_NOT_RECRUITING] | Investigaciones Clinico Moleculares (ICM), CABA, Argentina, [ACTIVE_NOT_RECRUITING] | Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica, Córdoba, Argentina, [ACTIVE_NOT_RECRUITING] | Centro Urologico Profesor Bengio, Córdoba, Argentina, [ACTIVE_NOT_RECRUITING] | Hospital Privado de la Comunidad, Mar del Plata, Argentina, [COMPLETED] | Fundacao Pio XII, Barretos, Brazil, [ACTIVE_NOT_RECRUITING] | NAIC Nair Antunes Instituto do Cancer, Bauru, Brazil, [COMPLETED] | Hospital das Clinicas da Universidade Estadual de Campinas UNICAMP, Campinas, Brazil, [ACTIVE_NOT_RECRUITING] | Liga Paranaense de Combate ao Cancer, Curitiba, Brazil, [ACTIVE_NOT_RECRUITING] | Irmandade Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil, [ACTIVE_NOT_RECRUITING]",Non-Muscle Invasive Bladder Neoplasms,2,[1] Group A: TAR-200 (EXPERIMENTAL): Participants will receive intravesical TAR-200 every 3 weeks during an induction phase and every 12 weeks during a maintenance phase. || [2] Group B: Mitomycin C (MMC) or Gemcitabine (ACTIVE_COMPARATOR): Participants will receive either single agent intravesical MMC or gemcitabine every week during an induction phase and every 4 weeks during a maintenance phase.,"* Histologically confirmed diagnosis by local pathology (within 90 days of documented informed consent) of recurrent, papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) \[defined as high-grade Ta or any T1, no carcinoma in situ (CIS)\] * Participants with variant histologic subtypes are allowed if tumor(s) demonstrate urothelial (transitional cell histology) predominance. However, neuroendocrine, and small cell variants will be excluded * Participants must be ineligible for or have elected not to undergo Radical Cystectomy (RC) * Have an Eastern Cooperative Oncology Group (ECOG) performance status Grade of 0, 1, or 2","* Presence of CIS at any point from time of diagnosis of papillary-only HR-NMIBC recurrence to randomization. Additionally, presence or history of histologically confirmed, muscle-invasive, locally advanced, nonresectable, or metastatic urothelial carcinoma (that is, T2, T3, T4, N+, and/or M+) * Presence of any bladder or urethral anatomic feature that, in the opinion of the Investigator, may prevent the safe placement, indwelling use, or removal of TAR-200. Participants with tumors involving the prostatic urethra in men will be excluded * A history of clinically significant polyuria with recorded 24-hour urine volumes greater than 4000 milliliters (\>4000 mL) * Indwelling catheters are not permitted; however, intermittent catheterization is acceptable * Previous treatment with TAR-200"
NCT04895436,"A Multicenter, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Venetoclax-Obinutuzumab Retreatment in Patients With Recurring Chronic Lymphocytic Leukemia",ReVenG,PHASE2,Brazil,"Hospital de Clinicas de Porto Alegre /ID# 243657, Porto Alegre, Brazil, [COMPLETED] | Hospital Nove de Julho /ID# 243658, São Paulo, Brazil, [RECRUITING] | Instituto de Ensino e Pesquisas Sao Lucas /ID# 243659, São Paulo, Brazil, [RECRUITING]",Chronic Lymphocytic Leukemia (CLL),2,[1] Cohort 1 - venetoclax + obinutuzumab (EXPERIMENTAL): Participants will receive venetoclax + obinutuzumab for six 28-day cycles followed by venetoclax for six 28-day cycles. || [2] Cohort 2 - venetoclax + obinutuzumab (EXPERIMENTAL): Participants will receive venetoclax + obinutuzumab for six 28-day cycles followed by venetoclax for eighteen 28-day cycles.,"* Documented diagnosis of chronic lymphocytic leukemia (CLL) that requires treatment for CLL according to International Workshop for Chronic Lymphocytic Leukemia (iwCLL) 2018 criteria. * Previously completed venetoclax + anti-CD20 antibody +/- X regimen as a fixed duration first-line (1L) therapy and achieved documented response, defined as complete remission, complete remission with incomplete marrow recovery, partial remission, or nodular partial remission. * More than 24 months (Cohort 1) or 12-24 months (Cohort 2) have elapsed between last dose of venetoclax and disease progression after completion of 1L treatment.",\- Received intervening treatment for CLL after completing previous treatment with a venetoclax + anti-CD20 antibody +/- X regimen.
NCT06820463,"A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Metastatic Colorectal Cancer",AndroMETa-CRC,PHASE2,Puerto Rico,"Pan American Center for Oncology Trials /ID# 268809, Rio Piedras, Puerto Rico, [RECRUITING]",Metastatic Colorectal Cancer,8,"[1] Substudy 1: Dose Escalation Telisotuzumab Adizutecan (EXPERIMENTAL): Participants will receive various doses of telisotuzumab adizutecan in combination with a fixed dose of fluorouracil, leucovorin, and oxaliplatin (FOLFOX) and bevacizumab as part of the approximate... || [2] Substudy 1: Dose Expansion Telisotuzumab Adizutecan High Dose (EXPERIMENTAL): Participants will receive the high dose of telisotuzumab adizutecan determined in the dose expansion arm in combination with a fixed dose of FOLFOX and bevacizumab as part of the approximately 6 ye... || [3] Substudy 1: Dose Expansion Telisotuzumab Adizutecan Low Dose (EXPERIMENTAL): Participants will receive the low dose of telisotuzumab adizutecandetermined in the dose expansion arm in combination with a fixed dose of FOLFOX and bevacizumab as part of the approximately 6 year... || [4] Substudy 1: Dose Expansion Compatator (EXPERIMENTAL): Participants will receive a fixed dose of FOLFOX and bevacizumab as part of the approximately 6 year study duration. || [5] Substudy 2: Dose Escalation Telisotuzumab Adizutecan (EXPERIMENTAL): Participants will receive various doses of telisotuzumab adizutecan in combination with a fixed dose of fluorouracil (5-FU) and leucovorin (LV) and panitumumab as part of the approximately 6 year s... || [6] Substudy 2: Dose Expansion Telisotuzumab Adizutecan High Dose (EXPERIMENTAL): Participants will receive the high dose of telisotuzumab adizutecan determined in the dose expansion arm in combination with a fixed dose of 5-FU/LV and panitumumab as part of the approximately 6 y... || [7] Substudy 2: Dose Expansion Telisotuzumab Adizutecan Low Dose (EXPERIMENTAL): Participants will receive the low dose of telisotuzumab adizutecan determined in the dose expansion arm in combination with a fixed dose of 5-FU/LV and panitumumab as part of the approximately 6 ye... || [8] Substudy 2: Dose Expansion Compatator (EXPERIMENTAL): Participants will receive a fixed dose of FOLFOX and panitumumab as ",* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Laboratory values meeting the criteria within the protocol. * Has measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1.,"* Prior systemic regimen containing c-Met targeting agent(s) (e.g., antibody, antibody drug conjugate, bispecific) and/or any topoisomerase inhibitor(s) (e.g., irinotecan). * History of other malignancies within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death."
NCT06760637,"AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE (FOURLIGHT-3)",FourLight-3,PHASE3,"Argentina, Brazil, Mexico","Organizacion Medica de Investigacion, CABA, Argentina, [NOT_YET_RECRUITING] | CIPREC, Buenos Aires, Argentina, [NOT_YET_RECRUITING] | CIPREC, Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Fundación Respirar, Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Fundación CORI para la Investigación y Prevención del Cáncer, La Rioja, Argentina, [NOT_YET_RECRUITING] | Hospital Brasilia, Brasília, Brazil, [NOT_YET_RECRUITING] | Santa Casa de Misericordia de Passos, Passos, Brazil, [NOT_YET_RECRUITING] | Associação Hospitalar Beneficente São Vicente de Paulo, Passo Fundo, Brazil, [NOT_YET_RECRUITING] | Hospital São Vicente de Paulo, Passo Fundo, Brazil, [NOT_YET_RECRUITING] | Faculdade de Medicina do ABC, Santo André, Brazil, [NOT_YET_RECRUITING]",Breast Cancer,2,[1] Arm A (EXPERIMENTAL): PF-07220060 tablet taken by mouth plus Letrozole tablet taken by mouth || [2] Arm B (ACTIVE_COMPARATOR): Investigator's Choice of CDK4/6 inhibitor (tablet/capsule) taken by mouth with letrozole tablet taken by mouth,"* Histological confirmation of breast cancer with evidence of locally advanced or metastatic disease, which is not amenable to surgical resection or radiation therapy with curative intent. * Documented estrogen receptor (ER) and/or progesterone receptor (PR)-positive tumor * Documented HER2-negative tumor * Previously untreated with any systemic anticancer therapy for their locally advanced or metastatic disease. * Measurable disease or non-measurable bone only disease as defined by RECIST version 1.1","* In visceral crisis at risk of immediately life-threatening complications in the short term. * Current or past history of central nervous system metastases. * Have received prior (neo)adjuvant endocrine therapy (ET) and had recurrence during or within 12 months after the last dose of ET. * Have received prior (neo)adjuvant CDK4/6i and had recurrence during or within 12 months after the last dose of CDK4/6i. * Inadequate renal function, hepatic dysfunction, or hematologic abnormalities."
NCT07066046,Artificial Intelligence-assisted Colonoscopy in the Detection and Characterization of Colorectal Lesions: Randomized Controlled Clinical Trial,,NA,Brazil,"Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo, Brazil, [RECRUITING]",Colorectal Cancer (CRC) | Adenomatous Polyposis | Colorectal Lesions | Colorectal Cancer,2,"[1] Colonoscopy with the aid of artificial intelligence (ACTIVE_COMPARATOR): Stratum 1: Patients aged 18 to 44 years

Stratum 2: Patients aged 45 to 75 years

Stratum 3: Patients aged 76 years or older || [2] Colonoscopy without the aid of artificial intelligence (ACTIVE_COMPARATOR): Stratum 1: Patients aged 18 to 44 years

Stratum 2: Patients aged 45 to 75 years

Stratum 3: Patients aged 76 years or older","* All patients aged 18 years or older, with an elective indication for colonoscopy who sign the informed consent form agreeing to participate in the study.","* History of inflammatory bowel disease. * History of colorectal cancer. * Personal history of colorectal surgery. * Contraindication to endoscopic biopsies. * History of intestinal polyposis syndromes. * Urgent or emergency cases. * Presence of severe, decompensated comorbidities, or with a score of 3 or higher according to the American Society of Anesthesiologists (ASA) classification. * Incomplete colonoscopy that does not reach the cecum. * Insufficient or inadequate bowel preparation, with a score lower than 6 on the Boston Bowel Preparation Scale. * Patients who do not agree to participate in the study and do not sign the informed consent form (ICF)."
NCT06156514,"Evaluation of Concomitant Chemo-radiotherapy With Cisplatin vs Gemcitabine as the First Line of Treatment in Patients With Locally Advanced Cervical Cancer, With Comorbidities and Preserved Renal Function, is a Phase III Clinical Trial.",MICHELE,PHASE3,Mexico,"National Cancer Institute of Mexico, Mexico City, Mexico, [RECRUITING]",Locally Advanced Cervical Cancer | Gemcitabine | Chemo-radiotherapy,2,[1] A (Gemcitanine) (EXPERIMENTAL): To receive concomitant chemotherapy based on gemcitabine at 300 mg / m2 weekly || [2] B (Cisplatin) (ACTIVE_COMPARATOR): To receive concomitant chemotherapy based on cisplatin 40 mg / m2 weekly,"* Singed informed consent. * Women with Age ≥ 18 years. 1. -In women of childbearing age it should be documented: a) negative pregnancy test in serum at the beginning of the study (14 days before the start of QT-RT); b) Accept the use of some method of contraception approved by your attending physician during the study and 12 weeks after the treatment has ended. 2. -In postmenopausal women (surgical or natural menopause) at least one of the following parameters must be met for inclusion. * Previous bilateral oophorectomy * Age ≥ 60 years * Age \<60 years and amenorrhea for at least 12 months and levels of follicle stimulating hormone and estradiol within postmenopausal interval parameters. * Diagnosis of CaCu EC IB2 mg/dl With histological confirmation (epidermoid, adenocarcinoma or adenoescamoso). * Patients who are candidates for treatment with concomitant QT / RT. * ECOG 0-2. * Measurable disease by CT scan and magnetic resonance imaging of the pelvis according to the RECIST criteria v1.1 * No previous treatment. * Creatinine clearance ≥ 60 ml / min calculated by the CKD-EPI formula. * Patients with adequate hematological and hepatic functioning, defined by the following parameters: 1. Hb equal to or greater than 10g /l. (Transfusion prior to treatment is allowed to reach this level of hemoglobin). 2. Leukocytes greater than or equal to 4000 / mm3. 3. Platelets equal to or greater than 100,000mm3. 4. Total bilirubin ≤1.5 times the upper limit of normal (ULN) and. Transaminases less than 1.5 times the LSN * Patients with a prior diagnosis of the following comorbidities: * Diabetes mellitus type 2, which has: fasting serum glucose \<250 mg/dl. * Systemic arterial hypertension G1 or G2 according to CTCAE v4.03 * Child Pugh A liver disease * Cardiovascular diseases such as: Ischemic heart disease undergoing asymptomatic treatment, without clinical data of stable or unstable angina or for acute myocardial infarction. * Compensated heart failure in functional class I o","* Patients with a second neoplasm. * Pregnant or lactating patients. * Patients with small cell and / or neuroendocrine CaCu. * Patients with impaired renal function with a GFR \<or equal to 60ml / min calculated by the CKD-EPI formula * Patients with a history of active TB (TB) * Patients with a history of Human Immunodeficiency Virus (HIV) infection * Patients with vesico-vaginal or vesicorectal fistulas at diagnosis * Concomitant treatment with another experimental drug. Social, family or geographical conditions that suggest a poor attachment to the study Criteria Interruption of Treatment (Withdrawal of patients) A patient will be discontinued from the study under the following circumstances: * Evidence of disease progression. * If treating physician considers that a change of therapy may benefit the patient. * If patient withdrew consent * Due to unmanageable toxicity By pregnancy or if the patient does not wish to continue using the contraceptive methods indicated by the attending physician"
NCT04597359,A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers,,PHASE2,Puerto Rico,"Cancer Center-Metro Medical Center Bayamon, Bayamón, Puerto Rico, [RECRUITING] | Puerto Rico Hematology Oncology Group, Bayamón, Puerto Rico, [RECRUITING] | Doctors Cancer Center, Manatí, Puerto Rico, [RECRUITING] | San Juan Community Oncology Group, San Juan, Puerto Rico, [RECRUITING] | Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico, [RECRUITING] | PROncology, San Juan, Puerto Rico, [RECRUITING] | San Juan City Hospital, San Juan, Puerto Rico, [RECRUITING]",Prostate Carcinoma,2,[1] Arm A (green tea catechins) (EXPERIMENTAL): Patients receive green tea catechins PO BID for up to 6 months in the absence of disease progression or unacceptable toxicity. || [2] Arm B (placebo) (PLACEBO_COMPARATOR): Patients receive placebo PO BID for up to 6 months.,"* INCLUSION CRITERIA FOR PREREGISTRATION (STEP 0: SCREENING) * Patient must have biopsy-proven (consisting of \>= 12 tissue cores) adenocarcinoma of the prostate with cancer present in at least one biopsy core in the most recent biopsy using initial transrectal ultrasound (TRUS) biopsy or TRUS biopsy followed by multiparametric magnetic resonance imaging (mpMRI) of the prostate and a confirmatory targeted biopsy * Patient must be on active surveillance (very low, low and favorable intermediate risk as defined by the National Comprehensive Cancer Network \[NCCN\]) * Patient must be scheduled for a follow up prostate biopsy 6 months after the initiation of treatment on this study * Patient must have a serum PSA \< 10 ng/mL or prostate specific antigen density (PSAD) \< 0.15 ng/mL/ g obtained within 30 days of registration * Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Patient must be willing to abstain from consumption of any supplements containing green tea catechins * Patient must be willing to restrict tea consumption to less than three (3) servings of hot tea or three (3) servings of iced tea per week (serving size of 8 oz) * Patient must be willing to discontinue current vitamin/mineral supplement use and use one provided by study * Patient must be willing to take study agent or placebo at the dose specified with meals * Patient must have the ability to understand and the willingness to sign a written informed consent document * Absolute neutrophil count \>= 1,200/mm\^3 (\>= 1.2 k/uL) (obtained within 30 days prior to registration) * Platelets \>= 75,000/mm\^3 (\>= 75 k/uL) (obtained within 30 days prior to registration) * Total bilirubin =\< 1.2 mg/dL (or =\< 3.0 mg/dL for patients with Gilbert's syndrome) (obtained within 30 days prior to registration) * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\<","* EXCLUSION CRITERIA FOR PREREGISTRATION (STEP 0: SCREENING) * Patient must not have had prior treatment for prostate cancer, including focal therapy, with surgery, irradiation, local ablative (i.e., cryosurgery or high-intensity focused ultrasound), or androgen deprivation therapy * Patient must not have a history of renal or hepatic disease, including history of hepatitis B and C * Patient must not have prostate cancer with distant metastases * Patient must not have undergone treatment of hormone therapy, immunotherapy, chemotherapy and/or radiation for any malignancies within the past 2 years. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Patient must not receive any other investigational agents while on this study * Patient must not have a history of allergic reactions attributed to tea or other compounds of similar chemical or biologic composition to green tea extracts"
NCT04449874,"A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation",,PHASE1,Brazil,"Santa Casa de Misericordia de Belo Horizonte - PPDS, Belo Horizonte, Brazil, [COMPLETED] | Hospital Erasto Gaertner, Curitiba, Brazil, [COMPLETED] | Hospital de Clinicas de Porto Alegre HCPA PPDS, Pôrto Alegre, Brazil, [RECRUITING] | Universidade de Caxias do Sul, Caxias do Sul, Brazil, [COMPLETED] | Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS), Porto Alegre, Brazil, [COMPLETED] | Hospital de Cancer de Barretos, Barretos, Brazil, [COMPLETED] | Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS, São José do Rio Preto, Brazil, [RECRUITING] | Instituto do Cancer do Estado de Sao Paulo - ICESP, São Paulo, Brazil, [WITHDRAWN] | Instituto Nacional de Câncer, Rio de Janeiro, Brazil, [COMPLETED]",Non-Small Cell Lung Cancer | Colorectal Cancer | Advanced Solid Tumors,7,"[1] Arm A: Dose-escalation (Stage I), Dose Expansion (Stage II) (EXPERIMENTAL): Participants in Stage I will receive GDC-6036 administered orally once daily (PO QD). The dose will be increased in successive cohorts until a study-specific threshold is reached.

Participants wit... || [2] Arm B: GDC-6036 + Atezolizumab (Stage I and Stage II) (EXPERIMENTAL): Participants with non-small cell lung cancer will receive GDC-6036 in combination with atezolizumab. || [3] Arm C: GDC-6036 + Cetuximab (Stage I and Stage II) (EXPERIMENTAL): Participants with colorectal cancer will receive GDC-6036 in combination with cetuximab. || [4] Arm D: GDC-6036 + Bevacizumab (Stage I and Stage II) (EXPERIMENTAL): Participants with solid tumors will receive GDC-6036 in combination with bevacizumab. || [5] Arm E: GDC-6036 + Erlotinib (Stage I and Stage II) (EXPERIMENTAL): Participants with non-small cell lung cancer will receive GDC-6036 in combination with erlotinib. || [6] Arm F: GDC-6036 + GDC-1971 (Stage I and Stage II) (EXPERIMENTAL): Participants with solid tumors will receive GDC-6036 in combination with GDC-1971 PO in Stage I.

Participants with select solid tumors will be treated with GDC-6036 in combination with GDC-1971 PO... || [7] Arm G: GDC-6036 + Inavolisib (Stage I and Stage II) (EXPERIMENTAL): Participants with solid tumors will receive GDC-6036 in combination with inavolisib PO in Stage I.

Participants with select solid tumors will be treated with GDC-6036 in combination with inavolisi...","* Histologically documented advanced or metastatic solid tumor with KRAS G12C mutation. * Women of childbearing potential must agree to remain abstinent or use contraception, and agree to refrain from donating eggs during the treatment period and after the final dose of study treatment as specified in the protocol. * Men who are not surgically sterile must agree to remain abstinent or use a condom, and agreement to refrain from donating sperm during the treatment period and after the final dose of study treatment as specified in the protocol.",* Active brain metastases. * Malabsorption or other condition that interferes with enteral absorption. * Clinically significant cardiovascular dysfunction or liver disease.
NCT06537843,"Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia: Multicenter, Phase 2, Clinical Trial",VenCM,PHASE2,Brazil,"Hospital Ophir Loyola, Belém, Brazil, [NOT_YET_RECRUITING] | Hospital de Clínicas da UFPR, Curitiba, Brazil, [NOT_YET_RECRUITING] | Hospital Universitario Polydoro Ernani de Sao Thiago, Florianópolis, Brazil, [NOT_YET_RECRUITING] | Hospital Amaral Carvalho, Jaú, Brazil, [RECRUITING] | Hospital Municipal Sao Jose, Joinville, Brazil, [RECRUITING]",Acute Myeloid Leukemia,1,"[1] VenCM (EXPERIMENTAL): Venetoclax, Cytarabine, Metformin","* Diagnosis of AML in accordance with the World Health Organization criteria. * Ineligibility for induction chemotherapy due to age (≥ 70 years) or, for patients 18 to 74 years of age, ECOG-PS 2 or 3, creatinine clearance below 60 mL/min/1,73m², left ventricular ejection fraction ≤ 50%. * Projected life expectancy of at least 12 weeks. * Not requiring supplemental oxygen or substitutive renal therapy. * Female participants must be either postmenopausal, surgically sterile or practicing at least one protocol specified method of birth control starting at Study Day 1 through at least 180 days after the last dose of study drug. * Male participants must agree, from Study Day 1 through at least 180 days after the last dose of study drug, to practice protocol specified methods of contraception and to refrain from sperm donation from initial study drug administration through at least 180 days after the last dose of study drug. * Participant must voluntarily sign and date an informed consent form, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.","* Diagnosis of acute promyelocytic leukemia (APL). * Known central nervous system (CNS) involvement with AML. * Known human immunodeficiency virus (HIV) infection, hepatitis B virus (HBV), or hepatitis C virus (HCV) infection, or other active viral, bacterial or fungal infection requiring treatment. * History of other malignancies prior to study entry, with the exception of non-melanoma skin cancer. * Chronic Liver Disease and Cirrhosis with a class B or C Child-Pugh score."
NCT06103864,"A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)",,PHASE3,"Argentina, Brazil, Mexico","Research Site, Buenos Aires, Argentina, [RECRUITING] | Research Site, CABA, Argentina, [RECRUITING] | Research Site, CABA, Argentina, [RECRUITING] | Research Site, CABA, Argentina, [WITHDRAWN] | Research Site, Ciudad de Buenos Aires, Argentina, [RECRUITING] | Research Site, Rosario, Argentina, [RECRUITING] | Research Site, San Nicolás de los Arroyos, Argentina, [RECRUITING] | Research Site, Barretos, Brazil, [RECRUITING] | Research Site, Curitiba, Brazil, [RECRUITING] | Research Site, Florianópolis, Brazil, [RECRUITING]",Breast Cancer,3,"[1] Dato-DXd + durvalumab (EXPERIMENTAL): Arm 1: Dato-DXd + durvalumab || [2] Investigator's Choice of Chemotherapy (ICC) in combination with pembrolizumab (ACTIVE_COMPARATOR): Arm 2: Investigator's Choice of Chemotherapy (ICC) in combination with pembrolizumab (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin) || [3] Dato-DXd (EXPERIMENTAL): Arm 3: Dato-DXd","* Histologically or cytologically documented locally recurrent inoperable, which cannot be treated with curative intent, or metastatic TNBC, as defined by the ASCO-CAP guidelines. * ECOG PS 0 or 1. * Participants are expected to provide an FFPE tumour sample collected from a locally recurrent inoperable or metastatic tumour. If no such sample is available, an archival FFPE tumour sample can be submitted; it must have been collected ≤ 3 years prior to the participant signing informed consent (screening start). * PD-L1 positive TNBC based on results from an appropriately validated investigational PD-L1 (22C3) assay (CPS ≥ 10) from a sponsor designated central laboratory. * No prior chemotherapy or other systemic anti-cancer therapy for metastatic or locally recurrent inoperable breast cancer. \- Patients with recurrent disease will be eligible if they have completed treatment for Stage I-III breast cancer, if indicated, and ≥6 months have elapsed between completion of treatment with curative intent and the first documented recurrence. * Eligible for one of the chemotherapy options listed as ICC (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin). * Measurable disease as per RECIST 1.1. * Adequate bone marrow reserve and organ function. * Male and female participants of childbearing potential must agree to use protocol-specified method(s) of contraception. Key","* As judged by investigator, any evidence of diseases (such as severe or uncontrolled medical conditions including systemic diseases, uncontrolled hypertension, serious gastrointestinal conditions associated with diarrhoea, chronic diverticulitis or previous complicated diverticulitis, history of allogeneic organ transplant, and active bleeding diseases, ongoing and active infection, significant cardiac conditions, substance abuse, psychiatric illness/social situation or psychological conditions) which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol. * History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 3 years before Cycle 1 Day 1 and of low potential risk for recurrence. * Participants with a history of previously treated neoplastic spinal cord compression or treated, clinically inactive brain metastases that are no longer symptomatic, who require no treatment with corticosteroids or anticonvulsants, may be included in the study if they have recovered from acute toxic effects of radiotherapy. \- Participants with treated clinically inactive brain metastases that are no longer symptomatic, who require no treatment with corticosteroids or anticonvulsants, may be included in the study if they have recovered from acute toxic effects of radiotherapy. * Uncontrolled infection requiring IV antibiotics, antivirals or antifungals. * Active or uncontrolled hepatitis B or C virus infection. * Known HIV infection that is not well controlled. * Uncontrolled or significant cardiac disease. * History of non-infectious ILD/pneumonitis (including radiation pneumonitis) that required steroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening. * Severe pulmonary function compromise. * Clinically significant corneal disease. * Active or prior documented "
NCT05555732,A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07),,PHASE3,"Argentina, Brazil, Chile, Mexico","Instituto Alexander Fleming, Buenos Aires, Argentina, [RECRUITING] | Fundacion CENIT para la investigacion en Neurociencias, Ciudad Autonoma de Buenos Aire, Argentina, [RECRUITING] | Hospital de La Comunidad, Mar del Plata, Argentina, [RECRUITING] | Centro de Investigacion Pergamino Sa, Pergamino, Argentina, [RECRUITING] | Instituto de Oncologia de Rosario, Rosario, Argentina, [RECRUITING] | Sanatorio Parque, Rosario, Argentina, [RECRUITING] | Sanatorio Britanico, Rosario, Argentina, [RECRUITING] | Centro Polivalente de Asistencia E Investigacion Clinica Cer San Juan, San Juan, Argentina, [RECRUITING] | Centro de Investigaciones Clinicas. Clinica Viedma S.A., Viedma, Argentina, [RECRUITING] | Personal Oncologia de Precisao - Cenantron, Belo Horizonte, Brazil, [RECRUITING]",Metastatic Non Small Cell Lung Cancer,3,[1] Dato-DXd + Pembrolizumab + Platinum Chemotherapy (EXPERIMENTAL): Participants will be randomized to receive 6.0mg/kg Dato-DXd plus 200 mg pembrolizumab plus platinum chemotherapy (cisplatin 75 mg/m\^2 or carboplatin area under the curve \[AUC) 5\]). || [2] Dato-DXd + Pembrolizumab (EXPERIMENTAL): Participants will be randomized to receive 6.0mg/kg Dato-DXd plus 200 mg pembrolizumab. || [3] Pembrolizumab + Pemetrexed + Platinum Chemotherapy (ACTIVE_COMPARATOR): Participants will be randomized to receive 200 mg pembrolizumab plus 500 mg/m\^2 pemetrexed plus platinum chemotherapy (cisplatin 75 mg/m\^2 or carboplatin area under the curve \[AUC) 5\]).,"1. Sign and date the Main ICF, prior to the start of any study- specific qualification procedures. Is willing and able to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions. 2. Adults ≥18 at the time the Main ICF is signed. (Follow local regulatory requirements if the legal age of adult voluntary consent for study participation is \>18 years old). 3. Has tumor with PD-L1 TPS \<50% as determined by PD-L1 IHC 22C3 pharmDx assay by central testing (minimum of six slides). PD-L1 expression results available at the same central laboratory from screening for the purpose of entry into another Dato-DXd study may be used for tissue screening purposes in this study as long as the subject has not been randomized/enrolled in the other study. 4. Has provided a formalin-fixed tumor tissue sample (minimum of 4 × 4-micron sections or block equivalent) for the measurement of TROP2 protein expression and for the assessment of other exploratory biomarkers. This tissue requirement is in addition to the tissue required for PD-L1 testing for tissue screening purposes. If a documented law or regulation prohibits (or does not approve) sample collection, then such sample will not be collected, and the subject is still eligible for the study. 5. Has not been treated with systemic anticancer therapy for advanced or metastatic non-squamous NSCLC. Subjects who received adjuvant or neoadjuvant therapy other than those listed in the","1. Has received prior systemic treatment for advanced/metastatic NSCLC. 2. Has received prior treatment with any of the following, including in the adjuvant/neoadjuvant setting (for NSCLC): 1. Any agent, including an ADC, containing a chemotherapeutic agent targeting topoisomerase I 2. TROP2-targeted therapy 3. Any anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX40, CD137) 4. Any other ICIs Subjects who received adjuvant or neoadjuvant therapy OTHER than those listed above are eligible if the adjuvant/neoadjuvant therapy was completed at least 6 months prior to the diagnosis of advanced or metastatic disease. 3. Has received a live vaccine within 30 days prior to the first dose of study treatment. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed. For any subject receiving an approved severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine, please follow the vaccine label and/or local guidance. The vaccine manufacturer and the date of administration should be recorded on the electronic case report form (Concomitant Medications page), as should any AEs relating to the vaccine (including hypersensitivity or allergies). Note: Any licensed SARS-CoV2 vaccine (including those authorized for emergency use) in a particular country is allowed in the study as long as the vaccine is an mRNA vaccine, replication-incompetent adenoviral vaccine, or inactivated vaccine. Such vaccines will be treated just as any other concomitant therapy. Investigational vaccines (ie, those not licensed or authorized for emergency use) are not allo"
NCT04728893,A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies,,PHASE2,"Argentina, Brazil","Hospital Aleman ( Site 0102), Ciudad Autonoma de Buenos Aires, Argentina, [RECRUITING] | Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0103), Buenos Aires, Argentina, [RECRUITING] | Fundacion Estudios Clinicos ( Site 0112), Rosario, Argentina, [RECRUITING] | FUNDALEU ( Site 0104), Caba, Argentina, [RECRUITING] | Hospital Privado Universitario de Córdoba ( Site 0107), Córdoba, Argentina, [RECRUITING] | Fundacion Centro Oncologico de Integración Regional-Medical Oncology ( Site 0110), Mendoza, Argentina, [COMPLETED] | Hospital das Clinicas FMUSP-Pesquisa Clínica Hematologia ( Site 0303), São Paulo, Brazil, [RECRUITING] | Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0300), Rio de Janeiro, Brazil, [RECRUITING] | BP - A Beneficencia Portuguesa de São Paulo ( Site 0302), São Paulo, Brazil, [COMPLETED] | Hospital Paulistano - Amil Clinical Research ( Site 0311), São Paulo, Brazil, [RECRUITING]",Hematologic Malignancies | Waldenstroms Macroglobulinaemia | Non-Hodgkins Lymphoma | Chronic Lymphocytic Leukaemia,1,[1] Nemtabrutinib (EXPERIMENTAL): Participants receive nemtabrutinib orally once daily (QD) until progressive disease (PD) or discontinuation.,"* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before C1D1 (the first dose of study treatment) * Has a life expectancy of at least 3 months, based on the investigator assessment * Has the ability to swallow and retain oral medication * Participants who are Hepatitis B surface antigen (HBsAg)-positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization * Participants with history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening * Has adequate organ function * Male participants agree to refrain from donating sperm and agree to either remain abstinent from penile-vaginal intercourse as their preferred and usual lifestyle OR agree to use contraception, during the intervention period and for at least the time required to eliminate the study intervention after last dose of study intervention * Female participants assigned female sex at birth who are not pregnant or breastfeeding are eligible to participate if not a participant of childbearing potential (POCBP), or if a POCBP they either use a contraceptive method that is highly effective OR remain abstinent from penile-vaginal intercourse as their preferred and usual lifestyle during the intervention period and for at least to eliminate study intervention after the last dose of study intervention * Participants with Human immunodeficiency virus (HIV) are eligible if they meet all of the following: the CD4 count is \>350 cells/uL at screening, the HIV viral load is below the detectable level, are on a stable ART regimen for at least 4 weeks prior to study entry, and are compliant with their ART Part 1 and Part 2 (Cohorts A to C and J) * Has a confirmed diagnosis of Chronic lymphocytic leukemia/ Small lymphocytic lymphoma (CLL/SLL) with * At least 2 lines of prior therapy (Part 1 only) * Part 2 Cohort A: CLL/SLL participants w","* Has active HBV/HCV infection (Part 1 and Part 2) * Has a history of malignancy ≤3 years before providing documented informed consent. Participants with basal cell carcinoma of skin, squamous cell carcinoma of skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potential curative therapy are not excluded. Participants with low-risk, early-stage prostate cancer (T1-T2a, Gleason score ≤6, and prostate-specific antigen \<10 ng/mL) either treated with definitive intent or untreated in active surveillance with SD are not excluded * Has active central nervous system (CNS) disease * Has an active infection requiring systemic therapy * Has received prior systemic anti-cancer therapy within 5 half-lives or 4 weeks (if prior therapy was a monoclonal antibody) before C1D1 * Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention * Has any clinically significant gastrointestinal abnormalities that might alter absorption * History of severe bleeding disorders"
NCT02201992,A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein,,PHASE3,Puerto Rico,"Cancer Center-Metro Medical Center Bayamon, Bayamón, Puerto Rico, [RECRUITING] | Doctors Cancer Center, Manatí, Puerto Rico, [SUSPENDED] | San Juan Community Oncology Group, San Juan, Puerto Rico, [RECRUITING] | San Juan City Hospital, San Juan, Puerto Rico, [RECRUITING]",ALK Gene Rearrangement | ALK Gene Translocation | ALK Positive | Stage IB Non-Small Cell Lung Carcinoma AJCC v7 | Stage II Non-Small Cell Lung Cancer AJCC v7,2,[1] Arm A (crizotinib) (EXPERIMENTAL): Patients receive crizotinib PO BID on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. || [2] Arm B (observation) (ACTIVE_COMPARATOR): Patients undergo observation.,"* Patients must have undergone complete surgical resection of their stage IB (\>= 4 cm), II, or non-squamous IIIA NSCLC per American Joint Committee on Cancer (AJCC) 7th edition and have had negative margins; N3 disease is not allowed * Baseline chest computed tomography (CT) with or without contrast must be performed within 6 months (180 days) prior to randomization to ensure no evidence of disease; if clinically indicated additional imaging studies must be performed to rule out metastatic disease * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Patients must be registered to the ALCHEMIST-SCREEN (ALLIANCE A151216) trial prior to randomization * Positive for translocation or inversion events involving the ALK gene locus (e.g. resulting in echinoderm microtubule associated protein like 4 \[EML4\]-ALK fusion) as determined by the Vysis Break Point fluorescence in situ hybridization (FISH) assay and defined by an increase in the distance between 5? and 3? ALK probes or the loss of the 5? probe; this must have been performed: * By a local Clinical Laboratory Improvement Amendments (CLIA) certified laboratory: report must indicate the results as well as the CLIA number of the laboratory which performed the assay; tissue must be available for submission for central, retrospective confirmation of the ALK fusion status via ALCHEMIST-SCREEN (ALLIANCE A151216) OR * Patient registered to and the ALK fusion status performed centrally on the ALCHEMIST-SCREEN (ALLIANCE A151216) * Women must not be pregnant or breast-feeding * All females of childbearing potential must have a blood or urine pregnancy test within 72 hours prior to randomization to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutiv",
NCT06846671,"A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors",CaDAnCe-302,PHASE3,"Argentina, Brazil","Hospital Aleman, CABA, Argentina, [NOT_YET_RECRUITING] | FUNDALEU, Caba, Argentina, [NOT_YET_RECRUITING] | Hospital Italiano de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina, [NOT_YET_RECRUITING] | Instituto Alexander Fleming (Iaf), Ciudad Autonoma Buenos Aires, Argentina, [NOT_YET_RECRUITING] | CETUS, Belo Horizonte, Brazil, [NOT_YET_RECRUITING] | Hospital Sirio Libanes Brasilia, Brasília, Brazil, [NOT_YET_RECRUITING] | Hospital Erasto Gaertner, Curitiba, Brazil, [NOT_YET_RECRUITING] | Centro de Ensino E Pesquisa Em Oncologia de Santa Catarina (Cepen), Florianópolis, Brazil, [NOT_YET_RECRUITING] | Instituto Joinvilense de Hematologia E Oncologia, Joinville, Brazil, [RECRUITING] | Complexo Hospitalar de Niteroi, Niterói, Brazil, [NOT_YET_RECRUITING]",CLL | Chronic Lymphocytic Leukemia,2,"[1] Arm A: BGB-16673 monotherapy (EXPERIMENTAL): Participants will receive BGB-16673 once daily until any of the treatment discontinuation criteria are met || [2] Arm B: Investigator's Choice (ACTIVE_COMPARATOR): Participants will receive investigator's choice of idelalisib plus rituximab for CLL only or bendamustine plus rituximab, or venetoclax plus rituximab retreatment.","1. Confirmed diagnosis of CLL or SLL, requiring treatment, based on 2018 international workshop on chronic lymphocytic leukemia (iwCLL) criteria. 2. Previously received treatment for CLL/SLL with both a BTKi and a BCL2i. 3. Participants with SLL must have measurable disease by computer tomography (CT)/magnetic resonance imaging (MRI) 4. Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2 5. Adequate liver function 6. Adequate blood clotting function","1. Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation 2. Prior autologous stem cell transplant or chimeric antigen receptor-T cell therapy in the last 3 months 3. Known central nervous system involvement 4. Prior exposure to any BTK protein degraders 5. Active fungal, bacterial and/or viral infection requiring parenteral systemic therapy 6. Clinically significant cardiovascular disease NOTE: Other protocol defined Inclusion/Exclusion criteria may apply."
NCT06422533,Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia Due to Enterobacteriaceae and Pseudomonas Aeruginosa in Hemato-oncological Patients With Severe Neutropenia and Fever: Non-inferiority Study,,NA,Mexico,"Instituto Nacional de Cancerologia, Mexico City, Mexico, [RECRUITING]",Hematologic Neoplasms | Neutropenia,2,"[1] Ceftolozane/tazobactam (EXPERIMENTAL): Ceftozolane/tazobactam (C/T) is a combination antibiotic with a new cephalosporin, structurally similar to ceftazidime, plus tazobactam. The FDA approved This known beta-lactamase inhibitor in 2018... || [2] Piperacillin/tazobactam (ACTIVE_COMPARATOR): At our hospital, Piperacillin/tazobactam is the primary drug used as an empirical treatment in patients with severe neutropenia and fever, according to Clinical Practice Guidelines for the use of a...","* All patients \>18 years old * Diagnosis of any hematological malignancy * Severe neutropenia (polymorphonuclear \<500 cells/mm3) * Fever (≥38.3 degrees Celsius in one measure, or ≥38 degrees Celsius in at least two measures) * Median arterial pressure ≥65 mmHg on admission * A life expectancy ≥ 5 days * Agree to participate in the study",* Known hypersensitivity to cephalosporins or anaphylaxis with beta-lactams * Clinical signs related to hemodynamic instability * Concomitant use of another antibiotic with activity against Gram-negatives (except Trimethoprim/Sulfamethoxazole (TMP/SMX) as prophylaxis for P. jirovecii * Patients with end-stage chronic renal failure (\<10 ml/min by creatinine clearance-ACCr) or on renal replacement therapy. * Patients with grade IV mucositis
NCT04729114,"Phase 1, Open-Label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer",,PHASE1,Puerto Rico,"Pan American Center for Oncology Trials, LLC, San Juan, Puerto Rico, [RECRUITING]",Prostate Cancer | Metastatic Castration Resistant Prostate Cancer | Metastatic Castration-sensitive Prostate Cancer,5,"[1] Phase 1a Dose Escalation: Group A (EXPERIMENTAL): Participants with metastatic castration-sensitive prostate cancer (mCSPC), nonmetastatic castration-sensitive prostate cancer (nmCSPC) with biochemical relapse, or metastatic castration-resistant p... || [2] Phase 1a Dose Escalation: Group B (EXPERIMENTAL): Participants with mCSPC, nmCSPC with biochemical relapse, or mCRPC will receive escalating doses of PRL-02 + dexamethasone. || [3] Phase 1a Dose Escalation: Group H (EXPERIMENTAL): Participants with mCSPC or mCRPC will receive escalating doses of PRL-02 + dexamethasone + enzalutamide. || [4] Phase 1b Dose Expansion: Group D (EXPERIMENTAL): Participants with mCRPC with prior treatment with abiraterone acetate will receive escalating doses of PRL-02 + dexamethasone. || [5] Phase 1b Dose Expansion: Group E (EXPERIMENTAL): Participants with mCRPC with prior treatment with 1 of the following androgen receptor pathway inhibitor (ARPIs) (enzalutamide, apalutamide, and/or darolutamide) will receive escalating doses of PR...","* Histological evidence of adenocarcinoma of the prostate * Phase 1a Dose Escalation Groups A and B: participants must have one of the following documented conditions: * mCSPC (must have documentation by positive bone scan \[for bone disease\] or metastatic lesions on computed tomography \[CT\] or magnetic resonance imaging \[MRI\] scan \[for soft tissue\]) * nmCSPC with biochemical relapse of prostate cancer * mCSPC with oligometastatic prostate cancer (e.g., positron emission tomography positive) * mCRPC (must have documentation by positive bone scan \[for bone disease\] or metastatic lesions on CT or MRI scan \[for soft tissue\]) * NOTE: For participants in the Dose Escalation Cohorts (including backfill) at each of the dose levels up to approximately 10 participants with ARPI-naïve mCRPC who have not received prior treatment with an ARPI (e.g., abiraterone acetate, enzalutamide, apalutamide, darolutamide) will be enrolled. * Phase 1a Dose Escalation Groups A and B: participants with mCRPC must have evidence of disease progression defined as one or more of the following: * Evidence of radiographic progression of disease following the most recent prostate cancer treatment, defined as progressive disease on CT/MRI per RECIST v1.1 or on a bone scan per PCWG3. * PSA progression defined as the following: * PSA nadir is defined as the lowest PSA during or after the most recent treatment. PSA progression is defined as an increased PSA of at least 25% and ≥1 ng/mL above the nadir confirmed by at least 2 measurements with a minimum of 1 week apart, and with at least 1 of the measurements within 90 days prior to screening. * Participants with nmCSPC and biochemical recurrence, who had a radical prostatectomy (with or without radiotherapy) as the primary treatment for prostate cancer, must have a screening PSA ≥1 ng/mL. Participants with nmCSPC and biochemical recurrence who had radiotherapy only, as primary treatment for prostate cancer, must have a screening PSA ≥2 ng/mL ","* Known active central nervous system (CNS) metastases. Note: Participants with CNS metastases that have been treated with surgery and/or radiation therapy, who are off pharmacologic doses of glucocorticoids, and who are neurologically stable are eligible. * Impending bone fracture due to bone metastases * Has a known additional malignancy beyond prostate cancer that required active treatment with the exception of any of the following: * Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ carcinoma of any type * Adequately treated Stage I cancer from which the participant is currently in remission and has been in remission for ≥2 years * Any other cancer from which the participant has been disease-free for ≥5 years * Clinically significant cardiac disease, defined as any of the following: * Clinically significant cardiac arrhythmias including bradyarrhythmia which are poorly controlled. * Congenital long QT syndrome * QT interval corrected by Fridericia's formula (QTcF) ≥450 msec at screening (based on average of triplicate ECGs at baseline). If the QT interval corrected for heart rate intervals (QTc) is prolonged in a participant with a pacemaker or bundle branch block, the participant may be enrolled in the study if confirmed by the Medical Monitor. * History of clinically significant cardiac disease or congestive heart failure greater than New York Heart Association (NYHA) Class II or left ventricular ejection fraction measurement of \<50% at baseline. Participants must not have unstable angina (symptoms at rest) or new-onset angina within the last 3 months or myocardial infarction within the past 6 months \[NYHA Classification 2014\]. * Uncontrolled hypertension, defined as systolic blood pressure (BP) \>160 mmHg or diastolic BP \>100 mmHg which has been confirmed by 2 successive measurements despite optimal medical management. * Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including trans"
NCT01949129,Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia,,"PHASE2, PHASE3","Argentina, Chile, Mexico","Hospital de Pediatria ""Juan P. Garrahan"" Combate de Los Pozos N°1800 CABA, Buenos Aires, Argentina, [RECRUITING] | Hospital Sor Maria Ludovica, Department Hematology Stem Cell Transplant Unit, La Plata, Argentina, [RECRUITING] | Hospital Dr Luis Calvo Mackenna, Santiago, Chile, [RECRUITING] | Instituto Nacional de Peditria, Mexico City, Mexico, [RECRUITING]",Acute Lymphoblastic Leukaemia,4,"[1] Flu/Thio/Treo (EXPERIMENTAL): Fludarabine/Thiotepa/Treosulfan is used as conditioning regimen for haematopoietic stem cell transplantation (HSCT) in patients with:

* MSD (matched sibling donors) or MD (matched related or unrel... || [2] TBI/VP16 (ACTIVE_COMPARATOR): TBI (Total Body Irradiation) / VP16 is used as conditioning regimen for haematopoietic stem cell transplantation (HSCT) in patients older than 48 months with:

* MSD (matched sibling donors) or MD ... || [3] Flu/Thio/ivBu (EXPERIMENTAL): Fludarabine/Thiotepa/iV Busulfan is used as conditioning regimen for haematopoietic stem cell transplantation (HSCT) in patients with:

* MSD (matched sibling donors) or MD (matched related or unre... || [4] Bu/VP16/Cy (EXPERIMENTAL): Busulfan/VP16/Cyclophosphamide is an alternative conditioning arm that may optionally be used for HSCT with MSD/MD and MMD graft in patients aged 0-24 months. Patients undergoing MD HSCT will also ...","Patients with ALL (except for patients with B-ALL) who fulfil the following criteria: * age at diagnosis ≤ 18 years. Age at HSCT ≤ 21 years * indication for allogeneic HSCT * complete remission (CR) before HSCT * written consent of the parents (legal guardian) and, if necessary, the minor patient via ""Informed Consent Form"" * no pregnancy * no secondary malignancy * no previous HSCT * HSCT is performed in a study participating centre","* patients who do not fulfil the inclusion criteria * Non Hodgkin-Lymphoma * the whole protocol or essential parts are declined either by patient himself/herself or the respective legal guardian * no consent is given for saving and propagation of anonymous medical data for study reasons * severe concomitant disease that does not allow treatment according to the protocol at the investigator's discretion (e.g. malformation syndromes, cardiac malformations, metabolic disorders) * Karnofsky / Lansky score \< 50% * subjects unwilling or unable to comply with the study procedures"
NCT06596694,A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers,,"PHASE1, PHASE2",Chile,"Fundacion Arturo Lopez Perez ( Site 0301), Santiago, Chile, [RECRUITING] | Centro de Oncología de Precisión ( Site 0305), Santiago, Chile, [RECRUITING] | Clínica UC San Carlos de Apoquindo ( Site 0302), Santiago, Chile, [RECRUITING] | Bradfordhill ( Site 0300), Santiago, Chile, [RECRUITING]",Gastrointestinal Cancer,1,"[1] Patritumab deruxtecan (EXPERIMENTAL): Participants receive patritumab deruxtecan intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision.",The main inclusion criteria include but are not limited to the following: * Has one of the following cancers: * Unresectable or metastatic colorectal cancer. * Advanced and/or unresectable biliary tract cancer (BTC) * Hepatocellular carcinoma (HCC) not amenable to locoregional therapy * Has received prior therapy for the cancer. * Has recovered from any side effects due to previous cancer treatment,"The main exclusion criteria include but are not limited to the following: * Has a history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids, or has current ILD/pneumonitis, and/or suspected ILD/pneumonitis that cannot be ruled out by standard diagnostic assessments at Screening * Has clinically severe respiratory compromise (based on the investigator's assessment) resulting from intercurrent pulmonary illnesses * Has evidence of any leptomeningeal disease * Has clinically significant corneal disease * Has uncontrolled, significant cardiovascular disease or cerebrovascular disease * Has evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection"
NCT06140836,"Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)",,PHASE3,"Argentina, Brazil, Chile","Local Institution - 0092, Ciudad Autónoma de Buenos Aires, Argentina, [COMPLETED] | Instituto Alexander Fleming, Ciudad Autónoma de Buenos Aires, Argentina, [RECRUITING] | Local Institution - 0091, ABB, Argentina, [COMPLETED] | Local Institution - 0106, Buenos Aires, Argentina, [COMPLETED] | Local Institution - 0207, Buenos Aires, Argentina, [COMPLETED] | Local Institution - 0093, Córdoba, Argentina, [COMPLETED] | Local Institution - 0073, Belo Horizonte, Brazil, [COMPLETED] | Local Institution - 0033, Porto Alegre, Brazil, [ACTIVE_NOT_RECRUITING] | Local Institution - 0034, Porto Alegre, Brazil, [ACTIVE_NOT_RECRUITING] | Local Institution - 0029, Barretos, Brazil, [ACTIVE_NOT_RECRUITING]","Carcinoma, Non-Small-Cell Lung",2,[1] Arm A (EXPERIMENTAL): No description || [2] Arm B (ACTIVE_COMPARATOR): No description,"* Participant has histologically or cytologically confirmed diagnosis of locally advanced or metastatic NSCLC * Participant has a ROS1 gene rearrangement/fusion as detected by a local test. * At least 1 measurable lesion according to RECIST v1.1, as assessed by the investigator. * Participants must not be exposed previously with TKIs that demonstrated activities in ROS1-positive NSCLC * Up to 1 prior line of systemic treatment for NSCLC is permitted * ECOG Performance Status ≤ 2","* Symptomatic brain metastases or symptomatic leptomeningeal involvement. * History of previous cancer requiring therapy within the previous 2 years, except for NSCLC under study, squamous cell or basal-cell carcinoma of the skin, or any in situ carcinoma that has been completely resected. * Known tumor targetable co-mutations or rearrangements * Clinically significant cardiovascular disease (either active or within 6 months prior to enrollment) Note: Other protocol-defined inclusion/exclusion criteria apply"
NCT06788912,KEYMAKER-U01 Substudy 01E: A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With or Without Chemotherapy in Combination With Pembrolizumab in Treatment of Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC),,PHASE2,Chile,"Centro de Estudios Clínicos SAGA ( Site 0162), Santiago, Chile, [RECRUITING] | FALP ( Site 0161), Santiago, Chile, [RECRUITING] | Bradfordhill ( Site 0160), Santiago, Chile, [RECRUITING]",Lung Neoplasm Malignant,2,"[1] Pembrolizumab + Platinum (ACTIVE_COMPARATOR): Neoadjuvant: Prior to surgery pembrolizumab 200 mg every three weeks (Q3W) for 4 cycles (each cycle is 21 days); Cisplatin 75 mg/m\^2 Q3W with gemcitabine 1000 mg/m\^2 on Day 1 and Day 8 Q3W (squam... || [2] Pembrolizumab + Sacituzumab tirumotecan (EXPERIMENTAL): Neoadjuvant: Prior to surgery pembrolizumab 200 mg Q3W for 4 cycles (each cycle is 21 days); sacituzumab tirumotecan 4 mg/kg Q2W for 6 cycles (each cycle is 14 days), followed by surgery.

Adjuvant...","* Has previously untreated and pathologically confirmed resectable Stage II, IIIA, or IIIB (N2) non-small cell lung cancer (NSCLC) * Able to undergo protocol therapy, including necessary surgery * Confirmation that epidermal growth factor receptor (EGFR) -directed therapy is not indicated as primary therapy * Has an Eastern Cooperative Oncology Group (ECOG) performance status of either 0 or 1 as assessed within 10 days before initiation of study intervention. * Is able to provide archival or newly obtained core/excisional biopsy of the primary lung tumor or lymph node metastasis.","* Has one of the following tumor locations/types: NSCLC involving the superior sulcus, large-cell neuro-endocrine cancer, mixed tumors containing small cell and non-small cell elements, or sarcomatoid tumor. * Has Grade ≥2 peripheral neuropathy. * Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing. * Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea). * Has uncontrolled, significant cardiovascular disease or cerebrovascular disease. * Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention * Received prior radiotherapy within 2 weeks of start of study intervention, or radiation related toxicities, requiring corticosteroids. * Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention. * Known additional malignancy that is progressing or has required active treatment within the past 5 years. * Severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients. * Active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid) is allowed. * History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease. * Active infection requiring systemic therapy. * Hepatitis B (defined as hepatitis B surface antigen \[HBsAg\] reactive) or Hepatitis C virus (defined as detectable hepatitis C virus (HCV) ribonucleic acid (RNA) \[qualitative\]) infection. * Known history of human immunodeficiency virus (HIV) infection. * His"
NCT06564844,"A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer Who Are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12)",TROPION-Lung12,PHASE3,Brazil,"Research Site, Barretos, Brazil, [RECRUITING] | Research Site, Brasília, Brazil, [RECRUITING] | Research Site, Florianópolis, Brazil, [RECRUITING] | Research Site, São Paulo, Brazil, [RECRUITING] | Research Site, Teresina, Brazil, [RECRUITING]",Non-small Cell Lung Cancer,3,[1] Dato-DXd + rilvegostomig (EXPERIMENTAL): Participants in the Dato-DXd in combination with rilvegostomig group will receive Dato-DXd and rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W). || [2] Rilvegostomig (EXPERIMENTAL): Participants in the rilvegostomig monotherapy group will receive rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W). || [3] Standard of Care (SoC) (ACTIVE_COMPARATOR): Patients in SoC group will undergo observation or will receive Investigator's Choice of Chemotherapy (ICC).,"1. Histologically documented treatment-naive Stage I (T \< 4 cm, AJCC 8th ed) adenocarcinoma NSCLC 2. Complete surgical resection (R0) of the primary NSCLC 3. Unequivocal no evidence of disease at post-surgical 4. Pre-surgical ctDNA-positive result (Stage IA or IB) OR presence of at least one high-risk pathological feature (visceral pleural invasion (VPI), lymphovascular invasion (LVI), high-grade histology) (Stage IB only) 5. ECOG of 0 or 1, life expectancy of \> 6 months and complete recovery after surgery 6. Adequate bone marrow reserve and organ function","1. Sensitizing EGFR mutation and/or ALK alteration 2. History of non-infectious ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening 3. Significant pulmonary function compromise 4. History of another primary malignancy within 3 years (with exceptions) 5. Any evidence of severe or uncontrolled systemic diseases, including but not limited to bleeding diseases, active infection and cardiac disease 6. Active or prior documented autoimmune or inflammatory disorders (with exceptions) 7. Active infection with tuberculosis, hepatitis B or C virus, hepatitis A, or known HIV infection that is not well controlled 8. History of active primary immunodeficiency 9. Clinically significant corneal disease"
NCT06101381,CD19-directed CAR-T Cell Therapy for Refractory or Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma: a Multicenter Phase I/II Trial.,CARTHEDRALL,"PHASE1, PHASE2",Brazil,"Hospital de Clínicas da UNICAMP, Campinas, Brazil, [RECRUITING] | Ribeirao Preto School of Medicine, University of Sao Paulo, Ribeirão Preto, Brazil, [RECRUITING] | Hospital Sírio-Libanês, São Paulo, Brazil, [RECRUITING] | Hospital das Clinicas de São Paulo, São Paulo, Brazil, [RECRUITING] | A Beneficência Portuguesa de São Paulo, São Paulo, Brazil, [RECRUITING]","Leukemia, Acute Lymphoblastic | Lymphoma, Non-Hodgkin",1,"[1] CD19-directed CAR-T cell (EXPERIMENTAL): After lymphodepletion, a single intravenous infusion of an academic, locally produced, autologous CD19-directed CAR-T cells will be administered.","For non-Hodgkin Lymphomas (B-NHL): * Provision of signed Informed Consent form; * Age between 18 and 70 years; * Performance status according to the Eastern Cooperative Oncology Group \< 2; * Relapsed or refractory B-NHL of the following types (confirmed by biopsy): * Diffuse large B-cell lymphoma (DLBCL, NOS); * High-grade B-cell lymphoma (HGBCL); * Diffuse large B-cell lymphoma/high-grade B-cell lymphoma with MYC and BCL-2 rearrangement; * Follicular lymphoma (FL) grade 3B; or * Transformed follicular lymphoma (tFL) * Refractory or relapsed to two or more lines of systemic therapy, with at least one scheme containing an anti-CD20 monoclonal antibody and anthracycline, as defined below: * Refractoriness: partial response (PR), stable disease (SD), or progressive disease (PD) as the best response to the last treatment, assessed by PET-CT, according to the Lugano criteria and confirmed by a new biopsy. * Relapsed disease: disease reappearance after obtaining a complete response to the last treatment, assessed by PET-CT, according to the Lugano criteria and confirmed by a new biopsy. * Have performed, or be ineligible for, autologous hematopoietic progenitor cell transplantation (ASCT). Ineligibility is defined by: * Lack of at least partial response after salvage chemotherapy; or * Failure to mobilize and/or collect hematopoietic progenitor cells (HPC), as defined by the investigator. * Measurable disease, defined as: * Nodal lesions \>15 mm in the long axis, regardless of the length of the short axis, and/or * Extranodal lesions (outside lymph node or nodal mass, but including liver and spleen) \>10 mm in long axis, regardless of the length of the short axis. * Adequate organ function: Renal function defined as: * estimated glomerular filtration rate (eGFR) ≥ 40 mL/min/1.73 m2 Hepatic function defined as: * Alanine Transaminase (ALT) and Aspartate Transaminase (AST) ≤ 2.5 × ULN; and * Total bilirubin ≤ 1.5 × ULN, except for patients with Gilbert syndrome. Hematologi","For non-Hodgkin Lymphomas (B-NHL): * Previous or concurrent cancer distinct from B-NHL within 2 years before screening, except for the following: * Curatively treated nonmelanomatous skin cancer; * Curatively treated cervical carcinoma in situ; * Localized breast cancer treated with curative intent with no evidence of active disease; or * Localized prostate cancer undergoing active surveillance or anti-androgenic therapy, without evidence of metastatic disease. * Syndromes and/or genetic diseases with impact on the hematopoietic system, including Down's syndrome, Fanconi anemia, telomeropathies, Li Fraumeni, Blackfan-Diamond anemia, or congenital immunodeficiencies; * History of previous CAR-T therapy; * History of previous solid organ transplantation; * Active central nervous system (CNS) involvement by disease, detected by image or cytology/immunophenotyping of cerebrospinal fluid (CSF); * Primary central nervous system lymphoma (PCNSL); * Primary mediastinal large B cell lymphoma (PMBCL); * Evidence of uncontrolled systemic infection (viral, bacterial, or fungal) which requires IV antibiotics, within 2 weeks before the screening visit; * Known HIV infection; * Known HTLV I and II infection; * History of previous tuberculosis; * Positive Chagas disease serology; * Hepatitis B or hepatitis C testing indicating active/ongoing infection, as defined as: * HBV: Patients with positive HBsAg are excluded. Patients with positive anti-HBc and negative HBsAg require hepatitis B PCR evaluation before randomization. Patients who are hepatitis B PCR-positive will be excluded. * HCV: Patients with positive hepatitis C antibody may be enrolled with a negative result for hepatitis C RNA before study inclusion. Patients who are hepatitis C RNA-positive will be excluded. * History of a symptomatic CNS disease (or which required treatment within the past year), such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease; * Significant cardiovascular disease defined as ≥ g"
NCT05235165,A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma,,PHASE3,Puerto Rico,"HIMA San Pablo Oncologic Hospital, Caguas, Puerto Rico, [ACTIVE_NOT_RECRUITING]",Metastatic Malignant Neoplasm in the Lung | Metastatic Osteosarcoma | Osteosarcoma,2,[1] Arm A (thoracotomy) (EXPERIMENTAL): Patients undergo open thoracic surgery (thoracotomy). Patients undergo CT throughout the trial. Patients may also undergo collection of tissue on study and blood throughout the trial. || [2] Arm B (thoracoscopy) (EXPERIMENTAL): Patients undergo thoracoscopy (video-assisted thoracoscopic surgery or VATS). Patients undergo CT throughout the trial. Patients may also undergo collection of tissue on study and blood throughout ...,"* Patients must be \< 50 years at the time of enrollment. * Patients must have =\< 4 nodules per lung consistent with or suspicious for metastases, with at least one of which being \>= 3 mm and all of which must be =\< 3 cm size. * Note: Patient must have eligibility confirmed by rapid central imaging review. * Lung nodules must be considered resectable by either open thoracotomy or thoracoscopic surgery. Determination of resectability is made by the institutional surgeon. * Patients must have a histological diagnosis of osteosarcoma. * Patients must have evidence of metastatic lung disease at the time of initial diagnosis, or at time of 1st recurrence following completion of therapy for initially localized disease. * Patients with newly diagnosed disease must have completed successful gross tumor resection for their primary tumor or surgical local control of primary tumor must be planned to be performed simultaneously with thoracic surgery. * Newly diagnosed patients must be receiving or recently completed (within 60 days) systemic therapy considered by the treating physician to be standard treatment for newly diagnosed osteosarcoma (eg, cisplatin-doxorubicin or ifosfamide-based drug regimens) at the time of enrollment on this study. Dose and drug modifications for toxicity do not exclude patients from participation. * Patients at time of 1st recurrence must have completed systemic therapy for their initial primary tumor, considered by the treating physician to be standard treatment for newly diagnosed osteosarcoma (eg, cisplatin-doxorubicin or ifosfamide-based drug regimens) at the time of enrollment on this study. Dose and drug modifications for toxicity do not exclude patients from participation.","* Patients with unresectable primary tumor. * Patients with pulmonary metastatic lesions that would require anatomic resection (lobectomy or pneumonectomy) or lesions that are defined as ""central"" (i.e., central lesion involves or is proximal to segmental bronchi and peripheral is lesion distal to segmental bronchi). * Patients with chest wall or mediastinal based metastatic lesions, or with significant pleural effusion. * Patients with disease progression at either the primary or pulmonary metastatic site while on initial therapy. Note: Once the patient has been enrolled on the study, additional computed tomography (CT) scans are not anticipated prior to thoracic surgery. Note: Some variation in nodule size measurements over the course of pre-operative therapy is anticipated and does not qualify for exclusion unless deemed true disease progression by the primary treatment team. * Patients with evidence of extrapulmonary metastatic disease. * Patients who received therapeutic pulmonary surgery for lung metastasis prior to enrollment. * All patients and/or their parents or legal guardians must sign a written informed consent. * All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met."
NCT03366051,"Sentinel Node Mapping Versus Sentinel Node Mapping With Systematic Lymphadenectomy in High Risk Endometrial Cancer: a Open Label, Non-inferiority, Randomized Trial.",ALICE,NA,Brazil,"Hospital Erasto Gaertner, Curitiba, Brazil, [RECRUITING] | Hospital do Cancer de Barretos, Barretos, Brazil, [RECRUITING] | AC Camargo Cancer Center, São Paulo, Brazil, [RECRUITING] | Albert Einstein Hospital, São Paulo, Brazil, [RECRUITING] | Sao Camilo Oncologia, São Paulo, Brazil, [RECRUITING]",Endometrial Cancer | Lymph Node Metastases,2,[1] Sentinel Node Mapping plus Lymphadenectomy (ACTIVE_COMPARATOR): Patients with high risk endometrial cancer will undergo Sentinel Node Mapping followed by Systematic Pelvic and Para-Aortic Lymphadenectomy || [2] Sentinel Node Mapping (EXPERIMENTAL): Patients with high risk endometrial cancer will undergo Sentinel Node Mapping per NCCN algorithm,"* High grade histologies (endometrioid grade 3, serous, clear cell and carcinosarcoma) * Endometrioid grades 1 or 2 with myometrial invasion of ≥50% * Endometrioid grades 1 or 2 with cervical invasion * Clinically suitable to receive systematic lymphadenectomy * Consent statement","* Previous hysterectomy in other institution * Presence of extra-uterine disease (peritoneal, visceral or suspicious lymph node metastasis) * Previous pelvic node dissection"
NCT05453292,"Feasibility, Safety, and Efficacy of EUS-guided Thermal Radiofrequency Ablation in the Treatment of Gastrointestinal Stromal Tumors",,NA,Ecuador,"Instituto Ecuatoriano de Enfermedades Digestivas (IECED), Guayaquil, Ecuador, [RECRUITING]",Gastrointestinal Stromal Tumor (GIST),1,[1] EUS guided RFA (EXPERIMENTAL): This group is comprised by patients with diagnosis of resectable GISTs with/without liver metastasis. The patients included are naïve (without previous treatment) or patients with stable/progressiv...,"* Adults (\> 18 years of age) * Confirmed resectable GISTs lesions in esophagus, stomach, and intestine (between 2\<5 cm or 5-10cm and \<5mitotes/HPF) * Non-amenable to surgery * written informed consent * No evidence of metastatic disease on imaging of the chest abdomen and pelvis contrast enhanced computed tomography (CE-CT) or limited liver metastatic disease (maximum 5 lesions \<= 3 cm) * Adequate renal, hepatic, and hematological function","* Pregnancy * Rectal GISTs * Altered renal, hepatic, or hematological function * Inability to provide informed consent * Patients with cardiac pacemakers or other implanted electronic devices and/or electrodes * Patients that have right-to-left shunts, severe pulmonary hypertension (pulmonary artery pressure \>90 mmHg), uncontrolled systemic hypertension, and in patients with adult respiratory distress syndrome or any condition that contraindicates the procedure * Inability to tolerate general anesthesia."
NCT05475106,Pilot Study of Personalized Neoantigen Peptide Vaccines and Leukine for the Treatment of Neoplasms,,EARLY_PHASE1,Mexico,"Instituto de Medicina Regenerativa, Tijuana, Mexico, [RECRUITING]",Neoplasms,1,[1] Treatment (EXPERIMENTAL): Patients will receive intradermal injection of individualized neoantigen peptides vaccine at a dose of \~500ug per peptide once a week for 4 weeks and once every month after that for 5 months.,"* 16 years of age or older, male or female * Life expectancy of at least 3 months * Confirmed tumor by imaging studies * Have adequate organ function, as measured by laboratory values: Lymphocyte ratio \>20%; WBC \>3.0×10\^9/L; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN; if the patient has liver metastases, ALT and AST ≤5 × ULN; Alkaline phosphatase (ALP）≤2.5 × ULN; total serum bilirubin (TBIL) \< 1.5 × ULN; Urea nitrogen (BUN）≤1.5 × ULN; Creatinine (Cr）1.5≤ULN; Normal blood coagulation function, urine routine, and electrocardiogram (ECG) * Available tumor specimen for sequencing and neoantigen determination * Ability to find 3 or more neoantigen epitopes * Ability to follow research and follow-up procedures * Able to understand and willing to sign an IRB approved written informed consent document * Agree with the use of contraception or partner of child-bearing potential agrees to use adequate contraception which will include two of the following: hormonal or barrier method of birth control, or abstinence prior to study entry, for the duration of study participation, and for 30 days following completion of therapy","* History of immunodeficiency disorder or autoimmune condition requiring active immunosuppressive therapy * Evidence of Liver and kidney dysfunction, severe heart disease, or coagulation dysfunction * Known diagnosis of an infectious condition including hepatitis, HIV, CMV, and Treponema pallidum * Participant becomes pregnant and/or is breastfeeding or plans on becoming pregnant during study * A psychiatric illness that would limit compliance with study requirements as determined by the investigator or the investigator believes that participant is not suitable for inclusion"
NCT04073706,A Phase III Randomised Clinical Trial Comparing Sentinel Node Biopsy With No Retroperitoneal Node Dissection in Apparent Early-Stage Endometrial Cancer,ENDO-3,PHASE3,"Argentina, Brazil, Colombia","Hospital Britanico, Ciudad, Argentina, [NOT_YET_RECRUITING] | Hospital Municipal Vila Santa Catarina, Santa Catarina, Brazil, [NOT_YET_RECRUITING] | Liga Paranaense de Combate ao Câncer, Curibita, Brazil, [NOT_YET_RECRUITING] | Hospital de Base, São José do Rio Preto, Brazil, [NOT_YET_RECRUITING] | Fundacao Antonio Prudente, AC Camargo Cancer Center, São Paulo, Brazil, [NOT_YET_RECRUITING] | Hospital Israelita Albert Einstein, São Paulo, Brazil, [NOT_YET_RECRUITING] | Instituto Nacional de Cancerología, Astorga, Colombia, [NOT_YET_RECRUITING]",Endometrial Cancer Stage I | Sentinel Lymph Node | Surgery,2,"[1] TH BSO with SNB (EXPERIMENTAL): Total Laparoscopic/Robotic Hysterectomy, Bilateral Salpingo-Oophorectomy (TH BSO) with Sentinel Node Biopsy (SNB) using Indocyanine Green (ICG)+/- Methylene Blue Dye (+/- omentectomy in high risk c... || [2] TH BSO without retroperitoneal node dissection (ACTIVE_COMPARATOR): Total Laparoscopic/Robotic Hysterectomy, Bilateral Salpingo-Oophorectomy (TH BSO) without retroperitoneal node dissection (+/- omentectomy in high risk cell types) Note: If participants (≤45 years ...","1. Females, over 18 years, with histologically confirmed primary epithelial cancer of the endometrium of any cell type or uterine carcinosarcoma (mixed malignant mullerian tumour); 2. Clinically stage I disease (disease confined to body of uterus); 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; 4. Signed written informed consent; 5. Participant must meet criteria for a laparoscopic or robotic surgical approach as determined by the treating physician (e.g. suitable for TH BSO, ability to tolerate Trendelenberg positioning) 6. All available clinical evidence (physical examination findings, or medical imaging such as CT, MRI or ultrasound) demonstrates no evidence of extrauterine disease 7. Myometrial Invasion on MRI of not more than 50%. (Only if participant is \<45yo, has ONLY Grade 1 EAC and wishes to retain their ovaries). 8. Negative (serum or urine) pregnancy test ≤ 30 days of surgery in pre-menopausal women and women \< 2 years after the onset of menopause.","1. Evidence of extrauterine disease (apparent involvement of cervix, vagina, parametria, adnexa, lymph nodes, bladder, bowel or distant sites) by clinical examination and/or through medical imaging. 2. Enlarged retroperitoneal pelvic and/or aortic lymph nodes (\>1 cm) on medical imaging; 3. Estimated life expectancy of less than 6 months; 4. Patients who have absolute contraindications for adjuvant radiotherapy and/or chemotherapy; 5. Patients who have previously received radiation treatment to the pelvis 6. Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator); 7. Patient compliance and geographic proximity that do not allow adequate follow-up; 8. Patients with allergy to Indocyanine Green (ICG) 9. Patients who have had previous retroperitoneal surgery 10. Patients who require a retroperitoneal (pelvic +/- para-aortic) lymph node dissection (lymphadenectomy) 11. Other prior malignancies \<5 years before inclusion, except for successfully treated keratinocyte skin cancers, or ductal carcinoma of the breast insitu 12. Uterine perforation during endometrial tissue sampling"
NCT06767514,"A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression",HARMONi-7,PHASE3,Mexico,"Clinical Study Site, Guadalajara, Mexico, [RECRUITING] | Clinical Study Site, Mexico City, Mexico, [RECRUITING] | Clinical Study Site, Monterrey, Mexico, [RECRUITING] | Clinical Study Site, Veracruz, Mexico, [RECRUITING]",Non-Small Cell Lung Cancer,2,[1] Arm A - Ivonescimab (EXPERIMENTAL): Subject will receive ivonescimab as an IV injection || [2] Arm B - Pembrolizumab (ACTIVE_COMPARATOR): Subject will receive pembrolizumab as an IV injection,* Age ≥ 18 years old at the time of enrollment * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1 * Expected life expectancy ≥ 3 months * Metastatic (Stage IV) NSCLC * Histologically or cytologically confirmed squamous or non-squamous NSCLC * Tumor demonstrates high PD-L1 expression ( TPS\>50%) based on a 22C3 immunohistochemistry ( IHC) clinical assay approved / cleared by local health authorities. * At least one measurable noncerebral lesion according to RECIST 1.1 * No prior systemic treatment for metastatic NSCLC.,"* Histologic or cytopathologic evidence of the presence of small cell lung carcinoma for which first-line approved therapies are indicated. For patients with non-squamous histology, actionable driver mutation testing results are required before randomization. * Has received any prior therapy for NSCLC in the metastatic setting. * Concurrent enrollment in another clinical study, unless patient is enrolled in a non-interventional clinical study or is completing survival follow -up. * Known actionable genomic alterations for which first-line approved therapies are indicated * Symptomatic CNS metastases, CNS metastasis ≥ 1.5 cm, CNS radiation within 7 days prior to randomization, potential need for CNS radiation within the first cycle, or leptomeningeal disease * Other prior malignancy (including previously treated NSCLC) unless the patient has undergone curative therapy with no evidence of recurrence of the disease for 3 years prior to randomization * Active autoimmune or lung disease requiring systemic therapy * Has pre-existing peripheral neuropathy that is ≥ Grade 2 by CTCAE version 5 * Severe infection within 4 weeks prior to randomization * Major surgical procedures or serious trauma within 4 weeks prior to randomization * History of noninfectious pneumonia requiring systemic corticosteroids, or current interstitial lung disease"
NCT05592938,Partial Breast Re-irradiation Using Ultra Hypofractionation: Phase 2 Multi-institutional Study (PRESERVE),PRESERVE,NA,Brazil,"A.C.Camargo Cancer Center, São Paulo, Brazil, [RECRUITING]",Breast Cancer | Breast Cancer Recurrent,1,[1] rPBI (EXPERIMENTAL): 26Gy in 5 daily fractions over 1-week,"* Age \> 18 years * In-breast recurrence or new primary (ductal carcinoma in situ (DCIS) or invasive carcinoma) * Tumour \<3.0 cm in greatest diameter on pathologic examination, including both invasive and non-invasive components * \>5 years after completion of prior adjuvant whole or partial breast radiotherapy (prior nodal radiotherapy permitted) * Clinically node negative * Negative margins (no tumour on ink) * Recovered from surgery with the incision completely healed and no signs of infection","* Multicentric disease (patients with multifocal breast cancer in the same quadrant are eligible) * Tumour histology limited to lobular carcinoma only * Extensive intraductal component * T4 disease * Node positive or distant metastatic disease * Serious non-malignant disease (cardiovascular, pulmonary, systemic lupus erythematosus, scleroderma), which would preclude radiation treatment * Currently pregnant or lactating * Presence of an ipsilateral breast implant or pacemaker * Unable to commence radiation within 16 weeks of breast-conserving surgery (or last surgical procedure on the breast) or within 12 weeks from last cycle of adjuvant chemotherapy * Unable to clearly define the surgical cavity (oncoplastic procedures are permitted provided the tumor bed is well delineated with surgical clips). * Psychiatric disorders which would preclude obtaining informed consent or adherence to protocol * Grade II or more late skin toxicity from prior radiation evaluated and graded using CTCAE v5.0"
NCT05083481,A Phase 1/2 Study of ASP1570 as Monotherapy and in Combination With Pembrolizumab or Standard Therapies Including Chemotherapy and/or Immunotherapy in Participants With Locally Advanced or Metastatic Solid Tumors,,"PHASE1, PHASE2",Puerto Rico,"Site PR1601, Río Piedras, Puerto Rico, [RECRUITING]",Advanced Solid Tumors,9,"[1] ASP1570 Monotherapy Dose Escalation (Part 1) (EXPERIMENTAL): Participants will receive daily dose of ASP1570 in a 21-day cycle. || [2] ASP1570 + pembrolizumab Combination therapy Dose Escalation (Part 1) (EXPERIMENTAL): Participants will receive daily dose of ASP1570 in a 21-day cycle. pembrolizumab will be administered every 6 weeks on day 1 of every other ASP1570 cycle. || [3] ASP1570 + Docetaxel Combination therapy Dose Expansion - NSCLC 2L+ (Part 2) (EXPERIMENTAL): Participants who have NSCLC will receive RP2D of ASP1570 daily in a 21-day cycle. Docetaxel will be administered every 6 weeks on day 1 of every other ASP1570 cycle. || [4] ASP1570 Monotherapy Dose Expansion - Food Effect (Part 2) (EXPERIMENTAL): Participants will receive RP2D of ASP1570 after the meal in a 21-day cycle. This cohort will be opened at the discretion of the sponsor. || [5] ASP1570 Monotherapy Dose Expansion - Prophylactic (Part 2) (EXPERIMENTAL): Participants will receive RP2D of ASP1570 along with the standard prophylactic medication in a 21-day cycle. This cohort will be opened at the discretion of the sponsor. || [6] ASP1570 Monotherapy Dose Expansion - Intermittent dosing (Part 2) (EXPERIMENTAL): Participants will receive RP2D of ASP1570 with some periodical drug holiday in a 21-day cycle. This cohort will be opened at the discretion of the sponsor. || [7] ASP1570 Monotherapy Dose Expansion - Stepwise dosing (Part 2) (EXPERIMENTAL): Participants will receive ASP1570 administered by intra-subject dose escalation with gradual multiple dose steps (e.g., 3 steps) and increased dose up to RP2D in a 21-day cycle. This cohort will be... || [8] ASP1570 Monotherapy Dose Expansion Microsatellite stable - colorectal cancer (MSS-CRC) (Part 2) (EXPERIMENTAL): Participants who have MSS-CRC will receive ASP1570 in a 21-day cycle. || [9] ASP1570 + TAS-102 + Bevacizumab Combination therapy Dose Expansion - MSS-CRC 3L+ (Part 2) (EXPERIMENTAL): Participants who have MSS-CRC will receive ASP1570 da","* Participant has locally-advanced (unresectable) or metastatic solid tumor malignancy which is confirmed by available pathology records or current biopsy. * Participant has at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions. * Monotherapy and Combination Escalation Cohorts and China-specific Safety Lead-in Cohort: a) Participant has progressed on standard therapies, is no longer eligible for standard therapies or has refused standard approved therapies (no limit to the number of prior treatment regimens). (UNIQUE to China: Tumor types will be determined at the sponsor's discretion.) * Monotherapy Expansion Cohorts and China-specific Safety Lead-in Cohort: a) Participant has histologically confirmed diagnosis of locally advanced or metastatic MSS-CRC and has progressed was intolerant to at least 2 prior cancer therapy regimens administered for metastatic disease. * Monotherapy Dose Optimization Cohorts: a) Participant has histologically confirmed diagnosis of locally advanced or metastatic MSS-CRC and has progressed or was intolerant to at least 2 prior cancer therapy regimens administered for metastatic disease. * Combination Therapy Cohorts: a) For NSCLC Combination Therapy Cohort only: * Participant has histologically confirmed or cytologically confirmed diagnosis of Stage IV NSCLC and has progressed on or after platinum-based chemotherapy and/or checkpoint inhibitors. * Participant is eligible to receive docetaxel. b) For MSS CRC Combination Therapy Cohort only: * Participant has histologically confirmed diagnosis of locally advanced or metastatic MSS-CRC. * Participant must have progressed or was intolerant to at least 2 prior cancer therapy regimens administered for metastatic disease. * Participant is eligible to receive TAS-102 and bevacizumab. Monotherapy and Combination Therapy Additional ","* Participant has received investigational therapy within 21 days or 5 half-lives, whichever is shorter, (UNIQUE to China: and/or antitumor Chinese traditional medicine within 28 days) prior to the first dose of ASP1570 or 4 weeks prior to the first dose of pembrolizumab or standard therapies. * Participants may continue the following therapies until 4 days prior to the start of study intervention administration: 1. An EGFR TKI in a participant with EGFR-activating mutations (not applicable to NSCLC participants), 2. ALK inhibitor in a participant with an ALK mutation (not applicable to NSCLC participants) or, 3. NTRK inhibitor in a participant with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation (not applicable to NSCLC participants). * Participant requires or has received systemic steroid therapy or any other immunosuppressive therapy within 14 days prior to the first dose of IP. Participants using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 10 mg prednisone) are allowed. * Participant requires strong or moderate CYP2D6 inhibitors (e.g., bupropion, fluoxetine, paroxetine, duloxetine, abiraterone) during the study. * Participant has symptomatic central nervous system (CNS) metastases or participant has evidence of unstable CNS metastases even if asymptomatic (e.g., progression on scans). Participants with previously treated CNS metastases are eligible, if they are clinically stable and have no evidence of CNS progression by imaging for at least 4 weeks prior to start of study treatment and are not requiring immunosuppressive doses of systemic steroids (\> 10 mg per day of prednisone or equivalent) for no longer than 2 weeks. * Participant has an autoimmune disease. Participants with type 1 diabetes mellitus, endocrinopathies stably maintained on appropriate replacement therapy, or skin disorders (e.g., vitiligo, psoriasis, or alopecia) not requiring systemic treatment are allowed. * Par"
NCT03723928,Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer,,NA,Puerto Rico,"Advance Oncology Center, Aguadilla, Puerto Rico, [SUSPENDED] | Doctor's Cancer Center-Arecibo, Arecibo, Puerto Rico, [SUSPENDED] | Cancer Center-Metro Medical Center Bayamon, Bayamón, Puerto Rico, [RECRUITING] | Hematologia Oncologia San Pablo, Bayamón, Puerto Rico, [SUSPENDED] | HIMA San Pablo Oncologic Hospital, Caguas, Puerto Rico, [SUSPENDED] | Doctors Cancer Center, Manatí, Puerto Rico, [RECRUITING] | Instituto Oncologia Moderna Ponce, Ponce, Puerto Rico, [SUSPENDED] | San Juan Community Oncology Group, San Juan, Puerto Rico, [RECRUITING] | Primary Care Physician Group, San Juan, Puerto Rico, [SUSPENDED] | Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico, [RECRUITING]",Anatomic Stage IV Breast Cancer AJCC v8 | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Prognostic Stage IV Breast Cancer AJCC v8,2,"[1] Arm I (usual care) (ACTIVE_COMPARATOR): Patients will have imaging studies (modality and frequency per treating physician, however at a minimum frequency of every 12 weeks) alone or in conjunction with STMs (frequency determined by treat... || [2] Arm II (serum tumor directed disease monitoring) (EXPERIMENTAL): Patients undergo disease specific serum tumor marker evaluation (CEA and either CA 15-3 or CA 27.29, whichever were tested at Step 1 Registration and Step 2 Registration) every 4-8 weeks (starting ...","* STEP 1 REGISTRATION * Patients must have a diagnosis of hormone receptor positive (estrogen receptor positive \[ER+\] and/or progesterone receptor positive \[PR+\]), HER-2 negative, metastatic (M1) breast cancer and must be receiving or plan to receive first-line systemic treatment for metastatic disease. (Systemic treatment is any treatment meant to treat the whole body such as endocrine therapy +/- targeted therapy +/- chemotherapy). * NOTE: Participants are eligible if they have either de-novo metastatic breast cancer and/or recurrent breast cancer from an earlier stage that is now metastatic * Patients must be registered to step 1 between 14 days prior to and 60 days after start of first-line systemic treatment for metastatic disease * Patients must have been tested for the following breast cancer specific STMs after diagnosis of metastatic disease and within +/-14 days of initiation of first-line systemic treatment for metastatic disease: * CEA (must be tested) * CA 15-3 or CA 27.29 (at least one of these must be tested) * At least one of the tested STMs must have been \>= 1.5 x the institutional upper limit of normal at this time. Testing all three STMs is encouraged but only two are required. Patients must plan to have the same two STMs tested for the duration that the patient is on protocol-specified disease monitoring. * Patients must have systemic radiographic imaging prior to initiation of systemic therapy or within 30 days of initiation of treatment for metastatic breast cancer and prior to step 1 registration. Modality of imaging is at the discretion of the treating physician. * Note: the treating physician can order additional imaging tests at any point prior to randomization at their discretion * Patients must be willing to obtain disease monitoring (imaging and/or serum tumor markers) from a consistent facility in which the registering site has access to the results for the duration of the study intervention (312 weeks after step 2 randomization). ",
NCT06486441,"A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy",ASCENT-GYN-01,PHASE3,Brazil,"Clínica de Neoplasias Litoral, Itajaí, Brazil, [RECRUITING] | Centro de Pesquisa Clínica do Hospital Moinhos de Vento, Porto Alegre, Brazil, [RECRUITING] | Instituto D'Or Pesquisa e Ensino, Rio de Janeiro, Brazil, [RECRUITING] | Ensino e Terapia de Inovação Clínica AMO - ETICA, Salvador, Brazil, [RECRUITING] | Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil, [RECRUITING] | BP - A Beneficência Portuguesa da São Paulo / Hospital BP Mirante, São Paulo, Brazil, [RECRUITING] | DASA - Hospital 9 de Julho, São Paulo, Brazil, [RECRUITING] | AC Camargo Cancer Center (Fundação Antonio Prudente), São Paulo, Brazil, [RECRUITING]",Endometrial Cancer,2,"[1] Sacituzumab Govitecan (SG) (EXPERIMENTAL): Participants will receive SG at a dose of 10 mg/kg on Days 1 and 8 of a 21-day cycle. || [2] Treatment of Physician's Choice (TPC) (ACTIVE_COMPARATOR): Participants will receive one of the following TPC, regimens determined prior to randomization.

* Doxorubicin 60 mg/m\^2 IV on Day 1 of a 21-day cycle
* Paclitaxel 80 mg/m\^2 IV on Days 1, 8, and ...","* Documented evidence of recurrent/persistent endometrial cancer (endometrial carcinoma or carcinosarcoma). * Up to 3 prior lines of systemic therapy for endometrial cancer, including systemic platinum-based chemotherapy and anti-PD-1/PD-L1 therapy, either in combination or separately. * Eligible for treatment with either doxorubicin or paclitaxel as determined by the investigator. * Radiologically evaluable disease (either measurable or nonmeasurable) by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1. * Eastern Cooperative Oncology Group performance status score of 0 or 1. * Adequate organ function Key","* Uterine leiomyosarcoma and endometrial stromal sarcomas are excluded. * Participants who are candidates for curative-intent therapy at the time of study enrollment. * Participants eligible for rechallenge with platinum-based chemotherapy as determined by the investigator. * Received any prior treatment with a Trop-2-directed antibody-drug conjugate (ADC). * Have an active second malignancy. * Have an active serious infection requiring systemic antimicrobial therapy. * Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or gastrointestinal perforation within 6 months prior to randomization. * Have a positive serum pregnancy test or are breastfeeding for participants who are assigned female at birth. Note: Other protocol defined Inclusion/Exclusion criteria may apply."
NCT06629779,"A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)",,PHASE3,"Argentina, Brazil, Chile","Centro de Urología (CDU), CABA, Argentina, [RECRUITING] | Hospital Sirio Libanes, Capital Federal, Argentina, [RECRUITING] | Imagenes Mdq, Mar del Plata, Argentina, [RECRUITING] | Instituto de Investigaciones Clínicas Mar del Plata, Mar del Plata, Argentina, [RECRUITING] | Centro Medico Privado CEMAIC, Capital, Argentina, [RECRUITING] | Hospital Privado Universitario de Córdoba, Córdoba, Argentina, [RECRUITING] | IMAXE, Buenos Aires, Argentina, [RECRUITING] | Asociación de Beneficencia Hospital Sirio Libanés, Buenos Aires, Argentina, [RECRUITING] | Centro Medico Fleischer, Buenos Aires, Argentina, [RECRUITING] | Oncocentro Servico Medicos e Hospitalares Ltda, Fortaleza, Brazil, [RECRUITING]",Metastatic Castration-Resistant Prostate Cancer,2,[1] Arm A (EXPERIMENTAL): Participants will receive PF-06821497 (875 mg) BID (twice daily) + enzalutamide 160 mg QD (once daily) || [2] Arm B (ACTIVE_COMPARATOR): Participants will receive Placebo BID (twice daily) + enzalutamide 160 mg QD (once daily),"* Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features. * Metastatic disease in bone documented on bone scan, or in soft tissue documented on CT/MRI scan. * Progressive disease in the setting of medical or surgical castration. * ECOG performance status 0 or 1, with a life expectancy of ≥12 months as assessed by the investigator.","* Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that make the participant inappropriate for the study. * Known history of active inflammatory gastrointestinal disease, chronic diarrhea, or previous gastric resection or lap-band surgery. * Clinically significant cardiovascular disease. * Known or suspected brain metastasis or active leptomeningeal disease or clinically significant history of seizure. * Any history of myelodysplastic syndrome, acute myeloid leukemia, or any other prior malignancy with a few exceptions. * Participants must be treatment naïve at the mCRPC stage, eg, no cytotoxic chemotherapy, radio-ligand therapy (i.e. 177Lu- PSMA-617), CDK4/6 inhibitors, 5-alpha reductase inhibitors for prostate cancer in any setting, androgen receptor signaling inhibitors (ARSi) including enzalutamide, apalutamide, darolutamide, poly ADP-ribose polymerase (PARP) monotherapy or other systemic anti-cancer treatment with the following exceptions: 1. Treatment with first-generation antiandrogen (ADT) agents; 2. Docetaxel treatment is allowed for mCSPC, as long as no signs of failure, or disease progression occurred during treatment or within 3 months of treatment completion. * Previous administration with an investigational product (drug or vaccine) within 30 days or 5 half-lives preceding the first dose of study intervention (whichever is longer). * Inadequate organ function."
NCT06034561,Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia in Adults,,PHASE2,Brazil,"Instituto do Cancer do Estado de Sao Paulo, São Paulo, Brazil, [RECRUITING]","Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia With Failed Remission",1,"[1] Bortezomib (EXPERIMENTAL): Patients with refractory or relapsed acute lymphoblastic leukemia will receive one-two courses of salvage regimen composed by:

* Bortezomib 1.3 mg/m2 I.V. D1,D4,D8,D11;
* Vincristine 1.5 mg/m2 I.V...","* Patients between 16 and 60 years-old with refractory or relapsed ALL (≥1% of anomalous blasts by flow cytometry in bone marrow or peripheral blood) after one or two lines of therapy, regardless of their phenotype or baseline genetic alteration; * Patients are eligible after allogeneic HSCT as long as patients are not actively being treated for graft-versus-host-disease (GvHD).","* Burkitt leukemia; * Prior myeloproliferative disease; * Drug allergies; * Eastern Cooperative Oncology Group (ECOG) scale \>2; * Total bilirubin\>2x upper limit of normal (ULN); * Transaminases\>5x ULN; * Creatinine\>2,5 mg/dl; * Active uncontrolled infection; * History of asparaginase-induced pancreatitis; * Prior exposure to bortezomib; * Heart failure New York Heart Association (NYHA) Class III or IV; * Patients with more than 400mg/m2 lifetime exposure of anthracycline; * Severe psychiatric disorder which prevents adequate compliance; * Refusal to participate in the study."
NCT04464226,"An Open-label, Single Arm, Roll-over Study to Provide Continued Treatment With Darolutamide in Participants Who Were Enrolled in Previous Bayer Sponsored Studies",,PHASE3,"Argentina, Brazil, Colombia, Mexico, Peru","Centro de Urología, Buenos Aires, Argentina, [COMPLETED] | Instituto do Cancer do Ceará, Fortaleza, Brazil, [COMPLETED] | Hospital Evangélico de Cachoeiro de Itapemirim, Cachoeiro de Itapemirim, Brazil, [COMPLETED] | Hospital São Rafael, Salvador, Brazil, [COMPLETED] | Santa Casa de Misericórdia da Bahia, Salvador, Brazil, [ACTIVE_NOT_RECRUITING] | Hosp. Araujo Jorge da Associação de Combate ao Câncer, Goiânia, Brazil, [COMPLETED] | COT Centro Oncologico do Triangulo Ltda, Uberlândia, Brazil, [COMPLETED] | Liga Paranaense de Combate ao Cancer-Hosp Erasto Gaertner, Curitiba, Brazil, [ACTIVE_NOT_RECRUITING] | Liga Norte Riograndense Contra o Cancer | Centro de Pesquisa Clínica, Natal, Brazil, [COMPLETED] | Associação Hospitalar Beneficente São Vicente de Paulo, Passo Fundo, Brazil, [COMPLETED]",Cancer,1,[1] Darolutamide (BAY1841788) (EXPERIMENTAL): Participants enrolled in the current study will use the dose they were assigned to in the feeder study they come from.,"* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. * Participants enrolled in any Bayer-sponsored darolutamide feeder study at the time of study closure or primary completion, who are currently receiving darolutamide and are experiencing clinical benefit from treatment. * Participants who have not met any treatment discontinuation criteria in the feeder study protocol. * Willingness to continue practicing acceptable methods of birth control during the study.",* Participant is unable to comply with the requirements of the study. * Negative benefit/ risk ratio as determined by the investigator. * Meet any criteria for treatment discontinuation of the feeder study the participant is coming from.
NCT06047080,"A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma",,PHASE3,"Argentina, Brazil, Mexico, Puerto Rico","Instituto Alexander Fleming, Buenos Aires, Argentina, [ACTIVE_NOT_RECRUITING] | FUNDALEU, Buenos Aires, Argentina, [ACTIVE_NOT_RECRUITING] | Hospital Aleman de Buenos Aires, Buenos Aires, Argentina, [ACTIVE_NOT_RECRUITING] | Sanatorio Allende, Córdoba, Argentina, [ACTIVE_NOT_RECRUITING] | Hospital Austral, Pilar, Argentina, [WITHDRAWN] | Hospital Erasto Gaertner, Curitiba, Brazil, [RECRUITING] | Instituto D'Or Pesquisa e Ensino, São Paulo, Brazil, [RECRUITING] | Hospital das Clinicas - FMUSP, Oncologia, São Paulo, Brazil, [RECRUITING] | Health Pharma Professional Research, Mexico City, Mexico, [RECRUITING] | Inst. Nacional de Cancerologia, Mexico City, Mexico, [RECRUITING]",Large B-Cell Lymphoma,2,"[1] Glofitamab + Pola-R-CHP (EXPERIMENTAL): Participants will receive glofitamab in combination with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP). || [2] Pola-R-CHP (ACTIVE_COMPARATOR): Participants will receive Pola-R-CHP.","* Previously untreated participants with CD20-positive LBCL * Ability to provide tumor tissue * International prognostic index (IPI) score 2-5 * Eastern cooperative oncology group (ECOG) performance status of 0, 1, or 2 * At least one bi-dimensionally measurable lesion, defined as \> 1.5 cm in its longest dimension as measured by CT or MRI * Left ventricular ejection fraction (LVEF) \>/=50% on cardiac multiple-gated acquisition (MUGA) scan or cardiac echocardiogram (ECHO) * Adequate hematologic function * Negative HIV test at screening with exceptions as defined by the protocol * Negative SARS-CoV-2 antigen or PCR test","* Contraindication to any of the individual components of Pola-R-CHP or glofitamab, including prior receipt of anthracyclines, or history of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies, or known sensitivity or allergy to murine products * Prior solid organ transplantation * Participants receiving systemic immunosuppressive agent such as, but not limited to cyclosporin, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents within 4 weeks prior to first dose of study treatment * Current Grade \> 1 peripheral neuropathy by clinical examination or demyelinating form of Charcot-Marie-Tooth disease * History of indolent lymphoma (e.g., Follicular Lymphoma, Marginal Zone Lymphoma, Waldenstrom macroglobulinemia) * Current diagnosis of the following: Follicular lymphoma grade 3B; transformations of indolent B-cell lymphomas (e.g., de novo transformed follicular lymphoma); mediastinal grey zone lymphoma; primary mediastinal (thymic) large B-cell lymphoma; Burkitt lymphoma; primary large B-cell lymphoma of immune-privileged sites (encompassing primary diffuse large B-cell lymphoma of the CNS, primary large B-cell lymphoma of the vitreoretina and primary large B-cell lymphoma of the testis); primary effusion DLBCL; and primary cutaneous DLBCL, leg type * Primary or secondary CNS lymphoma at the time of recruitment or history of CNS lymphoma * Prior treatment with systemic immunotherapeutic agents * Prior use of any monoclonal antibody for the purposes of treating cancer within 3 months of the start of Cycle 1 * Any investigational therapy for the purposes of treating cancer within 28 days prior to the start of Cycle 1 * Prior radiotherapy to the mediastinal/pericardial region * Prior therapy for LBCL, with the exception of corticosteriods * Corticosteroid use \> 30 mg/day of prednisone or equivalent, for purposes other than lymphoma symptom control * History of other malignant or non-malignant diseases that cou"
NCT05951179,"A Phase 2, Open-Label Study to Evaluate the Safety and Anti-Tumor Activity of Intravesical Instillation of TARA-002 in Adults With High-Grade Non-Muscle Invasive Bladder Cancer",ADVANCED-2,PHASE2,"Argentina, Brazil","Centro Argentino de Urologia, CABA, Argentina, [RECRUITING] | Hospital Sirio Libanes, CABA, Argentina, [RECRUITING] | Centro Urologico Profesor Bengio SA, Córdoba, Argentina, [RECRUITING] | CEMAIC, Córdoba, Argentina, [RECRUITING] | Clinica Privada Independencia, Munro, Argentina, [RECRUITING] | Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil, [RECRUITING] | Nucleo de Pesquisa Clinica do Rio Grande so Sul, Porto Alegre, Brazil, [RECRUITING] | Instituto Dor de Pesquisa e Ensino, Jardim Paulista, Brazil, [RECRUITING] | Faculdade de Medicina ABC-CEPHO, Santo André, Brazil, [RECRUITING]",Non-muscle Invasive Bladder Cancer,1,"[1] TARA-002 (EXPERIMENTAL): TARA-002 is a lyophilized biological preparation for instillation containing cells of Streptococcus pyogenes (Group A, type 3) Su strain treated with benzylpenicillin.","* Male or female participants 18 years of age or older at the time of signing informed consent * Participants who have voluntarily given written informed consent after the nature of the study has been explained according to applicable requirements prior to study entry * Central histologic confirmation of high-grade non-muscle invasive CIS (± Ta/T1) with active disease * Participants who are BCG naive, or participants who are BCG exposed and have not received intravesical BCG for at least 24 months prior to the most recent CIS diagnosis (Cohort A). Participants with persistent or recurrent CIS (± Ta/T1) who are BCG unresponsive within 12 months of completion of adequate BCG therapy (Cohort B).","* Penicillin allergy (participants with a questionable history of allergy to penicillin will undergo penicillin blood allergy testing via central laboratory * Predominant (defined as \> 50%) adenocarcinoma, squamous cell carcinoma, or histological variants including plasmacytoid, sarcomatoid, or squamous components according to central review * Concomitant prostatic or upper tract urothelial involvement per Investigator's assessment * Nodal and metastatic disease are excluded if they existed at any time (whether present or in the past) * Any history of ≥ T2 bladder cancer that existed at any point in time in the participant's history For more information on eligibility criteria, please contact the Sponsor"
NCT02861573,Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365),,"PHASE1, PHASE2",Mexico,"MSD Comercializadora, S. de R.L. de C.V., Mexico City, Mexico, [RECRUITING]",Metastatic Castration-Resistant Prostate Cancer,12,"[1] Pembrolizumab+Olaparib (EXPERIMENTAL): Participants with adenocarcinoma (AC) mCRPC in Cohort A will receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week dosing cycle (Q3W) and olaparib 400 mg capsules or 300 mg tablet... || [2] Pembrolizumab+Docetaxel+Prednisone (EXPERIMENTAL): Participants with AC mCRPC in Cohort B will receive pembrolizumab 200 mg IV on Day 1 Q3W, docetaxel 75 mg/m\^2 IV on Day 1 Q3W, and prednisone 5 mg tablet PO BID continuously from Day 1 of Cycle 1.... || [3] Pembrolizumab+Enzalutamide (EXPERIMENTAL): Participants with AC mCRPC in Cohort C will receive pembrolizumab 200 mg IV on Day 1 Q3W and enzalutamide 160 mg PO every day (QD) continuously from Day 1 of Cycle 1. Treatment with pembrolizumab w... || [4] Pembrolizumab+Abiraterone+Prednisone (EXPERIMENTAL): Participants with AC mCRPC in Cohort D will receive pembrolizumab 200 mg IV on Day 1 Q3W, abiraterone acetate 1000 mg PO QD and prednisone 5 mg tablet PO BID continuously from Day 1 of Cycle 1. Tre... || [5] Pembrolizumab+Lenvatinib: AC (EXPERIMENTAL): Participants with AC mCRPC in Cohort E will receive pembrolizumab 200 mg IV on Day 1 Q3W, and lenvatinib 20 mg PO QD continuously from Day 1 of Cycle 1. Treatment with pembrolizumab will continue f... || [6] Pembrolizumab+Lenvatinib:t-NE (EXPERIMENTAL): Participants with neuroendocrine (t-NE) mCRPC in Cohort F will receive pembrolizumab 200 mg IV on Day 1 Q3W, and lenvatinib 20 mg PO QD continuously from Day 1 of Cycle 1. Treatment with pembrolizu... || [7] Pembrolizumab/Vibostolimab coformulation (EXPERIMENTAL): Participants with AC mCRPC in Cohort G will receive a coformulation fixed dose combination of 200 mg pembrolizumab and 200 mg vibostolimab (MK-7684) Q3W IV from Day 1 of Cycle 1. Treatment will con... || [8] Pembrolizumab/Vibostolimab coformulation:t-NE (EXPERIMENTAL): Participants with t-NE mCRPC in Cohort H will receive a coformulation fixed dose combination of 200 mg pembrolizumab and 200 mg vibostolimab (MK","* For Cohorts A, B, C, D, E, G, J: Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology * For Cohorts F, H, I: Has t-NE or de novo metastatic prostate cancer defined by ≥1% neuroendocrine cells that are located in discrete regions of a recent biopsy specimen from a metastasis as determined by the investigational site and confirmed by central histology review prior to enrollment. Epstein criteria of neuroendocrine differentiation in prostate cancer is used for eligibility. Specimens must have one of the morphologies of Small cell carcinoma or Large cell neuroendocrine carcinoma (LCNEC) or Mixed (small or large cell) NE carcinoma - acinar adenocarcinoma with positive IHC confirmed by central pathology review * Is able to provide tumor tissue from a site not previously irradiated as follows: Cohorts A, E, G and J: must provide a core or excisional biopsy from soft tissue or bone biopsy within 1 year of screening and after developing mCRPC; Cohort B: must provide an archival tumor tissue sample or tumor tissue from a newly obtained core or excisional biopsy from soft tissue if the lesion is clinically accessible; Cohorts C and D with soft tissue disease: must provide a core or excisional biopsy from a soft tissue lesion if clinically accessible within 1 year of screening and after developing mCRPC and an archival specimen if available; and Cohorts F, H, and I must provide a core or excisional biopsy from soft tissue or a bone biopsy. For de novo metastatic neuroendocrine prostate participants, biopsies must be performed within 1 year of screening. Participants with bone metastasis only must provide an archival tumor tissue specimen * Has prostate cancer progression within 6 months prior to screening, as determined by the investigator, by means of one of the following: PSA progression as defined by a minimum of 2 rising PSA levels with an interval of ≥1 week between each assessment where the PSA value at screening sho","* Has had a prior anticancer monoclonal antibody (mAb) within 4 weeks prior to first dose study therapy or who has not recovered (i.e., Grade ≤1 or at baseline) from AEs due to mAbs administered \>4 weeks earlier * Has had prior chemotherapy, targeted small molecule therapy abiraterone treatment, enzalutamide treatment, or radiation therapy within 2 weeks prior to first dose of study therapy or who has not recovered (ie, Grade ≤1 or at baseline) from AEs due to a previously administered agent * Is currently participating in and receiving study therapy or has participated in a study of an investigational agent and received study drug or used an investigational device within 4 weeks of treatment allocation/randomization * Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to treatment allocation/randomization * Has had prior treatment with therapeutic radiopharmaceuticals for prostate cancer, such as Radium-223 or Leutitium-177, within 4 weeks prior to the first dose of trial treatment * Has an active autoimmune disease that has required systemic treatment in past 2 years * Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease * Has previously participated in any other pembrolizumab trial, or received prior therapy with an anti-programmed cell death 1 (anti-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), and anti-programmed cell death ligand 1 (anti-PD-L2) * Has a known history of Human Immunodeficiency Virus (HIV) * Has known active Hepatitis B or Hepatitis C * Has received a live vaccine or live-attenuated vaccine within 30 days of the first dose of study therapy * Has known active central nervous system metastases and/or carcinomatous meningitis * Has a ""superscan"" bone scan defined as an intense symmetric activity in the bones and diminished renal parenchymal activity on basel"
NCT06208150,"A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",MonumenTAL-6,PHASE3,"Argentina, Brazil, Mexico","Fundaleu, Buenos Aires, Argentina, [RECRUITING] | Hospital Aleman, Buenos Aires, Argentina, [RECRUITING] | Hospital Britanico de Buenos Aires, Buenos Aires, Argentina, [RECRUITING] | Cetus Oncologia, Belo Horizonte, Brazil, [RECRUITING] | DF Star, Brasília, Brazil, [RECRUITING] | Fundacao Universidade de Caxias do Sul, Caxias do Sul, Brazil, [RECRUITING] | Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer, Curitiba, Brazil, [RECRUITING] | Hospital De Clinicas De Porto Alegre, Porto Alegre, Brazil, [RECRUITING] | Instituto D Or de Pesquisa e Ensino IDOR, Recife, Brazil, [RECRUITING] | Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI), Rio de Janeiro, Brazil, [RECRUITING]",Relapsed or Refractory Multiple Myeloma,3,[1] Arm A: Talquetamab + Pomalidomide (Tal-P) (EXPERIMENTAL): Participants will receive talquetamab as subcutaneous (SC) injections; pomalidomide will be self-administered as a single dose orally; dexamethasone may be given orally or intravenously as a pretre... || [2] Arm B: Talquetamab + Teclistamab (Tal-Tec) (EXPERIMENTAL): Participants will receive teclistamab in combination with talquetamab both as SC injection; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug. || [3] Arm C: Elotuzumab+ Pomalidomide+Dexamethasone (EPd) or Pomalidomide+Bortezomib+Dexamethasone (PVd) (ACTIVE_COMPARATOR): Participants will either receive elotuzumab intravenous (IV) injection in combination with pomalidomide and dexamethasone orally; or pomalidamide orally in combination with bortezomib SC injection ...,"* Documented multiple myeloma as defined by the criteria below: (a) multiple myeloma diagnosis according to the international myeloma working group (IMWG) diagnostic criteria (b) measurable disease at screening as assessed by central laboratory, defined by any of the following: (i) serum M-protein level greater than or equal to (\>=) 0.5 gram per deciliter (g/dL); or (ii) urine M-protein level \>= 200 milligram (mg) per 24 hours; or (iii) light chain multiple myeloma without measurable M-protein in the serum or the urine: serum immunoglobulin (Ig) free light chain (FLC) \>= 10 milligrams per deciliter (mg/dL) and abnormal serum Ig kappa lambda FLC ratio * Relapsed or refractory disease as defined below: a) Relapsed disease is defined as an initial response to prior treatment, followed by confirmed progressive disease (PD) by IMWG criteria greater than (\>) 60 days after cessation of treatment. b) Refractory disease is defined as less than (\<) 25 percent (%) reduction in M-protein or confirmed PD by IMWG criteria during previous treatment or less than or equal to (\<=) 60 days after cessation of treatment * Documented evidence of PD or failure to achieve a minimal response to the last line of therapy based on investigator's determination of response by IMWG criteria on or after their last regimen * Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 at screening and immediately prior to the start of administration of study treatment * A participant must agree not to be pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 6months after the last dose of study treatment","* Contraindications or life-threatening allergies, hypersensitivity, or intolerance to any study drug or its excipients * Stroke, transient ischemic attack, or seizure within 6 months prior to signing informed consent form (ICF) * Major surgery or had significant traumatic injury within 2 weeks prior to the start of administration of study treatment, or will not have fully recovered from surgery, or has major surgery planned during the time the participant is expected to be treated in the study or within 2 weeks after administration of the last dose of study treatment * A maximum cumulative dose of corticosteroids of \>=140 mg of prednisone or equivalent within 14-day period before the first dose of study drug * Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required"
NCT05215340,"A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)",TROPION-Lung08,PHASE3,"Argentina, Brazil, Chile, Mexico","Fundacion CENIT para la investigación en Neurociencias, Ciudad Autonoma de Buenos Aire, Argentina, [RECRUITING] | Hospital Privado de la Comunidad, Mar del Plata, Argentina, [RECRUITING] | Centro de Investigación Pergamino S. A., Pergamino, Argentina, [RECRUITING] | Instituto de Oncología de Rosario, Rosario, Argentina, [RECRUITING] | Sanatorio Parque, Rosario, Argentina, [RECRUITING] | Sanatorio Británico de Rosario, Rosario, Argentina, [RECRUITING] | CER SAN JUAN - Centro Polivalente de Asistencia e Investigación Clínica, San Juan, Argentina, [RECRUITING] | Clinica Viedma SA, Viedma, Argentina, [RECRUITING] | Instituto de Pesquisas em Saúde - IPS, Caxias do Sul, Brazil, [RECRUITING] | Hospital Erasto Gaertner, Curitiba, Brazil, [RECRUITING]",Metastatic Non Small Cell Lung Cancer,2,[1] Pembrolizumab + Datopotamab Deruxtecan (Dato-DXd) (EXPERIMENTAL): Participants will be randomized to receive 200 mg pembrolizumab followed by 6.0mg/kg Dato-DXd. || [2] Pembrolizumb (ACTIVE_COMPARATOR): Participants will be randomized to receive 200 mg pembrolizumab.,"Participants eligible for inclusion in the study must meet all inclusion criteria within 28 days of randomization into the study. * Sign and date the Tissue Screening and Main Informed Consent Forms, prior to the start of any study-specific qualification procedures. * Adults ≥18 years or the minimum legal adult age (whichever is greater) at the time of informed consent. * Histologically documented non-squamous NSCLC that meets all of the following criteria (Note: Subjects with squamous histology were eligible prior to Protocol Version 5.0. After Protocol Version 5.0, subjects with squamous histology are not eligible. Subjects with mixed histology, including those with a squamous component, remain eligible the study even after Protocol Version 5.0): 1. Stage IIIB or IIIC disease and not candidates for surgical resection or definitive chemoradiation, or Stage IV NSCLC disease at the time of randomization (based on the American Joint Committee on Cancer, Eighth Edition). Participants with early-stage NSCLC who have relapsed should be restaged during screening to ensure their eligibility for the study. 2. Documented negative test results for epidermal growth factor receptor (EGFR), lymphoma kinase (ALK), and proto-oncogene1 (ROS1) actionable genomic alterations (AGAs) based on analysis of tumor tissue. If test results for EGFR, ALK, and ROS1 are not available, subjects are required to undergo testing performed locally for these genomic alterations. 3. No known AGAs in neurotrophic tyrosine receptor kinase (NTRK), proto-oncogene B-raf (BRAF), rearranged during transfection (RET), mesenchymal-epithelial transition factor (MET), or other actionable driver kinases with locally approved therapies. (Testing for genomic alterations besides EGFR, ALK, and ROS1 is not required prior to randomization). Subjects whose tumors harbor KRAS mutations are eligible for the study. * Has provided a formalin-fixed tumor tissue sample for the measurement of trophoblast cell surface protein ","* Has received prior systemic treatment for advanced or metastatic NSCLC. * Has received prior treatment for NSCLC with any of the following, including in the adjuvant/neoadjuvant setting: 1. Any agent, including an antibody-drug conjugate, containing a chemotherapeutic agent targeting topoisomerase I. 2. TROP2-targeted therapy. 3. Any anti-programmed death receptor-1 (PD-1), anti-PD-L1, or anti-PD-ligand 2 (L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX40, CD137). 4. Any other immune checkpoint inhibitors. Participants who received adjuvant or neoadjuvant therapy OTHER than those listed above, are eligible if the adjuvant/neoadjuvant therapy was completed at least 6 months prior to the diagnosis of advanced/metastatic disease. * Has spinal cord compression or active and untreated central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases and who are asymptomatic may participate provided they are radiologically stable. * Has received prior radiotherapy \< 4 weeks of start of study intervention or more than 30 Gy (unit of ionizing radiation dose in the International System of Units) to the lung within 6 months of Cycle 1 Day 1. * History of another primary malignancy (beyond NSCLC) except for: 1. Malignancy treated with curative intent and with no known active disease ≥3 years before the first dose of study treatment and of low potential risk for recurrence. 2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease. 3. Adequately treated carcinoma in situ without evidence of disease. 4. Participants with a history of prostate cancer (tumor/node/metastasis stage) of Stage ≤T2cN0M0 without biochemical recurrence or progression and who in the opinion of the Investigator are not deemed to require active intervention. * Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis including rad"
NCT06525220,"A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Recurrent or Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma",,PHASE3,"Argentina, Brazil, Chile","Site 96, CABA, Argentina, [RECRUITING] | Site 37, CABA, Argentina, [RECRUITING] | Site 31, Córdoba, Argentina, [RECRUITING] | Site 30, La Rioja, Argentina, [RECRUITING] | Site 76, Rosario, Argentina, [RECRUITING] | Site 46, Viedma, Argentina, [RECRUITING] | Site 149, Rio de Janeiro, Brazil, [RECRUITING] | Site 141, Belo Horizonte, Brazil, [RECRUITING] | Site 144, Natal, Brazil, [RECRUITING] | Site 140, Porto Alegre, Brazil, [RECRUITING]",Head and Neck Squamous Cell Carcinoma,2,[1] Petosemtamab + Pembrolizumab (EXPERIMENTAL): Combination Therapy || [2] Pembrolizumab (ACTIVE_COMPARATOR): Monotherapy,"1. Signed ICF before initiation of any study procedures 2. Age ≥ 18 years at signing of ICF 3. Histologically confirmed HNSCC with evidence of metastatic or locally recurrent disease not amenable to local therapy with curative intent. 4. The eligible HNSCC primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx. 5. HNSCC patients eligible to receive pembrolizumab as 1L monotherapy with tumors expressing PD-L1, CPS ≥1. 6. HNSCC patients should not have had previous systemic therapy administered in the incurable recurrent or metastatic setting 7. A new tumor biopsy, unless the patient has an available archival tumor sample with sufficient material 8. Measurable disease per Investigator assessment as defined by RECIST v1.1 by radiologic methods 9. ECOG Performance Status (PS) of 0-1 10. Life expectancy ≥ 12 weeks, as per investigator assessment. 11. Left ventricular ejection fraction (LVEF) ≥50% or ≥ institutional normal limit, whichever is higher, by echocardiogram (ECHO) or multigated acquisition (MUGA) scan 12. Adequate organ function as defined per protocol. 13. HIV-positive patients are eligible only if the cluster of differentiation 4 (CD4+) count is ≥ 300/µl, viral load is undetectable, and the patient is currently receiving highly active antiretroviral therapy","1. Central nervous system metastases that are untreated or already treated but symptomatic, or require radiation, surgery, or continued steroid therapy to control symptoms within 21 days prior to randomization 2. Known leptomeningeal involvement 3. Any systemic anticancer therapy or investigational drug within 4 weeks or 5 half-lives, whichever is shorter, before randomization 4. Requirement for immunosuppressive medication 5. Major surgery or radiotherapy within 3 weeks of randomization 6. Clinically significant toxicities related to prior anticancer therapies that have not returned to ≤ Grade 1 or baseline except for Grade ≤2- myalgia, neuropathy, alopecia, and any prior therapy related endocrinopathies 7. History of hypersensitivity reaction to any of the excipients of petosemtomab or pembrolizumab. 8. Unstable angina; history of congestive heart failure of Class II-IV New York Heart Association (NYHA) criteria, or serious cardiac arrhythmia requiring treatment; or history of myocardial infarction within 6 months prior to randomization 9. History of prior malignancies within the last 5 years, with the exception of excised local cancer 10. Current dyspnea at rest of any origin, or other diseases requiring continuous oxygen therapy 11. Current serious illness or medical conditions including, but not limited to, uncontrolled active infection, clinically significant pulmonary, metabolic or psychiatric disorders 12. Patients with known infectious diseases as per protocol. 13. Pregnant or breastfeeding patients. 14. The patient has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy of prednisone \>10 mg/day or equivalent, or any other form of immunosuppressive therapy 15. The patient has an active autoimmune disease that has required systemic immune suppressive treatment in the past 2 years; replacement therapy is not considered immune suppressive treatment 16. The patient has had an allogeneic tissue/solid organ transplant. 17. Patient ha"
NCT05412680,Transoral Endoscopic Thyroidectomy by Vestibular Approach (TOETVA) Compared to Conventional Thyroidectomy by Cervical Approach: a Randomized Clinical Trial,TOETVA,NA,Brazil,"ICESP, São Paulo, Brazil, [RECRUITING]",Thyroid Diseases | Thyroid Cancer,2,[1] TOETVA (ACTIVE_COMPARATOR): Patients submitted to transoral endoscopic thyroidectomy by vestibular approach || [2] CONVENTIONAL THYROIDECTOMY (ACTIVE_COMPARATOR): Patients submitted to conventional open thyroidectomy by cervical approach,"* history of hypertrophic scarring and/or motivation to avoid cervical scarring, * maximum diameter of the thyroid \< 10 cm and of the dominant nodule \< 6 cm, * estimated thyroid volume \< 45 ml * benign lesion (multinodular goiter, cyst), * indeterminate nodule (Bethesda III or IV), * suspicious nodule for well-differentiated thyroid carcinoma (Bethesda V and VI) \< 2 cm",* history of previous surgery or irradiation in the head and neck region and superior mediastinum * evidence of clinical hyperthyroidism * preoperative recurrent nerve palsy * lymph node metastasis * extra-thyroid extension * plunging goiter * oral abscess
NCT05774951,"CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurre",CAMBRIA-1,PHASE3,"Argentina, Brazil, Chile, Colombia, Mexico, Peru","Research Site, Buenos Aires, Argentina, [ACTIVE_NOT_RECRUITING] | Research Site, Buenos Aires, Argentina, [ACTIVE_NOT_RECRUITING] | Research Site, Buenos Aires, Argentina, [WITHDRAWN] | Research Site, CABA, Argentina, [RECRUITING] | Research Site, Capital Federal, Argentina, [ACTIVE_NOT_RECRUITING] | Research Site, Ciudad Autónoma Buenos Aires, Argentina, [RECRUITING] | Research Site, Ciudad de Buenos Aires, Argentina, [ACTIVE_NOT_RECRUITING] | Research Site, Córdoba, Argentina, [RECRUITING] | Research Site, Córdoba, Argentina, [ACTIVE_NOT_RECRUITING] | Research Site, La Plata, Argentina, [ACTIVE_NOT_RECRUITING]","Breast Cancer, Early Breast Cancer",2,"[1] Arm A: standard endocrine therapy of investigator´s choice (ACTIVE_COMPARATOR): Continue standard endocrine therapy of investigator's choice (aromatase inhibitors \[AI; exemestane, letrozole, anastrozole\] or tamoxifen) || [2] Arm B: camizestrant (EXPERIMENTAL): Camizestrant","* Women and Men, ≥18 years at the time of screening (or per national guidelines) * Histologically confirmed ER+/HER2- early-stage resected invasive breast cancer with high or intermediate risk of recurrence, based on clinical-pathological risk features, as defined in the protocol. * Completed adequate (definitive) locoregional therapy (surgery with or without radiotherapy) for the primary breast tumour(s), with or without (neo)adjuvant chemotherapy * Completed at least 2 years but no more than 5 years (+3 months) of adjuvant ET (+/- CDK4/6 inhibitor) * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 * Adequate organ and marrow function","* Inoperable locally advanced or metastatic breast cancer * Pathological complete response following treatment with neoadjuvant therapy * History of any other cancer (except non-melanoma skin cancer or carcinoma in situ of the cervix or considered at very low risk of recurrence per investigator judgement) unless in complete remission with no therapy for a minimum of 5 years from the date of randomisation * Any evidence of severe or uncontrolled systemic diseases which, in the investigator's opinion precludes participation in the study or compliance * Known LVEF \<50% with heart failure NYHA Grade ≥2. * Mean resting QTcF interval \>480 ms at screening * Concurrent exogenous reproductive hormone therapy or non-topical hormonal therapy for non-cancer-related conditions * Any concurrent anti-cancer treatment not specified in the protocol with the exception of bisphosphonates (e.g. zoledronic acid) or RANKL inhibitors (eg, denosumab) * Previous treatment with camizestrant, investigational SERDs/investigational ER targeting agents, or fulvestrant * Currently pregnant (confirmed with positive serum pregnancy test) or breastfeeding * Patients with known hypersensitivity to active or inactive excipients of camizestrant or drugs with a similar chemical structure or class to camizestrant. In pre-/peri-menopausal female and male patients, known hypersensitivity or intolerance to LHRH agonists, that would preclude the patient from receiving any LHRH agonist"
NCT05352672,"A Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma",,PHASE3,"Argentina, Brazil, Chile, Mexico, Peru","Fundacion Cenit para la Investigacion en Neurociencias, Buenos Aires, Argentina, [RECRUITING] | DIABAID - Instituto de Asistencia Integral en Diabetes, Buenos Aires, Argentina, [RECRUITING] | Fundacion CENIT Centro Medico de Neurociencias, Buenos Aires, Argentina, [RECRUITING] | Clinica Adventista Belgrano, Caba, Argentina, [RECRUITING] | Instituto de Oncologia de Rosario, Rosario, Argentina, [RECRUITING] | Centro Medico San Roque, San Miguel de Tucumán, Argentina, [RECRUITING] | Fundacao Pio XII - Hospital de Amor de Barretos, Barretos, Brazil, [RECRUITING] | Centro Avancado de Tratamento Oncologico (CENANTRON), Belo Horizonte, Brazil, [RECRUITING] | Liga Paranaense de Combate ao Cancer - Hospital Erasto Gaertner, Curitiba, Brazil, [RECRUITING] | Oncosite Centro De Pesquisa Clinica Em Oncologia, Ijuí, Brazil, [RECRUITING]",Melanoma,4,[1] A: fianlimab+cemiplimab dose 1 (EXPERIMENTAL): As defined in Protocol Amendment 5 || [2] A1: fianlimab+cemiplimab dose 2 (EXPERIMENTAL): As defined in Protocol Amendment 5 || [3] B: pembrolizumab+placebo (EXPERIMENTAL): As defined in Protocol Amendment 5 || [4] C: cemiplimab+placebo (EXPERIMENTAL): As defined in Protocol Amendment 5,"1. Age ≥12 years on the date of providing informed consent 2. Patients with histologically confirmed unresectable Stage III and Stage IV (metastatic) melanoma (AJCC, 8th revised edition) who have not received prior systemic therapy for advanced unresectable disease 1. Patients who received adjuvant and/or neoadjuvant systemic therapies are eligible if they did not have evidence of progression or recurrence of disease and/or discontinued due to occurrence of unmanageable imAEs ≥ grade 3 (with the","1. Uveal melanoma 2. Ongoing or recent (within 2 years) evidence of an autoimmune disease that required systemic treatment with immunosuppressive agents. The following are non-exclusionary: vitiligo, childhood asthma that has resolved, residual hypothyroidism that requires only hormone replacement, psoriasis not requiring systemic treatment. 3. Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B (HBV) or hepatitis C virus (HCV) infection; or diagnosis of immunodeficiency that is related to, or results in chronic infection 4. Unknown BRAF V600 mutation status as described in the protocol 5. Systemic immune suppression: 1. Use of immunosuppressive doses of corticosteroids (\>10mg of prednisone per day or equivalent) within 14 days of the first dose of study medication. Physiologic replacement doses are allowed up to and including 10mg of prednisone/day or equivalent. Inhaled or topical steroids are permitted, if they are not for treatment of an autoimmune disorder. 2. Other clinically relevant forms of systemic immune suppression 6. Treatment with other anti-cancer therapy including immuno- therapy, chemotherapy, major surgery or biological therapy within 21 days prior to the first dose of trial treatment. Adjuvant hormonotherapy used for breast cancer or other hormone-sensitive cancers in long term remission is allowed. 7. History or current evidence of significant (CTCAE Grade ≥2) local or systemic infection (e. g., cellulitis, pneumonia, septicemia) requiring systemic antibiotic treatment within 14 days prior to the first dose of trial medication. 8. Active or untreated brain metastases or spinal cord compression. Patients with leptomeningeal disease are excluded. Patients with known brain metastases are eligible if they: 1. Received radiotherapy or another appropriate standard therapy for the brain metastases, 2. Have neurologically returned to baseline (except for residual signs and symptoms related to the CNS treatment) for at least 14 da"
NCT06989112,"DESTINY-Endometrial01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer",DE-01,PHASE3,Brazil,"Research Site, Barretos, Brazil, [NOT_YET_RECRUITING] | Research Site, Belo Horizonte, Brazil, [NOT_YET_RECRUITING] | Research Site, Goiânia, Brazil, [NOT_YET_RECRUITING] | Research Site, Londrina, Brazil, [NOT_YET_RECRUITING] | Research Site, Porto Alegre, Brazil, [NOT_YET_RECRUITING] | Research Site, Porto Alegre, Brazil, [NOT_YET_RECRUITING] | Research Site, Rio de Janeiro, Brazil, [NOT_YET_RECRUITING] | Research Site, Salvador, Brazil, [NOT_YET_RECRUITING] | Research Site, São Paulo, Brazil, [NOT_YET_RECRUITING] | Research Site, São Paulo, Brazil, [NOT_YET_RECRUITING]",Endometrial Cancer,3,"[1] Arm A: T-DXd + Rilvegostomig (EXPERIMENTAL): T-DXd IV Q3W plus rilvegostomig IV Q3W. Treatment will continue until objective disease progression according to RECIST v1.1 as assessed by the Investigator and confirmed by BICR or until other dis... || [2] Arm B: T-DXd + Pembrolizumab (EXPERIMENTAL): T-DXd IV Q3W plus pembrolizumab IV Q3W. Treatment will continue until objective disease progression according to RECIST v1.1 as assessed by the Investigator and confirmed by BICR or until other dis... || [3] Arm C: Carboplatin + Paclitaxel + Pembrolizumab (ACTIVE_COMPARATOR): Carboplatin, paclitaxel and pembrolizumab administered Q3W during 6 cycles, followed by maintenance with pembrolizumab IV Q6W during 14 cycles. Treatment with pembrolizumab will continue for up to ...","* Participants must be ≥ 18 years of age at the time of screening. Other age restrictions may apply as per local regulations. * Histologically confirmed diagnosis of epithelial endometrial carcinoma. All histologies are allowed except for sarcomas (carcinosarcomas are allowed). * Following surgery or diagnostic biopsy, participant must have primary advanced disease (Stage III/IV) or first recurrent endometrial cancer and meet at least one of the following criteria: * Primary Stage III (per FIGO 2023) disease with measurable disease at baseline per RECIST 1.1 based on the investigator's assessment. * Primary Stage IV disease (per FIGO 2023) regardless of presence of measurable disease at baseline. * First recurrent disease regardless of presence of measurable disease at baseline. * Endometrial cancer with HER2 IHC expression of 3+ or 2+ as assessed by prospective central testing. * Endometrial cancer that is determined pMMR by prospective central IHC testing. * Provision of adequate FFPE tumor tissue sample of a tumor lesion that was not previously irradiated for central HER2, MMR, and PD-L1 IHC testing and valid central test results for randomization/ stratification. * Prior therapy: * Naïve to first-line systemic anticancer therapy. Participants may have received one prior line of adjuvant/neoadjuvant chemotherapy with curative intent (chemotherapy or chemoradiation) if disease recurrence or progression occurred ≥ 6 months after last dose of chemotherapy. Prior trastuzumab in the adjuvant/neoadjuvant setting is allowed. * No prior exposure to ADCs or immune checkpoint inhibitors including (but not limited to) anti-PD-1/PD-L1/PD-L2 and anti-CTLA-4 antibodies and therapeutic anticancer vaccines. * Participants may have received prior radiation therapy for the treatment of endometrial cancer. Prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para-aortic radiation therapy, and/or intravaginal brachytherapy. Adequate treatment was","* History of organ transplant * Uncontrolled intercurrent illness, including, but not limited to ongoing or active known infection, serious chronic gastrointestinal conditions associated with diarrhea and active non-infectious skin disease requiring systemic treatment. * Spinal cord compression or clinically active central nervous system metastases * Participants with a medical history of myocardial infarction (MI) within 6 months before randomization, or symptomatic congestive heart failure (CHF) (NYHA Class II to IV), clinically significant arrhythmia, or cardiomyopathy of any etiology. Participants with troponin levels above ULN at screening (as defined by the manufacturer), should have a cardiologic consultation before enrollment to rule out MI * History of (non-infectious) ILD/pneumonitis that required steroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening. * Lung criteria: * Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (e.g., pulmonary emboli within 3 months of the study enrollment, severe asthma, severe chronic obstructive pulmonary disease (COPD), restrictive lung disease, pleural effusion etc.). * Any autoimmune, connective tissue or inflammatory disorders where there is documented, or a suspicion of pulmonary involvement at the time of screening. * Prior pneumonectomy (complete). * Active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment. * Active primary immunodeficiency/ active infectious disease(s) including: * Tuberculosis (TB) * HIV infection that is not well controlled. * Chronic or active hepatitis B, chronic or active hepatitis C; however, participants who have chronic hepatitis B and are receiving suppressive antiviral therapy are allowed to be enrolled if alanine aminotransferase (ALT) is normal and viral load is controlled. *"
NCT06625320,"RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of Daraxonrasib (RMC-6236) Versus Investigator's Choice of Standard of Care Therapy in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)",RASolute 302,PHASE3,Puerto Rico,"Pan-American Center for Oncology Trials, San Juan, Puerto Rico, [ACTIVE_NOT_RECRUITING]",Pancreatic Cancer | PDAC | PDAC - Pancreatic Ductal Adenocarcinoma,2,"[1] RMC-6236 (EXPERIMENTAL): Study drug || [2] Investigator's choice of standard of care therapy (ACTIVE_COMPARATOR): Patients randomized to Investigator's choice of standard of care chemotherapy will receive one of the following four treatments:

* Gemcitabine and nab-paclitaxel (GnP)
* Oxaliplatin, leucovorin, i...","* At least 18 years old and has provided informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Histologically or cytologically confirmed PDAC with metastatic disease. * Measurable disease per RECIST 1.1. * Adequate organ function (bone marrow, liver, kidney, coagulation) * Documented RAS mutation status, either mutant or wild-type. RAS mutations defined as nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61). * Able to take oral medications.",* Prior therapy with direct RAS-targeted therapy (eg. degraders and/or inhibitors). * History of or known central nervous system metastatic disease. * Any conditions that may affect the ability to take or absorb study treatment * Major surgery within 4 weeks prior to randomization. * Patient is unable or unwilling to comply with protocol-required study visits or procedures
NCT06112379,"A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001; TROPION-Breast04)",,PHASE3,Brazil,"Research Site, Brasília, Brazil, [ACTIVE_NOT_RECRUITING] | Research Site, Curitiba, Brazil, [ACTIVE_NOT_RECRUITING] | Research Site, Fortaleza, Brazil, [RECRUITING] | Research Site, Londrina, Brazil, [RECRUITING] | Research Site, Natal, Brazil, [RECRUITING] | Research Site, Porto Alegre, Brazil, [RECRUITING] | Research Site, Porto Alegre, Brazil, [ACTIVE_NOT_RECRUITING] | Research Site, Ribeirão Preto, Brazil, [ACTIVE_NOT_RECRUITING] | Research Site, Santo André, Brazil, [ACTIVE_NOT_RECRUITING] | Research Site, São Paulo, Brazil, [ACTIVE_NOT_RECRUITING]",Breast Cancer,2,"[1] Dato-DXd plus durvalumab (EXPERIMENTAL): Participants receive durvalumab every 3 weeks (Q3W) + Dato-DXd Q3W as neoadjuvant therapy prior to surgery; followed by 9 cycles of durvaluamb Q3W as adjuvant therapy post-surgery. Adjuvant chemoth... || [2] Pembrolizumab plus chemotherapy (ACTIVE_COMPARATOR): Participants receive pembrolizumab every 3 weeks (Q3W) + paclitaxel weekly + carboplatin (weekly or Q3W) x 4 cycles, followed by pembrolizumab Q3W + (doxorubicin OR epirubicin) + cyclophosphamide Q...","* Participant must be ≥ 18 years, at the time of signing the ICF. * Histologically confirmed Stage II or III unilateral or bilateral primary invasive TNBC or hormone receptor-low/HER2-negative breast cancer * ECOG PS of 0 or 1 * Provision of acceptable tumor sample * Adequate bone marrow reserve and organ function * Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies and aligned with protocol requirements.","* History of any prior invasive breast malignancy * History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 5 years before randomization. * active or prior documented autoimmune or inflammatory disorders. * Evidence of distant disease. * Clinically significant corneal disease. * Has active or uncontrolled hepatitis B or C virus infection. * Known HIV infection that is not well controlled. * Uncontrolled infection requiring i.v. antibiotics, antivirals or antifungals; suspected infections; or inability to rule out infections. * Known to have active tuberculosis infection * Mean resting corrected QTcF interval \> 470 ms obtained from ECG * Uncontrolled or significant cardiac disease. * History of non-infectious ILD/pneumonitis * Has severe pulmonary function compromise * Any prior or concurrent surgery, radiotherapy or systemic anticancer therapy for TNBC or hormone receptor-low/HER2-negative breast cancer * For females only: is pregnant (confirmed with positive serum pregnancy test) or breastfeeding, or planning to become pregnant. * Female participants should refrain from breastfeeding from enrolment throughout the study and for at least 7 months after last dose of study intervention, or as dictated by local PI for SoC if longer. * Concurrent use of systemic hormone replacement therapy or oral hormonal contraception"
NCT05243797,Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4,MajesTEC-4,PHASE3,"Argentina, Brazil","Hospital Italiano, Buenos Aires, Argentina, [RECRUITING] | Hospital Privado, Córdoba, Argentina, [RECRUITING] | Sanatorio Britanico Rosario, Rosario, Argentina, [RECRUITING] | Hospital Mãe de Deus - Centro Integrado de Oncologia, Porto Alegre, Brazil, [RECRUITING] | Hospital Santa Rita, Porto Alegre, Brazil, [RECRUITING] | Instituto Americas de Ensino,Pesquisa e Inovação, Rio de Janeiro, Brazil, [RECRUITING] | IDOR- Instituto D'or de pesquisa. Av. São Rafael, Salvador, Brazil, [RECRUITING] | A Real e Benemérita Associação Portuguesa de Beneficência, São Paulo, Brazil, [RECRUITING] | Clínica Medica São Germano,Grupo Oncoclínicas Pesquisa Clínica, São Paulo, Brazil, [RECRUITING] | Departamento de Oncologia Clínica AC Camargo Cancer Center, São Paulo, Brazil, [RECRUITING]",Multiple Myeloma,3,[1] Arm A: Teclistamab-Lenalidomide (Tec-Len) (EXPERIMENTAL): Teclistamab will be administered via a subcutaneous injection (SC) || [2] Arm B Lenalidomide Alone (Len) (ACTIVE_COMPARATOR): Lenalidomide orally. || [3] Arm C Teclistamab-Alone (Tec) (EXPERIMENTAL): Teclistamab will be administered via a subcutaneous injection (SC),"* Must have a new diagnosis of multiple myeloma according to IMWG criteria and have received induction +/- consolidation. * Must have received only one line of therapy and achieved at least a partial response (≥PR) as per IMWG 2016 response criteria (Kumar 2016) without evidence of progression at the time of first treatment dose. * Must not be intolerant to the starting dose of lenalidomide. * Must not have received any maintenance therapy. * Have an ECOG performance status score of 0, 1, or 2 at screening and immediately prior to the start of administration of study treatment * Have clinical laboratory values within prespecified range.","* Received any prior BCMA-directed therapy. * Any previous therapy with an immune cell redirecting agent or gene modified adoptive cell therapy (eg, chimeric antigen receptor modified T cells, NK cells). * Discontinued treatment due to any AE related to lenalidomide as determined by the investigator. * Progressed on multiple myeloma therapy at any time prior to screening. * Received a cumulative dose of corticosteroids equivalent to ≥140 mg of prednisone within the 14 days prior to first treatment dose. * Received a live, attenuated vaccine within 4 weeks before first treatment dose. Non-live vaccines or non-replicating authorized for emergency use (eg. COVID-19) are allowed."
NCT05564377,Molecular Analysis for Combination Therapy Choice (ComboMATCH),,PHASE2,Puerto Rico,"Puerto Rico Hematology Oncology Group, Bayamón, Puerto Rico, [RECRUITING] | Doctors Cancer Center, Manatí, Puerto Rico, [RECRUITING] | Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico, [RECRUITING] | PROncology, San Juan, Puerto Rico, [RECRUITING]",Advanced Malignant Solid Neoplasm | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Locally Advanced Malignant Solid Neoplasm | Malignant Female Reproductive System Neoplasm,20,"[1] EAY191-A2 (Cohort 1, Arm A) (EXPERIMENTAL): Cohort 1, Arm A: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptabl... || [2] EAY191-A2 (Cohort 2, Arm B) (EXPERIMENTAL): Cohort 2, Arm B: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptabl... || [3] EAY191-A2 (Cohort 2, Arm C) (EXPERIMENTAL): Cohort 2, Arm C: Patients receive olaparib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone mar... || [4] EAY191-A2 (Cohort 3, Arm D) (EXPERIMENTAL): Cohort 3, Arm D: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptabl... || [5] EAY191-A3 Combo Cohorts 1, 2, 3, 4 (palbociclib, binimetinib) (EXPERIMENTAL): Patients receive palbociclib PO and binimetinib PO throughout the trial. Patients may also undergo biopsy at screening and undergo MRI, CT, bone scan, and collection of blood samples during screeni... || [6] EAY191-A3 Monotherapy Cohort 1 (binimetinib) (EXPERIMENTAL): Patients receive binimetinib PO throughout the trial. Patients may also undergo biopsy at screening and undergo MRI, CT, bone scan, and collection of blood samples during screening, on study, and/o... || [7] EAY191-A6 Arm I (RAS/RAF/MEK/ERK mutations) (EXPERIMENTAL): Patients receive leucovorin IV, oxaliplatin IV, and fluorouracil IV on study. Patients undergo ECHO and MUGA during screening and on study, a CT with contrast, MRI, or a FDG-PET during screening, c... || [8] EAY191-A6 Arm II (RAS/RAF/MEK/ERK mutations) (EXPERIMENTAL): Patients receive binimetinib PO, leucovorin IV, oxaliplatin IV, and fluorouracil IV on study. Patients u",* Patient must have measurable disease * Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status between 0-2 OR patient must have Lansky performance status of \>= 50% or Karnofsky performance status of \>= 50% * Patient must be deemed potentially eligible for a ComboMATCH Treatment Trial as assessed by the enrolling provider * All patients must have sequencing results available from a National Cancer Institute (NCI) credentialed Designated Laboratory (DL) * Patients must have locally advanced or advanced histologically documented solid tumors requiring therapy and meet one of the following criteria: * Patients must have progressed on at least one line of standard systemic therapy OR * Patients whose disease has no standard treatment that has been shown to prolong overall survival * Patient must meet one of the following requirements: * Patients 18 years and older who have tumor amenable to minimal risk image-guided or direct vision biopsy and must be willing and able to undergo a tumor biopsy to obtain samples for research if the patient is to enroll in a ComboMATCH treatment trial OR * Patients 18 years and older who do not have disease that is biopsiable at minimal risk to the patient must confirm availability of an archival tumor tissue specimen for submission for research if the patient enrolls to a ComboMATCH Treatment Trial. This tumor tissue must meet the following criteria: * Tissue must have been collected within 12 months prior to registration to the EAY191 Registration Trial * Patient must not have had a Response Evaluation Criteria in Solid Tumors (RECIST) response (complete response \[CR\] or partial response \[PR\]) to any intervening therapy after collection of the tissue * Formalin-fixed paraffin-embedded tumor tissue block(s) or slides must be available OR * Patients under 18 years old must confirm availability of an archival tumor tissue specimen for submission for research if patient enrolls to a ComboMATCH Treatment Tria,
NCT05514054,"EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence",EMBER-4,PHASE3,"Argentina, Brazil, Mexico","Centro de Oncología e Investigación de Buenos Aires, Berazategui, Argentina, [RECRUITING] | Investigaciones Clinicas Moleculares (ICM), Buenos Aires, Argentina, [RECRUITING] | Centro Oncologico Korben, Buenos Aires, Argentina, [RECRUITING] | CIPREC, Buenos Aires, Argentina, [RECRUITING] | Mautalen Salud e Investigación, Buenos Aires, Argentina, [RECRUITING] | Fundación Respirar, Buenos Aires, Argentina, [RECRUITING] | Instituto Alexander Fleming, Buenos Aires, Argentina, [RECRUITING] | Fundación Cenit Para La Investigación En Neurociencias, CABA, Argentina, [RECRUITING] | Clinica Adventista Belgrano, CABA, Argentina, [RECRUITING] | Centro Medico Privado CEMAIC, Capital, Argentina, [RECRUITING]",Breast Neoplasms,2,"[1] Imlunestrant (EXPERIMENTAL): Imlunestrant administered orally. || [2] Investigator's Choice of Endocrine Therapy (ACTIVE_COMPARATOR): Investigator's choice of tamoxifen, anastrozole, letrozole, or exemestane administered per local approved label.","* Have a diagnosis of ER+, HER2- early-stage, resected, invasive breast cancer without evidence of distant metastasis. * Participants must have received at least 24 months but not more than 60 months of any adjuvant ET, from time of adjuvant ET initiation. * Participants may have received (neo) adjuvant chemotherapy and/or targeted therapy with a CDK4/6- or PARP- inhibitor. * Must have an increased risk of disease recurrence based on clinical-pathological risk features. * Have a Performance Status of 0 or 1 on the Eastern Cooperative Oncology Group scale. * Have adequate organ function.","* Have any evidence of metastatic disease (including contralateral ALN) or inflammatory breast cancer at primary breast cancer diagnosis. * Participants with more than a 6-month consecutive gap in therapy during the course of prior adjuvant ET. * Participants who have completed or discontinued prior adjuvant ET \>6 months prior to screening. * Participants with a history of previous breast cancer are excluded, with the exception of ipsilateral DCIS treated by locoregional therapy alone ≥5 years ago. * Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 180 days after the last dose of study intervention. * Participant has previously received ET of any duration for breast cancer prevention (tamoxifen or AIs) or raloxifene. * Participants with a history of any other cancer. * Have serious preexisting medical conditions that, in the judgment of the investigator, would preclude participation in this study."
NCT06833073,A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011),,PHASE2,"Argentina, Brazil, Chile, Colombia, Peru","Hospital Italiano de Buenos Aires ( Site 0307), CABA, Argentina, [RECRUITING] | Instituto Alexander Fleming ( Site 0306), Ciudad Autónoma de Buenos Aires, Argentina, [RECRUITING] | Instituto de Investigaciones Clinicas Mar dle Plata ( Site 0305), Mar del Plata, Argentina, [RECRUITING] | Asociación de Beneficencia Hospital Sirio Libanés ( Site 0303), Buenos Aires, Argentina, [RECRUITING] | Fundacion Estudios Clinicos ( Site 0304), Rosario, Argentina, [RECRUITING] | Sanatorio Parque ( Site 0300), Rosario, Argentina, [RECRUITING] | Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0301), La Rioja, Argentina, [RECRUITING] | Instituto do Câncer e Transplante de Curitiba ( Site 0402), Curitiba, Brazil, [RECRUITING] | Hospital de Clínicas de Passo Fundo ( Site 0406), Passo Fundo, Brazil, [RECRUITING] | Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0400), Barretos, Brazil, [RECRUITING]",Urinary Bladder Neoplasms | Non-Muscle Invasive Bladder Neoplasms | Carcinoma in Situ,3,"[1] Intismeran autogene + BCG (EXPERIMENTAL): Participants receive 1 mg of intismeran autogene via intramuscular (IM) injection every 3 weeks (Q3W) for 9 doses. Participants also receive 50 mg of TICE® BCG once weekly for 6 weeks, then once we... || [2] BCG (ACTIVE_COMPARATOR): Participants receive 50 mg of TICE® BCG once weekly for 6 weeks, then once weekly on weeks 13-15, 25-27, 49-51, and 73-75. || [3] Intismeran autogene (EXPERIMENTAL): Participants receive 1 mg of intismeran autogene via intramuscular (IM) injection every 3 weeks (Q3W) for 9 doses.","The main inclusion criteria include but are not limited to the following: \- Is an individual whose most recent TURBT was performed within 12 weeks before randomization/allocation and showed BICR-confirmed high-risk NMIBC histology BCG Arms: * Has high-risk non-muscle invasive (HG Ta, T1, and/or CIS) UC of the bladder * Is BCG-naïve defined as either having never received BCG or having received BCG more than 2 years before high-risk NMIBC recurrence. Recurrence must be at least 24 months from the last exposure to BCG with evidence of complete response during the 2-year period post BCG Intismeran autogene Monotherapy Arm: * Has CIS +/-papillary non-muscle invasive UC of the bladder * Is ineligible for, or refusing, any IVESIC therapy * Is either BCG-naïve (as defined above) or BCG-exposed but did not receive protocol-specified minimum dosing of BCG and experienced recurrence of high-risk NMIBC within 2 years of the last dose of BCG * Human immunodeficiency virus (HIV)-infected individuals must have well controlled HIV on antiretroviral therapy (ART)","The main exclusion criteria include but are not limited to the following: * Has a history of or concurrent locally-advanced (ie, T2, T3, T4) or metastatic UC * Has concurrent extravesical (ie, urethra, ureter, renal pelvis) non-muscle invasive UC or a history of extravesical non-muscle invasive UC that recurred within the last 2 years, with certain exceptions * Has a known additional malignancy that is progressing or has required active treatment within the last 3 years * Has had a myocardial infarction within 6 months of randomization/allocation * Has received any systemic anticancer therapy including investigational agents within 4 weeks before randomization/allocation * Has received prior treatment with a cancer vaccine * Has immunodeficiency or is receiving chronic systemic steroid therapy * Has active autoimmune disease that has required systemic treatment in the last 2 years * Has any contraindication to IV contrast and gadolinium or is otherwise unable to have imaging with either computerized tomography urogram (CTU) or Magnetic resonance urography (MRU) BCG Arms: * Has current active tuberculosis * Has a known history of HIV infection Intismeran autogene Monotherapy Arm: \- HIV-infected individuals with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease"
NCT06864169,"A Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers",REJOICE-GI01,PHASE2,"Argentina, Chile","Instituto de Investigaciones Clinicas Mar del Plata ( Site 0001), Mar del Plata, Argentina, [RECRUITING] | Nefra Medical Care - CEMIC Saavedra ( Site 0008), Buenos Aires, Argentina, [RECRUITING] | Instituto Medico de la Fundacion Estudios Clinicos ( Site 0007), Rosario, Argentina, [RECRUITING] | Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0006), La Rioja, Argentina, [RECRUITING] | FALP ( Site 0062), Santiago, Chile, [RECRUITING] | Centro de Estudios Clínicos SAGA ( Site 0064), Santiago, Chile, [RECRUITING] | Clínica UC San Carlos de Apoquindo ( Site 0066), Santiago, Chile, [RECRUITING] | Bradfordhill ( Site 0069), Santiago, Chile, [RECRUITING]",Gastrointestinal Cancer,1,[1] Raludotatug Deruxtecan (R-DXd) (EXPERIMENTAL): R-DXd will be administered via IV infusion.,"The main inclusion criteria include but are not limited to the following: * Has one of the following cancers: * Unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC) * Unresectable or metastatic adenocarcinoma of the biliary tract \[intra- or extrahepatic holangiocarcinoma (CCA) or gallbladder cancer (GBC)\] * Unresectable or metastatic colorectal adenocarcinoma * Unresectable or metastatic gastric adenocarcinoma * Gastroesophageal junction adenocarcinoma (GEJAC) * Esophageal adenocarcinoma (EAC) * Has received prior therapy for the cancer * Has a life expectancy of at least 3 months * If human immunodeficiency virus (HIV) infected, must have well controlled HIV on antiretroviral therapy (ART)","The main exclusion criteria include but are not limited to the following: * Has a history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids or has current ILD/pneumonitis, and/or suspected ILD/pneumonitis * Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses * Has uncontrolled or significant cardiovascular disease * Has a known additional malignancy that is progressing or has required active treatment within the past 3 years * Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis * Active autoimmune disease that has required systemic treatment in the past 2 years * Has not adequately recovered from major surgery or has ongoing surgical complications * HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease"
NCT05879926,"A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)",OFSET,PHASE3,"Mexico, Peru, Puerto Rico","Instituto Nacional De Cancerologia de Mexico, Mexico City, Mexico, [SUSPENDED] | Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru, [SUSPENDED] | Cancer Center-Metro Medical Center Bayamon, Bayamón, Puerto Rico, [RECRUITING] | Puerto Rico Hematology Oncology Group, Bayamón, Puerto Rico, [RECRUITING] | Doctors Cancer Center, Manatí, Puerto Rico, [RECRUITING] | San Juan Community Oncology Group, San Juan, Puerto Rico, [RECRUITING] | Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico, [RECRUITING] | PROncology, San Juan, Puerto Rico, [RECRUITING] | San Juan City Hospital, San Juan, Puerto Rico, [RECRUITING]",Breast Cancer,2,[1] Arm 1: Ovarian Function Suppression + Aromatase Inhibitor (ACTIVE_COMPARATOR): Aromatase inhibitor co-administered with a GnRH agonist (gonadotropin releasing hormone) for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule... || [2] Arm 2 Adjuvant Chemotherapy + Ovarian Function Suppression + Aromatase Inhibitor (ACTIVE_COMPARATOR): Adjuvant chemotherapy of investigator's choice followed by an aromatase inhibitor (AI) co-administered with an GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice ...,"* A patient cannot be considered eligible for this study unless ALL of the following conditions are met. * The patient or a legally authorized representative must provide study-specific informed consent prior to pre-entry and, for patients treated in the U.S., authorization permitting release of personal health information. * Female patients must be greater than or equal to 18 years of age. * Patients must be premenopausal (evidence of functioning ovaries) at the time of pre-entry. For study purposes, premenopausal is defined as: * Age 50 years or under with spontaneous menses within 12 months; or * Age greater than 50-60 years with spontaneous menses within 12 months plus follicle-stimulating hormone (FSH) and estradiol levels in the premenopausal range; or * Patients with amenorrhea due to IUD or prior uterine ablation must have FSH and estradiol levels in the premenopausal range; or * Patients with prior hysterectomy must have FSH and estradiol levels in the premenopausal range. * The patient must have an ECOG performance status of less than or equal to 2 (or Karnofsky greater than or equal to 60%). * Patients may have ipsilateral or contralateral synchronous breast cancer if the highest stage tumor meets entry criteria, and the other sites of disease would not require chemotherapy or HER2-directed therapy. * Patients may have multicentric or multifocal breast cancer if the highest stage tumor meets entry criteria, and the other sites of disease would not require chemotherapy or HER2-directed therapy. * Patient may have undergone a total mastectomy, skin-sparing mastectomy, nipple-sparing mastectomy, or a lumpectomy. * For patients who undergo a lumpectomy, the margins of the resected specimen or re-excision must be histologically free of invasive tumor and DCIS (ductal carcinoma in situ) with no ink on tumor as determined by the local pathologist. If pathologic examination demonstrates tumor at the line of resection, additional excisions may be performed to obta","* • Definitive clinical or radiologic evidence of metastatic disease. * pT4 (pathological state) tumors, including inflammatory breast cancer. * History of ipsilateral or contralateral invasive breast cancer. (Patients with synchronous and/or previous DCIS or LCIS are eligible.) * If prior ipsilateral DCIS was treated with lumpectomy and XRT (ionizing radiation therapy), a mastectomy must have been performed for the current cancer. * Life expectancy of less than 10 years due to co-morbid conditions in the opinion of the investigator. Known results from most recent lab studies obtained as part of routine care prior to study entry showing ANY of the following values: * ANC (absolute neutrophil count) less than 1200/mm3; * Platelet count less than 100,000/mm3; * Hemoglobin less than 10 g/dL; * Total bilirubin greater than ULN (upper limit of normal) for the lab or greater than 1.5 x ULN for patients who have a bilirubin elevation due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin; * AST(aspartate aminotransferase)(SGOT)/ALT (alanine transminase)(SGPT): greater than 3 × institutional ULN; * Renal function of GFR (glomular filtration rate) less than 30 mL/min/1.73m2. * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better. * Non-epithelial breast malignancies such as sarcoma or lymphoma. * Any treatment with radiation therapy, chemotherapy, or biotherapy administered for the currently diagnosed breast cancer prior to pre-entry. (Patients with prior ET of more than 6 weeks duration for treatment of this cancer are not eligible.) Prior tamoxifen given for breast cancer prevention is allowed. Prior AI or GnRH for fertility preservation is allowed. * Hormonally based contraceptive measures m"
NCT05318274,"Hypofractionated Radiation Therapy (1 Week) Compared With Standard Treatment (3.1 Weeks), Evaluation of Local Control of Breast Cancer Treated With Conservative Surgery.",,NA,Mexico,"Unidad Medica de Alta Especialidad, Mérida, Mexico, [RECRUITING]",Ductal Breast Carcinoma in Situ | Invasive Breast Cancer | Early-stage Breast Cancer | Stage 0 Breast Cancer | Stage I Breast Cancer,2,"[1] ARM I (EXPERIMENTAL): Radiotherapy treatment with high hypofractionation, 26 Gy in 5 fractions to the whole breast. || [2] ARM II (ACTIVE_COMPARATOR): Radiotherapy treatment with standard hypofractionation, 42.5 Gy in 16 fractions with simultaneous integrated increase of 5.5 Gy to the tumor bed in high-risk patients.",* Patients diagnosed by histopathological report of ductal carcinoma in situ (DCIS) or invasive breast carcinoma. * Treated with breast-conserving surgery and stage pT1-2 pN0 M0. * Over 18 years. * Patients who sign informed consent for research study.,* Positive nodes. * Clinical or pathological stage T3-T4. * History of previous irradiation. * Postoperative positive margin.
NCT05580562,"ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study",ACTION,PHASE3,"Argentina, Brazil","FLENI Neurologia, Buenos Aires, Argentina, [RECRUITING] | Hospital do GRAACC, São Paulo, Brazil, [RECRUITING] | Hcor Research Institute, São Paulo, Brazil, [RECRUITING] | Instituto Do Cancer Do Estado De São Paulo, São Paulo, Brazil, [RECRUITING]",H3 K27M | Glioma,3,[1] ONC201 Twice Weekly Group (EXPERIMENTAL): No description || [2] ONC201 Once Weekly Group (EXPERIMENTAL): No description || [3] Placebo Group (PLACEBO_COMPARATOR): No description,"1. Able to understand the study procedures and agree to participate in the study by providing written informed consent (by participant or legally authorized representative), and assent when applicable. 2. Body weight ≥ 10 kg at time of randomization. 3. Histologically diagnosed H3 K27M-mutant diffuse glioma (new diagnosis). Detection of a missense K27M mutation in any histone H3-encoding gene detected by testing of tumor tissue (immunohistochemistry \[IHC\] or next-generation sequencing \[NGS\] in a Clinical Laboratory Improvement Amendments \[CLIA\]-certified or equivalent laboratory). \[Site to provide (as available): ≥ 10 unstained formalin-fixed paraffin-embedded (FFPE) slides from tumor tissue.\] 4. At least one, high-quality, contrast-enhanced MRI of the brain obtained prior to starting radiotherapy for submission to sponsor's imaging vendor for central read. For participants who had a surgical resection, this scan must be post-resection; for participants who did not have a resection, this scan may be pre- or post-biopsy. 5. At least one, high-quality, contrast-enhanced MRI of the brain obtained 2 to 6 weeks after completion of frontline radiotherapy. If unable to obtain contrast-enhanced imaging due to lack of venous access after multiple attempts, a patient may still be eligible after collection of a nonenhanced MRI of the brain. \[Site to also provide all available MRIs completed prior to initiating treatment with study intervention.\] 6. Received frontline radiotherapy 1. Initiated radiotherapy within 12 weeks from the initial diagnosis of H3 K27M-mutant diffuse glioma. 2. Completed radiotherapy within 2 to 6 weeks prior to randomization 3. Completed standard fractionated radiotherapy (eg. 54 to 60 Gy in 28 to 33 fractions given over approximately 6 weeks or hypofractionated radiotherapy (eg. 40 Gy in 15 fractions given over approximately 3 weeks). 7. Karnofsky Performance Status or Lansky Performance Status ≥ 70 at time of randomization. 8. Stable or decr","1. Primary spinal tumor. 2. Diffuse intrinsic pontine glioma (DIPG), defined as tumors with a pontine epicenter and diffuse involvement of the pons. 3. Evidence of leptomeningeal spread of disease or cerebrospinal fluid dissemination. 4. Any known concurrent malignancy. 5. New lesion(s) outside of the radiation field. 6. Received whole-brain radiotherapy. 7. Received proton therapy for glioma. 8. Use of any of the following treatments within the specified time periods prior to randomization: 1. ONC201 or ONC206 at any time. 2. Systemic bevacizumab (includes biosimilars) at any time since the initial diagnosis of H3 K27M-mutant diffuse glioma. 3. Temozolomide within past 3 weeks. 4. Tumor treating fields at any time. 5. DRD2 antagonist within past 2 weeks. 6. Any investigational therapy within past 4 weeks. 7. Strong CYP3A4 inhibitors within 3 days. 8. Strong CYP3A4 inducers (includes enzyme-inducing antiepileptic drugs) within 2 weeks. 9. Laboratory test results meeting any of the following parameters within 2 weeks prior to randomization: 1. Absolute neutrophil count \< 1.0 × 109/L or platelets \< 75 × 109/L. 2. Total bilirubin \> 1.5 × upper limit of normal (ULN) (participants with Gilbert's syndrome may be included with total bilirubin \> 1.5 × ULN if direct bilirubin is ≤ 1.5 × ULN). 3. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2.5 × ULN. 4. Creatinine clearance ≤ 60 mL/min as calculated by the Cockcroft Gault equation (or estimated glomerular filtration rate \< 60 mL/min/1.73 m2). 10. QTc \> 480 msec (based on mean from triplicate electrocardiograms) during screening. 11. Known hypersensitivity to any excipients used in the study intervention formulation. 12. Pregnant, breastfeeding, or planning to become pregnant while receiving study intervention or within 3 months after the last dose. Participants of childbearing potential must have a negative serum pregnancy test within 72 hours prior to receiving the first dose of study interven"
NCT06952803,"A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients With BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy (EvoPAR-Prostate02).",EvoPAR-PR02,PHASE3,"Brazil, Chile, Peru","Research Site, Cachoeiro de Itapemirim, Brazil, [NOT_YET_RECRUITING] | Research Site, Curitiba, Brazil, [NOT_YET_RECRUITING] | Research Site, Jaú, Brazil, [NOT_YET_RECRUITING] | Research Site, Londrina, Brazil, [NOT_YET_RECRUITING] | Research Site, Pelotas, Brazil, [NOT_YET_RECRUITING] | Research Site, Porto Alegre, Brazil, [NOT_YET_RECRUITING] | Research Site, Porto Alegre, Brazil, [NOT_YET_RECRUITING] | Research Site, Rio de Janeiro, Brazil, [NOT_YET_RECRUITING] | Research Site, Salvador, Brazil, [NOT_YET_RECRUITING] | Research Site, São Paulo, Brazil, [NOT_YET_RECRUITING]",Prostate Cancer,4,"[1] Cohort A: Saruparib (AZD5305) + Physician's Choice ADT (EXPERIMENTAL): Participants will receive saruparib along with ADT. || [2] Cohort A: Placebo + Physician's Choice ADT (PLACEBO_COMPARATOR): Participants will receive matching placebo to saruparib along with ADT. || [3] Cohort B: Saruparib (AZD5305) + Physician's Choice ADT + Abiraterone (and prednisone/prednisolone) (EXPERIMENTAL): Participants will receive saruparib, abiraterone and prednisolone/prednisone along with ADT. || [4] Cohort B: Placebo + Physician's Choice ADT + Abiraterone (and prednisone/prednisolone) (PLACEBO_COMPARATOR): Participants will receive matching placebo to saruparib, abiraterone and prednisolone/prednisone along with ADT.","* Male participants with a histologically documented diagnosis of prostate adenocarcinoma. * Newly diagnosed high-risk and very high-risk (localised/locally advanced) prostate cancer or a high-risk biochemical recurrence (BCR) following radical prostatectomy. * Provision of a formalin fixed and paraffin embedded (FFPE) tumour tissue sample. * Confirmed BRCA1 or BRCA2 mutation status by central tumour tissue is required for enrolment. * Participants required to have a computed tomography (CT) or magnetic resonance imaging (MRI) and a bone scan following the completion of their planned RT. This screening scan must confirm no evidence of disease or evidence of disease confined to the pelvis (M0). * Participants required to have a prostate-specific membrane antigen-positron emission tomography (PSMA-PET) following the completion of their planned RT. This screening scan must confirm no evidence of disease or evidence of disease confined to the pelvis (M0). * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with no deterioration over the 2 weeks prior to randomization. * Minimum life expectancy of 12 months. * Adequate organ and bone marrow function as described in study protocol. * All participants will have received either primary or salvage RT. Participants must be eligible for randomisation within 10 months of initial diagnosis (de novo or BCR). Radiotherapy administered to the prostate (± pelvis) either in the primary or salvage setting must be delivered with curative intent. Use of metastases-directed therapy, as part of the RT radiation plan, is permitted as localised RT treatment for a metastatic lesion(s) outside the pelvis. * All participants will have received a planned regimen of ADT with a gonadotropin releasing hormone (GnRH) analogue. * Participants must not father children or donate sperm from signing informed consent form (ICF), during the study intervention and for 6 months after the last dose of study intervention. * Participants m","* Participants with a history of myelodysplastic syndrome (MDS)/ acute myeloid leukemia (AML) or with features suggestive of MDS/AML. * Participants with any known predisposition to bleeding \[e.g., active peptic ulceration, recent (within 6 months) hemorrhagic stroke, proliferative diabetic retinopathy\]. * Any history of persisting (\> 2 weeks) severe cytopenia due to any cause. * Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of saruparib and/or abiraterone. * History of another primary malignancy, with exceptions. * Persistent toxicities \[Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥ 2\] caused by previous anticancer therapy. * Cardiac criteria, including history of arrhythmia and cardiovascular disease. * Evidence of active and uncontrolled hepatitis B and/or hepatitis C. * Evidence of active and uncontrolled human immunodeficiency virus (HIV) infection. * Active tuberculosis infection. * Any prior chemotherapy (i.e., docetaxel) or immunotherapy; any prior treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor. * Prior treatment within 14 days with blood product support or growth factor support. * Concomitant use of strong inducers and inhibitors of CYP3A4 (applies to saruparib and abiraterone) or herbal supplements within 21 days or at least 5 half-lives (whichever is longer), of randomization. * Concomitant use of drugs that are known to prolong QT and have a known risk of Torsades de Pointes (TdP). * Participants with a known hypersensitivity to saruparib or any excipients of these products."
NCT06667154,Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-Dose Nivolumab Combined With Chemotherapy,,PHASE2,Brazil,"Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto, São José do Rio Preto, Brazil, [RECRUITING]","Lung Cancer, Nonsmall Cell | Non-Small Cell Lung Cancer NSCLC",1,[1] Low-dose nivolumab combined with platinum-based doublet chemotherapy (EXPERIMENTAL): No description,"* Able to provide a signed Informed Consent Form (ICF), indicating agreement to comply with the requirements and restrictions in the ICF and protocol. * Male or female, aged 18 years or older. * Diagnosed with non-small cell lung cancer (NSCLC) with clinical staging IB, II, or IIIA. * Receiving treatment at Hospital de Base. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment, with no decline from two weeks prior to the baseline period or the day of the first dose. * Tumor sample meets the following requirements: * Negative for EGFR gene expression. * Negative for ALK and ROS1 protein expression. * PD-L1 protein expression documented and assessable. * Tumor is considered resectable upon initial assessment by three thoracic oncology surgeons (IR, CM, and HN) following a multidisciplinary review. * Adequate organ and bone marrow function as defined below: * Hemoglobin: ≥ 9.0 g/dL\* * Absolute neutrophil count: ≥ 1.5 × 10\^9 /L\* * Platelet count: ≥ 100 × 10\^9 /L\* * \*Note: Granulocyte colony-stimulating factor (G-CSF), platelet transfusions, and blood transfusions are not permitted to meet these values. * Serum bilirubin: ≤ 1.5 × upper limit of normal (ULN), except for participants with confirmed Gilbert syndrome, who may be included upon physician consultation. * ALT and AST: ≤ 2.5 × ULN. * Creatinine clearance: ≥ 50 mL/min (calculated using the Cockcroft and Gault formula). * Life expectancy greater than six months prior to randomization.","* Refusal to sign the Informed Consent Form (ICF). * NSCLC clinical stages IA, IIIB N3, IIIC, IVA, and IVB. * Tumors with T4 invasion of the aorta, esophagus, and/or heart; or presence of bulky N2 disease. * Tumor deemed unresectable. * Prior systemic anticancer therapy for NSCLC, including chemotherapy, biologic therapy, immunotherapy, or any investigational drugs. * History of another primary malignancy, with exceptions for: * Malignancies treated with curative intent and no active disease for ≥ 2 years before the first dose of investigational product (IP) and with a low risk of recurrence. * Adequately treated non-melanoma skin cancer or lentigo maligna with no evidence of disease. * Adequately treated carcinoma in situ with no evidence of disease. * Incomplete basic medical information in the electronic medical record. * Positive for EGFR gene expression. * Positive for ALK protein expression. * No available data on PD-L1 protein expression. * Positive for ROS1 protein expression. * Pregnant or breastfeeding at the time of enrollment."
NCT04877522,"An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment",,PHASE4,"Argentina, Brazil, Mexico","Novartis Investigative Site, CABA, Argentina, [RECRUITING] | Novartis Investigative Site, Capital Federal, Argentina, [RECRUITING] | Novartis Investigative Site, Rio de Janeiro, Brazil, [RECRUITING] | Novartis Investigative Site, São Paulo, Brazil, [RECRUITING] | Novartis Investigative Site, São Paulo, Brazil, [RECRUITING] | Novartis Investigative Site, Monterrey, Mexico, [RECRUITING]","Chronic Myelogenous Leukemia | Leukemia, Myelogenous, Chronic, BCR-ABL Positive",10,"[1] Asciminib single agent group (EXPERIMENTAL): Participants with CML or ALL, from Novartis sponsored asciminib studies, including but not limited to CABL001A2301, CABL001A2302, CABL001X2101, CABL001A2202, CABL001AUS04 and CABL001AUS08 studies, ... || [2] Bosutinib single agent group (OTHER): Participants with CML-CP, from Novartis sponsored asciminib study CABL001A2301, that were receiving bosutinib || [3] Bosutinib-Asciminib switch group (EXPERIMENTAL): Participants with CML-CP, from Novartis sponsored asciminib study CABL001A2301 that were receiving bosutinib treatment and switched to asciminib when entering this study or during the course of thi... || [4] Asciminib in combination with imatinib group (EXPERIMENTAL): Participants with CML from Novartis sponsored asciminib studies CABL001E2201 or CABL001X2101 that were receiving asciminib combined with imatinib || [5] Asciminib in combination with nilotinib group (EXPERIMENTAL): Participants with CML or ALL from Novartis sponsored asciminib studies CABL001E2201or CABL001X2101 that were receiving asciminib combined with nilotinib || [6] Imatinib single agent group (OTHER): Participants with CML-CP, from Novartis sponsored asciminib study CABL001E2201 that were receiving imatinib || [7] Nilotinib single agent group (OTHER): Participants with CML-CP, from Novartis sponsored asciminib study CABL001E2201 and CABL001J12302 that were receiving nilotinib || [8] Asciminib in combination with dasatinib group (EXPERIMENTAL): Participants with CML from Novartis sponsored study CABL001X2101 that were receiving asciminib with dasatinib || [9] Dasatinib single agent group (OTHER): Participant with CML-CP , from Novartis sponsored asciminib study CABL001A2202, CABL001J12301, that were receiving Dasatinib. || [10] Dasatinib-Asciminib switch group (EXPERIMENTAL): Participants with CML-CP, from Novartis sponsored asciminib study CABL001A2202 that were receiving best available therapy (dasatinib) and switched to asciminib when enteri","1. Participant with PH+ CML or PH+ ALL currently receiving treatment with asciminib (single agent or in combination with imatinib, nilotinib or dasatinib), imatinib, nilotinib or bosutinib alone within a Novartis-sponsored study and, in the opinion of the Investigator, would benefit from continued treatment. 2. Participant has demonstrated compliance on the parent study protocol and is willing and able to comply with scheduled visits, treatment plans and any other study procedures. Key","1. Participant has been discontinued from parent study treatment. 2. Participant currently has unresolved toxicities reported as possibly related to study treatment in the parent study. 3. Participant's ongoing treatment is currently approved and reimbursed at country level. 4. Pregnant or nursing (lactating) women. 5. Women of child-bearing potential, unless they are using highly effective methods of contraception and willing to continue while taking study treatment. 6. Sexually active males receiving imatinib, nilotinib, bosutinib or dasatinib unwilling to follow the relevant contraception requirements in the local prescribing information. 7. Applicable for participants on bosutinib treatment at the end of the CABL001A2301 and on other TKIs for CABL001A2202 study that switch to asciminib treatment: * Asymptomatic (grade 2) pancreatitis if not resolved within 28 days * QTcF\>480msec or inability to determine QTc interval * any grade 3 or 4 toxicity not resolved to grade 2 or lower within 28 days before starting asciminib treatment Other protocol-defined Inclusion/Exclusion criteria may apply."
NCT06780085,"KEYMAKER-U01 Substudy 01H: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC)",,PHASE2,Chile,"Centro de Estudios Clínicos SAGA ( Site 0161), Santiago, Chile, [RECRUITING] | FALP ( Site 0160), Santiago, Chile, [RECRUITING] | Bradfordhill ( Site 0162), Santiago, Chile, [RECRUITING]","Carcinoma, Non-Small-Cell Lung",3,[1] Raludotatug Deruxtecan (EXPERIMENTAL): Participants receive raludotatug deruxtecan (R-DXd) 5.6 mg/kg via intravenous (IV) Infusion every 3 weeks (q3w) until disease progression or discontinuation criterion is met. || [2] Ifinatamab Deruxtecan (EXPERIMENTAL): Participants receive ifinatamab deruxtecan (I-DXd) 12 mg/kg via IV infusion q3w until disease progression or discontinuation criterion is met. || [3] Docetetaxel (ACTIVE_COMPARATOR): Participants receive docetaxel 75mg/m2 via IV infusion q3w until disease progression or discontinuation criterion is met.,"The main inclusion criteria include but are not limited to the following: * Histologically or cytologically confirmed diagnosis of Stage IV nonsquamous non-small cell lung cancer (NSCLC) * Documented disease progression per RECIST 1.1 after receiving an anti-programmed cell death 1 protein (PD-1)/programmed cell death ligand 1 (PD-L1) treatment and platinum-based chemotherapy * Confirmation per local test report that epidermal growth factor receptor negative (EGFR-), anaplastic lymphoma kinase negative (ALK-), or c ros oncogene 1 negative (ROS1-) directed therapy is not indicated as primary therapy * Measurable disease per RECIST 1.1 as assessed by investigator and verified by BICR * Life expectancy of at least 3 months * An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 7 days before randomization * Is an individual of any sex/gender who is at least 18 years of age at the time of providing the informed consent * Has adequate organ function * If capable of producing sperm refrains from donating sperm plus either abstains from penile-vaginal intercourse or uses a penile/external condom, with contraceptive use consistent with local regulations * Participant/participants of childbearing potential (POCBP) is not pregnant and has a negative highly sensitive pregnancy test; and is not breastfeeding and uses a highly effective contraceptive method * Archival tumor tissue sample of a tumor lesion not previously irradiated has been provided * Has provided tissue prior to treatment randomization from a newly obtained formalin-fixed sample from a new biopsy * Human Immunodeficiency Virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART) * Participants who are hepatitis B surface antigen (HBsAg) positive have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization * Participants with history of hepatitis C virus (HCV) infect","The main exclusion criteria include but are not limited to the following: * Diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements * Received radiation therapy to the lung * Has uncontrolled or significant cardiovascular disorder prior to randomization * Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses * Participants who have adverse events (AEs) (other than alopecia) due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline * Has known severe hypersensitivity (≥Grade 3) to study intervention and/or any of its excipients * Has evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection (including HIV infection) * Has clinically significant corneal disease * Has received prior radiotherapy within 2 weeks of start of study intervention, or radiation related toxicities, requiring corticosteroids * Has inadequate washout period prior to randomization * Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention * Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy * Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration * Has known additional malignancy that is progressing or has required active treatment within the past 3 years * Has known untreated central nervous system (CNS) metastases and/or carcinomatous meningitis * Has evidence of any leptomeningeal disease * Has history of (noninfectious) pneumonitis/ interstitial lung disease (ILD) that required steroids or has current pneumonitis/ILD, and/or suspected ILD/pneumonitis * Has active autoimmune disease that has required systemic treatment in the past 2 years * Has active infection requiring systemic therapy * HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Has active inflammatory bowel di"
NCT06422143,Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer,,PHASE3,"Argentina, Brazil, Chile, Colombia, Peru","Instituto Alexander Fleming ( Site 0203), Ciudad Autónoma de Buenos Aires, Argentina, [RECRUITING] | Instituto de Investigaciones Clínicas Mar del Plata ( Site 0200), Mar del Plata, Argentina, [RECRUITING] | Instituto Médico Río Cuarto ( Site 0204), Río Cuarto, Argentina, [RECRUITING] | Fundacion Intecnus ( Site 0205), Bariloche, Argentina, [RECRUITING] | Sanatorio Parque ( Site 0201), Rosario, Argentina, [RECRUITING] | Hospital Aleman-Oncology ( Site 0202), Buenos Aires, Argentina, [RECRUITING] | Hospital do Cancer de Pernambuco ( Site 0312), Recife, Brazil, [RECRUITING] | Vencer Centro de Pesquisa Clínica ( Site 0309), Teresina, Brazil, [RECRUITING] | Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 0311), Porto Alegre, Brazil, [RECRUITING] | Hospital Nossa Senhora da Conceição ( Site 0300), Porto Alegre, Brazil, [RECRUITING]",Non-small Cell Lung Cancer | NSCLC,2,"[1] Maintenance Arm A: Pembrolizumab + sac-TMT (EXPERIMENTAL): During the Induction phase, participants receive pembrolizumab 200 mg q3w for 4 cycles, carboplatin area under the curve (AUC) 6 (mg/mL/min) q3w for 4 cycles, and paclitaxel 200 mg/m2 q3w for 4 cyc... || [2] Maintenance Arm B: Pembrolizumab Monotherapy (ACTIVE_COMPARATOR): During the induction phase, participants receive pembrolizumab 200 mg q3w for 4 cycles, carboplatin AUC 6 (mg/mL/min) q3w for 4 cycles, and paclitaxel 200 mg/m2 q3w for 4 cycles or nab-paclitaxel 1...","* Histologically or cytologically confirmed diagnosis of squamous non-small cell lung cancer (NSCLC) \[Stage IV: M1a, M1b, M1c, American Joint Committee on Cancer Staging Manual, version 8\] * Measurable disease per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 as assessed by the local site investigator/radiology * Has life expectancy ≥3 months * Has Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1 assessed within 7 days prior to allocation * Archival tumor tissue sample or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated has been provided * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART) * Participants who are hepatitis B surface antigen (HBsAg)-positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load before allocation * Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening * Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to Grade ≤1 or baseline (participants with endocrine-related AEs who are adequately treated with hormone replacement are eligible). Note: Participants with Grade =2 neuropathy are eligible * Has adequate organ function * For Maintenance only (prior to randomization): is without disease progression of their NSCLC, as determined by BICR using RECIST 1.1 after completion of study-specified Induction with an evaluable scan at Week 12 or most recent scan before randomization * For Maintenance only (prior to randomization): has ECOG PS of 0 or 1 as assessed at the Prerandomization Visit * For Maintenance only (prior to randomization): all AEs (with the exception of alopecia, Grade 2 fatigue, and Grade ≤2 endocrine-related AEs requiring treatment or hormone replacement) have recovered","* Diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements * History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing * Active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea) * Has uncontrolled, significant cardiovascular disease or cerebrovascular disease including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QTcF interval to \>480 ms, and other serious cardiovascular and cerebrovascular diseases within 6 months before study intervention * HIV-infected participants who have been newly diagnosed or with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC. Note: Prior treatment with chemotherapy and/or radiation as a part of neoadjuvant or adjuvant therapy or chemoradiation therapy for nonmetastatic NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC * Received prior therapy with an anti-programmed cell death 1 protein (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti programmed cell death ligand 2 (PD-L2) agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, cytotoxic T lymphocyte-associated protein 4, OX-40, CD137). Note: Prior treatment with an anti-PD-1 or anti-PD-L1 agent for nonmetastatic NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC * Received prior treatment with a trophoblast cell-surface antigen 2 (TROP2)-targeted antidrug conjugate (ADC) * Received radiation therapy to the lung tha"
NCT05317416,"A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION",MagnetisMM-7,PHASE3,Brazil,"Instituto D'Or de Pesquisa e Ensino (IDOR) - Filial Salvador, Salvador, Brazil, [RECRUITING] | Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa, Porto Alegre, Brazil, [RECRUITING] | Centro de Pesquisa Clínica - Área Administrativa, Porto Alegre, Brazil, [RECRUITING] | Hospital Mae de Deus, Porto Alegre, Brazil, [RECRUITING] | Hospital Amaral Carvalho, Jaú, Brazil, [RECRUITING] | Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (USP), Ribeirão Preto, Brazil, [RECRUITING] | BP - A Beneficencia Portuguesa de São Paulo, São Paulo, Brazil, [ACTIVE_NOT_RECRUITING] | Clínica Médica São Germano LTDA, SP, Brazil, [RECRUITING] | Fundação Doutor Amaral Carvalho, Jaú, Brazil, [RECRUITING] | Américas Medical City, Rio de Janeiro, Brazil, [RECRUITING]",Multiple Myeloma,4,[1] Arm A - Part 1 (EXPERIMENTAL): Elranatamab || [2] Arm B - Part 1 (ACTIVE_COMPARATOR): Lenalidomide || [3] Arm B - Part 2 (ACTIVE_COMPARATOR): Lenalidomide || [4] Arm C - Part 2 (EXPERIMENTAL): Elranatamab,"* Diagnosis of MM as defined according to IMWG criteria (Rajkumar, 2014) with measurable disease at diagnosis * Part 1 patients must be MRD positive, Part 2 patients can be MRD negative or MRD positive * History of induction therapy for newly diagnosed MM, followed by high dose therapy and autologous stem cell transplant. Randomization must occur within 120 days from the stem cell transplant. For participants who receive consolidation therapy after ASCT, randomization must occur within 60 days of consolidation and within 7 months from ASCT. * Partial Response or better according to IMWG criteria at the time of randomization * Must have an archival bone marrow aspirate sample(s) to identify the dominant malignant (index) clone by central laboratory NGS test (ClonoSEQ assay) that is used to track MRD status. This sample should preferably be collected before induction treatment (eg, at diagnosis) or before transplant. * ECOG performance status ≤1 * Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤ 1 * Not pregnant and willing to use contraception","* Plasma cell leukemia * Amyloidosis, Waldenström's macroglobulinemia * POEMS syndrome * Known active CNS involvement or clinical signs of myelomatous meningeal involvement * Previous MM maintenance treatment * Prior treatment with BCMA targeted therapy * Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ * Active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) HBV, HCV, and known HIV or AIDS-related illness * Previous administration with an investigational drug or vaccine within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer)"
NCT06619509,"A Phase II, Single-arm, Open-label, Long-term Safety Rollover Trial of Oral Brigimadlin in Patients With Solid Tumours",,PHASE2,"Argentina, Brazil","Sanatorio Finochietto, CABA, Argentina, [RECRUITING] | H.S.J. Beneficência Portuguesa - São Paulo, São Paulo, Brazil, [NOT_YET_RECRUITING]",Solid Tumours,1,[1] Brigimadlin (EXPERIMENTAL): No description,"All patients: 1. Patient is ongoing on brigimadlin treatment or qualifies for crossover to brigimadlin treatment in any trial sponsored by Boehringer Ingelheim (hereafter referred to as the 'parent trial'). 2. Provision of signed and dated, written informed consent form (ICF) in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-GCP) and local legislation prior to any trial-specific procedures, sampling, or analyses. 3. Women of childbearing potential (WOCBP) and men able to father a child must be ready and able to use 2 medically acceptable methods of birth control per ICH M3 (R2) that result in a low failure rate of \<1% per year when used consistently and correctly beginning at Screening, during trial participation, and until 6 months and 12 days after the last dose for women and 102 days after the last dose for men. A list of contraception methods meeting these criteria and instructions on the duration of use is provided in the participant information. 4. Participants must be willing and able to comply with the scheduled visits, treatment plan, lifestyle, laboratory tests, contraceptive guidelines, and other study procedures. 5. Adequate organ function. 6. All toxicities related to previous anti-cancer therapies have resolved Common Terminology Criteria for Adverse Events (CTCAE) Grade ≤1 prior to trial treatment administration (except for alopecia and amenorrhea/menstrual disorders which can be any grade and peripheral neuropathy which must be CTCAE Grade ≤2). Cohort 1 only: 7. Patient is eligible to receive continued treatment according to the clinical trial protocol of the parent trial they are currently participating in. Patients currently experiencing a dose delay in the parent trial due to adverse events are eligible if recovery from the adverse event takes place within the allowed time window in the parent trial. Cohort 2 only: 8. Patient is eligible to receive ","1. Any medical condition which in the opinion of the investigator should exclude the patient from receiving treatment with brigimadlin. 2. Participants who must receive or intend to receive restricted medications or any drug considered likely to interfere with the safe conduct of the trial. 3. Women who are pregnant, nursing, or who plan to become pregnant while in the trial. Female patients who do not agree to the interruption of breastfeeding from the start of study treatment until 6 months and 12 days after the last dose of study treatment. Cohort 1 only: 4. Patient has disease progression or unacceptable toxicity on brigimadlin at the time of transition into this trial. 5. Patient has an adverse event (AE) which has caused a dose delay and has not recovered within the allowed time window in the parent trial. 6. Patient who has already required 2 dose reductions and would require a third dose reduction at trial entry, unless the investigator deems treatment continuation beneficial, and the third dose reduction is agreed between the investigator and the sponsor. Further exclusion criteria apply."
NCT06132958,"A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095)",TroFuse-005,PHASE3,"Argentina, Brazil, Chile, Mexico, Puerto Rico","Hospital Británico de Buenos Aires-Oncology ( Site 1002), Ciudad Autónoma de Buenos Aires, Argentina, [RECRUITING] | Instituto Alexander Fleming-Alexander Fleming ( Site 1007), Buenos Aires, Argentina, [RECRUITING] | Instituto Argentino de Diagnóstico y Tratamiento (IADT) ( Site 1008), Buenos Aires, Argentina, [COMPLETED] | Hospital Aleman-Oncology ( Site 1001), Buenos Aires, Argentina, [RECRUITING] | Instituto de Oncología Angel H. Roffo ( Site 1003), Buenos Aires, Argentina, [RECRUITING] | Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 1004), Buenos Aires, Argentina, [RECRUITING] | Fundación CORI para la Investigación y Prevención del Cáncer ( Site 1006), La Rioja, Argentina, [RECRUITING] | Hospital São Domingos ( Site 1365), São Luís, Brazil, [COMPLETED] | Centro Oncologico do Triangulo ( Site 1360), Uberlândia, Brazil, [COMPLETED] | Hospital Moinhos de Vento ( Site 1359), Porto Alegre, Brazil, [ACTIVE_NOT_RECRUITING]",Endometrial Cancer,2,"[1] Sacituzumab tirumotecan (EXPERIMENTAL): Participants will receive 4 mg/kg of sacituzumab tirumotecan via intravenous (IV) infusion on Day 1 of each 14-day cycle. Additionally, participants receive diphenhydramine (or equivalent), a Hista... || [2] Chemotherapy (ACTIVE_COMPARATOR): Participants will receive 60 mg/m\^2 of doxorubicin by IV infusion on Day 1 of each 21-day cycle; or 80 mg/m\^2 of paclitaxel by IV infusion on Days 1, 8, and 15 of each 28-day cycle. Participants ...","* Has a histologically-confirmed diagnosis of endometrial carcinoma or carcinosarcoma. * Has radiographically evaluable disease, either measurable or nonmeasurable per response evaluation criteria in solid tumors (RECIST 1.1), as assessed by blinded independent central review (BICR). * Has received prior platinum-based chemotherapy and anti-programmed cell death 1 protein (PD-1)/anti- programmed cell death ligand 1 (PD-L1) therapy, either separately or in combination.","* Has neuroendocrine tumors or endometrial sarcoma, including stromal sarcoma, leiomyosarcoma, adenosarcoma, or other types of pure sarcomas * Has a history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing * Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease * Has had a recurrence of endometrial carcinoma or carcinosarcoma more than \>12 months after completing platinum-based therapy administered in the curative-intent setting without any additional platinum-based therapy received in the recurrent setting. Note: 1) If Immunotherapy-based treatment is administered in the recurrent setting, then platinum rechallenge is not required, regardless of the duration of the platinum-free interval from time of adjuvant therapy 2) For Stage IVb disease, treatment that includes gynecological surgery followed by a platinum-based regimen is NOT considered curative-intent per protocol and does not require platinum rechallenge in the recurrent setting, regardless of the duration of the platinum-free interval * Has received more than 3 prior lines of therapy for endometrial carcinoma or carcinosarcoma * Has history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease * Has received prior treatment with single-agent nonplatinum based chemotherapy in the third-line setting * Has received prior treatment with a trophoblast cell surface antigen 2 (TROP2)-targeted antibody drug conjugate (ADC) (eg, sacituzumab govitecan) * Has received prior treatment with a topoisomerase I inhibitor-containing ADC (eg, sacituzumab govitecan or fam-trastuzumab deruxtecan-nxki) * Has previously received both single-agent paclitaxel and single-agent doxorubicin in any setting for prior treatment of endometrial cancer * Requires recurrent drainage of ef"
